0001720725-20-000006.txt : 20200227 0001720725-20-000006.hdr.sgml : 20200227 20200227162115 ACCESSION NUMBER: 0001720725-20-000006 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20191231 FILED AS OF DATE: 20200227 DATE AS OF CHANGE: 20200227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 20662378 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 10-K 1 oyst-20191231.htm 10-K oyst-20191231
FALSE000172072512/31FY2019.353P4Y00017207252019-01-012019-12-31iso4217:USD00017207252019-12-31xbrli:shares00017207252020-02-2100017207252018-12-31iso4217:USDxbrli:shares0001720725us-gaap:SeriesAPreferredStockMember2019-12-310001720725us-gaap:SeriesAPreferredStockMember2018-12-3100017207252018-01-012018-12-3100017207252017-12-310001720725us-gaap:CommonStockMember2017-12-310001720725us-gaap:AdditionalPaidInCapitalMember2017-12-310001720725us-gaap:RetainedEarningsMember2017-12-310001720725us-gaap:RetainedEarningsMember2018-01-012018-12-310001720725us-gaap:AdditionalPaidInCapitalMember2018-01-012018-12-310001720725us-gaap:CommonStockMember2018-12-310001720725us-gaap:AdditionalPaidInCapitalMember2018-12-310001720725us-gaap:RetainedEarningsMember2018-12-310001720725us-gaap:RetainedEarningsMember2019-01-012019-12-310001720725us-gaap:SeriesBPreferredStockMember2019-04-012019-06-300001720725us-gaap:SeriesBPreferredStockMember2019-01-012019-12-310001720725us-gaap:CommonStockMember2019-01-012019-12-310001720725us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001720725us-gaap:CommonStockMember2019-12-310001720725us-gaap:AdditionalPaidInCapitalMember2019-12-310001720725us-gaap:RetainedEarningsMember2019-12-310001720725us-gaap:IPOMember2019-11-042019-11-0400017207252019-11-040001720725us-gaap:RedeemableConvertiblePreferredStockMember2019-11-042019-11-04oyst:segment0001720725us-gaap:OfficeEquipmentMember2019-01-012019-12-310001720725us-gaap:FurnitureAndFixturesMember2019-01-012019-12-3100017207252019-10-182019-10-180001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2019-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2019-12-310001720725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2019-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310001720725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2019-12-310001720725us-gaap:FairValueMeasurementsRecurringMember2019-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2018-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2018-12-310001720725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2018-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2018-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2018-12-310001720725us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2018-12-310001720725us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2018-12-310001720725us-gaap:FairValueMeasurementsRecurringMember2018-12-310001720725us-gaap:LeaseholdsAndLeaseholdImprovementsMember2019-12-310001720725us-gaap:OfficeEquipmentMember2019-12-310001720725us-gaap:FurnitureAndFixturesMember2019-12-310001720725oyst:AcquisitionOfOC02CompoundMember2016-10-310001720725oyst:AcquisitionOfOC02CompoundMember2016-10-012016-10-31xbrli:pure0001720725us-gaap:LicensingAgreementsMember2019-10-182019-10-180001720725oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2020Member2018-01-310001720725oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2020Member2019-01-012019-12-310001720725oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2022Member2019-04-300001720725oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2022Member2019-01-012019-12-3100017207252019-07-010001720725oyst:LeaseAmendmentMemberus-gaap:SubsequentEventMember2020-01-200001720725us-gaap:DomesticCountryMember2019-12-310001720725us-gaap:StateAndLocalJurisdictionMember2019-12-310001720725us-gaap:DomesticCountryMember2018-12-310001720725us-gaap:StateAndLocalJurisdictionMember2018-12-310001720725us-gaap:SeriesBPreferredStockMember2019-02-150001720725us-gaap:SeriesBPreferredStockMember2019-02-012019-02-280001720725us-gaap:SeriesBPreferredStockMember2019-04-012019-04-300001720725us-gaap:RedeemableConvertiblePreferredStockMember2019-12-310001720725us-gaap:CommonStockMember2019-12-31oyst:vote0001720725oyst:The2016EquityIncentivePlanMember2019-12-310001720725oyst:The2016EquityIncentivePlanMember2018-12-310001720725oyst:The2019EquityIncentivePlanMember2019-12-310001720725oyst:The2019EquityIncentivePlanMember2018-12-310001720725us-gaap:RestrictedStockUnitsRSUMemberoyst:The2019EquityIncentivePlanMember2019-12-310001720725us-gaap:RestrictedStockUnitsRSUMemberoyst:The2019EquityIncentivePlanMember2018-12-310001720725oyst:The2019EquityIncentivePlanMember2019-10-310001720725oyst:The2016EquityIncentivePlanMember2019-10-310001720725us-gaap:EmployeeStockOptionMemberoyst:The2016EquityIncentivePlanMember2019-01-012019-12-310001720725oyst:The2016EquityIncentivePlanMemberoyst:IncentiveStockOptionsMember2019-01-012019-12-310001720725us-gaap:EmployeeStockMemberoyst:The2019EmployeeStockPurchasePlanMember2019-10-310001720725oyst:The2016EquityIncentivePlanMember2017-12-310001720725oyst:The2016EquityIncentivePlanMember2017-01-012017-12-310001720725oyst:The2016EquityIncentivePlanMember2018-01-012018-12-310001720725oyst:The2016EquityIncentivePlanMember2019-01-012019-12-310001720725us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001720725us-gaap:RestrictedStockUnitsRSUMember2019-12-310001720725us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001720725us-gaap:ResearchAndDevelopmentExpenseMember2018-01-012018-12-310001720725us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-12-310001720725us-gaap:GeneralAndAdministrativeExpenseMember2018-01-012018-12-310001720725srt:MinimumMember2019-01-012019-12-310001720725srt:MaximumMember2019-01-012019-12-310001720725us-gaap:SeriesAPreferredStockMember2019-01-012019-12-310001720725us-gaap:SeriesAPreferredStockMember2018-01-012018-12-310001720725us-gaap:StockOptionMember2019-01-012019-12-310001720725us-gaap:StockOptionMember2018-01-012018-12-310001720725us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-12-310001720725us-gaap:RestrictedStockUnitsRSUMember2018-01-012018-12-3100017207252019-01-012019-03-3100017207252019-04-012019-06-3000017207252019-07-012019-09-3000017207252019-10-012019-12-3100017207252018-01-012018-03-3100017207252018-04-012018-06-3000017207252018-07-012018-09-3000017207252018-10-012018-12-31


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________________________
FORM 10-K
______________________________________
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____________ to ____________
Commission File Number: 001-39112
______________________________________
OYSTER POINT PHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
______________________________________
Delaware81-1030955
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
202 Carnegie Center, Suite 109 Princeton, New Jersey
08540
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (609) 382-9032

Securities registered pursuant to Section 12(b) of the Act:
Title of each class

Trading
Symbol(s)

Name of each exchange on which registered
Common stock, par value $0.001

OYST

Nasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None
______________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐  Accelerated filer ☐
Non-accelerated filer ☒  Smaller reporting company ☒
Emerging growth company

☒




If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes   ☐   No ☒ 
The aggregate market value of the voting stock and non-voting common stock held by non-affiliates of the registrant, based on the closing price of a share of the registrant’s common stock on December 31, 2019 as reported by the NASDAQ Global Select Market on such date, was approximately $168.0 million. The registrant has elected to use December 31, 2019, which was the last business day of the registrant’s most recently completed fiscal


year, as the calculation date because on June 30, 2019 (the last business day of the registrant’s most recently completed second fiscal quarter), the registrant was a privately-held company. Shares of common stock held by each executive officer and director and by each other person who may be deemed to be an affiliate of the registrant, have been excluded from this computation. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes.

As of February 21, 2020, the registrant had 21,366,950 shares of common stock, $0.001 par value per share, outstanding.

DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2019.





Table of Contents

OYSTER POINT PHARMA, INC.
Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2019

Page
PART I.
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
PART II.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART III.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
PART IV.
Item 15.
Item 16.



SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about:

•the likelihood of our clinical trials demonstrating safety and efficacy of our product candidates, and other positive results;

•the timing of initiation of our future clinical trials, and the reporting of data from our completed, current and future preclinical and clinical trials;

•our plans relating to the clinical development of our product candidates, including the size, number and disease areas to be evaluated;

•the size of the market opportunity and prevalence of dry eye disease (DED) for our product candidates;

•our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;

•the success of competing therapies that are or may become available;

•our estimates of the number of patients in the United States who suffer from DED and the number of patients that will enroll in our clinical trials;

•the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates;

•the timing or likelihood of regulatory filings and approval for our product candidates;

•our ability to obtain and maintain regulatory approval of our product candidates;

•our plans relating to the further development and manufacturing of our product candidates, including additional indications for which we may pursue;

•the expected potential benefits of strategic collaborations with third parties and our ability to attract collaborators with development, regulatory and commercialization expertise;

•existing regulations and regulatory developments in the United States and other jurisdictions;

•our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available;

•our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for preclinical studies and clinical trials;

•the need to hire additional personnel, and our ability to attract and retain such personnel;

•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

•our financial performance;




1


•the sufficiency of our existing capital resources to fund our future operating expenses and capital expenditure requirements;

•our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and

•our anticipated use of our existing resources and the proceeds from our initial public offering.

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and growth prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements after the date of this Annual Report on Form 10-K, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements.





2


PART I
ITEM 1. BUSINESS

Overview

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Our lead product candidate OC-01 (varenicline), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s novel mechanism of action is designed to re-establish tear film homeostasis by activating the trigeminal parasympathetic pathway and stimulating the glands and cells responsible for natural tear film production. In our Phase 2b clinical trial (ONSET-1) in 182 subjects, OC-01 demonstrated statistically significant improvements (as compared to placebo) in both signs and symptoms of DED in a single registrational clinical trial. Based on OC-01’s clinical trial results and its rapid onset of action, we believe OC-01, if approved, has the potential to become the new standard of care and redefine how DED is treated for millions of patients. We initiated a Phase 3 clinical trial (ONSET-2) in July 2019 and expect to report top-line results by the end of the second quarter 2020. Based on the results from this second registrational trial, we plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2020. We believe that targeting the parasympathetic nervous system through the use of locally administered cholinergic agonists has the potential to treat a wide range of diseases and disorders. We have identified several indications, including several outside of ophthalmology, where we believe this approach could provide a meaningful benefit to patients.

DED is a multifactorial chronic disease of the ocular surface characterized by the loss of tear film homeostasis, resulting in pain, visual impairment, tear film hyperosmolarity and instability, inflammation, and corneal wounding. More than 340 million adults globally and approximately 34 million adults in the United States are estimated to suffer from DED. In the United States, DED is most commonly treated with a variety of over-the-counter eye drops, often referred to as “artificial tears,” and three FDA-approved prescription eye drop therapies: Restasis, Xiidra and Cequa. Artificial tears are intended to supplement insufficient tear production or improve tear film instability, but are primarily saline-based and provide only temporary relief. Restasis and Cequa, both calcineurin inhibitor immunosuppressants, and Xiidra, a lymphocyte function-associated antigen-1 (LFA-1) antagonist, address chronic inflammation associated with DED. Despite the commercial uptake of these therapies—as examples, Restasis, marketed by Allergan, and Xiidra, recently acquired by Novartis, had U.S. sales in 2018 of $1.2 billion and $383 million, respectively—respondents in a survey we commissioned in June 2017 of 150 board-certified or board-eligible eye care practitioners (ECPs) were generally “neutral” or “completely disagreed” with the statement that they could, in their opinion, successfully treat all DED patients with the currently available treatment options whereas only 10% “completely agreed” with such statement. We estimate that of the approximately seven million patients who have started a prescription treatment to date, fewer than two million remain on prescription at any given time due to the significant limitations of these therapies, which include:

•
Mechanisms of action only address inflammation. Currently approved therapies only target inflammation for moderate to severe DED; no approved pharmaceutical products replicate natural tear film, which is highly complex in composition. As these prescription therapies fail to address the fundamental characteristic of DED, the loss of tear film homeostasis, we estimate that 75% of patients still require over-the-counter therapies to supplement their treatment.

•
Slow onset of action. Based on data reported from clinical trials, currently available treatments can take between three to six months to demonstrate a significant effect in clinical signs. We believe this delayed onset of action hinders compliance and in turn limits the benefit that patients derive from such treatments.

•
Tolerability and compliance issues. Currently approved pharmaceutical therapies for DED are typically administered in an eye-drop formulation and are commonly associated with ocular burning, reduced visual acuity and bad taste after application. The effective use of eye drops can be challenging for some patients, and such challenges can result in reduced compliance.

To address these limitations and the high unmet need expressed by patients, ECPs and payors, we are developing a product candidate that we believe has the potential to become the new standard of care for DED. However, there is no guarantee that such product candidate will be approved by the FDA or, if approved, will provide revenues comparable to Restasis or Xiidra.

Our novel approach leverages the parasympathetic nervous system to promote natural tear film production and re-establish tear film homeostasis. Human tear film is a complex mixture of more than 1,500 different proteins, including antibodies, and numerous classes of lipids and mucins that are responsible for forming the primary refracting surface of the cornea, as well as protecting and moisturizing the cornea. The Lacrimal Functional Unit (LFU), which is controlled by the parasympathetic nervous
3

system, is comprised of glands and cells responsible for producing the three layers that comprise healthy tear film. To stimulate the LFU, we are targeting a class of receptors called nicotinic acetylcholine receptors (nAChR) that are located on the trigeminal nerve and readily accessible within the anterior nasal cavity. Administered as a preservative-free, aqueous nasal spray, OC-01’s novel mechanism of action activates the trigeminal parasympathetic pathway to promote natural tear film production. We believe that increasing tear film volume and re-establishing tear film homeostasis will address the fundamental characteristic of DED, regardless of etiology, and has the potential to treat a broad population of patients throughout the dry eye continuum.

To date, we have treated over 500 subjects across five trials with OC-01 and OC-02 (simpinicline, which was formerly called simpanicline), our second nAChR agonist product candidate. We have consistently designed our clinical trials to be placebo (vehicle)-controlled, statistically rigorous and evaluated using pre-specified sign and symptom endpoints. In October 2018, we reported results from ONSET-1, a dose-ranging, randomized, double-masked, placebo-controlled, registrational Phase 2b clinical trial that evaluated the safety and efficacy of OC-01 in 182 subjects with DED in the United States. The study compared three different doses of OC-01 to placebo. The pre-specified primary (sign) endpoint was the assessment of tear production as measured by Schirmer’s Score at Week 4 and the two pre-specified secondary (symptom) endpoints were patient-reported symptoms of DED as measured by Eye Dryness Score (EDS) at Weeks 3 and 4. These endpoints are consistent with those that have been previously utilized in clinical trials of FDA-approved products for DED. Results showed statistically significant improvements of the primary endpoint (Schirmer’s Score) at all doses compared to placebo. In addition, results showed statistically significant improvements of the secondary endpoint (EDS) at Week 3 in the 0.6 mg/ml (p=0.006) and 1.2 mg/ml (*p<0.001) dose groups and at Week 4 in the 0.6 mg/ml (p=0.021) dose group. Moreover, OC-01 is designed to promote rapid production of tear film, and improvements in signs and symptoms were observed as quickly as five minutes after administration. OC-01 was well tolerated at all doses assessed in the study with no serious drug-related adverse events reported.

We met with the FDA in February 2019 for an end of Phase 2 meeting following the completion of ONSET-1, and the FDA indicated ONSET-1 could serve as one of the two pivotal safety and efficacy studies required to support an NDA filing for OC-01. Based on this feedback we initiated ONSET-2, a 750-subject, multicenter, randomized, double-masked, placebo-controlled Phase 3 trial, in July 2019. Assuming the effect size seen in ONSET-1, and based on this sample size, the power for each dose group for both sign and symptom endpoints would be 99% or greater. We expect to report top-line results from this second registrational trial by the end of the second quarter 2020 and, if successful, submit an NDA to the FDA in the second half of 2020.

We also completed a comparative pharmacokinetic “bridge” trial (ZEN) to evaluate the relative bioavailability of varenicline administered as a nasal spray (OC-01) compared to varenicline administered orally (Chantix). The FDA has indicated that reliance upon the varenicline tartrate data in our 505(b)(2) NDA submission would be considered scientifically justified if exposure levels following nasal spray administration of our final clinical formulation are less than or equal to that of Chantix at its approved dose and route of administration. We reported positive top-line results in November 2019 illustrating that the exposure levels following nasal spray administration are significantly lower than those seen with oral varenicline.

Leveraging our nAChR domain expertise, we continue to explore the development of OC-01 for a number of potential indications and uses associated with and beyond DED, including neurotrophic keratitis, dry eye associated with contact lens intolerance and ocular surface treatment for refractive surgeries. We have also studied OC-02 in two Phase 2b clinical trials in subjects with DED. However, we do not currently intend to pursue FDA approval for OC-02 in DED. We believe that targeting the parasympathetic nervous system through the use of locally administered cholinergic agonists has the potential to treat a wide range of diseases and disorders in the eye and systemically.

To execute on our vision to develop and commercialize a new standard of care for DED, we have assembled a team with extensive experience developing and commercializing leading ophthalmic products and therapies. Members of our management team have held senior positions at Allergan, Eyetech, Genentech, Johnson & Johnson, Novartis, Oculeve, Ophthotech, Pfizer, Pharmasset, and Shire. We intend to leverage this expertise and experience to rapidly pursue the development of OC-01, OC-02 and any other future product candidates that we may identify and develop. We also have leading financial investors which include New Enterprise Associates, Versant Ventures, Invus Opportunities, Flying L Ventures (investing through its Oyster Point Pharma I fund), KKR (investing through its Falcon Vision fund) and Vida Ventures.


Our Strategy

Our goal is to transform the treatment of DED and other ocular surface diseases by developing a broad portfolio of innovative therapies that target significant unmet medical needs. We intend to achieve this goal by pursuing the following key strategic objectives:

4

•
Completing development and obtaining approval of OC-01 for the treatment of DED. OC-01 demonstrated statistically significant improvements (as compared to placebo) in both signs and symptoms of DED in a single registrational clinical trial. We are not aware of another therapy that has shown statistically significant improvements in both signs and symptoms of DED in a single registrational clinical trial. However, to date our trials have been designed as randomized, masked, placebo-controlled clinical trials and, as such, we have not tested OC-01 head-to-head with any other products or therapies, nor are we aware of any head-to-head results indicating that such other products or therapies could not have shown similar results. Based on the strength of the data observed in ONSET-1, our Phase 2b registrational clinical trial, we initiated a Phase 3 multicenter, randomized, double-masked, placebo-controlled clinical trial (ONSET-2). We expect to report top-line results from this second registrational trial by the end of the second quarter 2020 and, if successful, submit a 505(b)(2) NDA to the FDA in the second half of 2020.
•
Establishing our own specialty sales organization to commercialize OC-01 in the United States. If OC-01 is approved for the treatment of the signs and symptoms of DED, we intend to commercialize our lead product candidate by deploying a specialty sales force at launch of approximately 150 to 200 field representatives targeting the top-prescribing ophthalmologists and optometrists. Given the importance of increasing awareness and educating patients with DED, we also anticipate deploying focused direct-to-consumer marketing campaigns for OC-01. We anticipate that this sales organization could also support the commercialization of additional product candidates treating ocular diseases.

•
Maximizing the value of OC-01 and our other product candidates outside the United States. With more than 300 million additional DED patients outside of the United States, we believe there is a significant commercial opportunity for our product candidates internationally. To address these markets, we may seek one or more partners with regional capabilities and infrastructure to support and potentially accelerate the clinical development and commercialization of our product candidates, if approved, in such geographies.

•
Developing OC-01 for additional indications associated with and beyond DED. Based on the fundamental role of natural tear film in ocular surface health, we plan to pursue development of OC-01 in other indications where this equilibrium is disturbed. First, we plan to pursue development for patients with neurotrophic keratitis, a degenerative disease resulting from a loss of corneal sensation, which causes progressive damage to the top layer of the cornea. As natural tear film contains a myriad of beneficial components, including endogenous growth factors, proteins and antibodies, we believe that our product candidate could be beneficial in improving the health of the cornea in these patients. A second population of potential clinical benefit is in subjects with DED associated with contact lens intolerance. In addition, based on the unique characteristics of this product candidate, we see the potential for use in patients that are preparing for refractive surgery where there is often an underlying dry eye condition that could impact refraction and ultimately patient satisfaction and quality of life post-surgery.

•
Leveraging the capabilities of our experienced discovery and development team and our nAChR domain expertise to continue expanding our pipeline of product candidates. We have studied a second nAChR agonist product candidate OC-02 (simpinicline) in two Phase 2b clinical trials for DED. We have identified several indications, other than DED, where we believe this product candidate has the potential to provide a meaningful benefit to patients. In certain indications, we believe OC-02 could advance directly into a Phase 2 proof of concept study, supported by preclinical and clinical data that we and others have generated. However, we cannot guarantee that the FDA will permit us to advance OC-02 into a Phase 2 proof of concept study nor can we guarantee that the FDA will grant marketing approval to OC-02 for the treatment of any indication. Beyond OC-02, we plan to continue our efforts to identify and develop additional product candidates.


•
Selectively evaluating external opportunities to expand the scope of our pipeline or product offerings. We may pursue acquisition or in-licensing of product candidates, particularly in our core disease area of ocular surface diseases.

Dry Eye Disease Overview

Dry eye disease (DED) is a multifactorial, age-related chronic progressive disease of the ocular surface resulting in pain, visual impairment, tear film hyperosmolarity and instability, and inflammation. Patients with DED are also more susceptible to eye infections and damage to the surface of the eye (cornea). DED is characterized by a reduction in tear volume, rapid breakup of the tear film, or an increase in the evaporative properties of the tear film layer. DED affects daily life, including reading and
5

driving at night and has been associated with depression and migraines. DED can also limit patients’ ability to tolerate contact lenses and impacts patient satisfaction with post-op cataract and refractive patients.

As illustrated below, the Lacrimal Functional Unit (LFU), which is controlled by the parasympathetic nervous system, is comprised of Meibomian glands, lacrimal glands, and goblet cells that are responsible for producing the three layers that comprise healthy tear film. The National Eye Institute defines healthy tear film as “a complex mixture of fatty oils, water, mucus, and more than 1,500 different proteins that keep the surface of the eye smooth and protected from the environment, irritants, and infectious pathogens.” The outermost layer of tear film is a lipid layer produced by the Meibomian glands that keeps tear film from evaporating too quickly. The lacrimal glands produce the aqueous layer, which comprises the bulk of tear volume and flow. This middle layer is not just water – it contains thousands of proteins, enzymes, antibodies and growth factors that are cytoprotective, anti-inflammatory, and anti-microbial. The aqueous layer nourishes the cornea and the conjunctiva, the mucous membrane that covers the entire front of the eye and the inside of the eyelids. Finally, the innermost mucin layer is produced by goblet cells and binds water from the aqueous layer to ensure that the eye remains wet. The LFU receives stimulus from the trigeminal nerve, which has sensory nerve endings in the nasal cavity.

oyst-20191231_g1.jpg


LFU dysfunction leads to the loss of tear film homeostasis and can ultimately lead to the cycle of chronic DED. Disruption and instability of the tear film results in irritation, inflammation, and ultimately cellular damage. Chronic symptoms of DED include a scratchy sensation (foreign body sensation), stinging or burning, episodes of excess tearing that follow periods of dryness, discharge, pain, and redness in the eye. In addition, patients with dry eye often experience blurred vision as the cornea and the tear film are responsible for 65%-75% of the eye’s focusing power. Approved prescription treatments for DED, as well as therapies in clinical development, target inflammation further down the DED continuum. We believe these therapies only treat patients with moderate to severe DED and do not address the loss of tear film homeostasis, the fundamental characteristic of DED. Our lead product candidate OC-01 is designed to stimulate the LFU to produce natural tear film, re-establish tear film homeostasis and improve the signs and symptoms of patients with DED.

oyst-20191231_g2.jpg



Market opportunity in DED

6

DED is highly prevalent and growing, currently affecting more than 340 million people globally. In the United States, DED affects an estimated 14.5% of the adult population, or 34 million adults, resulting in greater than $55 billion in annual indirect costs, such as reductions in productivity. Prevalence of DED continues to grow due to an aging population, increase in autoimmune diseases, contact lens wear and digital screen time. Although DED is one of the most common reasons people visit an ECP in the United States, it is estimated that only 16 million adults have been diagnosed with DED by an ECP, which we believe is due in part to lack of education and insufficient awareness on the part of the patient.

Despite the number of patients diagnosed with DED, we estimate that only seven million patients to date have started a prescription treatment regimen which we believe is based at least in part on a lack of treatment options that are suitable for chronic use. In a survey we commissioned in June 2017 (the ECP Survey) of eye care practitioners (ECPs), respondents were generally neutral or dissatisfied with their treatment options for patients with DED. The ECP Survey was conducted by means of a distributed questionnaire to 150 respondent ECPs who specialize primarily in ophthalmology or optometry, are board-certified or board-eligible, manage at least 40 unique patients per month with DED and are familiar with, or prescribe, currently available prescription therapies. In the ECP Survey, we asked ECPs to select whether they completely disagreed, were neutral or completely agreed with the statement that they “can successfully treat all Dry Eye patients with currently available options.” Approximately 40% of ECPs responded that they completely disagreed with the statement, approximately 50% responded that they were neutral and only 10% responded that they completely agreed. Similarly, the top clinical reasons patients discontinued therapy were insufficient symptom improvement, side effects, and delayed onset of action. Medication cost was also a factor in discontinuing therapy. However, in our survey of patients who had discontinued Restasis due to costs, 72% stated they would have been willing to pay the same price if the medication had worked better. As a result of these factors, we believe that only two million patients are on a prescription therapy at any given time. Despite the small percentage of DED patients on prescription therapy, Restasis (marketed by Allergan) and Xiidra (recently acquired by Novartis for a total consideration of up to $5.3 billion) had U.S. sales in 2018 of $1.2 billion and $383 million, respectively. However, we cannot guarantee that OC-01 or any of our other future product candidates will be approved by the FDA and, even if one of our product candidates is approved, there is no guarantee that our revenues will be comparable to those of Restasis or Xiidra.

Current treatment options and their limitations

DED is primarily treated with a variety of over-the-counter eye drops, often referred to as “artificial tears,” and three FDA-approved prescription eye drop therapies: Restasis, Xiidra and Cequa. Artificial tears are intended to supplement insufficient tear production or improve tear film instability, but are primarily saline-based and provide only temporary relief. Restasis and Cequa, both calcineurin inhibitor immunosuppressants, and Xiidra, a lymphocyte function-associated antigen-1 (LFA-1) antagonist, which has been approved for the treatment of the signs and symptoms of DED, address chronic inflammation associated with DED. Other treatment options include ointments, gels, warm compresses, omega-3 fatty acid supplements and a number of medical devices. Unfortunately, all currently approved treatment options for DED have significant limitations, which include:

•
Mechanisms of action only address inflammation. Currently approved therapies only target inflammation for moderate to severe DED; no approved pharmaceutical products replicate natural tear film, which is highly complex in composition. As these prescription therapies fail to address the fundamental characteristic of DED, the loss of tear film homeostasis, we estimate that 75% of patients still require over-the-counter therapies to supplement their treatment.

•
Slow onset of action. Based on data reported from clinical trials, currently available treatments can take between three to six months to demonstrate a significant effect in clinical signs. We believe this delayed onset of action hinders compliance and in turn limits the benefit that patients derive from such treatments.

•
Tolerability and compliance issues. Currently approved pharmaceutical therapies for DED are typically administered in an eye-drop formulation and are commonly associated with ocular burning, reduced visual acuity and bad taste after application. The effective use of eye drops can be challenging for some patients and result in reduced compliance.

To address these limitations and the high unmet need expressed by patients, ECPs and payors, we have been developing OC-01, which we believe, if approved, has the potential to become the new standard of care for DED. However, there is no guarantee that it will provide revenues comparable to existing treatments. OC-01’s highly differentiated mechanism of action is designed to re-establish tear film homeostasis, addressing the fundamental disease process, regardless of stage of disease or underlying cause. We are not aware of any other drug companies focused on activating the trigeminal parasympathetic pathway (TPP) and stimulating the LFU to increase tear production. OC-01 has demonstrated rapid onset of action to significantly improve signs and symptoms in the same patient population within a single registrational clinical trial. Furthermore, the novel delivery of
7

OC-01 in a nasal spray spares the ocular surface and contributes to a favorable tolerability profile. To date, there have been no reports of burning or stinging to the ocular surface or negative effects on taste or smell in clinical trials of OC-01. We believe OC-01, if approved, has the potential to offer improved clinical outcomes and patient compliance based on its registrational trial results, favorable tolerability profile and rapid onset of action, therefore making it particularly suitable for use broadly across mild, moderate and severe patient populations.

Our approach: activating the trigeminal parasympathetic pathway to promote natural tear film production

To address these limitations and the high unmet need expressed by patients, ECPs and payors, we are developing a product candidate that we believe has the potential to serve as the new standard of care for DED. Our novel approach is designed to leverage the parasympathetic nervous system to stimulate natural tear film production and re-establish tear film homeostasis. A healthy tear film protects and lubricates the eyes, washes away foreign particles, contains antimicrobials to reduce the risk of infection, and creates a smooth surface that contributes refractive power for clear vision.

The Trigeminal Parasympathetic Pathway

The parasympathetic nervous system (PNS) is a division of the autonomic nervous system and is responsible for actions such as stimulating gland function, constriction of the pupil, slowing down heart rate and contractility, contracting bronchial musculature and stimulating bronchial secretions, and increasing gut motility for digestion. The parasympathetic nervous system controls tear film homeostasis and the activity of the LFU partially via the trigeminal nerve. The PNS uses acetylcholine (ACh) as its neurotransmitter.

Anesthetizing the nasal mucosa has been shown to result in a 34% reduction in tear film production. This has also been observed in patients with reduced nasal air flow resulting from severe nasal allergy and patients with tracheostomy, suggesting that stimulation of the trigeminal nerve is important for tear production. Since then, additional studies have demonstrated a persistent decrease in aqueous tear production in patients with trigeminal nerve damage (such as trauma, trigeminal nerve ablation and herpetic infection) or pathology.

We refer to the communication between the trigeminal nerve and the LFU as the TPP. The efferent paths (away from the nose) of the TPP proceed from the superior salivary nucleus along the facial nerve to the geniculate ganglion and from there through the greater superficial petrosal nerve via the sphenopalatine ganglion to the LFU. Activating the TPP results in the stimulation of the Meibomian glands, lacrimal glands (main and accessory), and goblet cells comprising the LFU and promotes natural tear film production.

Targeting nicotinic acetylcholine receptors (nAChR) on the trigeminal nerve

Our approach to DED relies on a pharmaceutical stimulation of a class of receptors called nicotinic acetylcholine receptors (nAChR) that are located on the trigeminal nerve and readily accessible within the anterior nasal cavity. nAChRs are ligand-gated ion channels that when bound by an agonist have the potential for ganglionic neurotransmission. The nAChRs subtypes found on human neurons are comprised of various homomeric (all one subunit) or heteromeric (at least one α and one ß subunit) combinations of 12 different nicotinic receptor subunits: α2-α10 and ß2-ß4. Stimulation of these receptors results in a rapid increase in cellular permeability to Na + and Ca 2+ resulting in depolarization of the cell membrane and initiation of an action potential. However, not all subtypes of nAChRs have the ability to activate the TPP (for example, treatment with a homomeric α7 agonist has no effect on this pathway). Additionally, the functional response of an nAChR to agonists is comprised of two dose-dependent, opposing effects: receptor activation after short exposure to high agonist concentrations (µM range), and desensitization upon prolonged exposure to low agonist concentrations (nM range).

Our product candidates OC-01 and OC-02 contain APIs that are highly selective to the nAChRs that activate the TPP. We believe this is the first application of nAChR agonists to be delivered nasally to stimulate the nerves of the PNS. Additionally, we have found that OC-01 and OC-02’s unique receptor binding characteristics and the localized nasal delivery allows for short-term agonist exposure with a high local concentration, and, once absorbed across the nasal mucosa, results in low systemic exposure and therefore avoids desensitization.







Our Product Candidates

8

oyst-20191231_g3.jpg

OC-01 (varenicline) nasal spray for Dry Eye Disease

Our lead product candidate OC-01 is being developed as a nasal spray to treat the signs and symptoms of DED. The API of OC-01, varenicline, is a highly selective nicotinic acetylcholine receptor (nAChR) agonist with full agonist activity at the α7 receptor and partial agonist activity at the α3ß4, α3α5ß4, α4ß2, and α4α6ß2 receptors. Varenicline tartrate, marketed as Chantix, was developed and commercialized by Pfizer as an aid to smoking cessation treatment. The compound was studied in multiple dose-ranging, placebo-controlled Phase 2 studies as well as two confirmatory Phase 3 studies to study the safety and efficacy in otherwise healthy smokers in the United States. In 2006, varenicline was approved by both the FDA and the European Medicines Agency and subsequently has been approved in more than 80 other countries throughout the world. To date, varenicline oral tablets have been prescribed to more than 20 million patients worldwide, including more than 11 million adults in the United States.

OC-01 is a preservative-free, aqueous nasal spray designed to be delivered twice daily to each nostril in a 50 µl spray for the treatment of dry eye disease. The highest intranasal concentration of varenicline being studied in ONSET-1 and ONSET-2 is 1.2 mg/ml, approximately ten-fold lower than the maintenance dose of Chantix (2 mg/day) on a nominal daily dosing basis. The lower dose of 0.6 mg/ml varenicline being studied in these two registrational trials is approximately 20-fold lower than the maintenance dose of oral Chantix on a nominal daily dosing basis.

OC-01’s novel mechanism of action

OC-01’s novel mechanism of action is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the TPP and stimulating the glands and cells responsible for natural tear film production. We believe that the development of OC-01 as a nasal spray represents the first pharmacological treatment approach for DED targeting the nerves that control the LFU. OC-01, when sprayed into the anterior portion of the nasal cavity, stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.

Once OC-01 is bound to an nAChR, it stabilizes the open state of the ion channel allowing influx of cations such as Ca2+ and Na + ions, thus creating an action potential. This action potential ultimately activates the glands and cells of the LFU to produce natural tear film. Once the nasal spray is delivered, it takes approximately 10-15 seconds before tear film is produced. The receptors can be in the activated state for many minutes to hours after stimulation (a process termed smoldering activation).

We believe that increasing tear film volume and re-establishing tear film homeostasis will address the fundamental characteristic in the development and treatment of DED, regardless of etiology, and has the potential to treat a broad population of patients throughout the dry eye continuum.

Our development program for OC-01

In October 2018, we reported results from ONSET-1, a multicenter, dose-ranging, randomized, double-masked, placebo (vehicle)-controlled, registrational Phase 2b clinical trial that evaluated the safety and efficacy of OC-01 in 182 subjects with DED in the United States. Following ONSET-1, we initiated a Phase 3 registrational clinical trial (ONSET-2) in July 2019 and expect to report top-line results by the end of the second quarter 2020.

We also completed a comparative pharmacokinetic “bridge” trial (ZEN) to evaluate the relative bioavailability of varenicline administered as a nasal spray (OC-01) compared to varenicline administered orally (Chantix) and reported top line results in November 2019. The exposure levels following nasal spray administration of varenicline are significantly lower than those seen with oral varenicline. If the FDA determines that the results of this trial establish an adequate bridge between OC-01 and Chantix, it will allow us to reference certain FDA conclusions regarding the safety of varenicline from the Agency’s review of the Chantix
9

NDA. If both ONSET-2 and ZEN are successful, we intend to submit the results of ONSET-2 and ZEN together with the results from ONSET-1 as part of a 505(b)(2) NDA to the FDA in the second half of 2020.

In January 2020, we reported results from MYSTIC, a randomized, single-masked, vehicle-controlled Phase 2 clinical trial that evaluated the safety and efficacy of OC-01 in 123 subjects with DED. The goal of this study was to assess the safety and efficacy of twice daily dosing of OC-01 nasal spray administered for 84 days. Although the study will add to the totality of the data in support of the efficacy of OC-01 nasal spray in subjects with DED, the MYSTIC data will only be used to support the safety of OC-01 in terms of NDA submission.

Statistical Significance

In the description of our clinical trials below, n represents the number of patients in a particular group and p or p-values represent the probability that random chance caused the result (e.g., a p-value=0.001 means that there is a 0.1% probability that the difference between the placebo group and the treatment group is purely due to random chance). A p-value ≤ 0.05 is a commonly used criterion for statistical significance, and may be supportive of a finding of efficacy by regulatory authorities. The confidence interval (CI) means a range of values for a variable of the measure of treatment effect, constructed so that this range has a specified probability of including the true value of the variable.

ONSET-1: Phase 2b clinical trial results

In ONSET-1, OC-01 demonstrated statistically significant improvements in both signs and symptoms of DED. The study compared three different doses of OC-01 to placebo. The pre-specified primary (sign) endpoint was the assessment of tear production as measured by Schirmer’s Score (compared to the baseline Schirmer’s Score) at Week 4 and the two pre-specified secondary (symptom) endpoints were patient-reported symptoms of DED as measured by EDS at Weeks 3 and 4. We also evaluated corneal fluorescein staining, a marker of corneal epithelial cell health, at Week 4, as an exploratory endpoint in ONSET-1. Due to the relatively small sample size of the study and the use of the controlled adverse environment chamber (CAE) that can exacerbate staining, ONSET-1 was not designed or powered to assess statistical significance for this endpoint. Baseline disease characteristics were generally similar across all treatment groups, with the exception of the 1.2 mg/ml OC-01 dose group where lower average disease severity was observed as indicated by a higher mean Schirmer’s test (5.5 mm) relative to the other dose groups (range: 4.5 to 5.2 mm) and a lower mean EDS (53.5 mm) relative to the other dose groups (range: 63.7 to 65.6 mm).

Although we cannot guarantee that the FDA will grant marketing approval for OC-01 based on the use of these endpoints, ONSET-1’s pre-specified endpoints are consistent with those that have been previously utilized in clinical trials of FDA-approved products for DED. The Schirmer’s Score, which was the same primary sign endpoint used in the FDA’s approval of Restasis, is determined by placing a test strip in the lower eyelid pouch and measuring the length of the test paper strip that is moistened after five minutes. Sometimes a topical anesthetic is placed into the eye before the filter paper to prevent tearing due to the irritation from the paper. The study eye was pre-defined as the eye that met eligibility criteria in the study and in the event that both eyes met criteria, was the eye with more tearing at baseline upon stimulation or in the event that both eyes were again equal, the eye with the worse baseline Schirmer’s Score. The fellow eye is the eye that was not defined as the study eye and may or may not have met all study eligibility criteria. The EDS, which was the primary symptom endpoint used in the FDA’s approval of Xiidra, is based on the patient’s rating of eye dryness on a visual analog scale (where 0=no discomfort and 100=maximal discomfort) with respect to both eyes. The study was designed and pre-specified to statistically analyze the 0.6 mg/ml and 1.2 mg/ml OC-01 dose groups. The study was not designed to formally analyze the 0.12 mg/ml dose group to avoid spending statistical power on a dose that was not hypothesized to provide clinically meaningful results. Therefore, no p-value is formally reported for the 0.12 mg/ml dose group.

The study design is included below:













10

Figure 1. ONSET-1 Study Design

oyst-20191231_g4.jpg


In ONSET-1, the 182 subjects were randomly sorted into the four treatment groups following assessment of each subject’s baseline Schirmer’s Score and EDS. The mean baseline disease characteristics across all treatment groups were generally similar with the exception of the 1.2 mg/ml OC-01 dose group. In this group, subjects showed lower baseline disease severity, with a higher mean Schirmer’s Score (5.5 mm) relative to the other dose groups (range: 4.5 to 5.2 mm) and a lower mean EDS (53.5 mm) relative to the other dose groups (range: 63.7 to 65.6 mm).

As shown in Figure 2, a statistically significant improvement in Schirmer’s Score at Week 4 was observed in all three doses compared to placebo. The 0.6 mg/ml was associated with a least squares (LS) mean change from baseline Schirmer’s Score of 11.4 mm (95% CI 8.9-13.9; p<0.001). The 1.2 mg/ml dose group was associated with a LS mean change from baseline Schirmer’s Score of 11.1 mm (95% CI 8.5-13.7; p<0.001). The 0.12 mg/ml dose group was not formally tested, although it was associated with a LS mean change from baseline Schirmer’s Score of 10.1 mm. Anesthetized Schirmer’s Score results were similar in the fellow eyes of subjects (p<0.01).

Figure 2. ONSET-1: Primary (Sign) Endpoint

oyst-20191231_g5.jpg

1ANCOVA, Least Squares mean. ITT-observed population. Analysis of Covariance (ANCOVA) is a general linear statistical model which blends analysis of variance and regression. Intent to Treat (ITT) population analysis is an analysis of all randomized subjects, regardless of whether they received study treatment.

The proportion of subjects who had a change of greater than or equal to (or ≥) 10 mm in Schirmer’s Score from baseline at Week 4 was statistically significantly higher compared to subjects treated with placebo (vehicle nasal spray; 6 of 43 subjects, 14%) in the 0.6 mg/ml (25 of 46 subjects, 54%; 95% CI 40-69; P<0.001) and 1.2 mg/ml (19 of 40 subjects, 48%; 95% CI 32-63; P=0.001) dose groups. Similar changes from baseline were observed for the OC-01 0.12 mg/ml group (21 of 47 subjects, 45%; 95% CI 30-59; P=0.001).

ONSET-1 had two pre-specified secondary endpoints. The first secondary endpoint was the mean change from baseline to Week 4 in EDS (both eyes). As shown in Figure 3, a statistically significant reduction in mean EDS from baseline to Week 4 was
11

observed in the 0.6 mg/ml dose group, with a LS mean change from baseline EDS of -19.0 mm (95% CI -26.2 to -11.7; p=0.021). The LS mean change from baseline EDS to Week 4 for the 1.2 mg/ml dose group was -15.4 mm (95% CI -23.3 to -7.5; p=0.13).
The other secondary endpoint was the change from baseline to Week 3 in mean EDS at five minutes post treatment in the CAE. As shown in Figure 3, a statistically significant reduction in mean EDS from baseline to Week 3 at five minutes post treatment in CAE was observed in the 0.6 mg/ml dose group, with a LS mean change from baseline EDS of -16.0 mm (95% CI -21.3 to -10.6; p=0.006). The LS mean change from baseline EDS to Week 3 at five minutes post treatment in CAE for the 1.2 mg/ml dose group was -18.4 mm (95% CI -24.3 to -12.5, *p<0.001). As the first secondary outcome was statistically different from placebo only in the 0.6 mg/ml dose group, change in EDS was formally tested in that dose group alone. At Week 3, in the CAE, the LS mean difference in change from baseline of the EDS between the 0.6 mg/ml dose and placebo groups at five minutes post treatment in CAE was -11.6 mm (95% CI -20.1 to -3.0; p=0.006). The LS mean difference between the 1.2 mg/ml dose and placebo groups in the change from baseline EDS was -14.0 mm (95% CI -22.9 to -5.1). While no formal analysis was performed on the 1.2 mg/ml dose group, as this dose group was not statistically significant in the first secondary endpoint, the nominal p-value was p<0.001.

Figure 3. ONSET-1: Secondary (Symptom) Endpoints

oyst-20191231_g6.jpg


1
ANCOVA, Least Squares mean. ITT-observed population. Controlled Adverse Environment (CAE).
2
ANCOVA, Least Squares mean. ITT-observed population.
*
Nominal p-value

Sensitivity analyses at ten and fifteen minutes post treatment in the CAE showed similar reductions in EDS as those seen at five minutes post treatment in subjects treated with OC-01 compared to subjects treated with placebo.

ONSET-1 was not designed or powered to assess corneal fluorescein staining, although we did ultimately measure this as an exploratory analysis using the National Eye Institute Corneal Fluorescein grading scale. This scale measures corneal staining in five distinct regions on the cornea: central, superior, inferior, nasal, and temporal, as well as a total score that includes all regions. At Week 4, in the 0.6 mg/ml dose group, total corneal staining (95% CI -2.9 to -0.2; p=0.020), nasal corneal staining (95% CI -0.8 to -0.0; p=0.026), and inferior corneal staining (95% CI -0.8 to -0.1; p=0.006) showed a statistically significant benefit as compared to placebo. There was a directional benefit in the 0.6 mg/ml dose group favoring OC-01 in central, superior, and temporal staining as compared to placebo. We believe that this is the only registrational study to show a statistically significant benefit in corneal fluorescein staining as soon as Week 4. There was no statistically significant benefit in corneal fluorescein staining in 1.2 mg/ml dose group, although there was a directional benefit favoring OC-01 in total, central, temporal, inferior, and nasal staining as compared to placebo.

OC-01 was well tolerated at all doses assessed in the study with only one serious adverse event reported (in the 0.6 mg/ml dose), which was not suspected to be related to the study drug. The most commonly reported drug-related adverse events in ONSET-1 were non-ocular, whereas reports of ocular adverse events were few and transient. Only one subject each in the 0.12 mg/ml and 1.2 mg/ml dose groups and two subjects in the 0.6 mg/ml dose group reported ocular adverse events compared to seven subjects in the placebo group. Of these reported events, reduced visual acuity was reported by one subject each in the 0.12 mg/ml and 0.6 mg/ml dose groups compared to three subjects in the placebo group, and each instance of reduced visual acuity reported was resolved by the next visit. No other ocular adverse event was reported by more than one subject.

12

Four subjects discontinued the study due to adverse events. One subject in the 0.6 mg/ml dose group withdrew from the study after one day of treatment due to dizziness. Three subjects in the 1.2 mg/ml dose group withdrew from the study. The first subject withdrew from the 1.2 mg/ml dose group after one day of treatment due to sneezing and throat irritation. The other two subjects withdrew from the 1.2 mg/ml dose group after two days of treatment due to (i) nasopharyngitis and (ii) tinnitus, headache and eyelid edema, respectively. No subjects withdrew from the study after the second day of treatment. The most commonly reported non-adverse events in ONSET-1 were sneezing and coughing, as shown in Figure 4 below. No subjects in the placebo group reported either sneezing or cough.






Figure 4. Non-Ocular Adverse Events Occurring in More than One Subject in any Treatment Group
oyst-20191231_g7.jpg

Based on OC-01’s clinical trial results in ONSET-1 and its rapid onset of action, we believe that OC-01, if approved, has the potential to become the standard of care and redefine how DED is treated for millions of patients.

ZEN: Phase 1 comparative pharmacokinetic clinical trial results

We completed a comparative pharmacokinetic “bridge” trial (ZEN) where we evaluated the relative bioavailability of varenicline administered as a nasal spray (OC-01) compared to varenicline administered orally (Figure 5). We reported positive top-line results in November 2019. ZEN is a Phase 1, open-label, randomized, two-way crossover study to evaluate the relative bioavailability of OC-01 compared to varenicline administered orally. The study design is included below:

Figure 5. ZEN Study Design
oyst-20191231_g8.jpg

The ZEN study was designed to assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength (1.2 mg/ml in a 50 microliter nasal spray) compared to varenicline administered as a single oral dose at
13

its commercially available maintenance oral tablet strength (1 mg). The treatment cohort consisted of 22 healthy volunteers between 18-65 years of age meeting all other study eligibility criteria who were randomized (Treatment Period 1) to receive an intranasal dose of 0.12 mg OC-01 (50 µL spray of 0.06 mg into each nostril) or a single 1 mg oral dose of varenicline. Both administrations were delivered while the subject was in an overnight fasted state. Subjects then returned at least 14 days later (Treatment Period 2) to receive the alternate dose of varenicline that was delivered at Treatment Period 1.

Top-line results (Figure 6) indicate that the relative bioavailability (systemic exposure as defined by adjusted geometric mean AUC0-inf) was 13 times lower for a single dose of the highest strength of OC-01 nasal spray as compared to a single dose of the highest strength varenicline tablet (7.46 vs. 99.67 h*ng/ml). Maximal concentration (as defined by adjusted geometric mean Cmax) was 14 times lower for a single dose of the highest strength of OC-01 nasal spray as compared to a single dose of the highest strength varenicline tablet (0.32 vs. 4.55 ng/ml).

The study demonstrated that OC-01 nasal spray was safe and well-tolerated at the doses tested. The number of subjects reporting any treatment-emergent adverse event (TEAE) was 13 out of 21 (61.9%) after nasal spray administration and 9 out of 22 (40.9%) after oral tablet administration but there were no reports of serious TEAE noted with either oral or nasal administration. The most common adverse events in the nasal spray group were sneeze in 7 volunteers (33.3%) and cough in 6 volunteers (28.6%). All events were mild. There were no events of sneeze or cough in the oral tablet administration group. The most common adverse events in the oral tablet administration group were nausea in 5 volunteers (22.7%) and vomiting in 4 volunteers (18.2%). All events were mild or moderate in severity. There were no events of nausea or vomiting in the nasal spray administration group.

Figure 6. ZEN Study Results: Mean (+/-SD) Systemic Exposure for Nasal Varenicline and Oral Varenicline
oyst-20191231_g9.jpg
Plasma concentration values below the LLOQ (0.1) are presented as '0' (zero) in the arithmetic mean calculations.
Treatment A: Single oral dose of 1 mg varenicline (Chantix®) administered orally;
Treatment B: Intranasal dose of 0.12 mg OC-01 (varenicline)- delivered as a 50 μL (0.06 mg) spray into each nostril.

This trial could allow us to reference certain FDA conclusions regarding the safety of varenicline tartrate from the Agency’s review of the Chantix NDA. The FDA has indicated that reliance upon the varenicline tartrate data in our 505(b)(2) NDA submission would be considered scientifically justified if exposure levels following nasal spray administration of our final clinical formulation are less than or equal to that of Chantix at its approved dose and route of administration.

MYSTIC: Phase 2 clinical trial results

The MYSTIC study was a randomized, single-masked, vehicle-controlled Phase 2 clinical trial that evaluated the safety and efficacy of OC-01 in 123 subjects with Dry Eye Disease at the Asociación para Evitar la Ceguera (APEC) in Mexico City. APEC is the largest specialized ophthalmology hospital in North America by patient volume. The study compared two different doses of OC-01 nasal spray (0.6 mg/ml or 1.2 mg/ml) to vehicle control nasal spray (1:1:1 randomization). The goal of this study was to assess the safety and efficacy of twice daily dosing of OC-01 nasal spray administered for 84 days. The pre-specified primary endpoint was the assessment of tear production as measured by mean change in Schirmer’s score at Day 84 as compared to vehicle control. The study design is included below:









14



Figure 7. MYSTIC Study Design
oyst-20191231_g10.jpg

As shown in Figure 8, a statistically significant improvement in Schirmer’s Score at Day 84 was observed in both doses as compared to placebo. The 0.6 mg/ml dose was associated with a least squares (LS) mean change from baseline Schirmer’s Score of 10.6 mm (95% CI 7.9-14.0; p<0.05), while the 1.2 mg/ml dose was associated with a least squares (LS) mean change from baseline Schirmer’s Score of 11.0 mm (95% CI 7.9-13.4; p<0.05). Results were statistically significant in both the observed and Last Observation Carried Forward analyses.

Figure 8. MYSTIC: Primary (Sign) Endpoint
oyst-20191231_g11.jpg

OC-01 was well tolerated at all doses assessed in the study with no serious adverse events reported suspected to be related to the study drug. The most commonly reported drug-related adverse events in MYSTIC were non-ocular, whereas reports of ocular adverse events were few and transient. The number of subjects reporting non-ocular treatment-emergent adverse event (TEAE) in any dose group was 6 out of 41 (14.6%) in each OC-01 nasal spray dose groups and 9 out of 41 (22.0%) in the vehicle control group. There were no reports of serious TEAE in the study and no serious adverse events related to study drug administration. The most common overall adverse events in the nasal spray groups were blurry vision, sneezing, and headache. All events were mild in the OC-01 nasal spray groups and resolved by the next visit.

Figure 9. MYSTIC: Non-Ocular Adverse Events Occurring in More than One Subject in any Treatment Group

15

oyst-20191231_g12.jpg

ONSET-2: Phase 3 clinical trial

ONSET-2 is a multicenter, dose-ranging, randomized, double-masked, placebo (vehicle)-controlled, Phase 3 clinical trial that evaluated the safety and efficacy of OC-01 in approximately 750 subjects with DED in the United States The study design is included below:
Figure 10. ONSET-2 Study Design
oyst-20191231_g13.jpg

We expect to report top-line results from this second registrational trial by the end of the second quarter 2020.

Regulatory

We met with the FDA in February 2019 for an end of Phase 2 meeting following the completion of ONSET-1, and the FDA indicated that ONSET-1 could serve as one of the two pivotal safety and efficacy studies required to support a 505(b)(2) NDA filing for OC-01. Based on this feedback, we initiated ONSET-2, a 750-subject, multicenter, randomized, double-masked, placebo-controlled Phase 3 trial, in July 2019. The objective of this study is to evaluate the safety and efficacy of OC-01 at 0.6 mg/ml and 1.2 mg/ml doses as compared to placebo on signs and symptoms of DED. Assuming the effect size seen in ONSET-1, and based on this sample size, the power for each dose for both sign and symptom endpoints would be 99% or greater. This study, in addition to ONSET-1, allows us to achieve the minimum number of subjects for safety-monitoring purposes. This study has similar eligibility criteria and design to ONSET-1.

We met with the FDA again in July 2019 for another end of Phase 2 meeting focused on Chemistry, Manufacturing, and Controls (CMC) with regard to OC-01. The purpose of this meeting was to discuss with the FDA our proposed manufacturing plan that included stability testing, microbiology testing, and the size of our drug product registration batches to support NDA submission. We will continue to engage with the FDA in an ongoing fashion on manufacturing topics as we move toward commercialization of OC-01.

Developing OC-01 for additional indications associated with and beyond DED

16

Leveraging our nAChR domain expertise, we continue to explore the development of OC-01 for a number of potential indications and uses associated with and beyond DED including neurotrophic keratitis, dry eye associated with contact lens intolerance, and ocular surface treatment for refractive surgeries.

Neurotrophic keratitis

Neurotrophic keratitis (NK) is caused when the nerves that supply the cornea cannot function properly. NK reduces sensitivity of the cornea. When the cornea senses stimulation or pressure, the eyelids will close and tears will be produced to protect the cornea and the eye. Because these nerves do not function properly in NK, the outer layer of the cornea, called the epithelium, can break down, resulting in an epithelial defect. In more advanced NK, an interior layer called the cornea stroma can break down as well, resulting in thinning of the cornea. This is called stromal “melting.” In advanced stromal melting, the cornea can thin to a severe degree, which can result in a hole or opening to the inside of the eye, which can lead to infection and potentially loss of the eye. NK can lead to a variety of complications, including poor wound healing of the cornea, scarring of the cornea, and loss of vision. There are many different conditions that can damage the nerves serving the cornea.

A variety of therapies can be used to treat this disorder depending on how far the disorder has progressed in an individual. Most recently, Oxervate, a recombinant human nerve growth factor, has been approved for the treatment of NK. Unfortunately there are several limitations to this therapy, including that the product must be refrigerated, administered six times per day at two-hour intervals for eight weeks, and delivered with a pipette that can be cumbersome for self-administration. Additionally, the cost of the product is more than $90,000 for an eight-week course of therapy.

Normal tear film contains a number of biologically active growth factors including nerve growth factor, epidermal growth factor, transforming growth factor-beta, hepatocyte growth factor, platelet-derived growth factor, vascular endothelial growth factor, fibroblast growth factor, keratinocyte growth factor, and insulin-like growth factor. We believe that stimulating natural tear film production twice daily for eight weeks may provide appropriate nourishment and lubrication that will be beneficial in treating NK. The study design is included below:

Figure 11. OLYMPIA Study Design
oyst-20191231_g14.jpg

Preclinical data for OC-01

As varenicline was previously studied by Pfizer in support of the approval of NDA 21-928 for Chantix, the appropriate preclinical studies including toxicology studies in rats, dogs, mice, and monkeys with duration of single dose to 12 months, two-year carcinogenicity studies in mice and rats, standard battery of genotoxicity studies, reproductive toxicity studies in rats and rabbits, and special toxicology studies were performed.

OC-01 pharmacodynamic assessment

We conducted a non-GLP pilot study to examine the agonist effects of OC-01 at human neuronal nAChRs subtypes by utilizing Xenopus oocytes, overexpressing human α3ß4, α3α5ß4, α4ß2, α4α6ß2 and α7 receptors, and a two-electrode voltage clamp design. Determination of the agonistic effects of OC-01 at the human α3ß4, α3α5ß4, α4ß2, α4α6ß2 and α7 nAChRs revealed that OC-01 has full agonist activity at the α7 receptor and partial agonist activity at the α3ß4, α3α5ß4, α4ß2, and α4α6ß2 receptors.

17

OC-01 toxicology studies

In support of the approval of NDA 21-928, a number of preclinical studies including toxicology studies in rats, dogs, mice, and monkeys with duration of single dose to 12 months, two-year carcinogenicity studies in mice and rats, standard battery of genotoxicity studies, reproductive toxicity studies in rats and rabbits, and special toxicology studies were performed by Pfizer. We have also conducted repeat-dose toxicity studies of OC-01 in rats and rabbits for up to 28 days and a 26-week study in Dutch Belted rabbits is ongoing. This section includes a summary of the preclinical experience with varenicline to date, although it is not an exhaustive review of all studies performed to support the approval of varenicline.

Repeat-dose, seven-day GLP toxicology studies of OC-01 administered three times daily by intranasal instillation to Sprague-Dawley rats did not result in any mortality, adverse clinical signs, macroscopic findings or microscopic findings in the nasal cavity or nasopharynx. Based on these results, the no observed adverse effect level (NOAEL) was considered to be 3.6 mg/day.

Repeat-dose, seven-day GLP toxicology studies of OC-01 in Dutch Belted Rabbits did not result in any mortality, adverse clinical signs, macroscopic findings or microscopic findings in the nasal cavity or nasopharynx when given three times daily by intranasal instillation to Dutch Belted rabbits at doses up to 12.0 mg/day. Based on these results, the NOAEL was considered to be 12.0 mg/day.

Repeat-dose, 28-day GLP toxicology studies of OC-01 administered twice daily by intranasal instillation to Sprague-Dawley rats did not result in any mortality, and no OC-01-related adverse clinical signs or changes in bodyweight, food consumption, ophthalmology, electroretinography (ERGs) and functional observational battery (FOBs) were observed during the study. Administration of OC-01 three times daily for 28 days by intranasal instillation was well tolerated in the rats at levels up to 0.9 mg/day for the males and 0.18 mg/day for the females. Repeat-dose, 28-day GLP toxicology studies of OC-01 did not result in any changes to mortality, clinical signs, body weight, food consumption, nasal assessment, ophthalmology (including ERG and intraocular pressure), Schirmer’s Score, clinical pathology, gross pathology, and histopathology when given two times daily by intranasal instillation to Dutch Belted rabbits at doses up to 8.0 mg/day. Based on these results, the NOAEL was considered to be 8.0 mg/day.

A repeat-dose, six-month GLP toxicology study in Dutch Belted rabbits completed in 2019 evaluated the potential toxicity of OC-01 when administered twice daily at doses up to 8.0 mg/day with a full report to be provided first half of 2020.

Figure 12. Completed Intranasal GLP Toxicology Studies with OC-01 (varenicline) Nasal Spray

NON-PIVOTAL STUDIES
Study TypeSpecies and StrainDuration of Dosing
Repeat-dose toxSprague-Dawley Rat7 days
Repeat-dose toxDutch Belted Rabbit7 days

PIVOTAL STUDIES
Study TypeSpecies and StrainDuration of Dosing
Repeat-dose tox with 2-week recoverySprague-Dawley Rat28 days
Repeat-dose tox with 2-week recoveryDutch Belted Rabbit28 days
Repeat-dose tox with 1-month recoveryDutch Belted Rabbit6 months


OC-02 (simpinicline)

We are also developing a second nAChR agonist product candidate OC-02 (simpinicline), which has the ability to activate the parasympathetic nervous system in a similar fashion to OC-01. OC-02 shows full agonist activity at the α3ß4, α3α5ß4, α4ß2, and α4α6ß2 receptors and weak agonist activity at the α7 receptor. We have studied OC-02 in two Phase 2b clinical trials (PEARL and RAINIER) for DED. Despite positive efficacy and safety results demonstrated in both trials, we selected OC-01 as our lead product candidate for DED due to its favorable clinical profile, the potential to leverage the 505(b)(2) regulatory pathway and significantly lower cost of development. We do not currently intend to pursue FDA approval for OC-02 in DED. However, we believe that the strong clinical data from both OC-01 and OC-02 validates this class of receptors and our mechanism of action. We believe that targeting the parasympathetic nervous system through the use of locally administered cholinergic agonists has the potential to treat a wide range of diseases and disorders. We have identified several indications other than DED where we believe
18

OC-02 could provide a meaningful benefit to patients. In certain indications, we believe OC-02 could advance directly into a Phase 2 proof of concept study, supported by the preclinical and clinical data that we and others have generated in DED as well as other systemic indications. However, we cannot guarantee that the FDA will permit us to advance OC-02 into a Phase 2 proof of concept study nor can we guarantee that the FDA will grant marketing approval to OC-02 for the treatment of any indication.

Our development program for OC-02

PEARL: Phase 2b clinical trial results

In July 2018, we reported results from PEARL, a multicenter, dose-ranging, randomized, double-masked, placebo-controlled Phase 2b clinical trial that evaluated the efficacy and preliminary safety of OC-02 in 165 patients with DED in the United States. The study compared three different doses of OC-02 to placebo. The first pre-specified co-primary (sign) endpoint was the assessment of tear production as measured by Schirmer’s Score at Day 1 and the second pre-specified co-primary (symptom) endpoint was patient-reported symptoms of DED as measured by EDS in the CAE at Week 2. The study design is included below:

Figure 13. PEARL Study Design

oyst-20191231_g15.jpg

The PEARL study was important in validating that an nAChR agonist delivered as a nasal spray could improve the signs and symptoms of DED, endpoints that had not been previously achieved in a single clinical trial by currently marketed therapies in their respective development programs. As shown in Figure 14, a statistically significant improvement in Schirmer’s Score was observed at Day 1 in all three doses compared to the vehicle-controlled placebo. The 1.1 mg/ml dose group was associated with a mean change in Schirmer’s Score of 8.6 mm (p=0.0018). A mean change in Schirmer’s Score of 17.1 mm (p<0.0001) was observed in the 5.5 mg/ml treatment group. A mean change in Schirmer’s Score of 19.3 mm (p<0.0001) was observed in the 11.1 mg/ml treatment group. The mean change in Schirmer’s Score in the control arm was observed to be 2.6 mm. Also shown in Figure 14, fellow eye results were similar.

Figure 14. PEARL: Co-Primary (Sign) Endpoint

oyst-20191231_g16.jpg
1
ANCOVA primary analysis. ITT-observed population.

19

Although the low dose of 1.1 mg/ml of OC-02 was associated with a statistically significant improvement in anesthetized Schirmer’s Score, it did not yield a statistically significant difference in the symptom endpoint of EDS (p=0.4640) as shown in Figure 15. A mean change in EDS of -16.5 mm was observed in the 5.5 ml/mg dose group (p=0.0067). A mean change in EDS of -19.0 mm was observed in the 11.1 mg/ml dose group (p=0.0006). The control arm had a mean change in EDS of -6.8 mm.

Figure 15. PEARL: Co-Primary (Symptom) Endpoint
oyst-20191231_g17.jpg

1
ANCOVA primary analysis ITT-observed population

OC-02 was observed to be well tolerated at all doses assessed in the study. Only one serious adverse event was reported and determined to be unrelated to the study drug. The most common adverse events were typical of nasal sprays (cough, throat irritation, sneezing) and were predominantly mild, transient and self-limiting.

RAINIER: Phase 2b clinical trial results

In October 2018, we reported results from RAINIER, a multicenter, randomized, double-masked, placebo-controlled, Phase 2b clinical trial that evaluated the safety and efficacy of 11.1 mg/ml OC-02 in 53 subjects with DED in the United States. At the time of the study, the sample size was limited by the amount of available OC-02. The study design is included below:

Figure 16. RAINIER Study Design

oyst-20191231_g18.jpg

The study’s sole pre-specified endpoint was the assessment of tear production as measured by anesthetized Schirmer’s Score at Week 4. As shown in Figure 17, although the results were not statistically significant for the pre-specified endpoint, OC-02 was associated with an increase in tear film production as measured by an improvement in Schirmer’s Score in the study eye at Week 4 compared to the vehicle-controlled placebo. The OC-02 treatment group had a mean change in Schirmer’s Score of 10.5 mm (p=0.076). The vehicle-controlled placebo treatment group had a mean change in anesthetized Schirmer’s Score of 5.7 mm. Also shown in Figure 17, the anesthetized Schirmer’s Score results were statistically significant in the fellow eyes of subjects (p=0.003).

Figure 17. RAINIER: Primary (Sign) Endpoint

20

oyst-20191231_g19.jpg
1
ANCOVA, Least Squares mean. ITT-observed population.

OC-02 was observed to be well tolerated at the 11.1 mg/ml dose assessed in the study. The most common adverse event in all treatment groups was sneezing, which was temporally related to the administration of the study drug and resolved soon after administration. Sneezing adverse events were characterized as mild to moderate, with no severe adverse events reported.

Preclinical data for OC-02

OC-02 pharmacodynamic assessment

A non-GLP pilot study was conducted to examine the agonist effects of OC-02 at human neuronal nAChRs subtypes by utilizing Xenopus oocytes, overexpressing human α3ß4, α3α5ß4, α4ß2, α4α6ß2 and α7 receptors with a two-electrode voltage clamp design. OC-02 was shown to be a weak agonist at the α7 receptors, evoking only 24% of the maximal acetylcholine (Ach)-evoked current at the highest dose tested. In contrast, OC-02 evoked two times the maximal Ach-evoked current at the highest dose tested at the α4ß2 receptor. Moreover, at the α3ß4 and at α3α5ß4 receptors, OC-02 was shown to evoke approximately 94% of the maximal ACh-evoked currents. OC-02 was shown to have full agonist activity at the α3ß4, α3α5ß4, α4ß2, and α4α6ß2 receptors and weak agonist activity at the α7 receptor.

OC-02 toxicology studies

Single-dose administration of the 5% dose of OC-02 in New Zealand White rabbits did not result in any test substance-related clinical observations, skin reactions inside or outside the nose, nasal reactions, gross observations at necropsy or histopathological effects for the seven-day evaluation period.

Repeat-dose, seven-day GLP toxicology studies of OC-02 did not result in any mortality, adverse clinical signs, macroscopic findings or microscopic findings in the nasal cavity or nasopharynx when given three times daily by intranasal instillation to Sprague-Dawley rats. Based on these results, the NOAEL was considered to be 6%. Repeat-dose, seven-day GLP toxicology studies of OC-02 did not result in any mortality, adverse clinical signs, macroscopic findings or microscopic findings in the nasal cavity or nasopharynx when given three times daily by intranasal instillation to New Zealand White rabbits. Based on these results, the NOAEL was considered to be 6%.

In repeat-dose, 28-day GLP toxicology studies, OC-02 was administered three times daily in Sprague-Dawley rats. There were no related adverse clinical signs or changes in bodyweight, food consumption, ophthalmology, ERGs and FOBs determined to be OC-02 related. Administration of OC-02 three times daily for 28 days by intranasal instillation was well tolerated in rats at levels up to 6%. Repeat-dose, 28-day GLP toxicology studies of OC-02 did not result in any changes to mortality, clinical signs, body weight, food consumption, nasal assessment, ophthalmology (including ERG and intraocular pressure), Schirmer’s Score, clinical pathology, gross pathology, and histopathology when given three times daily by intranasal instillation to Dutch Belted rabbits at doses up to 8.0 mg/day. Based on these results, the NOAEL was considered to be 6%.

A repeat dose, six-month GLP toxicology study in Sprague-Dawley rats completed in 2019 evaluated the potential toxicity of OC-02 when administered twice daily at doses up to 3.98 mg/day. A repeat dose, nine-month GLP toxicology study in New Zealand White rabbits completed in 2019 evaluated the potential toxicity of OC-02 when administered twice daily at doses up to 13.28 mg/day. A full report will be available in the first half of 2020.

21

Figure 18. Completed Intranasal Toxicology Studies with OC-02 (simpinicline) Nasal Spray

NON-PIVOTAL STUDIES
Study TypeSpecies and StrainDuration of Dosing
Single Dose ToxicityNew Zealand White Rabbit1 day
Repeat-dose toxSprague-Dawley Rat7 days
Repeat-dose toxNew Zealand White Rabbit7 days

PIVOTAL STUDIES
Study TypeSpecies and StrainDuration of Dosing
Repeat-dose tox with 2-week recoverySprague-Dawley Rat28 days
Repeat-dose tox with 2-week recoveryNew Zealand White Rabbit28 days
Repeat-dose tox with 1-month recoverySprague-Dawley Rat6 months
Repeat-dose tox with 1-month recoveryDutch Belted Rabbits9 months

Competition

The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition and an emphasis on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, combinability, safety profile, convenience, cost, level of promotional activity devoted to them and intellectual property protection.

A number of therapies are currently available for the treatment of DED in the United States. The most commonly used treatments for DED in the United States are over-the-counter eye drops, often referred to as “artificial tears,” and three FDA-approved prescription eye drop therapies: Restasis, Xiidra and Cequa. Artificial tears are intended to supplement insufficient tear production or improve tear film instability, but are primarily saline-based and provide only temporary relief. Restasis and Cequa, both calcineurin inhibitor immunosuppressants, and Xiidra, a LFA-1 antagonist, address chronic inflammation associated with DED. Other treatment options include ointments, gels, warm compresses, omega-3 fatty acid supplements and a number of medical devices. We are aware of many other companies developing therapies for DED, including Aerie Pharmaceuticals, Alcon, Aldeyra Therapeutics, Allergan, Aurinia Pharmaceuticals, Azura Ophthalmics, Bausch Health (Novaliq), HanAll BioPharma, Johnson & Johnson, Kala Pharmaceuticals, Mitotech, Novartis, Parion Sciences, ReGenTree, Silk Technologies, Sylentis, TopiVert Pharma, and TearSolutions.

Many of the companies against which we may compete have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

Sales and Marketing

In light of our stage of development, we have not yet established a commercial organization or distribution capabilities. If our product candidates receive marketing approval, we plan to commercialize them in the United States with a focused, specialty sales force that could consist of our own employees, outsourced sales professionals, or a hybrid model utilizing both internal and external resources. We believe that this commercial organization at the launch of OC-01 will consist of approximately 150 to 200 field sales representatives that will call on top-prescribing ophthalmologists and optometrists. We believe an organization of this size would allow us to reach ECPs that collectively care for more than 80% of patients diagnosed with DED in the United States. Given the importance of increasing awareness and educating patients with DED, we also anticipate deploying focused direct-to-consumer marketing campaigns for OC-01. We anticipate that our sales force could also support the commercialization of additional product candidates treating ocular diseases. We would expect to conduct most of the buildout of this organization following NDA approval of our product candidates. We expect to explore commercialization of OC-01 and potentially other
22

product candidates in certain markets outside the United States, including the European Union, utilizing a variety of collaboration, distribution and other marketing arrangements with one or more third parties.

Manufacturing

We do not currently own or operate facilities for manufacturing, storing, distributing or testing our product candidates. We rely, and expect to continue to rely for the foreseeable future, on third-party contract manufacturing organizations (CMOs), to manufacture and supply our preclinical and clinical materials to be used during the development of our product candidates.

The product candidate OC-01 is a presentation of varenicline, the API, formulated into a nasal spray formulation comprised of phosphate buffer to provide appropriate pH control and sodium chloride to obtain suitable osmolality for a nasal spray. We believe the amounts of the API as well as OC-01 we currently have on hand are sufficient to complete ONSET-2 and ZEN. Additional cGMP API campaigns for varenicline are in process to ensure full supply for our commercial scale-up, validation and commercial launch activities if OC-01 is approved.

The product candidate OC-02 is a presentation of simpinicline, the API, formulated into a nasal spray formulation comprised of phosphate buffer to provide appropriate pH control and sodium chloride to obtain suitable osmolality for a nasal spray. We believe that we will be able to continue to obtain the OC-02 API on commercially reasonable terms for any future clinical trials.

Although we currently rely on separate, single CMOs as our sole suppliers for both the non-clinical and clinical supply for the OC-01 API and OC-02 API under cGMP protocols and a single CMO to manufacture OC-01 and OC-02 and to perform analytical testing services, it is our intent to identify and qualify additional manufacturers to provide OC-01 API and drug product manufacturing and analytical testing services, if possible, prior to submission of the NDA for OC-01. We expect that we can easily find additional OC-01 API manufacturers as the OC-01 API is a small molecule currently being manufactured by a number of suppliers throughout the world. Additionally, the drug product manufacturing is a simple compounding and aseptic filling operation that could also be transferred to additional CMOs as necessary.

Our third-party service providers, our third-party supply chain providers, their facilities and the OC-01 and OC-02 used in our clinical trials or for commercial sale are required to be in compliance with current Good Manufacturing Practices (cGMP). The cGMP regulations govern manufacturing processes and procedures, including requirements relating to organization of personnel, buildings and facilities, equipment, control of components and packaging containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports, and returned or salvaged products. Product candidates used in late-stage clinical trials must be manufactured in accordance with cGMP requirements and satisfy FDA or other authorities’ requirements before any product is approved and before we can manufacture commercial products. Our third-party manufacturers are also subject to periodic inspections of facilities by the FDA and other authorities, including procedures and operations used in the testing and manufacture of OC-01 and OC-02 to assess compliance with applicable regulations. Our failure, or the failure to our third-party providers and supply chain providers, to comply with such statutory and regulatory requirements could subject us to possible legal or regulatory action, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, suspension of production, warning letters, the seizure or recall of products, operating restrictions and criminal prosecutions. Any of these actions could have a material impact on clinical supplies of OC-01 or our other product candidates. Contract manufacturers at times encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel.

Intellectual Property

Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates and components thereof, their methods of use and processes for their manufacture, our proprietary reagents and assays and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product candidates.

Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay by the U.S. Patent and Trademark Office (USPTO) in examining the patent application (patent term adjustment, or PTA) or extended to account for term effectively lost as a result of the FDA regulatory review period (patent term extension, or PTE), or both. In addition, we cannot provide any assurance that any
23

patents will be issued from our pending or future applications or that any issued patents will adequately protect our products or product candidates.

Our patent portfolio as of December 31, 2019 contains approximately 15 issued and unexpired U.S. patents, six pending U.S. patent applications, and two pending patent cooperation treaty (PCT) applications that are solely owned by us and certain foreign counterparts of a subset of these patents and patent applications in foreign countries, including Australia, Brazil, Canada, China, Japan, South Korea, Mexico, and countries within the European Patent Convention and the Eurasian Patent Organization. Owing to the substantial cost of prosecuting patent application internationally, we have selectively and strategically abandoned certain of our patent applications in countries with smaller markets and/or a history of weak patent enforcement record. With respect to our candidate OC-01, our patents and patent applications include methods of treatment. With respect to our candidate OC-02, our patents and patent applications cover chemical composition, synthesis and preparation, formulations, and methods of treatment. We continue to seek to maximize the scope of our patent protection for all our programs. We have five issued U.S. patents relating to methods of treating dry eye disease, increasing tear production, and improving ocular discomfort using varenicline, as well as pharmaceutical formulations for local nasal administration of varenicline. The patents are U.S. Pat. Nos.: 9,504,644, 9,504,645, 9,532,944, 9,597,284 and 10,456,396. These patents expire in 2035.

In October 2016, we purchased simpinicline, the compound we refer to as OC-02 and all of the intellectual property rights in and to such compound, including the related know-how and patents, pursuant to an asset purchase agreement, which was subsequently amended in November 2016 and May 2017 (as amended, the OC-02 Agreement). Under the OC-02 Agreement we are obligated to make milestone payments of up to an aggregate of $37.0 million upon achievement of certain development and regulatory milestone events. In March 2018, we made a payment of $1.5 million upon completion of the first of these milestones. The next milestone payment is payable on the first dosing of a patient in a Phase 3 clinical trial of OC-02. Under the OC-02 Agreement, we are also obligated to make royalty payments at a mid-single digit percentage rates on net worldwide sales of the covered products. In addition, we are required to pay 15% of any (i) licensing revenue we receive that is related to OC-02 and (ii) revenue received from the sale of OC-02, up to a maximum aggregate amount of $10.0 million. We do not currently receive any licensing or sales revenue for OC-02.

We believe that we have certain know-how and trade secrets relating to our technology and product candidates. We rely on trade secrets to protect certain aspects of our technology related to our current and future product candidates. However, trade secrets can be difficult to protect. We seek to protect our trade secrets, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, service providers, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems.

Licenses

On October 18, 2019, we entered into a non-exclusive patent license agreement (the License Agreement) with Pfizer. Pursuant to the License Agreement, Pfizer granted us non-exclusive rights under Pfizer’s patent rights covering varenicline tartrate and related salts thereof, including U.S. Patent Nos.: 7,265,119 and 6,890,927 to develop, manufacture, and commercialize our OC-01 varenicline product candidate for the treatment of any ophthalmic disease or condition via nasal administration in the United States.

Under the terms of the agreement, we made an upfront payment to Pfizer of $5.0 million. If we successfully commercialize OC-01, we may be required to pay to Pfizer a single milestone payment in the very low double-digit millions if we achieve a specified level of annual aggregate net sales of OC-01 within a specified timeframe. We will also be required to pay Pfizer tiered royalties on net sales of OC-01 by us, our affiliates, or sublicensees, at percentages ranging from the mid-single digits to the mid-teens. Our royalty obligation to Pfizer will commence upon first commercial sale of OC-01 and will expire upon the later of (a) the expiration of all regulatory or data exclusivity granted to Pfizer in connection with varenicline in the United States; and (b) the expiration or abandonment of the last valid claims of the licensed patents.

The License Agreement will terminate when all claims in all the licensed patents expire or are irretrievably abandoned, which we expect to be no later than August 2022. The License Agreement may be terminated earlier by us for any reason, or by Pfizer upon 60 days’ written notice for our uncured material breach (30 days in the case of non-payment), or immediately upon our insolvency.

Regulatory Pathway

Varenicline tartrate is currently marketed by Pfizer in the United States under the trade name Chantix as an aid to smoking cessation treatment. We have filed an Investigational New Drug Application (IND) with the FDA to study varenicline for the
24

treatment of the signs and symptoms of dry eye disease and intend to submit a 505(b)(2) NDA, relying in part upon certain FDA conclusions regarding the safety of varenicline from the Agency’s review of the Chantix NDA.

Government Regulation

Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.

U.S. Drug Regulation

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations. FDA approval is required before any new unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. Drugs also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-marketing may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA’s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal fines or penalties. Any agency or judicial enforcement action could have a material adverse effect on our business, market acceptance of our products, and our reputation.

Our product candidates are considered small molecule drugs and must be approved by the FDA through the NDA process before they may be legally marketed in the United States. The process generally involves the following:

•completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in accordance with good laboratory practice (GLP) requirements;

•submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin and must be updated annually or when significant changes are made;

•approval by an independent institutional review board (IRB) or independent ethics committee at each clinical trial site before each trial may be initiated;

•performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (GCP) requirements and other clinical trial-related regulations to establish substantial evidence of the safety and efficacy of the investigational product for each proposed indication;

•submission to the FDA of an NDA;

•a determination by the FDA within 60 days of its receipt of an NDA to accept the filing for review;

•satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with current good manufacturing practice (cGMP) requirements, and of selected clinical investigational sites to assess compliance with GCD;

•potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA filing;

•payment of user fees for FDA review of the NDA;

•FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States; and

25

•compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (REMS), and the potential requirement to conduct post-approval studies.

The data required to support an NDA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process can take many years and the actual time required to obtain approval, if any, may vary substantially based upon the type, complexity and novelty of the product or condition being treated.

Preclinical Studies and IND Submission

Before testing any drug product candidate in humans, the product candidate must undergo rigorous preclinical testing. The preclinical developmental stage generally involves laboratory evaluations of drug chemistry, formulation and stability, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND is a request for authorization from the FDA to administer an investigational product to humans, and must become effective before human clinical trials may begin.

An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development along with any subsequent changes to the investigational plan.

Clinical Trials

The clinical stage of development involves the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor’s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries, including the website maintained by the U.S. National Institutes of Health, ClinicalTrials.gov.

A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection, if deemed necessary, and the practice of medicine in the foreign country is consistent with the United States.

Clinical trials in the United States generally are conducted in three sequential phases, known as Phase 1, Phase 2 and Phase 3. Although the phases are usually conducted sequentially, they may overlap or be combined.

26

•Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug in humans, the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness.
•Phase 2 clinical trials generally involve studies in disease-affected patients to determine the dose and dosing schedule required to produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted.
•Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the safety and effectiveness of the product for its intended use and to establish the overall benefit/risk relationship of the product to provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing.

Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.

Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol.

Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal safety studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of our product candidates. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their labeled shelf life.

NDA Review

Following completion of clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling, chemistry and manufacturing information in a request for approval to market the drug for one or more specified indications. The application must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product’s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the United States.

Under the Prescription Drug User Fee Act (PDUFA), as amended, each NDA must be accompanied by an application user fee. FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for each marketed human drug. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a qualifying small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.

The FDA reviews all submitted NDAs before it accepts them for filing to determine if they are sufficiently complete to permit a substantive review, and the FDA may request additional information rather than accepting the NDA for filing. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the
27

FDA begins an in-depth review of the NDA. Under PDUFA, the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, standard review and priority review. According to PDUFA performance goals, the FDA endeavors to review applications subject to standard review within ten to twelve months, whereas the FDA’s goal is to review priority review applications within six to eight months, depending on whether the drug is a new molecular entity. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification.

Before approving an NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA also closely analyzes the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data, including the potential requirement to conduct additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing changes. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.

Section 505(b)(2) New Drug Applications

Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy conducted by or on behalf of the applicant. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA’s prior findings of safety and efficacy for an existing product, or published literature, in support of its application.

505(b)(2) NDAs often provide an alternate path to FDA approval for new or improved formulations, new routes of administration, or new uses of previously approved products. If the Section 505(b)(2) applicant can establish that reliance on the FDA’s prior findings of safety and/or effectiveness is scientifically appropriate, it may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new product candidate for all, or some, of the indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant.

To the extent that the Section 505(b)(2) applicant is relying on the FDA’s prior findings of safety or effectiveness for an already approved product, the applicant is required to provide a certification to the FDA concerning each patent listed for the approved product in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). Depending on the type of certification, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, listed in the Orange Book for the reference product, such as the 5 years of exclusivity for obtaining approval of a new chemical entity has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit brought by the holder of the listed patent, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant.

Post-Approval Requirements

Following approval of a new product, the product is subject to continuing regulation by the FDA, including, among other things, requirements relating to facility registration and drug listing monitoring and record-keeping adverse event and other periodic reporting, product sampling and distribution, and product promotion and advertising including restrictions on promoting
28

drugs for unapproved uses or patient populations, known as “off-label use,” and limitations on industry-sponsored scientific and educational activities. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. Further, if there are any modifications to the drug, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical trials.

The FDA may also place other conditions on approvals including the requirement for REMS, to assure the safe use of the product. If the FDA concludes that a REMS is needed, the NDA sponsor must submit a proposed REMS. The FDA will not approve the FDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.

FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP regulations. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation, and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, its manufacturer or the NDA holder, including recalls.

The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay drug distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

•restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market, or product recalls;

•fines, warning letters, or holds on post-approval clinical trials;

•refusal of the FDA to approve pending applications or supplements to approved applications;

•suspension or revocation of product approvals;

•product seizure or detention, or refusal to permit the import or export of products; or

•injunctions or the imposition of civil or criminal penalties.

Other Regulatory Matters

Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Manufacturing, sales, promotion and other activities following product approval are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including CMS, other divisions of the Department of Health and Human Services, the Department of Justice, the
29

Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety & Health Administration, the Environmental Protection Agency, and state and local governments.

For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. These laws include the following:
•the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;
•the federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act that can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
•the Federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

•federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

•the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;

•the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members; and

•analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non- governmental third-party payors, including private insurers, state laws that require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws that require biotechnology companies to report information on the pricing of certain drug products, and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.

30

The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.

The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative penalties, including damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts.

U.S. Patent-Term Restoration and Marketing Exclusivity

Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product’s approval date. The patent-term restoration period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever is later, and the submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.

Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (ANDA) or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.

European Union Drug Development

Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the European Union Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA) and one or more Ethics Committees (ECs). Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred.

The EU clinical trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency. Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU.

31

European Union Drug Review and Approval

In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of marketing authorizations.

•The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the EMA, and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the European Union.

•National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the European Union, this National MA can be recognized in another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned).

Under the above described procedures, before granting the MA, EMA or the competent authorities of the Member States of the European Union make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. Similar to the U.S. patent term-restoration, Supplementary Protection Certificates (SPCs) serve as an extension to a patent right in Europe for up to five years. SPCs apply to specific pharmaceutical products to offset the loss of patent protection due to the lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval.

Coverage and Reimbursement

Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance, and managed healthcare organizations. There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS’s decisions regarding coverage and reimbursement to a substantial degree. However, no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis.

Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.

32

In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.

Healthcare Reform

The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution of generic products for branded prescription drugs. For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was passed which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies’ share of sales to federal health care programs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate agreement with the HHS Secretary as a condition for states to receive federal matching funds for the manufacturer’s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers’ rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP and adding a new rebate calculation for “line extensions” (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. Effective April 1, 2020, Medicaid rebate liability will be expanded to include the territories of the United States as well. Additionally, for a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.

Some of the provisions of the ACA have yet to be implemented, and there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have passed. On December 22, 2017, President Trump signed into law new federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (the Tax Act) which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare Part D drug plans. In July 2018, CMS published a final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case to the District Court to determine whether the remaining provisions of the ACA are invalid. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA.

33

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations.

Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the Trump administration released a “Blueprint” to lower prescription drug prices and reduce out-of-pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out-of-pocket costs of drug products paid by consumers. Additionally, on January 31, 2019, HHS Office of Inspector General (OIG) issued proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufactures to Medicare Part D plan sponsors, Medicaid managed care organizations, and those entities’ pharmacy benefit managers, the purpose of which is to further reduce the cost of drug products to consumers. On October 9, 2019, HHS, OIG and CMS issued two proposed rules that set forth modifications to the Federal Anti-Kickback Statute, Civil Monetary Penalties Law and Physician Self-Referral Law (or the Stark Law) regulations to promote value-based and coordinated care arrangements. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

Moreover, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment limitations in setting their own payment rates.

Research and Development

We recognized $33.6 million and $13.8 million of research and development expenses in the years ended December 31, 2019 and 2018, respectively.

Financial Information about Segments

We operate and manage our business as one reportable operating segment. Our Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. See "Note 1- Organization and Summary of Significant Accounting Policies" in the notes to the financial statements included elsewhere in this Annual Report on Form 10-K.

Employees

As of December 31, 2019, we had 30 full-time employees, 17 of whom were engaged in research and development activities. None of our employees are represented by a labor union or covered under a collective bargaining agreement.

Corporate Information

34

We were incorporated in Delaware in June 2015. We were spun out from Oculeve, Inc., a Delaware corporation focused on the treatment of dry eye disease, prior to its acquisition by Allergan. Our principal executive offices are located at 202 Carnegie Center, Suite 109, Princeton, New Jersey 08540. Our telephone number is (609) 382-9032. Our website address is www.oysterpointrx.com. We also use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

We file electronically with the SEC our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make available on our website at www. oysterpointrx.com, free of charge, copies of these reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The public may read or copy any materials we file with the SEC at the SEC's Public Reference Room at 100 F Street NE, Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. The address of that website is www.sec.gov. The information in or accessible through the SEC and our website or social media sites does not constitute part of this Annual Report on Form 10-K or any other report or document we file with the SEC, and any references to our website and social media sites are intended to be inactive textual references only.

Oyster Point, the Oyster Point logo and our other registered or common law trademarks appearing in this periodic report are the property of Oyster Point Pharma, Inc. This periodic report contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this periodic report, including logos, artwork and other visual displays, may appear without the ® or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.

ITEM 1A. RISK FACTORS

Investing in our common stock involves a high degree of risk. Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K and in other documents that we have filed and will file with the SEC, in evaluating our company and our business. Additional risks and uncertainties not presently known to us or that we currently see as immaterial may also harm our business. If any of these risks occur, our business, growth prospects, operating results and financial condition could be materially and adversely affected, the trading price of our common stock could decline and you could lose part or all of your investment.


Risks Related to Our Business

We are a clinical stage biopharmaceutical company with limited operating history. We have incurred significant losses and negative cash flows from operations since our formation, and we anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.

We are a clinical stage biopharmaceutical company with a limited operating history. Our operations to date have been limited to organizing our company, raising capital and developing our product candidates. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history. In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition from a company with a clinical development focus to a company capable of supporting commercial activities. We have not yet demonstrated our ability to successfully obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization, and we may not be successful in such a transition.

We do not have any products approved for sale, we have not generated any revenue and have incurred net losses in each reporting period since our company’s formation. We have funded our operations primarily from the sale and issuance of our securities. Our net losses were $45.7 million and $16.5 million for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, we had an accumulated deficit of $84.2 million. Additionally, the net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indicator of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.

35

We expect to continue incurring significant expenses and increasing operating losses for the foreseeable future. We expect that our expenses will increase substantially if and as we:

•initiate additional preclinical, clinical and other studies for our product candidates or expand or modify existing studies or currently planned studies;
•change or add additional manufacturers or suppliers, some of which may require additional permits or other governmental approvals;
•create additional infrastructure to support our operations as a public company and our product development and planned future commercialization efforts;
•seek marketing approvals and reimbursement for our product candidates;
•establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval;
•seek to identify and develop additional product candidates;
•acquire or in-license other product candidates and technologies;
•make milestone or other payments in connection with the development or approval of our product candidates;
•maintain, protect, and expand our intellectual property portfolio; and
•experience any delays or encounter issues with any of the above.

Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability.

We are highly dependent on the success of our lead product candidate OC-01 for the treatment of dry eye disease. If we are unable to successfully complete our clinical development program for OC-01 and obtain the marketing approvals necessary to commercialize OC-01 or experience significant delays in doing so, or if after obtaining marketing approvals, we fail to commercialize this product candidate, our business will be materially harmed.

We have devoted a significant portion of our financial resources and business efforts to the development of OC-01 for the treatment of dry eye disease (DED). Although we are also developing OC-01 for other indications and a second product candidate OC-02, we do not anticipate receiving marketing approvals for any product candidates other than OC-01 in the next several years. Our ability to generate revenues from product sales will depend on our obtaining marketing approval for and commercializing OC-01, and we cannot accurately predict when or if OC-01 will be proven to be effective or safe in humans or whether it will receive marketing approval for DED or a secondary indication. Because we have focused our resources and efforts on developing OC-01 for DED, we have limited resources and may fail to commit adequate resources to, or delay the pursuit of opportunities for, other indications or other product candidates that may have greater commercial potential, and our resource allocation decisions may cause us to fail to capitalize on viable product candidates and profitable market opportunities. If we fail to successfully develop OC-01 for DED, we may not be able to identify, assess and develop OC-01 for other indications or OC-02 or a second lead product candidate or other product candidates on a timely basis, which could materially affect our business, financial condition, results of operations and growth prospects.

Our business depends entirely on the successful discovery, development and commercialization of OC-01, OC-02 and other future product candidates. We currently generate no revenues from sales of any products and may never generate revenue or be profitable.

We have no products approved for commercial sale and do not anticipate generating any revenue until either OC-01 or another product candidate receives the regulatory and marketing approvals necessary for commercialization. Our ability to generate revenue and achieve profitability depends significantly on our ability, or any future collaborator’s ability, to achieve a number of objectives, including:

•successful and timely completion of preclinical and clinical development of our product candidates, including OC-01, OC-02 and any other future product candidates;

•establishing and maintaining relationships with contract research organizations (CROs) and clinical sites for the clinical development, both in the United States and internationally, of our product candidates, including OC-01, OC-02 and any other future product candidates;

•timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development;

36

•making any required post-marketing approval commitments to applicable regulatory authorities;

•establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for product candidates that we develop, if approved;

•successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators;

•a continued acceptable safety profile both prior to and following any marketing approval of our product candidates;

•commercial acceptance of our product candidates by patients, the medical community and third-party payors;

•identifying, assessing and developing new product candidates;

•obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;

•protecting our rights in our intellectual property portfolio;

•defending against third-party interference or infringement claims, if any;

•obtaining favorable terms in any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our existing or acquired product candidates;

•obtaining coverage and adequate reimbursement by hospitals, government and third-party payors for product candidates that we develop;

•addressing any competing therapies and technological and market developments; and

•attracting, hiring and retaining qualified personnel.

We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability, or comparable to the revenues of existing therapies, including Restasis and Xiidra. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business, retain key employees and continue our operations.

Our lead product candidate OC-01 is based on an active pharmaceutical ingredient (API) that is already on the market, which exposes us to additional risks.

The API in OC-01, varenicline (in the form of varenicline tartrate), has been previously approved by the FDA and the EMA as an oral tablet under the trade name Chantix, an aid to smoking cessation treatment, and is available in more than 80 countries throughout the world. From 2009 to 2016, the FDA required Chantix to carry a boxed warning advising consumers of potential serious mental health side effects from Chantix. Although the FDA removed this box warning from Chantix in 2016 in response to the EAGLES study sponsored by Pfizer, regulatory authorities may identify other adverse side effects related to varenicline in the future or may add back the warning. Additionally, we anticipate that manufacturers will begin selling varenicline in generic form in the future, which could lead to increased use of varenicline by patients and increase the possibility that patients experience adverse side effects related to varenicline. Any adverse side effects that arise from the use of any form of varenicline, whether Chantix, generic varenicline or our product candidate, or reporting thereof could prevent or inhibit the commercialization of OC-01 and seriously harm our business. Furthermore, if manufacturer demand for varenicline increases in the future, particularly as a result of generic forms of varenicline becoming available, we may not be able to continue to obtain varenicline on commercially reasonable terms, which would seriously harm our business.

OC-01 uses a novel and unproven therapeutic approach and mechanism of action to treat DED and therefore its efficacy and safety are difficult to predict, and there is no guarantee that OC-01 or any other product candidates will be approved by the FDA.

37

We are developing OC-01 as a preservative-free, aqueous nasal spray that will stimulate the lacrimal functional unit (LFU) to produce natural tear film. To our knowledge, OC-01 represents the first pharmacological treatment approach for DED that is aimed at stimulating the LFU. Other than with respect to data from studies and trials of OC-01 and OC-02, there is limited or no clinical evidence showing that natural tear film can be produced through the stimulation of the LFU. For instance, even though OC-01 has shown promising results in preclinical studies and prior clinical trials, we may not succeed in demonstrating safety and efficacy of OC-01 in larger-scale clinical trials, including ONSET-2, our ongoing Phase 3 clinical trial, or for other indications, including OLYMPIA, our upcoming Phase 2 clinical trial for neurotrophic keratitis (NK).

Advancing OC-01 as a novel product creates significant challenges for us, including:

•obtaining marketing approval;

•educating medical personnel, including eye care practitioners (ECPs), and patients regarding the potential efficacy and safety benefits, as well as the challenges, of incorporating our product candidates, if approved, into treatment regimens; and

•establishing the sales and marketing capabilities upon obtaining any marketing approvals to gain market acceptance.

We cannot guarantee that OC-01 or any of our other future product candidates will be approved by the FDA. Product candidates in later-stage clinical trials often fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, EMA and other comparable foreign regulatory authorities despite having successfully progressed through preclinical studies and other clinical trials. In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. For example, although we expect to enroll a subject population with similar eligibility criteria, OC-01 may not demonstrate the same or similar statistically significant results in ONSET-2 as it demonstrated in ONSET-1, our Phase 2b clinical trial, MYSTIC, our Phase 2 long-term chronic efficacy study, ZEN, our comparative pharmacokinetic “bridge” trial, or our other clinical trials. Additionally, we cannot guarantee that the safety profile of OC-01 in healthy volunteers and patients with DED will be replicated in trials and studies for other indications, such as NK. Assessments of efficacy can vary widely for a particular participant, and from participant to participant and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. In addition, participants treated with OC-01 may also be treated with other investigational drugs, prescription drugs or even over-the-counter treatments following the treatment period of our OC-01 studies, any of which can cause side effects or adverse events that are unrelated to our product candidate, but which are observed during the long-term safety follow-up for OC-01. The occurrence of such side effects or adverse events could have a negative impact on OC-01’s safety profile.

Drug development is a highly uncertain undertaking and involves a substantial degree of risk. The outcome of preclinical testing and earlier clinical trials may not be predictive of the success of later clinical trials. The results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidate.

Research and development of biopharmaceutical products is inherently risky. We cannot give any assurance that any of our product candidates will receive regulatory, including marketing, approval, which is necessary before they can be commercialized. Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical studies and clinical trials that our product candidates are both safe and effective for use in each target indication. Product candidates in later stages of clinical trials may fail to show the desired safety, efficacy and durability profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization.

Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical and clinical studies of our product candidates may not be predictive of the results of early-stage or later-stage clinical trials, and results of early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. The results of clinical trials in one set of subjects may not be predictive of those obtained in another. In some instances, there can be significant variability in safety, efficacy or durability results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants.

38

We may also experience issues in implementing our clinical trials that would delay or prevent us from satisfying the applicable requirements of the FDA and other regulatory authorities, including:

•the number of participants required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;

•our third-party contractors may fail to comply with regulatory requirements or meet their obligations to us in a timely manner, or at all;

•other regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; and

•we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites.

We may be unable to design and execute clinical trials that support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. For example, use of OC-01 requires the patient to follow a prescribed technique to administer the nasal spray. Failure to properly administer the nasal spray by the patient or inappropriate technique demonstration by the ECP, may adversely affect the outcome of OC-01 in demonstrating efficacy in one or more clinical trials. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could materially affect our business, financial condition, results of operations and growth prospects.

In addition, even if such clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential.

If we experience delays or difficulties in the enrollment of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of subjects to participate in these trials to such trial’s conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. Any difficulties we experience relating to enrollment in ONSET-2 could delay regulatory approval for OC-01.

Patient enrollment may be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and subjects who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors’ product candidates. Patient enrollment for any of our future clinical trials may be affected by other factors, including:

•size and nature of the patient population;

•severity of the disease under investigation;

•availability and efficacy of approved drugs for the disease under investigation;

•participant eligibility criteria for the trial in question as defined in the protocol;

•perceived risks and benefits of the product candidate under study;

•ECPs’ and participants’ perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;

39

•efforts to facilitate timely enrollment in clinical trials;

•participant referral practices of ECPs;

•the ability to monitor participants adequately during and after treatment;

•proximity and availability of clinical trial sites for prospective trial subjects;

•continued enrollment of prospective subjects by clinical trial sites; and

•the risk that subjects enrolled in clinical trials will drop out of the trials before completion.

Our inability to enroll a sufficient number of subjects for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of subjects for our clinical trials, we may have difficulty maintaining enrollment of such subjects in our clinical trials.

Our current or future product candidates may cause or reveal significant adverse events, toxicities or other undesirable side effects which may delay or prevent marketing approval. In addition, if we obtain approval for any of our product candidates, significant adverse events, toxicities or other undesirable side effects may be identified during post-marketing surveillance, which could result in regulatory action or negatively affect our ability to market the product.

Adverse events or other undesirable side effects caused by or associated with treatment by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, EMA or other comparable foreign regulatory authorities.

During the conduct of clinical trials, subjects report changes in their health, including illnesses, injuries, and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. It is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational products are tested in large-scale, Phase 3 clinical trials or, in some cases, after they are made available to subjects on a commercial scale after approval.

The most commonly reported adverse events in ONSET-1, ZEN and MYSTIC were non-ocular in nature, which were sneezing and coughing. If approved, we expect that OC-01 will be used chronically over a prolonged period of time. However, we have no clinical safety data on patients treated with OC-01 for longer than 84 days and these adverse events are subjective and based on subjects' self-report, which may not accurately reflect the actual number of adverse events. Our understanding of the relationship between our product candidates and these adverse events may change as we gather more information, and additional unexpected adverse events may occur. If additional clinical experience indicates that OC-01 or any other product candidate has side effects or causes serious or life- threatening side effects, participant recruitment for studies and the ability of enrolled subjects to complete studies could be negatively impacted, and the development of the product candidate may fail or be delayed, which would severely harm our business, growth prospects, operating results and financial condition.

Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects or adverse events caused by such products, a number of potentially significant negative consequences could result, including but not limited to:

•regulatory authorities may withdraw approvals of such product or require additional warnings on the label;

•we may be required to change the way the product is administered or conduct additional clinical trials or post-approval studies;

•we may be required to create a Risk Evaluation and Mitigation Strategy (REMS) plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, including ECPs, and/or other elements to assure safe use;

•we could be sued and held liable for harm caused to patients; and

40

•our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could materially affect our business, financial condition, results of operations, and growth prospects.

Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between interim data and final data could materially affect our business, financial condition, results of operations and growth prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize our product candidates may be harmed, which could materially affect our business, financial condition, results of operations and growth prospects.

Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.

To succeed, we must recruit, retain, manage and motivate qualified executives as we build out the management team, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and need to continue to add executives with operational and commercialization experience as we plan for commercialization of our product candidates and build out a leadership team that can manage our operations as a public company. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts.

Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed.

If we engage in acquisitions, in-licensing or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.

We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including:

41

•increased operating expenses and cash requirements;

•the assumption of indebtedness or contingent liabilities;

•the issuance of our equity securities which would result in dilution to our stockholders;

•assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel;

•the diversion of our management’s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership;

•retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;

•risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and

•our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs.

In addition, if we undertake such a transaction, we may incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense.

We expect to significantly expand our organization, including building sales and marketing capability and creating additional infrastructure to support our operations as a public company, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of sales and marketing and finance and accounting. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and our limited experience in managing such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert or stretch our management and business development resources in a way that we may not anticipate. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

Our business and operations would suffer in the event of security breaches, system failures and other disruptions.

Despite the implementation of security measures, our computer systems, as well as those of our contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), terrorism, war and telecommunication and electrical failures. The application and data we possess contain critical information, including research and development information, commercial information, personal information about our employees and consultants, and business and financial information. Protecting this critical information includes risks, including loss of access risk, inappropriate disclosure risk, inappropriate modification risk and the risk of being unable to adequately monitor our internal controls to prevent security breaches, system failures and other cybersecurity disruptions.

If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product candidate development programs. For example, the loss of preclinical study or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed.

The secure processing, storage, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the
42

information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, and such an event could disrupt our operations, damage our reputation, and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay clinical development of our product candidates.

Furthermore, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business.

Internal computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer other breakdowns, cyber-attacks or information security breaches that could compromise the confidentiality, integrity, and availability of such systems and data, expose us to liability, and affect our reputation.

We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. We also rely on third party vendors and their information technology systems. Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants may be vulnerable to damage from computer viruses or unauthorized access, or breached due to operator error, malfeasance or other system disruptions. As the cyber-threat landscape evolves, these attacks are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to detect. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack. Cyber-threats may be generic, or they may be custom-crafted against our information systems. Over the past few years, cyber-attacks have become more prevalent, intense, sophisticated and much harder to detect and defend against. Such attacks could include the use of key loggers or other harmful and virulent malware, including ransomware or other denials of service, and can be deployed through malicious websites, the use of social engineering and/or other means. We and our third party vendors may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources. Although to our knowledge we and our vendors have not experienced any such material system failure or security breach to date, if a breakdown, cyber-attack or other information security breach were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations , whether due to a loss of trade secrets or other proprietary information or other similar disruption and we could incur liability and reputational damage. For example, the loss of clinical trial data from completed, ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on our third-party research institution collaborators for research and development of our product candidates and other third parties for the manufacture of our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business.

Cyber-attacks, breaches, interruptions or other data security incidents could result in legal claims or proceedings, liability under federal or state laws that protect the privacy of personal information, regulatory penalties, significant remediation costs, disrupt key business operations and divert attention of management and key information technology resources. In the United States, notice of breaches must be made to affected individuals, the U.S. Secretary of the Department of Health and Human Services, or HHS, and for extensive breaches, notice may need to be made to the media or U.S. state attorneys general. Such a notice could harm our reputation and our ability to compete. The HHS has the discretion to impose penalties without attempting to resolve violations through informal means. In addition, U.S. state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. There can be no assurance that we, our collaborators, CROs, vendors, and any other business counterparties will be successful in efforts to detect, prevent, protect against or fully recover systems or data from all break-downs, service interruptions, attacks or breaches of systems. In addition, we do not maintain standalone cyber-security insurance and have limited insurance coverage in the event of any breach or disruption of our or our collaborators’, CROs’, or vendors’ systems, including any unauthorized access or loss of any personal data that we may collect, store or otherwise process. The costs related to significant security breaches or disruptions could be material and exceed the limits of any insurance coverage we may have. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems, or inappropriate disclosure of confidential or proprietary information, including data related to our personnel, we could incur liability and the further development and commercialization of our product candidates could be delayed and our business and operations could be adversely affected and/or could result in the loss or disclosure of critical or sensitive data, which could result in financial, legal, business or reputational harm to us.

Our business is subject to complex and evolving U.S. and foreign laws and regulations, information security policies and contractual obligations relating to privacy and data protection, including the use, processing, and cross-border transfer of personal information. These laws and regulations are subject to change and uncertain interpretation, and could result in claims, changes to our business practices, or monetary penalties, and otherwise may harm our business.

43

We receive, generate and store significant and increasing volumes of sensitive information and business-critical information, including employee and personal data (including protected health information), research and development information, commercial information, and business and financial information. We heavily rely on external security and infrastructure vendors to manage our information technology systems and data centers. We face a number of risks relative to protecting this critical information, including loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data.

A wide variety of provincial, state, national, and international laws, and regulations apply to the collection, use, retention, protection, disclosure, transfer and other processing of personal data. These data protection and privacy-related laws and regulations are evolving and may result in ever-increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions. For example, the collection and use of personal data in the European Union are governed by the European Union General Data Protection Regulation ("GDPR"), which became fully effective on May 25, 2018. The GDPR imposes stringent data protection requirements, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries and in the context of clinical trials, we currently rely on patient informed consent as the legal basis for such transfers. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. The GDPR provides for penalties for noncompliance of up to the greater of €20 million or four percent of worldwide annual revenues. The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with any European Union clinical trials. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and growth prospects.

Further, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations that impose restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. These laws and regulations are not necessarily preempted by HIPAA, particularly if a state affords greater protection to individuals than HIPAA. Where state laws are more protective, we have to comply with the stricter provisions. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal information has been misused. For example, California recently enacted legislation, the California Consumer Privacy Act ("CCPA"), that will, among other things, require covered companies to provide new disclosures to California consumers, and afford such consumers new abilities to opt-out of certain sales of personal information, that became effective on January 1, 2020. The CCPA was amended several times throughout 2018 and 2019, and it is unclear whether further modifications will be made to this legislation or how it will be interpreted. In addition, the CCPA requires covered companies to provide new disclosures to individuals and consumers in California, and afford such individuals and consumers new data protection rights, including the ability to opt-out of certain sales of personal information. The GDPR, CCPA and many other laws and regulations relating to privacy and data protection are still being tested in courts, and they are subject to new and differing interpretations by courts and regulatory officials. Additionally, the interplay of federal and state laws may be subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and data we receive, use and share, potentially exposing us to additional expense, adverse publicity and liability. We are working to comply with the GDPR, CCPA and other privacy and data protection laws and regulations that apply to us, and we anticipate needing to devote significant additional resources to complying with these laws and regulations.

It is possible that the GDPR, CCPA or other laws and regulations relating to privacy and data protection may be interpreted and applied in a manner that is inconsistent from jurisdiction to jurisdiction or inconsistent with our current policies and practices and compliance with such laws and regulations could require us to change our business practices and compliance procedures in a manner adverse to our business. We cannot guarantee that we are in compliance with all such applicable data protection laws and regulations and we cannot be sure how these regulations will be interpreted, enforced or applied to our operations. Furthermore, other jurisdictions outside the European Union are similarly introducing or enhancing privacy and data security laws, rules, and regulations, which could increase our compliance costs and the risks associated with noncompliance. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices and our efforts to comply with the evolving data protection rules may be unsuccessful. We cannot guarantee that we or our vendors may be in compliance with all applicable international laws and regulations as they are enforced now or as they evolve. For example, our privacy policies may be insufficient to protect any personal information we collect or may not comply with applicable laws. Our non-compliance could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies,
44

procedures and systems. In addition, if we are unable to properly protect the privacy and security of protected health information, we could be found to have breached our contracts.

Our actual or perceived failure to adequately comply with applicable laws and regulations relating to privacy and data protection, or to protect personal data and other data we process or maintain, could result in regulatory enforcement actions against us, including fines, imprisonment of company officials and public censure, claims for damages by affected individuals, other lawsuits or reputational and damage, all of which could materially affect our business, financial condition, results of operations and growth prospects.

Risks Related to Development and Commercialization of Our Product Candidates

Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes, and results of earlier studies and trials may not be predictive of future results. If clinical trials of our product candidates, particularly OC-01, are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all.

Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates in humans. To date, we have focused substantially all of our efforts and financial resources on identifying, acquiring, and developing our product candidates, including conducting preclinical studies and initial clinical trials. Clinical testing is expensive and can take many years to complete, and we cannot be certain that any clinical trials will be conducted as planned or completed on schedule, if at all. Our inability to successfully complete preclinical and clinical development could result in additional costs to us and negatively impact our ability to generate revenue. Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize product candidates. We currently generate no revenues from sales of any products, and we may never be able to develop or commercialize a marketable product.

Each of our product candidates will require additional clinical development, management of clinical, preclinical and manufacturing activities, regulatory approval in multiple jurisdictions, achieving and maintaining commercial-scale supply, building of a commercial organization, substantial investment and significant marketing efforts before we generate any revenues from product sales. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We may experience delays in our ongoing clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all.

We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize OC-01 or any other product candidates that we may develop, including:

•we may experience delays in or failure to reach agreement on acceptable terms with prospective CROs and clinical sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•we may fail to obtain sufficient enrollment in our clinical trials or participants may fail to complete our clinical trials;

•clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;

•we may decide, or regulators or institutional review boards may require us, to suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;

•regulators or institutional review boards may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval;

•regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate;

•the cost of clinical trials of our product candidates may be greater than we anticipate, and we may need to delay or suspend one or more trials until we complete additional financing transactions or otherwise receive adequate funding;

45

•the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate or may be delayed;

•our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate trials; and

•regulatory authorities may suspend or withdraw their approval of a product or impose restrictions on its distribution.

We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations.

We are in the process of validating our manufacturing process and to date, do not have the stability and microbiology data on our product registration batches necessary for regulatory approval for OC-01.

We are still currently collecting stability and microbiology data on our product registration batches to support NDA approval and to date we do not yet have data to support an NDA filing. We expect to report top-line results for ONSET-2 by the end of the second quarter 2020 and if results are considered approvable, we plan to submit an NDA to the FDA in the second half of 2020. However, we manufactured our FDA registration batches of 0.6 mg/ml and 1.2 mg/ml OC-01 nasal spray July and August 2019, and as the FDA requires 12 months stability data to support NDA filing, the data will not be available until after August 2020. Stability data is collected after subjecting our batches to various conditions, such as refrigeration, room temperature, and high temperatures, and it is possible that impurities, particulates, leachables, microbiology, and/or degradation of the active pharmaceutical ingredient, varenicline, or OC-01 nasal spray could occur or other issues could be detected. If the stability data is not acceptable, we may need to change our manufacturing process, which could result in a delay of the NDA submission or impact the approval of the product or both, which could materially affect our business, financial condition, results of operations and growth prospects. The FDA may also impose specific conditions, such as requiring the final product to be shipped and stored under refrigerated conditions. Any additional requirements could result in an increase in the overall cost of the product and complicate the supply chain, which could also materially affect our business, financial condition, results of operations and growth prospects.

OC-01 and our other product candidates have never been manufactured on a commercial scale, and there are risks associated with scaling up manufacturing to commercial scale.

To date, our third-party manufacturer has only manufactured our OC-01 nasal spray in limited quantities in batch sizes appropriate for our clinical trials and registration batches to support the NDA submission, for which batch sizes are a fraction of the size we expect will be necessary for commercialization. The manufacturing processes for commercial scale are still being developed and have not been tested and the process validation requirement has not yet been satisfied. Although we plan to manufacture commercial scale batches of OC-01 nasal spray on the same manufacturing line as the registration batches, with the same equipment, only at higher scale, there are risks associated with scaling up manufacturing to commercial volumes including, among others, cost overruns, technical or other problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. There is no assurance that our manufacturer will be successful in establishing a larger-scale commercial manufacturing process for OC-01 that achieves our objectives for manufacturing capacity and cost of goods, in a timely manner or at all. In addition, there is no assurance that our manufacturers will be able to manufacture OC-01 to specifications acceptable to the FDA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of OC-01 or to meet potential future demand. If our manufacturers are unable to produce sufficient quantities of approved products for commercialization, either on a timely basis or at all, and in a cost-effective manner, our commercialization efforts would be impaired, including impacting the launch of OC-01 or inventory levels, which could materially affect our business, financial condition, results of operations and growth prospects.

If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates on acceptable terms, we may be unable to successfully commercialize our product candidates that obtain regulatory approval.

We currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements
46

with third parties to perform these services for each of the territories in which we may have approval to sell and market our product candidates. We may not be successful in accomplishing these required tasks.

Establishing an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.

Furthermore, we believe that approximately 26% of prescribing ECPs account for 80% of the volume of DED prescription treatments. If we are unable to obtain access to these ECPs or persuade adequate numbers of ECPs to prescribe our products, if and when approved, our efforts to commercialize such products will be severely inhibited, which would have a material adverse effect on our business.

Even if OC-01 or any other product candidate receives marketing approval, they may fail to achieve market acceptance by ECPs and patients, or adequate formulary coverage, pricing or reimbursement by third-party payors and others in the medical community, and the market opportunity for these products may be smaller than we estimate.

If OC-01 or any other product candidate that we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by ECPs, patients, third-party payors and others in the medical community. Current treatments that are commonly used in the United States for DED include over-the-counter eye drops, often referred to as “artificial tears”, Restasis, Xiidra and off-label use of corticosteroids. In particular, existing prescription therapies, notably Restasis and Xiidra, are marketed by much larger biopharmaceutical companies with established brand recognition. As a result, even if OC-01 demonstrates promising or superior clinical results, including the treatment of both signs and symptoms of DED, it is possible that ECPs may continue to rely on these treatments rather than OC-01 or any other product candidate, if and when approved for marketing by the FDA. In addition, if generic versions of any products that compete with any of our product candidates are approved for marketing by the FDA, they would likely be offered at a substantially lower price than we expect to offer for our product candidates, if approved. As a result, ECPs, patients and third-party payors may choose to rely on such products rather than our product candidates.

If OC-01 or any other product candidate does not achieve an adequate level of acceptance, formulary coverage, pricing or reimbursement we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of OC-01 or any other product candidate that we develop, if approved for commercial sale, will depend on a number of factors, including:

•the efficacy and potential advantages of our product candidates compared to alternative treatments, including the existing standard of care;

•our ability to offer our products for sale at competitive prices, particularly in light of the lower cost of alternative treatments;

•the clinical indications for which the product is approved;

•the convenience and ease of administration compared to alternative treatments;

•the willingness of the target patient population to try new therapies and of ECPs to prescribe these therapies;

•the strength of our marketing and distribution support;

•publicity concerning our products or competing products and treatments;

47

•the timing of market introduction of competitive products;

•the potential for our competitors to limit our access to the market through anti-competitive contracts or other arrangements;

•the availability of third-party formulary coverage and adequate reimbursement, particularly by Medicare in light of the prevalence of DED in persons over age 55;

•the prevalence and severity of any side effects; and

•any restrictions on the use of our products together with other medications.

Our assessment of the potential market opportunity for OC-01 and other product candidates is based on industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties, some of which we commissioned. Industry publications and third- party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Similarly, although the studies we have commissioned are based on information that we believe to be complete and reliable, we cannot guarantee that such information is accurate or complete. The potential market opportunity for the treatment of DED in particular is difficult to precisely estimate. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and fail to accurately reflect market opportunities. Further, we have commissioned a number of market studies that are specific to us and to our product candidates and used the results of these studies to help assess our market opportunity. While we believe that our internal assumptions and the bases of our commissioned studies are reasonable, no independent source has verified such assumptions or bases. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for OC-01 or any of our other product candidates may be smaller than we expect, and as a result our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability.

Even if we obtain regulatory approval for any of our product candidates, we may be subject to ongoing regulatory obligations or post-marketing commitments as specified by the FDA or other regulatory authorities, which may result in additional costs associated with those commitments.

If we obtain regulatory approval for OC-01 or any other product candidate, such approved products will be subject to continual regulatory review by the FDA and/or non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with such products.

If FDA or a comparable foreign regulatory authority approves any of our product candidates, including OC-01, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with current Good Manufacturing Practices (cGMP), as well as Good Clinical Practice (GCP) for any clinical trials that we conduct post-approval, all of which may result in significant expense and limit our ability to successfully commercialize such products. In addition, any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved indications or conditions of use for which the product may be marketed or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product.

Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers’ processes, or failure to comply with regulatory requirements, may result in, among other things:

•restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;

•fines, warning letters or holds on clinical trials;

48

•refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;

•product seizure or detention, or refusal to permit the import or export of products; and

•injunctions or the imposition of civil or criminal penalties.

Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.

We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. Our product candidates will, if approved, also compete with existing branded, generic and off-label products.

The development and commercialization of new drug products is highly competitive. We face competition with respect to OC-01 for the treatment of DED, and will face competition with respect to OC-01 for other indications and any other product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

The DED market is already served by a variety of competing products. Many of these existing products have achieved widespread acceptance among ECPs, patients and payors. In addition, certain of these products are available, or may become available, on a generic basis, and our product candidates may not demonstrate sufficient additional clinical benefits to ECPs, patients or payors to justify a higher price compared to generic products. In many cases, insurers or other third-party payors, particularly Medicare, seek to encourage the use of generic products.

Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.

In addition, our ability to compete may be affected in many cases by insurers or other third-party payors, particularly Medicare, seeking to encourage the use of generic products. Generic products are currently being used for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years.

Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.

If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.

Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If our product candidates are approved for marketing, such claims could still result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of such products, our manufacturing processes and facilities or our marketing programs. These investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or
49

eventual outcome, liability claims may also result in injury to our reputation, withdrawal of clinical trial participants, costs to defend the related litigation, a diversion of management’s time and our resources, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business and cause our stock price to decline. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain or obtain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including those caused by product liability claims.

A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.

We plan to seek regulatory approval of our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including:
•differing regulatory requirements and reimbursement regimes in foreign countries;

•unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;

•economic weakness, including inflation, or political instability in particular foreign economies and markets;

•compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;

•foreign taxes, including withholding of payroll taxes;

•foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;

•difficulties staffing and managing foreign operations;

•workforce uncertainty in countries where labor unrest is more common than in the United States;

•potential liability under the U.S. Foreign Corrupt Practices Act (FCPA) or comparable foreign regulations;

•challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;

•production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and

•business interruptions resulting from geo-political actions, including war and terrorism.

These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain profitable operations.

Following the United Kingdom’s departure from the EU on January 31, 2020, commonly referred to as "Brexit", there is a “transition period” ending December 31, 2020 during which the United Kingdom will essentially be treated as a Member State of the EU and the regulatory regime will remain the same across the United Kingdom and the EU. The Withdrawal Agreement allows for this “transition period” to be extended by one or two years, but the U.K. government is currently legislating to require the transition period to end on December 31, 2020 without the possibility to extend further. In that scenario, the trading relationship between the United Kingdom and the EU will be governed by whatever agreement the two parties can reach in the course of 2020. On that short timetable the United Kingdom and EU are likely to focus on ensuring tariff-free trade but it is unclear whether there would be any formal regulatory alignment between United Kingdom and EU rules after January 1, 2021. In the unlikely event that the United Kingdom leaves the EU without an agreement, so called “hard Brexit,” the United Kingdom will be completely separated from a regulatory perspective from the EU immediately upon the exit date.

Since the regulatory framework for pharmaceutical products in the United Kingdom relating to quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit will materially impact the future regulatory regime which applies to products
50

and the approval of product candidates in the United Kingdom. In the first instance, a separate United Kingdom authorization from any centralized authorization for the EU would need to be applied for in advance of a hard Brexit or before the end of any agreed transition period. In the immediately foreseeable future, the process is likely to remain very similar to that applicable in the EU, albeit that the processes for applications will be separate. Longer term, the United Kingdom is likely to develop its own legislation that diverges from that in the EU.

Risks Related to Intellectual Property

If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trademarks, trade secret protection, and confidentiality agreements to protect the intellectual property related to our development programs and product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States and other countries with respect to OC-01, OC-02, and any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our development programs and product candidates. The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner.

The patents and patent applications that we own may fail to result in issued patents with claims that protect OC-01, OC-02 or any future product candidate in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents cover OC-01, OC-02 or any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.

The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following:

•the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;

•patent applications may not result in any patents being issued;

•patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;

•our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates;

•there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and

•countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products.

The patent prosecution process is also expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we choose to license certain patent rights in the future from third parties, we may not have the right to control the preparation, filing and prosecution of such patent applications, or to
51

maintain the patents, directed to technology that we license from those third parties. We may also require the cooperation of our future licensor, if any, in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, any licensed patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by any of our future licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products.

If the patent applications we hold or may in-license in the future with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for OC-01, OC-02 or any future product candidate, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to commercialize OC-01, OC-02 or future product candidates. Any such outcome could have a materially adverse effect on our business.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.

Moreover, we may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and patents in which we have an interest may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest claimed non-provisional filing date. In certain instances, patent term can be adjusted to recapture a portion of delay incurred by the USPTO in examining the patent application (patent term adjustment). The scope of patent protection may also be limited.

Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.

Depending upon the timing, duration and specifics of FDA marketing approval of OC-02 and future product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during drug development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is based on the first approved use of a product and is limited to only one patent that covers the approved product, the approved use of the product, or a method of manufacturing the product. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other
52

countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time-period or the scope of patent protection afforded could be less than we request. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.

Periodic maintenance fees on any issued patent are due to be paid to the USPTO and other foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment, and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, non-payment of fees, and failure to properly legalize and submit formal documents. If we or any of our licensors fail to maintain the patents and patent applications covering OC-01, OC-02 or any future product candidate, our competitors may be able to enter the market, which would have an adverse effect on our business.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products.

We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our current and future product candidates in any jurisdiction.

The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products.

Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development and commercialization of OC-01, OC-02, and any future product candidate.

Our commercial success depends in part on our avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation, and administrative law proceedings, inter partes review, and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization.

Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current and future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future product candidates may infringe.

53

We are aware of three issued U.S. patents owned by Pfizer (U.S. Pat. No.: 7,265,119 (the ‘119), 6,890,927 (the ‘927) and 6,410,550 (the ‘550)) that Pfizer has listed in the Orange Book as covering its varenicline tartrate product, which is marketed as Chantix as an aid to smoking cessation treatment. Certain claims of these three patents are directed toward the compound varenicline tartrate and related salts thereof, and therefore may be relevant to our candidate OC-01. Of the three issued patents, we anticipate that only the ‘119 and the ‘927 will be in force at the time that we could expect to receive FDA approval of OC-01 and on October 18, 2019, we entered into a non-exclusive patent license for these patents. The ‘550 is listed in the Orange Book as expiring May 10, 2020, with pediatric exclusivity expiring November 10, 2020, and based on our current development plans, we anticipate that both the patent and pediatric exclusivity associated with the ‘550 will no longer be in force at the time of our expected FDA approval. However, even with the aforementioned license, we cannot provide assurances that third parties won’t allege infringement, which could delay or prevent the development and commercialization of OC-01 or other product candidates.

In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon their rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process, methods of treating certain diseases or conditions that we are pursuing with our product candidates, our formulations including combination therapies, or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our current and future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.

During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.

We may become involved in lawsuits to protect or enforce our patents, the patents of any licensors or our other intellectual property rights, which could be expensive, time consuming, and unsuccessful.

Competitors may infringe or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use or misappropriations, we may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex
54

parte reexaminations, inter partes review, or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For any patents and patent applications that we license from third parties, we may have limited or no right to participate in the defense of such licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.

We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common shares.

Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties.

Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our in-licensed patents, any patents that may be issued as a result of our future patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some other non-litigious action or solution.

Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future.

We may not be able to protect our intellectual property rights throughout the world, which could impair our business.

Filing, prosecuting, and defending patents covering OC-01, OC-02 and any future product candidate throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may have or obtain patent protection, but where patent enforcement is not as strong as that in the United States. These unauthorized products may compete with our products in such jurisdictions and take away our market share where we do not have any issued or licensed patents and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.

Our future reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.

Because we expect to rely on third parties to manufacture OC-01, OC-02 and any future product candidates, and we expect to collaborate with third parties on the continuing development of OC-01, OC-02 and any future product candidates, we must, at times, share trade secrets with them. We also expect to conduct R&D programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including material transfer agreements, consulting agreements, manufacturing and supply agreements, confidentiality agreements or other similar agreements with our advisors,
55

employees, contractors, CMOs, CROs, other service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations.

In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors CMOs, CROs, other service providers and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties.

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies, or at research institutions. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators, and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.

Intellectual property rights do not necessarily address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:

•others may be able to make formulations or compositions that are the same as or similar to our current and future product candidates, but that are not covered by the claims of the patents that we own;

•others may be able to make product that is similar to our current and future product candidates we intend to commercialize that is not covered by the patents that we exclusively licensed and have the right to enforce;

•we, any of our future licensors or collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own;

•we or any of our future licensor might not have been the first to file patent applications covering certain of our inventions;

•others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;

•it is possible that our future patent applications will not lead to issued patents;

•issued patents that we own may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;

•our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; and

56

•we may not develop additional proprietary technologies that are patentable.

Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products.

Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that:

•collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations;

•collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities;

•collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our current and future product candidates;

•a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities;

•we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;

•collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;

•disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future products or that results in costly litigation or arbitration that diverts management attention and resources;

•collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future products;

•collaborators may own or co-own intellectual property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and

•a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.

If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks,
57

trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our business, growth prospects, operating results and financial condition.

If we fail to comply with our obligations under any license, collaboration or other agreements, including our license agreement with Pfizer, such agreements may be terminated, we may be required to pay damages and we could lose intellectual property rights that are necessary for developing and protecting our product candidates.

We currently and may in the future license from third parties certain intellectual property relating to current and future product candidates. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture, and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Specifically, our license agreement with Pfizer can be terminated by Pfizer upon 60 days’ written notice for our uncured material breach or 30 days following non-payment or immediately upon our insolvency.

Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:

•the scope of rights granted under the license agreement and other interpretation-related issues;

•whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

•our right to sublicense patents and other rights to third parties;

•our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;
•our right to transfer or assign the license; and

•the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by any of our licensors and us and our partners.

If disputes over intellectual property that we license prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.

In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities.

Further, we or our current or future licensors, if any, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our current or future licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our current or future licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

In addition, even where we have the right to control patent prosecution of patents and patent applications under a license from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution.

Our acquired technologies and current or future licensed technology may be subject to retained rights. Our predecessors or licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether
58

our predecessors or future licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.

If we are limited in our ability to utilize acquired technologies or current or future licensed technologies, or if we lose our rights to critical acquired or in-licensed technology, we may be unable to successfully develop, out-license, market and sell our products, which could prevent or delay new product introductions. Our business strategy depends on the successful development of acquired technologies, and current or future licensed technology, into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidates.

Risks Related to Government Regulation

If the FDA does not conclude that OC-01 satisfies the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetics Act (FFDCA), or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates may take longer, cost more or entail greater complications and risks than anticipated, and may not be successful.

We intend to seek FDA approval through the Section 505(b)(2) regulatory pathway for OC-01. Section 505(b)(2) of the FFDCA permits the submission of a New Drug Application (NDA) where some or all of the data required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Our ability to rely on certain of the FDA’s findings of safety and effectiveness in approval of another NDA or on studies published in the scientific literature will depend on our ability to demonstrate the relevance to OC-01.

In particular, we conducted ZEN, a comparative pharmacokinetic "bridge" trial, to evaluate the relative bioavailability of varenicline administered as a nasal spray (OC-01) compared to varenicline administered orally (Chantix) in order to reference certain FDA conclusions regarding the safety of varenicline from the Agency’s review of the Chantix NDA. If the FDA does not accept or disagrees with our conclusions from ZEN or the data required for approval of our Section 505(b)(2) NDA are different than anticipated, we may be required to conduct additional development activities or studies or provide additional data and information to pursue the 505(b)(2) regulatory pathway on our proposed timeline. Such delays could result in new competitive products reaching the market faster than OC-01, which could materially adversely impact our competitive position and growth prospects.

The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.

The time required to obtain approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval.

Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S. federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018 and 2019, may result in significant reductions to the FDA’s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. In addition, our competitors may file citizens’ petitions with the FDA in an attempt to persuade the FDA that our product candidates, or the clinical trials that support their approval, contain deficiencies. Such actions by our competitors could delay or even prevent the FDA from approving any of our NDAs.

Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following:

•the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials;

59

•the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use;

•the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval;

•the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

•the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;

•we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that a product candidate’s risk-benefit ratio for its proposed indication is acceptable;

•the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

•the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which could materially affect our business, financial condition, results of operations and growth prospects.

We may face difficulties from changes to current regulations and future legislation.

In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

For example, in March 2010, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), was passed, which substantially changes the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. Some of the provisions of the ACA have yet to be implemented, and there have been judicial, Congressional and executive branch challenges to certain aspects of the ACA, as well as recent efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have passed. On December 22, 2017, President Trump signed into law federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (Tax Act) which includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate.” On January 22, 2018, President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain ACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of 2018, among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare Part D drug plans. In July 2018, the Centers for Medicare and Medicaid Services (CMS) published a final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment
60

program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment.

On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Act. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA and our business.

In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2027 unless additional Congressional action is taken. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our product candidates, if approved, and accordingly, our financial operations.

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. There has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, at the federal level, the Trump administration released a “Blueprint” to lower drug prices and reduce out-of-pocket costs of prescription drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out-of-pocket costs of drug products paid by consumers. Additionally, on January 31, 2019, HHS Office of Inspector General proposed modifications to federal Anti-Kickback Statute safe harbors which, among other things, may affect rebates paid by manufactures to Medicare Part D plan sponsors, Medicaid managed care organizations, and those entities’ pharmacy benefit managers, the purpose of which is to further reduce the cost of drug products to consumers. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates.

In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever- increasing EU and national regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product candidates, if approved.

Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.

61

Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, comply with data privacy and security laws and accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Although we have adopted a code of business conduct and ethics with respect to our employees, agents and contractors, it is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations.

If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.

We and any contract manufacturers and suppliers we engage are subject to numerous federal, state, and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air, and water; and employee health and safety. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties.

Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or waste Although we maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not currently maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials. Accordingly, in the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or EMA grants
62

marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

In addition, we may choose to conduct international clinical trials. The acceptance of study data by the FDA, EMA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1) the data are applicable to the U.S. population and U.S. medical practice; (2) the trials are performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (3) audits by regulatory authorities of the clinical data do not identify significant data integrity issues. Additionally, the FDA’s clinical trial requirements, including the adequacy of the patient population studied and statistical powering, must be met. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.

Our business activities may be subject to the FCPA and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.

We recently completed a trial and may plan to initiate additional trials in countries other than the United States. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. The FCPA generally prohibits offering, promising, giving or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the healthcare providers, including ECPs, who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international activities, our ability to attract and retain employees and our business, growth prospects, operating results and financial condition.

In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our international sales and adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our products may create delays in the introduction of our products in international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, we may
63

be fined or other penalties could be imposed, including a denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or scope of existing regulations, or in the countries, persons, or technologies targeted by such regulations, could result in decreased use of our products by, or in our decreased ability to export our products to existing or potential customers with international operations. Any decreased use of our products or limitation on our ability to export or sell access to our products would likely adversely affect our business.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. For example, if we receive marketing approval for OC-01 as a treatment for the signs and symptoms of DED, physicians may nevertheless use our product for their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business, growth prospects, operating results and financial condition.

Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission (SEC) and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent years, including in 2013, 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.

Our operations, and those of our CROs, CMOs, suppliers, and other contractors and consultants, could be subject to wildfires, earthquakes, tsunamis, power shortages or outages, floods or monsoons, public health crises, such as pandemics and epidemics, political crises, such as terrorism, war (including trade wars), political instability or other conflict, and other natural or man-made disasters or other events outside of our control that can disrupt business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. For example, we rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain supplies of our product candidates or other necessary supplies could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. All of our operations including our corporate headquarters are located in a single location in Princeton, New Jersey. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption.

Risks Related to Reliance on Third Parties

64

We rely on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies.

We do not have the ability to independently conduct our clinical trials. We currently rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our current and planned clinical trials of OC-01 and OC-02, and we expect to continue to rely upon third parties to conduct additional clinical trials of OC-01, OC-02 and potential future product candidates. Third parties have a significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements with such third party, we have limited ability to control the amount or timing of resources that any such third party will devote to our clinical trials. Some of these third parties may terminate their engagements with us at any time. If we need to enter into alternative arrangements with a third party, it would delay our development activities.

Our reliance on these third parties for such development activities will reduce our control over these activities but will not relieve us of our regulatory responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The EMA also requires us to comply with similar standards. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under current cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the marketing approval process. We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

The third parties we rely on for these services may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.

We contract with third parties for the production of our product candidates for preclinical studies and our ongoing clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.

We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. If we were to experience an unexpected loss of supply of OC-01, OC-02 or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials.

We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

•the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them;
•the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us;

•the breach by the third-party contractors of our agreements with them;

65

•the failure of third-party contractors to comply with applicable regulatory requirements, including manufacturing drug supply pursuant to strictly enforced cGMPs;

•the failure of the third party to manufacture our product candidates according to our specifications;

•the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified;

•clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and

•the misappropriation of our proprietary information, including our trade secrets and know-how.

We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of our product candidates, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates and harm our business and results of operations.

We currently rely on single source manufacturers and suppliers for the supply of OC-01 and OC-02. If we decide to move to different or add additional manufacturers and suppliers in the future, any such transition or addition would require significant efforts in testing and validating the manufacturing and formulation process and could result in delays or other issues, which could have an adverse effect on the supply of our product candidates.

Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.

We may pursue collaborations with third parties for the development or commercialization of our product candidates. If we decide to pursue collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. If we do enter into collaborations that are not successful, we may not be able to capitalize on the market potential of these product candidates.

Our development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long- term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.

We would face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product
66

candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.

In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators.

If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales and marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.

Our business operations and current and future relationships with healthcare professionals, clinical investigators, consultants, patient organizations, customers, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.

Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, including ECPs, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include the following:

•the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;

•the federal civil and criminal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;

•the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

•federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

•the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;

•the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to
67

physicians and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; and

•analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.

Some state laws require biotechnology companies to comply with the biotechnology industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require biotechnology companies to report information on the pricing of certain drug products. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation (GDPR), which extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may be onerous and if our efforts to comply with GDPR or other applicable EU laws and regulations are not successful, it could adversely affect our business in the European Union.

Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices, including the provision of stock options as compensation for consulting services to physicians and other healthcare providers, some of whom may be in a position to recommend, purchase and/or prescribe our product candidates, if approved, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.

Risks Related to Ownership of Common Stock

We will need substantial additional funding in the future. If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and development programs or future commercialization efforts.

Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed significant amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we continue to conduct clinical trials of, and seek marketing approval for, OC-01, OC-02 and any other future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA, the EMA or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, including OC-01, we expect to incur significant commercialization expenses related to sales, marketing, manufacturing and distribution. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. In addition, we have incurred and will continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations.

68

As of December 31, 2019, we had $139.1 million in cash and cash equivalents. Although we believe that our available cash and cash equivalents will be sufficient to fund our planned operations for at least 12 months following the date of this Annual Report on Form 10-K, this belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned.

Advancing the development of OC-01, OC-02 and any other future product candidates will require a significant amount of capital. Our existing cash and cash equivalents may not be sufficient to fund all of the activities that are necessary to complete the development of OC-01, OC-02 and any other future product candidates. We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing, which may dilute our stockholders or restrict our operating activities. The amount of additional capital we will need to raise will depend on many factors, including:

•the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;

•the number and scope of clinical programs we decide to pursue;

•the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;

•the scope and costs of development and commercial manufacturing activities;

•the cost and timing associated with commercializing our product candidates, if they receive marketing approval;

•the extent to which we acquire or in-license other product candidates and technologies;

•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;

•our ability to establish and maintain collaborations on favorable terms, if at all;

•our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;

•our implementation of operational, financial and management systems; and

•the costs associated with being a public company.

We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our business, growth prospects, operating results and financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts.

An active trading market for our common stock may not be sustained.

Prior to the closing of our IPO in November 2019, there was no public trading market for our common stock. Although our common stock is listed on the NASDAQ Global Select Market, the market for our shares has demonstrated varying levels of trading activity. We cannot predict the prices at which our common stock will trade or whether an active trading market will be sustained in the future. The lack of an active market may impair investors’ ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable, may reduce the market value of their shares and may impair our ability to raise capital.

If securities or industry analysts do not continue to publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.

69

The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. If no additional securities or industry analysts commence coverage of us, our stock price could be negatively impacted. If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

The price of our stock may be volatile, and you could lose all or part of your investment.

The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. In addition to the factors discussed in this “Risk Factors” section and elsewhere in this Annual Report on Form 10-K, these factors include:

•the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors;

•the success of competitive products or announcements by potential competitors of their product development efforts;

•regulatory actions with respect to our products or our competitors’ products;

•actual or anticipated changes in our growth rate relative to our competitors;

•regulatory or legal developments in the United States and other countries;

•developments or disputes concerning patent applications, issued patents or other proprietary rights;

•the recruitment or departure of key personnel;

•announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;

•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

•fluctuations in the valuation of companies perceived by investors to be comparable to us;

•market conditions in the pharmaceutical and biotechnology sector;

•changes in the structure of healthcare payment systems;

•changes or expected changes to government and such implications for the health care industry;

•share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;

•announcement or expectation of additional financing efforts;

•sales of our common stock by us, our insiders or our other stockholders;

•expiration of market stand-off or lock-up agreements; and

•general economic, industry and market conditions.

The realization of any of the above risks or any of a broad range of other risks, including those described in this “Risk Factors” section, could have a dramatic and adverse impact on the market price of our common stock.

70

Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. As of February 21, 2020, we had 21,366,950 shares of common stock outstanding. Of these shares, approximately 3,278,800 shares sold in our IPO may be resold in the public market immediately without restriction, unless purchased by our affiliates. Of the remaining shares, 17,865,320 shares of our common stock are currently restricted as a result of securities laws or lock-up agreements, but will be able to be sold in the public market as early as April 28, 2020, which is 180 days following the date of our final prospectus filed with the SEC on October 31, 2019 pursuant to Rule 424(b) under the Securities Act of 1933, as amended, as further described below. Moreover, holders of an aggregate of 14,193,281 shares of our common stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. In addition, on October 31, 2019, we filed a registration statement on Form S-8 registering 5,822,484 shares of common stock that we may issue under our equity incentive plans. As a result, shares registered under this registration statement on Form S-8 can be freely sold in the public market subject to the satisfaction of vesting arrangements and the exercise of such options, volume limitations applicable to affiliates and the lock-up agreements described below.

We and our executive officers, directors and the holders of substantially all of our common stock have entered into market stand-off agreements with us and lock-up agreements with the underwriters under which they have agreed, subject to specific exceptions, not to sell, directly or indirectly, any shares of common stock without the permission of J.P. Morgan Securities LLC, Cowen and Company, LLC, and Piper Jaffray & Co. through April 27, 2020. We refer to such period as the lock-up period. When the lock-up period expires, we and our securityholders subject to a lock-up agreement or market stand-off agreement could sell our shares in the public market, which could cause our stock price to fall. In addition, J.P. Morgan Securities LLC, Cowen and Company, LLC, and Piper Jaffray & Co. may, in their sole discretion, release all or some portion of the shares subject to lock-up agreements at any time and for any reason prior to April 28, 2020. Sales of a substantial number of such shares upon expiration of the lock-up and market stand-off agreements, the perception that such sales may occur, or early release of these agreements, could cause our market price to fall or make it more difficult for you to sell your common stock at a time and price that you deem appropriate.

Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.

We may seek additional capital through a variety of means, including through public or private equity, debt financings or other sources, including up-front payments and milestone payments from strategic collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

As of December 31, 2019, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 72% of our voting stock. As a result, this group of stockholders will have the ability to control all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

71

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including:

•being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in our periodic reports;

•not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;

•not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

•reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and

•exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (2) the date we qualify as a “large accelerated filer,” with at least $700 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.

We have identified material weaknesses in our internal control over financial reporting and, if our remediation of the material weaknesses is not effected in a timely manner or it is not effective or if we identify additional material weaknesses in the future, we may not be able to accurately or timely report our financial results, or prevent fraud, and investor confidence in our company and the market price of our shares may be adversely affected.

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the Sarbanes-Oxley Act), requires that we evaluate and determine the effectiveness of our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

During 2019, in connection with the audits of our financial statements as of and for the years ended December 31, 2018 and 2017, we identified two material weaknesses in our control over financial reporting.

First, we did not design or maintain an effective control environment commensurate with our financial reporting requirements. Specifically, we lack a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. This material weakness contributed to an additional material weakness in that we did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries.

These material weaknesses resulted in an audit adjustment to decrease operating expenses and accounts payable in the year ended December 31, 2018, and audit adjustments to the income tax footnote in the year ended December 31, 2019, that were not
72

material. Additionally, each of the above material weaknesses could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected.

We have started to take some of the following steps to address the internal control deficiencies that contributed to the material weakness:

•hiring of additional finance and accounting personnel with prior experience working for finance departments of public companies and technical accounting experience, supplemented by third-party resources;

•documenting and formally assessing our accounting and financial reporting policies and procedures; and

•assessing significant accounting transactions and other technical accounting and financial reporting issues, preparing accounting memoranda addressing these issues and maintaining these memoranda in our corporate records.

However, our efforts are still preliminary and our Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2019, our disclosure controls and procedures were not ineffective due to the material weaknesses in our control environment and formal accounting policies.

While we believe that these efforts, including working to formalize and implement our accounting policies and internal controls and the related documentation, will improve our internal control over financial reporting, the implementation of these measures is ongoing and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles. We cannot assure you that the measures we have taken to date, and are continuing to implement, will be sufficient to remediate the material weaknesses we have identified or avoid potential future material weaknesses. If the steps we take do not correct the material weaknesses in a timely manner, we will be unable to conclude that we maintain effective internal controls over financial reporting. Accordingly, there could continue to be a reasonable possibility that these deficiencies or others could result in a misstatement of our accounts or disclosures that would result in a material misstatement of our financial statements that would not be prevented or detected on a timely basis.

We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. Additionally, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.

As a public company, we have incurred and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, and these expenses may increase even more after we are no longer an “emerging growth company.” We are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and to be adopted, by the SEC and Nasdaq. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations have and will continue to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly, which will increase our operating expenses. We cannot accurately predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

In addition, as a public company we will be required to incur additional costs and obligations in order to comply with SEC rules that implement Section 404 of the Sarbanes-Oxley Act. Under these rules, beginning with our second annual report on Form 10-K after we become a public company, we will be required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively, and implement a continuous reporting and improvement process for internal control over financial reporting.

The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation to meet the detailed standards under the rules. During the course of its testing, our management may identify material weaknesses or deficiencies which may not be remedied in time to meet the deadline imposed by the Sarbanes-Oxley Act. Our internal control over financial reporting will not prevent or
73

detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.

If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our stock could decline and we could be subject to sanctions or investigations by the stock exchange on which our common stock is listed, the SEC or other regulatory authorities.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.

These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of their stock.

Provisions in our restated certificate of incorporation and restated bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock.

Our restated certificate of incorporation and restated bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things:

•establish a classified board of directors so that not all members of our board are elected at one time;

•permit only the board of directors to establish the number of directors and fill vacancies on the board;

•provide that directors may only be removed “for cause” and only with the approval of two-thirds of our stockholders;

•authorize the issuance of “blank check” preferred stock that our board could use to implement a stockholder rights plan (also known as a poison pill);

•eliminate the ability of our stockholders to call special meetings of stockholders;

•prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;

•prohibit cumulative voting;

•authorize our board of directors to amend the bylaws;

•establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and

74

•require a super-majority vote of stockholders to amend some provisions described above.

In addition, Section 203 of the General Corporation Law of the State of Delaware (DGCL) prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.

Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock.

Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for:

•any derivative action or proceeding brought on our behalf;

•any action asserting a claim of breach of fiduciary duty;

•any action asserting a claim against us arising under the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws; and

•any action asserting a claim against us that is governed by the internal-affairs doctrine.

This exclusive-forum provision may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to this provision. If a court were to find this exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Nothing in our amended and restated bylaws, including the exclusive-forum provision, precludes stockholders that assert claims under the Securities Act or the Exchange Act from bringing such claims in state or federal court, subject to applicable law.

Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations.
Our net operating loss carryforwards (NOLs) could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. Our NOLs generated in tax years ending on or prior to December 31, 2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, our federal NOLs generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal NOLs generated in tax years beginning after December 31, 2017 is limited. It is uncertain if and to what extent various states will conform to the Tax Act. As of December 31, 2019, we had U.S. federal and state NOLs of $59.1 million, and $60.7 million, respectively, which will expire beginning in the year 2035.

In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code), if a corporation undergoes an “ownership change” (generally defined as a cumulative change in our ownership by “5-percent stockholders” that exceeds 50 percentage points over a rolling three-year period), the corporation’s ability to use its pre-change NOLs and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control. We have determined that no significant limitation would be placed on the utilization of our net operating loss and tax credit carryforwards due to prior ownership change. Our ability to utilize those NOLs could be limited by an “ownership change” as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have a material adverse effect on our cash flows and results of operations.

75

We may be subject to securities litigation, which is expensive and could divert management attention.

The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 2. PROPERTIES

Our corporate headquarters are currently located in Princeton, New Jersey, where we lease 12,007 square feet of office space pursuant to an amended lease agreement that expires on June 30, 2022. In January 2020, we amended our corporate headquarter lease to increase the office space from 8,607 square feet to 12,007 square feet. We believe that our existing facilities are adequate for our near-term needs, but expect to need additional space as we grow. We believe that suitable additional or alternative space would be available as required in the future on commercially reasonable terms.

ITEM 3. LEGAL PROCEEDINGS

We are not a party to any material legal proceedings at this time. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business, financial condition, results of operations or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

ITEM 4. MINE SAFETY DISCLOSURES

None.
76

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Our common stock has been listed on the NASDAQ Global Select Market under the symbol “OYST” since October 31, 2019. Prior to this date, there was no public market for our common stock.

Holders of Common Stock

As of February 21, 2020, there were approximately 80 holders of record of our common stock. The approximate number of holders is based upon the actual number of holders registered in our records at such date and excludes holders in “street name” or persons, partnerships, associations, corporations, or other entities identified in security positions listings maintained by depository trust companies.

Dividend Policy

We have never declared or paid any cash dividends on our common stock and do not anticipate paying cash dividends in the foreseeable future.

Recent Sales of Unregistered Securities

During the year ended December 31, 2019, we granted stock options to purchase an aggregate of 1,417,351 shares of common stock to our directors, officers, employees, consultants and other service providers under our 2016 Equity Incentive Plan (the 2016 Plan) at exercise prices per share ranging from $5.33 to $14.28. During the same period, we issued and sold to our directors, officers, employees, consultants and other service providers an aggregate of 7,291 shares of common stock upon the exercise of options under our 2016 Plan at an exercise price per share of $1.02, for an aggregate exercise price of $7,437.

Also during the year ended December 31, 2019, we issued and sold an aggregate of 6,581,590 shares of our Series B preferred stock at a purchase price of $14.13 per share for aggregate proceeds of $93.0 million.

We believe that the offers, sales and issuances of the securities described above were exempt from registration under the Securities Act under either (1) Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder as transactions by an issuer not involving a public offering or (2) Rule 701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule 701. The recipients of securities in each of these transactions represented their intention to acquire the securities for investment only and not with view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions.

Use of Proceeds from Initial Public Offering

On October 30, 2019, the U.S. Securities and Exchange Commission declared effective our registration statement on Form S-1 (File No. 333-234104), as amended, filed in connection with our initial public offering (“IPO”). The IPO closed on November 4, 2019. In connection with the IPO, we issued and sold an aggregate of 5,750,000 shares of our common stock, including 750,000 shares sold pursuant to the underwriters’ full exercise of their option to purchase additional shares, at a price to the public of $16.00 per share. The aggregate offering price for shares sold in the offering was $92.0 million. J.P. Morgan Securities LLC, Cowen and Company, LLC and Piper Jaffray & Co. acted as the joint book-running managers of the offering. After deducting underwriting discounts, commissions and offering expenses paid or payable by us, the net proceeds from the IPO were $82.1 million. No offering expenses were paid or are payable, directly or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities or to any of our affiliates.

There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with the SEC on October 31, 2019.

Purchases of Equity Securities by the Issuer and Affiliated Purchases

None.

ITEM 6. SELECTED FINANCIAL DATA

You should read the selected historical financial data below in conjunction with the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. The selected financial data set forth below is derived from our audited financial statements and may not be indicative of future operating results.

77

Year Ended December 31,
2019
2018
(in thousands, except per share data)
Statements of Operations and Comprehensive Loss Data:
Operating expenses
Research and development$33,628  $13,755  
General and administrative13,673  2,981  
Total operating expenses47,301  16,736  
Loss from operations(47,301) (16,736) 
Interest income1,590  233  
Related party interest expense—  —  
Net loss and comprehensive loss$(45,711) $(16,503) 
Net loss attributable to common stockholders$(45,711) $(16,503) 
Net loss per share attributable to common stockholders, basic and diluted$(9.97) $(11.69) 
As of December 31,
2019
2018
(in thousands)
Balance Sheet Data:
Cash and cash equivalents$139,147  $5,228  
Working capital (1)
136,781
4,678
Total assets143,209  5,704  
Total liabilities
5,911
946
Redeemable convertible preferred stock
—
43,001
Accumulated deficit
(84,231)
(38,520)
Total stockholders' equity (deficit)137,298  
(38,243)
(1) We define working capital as current assets less current liabilities.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Annual Report on Form 10-K, our actual results could differ materially from the results described, in or implied, by these forward-looking statements. Please also see the section of this Annual Report on Form 10-K titled “Special Note Regarding Forward-Looking Statements.”

Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Our lead product candidate OC-01 (varenicline), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s novel mechanism of action is designed to re-establish tear film homeostasis by activating the trigeminal parasympathetic pathway and stimulating the glands and cells responsible for natural tear film production. In our Phase 2b clinical trial (ONSET-1) in 182 subjects, OC-01 demonstrated statistically significant improvements (as compared to placebo) in both signs and symptoms of DED. Based on OC-01’s clinical trial results and its rapid onset of action, we believe OC-01, if approved, has the potential to become the new standard of care and redefine how DED is treated for millions of patients. We initiated a
78


Phase 3 clinical trial (ONSET-2) in July 2019 and expect to report top-line results by the end of the second quarter 2020. Based on the results from this second registrational trial, we plan to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2020. We believe that targeting the parasympathetic nervous system through the use of locally administered cholinergic agonists has the potential to treat a wide range of diseases and disorders. We have identified several indications, including several outside of ophthalmology, where we believe this approach could provide a meaningful benefit to patients.

Since our formation in June 2015, we have devoted substantially all of our resources to developing our product candidates. We have incurred significant operating losses to date. Our net losses were $45.7 million and $16.5 million for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, we had an accumulated deficit of $84.2 million. We expect that our operating expenses will increase significantly as we advance our product candidates through preclinical and clinical development, seek regulatory approval, and prepare for and, if approved, proceed to commercialization; acquire, discover, validate and develop additional product candidates; obtain, maintain, protect and enforce our intellectual property portfolio; and hire additional personnel. In addition, we have incurred and will continue to incur additional costs associated with operating as a public company.

We do not have any products approved for sale and have not generated any revenue since inception. Our ability to generate product revenue will depend on the successful development, regulatory approval and eventual commercialization of one or more of our product candidates. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of our product candidates.

We plan to continue to use third-party service providers, including clinical research organizations (CROs) and contract manufacturing organization (CMOs), to carry out our preclinical and clinical development and to manufacture and supply the materials to be used during the development and commercialization of our product candidates. We do not currently have a sales force. If OC-01 is approved for the treatment of the signs and symptoms of DED, we intend to deploy a specialty sales force at launch of approximately 150 to 200 field representatives.

Prior to our initial public offering (IPO), we funded our operations primarily from the sale and issuance of redeemable convertible preferred stock and convertible promissory notes. In February and April 2019, we raised net proceeds of $92.9 million from the sale of Series B redeemable convertible preferred stock.

In October 2019, we entered into a non-exclusive patent license agreement with Pfizer, pursuant to which we made an upfront payment of $5.0 million. If we successfully commercialize OC-01, we may be required to pay a single milestone payment in the very low double-digit millions and tiered royalties on net sales of OC-01 at percentages ranging from the mid-single digits to the mid-teens.

On November 4, 2019, we completed our IPO selling 5,750,000 shares of our common stock at $16.00 per share. Proceeds from our IPO, net of underwriting discounts and commissions and other offering expenses, were $82.1 million. In connection with the completion of our IPO on November 4, 2019, all then outstanding shares of redeemable convertible preferred stock converted into 14,193,281 shares of common stock.

As of December 31, 2019, we had cash and cash equivalents of $139.1 million. We believe that those cash and cash equivalents will be sufficient to fund our projected operations for at least 12 months from the issuance date of our financial statements as of and for the year ended December 31, 2019.

Components of Operating Results

Revenue

We have not generated any revenue from product sales and do not expect to do so in the near future.

Operating Expenses

Research and Development Expenses

79


Substantially all of our research and development expenses consist of expenses incurred in connection with the development of our product candidates. These expenses include fees paid to third parties to conduct certain research and development activities on our behalf, consulting costs, costs for laboratory supplies, product acquisition and license costs, certain payroll and personnel-related expenses, including salaries and bonuses, employee benefit costs and stock-based compensation expenses for employees dedicated to our research and product development and allocated overhead expenses, including rent, equipment, depreciation, information technology costs and utilities. We expense both internal and external research and development expenses as they are incurred.

We do not allocate our costs by product candidate, as a significant amount of research and development expenses include internal costs, such as payroll and other personnel expenses, laboratory supplies and allocated overhead expenses, and external costs, such as fees paid to third parties to conduct research and development activities on our behalf, are not tracked by product candidate. In particular, with respect to internal costs, several of our departments support multiple product candidate research and development programs, and therefore the costs cannot be allocated to a particular product candidate or development program. The following table shows our research and development expenses by type of activity (in thousands):

Year EndedDecember 31,
20192018
Clinical and preclinical$12,470  

$9,302  
Chemistry, Manufacturing and Controls (CMC)12,148  

2,885  
License costs5,000  —  
Regulatory and other costs4,010  

1,568  
Total research and development expenses$33,628  

$13,755  

We are focusing substantially all of our resources on the development of our product candidates, particularly OC-01. We expect our research and development expenses to increase substantially for at least the next few years, as we seek to initiate additional clinical trials for our product candidates, complete our clinical programs, pursue regulatory approval of our product candidates and prepare for the possible commercialization of these product candidates. Predicting the timing or cost to complete our clinical programs or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our product candidates will receive regulatory approval with any certainty.

General and Administrative Expenses

General and administrative expenses consist principally of payroll and personnel expenses, including salaries and bonuses, benefits and stock-based compensation expenses, professional fees for legal, consulting, accounting and tax services, allocated overhead expenses, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses.

We anticipate that our general and administrative expenses will increase as a result of increased personnel costs, expanded infrastructure and higher consulting, legal and accounting services costs associated with complying with the applicable stock exchange and Securities and Exchange Commission (SEC) requirements, investor relations costs and director and officer insurance premiums associated with being a public company.

Interest Income

Interest income consists primarily of interest income earned on our cash and cash equivalents.

Results of Operations
Comparison of the Years Ended December 31, 2019 and 2018
The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):
80


Year Ended December 31,
20192018Change%  
Operating expenses:
Research and development$33,628  $13,755  $19,873  144 %
General and administrative13,673  2,981  10,692  359 %
Loss from operations(47,301) (16,736) (30,565) 183 %
Interest income1,590  233  1,357  582 %
Net loss$(45,711) $(16,503) $(29,208) 177 %
Research and Development Expenses
Research and development expenses increased by $19.9 million, or 144%, from the year ended December 31, 2018 to the year ended December 31, 2019. The increase in research and development expenses was primarily due to our advancement of OC-01 and reflected an increase in fees due to CROs and CMOs of $12.5 million, an increase of $5.0 million related to the license acquisition payment made to Pfizer and an increase in payroll and personnel-related expenses, including salaries and bonuses, benefits and stock-based compensation expense, of $2.4 million. We expect that our research and development expenses will continue to increase as we continue to add personnel to support our research and development activities and incur further expenses for CROs and CMOs in order to continue the advancement of our product candidates.
General and Administrative Expenses
General and administrative expenses increased by $10.7 million, or 359%, from the year ended December 31, 2018 to the year ended December 31, 2019. The increase in general and administrative expenses was primarily due to the expansion of our organization and reflected an increase in payroll and personnel-related expenses, including salaries, benefits and stock-based compensation expense, of $4.4 million, an increase in professional services and other expenses incurred in relation to our IPO readiness of $3.5 million, an increase in marketing expenses, of $1.5 million, an increase in facilities expenses, consisting primarily of rent and depreciation, of $0.3 million; and an increase in other general and administrative expenses of $1.0 million.
Interest Income
Interest income increased by $1.4 million, or 582%, from the year ended December 31, 2018 to the year ended December 31, 2019, primarily due to an increase in cash and cash equivalents as a result of the IPO in November 2019 and the sale of Series B redeemable convertible preferred stock in February and April 2019.

Liquidity and Capital Resources

Sources of Liquidity

Since our formation in 2015 through December 31, 2019, we have funded our operations with an aggregate of $213.4 million in gross cash proceeds from the sale of redeemable convertible preferred stock and convertible promissory notes and the gross cash proceeds from our IPO. In February and April 2019, we received net cash proceeds of $84.9 million and $8.0 million, respectively, from the sale of Series B redeemable convertible preferred stock. On November 4, 2019, we received $82.1 million of net proceeds upon completion of our IPO.

As of December 31, 2019, we had cash and cash equivalents of $139.1 million.

Future Funding Requirements

We have incurred net losses since our inception. For the years ended December 31, 2019 and 2018, we had net losses of $45.7 million and $16.5 million, respectively. As of December 31, 2019, we had an accumulated deficit of $84.2 million. We believe that our existing cash and cash equivalents in the amount of $139.1 million will be sufficient to fund our projected operations for at least 12 months from the issuance date of our financial statements as of and for the year ended December 31, 2019.

To date, we have not generated any revenue. We do not expect to generate any meaningful revenue unless and until we obtain regulatory approval of and commercialize any of our product candidates or enter into collaborative agreements with third parties,
81


and we do not know when, or if, either will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business.

We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing. We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors, including: 
•the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;
•the number and scope of clinical programs we decide to pursue;
•the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;
•the scope and costs of development and commercial manufacturing activities;
•the cost and timing associated with commercializing our product candidates, if they receive marketing approval;
•the extent to which we acquire or in-license other product candidates and technologies;
•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
•our ability to establish and maintain collaborations on favorable terms, if at all;
•our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;
•our implementation of operational, financial and management systems; and
•the costs associated with being a public company.
A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.
Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition.

See the section of this Annual Report on 10-K titled “Risk Factors” for additional risks associated with our substantial capital requirements.

82


Summary Statement of Cash Flows

The following table sets forth the primary sources and uses of cash, cash equivalents, and restricted cash for each of the periods presented below:
Year Ended
December 31,
20192018
Net cash (used in) provided by:
Operating activities$(40,815) $(17,083) 
Investing activities(200) —  
Financing activities174,985  —  
Net increase (decrease) in cash, cash equivalents and restricted cash133,970  (17,083) 
Cash Flows from Operating Activities
Net cash used in operating activities was $40.8 million for year ended December 31, 2019. Cash used in operating activities was primarily due to the use of funds in our operations to develop our product candidates resulting in a net loss of $45.7 million, adjusted by non-cash stock-based compensation expense of $3.3 million and by a decrease in changes in assets and liabilities of $1.6 million. Decrease in changes in assets and liabilities included an increase in prepaid expenses and other current assets of $2.6 million due to change in prepayments made to CROs and CMOs, offset by an increase in accrued liabilities of $4.2 million due to an increase in accrued research and development expenses and professional fees.
Net cash used in operating activities was $17.1 million for the year ended December 31, 2018. Cash used in operating activities was primarily due to the use of funds in our operations to develop our product candidates resulting in a net loss of $16.5 million, increased by a decrease in accrued liabilities of $1.2 million primarily due to a decrease in accrued research and development and accrued compensation expenses, and partially offset decrease in prepaid expenses and other current assets of $0.5 million.

Cash Flows used in Investing Activities

Net cash used in investing activities was $0.2 million for the year ended December 31, 2019, which related to the purchase of property and equipment. Net cash used in investing activities was zero for the year ended December 31, 2018.

Cash Flows from Financing Activities

Net cash provided by financing activities was $175.0 million for the year ended December 31, 2019, due to net proceeds from the sale of Series B redeemable convertible preferred stock of $92.9 million and net proceeds from the IPO of $82.1 million.

We did not undertake any financing activities in the year ended December 31, 2018.

Contractual Obligations and Commitments

The following table summarizes our contractual obligations as of December 31, 2019:


Payments Due by Period (in thousands)
Less than 1 year1 to 3 yearsTotal
Operating lease obligations (1)$319  $502  $821  
___________________
(1) We lease our office facilities in Princeton, New Jersey under two non-cancellable operating leases with an expiration dates of March 15, 2020 and July 31, 2022. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.

In January 2020 we amended one lease of our office facilities in Princeton, New Jersey to include additional office space, with an expiration date of July 31, 2022. Total future minimum lease payments under this amendment are $0.4 million.

83


We enter into contracts in the normal course of business with third-party contract organizations for preclinical and clinical studies and testing, manufacture and supply of our preclinical materials and other services and products used for operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

In October 2016, we entered into an asset purchase agreement pursuant to which we acquired the compound OC-02. Under this agreement we are obligated to make milestone payments of up to an aggregate of $37.0 million upon achievement of certain development and regulatory milestone events. In March 2018, we made a payment of $1.5 million upon completion of the first of these milestones. We accrued such amount as of December 31, 2017 as we concluded that it was probable that such payment would be made. Under the asset purchase agreement, we are also obligated to make royalty payments at a mid-single digit percentage rates on net worldwide sales of the covered products. In addition, we are required to pay 15% of any (i) licensing revenue we receive that is related to OC-02 and (ii) revenue received from the sale of OC-02, up to a maximum aggregate amount of $10.0 million. These commitments are not included in the table above due to uncertainty of timing of any such payments.

In October 2019, we entered into a non-exclusive patent license agreement (the License Agreement) with Pfizer, which granted us non-exclusive rights under Pfizer’s patent rights covering varenicline tartrate to develop, manufacture, and commercialize our OC-01 varenicline product candidate. Under the terms of the License Agreement, we made an upfront payment to Pfizer of $5.0 million. If we successfully commercialize OC-01, we may be required to pay a single milestone payment in the very low double-digit millions and tiered royalties on net sales of OC-01 at percentages ranging from the mid-single digits to the mid-teens. The royalty obligation to Pfizer will commence upon first commercial sale of OC-01 and will expire upon the later of (a) the expiration of all regulatory or data exclusivity granted to Pfizer in connection with varenicline in the United States; and (b) the expiration or abandonment of the last valid claims of the licensed patents. These commitments are not included in the table above due to uncertainty of timing of any such payments.

Critical Accounting Policies, Significant Judgments and Use of Estimates

Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates. For more detail on our critical accounting policies, refer to Note 1 "Organization and Summary of Significant Accounting Policies" to our audited financial statements included elsewhere in this Annual Report on Form 10-K.


Accrued Research and Development

We have entered into various agreements with CMOs and CROs. Our research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets until the services are rendered. To date, our estimated accruals have not differed materially from the actual costs.

Stock-Based Compensation

We use a fair value-based method to account for all stock-based compensation arrangements with employees and non-employees, including stock options and stock awards. The fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period, which usually is the vesting period. We account for forfeitures as they occur. In determining fair value of the stock options granted, we use the Black–Scholes model, which requires the input of subjective assumptions. These assumptions include: estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of our common stock price over the expected term (expected volatility), risk-free interest rate and expected dividends. Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized; and the resulting change in fair value, if any, is recognized in our statement of
84


operations and comprehensive loss during the period the related services are rendered. There are several assumptions that are required in the Black Scholes model.

•Expected Term – The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.

•Expected Volatility – We use an average historical stock price volatility of a peer group of comparable publicly traded companies in biotechnology and pharmaceutical related industries to be representative of its expected future stock price volatility, as we do not have any trading history for our common stock. For purposes of identifying these peer companies, we consider the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, we measure historical volatility over a period equivalent to the expected term.

•Expected Dividend Rate – We have not paid and do not anticipate paying any dividends in the near future. Accordingly, we estimate the dividend yield to be zero.

•Risk-Free Interest Rate – The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock award.

Common Stock Valuations prior to our IPO

Prior to our IPO, the estimated fair value of the common stock underlying our stock options and stock awards was determined at each grant date by our board of directors, with input from management. All options to purchase shares of our common stock were intended to be exercisable at a price per share not less than the per-share fair value of our common stock underlying those options on the date of grant.

Prior to the IPO, on each grant date, we developed an estimate of the fair value of our common stock based on the information known to us on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock, and valuations from an independent third-party valuation firm.

Prior to the IPO our valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation, or the Practice Aid.

The assumptions used to determine the estimated fair value of our common stock prior to the IPO were based on numerous objective and subjective factors, combined with management judgment, including:

•external market conditions affecting the pharmaceutical and biotechnology industry and trends within the industry;

•our stage of development and business strategy;

•the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common stock;

•the prices at which we sold shares of our redeemable convertible preferred stock;

•our financial condition and operating results, including our levels of available capital resources;

•the progress of our research and development efforts;

•equity market conditions affecting comparable public companies; and

•general U.S. market conditions and the lack of marketability of our common stock.

The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods:

85


•Option Pricing Method. Under the option pricing method, or OPM, shares are valued by creating a series of call options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common stock are inferred by analyzing these

•Probability-Weighted Expected Return Method. The probability-weighted expected return method, or PWERM, is a scenario-based analysis that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class.

Based on our early stage of development and other relevant factors, we determined that OPM method as well as a hybrid approach of the OPM and the PWERM methods were the most appropriate methods for allocating our enterprise value to determine the estimated fair value of our common stock. In valuing the equity prior to the IPO, our board of directors also considered the fact that our stockholders could not freely trade our common stock in the public markets. Accordingly, we applied discounts to reflect the lack of marketability of our common stock based on the weighted-average expected time to liquidity. The estimated fair value of our common stock at each grant date prior to our IPO reflected a non-marketability discount partially based on the anticipated likelihood and timing of a future liquidity event.

Common Stock Valuations following our IPO

Subsequent to the IPO, the fair value of our common stock is based on the closing quoted market price of our common stock as reported by the NASDAQ Global Select Market on the date of grant.

Income Taxes

We provide for income taxes under the asset and liability method. Current income tax expense or benefit represents the amount of income taxes expected to be payable or refundable for the current year. Deferred income tax assets and liabilities arise due to differences between when assets or liabilities are recognized for tax purposes and when they are recognized for financial reporting purposes. Net operating losses and credit carryforwards are also deferred tax assets. Deferred tax assets and liabilities are measured using the enacted tax rates and laws that will be in effect when such items are expected to reverse. Deferred income tax assets are reduced, as necessary, by a valuation allowance when management determines it is more likely than not that some or all of the tax benefits will not be realized.

We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination that the position meets the more-likely-than-not threshold and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we will determine whether the factors underlying the more-likely-than-not threshold assertion have changed and the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Our policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Net operating loss carryforwards and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50 percentage points as defined under Sections 382 and 383 in the Internal Revenue Code, which could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. We have determined that no significant limitation would be placed on the utilization of our net operating loss and tax credit carryforwards due to prior ownership changes. Subsequent ownership changes may affect the limitation in future years.
As of December 31, 2019, and 2018, we had unrecognized tax benefits, all of which would affect income tax expense if recognized, before consideration of our valuation allowance. We do not expect that our uncertain tax positions will materially change in the next 12 months.


86


Off-Balance Sheet Arrangements

Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.

Indemnification Agreements

We enter into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, we indemnify, hold harmless and agree to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, including in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to our technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The maximum potential amount of future payments we could be required to make under these arrangements is not determinable. We have never incurred costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the fair value of these agreements is minimal.

We have also agreed to indemnify our directors and officers for certain events or occurrences while the director or officer is, or was serving, at our request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments we could be required to make under these indemnification agreements is not specified in the agreements; however, we have director and officer insurance coverage that reduces our exposure and enables us to recover a portion of any future amounts paid. We believe the estimated fair value of these indemnification agreements in excess of applicable insurance coverage is minimal.

JOBS Act Accounting Election

The Jumpstart Our Business Startups Act of 2012 (JOBS Act) permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. However, we have chosen to irrevocably “opt out” of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act.

We will remain an emerging growth company until the earliest to occur of: (1) the last day of our first fiscal year in which we have total annual revenues of more than $1.07 billion; (2) the date we qualify as a “large accelerated filer,” with at least $700.0 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering.

Recent Accounting Pronouncements

See the section titled “Organization and Summary of Significant Accounting Policies” in Note 1 to our financial statements included elsewhere in this Annual Report in the Form 10-K for additional information.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity
The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates or exchange rates. As of December 31, 2019, we had cash equivalents of $138.1 million, consisting of interest-bearing money market funds for which the fair value would be affected by changes in the general level of U.S. interest rates. However, due to the short-term maturities and the low-risk profile of our cash equivalents, an immediate 10% relative change in interest rates would not have a material effect on the fair value of our cash equivalents or on our future interest income.
We do not believe that inflation, interest rate changes or foreign currency exchange rate fluctuations have had a significant impact on our results of operations for any periods presented herein.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
The information required by this item may be found in Part IV, Item 15 of this Form 10-K.
87


ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES

None.
ITEM 9A. CONTROLS AND PROCEDURES

Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures

As of December 31, 2019, management, with the participation of our Chief Executive Officer and Chief Financial Officer, performed an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that, as of December 31, 2019, our disclosure controls and procedures were not effective due to the material weaknesses described below.

Notwithstanding the identified material weaknesses, management, including our Chief Executive Officer and our Chief Financial Officer, believes the financial statements included in this Annual Report on Form 10-K fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods presented in accordance with U.S. GAAP.

In designing and evaluating our disclosure controls and procedures, management recognizes that any disclosure controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Material Weaknesses in Internal Control over Financial Reporting

During 2019, in connection with the audits of our financial statements as of and for the years ended December 31, 2018 and 2017, we identified two material weaknesses in our control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis.

The first material weakness we identified is that we did not design or maintain an effective control environment commensurate with our financial reporting requirements. Specifically, we lacked a sufficient number of professionals with an appropriate level of accounting knowledge, training and experience to appropriately analyze, record and disclose accounting matters timely and accurately. This material weakness contributed to an additional material weakness in that we did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, including controls over the preparation and review of account reconciliations and journal entries.

These material weaknesses resulted in an audit adjustment to decrease operating expenses and accounts payable in the year ended December 31, 2018, and audit adjustments to the income tax footnote in the year ended December 31, 2019, that were not material. Additionally, each of the above material weaknesses could result in a misstatement of the aforementioned account balances or disclosures that would result in a material misstatement to our annual or interim financial statements that would not be prevented or detected.

Remediation Plan

We have taken or are in the process of taking the following actions to begin to address the material weaknesses described above:

•we hired a full-time Chief Financial Officer and Controller in July 2019 and October 2019, respectively, and replaced part-time contractors used in these positions previously;

•we have hired and are continuing to actively seek to hire additional accounting and finance staff members to augment our current staff and to improve the effectiveness of our closing and financial reporting processes;

88


•we proactively assessed significant accounting transactions and other technical accounting and financial reporting issues, and used technical accounting consultants to prepare accounting memoranda addressing these issues;

•we have strengthened our financial statements review procedures and the supervisory reviews by our management that are performed during the financial close process; and

•we are continuing to formalize and implement our accounting policies and internal controls and the related documentation.

While we believe that these efforts will improve our internal control over financial reporting, the implementation of these measures is ongoing and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period of financial reporting cycles.

We believe we are making progress toward achieving the effectiveness of our internal controls and disclosure controls. The actions that we are taking are subject to ongoing management review, as well as audit committee oversight. We will not be able to conclude whether the steps we are taking will fully remediate these material weaknesses in our internal control over financial reporting until we have completed our remediation efforts and subsequent evaluation of their effectiveness. We may also conclude that additional measures may be required to remediate the material weaknesses in our internal control over financial reporting, which may necessitate additional implementation and evaluation time. We will continue to assess the effectiveness of our internal control over financial reporting and take steps to remediate the known material weaknesses expeditiously.

Changes in Internal Control over Financial Reporting

We are taking actions to remediate the material weaknesses relating to our internal controls over financial reporting, as described above in the remediation plan. Except as otherwise disclosed herein, there have been no changes in our internal control over financial reporting during year ended December 31, 2019 that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Management recognizes that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud or error, if any, have been detected. These inherent limitations include the realities that judgments in decision making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Management’s Report on Internal Control over Financial Reporting

This Annual Report on Form 10-K does not include a report of management’s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies.


ITEM 9B. OTHER INFORMATION

None.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The information required by this item will be contained in our definitive proxy statement to be filed with the SEC in connection with the Annual Meeting of Stockholders within 120 days after December 31, 2019 (the Proxy Statement), and is incorporated in this Annual Report on Form 10-K by reference.
89


ITEM 11. EXECUTIVE COMPENSATION

The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS MATTERS

The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

The information required by this item will be contained in the Proxy Statement and is incorporated in this Annual Report on Form 10-K by reference.
90


PART IV
Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
(a) The following documents are filed as part of this report:
(1) Financial Statements:



(2) Financial Statement Schedules
All financial statement schedules are omitted because they are not applicable or the amounts
are immaterial or the required information is presented in the financial statements and
notes thereto.

(3) Exhibits
The following is a list of the exhibits filed as part of this report.
Exhibit
Number
DescriptionFormFile No.NumberFiling Date
Amended and Restated Certificate of Incorporation of the Registrant.8-K001-391123.1November 5, 2019
Amended and Restated Bylaws of the Registrant.8-K001-391123.2November 5, 2019
Description of Securities of the Registrant.
Form of Common Stock Certificate.S-1/A333-2341044.2October 15, 2019
Amended and Restated Investor Rights Agreement among the Registrant and certain of its stockholders, dated February 15, 2019.S-1333-2341044.1October 4, 2019
Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.S-1333-23410410.1October 4, 2019
2016 Equity Incentive Plan, as amended, and forms of agreement thereunder. S-1333-23410410.2October 4, 2019
2019 Equity Incentive Plan and forms of agreements thereunder.S-1/A333-23410410.3October 21, 2019
2019 Employee Stock Purchase Plan.S-1/A333-23410410.4October 21, 2019
Employment Offer Letter between the Registrant and Jeffrey Nau, Ph.D., M.M.S.S-1333-23410410.5October 4, 2019
Employment Offer Letter between the Registrant and Daniel Lochner.S-1333-23410410.6October 4, 2019
91


Employment Offer Letter between the Registrant and John Snisarenko.S-1333-23410410.7October 4, 2019
Form of Change in Control and Severance Agreement.S-1333-23410410.8October 4, 2019
Outside Director Compensation Policy.S-1333-23410410.9October 4, 2019
Executive Incentive Compensation Plan.S-1333-23410410.10October 4, 2019
Non-Exclusive Patent License Agreement between the Registrant and Pfizer Inc., dated as of October 18, 2019.S-1/A333-23410410.11October 21, 2019
Consent of Independent Registered Public Accounting Firm.
Power of Attorney (contained in the signature page to this Annual Report on Form 10-K).
Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Label Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
* Filed herewith.
# Certain confidential portions (indicated by brackets and asterisks) have been omitted from this exhibit.
+ The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed
filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the
Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made
before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained
in such filing.
^ Indicates management contract or compensatory plan
ITEM 16. FORM 10-K SUMMARY

None.
92


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

OYSTER POINT PHARMA, INC.
Date: February 27, 2020
By:/s/ Jeffrey Nau
Jeffrey Nau, Ph.D., M.M.S.
President, Chief Executive Officer and Director

Date: February 27, 2020
By:/s/ Daniel Lochner
Daniel Lochner
Chief Financial Officer
































93

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jeffrey Nau and Daniel Lochner, jointly and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:
















94

SignatureTitleData
/s/ Jeffrey NauChief Executive Officer, President and DirectorFebruary 27, 2020
Jeffrey Nau, Ph.D., M.M.S.(Principal Executive Officer)
/s/ Daniel LochnerChief Financial OfficerFebruary 27, 2020
Daniel Lochner(Principal Financial and Accounting Officer)
/s/ Michael AckermannChair of the BoardFebruary 27, 2020
Michael Ackermann, Ph.D.
February 27, 2020
/s/ Mark MurrayDirector
Mark Murray
/s/ Ali BehbahaniDirectorFebruary 27, 2020
Ali Behbahani, M.D.
/s/ William J. LinkDirectorFebruary 27, 2020
William J. Link, Ph.D.
/s/ Clare OzawaDirectorFebruary 27, 2020
Clare Ozawa, Ph.D.
/s/ Benjamin TsaiDirectorFebruary 27, 2020
Benjamin Tsai
/s/ Aimee WeisnerDirectorFebruary 27, 2020
Aimee Weisner

95

OYSTER POINT PHARMA, INC.
Index to Financial Statements





F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors and Stockholders of Oyster Point Pharma, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Oyster Point Pharma, Inc. (the “Company”) as of December 31, 2019 and 2018, and the related statements of operations and comprehensive loss, of redeemable convertible preferred stock and stockholders' equity (deficit) and of cash flows for the years then ended, including the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.



/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 27, 2020

We have served as the Company’s auditor since 2017.
F-2

OYSTER POINT PHARMA, INC.
Balance Sheets
(in thousands, except share and per share amounts)

December 31, 2019December 31, 2018
Assets
Current assets:
Cash and cash equivalents$139,147  $5,228  
Prepaid expenses and other current assets3,033  390  
Total current assets142,180  5,618  
Restricted cash51  —  
Operating lease right-of-use asset797  66  
Property and equipment, net181  —  
Other non-current assets—  20  
Total assets$143,209  $5,704  
Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)
Current liabilities:
Accounts payable$500  $462  
Accrued liabilities4,603  422  
Operating lease liability296  56  
Total current liabilities5,399  940  
Non-current liabilities:
Operating lease liability, non-current512  6  
Total liabilities5,911  946  
Commitments and contingencies (Note 5)
Series A redeemable convertible preferred stock: $0.001 par value per share - no shares authorized, issued and outstanding at December 31,2019 and 7,611,691 shares authorized, issued and outstanding at December 31, 2018; liquidation preference $43,126 at December 31, 2018
$—  $43,001  
Stockholders’ equity (deficit)
Preferred stock: $0.001 par value per share - 5,000,000 shares authorized and no shares issued and outstanding as of December 31, 2019 and no shares authorized, issued and outstanding as of December 31, 2018
—  —  
Common stock, $0.001 par value per share - 1,000,000,000 authorized shares at December 31, 2019, and 10,943,000 shares authorized at December 31, 2018; 21,366,950 shares issued and outstanding at December 31, 2019, and 1,411,966 shares issued and outstanding at December 31, 2018
21  1  
Additional paid-in-capital221,508  276  
Accumulated deficit(84,231) (38,520) 
Total stockholders’ equity (deficit)137,298  (38,243) 
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
$143,209  $5,704  



The accompanying notes are an integral part of these financial statements.






F-3

OYSTER POINT PHARMA, INC.
Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)

Year Ended December 31,
20192018
Operating expenses:
Research and development$33,628  $13,755  
General and administrative13,673  2,981  
Total operating expenses47,301  16,736  
Loss from operations(47,301) (16,736) 
Interest income1,590  233  
Net loss and comprehensive loss$(45,711) $(16,503) 
Net loss per share attributable to common stockholders, basic and 
diluted		$(9.97) $(11.69) 
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted
4,585,146  1,411,966  



The accompanying notes are an integral part of these financial statements.
F-4

OYSTER POINT PHARMA, INC.
Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share amounts)

Redeemable Convertible Preferred StockCommon StockAdditional Paid-In Capital  Accumulated Deficit  Total Stockholders’ Equity (Deficit)
Shares  Amount  Shares  Amount  
Balance at January 1, 20187,611,691  $43,001  1,411,966  $1  $122  $(22,017) 

$(21,894) 
Net loss—  —  —  —  —  (16,503) 

(16,503) 
Stock-based compensation—  —  —  —  154  —  

154  
Balance at December 31, 20187,611,691  $43,001  1,411,966  $1  $276  $(38,520) $(38,243) 
Net loss—  —  —  —  —  (45,711) (45,711) 
Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $148
6,581,590  92,852  —  —  —  —  

—  
Issuance of common stock upon initial public offering, net of issuance cost of $9,898
—  —  5,750,000  6  82,096  —  82,102  
Conversion of redeemable convertible preferred stock into common stock upon initial public offering(14,193,281) (135,853) 14,193,281  14  135,839  —  135,853  
Stock issued through exercise of stock options—  —  11,703  —  31  —  31  
Stock-based compensation expense—  —  —  —  3,266  —  3,266  
Balance at December 31, 2019—  $—  21,366,950  $21  $221,508  $(84,231) $137,298  




The accompanying notes are an integral part of these financial statements.
F-5

OYSTER POINT PHARMA, INC.
Statements of Cash Flows
(in thousands)

Year Ended December 31,
20192018
Cash flows from operating activities
Net loss$(45,711) $(16,503) 
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense3,266  154  
Depreciation and amortization19  —  
Changes in assets and liabilities:
Prepaid expenses and other current assets(2,643) 473  
Other non-current assets20  (20) 
Accounts payable38  44  
Operating lease right-of-use asset(731) (66) 
Operating lease liability746  62  
Accrued liabilities4,181  (1,227) 
Net cash used in operating activities(40,815) (17,083) 
Cash flows from investing activities
Purchases of property and equipment(200) —  
Net cash used in investing activities(200) —  
Cash flows from financing activities
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs92,852  —  
Proceeds from initial public offering, net of issuance costs82,102  —  
Proceeds from the issuance of common stock upon exercise of stock options31  —  
Net cash provided by financing activities174,985  —  
Net increase (decrease) in cash and cash equivalents133,970  (17,083) 
Cash and cash equivalents at the beginning of the period5,228  22,311  
Cash, cash equivalents and restricted cash at the end of the period$139,198  $5,228  
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents139,147  5,228  
Restricted cash51  —  
Cash, cash equivalents and restricted cash139,198  5,228  
Supplemental cash flow information
Right-of-use for office space acquired through operating leases$897  $113  
Supplemental non-cash investing and financing activities
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering$(135,853) $—  



The accompanying notes are an integral part of these financial statements.
F-6

OYSTER POINT PHARMA, INC.
Notes to Financial Statements
(in thousands, except share and per share data)
1. Organization and Summary of Significant Accounting Policies
Description of the Business
Oyster Point Pharma, Inc. (the “Company”) was incorporated on June 30, 2015. From inception through December 31, 2019, the Company has been primarily engaged in business planning, research, clinical development of its lead therapeutic product candidates, recruiting and raising capital. The Company is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The Company’s principal office is located in Princeton, New Jersey.
Initial Public Offering

On November 4, 2019, the Company completed its initial public offering (IPO) selling 5,750,000 shares of common stock at a price to the public of $16.00 per share. The aggregate net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were $82.1 million. In addition, upon the closing the IPO, all outstanding shares of redeemable convertible preferred stock outstanding were converted into an aggregate of 14,193,281 shares of the Company’s common stock.

Liquidity

Since inception, the Company has incurred recurring losses and negative cash flows from operations. The Company incurred net losses of $45.7 million and $16.5 million for the years ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $84.2 million as of December 31, 2019. The Company has historically financed its operations primarily through the sale and issuance of its securities. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. The Company expects to incur increased sales and marketing expenses with the commercialization of new and existing products, if approved for sale, as well as increased research and development expenses as it develops additional product candidates. The Company expects its operating losses to continue to increase for the foreseeable future.

While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms that are favorable, or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives.

The Company had cash and cash equivalents of $139.1 million as of December 31, 2019. Management believes that the Company’s current cash and cash equivalents will be sufficient to fund its planned operations for at least 12 months from the date of issuance of these financial statements.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Reverse Stock Split
In October 2019, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 2.832861-for-1 reverse stock split of the Company’s common stock and redeemable convertible preferred stock, which was effected on October 18, 2019. The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, redeemable convertible preferred stock, stock options, and related per share amounts as of and for the year ended December 31, 2018 and for the period through October 18, 2019 have been retroactively adjusted to give effect to the reverse stock split.

F-7


Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to the valuation of stock awards, income taxes and certain research and development accruals and for periods prior to the IPO, the valuation of convertible notes, derivative instruments, and redeemable convertible preferred stock. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.

Segments

The Company operates and manages its business as one reportable operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company's long-lived assets are located in the United States.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s cash equivalents are invested in highly rated money market funds.

Risks and Uncertainties

The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Company’s ability to attract and retain employees necessary to support its growth.

Product candidates developed by the Company will require approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance that the product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company.

The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.

The Company relies on single source manufacturers and suppliers for the supply of its product candidates. Disruption from these manufacturers or suppliers would have a negative impact on the Company’s business, financial position and results of operations. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December 31, 2019 and 2018, cash and cash equivalents consisted of cash on deposit with a bank denominated in U.S. dollars and investment in money market funds.




F-8

Restricted Cash

As of December 31, 2019, the Company had $51,000 of long-term restricted cash deposited with a financial institution. The entire amount is held in a separate bank account to support a letter of credit agreement related to one of the Company’s office facilities lease, which expires in 2022.

Property and Equipment

Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets as follows:

Office equipment   5 years
Furniture and fixtures  7 years
Leasehold improvements  Shorter of lease term or estimated useful life

Leases

The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of a contract. The Company’s operating lease asset is included in “operating lease right-of-use asset” (“ROU asset”), and the current and non-current portions of the operating lease liability are included in “operating lease liability”, and “operating lease liability, non-current”, respectively, on the balance sheets. As of December 31, 2019 and 2018, the Company had no finance leases.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease components as a single lease component for operating leases. The Company does not record leases with terms of 12 months or less on the balance sheets.

As the implicit rate for the operating lease was not determinable, the Company used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The Company’s incremental borrowing rate was estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determined the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated.

Fair Value of Financial Instruments

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities.

Redeemable Convertible Preferred Stock

The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition, or sale of all or substantially all of the Company’s assets (each, a “deemed liquidation event”), the redeemable convertible preferred stock have become redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of redeemable convertible preferred stock was not probable of occurring. All outstanding shares of redeemable convertible preferred stock were converted to common stock shares upon the closing of the IPO in November 2019.

Research and Development

Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (“CMOs”), costs for clinical research organizations (“CROs”), costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses within the statements of operations and comprehensive loss as incurred.
F-9

Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred.

The Company’s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, and the expected life of the award.

Comprehensive Loss

Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.

Income Taxes

The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line. Accrued interest and penalties are included within the related income tax liability line in the balance sheets. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Net Loss per Share Attributable to Common Stockholders

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was a participating security. The Company’s participating securities did not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.

Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.

F-10

Recently adopted accounting pronouncements
In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. This ASU simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants, preferred shares and convertible debt instruments issued by private companies and early-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in Part I should be applied (1) retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the first fiscal year and interim periods; (2) retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The ASU permits companies to reclassify disproportionate tax effects in accumulated other comprehensive income (“AOCI”) caused by the Tax Act to retained earnings. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.
Recently issued accounting pronouncements not yet adopted
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This ASU removes the requirement to disclose: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.
2. Fair Value Measurements
The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering
F-11

such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
Level 1 Quoted prices in active markets for identical assets or liabilities.
Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.
As of December 31, 2019, financial assets measured and recognized at fair value were as follows (in thousands):

Fair Value Measurements at December 31, 2019
Quoted Price in Active Markets for Identical Assets (Level 1)
Significant Other Observable Inputs (Level 2)
Significant Unobservable Inputs (Level 3)
Total
Assets
Money market funds$138,147  $—  $—  $138,147  
Total fair value of assets$138,147  $—  $—  $138,147  

As of December 31, 2018, financial assets measured and recognized at fair value were as follows (in thousands):

Fair Value Measurements at December 31, 2018
Quoted Price
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets
Money market funds$5,228  $—  $—  $5,228  
Total fair value of assets$5,228  $—  $—  $5,228  

Money market funds are included in cash and cash equivalents on the balance sheets and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

There were no financial liabilities measured and recognized at fair value as of December 31, 2019 and December 31, 2018.

F-12

3. Property and Equipment, net
Property and equipment consisted of the following (in thousands):

December 31, 2019
Leasehold improvements$105  
Office equipment45  
Furniture and fixtures50  
200  
Accumulated depreciation(19) 
Property and equipment, net$181  

The Company did not have any property and equipment as of December 31, 2018.
4. Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):

December 31,
20192018
Accrued compensation$1,214  $367  
Accrued professional services1,163  35  
Accrued research and development expense2,219  —  
Accrued other liabilities7  20  
Total$4,603  $422  

5. Commitments and Contingencies
Asset Purchase of OC-02
In October 2016, the Company entered into an asset purchase agreement pursuant to which the Company acquired the compound OC-02. The agreement provides for milestone payments of up to $37.0 million upon achievement of certain milestone events. The agreement also provides for royalty payments in the mid-single digit percentage on covered product net worldwide sales. The Company’s obligation to pay royalties will terminate at the latter of patent expiration in each country or ten years. In addition, the Company is required to pay 15% of any (i) licensing revenue received that is related to OC-02 and (ii) revenue received from the sale of OC-02, up to a maximum aggregate amount of $10.0 million.

License Agreement
In October 2019, the Company entered into a non-exclusive patent license agreement (the License Agreement) with Pfizer, which granted the Company non-exclusive rights under Pfizer’s patent rights covering varenicline tartrate to develop, manufacture, and commercialize the OC-01 varenicline product candidate. Under the terms of the License Agreement, the Company made an upfront payment to Pfizer of $5.0 million, which is included in research and development expense for the year ended December 31, 2019. If the Company successfully commercializes OC-01, it may be required to pay a single milestone payment in the very low double-digit millions and tiered royalties on net sales of OC-01 at percentages ranging from the mid-single digits to the mid-teens. The royalty obligation to Pfizer will commence upon the first commercial sale of OC-01 and will expire upon the later of (a) the expiration of all regulatory or data exclusivity granted to Pfizer in connection with varenicline in the United States; and (b) the expiration or abandonment of the last valid claims of the licensed patents.




F-13

Operating Lease Obligations

In January 2018, the Company entered a lease for office space under a non-cancelable operating lease with an expiration date of March 15, 2020, in Princeton, New Jersey. Rent expense is recorded on a straight-line basis over the term of the lease. The total lease payment over the life of the lease is $0.1 million. The remaining lease term was 0.2 years as of December 31, 2019.
In April 2019, the Company entered a lease for office space under a non-cancelable operating lease in Princeton, New Jersey, commencing on July 1, 2019, for a period of three years from the commencement date. Rent expense is recorded on a straight-line basis over the term of the lease. The total lease payment over the life of the lease is $0.9 million. The remaining lease term was 2.5 years as of December 31, 2019.
At the commencement date, the Company determined the amounts of the lease liability using a discount rate of 9%, which management determined represents the Company’s incremental borrowing rate. Lease expense was $0.2 million and less than $0.1 million for the twelve months ended December 31, 2019 and December 31, 2018, respectively. Cash paid for amounts included in the measurement of the lease liability was $0.2 million and less than $0.1 million for the twelve months ended December 31, 2019 and December 31, 2018, respectively, and was included in cash flows from operating activities in the statements of cash flows.

The maturities of the lease liabilities under non-cancelable operating leases are as follows (in thousands):


As of December 31, 2018Amount
2019$59  
20207  
Total undiscounted cash flows66  
Less: imputed interest(4) 
Total operating lease liability62  
Less: current portion(56) 
Operating lease liability$6  

As of December 31, 2019Amount
2020$319  
2021316  
2022186  
Total undiscounted cash flows821  
Less: imputed interest(13) 
Total operating lease liability808  
Less: current portion(296) 
Operating lease liability$512  

In January 2020 the Company amended the lease of one its office facilities in Princeton, New Jersey to include additional office space, with an expiration date of July 31, 2022. Total future minimum lease payments under this amendment are $0.4 million.
Contingencies and Indemnifications
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications, including for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend
F-14

any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.
The Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid.
6. Income Taxes
The Company did not record a federal or state income tax provision or benefit for the for the years ended December 31, 2019 and December 31, 2018 as it has incurred net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.

The Company’s loss before provision for income taxes for the years ended December 31, 2019 and 2018 was as follows (in thousands):
Year Ended December 31,
20192018
Domestic$(45,711) $(16,503) 
International—  —  
Loss before provision for income taxes$(45,711) $(16,503) 

The Company had an effective tax rate of 0% for the years ended December 31, 2019 and 2018. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:

Year Ended December 31,
20192018
Federal statutory income tax rate21.0 %21.0 %
State taxes (tax effected)8.5 %9.2 %
Research tax credit3.3 %2.6 %
Other permanent differences(2.0)%(0.2)%
Change in valuation allowance(30.8)%(32.6)%
Provision for income taxes0.0%0 %

The components of the Company’s net deferred tax assets and liabilities as of December 31, 2019 and 2018, were as follows (in thousands):

F-15

December 31,
20192018
Deferred tax assets:
Net operating loss carryforwards$12,454  $4,826  
Credits2,408  662  
Tangible and intangible assets1,977  269  
Lease liability227  —  
Stock compensation253  —  
Other36  57  
Gross deferred tax assets17,355  5,814  
Less: Valuation allowance(16,423) (5,750) 
Deferred tax assets, net of valuation allowance 932  64  
Deferred tax liabilities:
Prepaids(708) (64) 
Right of use asset(224) —  
Net deferred tax assets$—  $—  

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s historical operating performance and the U.S. cumulative net losses in all prior periods, the Company has provided a valuation allowance against its U.S. deferred tax assets. The Company’s valuation allowance increased by $10.7 million for the year ended December 31, 2019 and by $4.0 million for the year ended December 31, 2018.

As of December 31, 2019, the Company has U.S. federal and state net operating losses of $59.1 million and $60.7 million, respectively, which expire beginning in the year 2035. As of December 31, 2018, the Company had U.S. federal and state net operating losses of $22.8 million and $22.9 million, respectively, which expire beginning in the year 2035.

Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

A Section 382 ownership change generally occurs if one or more stockholders or groups of stockholders who own at least 5% of the Company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. The Company has experienced an ownership change; however, the change will have no material limit on the Company’s net operating loss carryforwards. The Company is not in a taxable position and no net operating loss carryforwards have been used to date.

As of December 31, 2019 and 2018, the Company also had federal research and experimentation credit carryforwards of $2.1 million and $0.6 million, respectively, and state research and experimentation credit carryforwards of $0.4 and $0.1 million. The federal research and experimentation credit carryforwards expire beginning 2037. The California tax credit can be carried forward indefinitely.

As of December 31, 2019 and 2018, the Company had the following unrecognized tax benefits (in thousands):

Year Ended December 31,
20192018
Balance at the beginning of the year$1,989  $508  
Additions based on tax positions related to current year3,399  1,481  
Balance at the end of the year$5,388  $1,989  


F-16

The reversal of the unrecognized tax benefits would not affect the Company’s effective tax rate to the extent that it continues to maintain a full valuation allowance against its deferred tax assets. The Company does not expect any changes to uncertain tax benefits within the next twelve months.

The Company recognizes interest and penalties related to income tax matters as a component of income tax expense. No accrued interest and penalties have been recorded as of December 31, 2019 and 2018.

The Company files income tax returns in the U.S. federal, California and New Jersey jurisdictions. Due to the Company’s net losses, its federal and state income tax returns are subject to examination for federal and state purposes since inception. As of December 31, 2019, there were no ongoing examinations.
7. Redeemable Convertible Preferred Stock

On February 15, 2019, the Company executed the Series B Preferred Stock Purchase Agreement to sell up to 6,581,590 shares of Series B redeemable convertible preferred stock. In February and April 2019, the Company received gross cash proceeds of $85.0 million and $8.0 million, respectively, from the sale of Series B redeemable convertible preferred stock.

On November 4, 2019, upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock were converted into an aggregate of 14,193,281 shares of the Company’s common stock and $135.9 million of mezzanine equity was reclassified to common stock and additional paid-in capital. As of December 31, 2019, there were no shares of redeemable convertible preferred stock issued and outstanding.

8. Common Stock

The Company amended and restated its certificate of incorporation, effective November 4, 2019, in connection with the IPO. The amended and restated certificate of incorporation authorizes the Company to issue 1,000,000,000 shares of common stock, at a par value of $0.001 per share. Each share of common stock is entitled to one vote.

The Company reserved common stock shares for future issuance as of December 31, 2019 and 2018 as follows:

December 31,

20192018
Conversion of Series A redeemable convertible preferred stock—  7,611,691  
Outstanding options under the 2016 Plan2,748,434  1,376,084  
Equity awards available for grants under the 2016 Plan—  216,333  
Outstanding options under the 2019 Plan29,466  —  
Unvested RSUs under the 2019 Plan23,125  —  
Equity awards available for grants under the 2019 Plan2,747,047  —  
Total5,548,072  9,204,108  

9. Equity Incentive Plans

In 2016, the Company established its 2016 Equity Incentive Plan (the “Plan”) which provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants.

In October 2019, the Company’s Board of Directors and stockholders approved the 2019 Equity Incentive Plan (the 2019 Plan), with an initial shares reserved of 2,700,000 shares of the Company's common stock plus 99,638 shares reserved but unissued under the 2016 Plan. The 2019 Plan provides for the granting of stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company's employees, directors, and others.
The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. To date, outstanding options have a term of 10 years and generally vest monthly over a four-year period.
As of December 31, 2019, there were 2,747,047 common stock shares reserved for future grants under the 2019 Plan.

In October 2019, the Company’s Board of Directors and stockholders also approved the 2019 Employee Stock Purchase Plan (the ESPP), which qualifies as an "employee stock purchase plan" under Section 423 of the Internal Revenue Code, and pursuant to which 270,000 shares of common stock were reserved for future issuance. The ESPP is designed to enable eligible employees to purchase shares of the Company's common stock at a discount on a periodic basis through payroll deductions. There were no ESPP purchases during the year ended December 31, 2019.

Option activity under the Company’s stock option plans is set forth below (in thousands, except share and per share data):


Outstanding Awards
Number of Shares Underlying Outstanding Options
Weighted- Average Exercise Price
Weighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at January 1, 2018
1,057,373
$1.00  9.85$25  
Options granted
318,711
1.02  
Outstanding at December 31, 20181,376,084  $1.00  8.90$5,950  
Options granted1,446,823  8.01  
Options exercised(11,703) 2.64  255  
Options canceled(33,304) 5.86  
Outstanding at December 31, 2019$2,777,900  $4.59  8.73$55,146  
Shares vested and exercisable as of December 31, 2019$1,108,041  $2.10  8.29$24,757  
Vested and expected to vest as of December 31, 2019$2,777,900  $4.59  8.73$55,146  
During the years ended December 31, 2019 and 2018, the Company granted options with a weighted-average grant date fair value of $8.62 and $0.53 per share, respectively.
The fair value of options that vested during the years ended December 31, 2019 and 2018 was $2.5 million and $0.2 million, respectively.

As of December 31, 2019, the total unrecognized stock-based compensation expense for stock options was $9.4 million, which is expected to be recognized over a weighted-average period of 3.21 years.

In October 2019, the Company granted restricted stock units (RSUs) for 23,125 common stock shares that will vest one-third annually over three years, subject to continuing services to be provided to the Company. Grant date fair value was $16.00 per share, which is the common stock market price at the grant date. As of December 31, 2019, the total unrecognized stock-based compensation expense for RSUs was $0.3 million, which is expected to be recognized over a weighted-average period of 2.83 years.
Stock-Based Compensation Expense

The following table is a summary of stock compensation expense by function recognized (in thousands):
Year Ended December 31,
20192018
Research and development$579  $21  
General and administrative2,687  133  
Total stock-based compensation$3,266  $154  

Fair Value of Options Granted

Prior to the IPO, the fair value of the Company’s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company’s common stock and the general and industry-specific economic outlook. Subsequent to the IPO, the fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Global Select Market on the date of grant.

In determining fair value of the stock options granted, the Company uses the Black-Scholes model, which requires the input of several assumptions. These assumptions include: estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), risk-free interest rate and expected dividend rate. Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized.

Expected term. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.

Expected volatility. The Company used an average historical stock price volatility of a peer group of comparable publicly traded companies in biotechnology and pharmaceutical related industries to be representative of its expected future stock price volatility, as the Company did not have any trading history for its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term.

Risk-free interest rate. The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock award.

Expected dividend rate. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero.

The fair value of options granted were calculated using the weighted average assumptions set forth below:
Year Ended December 31,
20192018
Expected volatility
69.0 - 84.0%
52.5%
Risk-free interest rate
1.48% - 2.38%
2.49% - 2.80%
Dividend yield
0.00%
0.00%
Expected term
5.04 - 6.08 years
6.02 years





F-17

10. Net Loss Per Share Attributable to Common Stockholders
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):

Year Ended December 31,
20192018
Numerator:
Net loss attributable to common stockholders$(45,711) $(16,503) 
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted4,585,146  1,411,966  
Net loss per share attributable to common stockholders, basic and diluted
$(9.97) $(11.69) 
The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

Year Ended December 31,
20192018
Series A redeemable convertible preferred stock—  7,611,691  
Options to purchase common stock2,777,900  1,376,084  
Unvested restricted stock units23,125  —  
Total2,801,025  8,987,775  

11. Quarterly Results of Operations Data (unaudited)
The following table sets forth our unaudited statement of operations and comprehensive loss data for each of the eight quarters in the two-year period ended December 31, 2019. The unaudited quarterly statement of operations and comprehensive loss data set forth below have been prepared on a basis consistent with the audited annual financial statements and include, in our opinion, all normal recurring adjustments necessary for a fair statement of the financial information contained in those statements. Our historical results are not necessarily indicative of the results that may be expected in the future. The following quarterly financial data should be read in conjunction with our audited financial statements and the related notes.
Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2019 (in thousands, except share and per share data):

F-20

Three months ended
March 31, 2019June 30, 2019September 30, 2019December 31, 2019
Operating expenses:
Research and development$2,405  $8,101  $8,088  $15,034  
General and administrative1,605  3,132  3,809  5,127  
Total operating expenses4,010  11,233  11,897  20,161  
Loss from operations(4,010) (11,233) (11,897) (20,161) 
Interest income250  503  400  437  
Net loss and comprehensive loss$(3,760) $(10,730) $(11,497) $(19,724) 
Basic and diluted net loss per share$(2.66) $(7.60) $(8.10) $(1.41) 
Weighted average shares outstanding1,411,966  1,412,354  1,419,064  13,993,730  

Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2018 (in thousands, except share and per share data):

Three months ended
March 31, 2018June 30, 2018September 30, 2018December 31, 2018
Operating expenses:
Research and development$2,374  $2,261  $5,775  $3,345  
General and administrative626  735  916  704  
Total operating expenses3,000  2,996  6,691  4,049  
Loss from operations(3,000) (2,996) (6,691) (4,049) 
Interest income66  70  59  38  
Net loss and comprehensive loss$(2,934) $(2,926) $(6,632) $(4,011) 
Basic and diluted net loss per share$(2.08) $(2.07) $(4.70) $(2.84) 
Weighted average shares outstanding1,411,966  1,411,966  1,411,966  1,411,966  


Per share amounts for each quarter have been calculated separately. Accordingly, quarterly amounts may not add to annual amounts.

F-21
 EX-4.1 2 q4-19ex41.htm EX-4.1 Document

Exhibit 4.1

DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934

The following summary describes our common stock and preferred stock, as well as certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions of our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to this Annual Report on Form 10-K, as well as to the applicable provisions of the Delaware General Corporation Law.

Authorized Capital Stock

Our authorized capital stock consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 5,000,000 shares of preferred stock, par value $0.001 per share. All outstanding shares of common stock are fully paid and non-assessable.

Common Stock

Our common stock is listed on the Nasdaq Global Select Market under the symbol “OYST.” The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar’s address is 250 Royall Street, Canton, MA 02021, and its telephone number is (800) 962-4284.

Voting Rights

Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors.

Dividends

Subject to preferences that may be applicable to any then-outstanding preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.

Liquidation

In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of preferred stock.
Rights and Preferences

Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate in the future.

Preferred Stock

Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to fix the designations, powers, preferences and rights, and the qualifications, limitations or restrictions thereof, of any wholly unissued series of Preferred Stock, including, without limitation, authority to fix by resolution or resolutions the dividend rights, dividend rate, conversion rights, voting rights, rights and terms of redemption (including sinking fund provisions), redemption price or prices, and


liquidation preferences of any such series, and the number of shares constituting any such series and the designation thereof, or any of the foregoing.
The issuance of shares of preferred stock will affect, and may adversely affect, the rights of holders of common stock. It is not possible to state the actual effect of the issuance of any shares of preferred stock on the rights of holders of common stock until our board of directors determines the specific rights attached to that preferred stock. The effects of issuing additional preferred stock could include one or more of the following:

•restricting dividends on the common stock;
•diluting the voting power of the common stock;
•impairing the liquidation rights of the common stock; or
•delaying or preventing changes in control or management of our Company.
Preferred stock will be fully paid and nonassessable upon issuance.

Registration Rights of Certain Stockholders

Certain of our stockholders have registration rights under an investors’ rights agreement, as amended (the “Investors’ Rights Agreement”), between us and such stockholders. These stockholders (and certain of their permitted transferees), may request that we file registration statements under the Securities Act of 1933 and, upon such request and subject to minimum size and other conditions, we will be required to effect any such registration. We are generally obligated to bear the expenses, other than underwriting discounts and sales commissions, of all of these registrations. This summary does not purport to be complete and is qualified in its entirety by the provisions of the Investors’ Rights Agreement, a copy of which has been filed as an exhibit to this Annual Report on Form 10-K.

Effect of Certain Provisions of our Amended and Restated Certificate of Incorporation and Bylaws and the Delaware Anti-Takeover Statute

Some provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could make the following transactions more difficult:

•acquisition of us by means of a tender offer;
•acquisition of us by means of a proxy contest or otherwise; or
•removal of our incumbent officers and directors.

Those provisions, summarized below, are expected to discourage coercive takeover practices and inadequate takeover bids and to promote stability in our management. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors.

Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws

Classified Board of Directors

Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated Class I, Class II, and Class III. Each class contains an equal number of directors, as nearly as possible, consisting of one-third of the total number of directors constituting our entire board of directors. The directors in each class are elected to serve for a three-year term, one class being elected each year by our stockholders. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term.

Removal of Directors

Our amended and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of at least a majority of the voting power of the issued and outstanding capital stock of our Company entitled to vote in the election of directors.

Director Vacancies



Vacancies and newly created directorships on our board of directors may be filled only by the affirmative vote of a majority of the remaining directors then in office, even though less than a quorum of the board of directors.

No Cumulative Voting

Our amended and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors.

Special Meetings of Stockholders

Our amended and restated certificate of incorporation and amended and restated bylaws provides that, except as otherwise required by law, special meetings of the stockholders may be called only by an officer at the request of a majority of our board of directors, by the chairperson of our board of directors, or by our Chief Executive Officer.

Amending our Certificate of Incorporation and Bylaws

Our amended and restated certificate of incorporation may be amended or altered in any manner provided by the DGCL. Our amended and restated bylaws may be adopted, amended, altered, or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the common stock, except for any amendment of certain provisions, including those listed above, which would require the approval of a two-thirds majority of our then outstanding common stock. Additionally, our amended and restated certificate of incorporation provides that our bylaws may be amended, altered, or repealed by our board of directors.

Authorized but Unissued Shares

Our authorized but unissued shares of common stock and preferred stock are available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of our Company by means of a proxy contest, tender offer, merger or otherwise.

Delaware Anti-Takeover Statute

We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. In general, Section 203 prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a period of three years following the date the person became an interested stockholder unless:

•prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

•upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers, and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or

•at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by


written consent, by the affirmative vote of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder.

Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock.



 EX-23.1 3 q4-19ex231.htm EX-23.1 Document

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (No. 333-234416) of Oyster Point Pharma, Inc. of our report dated February 27, 2020 relating to the financial statements, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP
Florham Park, New Jersey
February 27, 2020


 EX-31.1 4 q4-19ex311.htm EX-31.1 Document

Exhibit 31.1 
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Jeffrey Nau, certify that:

1.I have reviewed this Annual Report on Form 10-K of Oyster Point Pharma, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
    (a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    (b)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
     (a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

     (b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 27, 2020By:/s/ Jeffrey Nau


Jeffrey Nau, Ph.D., M.M.S.


President and Chief Executive Officer


(Principal Executive Officer)


 EX-31.2 5 q4-19ex312.htm EX-31.2 Document

Exhibit 31.2 
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Daniel Lochner, certify that:


1.I have reviewed this Annual Report on Form 10-K of Oyster Point Pharma, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
   (a)  Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

    (b)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

    (c)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
     (a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

     (b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date: February 27, 2020By:/s/ Daniel Lochner


Daniel Lochner


Chief Financial Officer


(Principal Financial and Accounting Officer)


 EX-32.1 6 q4-19ex321.htm EX-32.1 Document

Exhibit 32.1 
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Oyster Point Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey Nau, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 (1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 (2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: February 27, 2020By:/s/ Jeffrey Nau


Jeffrey Nau, Ph.D., M.M.S.


President and Chief Executive Officer


(Principal Executive Officer)


 EX-32.2 7 q4-19ex322.htm EX-32.2 Document

Exhibit 32.2 
CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Annual Report of Oyster Point Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel Lochner, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

 (1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

 (2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.


Date: February 27, 2020By:/s/ Daniel Lochner


Daniel Lochner


Chief Financial Officer


(Principal Financial and Accounting Officer)


 EX-101.SCH 8 oyst-20191231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2104102 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measures and Disclosures (Tables) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measures and Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Property and Equipment, net link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Property, Plant, and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Property, Plant, and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2110104 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2311303 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2412404 - Disclosure - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - Commitment and Contingencies link:presentationLink link:calculationLink link:definitionLink 2314304 - Disclosure - Commitment and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Commitment and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Commitment and Contingencies - Lease Maturity Schedules (Details) link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Commitment and Contingencies - Lease Maturity Schedules (Details) link:presentationLink link:calculationLink link:definitionLink 2117106 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2318305 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2419407 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2420408 - Disclosure - Income Taxes - Loss Before Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2421409 - Disclosure - Income Taxes - Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2422410 - Disclosure - Income Taxes - Deferred Tax Assets and liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2423411 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Redeemable Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 2425412 - Disclosure - Redeemable Convertible Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2126108 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 2428413 - Disclosure - Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Common Stock - Reserved Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2130109 - Disclosure - Equity Incentive Plans link:presentationLink link:calculationLink link:definitionLink 2331307 - Disclosure - Equity Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - Equity Incentive Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2433416 - Disclosure - Equity Incentive Plans - Option Activity During The Period (Details) link:presentationLink link:calculationLink link:definitionLink 2434417 - Disclosure - Equity Incentive Plans - Stock Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2435418 - Disclosure - Equity Incentive Plans - Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2136110 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 2337308 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 2438419 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 2439420 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2140111 - Disclosure - Quarterly Results of Operations Data (unaudited) link:presentationLink link:calculationLink link:definitionLink 2341309 - Disclosure - Quarterly Results of Operations Data (unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2442421 - Disclosure - Quarterly Results of Operations Data (unaudited) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 oyst-20191231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 10 oyst-20191231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 11 oyst-20191231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Less: Valuation allowance Deferred Tax Assets, Valuation Allowance Series A redeemable convertible preferred stock Series A Preferred Stock [Member] Acquisition Of OC-02 Compound Acquisition Of OC-02 Compound [Member] Acquisition Of OC-02 Compound Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Tax Credit Carryforward [Line Items] Tax Credit Carryforward [Line Items] Leases Lessee, Leases [Policy Text Block] Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Lease discount rate Lessee, Operating Lease, Discount Rate Commitments and Contingencies Commitments Contingencies and Guarantees [Text Block] Balance at the beginning of the year Balance at the end of the year Unrecognized Tax Benefits Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] International Income (Loss) from Continuing Operations before Income Taxes, Foreign Other non-current assets Increase (Decrease) in Other Noncurrent Assets Granted restricted stock units (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Increase in valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Entity Address, Postal Zip Code Entity Address, Postal Zip Code Outstanding options under the 2016 Plan (in shares) Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Issuance of common stock upon initial public offering, net of issuance cost of $9,898 Stock Issued During Period, Value, New Issues Payables and Accruals [Abstract] Stockholders’ equity (deficit) Retained Earnings (Accumulated Deficit) [Abstract] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Proceeds from initial public offering, net of issuance costs Proceeds from Issuance Initial Public Offering Total assets Assets Options exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Entity Shell Company Entity Shell Company Total operating lease liability Operating Lease, Liability Cover page. Shares vested and exercisable as of December 31, 2019, Weighted-Average Remaining Contractual Term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Document Type Document Type Temporary Equity Disclosure [Abstract] Subsequent Event Subsequent Event [Member] Net Income (Loss) Attributable to Parent [Abstract] Net Income (Loss) Attributable to Parent [Abstract] Operating lease liability Increase (Decrease) in Operating Lease Liability Increase (Decrease) in Operating Lease Liability Shares of redeemable convertible preferred stock issued (in shares) Temporary Equity, Shares Issued Share-based Payment Arrangement [Abstract] General and administrative General and Administrative Expense [Member] 2022 Lessee, Operating Lease, Liability, Payments, Due Year Four Current liabilities: Liabilities, Current [Abstract] Right-of-use for office space acquired through operating leases Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Leasehold improvements Leaseholds and Leasehold Improvements [Member] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Equity [Abstract] Number of Shares Underlying Outstanding Options Shares Granted or Issued, Share-based Payment Arrangement [Abstract] Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Income Tax Authority [Domain] Income Tax Authority [Domain] Commitments and contingencies (Note 5) Commitments and Contingencies Cash and cash equivalents at the beginning of the period Cash, cash equivalents and restricted cash at the end of the period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) Weighted average shares outstanding Weighted Average Number of Shares Outstanding, Basic and Diluted Class of Stock [Domain] Class of Stock [Domain] Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Money Market Funds Money Market Funds [Member] Domestic Income (Loss) from Continuing Operations before Income Taxes, Domestic Price per share (in usd per share) Sale of Stock, Price Per Share Entity File Number Entity File Number Vesting period of stock options (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Options canceled (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Document Fiscal Period Focus Document Fiscal Period Focus Research and experimentation credit carryforward Tax Credit Carryforward, Amount Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Loss from operations Operating Income (Loss) Operating Income (Loss) Reverse stock split Stockholders' Equity, Reverse Stock Split Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $148 Temporary Equity, Issuance Costs Temporary Equity, Issuance Costs Term of obligation to pay royalties Asset Acquisition, Royalty Payments, Term Asset Acquisition, Royalty Payments, Term Measurement Frequency [Domain] Measurement Frequency [Domain] Statement [Line Items] Statement [Line Items] Fair Value Disclosures [Abstract] Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering Conversion of Stock, Amount Converted Aggregate intrinsic value, options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Net Loss per Share Attributable to Common Stockholders Earnings Per Share, Policy [Policy Text Block] Plan Name [Axis] Plan Name [Axis] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Maximum milestone payments for acquisition Asset Acquisition, Maximum Milestone Payments Asset Acquisition, Maximum Milestone Payments 2019 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Statement of Stockholders' Equity [Abstract] Amendment Flag Amendment Flag Licensing Agreements Licensing Agreements [Member] Weighted- Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Loss before provision for income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Common stock shares outstanding (in shares) Beginning balance, common stock (in shares) Ending balance, common stock (in shares) Common Stock, Shares, Outstanding Right of use asset Deferred Tax Liabilities, Right-Of-Use Asset Deferred Tax Liabilities, Right-Of-Use Asset Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Quoted Price in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Unrecognized stock-based compensation expense Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Future minimum operating lease payments due under amended lease agreement Operating Leases, Future Minimum Payments Due Class of Stock [Axis] Class of Stock [Axis] Plan Name [Domain] Plan Name [Domain] Common Stock Stockholders' Equity Note Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Fair value of financial liabilities Financial Liabilities Fair Value Disclosure Other permanent differences Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Local Phone Number Local Phone Number Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Accrued liabilities Increase (Decrease) in Accrued Liabilities Lease payments due over the life of the lease Total undiscounted cash flows Lessee, Operating Lease, Liability, Payments, Due Property and Equipment Property, Plant and Equipment [Table Text Block] Lease expense (less than in 2018) Operating Lease, Expense Property, Plant and Equipment [Abstract] Additional paid-in-capital Additional Paid in Capital Organization and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Options canceled (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Stock-based compensation expense Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Par value of redeemable convertible preferred stock (in dollars per share) Temporary Equity, Par or Stated Value Per Share Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Options granted (in shares) Options granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Stock issued through exercise of stock options (in shares) Options exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Total current assets Assets, Current Entity Current Reporting Status Entity Current Reporting Status Issuance of Series B redeemable convertible preferred stock, net of issuance costs, shares Temporary Equity, Stock Issued During Period, Shares, New Issues Temporary Equity, Stock Issued During Period, Shares, New Issues Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Net loss and comprehensive loss Net loss Net Income (Loss) Attributable to Parent Net Income (Loss) Attributable to Parent Proceeds from the issuance of common stock upon exercise of stock options Proceeds from Stock Options Exercised Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments Common Stock Common Stock [Member] Current assets: Assets, Current [Abstract] Series B Preferred Stock Series B Preferred Stock [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Restricted cash Restricted Cash, Noncurrent Vested and expected to vest as of December 31, 2019, weighted average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Asset Acquisition [Domain] Asset Acquisition [Domain] Asset Acquisition Entity Small Business Entity Small Business Commitments and Contingencies Disclosure [Abstract] Entity Filer Category Entity Filer Category Condensed Income Statement Condensed Income Statement [Table Text Block] Accrued other liabilities Other Accrued Liabilities, Current Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Total stock-based compensation Share-based Payment Arrangement, Expense Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) Liabilities and Equity Quarterly Results of Operations Data (unaudited) Condensed Financial Information of Parent Company Only Disclosure [Text Block] Conversion of redeemable convertible preferred stock into common stock upon initial public offering (in shares) Stock Issued During Period, Shares, Conversion of Convertible Securities Entity Address, City or Town Entity Address, City or Town Income Tax Disclosure [Abstract] Document Annual Report Document Annual Report Deferred Tax Liabilities, Leasing Arrangements Deferred Tax Liabilities, Leasing Arrangements Operating lease liability, non-current Operating lease liability Operating Lease, Liability, Noncurrent Operating expenses: Operating Expenses [Abstract] Preferred stock authorized (in shares) Preferred Stock, Shares Authorized Additions based on tax positions related to current year Unrecognized Tax Benefits, Period Increase (Decrease) Risk-free interest rate, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Aggregate gross proceeds from offering Sale of Stock, Consideration Received on Transaction 2019 ESPP The 2019 Employee Stock Purchase Plan [Member] The 2019 Employee Stock Purchase Plan Document Fiscal Year Focus Document Fiscal Year Focus Number of common stock sold and issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Weighted-average grant-date fair value of options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Financial assets measured and recognized at fair value Fair Value, by Balance Sheet Grouping [Table Text Block] Deferred tax liabilities: Deferred Tax Liabilities, Deferred Expense [Abstract] Federal statutory income tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Vested and expected to vest as of December 31, 2019 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Fair Value, Recurring Fair Value, Recurring [Member] Net operating loss carryforwards Operating Loss Carryforwards Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Award Type [Axis] Award Type [Axis] Class of Stock [Line Items] Class of Stock [Line Items] Redeemable Convertible Preferred Stock Redeemable Convertible Preferred Stock [Member] Payments made for leases (less than in 2018) Operating Lease, Payments Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Issuance of Series B redeemable convertible preferred stock, net of issuance cost, amount Temporary Equity, Stock Issued During Period, Value, New Issues Accumulated Deficit Retained Earnings [Member] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Condensed Financial Information Disclosure [Abstract] Percent of shares owned by individual stockholder Share-Based Compensation Arrangement By Share-Based Payment Award, Company Stock Ownership By Stockholder, Percentage Share-Based Compensation Arrangement By Share-Based Payment Award, Company Stock Ownership By Stockholder, Percentage Document Period End Date Document Period End Date Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Statement [Table] Statement [Table] Entity Registrant Name Entity Registrant Name Property, Plant and Equipment, Useful Life Property, Plant and Equipment, Useful Life Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Maximum Maximum [Member] Shares authorized for 2019 Equity Incentive Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] State taxes (tax effected) Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent 2021 Lessee, Operating Lease, Liability, Payments, Due Year Three Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Weighted-average remaining contractual term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Term of outstanding options (in years) Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award Domestic Tax Authority Domestic Tax Authority [Member] Entity Public Float Entity Public Float Redeemable convertible preferred stock Redeemable convertible preferred stock, amount, beginning balance Redeemable convertible preferred stock, amount, ending balance Temporary Equity, Carrying Amount, Attributable to Parent Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Accumulated deficit Retained Earnings (Accumulated Deficit) Lease Arrangements [Domain] Lease Arrangements [Domain] Lease Arrangements Entity Tax Identification Number Entity Tax Identification Number Accrued interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Number of reportable segments Number of Reportable Segments Shares vested and exercisable as of December 31, 2019 Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Trading Symbol Trading Symbol Minimum Minimum [Member] Comprehensive Loss Comprehensive Income, Policy [Policy Text Block] Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs Proceeds from Issuance of Redeemable Convertible Preferred Stock Expected term of recognition of RSU compensation cost Share-based compensation arrangement by share based payment award, cost not yet recognized, weighted average term Share-based compensation arrangement by share based payment award, cost not yet recognized, weighted average term Options to purchase common stock Equity Option [Member] Statistical Measurement [Domain] Statistical Measurement [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Princeton New Jersey Office Space, Lease Ending in 2022 Princeton New Jersey Office Space, Lease Ending in 2022 [Member] Princeton New Jersey Office Space, Lease Ending in 2022 Activity in stock option plan Share-based Payment Arrangement, Option, Activity [Table Text Block] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Shares vested and exercisable as of December 31, 2019, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Number of votes per share Common Stock, Number Of Votes Per Share Common Stock, Number Of Votes Income tax provision or benefit Income Tax Expense (Benefit) Equity Incentive Plans Share-based Payment Arrangement [Text Block] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Lessee, Operating Lease, Liability, Payment, Due [Abstract] Vested and expected to vest as of December 31, 2019, aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value 2020 Lessee, Operating Lease, Liability, Payments, Due Year Two Accrued professional services Accrued Professional Fees, Current Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Tangible and intangible assets Deferred Tax Assets, Tangible And Intangible Assets Deferred Tax Assets, Tangible And Intangible Assets City Area Code City Area Code Risk-free interest rate, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Title of 12(b) Security Title of 12(b) Security Shares vested and exercisable as of December 31, 2019 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Required percentage of licensing revenue Asset Acquisition, Licensing Revenue Received, Percent Required To Pay Asset Acquisition, Licensing Revenue Received, Percent Required To Pay Total fair value of assets Assets, Fair Value Disclosure Total (in shares) Total (in shares) Common Stock, Capital Shares Reserved for Future Issuance Earnings Per Share [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Maturities of lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Furniture and fixtures Furniture and Fixtures [Member] Assets Assets [Abstract] Credits Deferred Tax Assets, Tax Credit Carryforwards Par value of preferred stock (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Ex Transition Period Entity Ex Transition Period Princeton New Jersey Office Space, Lease Ending In 2020 Princeton New Jersey Office Space, Lease Ending In 2020 [Member] Princeton New Jersey Office Space, Lease Ending In 2020 Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Total operating expenses Operating Expenses Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Remaining term on operating lease Lessee, Operating Lease, Remaining Lease Term Lessee, Operating Lease, Remaining Lease Term Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Supplemental non-cash investing and financing activities Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock issued through exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) Net loss per share attributable to common stockholders, basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Maximum aggregate amount of licensing revenue Asset Acquisition, Maximum Aggregate Amount Of Licensing Revenue Asset Acquisition, Maximum Aggregate Amount Of Licensing Revenue Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Income Statement Location [Domain] Income Statement Location [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Supplemental cash flow information Supplemental Cash Flow Information [Abstract] 2016 Plan The 2016 Equity Incentive Plan [Member] The 2016 Equity Incentive Plan Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Accounts payable Increase (Decrease) in Accounts Payable Statement of Financial Position [Abstract] Expected volatility, minimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 2019 Plan The 2019 Equity Incentive Plan [Member] The 2019 Equity Incentive Plan Lease Amendment Lease Amendment [Member] Lease Amendment Common stock authorized (in shares) Common Stock, Shares Authorized Statement of Cash Flows [Abstract] Entity Central Index Key Entity Central Index Key Shares of redeemable convertible preferred stock authorized (in shares) Temporary Equity, Shares Authorized Unrecognized stock-based compensation expense for RSUs Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Entity Emerging Growth Company Entity Emerging Growth Company Sale of Stock [Domain] Sale of Stock [Domain] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Operating lease liability Less: current portion Operating Lease, Liability, Current Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Other Deferred Tax Assets, Other State and Local Jurisdiction State and Local Jurisdiction [Member] Income Taxes Income Tax, Policy [Policy Text Block] Payments of Stock Issuance Costs Payments of Stock Issuance Costs Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Research tax credit Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Income Taxes Income Tax Disclosure [Text Block] Term of lease contract Lessee, Operating Lease, Term of Contract Upfront payment for non-exclusive license agreement Payments to Acquire Intangible Assets Antidilutive Securities [Axis] Antidilutive Securities [Axis] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Preferred Stock, Shares Issued Preferred Stock, Shares Issued Research and Development Research and Development Expense, Policy [Policy Text Block] Liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit) Liabilities and Equity [Abstract] Deferred tax assets: Deferred Tax Assets, Tax Deferred Expense [Abstract] Other non-current assets Other Assets, Noncurrent Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Entity Voluntary Filers Entity Voluntary Filers Segments Segment Reporting, Policy [Policy Text Block] Vested and expected to vest as of December 31, 2019 (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Interest income Investment Income, Interest and Dividend Asset Acquisition [Axis] Asset Acquisition [Axis] Asset Acquisition Sale of Stock [Axis] Sale of Stock [Axis] Weighted-average recognition period of unrecognized stock-based compensation expense (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Accounting Policies [Abstract] Redeemable convertible preferred stock, liquidation preference Temporary Equity, Liquidation Preference Additional Paid-In Capital Additional Paid-in Capital [Member] Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Stock-Based Compensation Share-based Payment Arrangement [Policy Text Block] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Redeemable Convertible Preferred Stock Temporary Equity, Redeemable Convertible Preferred Stock [Text Block] Temporary Equity, Redeemable Convertible Preferred Stock Lease liability Deferred Tax Asset, Lease Liability Deferred Tax Asset, Lease Liability Entity Address, Address Line One Entity Address, Address Line One Property and equipment, gross Property, Plant and Equipment, Gross Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Percent of estimated fair value of shares Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Schedule of unrecognized tax benefits roll forward Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Schedule of loss before provision for income taxes Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Entity Address, State or Province Entity Address, State or Province Income Statement Location [Axis] Income Statement Location [Axis] IPO IPO [Member] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Redeemable Convertible Preferred Stock Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] General and administrative General and Administrative Expense Accounts payable Accounts Payable, Current Accrued liabilities Total Accrued Liabilities, Current Entity Interactive Data Current Entity Interactive Data Current Common stock shares issued (in shares) Common Stock, Shares, Issued Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Common stock par value (in dollars per share) Common Stock, Par or Stated Value Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Measurement Frequency [Axis] Measurement Frequency [Axis] Conversion of preferred stock, shares converted (in shares) Conversion of Stock, Shares Converted Net Loss Per Share Attributable to Common Stockholders Earnings Per Share [Text Block] Issuance of options under the 2016 Plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Award Type [Domain] Award Type [Domain] Options granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Prepaids Deferred Tax Liabilities, Prepaid Expenses Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Issuance of common stock upon initial public offering, net of issuance cost of $9,898 (in shares) Stock Issued During Period, Shares, New Issues Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Research and development Research and Development Expense [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Provision for income taxes Effective Income Tax Rate Reconciliation, Percent Basic and diluted net loss per share Income (Loss) from Continuing Operations, Per Basic and Diluted Share Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total liabilities Liabilities Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Common stock, $0.001 par value per share - 1,000,000,000 authorized shares at December 31, 2019, and 10,943,000 shares authorized at December 31, 2018; 21,366,950 shares issued and outstanding at December 31, 2019, and 1,411,966 shares issued and outstanding at December 31, 2018 Common Stock, Value, Issued Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Research and development Research and Development Expense Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Expected volatility, maximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Accrued Research And Development, Current Accrued Research And Development, Current Accrued Research And Development, Current Stock compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Common stock reserved for future issuance Schedule of Conversions of Stock [Table Text Block] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Equity Components [Axis] Equity Components [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Net deferred tax assets Deferred Tax Assets, Net Reconciliation of cash, cash equivalents and restricted cash Additional Cash Flow Elements [Abstract] Incentive Stock Options Incentive Stock Options [Member] Incentive Stock Options Total stockholders’ equity (deficit) Beginning balance Ending balance Stockholders' Equity Attributable to Parent Fair value of options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Fair Value Measurements Fair Value Disclosures [Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Conversion of redeemable convertible preferred stock into common stock upon initial public offering Stock Issued During Period, Value, Conversion of Convertible Securities Preferred stock: $0.001 par value per share - 5,000,000 shares authorized and no shares issued and outstanding as of December 31, 2019 and no shares authorized, issued and outstanding as of December 31, 2018 Preferred Stock, Value, Issued Redeemable convertible preferred stock, outstanding (in shares) Redeemable convertible preferred stock, shares, beginning balance Redeemable convertible preferred stock, shares, ending balance Conversion of redeemable convertible preferred stock (in shares) Temporary Equity, Shares Outstanding Money market funds Cash and Cash Equivalents, Fair Value Disclosure Security Exchange Name Security Exchange Name Accrued compensation Accrued Salaries, Current Potentially dilutive securities excluded from the computation of diluted net loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Tax Credit Carryforward [Table] Tax Credit Carryforward [Table] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Lease Arrangements [Axis] Lease Arrangements [Axis] Lease Arrangements Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Equity Component [Domain] Equity Component [Domain] Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Document Transition Report Document Transition Report Office equipment Office Equipment [Member] Stock options Share-based Payment Arrangement, Option [Member] Gross deferred tax assets Deferred Tax Assets, Gross Operating lease right-of-use asset Increase (Decrease) In Operating Right-of-Use Assets Increase (Decrease) In Operating Right-of-Use Assets Employee Stock Employee Stock [Member] Income Statement [Abstract] EX-101.PRE 12 oyst-20191231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 13 oyst-20191231_g1.jpg begin 644 oyst-20191231_g1.jpg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end GRAPHIC 14 oyst-20191231_g10.jpg begin 644 oyst-20191231_g10.jpg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oyst-20191231_g11.jpg begin 644 oyst-20191231_g11.jpg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end GRAPHIC 16 oyst-20191231_g12.jpg begin 644 oyst-20191231_g12.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" $6 F8# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]#&^ /A)F M)+^(,GG_ )&34?\ X_1_PS_X2_O^(/\ PI=1_P#C]87[2GC[Q3\/]!T_4?#S MLEA"+FYUF:SMX[J]M;1(O^/J.W=AYT<4C1F15._:?EJJG[2<<,FLV0T.?5;_ M $FQ34F^PR$F\LFAB>.[B3;DJ[R[ @RV4? ;;B@#I_\ AG_PE_?\0?\ A2ZC M_P#'Z/\ AG_PE_?\0?\ A2ZC_P#'Z\]L_P!K.2\N[I;;PPNL).]G'I$.DWOG M2WK2V,EY*"2BJNU(F [DXSM^8K:U7]K)-+U#5HSX+U*2RTW[:\ETMY;Y,=I] MF-PP3=U"W<149^8AAQUH [C_ (9_\)?W_$'_ (4NH_\ Q^C_ (9_\)?W_$'_ M (4NH_\ Q^LKQ5XT\0:I\8I_!6EZG%XW< MV.3YBC([\!X'_; U'7?!]EJ-_P""+K[1]FT\374-RJV\EQ=(QBVKAG6-MA^8 M@XW+PP^T1>=$X@@G>"7G$;JEPO#'.5/R@%6-KQY\?-4 MM_A5!K.CZ='I.LW/B>#PK.U\XFATZ1[T6TD[$8#JHR5S@$E0: .N_P"&?_"7 M]_Q!_P"%+J/_ ,?H_P"&?_"7]_Q!_P"%+J/_ ,?KD?%_C3Q9\*_&VA+JOB>W MUW0;I]0GFMVM(+:9(8--><*TF0JGS(BP8[1AL'@9HL_VJM/O)K*%?#MZLMQ+ M>6V&D"K)<0 GR(F*@-(X *J_E[@3MW$$4 ==_P ,_P#A+^_X@_\ "EU'_P"/ MT?\ #/\ X2_O^(/_ I=1_\ C]9$7QP/B;P/X/U;1X8[6X\2ZXNC+O8R?9"# M*TI=656#A('&QE!#D BLK6_BWXA\-6/Q1U:::"[L_!VO6Z);_9PK36+6MM++ M%G/WQ]HCT4 >CT4 >CT4 >CT4 > ].\#S>)HI/#N ME6HL;&[T^U:VU'R$&(@\F\H&5< LJ#=C/&30!R]OH'PMNO%5UX>ANO$\FH6[ MW$.5UW5/+EF@1))H4?S\-(JR*2H]_0XWO!_PK\ ^.O">C>(])F\1R:7JUI%? M6KR^(=2C8Q2('4E3/D'!'!Z5!X?_ &?3X;\51:HNO&ZLK'4+_5[&.[A+3+=W M=N(9&FDW#>HS*V %.9.ORBNY^$O@NX^&_P ,?"WA6[O8M2GT738-/:\AA,*3 M>4@0.$+,5R .-QH Q?\ AG_PE_?\0?\ A2ZC_P#'Z/\ AG_PE_?\0?\ A2ZC M_P#'Z]&5@ZAE(93R".AI: /./^&?_"7]_P 0?^%+J/\ \?H_X9_\)?W_ !!_ MX4NH_P#Q^O1Z* /./^&?_"7]_P 0?^%+J/\ \?H_X9_\)?W_ !!_X4NH_P#Q M^O1Z* /./^&?_"7]_P 0?^%+J/\ \?H_X9_\)?W_ !!_X4NH_P#Q^O1Z* /. M/^&?_"7]_P 0?^%+J/\ \?H_X9_\)?W_ !!_X4NH_P#Q^O1Z* /G2*'X22WL M*&\\41Z=/J4FCPZQ)KNIK8R7B%@T0F,^,[D= ?NEE(!S4W@_2OAGXZNM(72( MO&L]AJZ2RZ?JK:MJJV=RD8R660SXPPY4G&XNOKB6J6S+>MF=[A(&FW[=BRR$[@N2JJ/4GJ_A_\+?$?A/P)IO@N]\41R:)I M5FEA9WFEVK6E^T48"Q%WWLH8*H#%5&[KQG% '(V^B_"R[UZ]TB&Z\4275K]K M 9=3Q%J2,T,J!T)4SY!VL.#TJEH?[/+^'=:2[375N+2QFU2[TU;J F5)[]5$ MAF<./,"G?@ *3OY/%>@?"WPA/\/?AGX4\+75Y'J$VAZ5;::UW%$8EF\F)8PX M0LVW(4'&30!@_P##/_A+^_X@_P#"EU'_ ./T?\,_^$O[_B#_ ,*74?\ X_7H MRL'4,I#*1D$=#2T >CT4 >??M ^+-6\"_!3QGXBT.X6UU?2]-E MN[:62$3*'09Y0\-G&,>] $/_ S_ .$O[_B#_P *74?_ (_1_P ,_P#A+^_X M@_\ "EU'_P"/UY=8_&+X@^$?%T3>+5B;PW-8:A>6$=Q%#:75Y'$M@(WEPQ6( M^;<3H%ZLH4E=V >CM?VL-&O-!U+6X]%NO[,T:P-_K!>>-)[1<7. D38,H)M7 M7C!^=?E/S[0#KO\ AG_PE_?\0?\ A2ZC_P#'Z/\ AG_PE_?\0?\ A2ZC_P#' MZ\UU/]IC7M#\%KZ'P\NE^9J&G*T1N+1S?Q6Z7*'(:5&29&" !B.<9X M/I/PO^-EC\3-0-I#IES8&;38M8M))&5UFM9)I8E)(^Y(&A)*'H&7!)W!0!?^ M&?\ PE_?\0?^%+J/_P ?H_X9_P#"7]_Q!_X4NH__ !^O1Z* /./^&?\ PE_? M\0?^%+J/_P ?H_X9_P#"7]_Q!_X4NH__ !^O1Z* .(T/X.^'/#MX]S9MK!E9 M#&?M&N7LZX)!^Z\Q / YQG\Z*[>B@#S'XN:QX-M?$W@G2/%OA>WUZ37+FYLK M&ZNX+>2&T80--(',K JKI$?N@Y*@$=*Y/X<>+?!7Q"AUKQ#J=O(]AK-K*&C\ M1-8[;:SM+M[<0+%&[$Q"82.K-NR6Z@X%;7QRL?"4OB[X=ZGXK\5:=H,>D7UU M>6NGZC"CIJ#&UDC=-B2,_ /3/05YEJ/[+>H:?\.;<>$_$,7B1VLGM[0QV MT4*F&?5%U SQ.) "R'.P;E!&/F'6@#O;._\ @KXV\9?\(R= \,7TS6ME=65Q M-:VCPWJ@S"%8#R6:+9+Q@8W''4U;NH?A-/XH\6Z5K?A#P_ITFER1QW=YJEA: MB*[-[&';#(%CDN;F"7[#=Z9%= MVWEI;/;O&Z.<.663<&/*D#@@D$ Z_P 07OPT\5VP&LMX?U6'3S/ /M:12B H M42:,9!QC>>-_#?@/XK2>+-,T_P\99]%@TW7)Y=(L;.<:[&89Q:Q M*&R)@JQNJARNUMI! &:M?$KX!^%[>P\3ZO=>)&\/+JUWI=PLUU%'):6UW!+" M%;R3A7$[16Z.AP&*C&"> O@/XZUI-6\=Z39WM[I]A8_P!D-!%9K;"V M2:0%$3@!EF=MN.% Z]2 <_X$;X2ZVMU9ZU\-H-,@TV>;19M<\66NGS>?<6Y2 M%H&E61V9@I4 D!=B8!PH%>E7'B;X0Z3I>L^'9K_PC:Z;+/-_:6F,UNL+S,6, MWFQ]"Q*L6W#/RDGI7&S?LN6^M*EXWB>+4$FU[4->"W6E0W-M)%>J!)"8V8JV M, I)U'<$$@OUW]E&WURPO+9_$7E_:=0UJ_:3^S(BW_$PMY8&0\\^6)G8'N<9 MH ] T/P/\-?$FFQMI6@^&]5L;5YX$:"U@F2)G3RID!P<%D^5AW4X.15JS^#' M@#3=PM?!/A^V#*RL(M,A4$$8(.%YR.*A^%WPS_X5K'K:?VG_ &B-3NH[H@6R MP"(K!%"0 I.<^4&_&NXH YVZ^'^@3:#;Z/!IT&GV-M<)=VZ6,:P^1.C[UD3 MP&W#XW76K/IUZT\?B<7XU2.%WB;11I8C\A7' M?S@P\KKORV/FS7T910!\Z?"^U\=+\U;P7ICZO<:?:WL5S>:X3:W5T+;[):Z:<,JC:2[ MNJLV2<99>@K>O?VFKR+6=2TZV\)R7S6[S1PMI\EQ>32%20K>1';9(XRVUC@9 MQF@#C?AY\0O$WQAU#4=+O]5EO].O-1CD%O!ILD<<5A%-<2?:$D,:[XIE@@C4 M!G.7)W71TOX0F"\&G2>(/$^N:;J\?]D)IIOUAAU!XSY3QJR[6AAQMQ M@@JV3D5[E\(?%6H>)=&UJWU1_M-YHNM7FD&]VA?M2PO\DA X#;656QQN5L = M /^!UG=:;\&_!-I>VMQ8WEOH]K#-;74;1RQ.L2@JRGD$$=#7<444 %%%% ! M1110 4444 %>3W=M=:?^TA<:R-+U!]-7P>T4MY!:R/%),MUO$08##2; M?>O6** /!OA_9:3>?M!:MKNG>&/$.@S2:=);7%U>:1<6\6HN[QRF:::0!7*8 M$<:Y+#,G"KBN,T_QS\9;?68KBY&N3VGVF-Y+5_#FV/R_[6-NR[@N0OV,^;G. M?D#9P<'2UK]J+5?!^BVFLW>GVMY%J#:O>RV]S="W:SM;&X6$Q(NT[Y"I+98_ M?..!@#H+S]IB^75=4TVW\)O=RV[RPPOI[7-](S*^P.8([;<4'WFVDD '&: . M+^&/Q"\4_&#[1::GJEQ?VLU]!?&WM],DC2WM(O/D29&:-?,CF>*$( 7Z?>.> M,K3?%'QCU;PW#;>)+/7=2BU#3K2+4+&3PYL&ZXTN9KI\5:AXJ\+WO]J-Y]]IFJ7FE/=A @NA!,T:RX' +*!G'&X-C XH N?".VN++X M4^#;:[MY[2[@T:SBFM[F,I+&ZPH&5E/(((((-=;110 4444 %%%% !1110 5 MG>(/#NE>+-&NM(UO3;36-*NT\NXL;Z!9H9ESG:Z,"&&0."*T:* .!\;:;\,_ MMNEZ?XMLO#+74ELUC86^JPP%S [(K11AQ]PMY8*CC(7VK-AT7X.Z2;FYM--\ M'+-86EQ'(MG;VK2QV[%C-'M4;MK,S97')8\9-0?&+X#I\6M4@O6UQM):+3)M M-"K9I,<23P2EP2001]G '^\3VK$UWX*_#K0KZ^OO$'B/4+<#%[,KZI]A\K,R M[)!);B.1?WFT+\^"<#DT /\ ^K?#'5O^%91Z3X"MM-36+*XO="+:5;Q#3UA M*2.A .8GR58!01E>2"!7J^@^#]"\+37DNC:/8Z7)>-ON&L[=(C*-?#7P%X0T&'X>RZ#X\&IZ;X/>ZTI6N)CAI=6/AH3V6@1ZRD%MIUKXCFB== M(2Q$,"Q/(D@A:*<>9M"DGKNR!7U-_:%K_P _,/\ W\%']H6O_/S#_P!_!0!\ MP7'P%\?PZ]J$]H([33-1\376I7<.FZR;:>1'@M4M[HR&%OGC>";,8 )$V0W& M*;!^SWX_:2&Y^W36>J%?$,K7A\174R)<378FTI_+. PBCRA7 ST:OJ'^T+7 M_GYA_P"_@H_M"U_Y^8?^_@H ^4M7^ OQ)U+P[I5D]O%>VW[F8Z?J/B!I3IMR ME]!!=>\2^.OA[J>B06BVNDWUY<:A/-/L M=!+926Z,J;3YA!=<@D<+UKTK^T+7_GYA_P"_@H_M"U_Y^8?^_@H ^7O"OP%^ M(")X4779+F5;)KN75(T\3RB.>Y^RI'%+$L<485'EC638<[26)W9.;7PI^"GQ M)\&^(O#-YJ-TTJ6LEA]O=O$$]PKJ--\F\(C=<-ON523MG@\$8KZ7_M"U_P"? MF'_OX*/[0M?^?F'_ +^"@"Q15?\ M"U_Y^8?^_@H_M"U_P"?F'_OX* +%%5_ M[0M?^?F'_OX*/[0M?^?F'_OX* +%%5_[0M?^?F'_ +^"C^T+7_GYA_[^"@"Q M15?^T+7_ )^8?^_@H_M"U_Y^8?\ OX* +%%5_P"T+7_GYA_[^"C^T+7_ )^8 M?^_@H L457_M"U_Y^8?^_@H_M"U_Y^8?^_@H L457_M"U_Y^8?\ OX*/[0M? M^?F'_OX* +%%5_[0M?\ GYA_[^"C^T+7_GYA_P"_@H L457_ +0M?^?F'_OX M*/[0M?\ GYA_[^"@"Q15?^T+7_GYA_[^"C^T+7_GYA_[^"@"Q15?^T+7_GYA M_P"_@H_M"U_Y^8?^_@H L457_M"U_P"?F'_OX*/[0M?^?F'_ +^"@"Q15?\ MM"U_Y^8?^_@H_M"U_P"?F'_OX* +%%5_[0M?^?F'_OX*/[0M?^?F'_OX* +% M%5_[0M?^?F'_ +^"C^T+7_GYA_[^"@"Q15?^T+7_ )^8?^_@H_M"U_Y^8?\ MOX* /,/$WC#X?^$?'Z^&]3TIY-4U9HKF1VL#-:H;F0P*[.053S'C"G'4X)]: ME\8?%^YT._\ $-AHFC_VB^A-8VMPS;PLE:=HNBVUMI40BL2 M#*F"6+ER79V8\LS,Q8L>222>:X2\^#/@_P#L/6M*TLQ:19ZTRK?1PS%E:(A% MD2-2VV/>L:*2H[#@D"O0X;NRMXDBCG@2-%"JH<8 ' % %NBJ_P#:%K_S\P_] M_!1_:%K_ ,_,/_?P4 6**K_VA:_\_,/_ '\%']H6O_/S#_W\% %BBJ_]H6O_ M #\P_P#?P4?VA:_\_,/_ '\% %BBJ_\ :%K_ ,_,/_?P4?VA:_\ /S#_ -_! M0!8HJO\ VA:_\_,/_?P4?VA:_P#/S#_W\% 'F/B7Q;\/O!GCJ'PUJ6DL^HZL M\=RS-8&:UC-S.( S.053S)@@('5F!(Y)J7QI\8+G0M0\16&BZ/\ VG+H?V&" MX=F8(DUTXV[@H)$<<7[QR 3\R@#J1I^*_A;X.\:>)(==U4S2:E"EJB/#J4L* M8M[D7,7R(X4XE4-TYP DZ,T_A?S+IK6QW^=!9HJ&[E5F0;) M%#LVP!PBS11J6Q'YB1HK%1R .,@$>BQWEG%& MJ)<0JJC <<"@"U15?\ M"U_Y^8?^_@H_M"U_P"?F'_OX* +%%5_[0M?^?F' M_OX*/[0M?^?F'_OX* +%%5_[0M?^?F'_ +^"C^T+7_GYA_[^"@"Q15?^T+7_ M )^8?^_@H_M"U_Y^8?\ OX* +%%5_P"T+7_GYA_[^"C^T+7_ )^8?^_@H \5 M^(OPU\;:U\9M.\3:)*$TNU;2P%;5I8@%CNI&O/W 4H2T#[!GKGM@&KFM?#.Z MUOQAX_:_M)KS[=)IVKZ)<)*8E26UBVK"7P0NV93)@C_EL2.02/7O[0M?^?F' M_OX*/[0M?^?F'_OX* /FVZ^#?C?1_A?XX\-3W[:G1L)/&QZX5P:* /+/%'PS^#G@VW2YU[0_#VEQ2;BK72*FX M*-SD#T5-1"(-N[S"W3;MYS MZ5QW[6/PC\3?%!_#4_A2#4;+7-'M]0GT_P 0:3J,5O/8W;K"L44D-8CGYRR*S #J M :V?^&?_ ((-7T[]XOB&RC\1P MQ2P7HCMU6]MY$V[[=FBE)A ;616L]'TC5] M1EUB!]7\ZUO89[Z>=+E-KB191&T2[&#*P+!@IY/3_$;]GWXIZW\=Y=;T#QI< MVG@6ZU"RN[C3GOYE=$>&:WOHXP'X4)Y4T8[2MGHN" >B3>"?@=;Z'?ZS+I_A M:/2K!YX[J\9HQ%"T+;9@S9P-AX;T[U>UCX5_!_P_X;G\0ZEH/AZQT*" 7,NH MSHJP)$0"'+DX"X(YZ5\J^)/V6?BWK$7B&2;1AJ4U]I'BW2+-)M<7]P+ZX62R M8@M@KL+*>I&.>BU[+\+_ (6_$'P[\$/B=X4\1:=-JYOII(M!TV\U..YS9R64 M$;0F1F(5?-$YVL<8;CTH ] TGX:_!K7KRWM--T3PY?W%Q9)J4*6RI)YEJYPD MRD'E">C#@UM_\,__ X_Z$S2?_ <5\TQ_LK_ !*^&=_JFE>"-3GN?APUW875 MAH"WXM[VUM#).]YIL=QN&V-9'B=#NQMW+FJ_A/X*_M%Z7X\\,:EJ>O7=T;6Y MT=;Z]_MD/;/"FGW$5\QMBX#GSVMB1P7\LL,9H ]]\4> O@EX)EABU[2O#.DR MS1O,D=V$1C&F-\F".*\ _LS?%_P/X/OO!MSK=]J"V?@V/3?#VM:;K;6MK8W8LY8Y M()(,[G7SG1XY0,@(F=NW! /H>]^%'PATW7M.T2Z\/^'[?5]261[.QD15EN%C M ,A13RVT$$XZ9K4_X9_^''_0F:3_ . XKY)L?@=\?;GQI'XBO=*G>>RMM3.G MBZ\1Q&2WFGT>*W54D!8Q[KJ-VRN<;PWTZ#X;_!'XW:EXP\+Q>.[O6+3PS:ZI MJEQ=?V=XD,;);216SVD9"2EG5)TGX+-@-U(.* /HJX^#'PJL]2L]/G\,:%%? MW@=K:V>-1),$ +E5ZD*",XZ9%5I/A3\((O$T7AU_#_A]-=FMFO(].9%$[P!M MK2*G4J&(!(Z$UYC\=_A;\3?%?Q9\,_$3POIMN]_X-UJWBTW3Y;I(S?Z9(A%^ M3(9-J>8'V[&0G,$39ZBN!_X9E^+/BCXE>(]2UJ[O+&ZO-(\06-KXIM]:^>&2 MXNTFT[R8U;=$L<<:1LH !VGKG- 'U#_PS_\ #C_H3-)_\!Q1_P ,_P#PX_Z$ MS2?_ '%> WGP;^-TFM>'IKG7-0DM/\ A&M]Y%HVK)!'%K3&1IDD67<6@<.D M:F,Y7RQ]W.:RM+^ OQPT?P[\.SI>O:HGB"WTT?V__;FO->6GVYE"-*I#[U*& M-'4*'1P[*R@Y) /H#Q)\)?A'X/T.[UG7/#N@:3I-FGF7%[=QK'%"N<;F8\ < M]353PO\ #OX+^-OM(T'1O#FK&V$;3+:HKF,2*6C) Z!@"0>X'%>71_!KXFZI M^QOX]\&:V^H:QX[U_29+,6VJZI!-&+E[=(I'BE4 +"[AI0');YFX&0*SX?@5 M\4V^&]KI>D2WF@^(]'U#3;ZWU34M622344&V.ZM)O(;FWCB+>6&YW!>!R2 > M_P#_ S_ /#C_H3-)_\ <5&WP'^&<$=%6:0%DC,*AF QD@=\9'YU\X M^/O@;\#4K@:E]NCTS7-&M-2CU])+RPAGU-9K20;WVRE;0SLQY&#C<<= 2!7;4 >?_\ #/\ \./^A,TG_P ! MQ1_PS_\ #C_H3-)_\!Q7H%% 'G__ S_ /#C_H3-)_\ <4?\,__ X_Z$S2 M?_ <5Z!10!Y__P ,_P#PX_Z$S2?_ '%'_#/_P ./^A,TG_P'%>@44 >?_\ M#/\ \./^A,TG_P !Q1_PS_\ #C_H3-)_\!Q7H%% 'G__ S_ /#C_H3-)_\ M <4?\,__ X_Z$S2?_ <5Z!10!Y__P ,_P#PX_Z$S2?_ '%'_#/_P ./^A, MTG_P'%>@44 >?_\ #/\ \./^A,TG_P !Q1_PS_\ #C_H3-)_\!Q7H%% 'G__ M S_ /#C_H3-)_\ <4A^ 'PX')\&Z0!_P!>XKT&N+^-/A'5/'WPF\6^'-%O M/L&J:IILUK!/YACPS*1MWCE=PRNXU &%IWPA^$FKZ:^HV7AWP_=:#@@8.3G'!I;#X0?"35+RXM+/P]X>N[NWCCEFMX51Y(DD!,;,H. M5# $@GK@XKD)OA[XNLO@KK.BLETT$.KVT^GZ/-.D\\6EQ30,]J70X;Y(Y<*" M>"$YK5U3X?\ BGQ%X\\>7VE2V^A:?KFFZ5!::I=PFY298FF,\30)+%(NY)0N M=RD9/I0!KP_"7X0W&AG6H]!\./HX1I3J"^7]GV D%O,SMP,'G..*ETOX-_"G M6XW>P\,:'=A-N_RHE)7H.:\MC^"?C>3X%>"O >IV5O-_8^H0:C M?)HTXLHIX(KIG6T3=(QW8*R!B0A\L*<9KL_A#X6\7:=XZL[SQ#<275U:^&(= M.U:\<<75YY[21@L !(\<3%6D'!+\>@ .M_X9_P#AQ_T)FD_^ XH_X9_^''_0 MF:3_ . XKT"B@#S_ /X9_P#AQ_T)FD_^ XH_X9_^''_0F:3_ . XKT"B@#S_ M /X9_P#AQ_T)FD_^ XH_X9_^''_0F:3_ . XKT"B@#S_ /X9_P#AQ_T)FD_^ M XH_X9_^''_0F:3_ . XKT"B@#S_ /X9_P#AQ_T)FD_^ XI&^ /PW12S>#M( M55&23 !7H-<+\I_$3X1>*O#6CW7V34-3LFMXW\TQ;@2-T>\'KJYLUC:YAA5&> .I9"Z@Y7< 2,]17*3>!?%]G\'7TV\%Q<1VOB. MUOH=*EE6>=-(BO(9#:LR<2$1HY"C.1A.>]S5/AQXL\1^,OB/%)HI$#!PN=P.": -Q?A/\ "!]!&N#0O#9T4Q^=_:/[ MO[/Y?]_S,[=OOG%3:;\&/A5K$;O8^%]#NA&0K^7"I*$@, PZ@D$'GL0:\O\ M^%+>-KCX-?#GP9JME'YGA\+Z?INJW;+M%YJ*23.7& [)&ZJT@X8MQ]W . MJ_X9_P#AQ_T)FD_^ XH_X9_^''_0F:3_ . XKT"B@#S_ /X9_P#AQ_T)FD_^ M XH_X9_^''_0F:3_ . XKT"B@#S_ /X9_P#AQ_T)FD_^ XH_X9_^''_0F:3_ M . XKT"B@#S_ /X9_P#AQ_T)FD_^ XH_X9_^''_0F:3_ . XKT"B@#S_ /X9 M_P#AQ_T)FD_^ XJMJ7P1^%NCV,]]?^%M#LK.!2\MQ<1JD<:CJ68G %>DUR?Q M4\'Q>// >JZ++]L'GJCQG3W1)Q)'(LD94R?)]Y5X;Y2,@\4 '_#MUI+(T@OH0C0[5)#'>#C ((//!!K&D\+_ #ACUIY(_!D::)M_M0M M3P-V,GBLJW^%?B?PK\'[*UO[LZMJC^+8_$NM06Z@J\+ZB+ MF>%%50&VJ=Q 4;V1L#YL4R[TGQ?'XJ\2^([#X6K)J,5HNFZ(S:C9K%]G$Q82 MA"V?,)D>4A]N,*H.2S$ ZJZ^&?P8L=#MM:N-(\+P:/=!3!J$C1""4,,J4DSM M8$ D8/09J_8?!/X6:HLC67A?0KM8VV.T,:N%; .#@\'!!^A!KA%^&WB&ST?X M9VNE^$I+/3O"L<[2:;%C;)<$95)9!Q'N[%L#@\UMZ'X^TC7+1Y_-;3 MMMS<6JQZCB!W:!BLA4$_,H*D[AQCGI0!R_\ PT=\/?\ H-S_ /@LN_\ XU1_ MPT?\/?\ H-S_ /@LN_\ XU78KXV\.MC;KVEGY2W%Y'T R3][I@@_2IF\4:-& M\R-J]BKPR+%*IN4!C=AE5;G@D= >30!Q'_#1_P /?^@W/_X++O\ ^-4?\-'_ M ]_Z#<__@LN_P#XU7..X1FF"YW% #\P&#G'3! MKC=-^//A/5O$U[H]K<3R"QO+G3[O4?*Q9VUS 98I92<1L-PQNP&.0I.#0!! M_P -'_#W_H-S_P#@LN__ (U1_P -'_#W_H-S_P#@LN__ (U77WWCKPYIMJ]Q M=:_IEO BN[227D:@!%WN>O\ "O)]!S46B_$/PSX@T/3]9L->T^?3+^T%_;7' MVA0LEN:3?M3> K'Q5 MK&@W]U?:;/I.LP:!>7EU8R+:17LZ!X(VE *@.&7:QP"649R<4 :7_#1_P]_Z M#<__ (++O_XU1_PT?\/?^@W/_P""R[_^-5T?A7XE:!XOTRUO;2\6V%T]PD-O M>D0S2"&1XW8(3DKE&.1QCFM%/%^@R);.FMZ_]!N?_ ,%EW_\ &J/^&C_A[_T&Y_\ P67?_P :K2TWXU>$=4\= M>(?"<.JQC5-!LX+^^D<@6\<4KNB'S<[<[XW4J3D$<]JZ.3Q9H<,DTCP MJ6E5KJ,&-1C)89X W+U]1ZT <5_PT?\ #W_H-S_^"R[_ /C5'_#1_P /?^@W M/_X++O\ ^-5Z-;W,-Y;QSV\J3P2*&22-@RL#T((ZBI: /-/^&C_A[_T&Y_\ MP67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P : MH_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O M_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#! M9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO M2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^ M&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T& MY_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67? M_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X: M/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G M_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ M !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* M/-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A M[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ MP67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P : MH_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O M_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#! M9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO M2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^ M&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T& MY_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67? M_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X: M/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G M_P#!9=__ !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ M !JO2Z* /-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* M/-/^&C_A[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* /-/^&C_A M[_T&Y_\ P67?_P :H_X:/^'O_0;G_P#!9=__ !JO2Z* .%T'XW>#/$UX]KIV MJRSSK&92K6%S'\H(!.6C ZD45W5% 'G?Q<^$EK\8$T[2-:@L+[PJ8[J+4["[ MA9I)UEA,:^6P8!&4G=NP2"!C%>#Z/^PKJ.CWGALW'C,^);71])GTM/[:%P94 M;[5+/;7*M%,H:15D".'#*V,^U?7E% 'R_P"&?V'M&T3P-\)]+^TV%EKO@ZZ6 M34=4TJP$']M0-"T,\4H))/FKY>6))&SBN=O/V$]8DNM2NH/&5N9TODO=/,]H M[>>PU@ZEF\PX\Q@"859<84Y[XK["HH ^5?@G^QQKGPL\;>$->NO%MI.-0L(=;FU:PU M+3M5TKPS#]FN/$%M"RELQ-#&DX5DD29F99 3NY!YK[.HH ^3_A3^ MQ9JGPT^*VA^+X_$&CM%8:E/>RVMIIKQ.\ZXD3:V MT.O1^.G\*_L0R67Q"T?Q'X@U71]8LK>;5+F;2?[-)A@ENA (FM=[$1F,VZOD M@DL[$8KZQHH ^(;+_@GWXBL84">--+S:P:3 B1V,\0U$6-S#? N@Z%>WZZI>:?9Q6TUZD"P"=U4!G\M>%R><#UKH: M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#@?B1\6K;X;^ M)O!6EWMI&;;Q)>S67V^:[2".T:.W>?+;A\P(C8#'?%8?PZ_:2\+>-/#>C:EJ M5U:^'+K5I[J&TL;BZ64NL,\T._>HV@.T$A7/4 XR0<=5XR^&=EXV\4>$=6UO;B$PS/)"\)\T/&Q("2-C:5Y.><5Y_X:_9.T#PI<02V/B3Q M&6VN+65F-INE66XFN P<6X:-HY+B7:T10X(#;@!0!N>./VC?"7A3P3=^(+&[ M777A8JMA:[A,Q5H@^X;28PHGB.7 '[Q.?F&>AG^,7@VW2^+Z];EK&7R)XT5V MD#CS,[4"EG \F8Y4$ 1.*H=<^U_;(K\36IDC8M<97 M)MSO4I=2QX?=\NW&"H( -[PO^T9X1UZ\\16MWJ%OI5SH]W-#YKZ/>Q:CIEVGF07,#91UZ9'X@C'8 MBO'_ !!^R7X=\2374UUXC\1"2:[N;]&62V/DW$LMM*'7= <['LX64-N!^8,& M!Q7KOAG08_#.AVNFQW$ETL"X,TR1HSDDDDK&JHN23PJ@#L!0!J4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% '!Z+\2[V_P#BA=^#[[PW<:8OV"34K/4&N4D6>*.9 M(FWHO,1+."@.=RACP5(K*U;X^:58:)I^J6VG76HV^HZP-*LQ;D9D47 MY+EO M[L2R'&3][*X^\*V_#_PTFT+QSJWB1_%FMZD-08EM,NUM!;Q #"*K) LI5 6V MJTC %F."3FN,F_95\':SHEMI>MV2WD>G7AFTZ\AD:.X2#[4;I8'/0J)'9>GW M<=#S0!K>._CU8>!_&H\/RZ JA&9%$BC>5^Z&SST MKM?!/C"T\"QX&\ M/RVCS+$M0\-7.D&&P_M*TOGN$E6>#S3%\ZKS$Q89"G M.0"3E<=>-KP MQ\,Y?#GB_6=>E\5ZWK U1V=]/OEM!!%V55:.!)"J#*JKNP&XGJ2:XU/V5_!^ MI:/H]CK=D+V30[J-M.OH9&28V\5PT\4,G8A6D<''4<@@F@#4\8_'RR\)^/\ M_A&#IK7+QR6$$UPUPL6R6]:5+<*A&77=%AF'W=XZX..X\$^,+/QUX;M]7LDD MB21Y89;>;'F0312-%+$V"1N5T93@X.,C(KG-8^#^G:]XBTK7M7G?7=1T::2[ MTT7T4*".8EC'N=(PY6/=A1G ^\0S $;/PY\%KX"\+IIGG_:KF2YN+ZZG"[1) M//,\TI4=EW.0!Z 9R: .GHHHH **** "BBB@ HHHH **** "O-/'7QQT_P " M^*9-)GT^:YALXK&?4KQ)55;2.[N_LL+;3RWSABV,852>3Q7I=<%XN^#.A>,_ M$QUF]ENXWFBM(;RUA=!#>I;7/VF!9,J6PLF3\I7(8@Y!H [VBBB@ HHHH ** M** "BBB@ HKYK_;,^+_B3X/S?#*XT*^U*&TU;7);'4[72+.&YNI[<6DTW[E9 M 1O!B&/7)'-')8HK:*!YGC5E# MD+N4JJR#*A6) STH ^O:*^0&_P""@\"VL%T/ \LD"Z9<:K?1C43'<6<<%W;6 MTT30R0JWGJUTI\LXSM.#@@FW\-_VO->UKQ*/#3W>N7;W=QJ4%F+. MSL=02WD&#&H8*LJE-->\,6>A:#:VEO/KT-EJ< M]U>-(GV232I-01X&6,;F*IMZ;DGB)M!M-'^'T]]J^NW%C'8 MV;ZJD2M'>6DUS;L\C1X1\0,KI_#D$%J /K6BO'_A5\>-0^(GQ&\6^#;[PHV@ M:IX7F\O40]Z9MJO'%);2*1& 5E$DF.>/);K7L% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8VN^"_#WBB^TV\ MUG0=,U>\TR7S[&XOK..:2TDX^>)F4E&X'*X/ K&C^#/P_A6V$?@;PW&+7SC M$TFW7RO-SYVW"?+OR=V/O9YS7944 >3WW[,G@._^)&A^+WT2RWZ/82V%KI/V M* V2!YDF,HC*<2B2-"'&",'UKKM-^%/@G1]0^WV'@[0+&_Q,/M5MI<$&K%8IHKF-;;2+>,)+$"(I!A.& M0,P5NHR<5/:_"/P-9/;O;^#/#\+V]X-0A:/2X 8KD# G4[?ED XWCG'&:ZVB M@#F?!O@.S\&W&L74=W>:E?ZKRZ+%=7-E_:\*0A7ACNH/FBN%\U M7B!RK,O(XR.,U?\ :@\8^%=0U>'^QUO+"T6>VM[>>TF%Y!Y5O9S>=<,-P;:) MY@X4=8CC."*^LZ* /F73_P!HSQ4VO16&I2:#96EOI9U"?4(K>\F2_@*SDW%H MHC!<1F.+!_VB_&7B#Q%X1TR[ATF ZH3=3?:+>X1VA:8#[*FQ M64W4<+Q2.,A0SD9PI-?3]% 'S!\>_P!H+7_#7B#QIX5TF3[$;;0[R2"^2RE, MT%REG'/%L/23?O=01@ K@98,!CVOQ@\7?#=M2\/6U[:WT0UU++3[[6X;@06T M#:;;W,0DD'F2,)II)D5B3@J5!'"CZWHH \.\/_&'Q)/\,_B+XOU3[$J:+>7U MK86MII\[.@MY9%#2*6#/N7RVX"@-QE'4JPSC(/6@#Q?P?\ $7Q5 MXB^&OCJ^\0V,-EJ&@PW6G2QQQR1I-=P)(9)(V5M_E,#%MP0PYYST\STG]IOQ MA;M%"EGI;67V-8;:*>&Y5EE&E178>29BQV^86B)(/+ DY!KZD\-^&M,\'Z): MZ1H]HMEIULNV*%26QSDDDDDDDDDDDG-:= 'R9:_'3Q1JNN:>VL/)#8W-_H @ MTRXLI;26)9IYH[J7?#(=X0H.K-&0,\J17(>!OC1K_@;PO;ZDNH:CJ>H2>&M+ MC6+5!&8J#]Q44 ?)%C^T!XLNY8M4GM?[7N7UY MSI^BQPS6[Q6[>'OM<2@J0) UP6CS*",G@!@,'B3]J+QUI=A+/8V>F7=M;V-Y M?I?&QG*WIAT^"Z^SHH.4?S9'@SS_ \;@PKZWHH BMKA;JWBF3E)$#K]",U+ M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110!X9X%U[2KS]HKQ#;Z7XMU.],-C+;7VCWEW<31R7?FH_FQQ-^[@2)! MY64"AS*)OB!\1+WP'X?U&TT;Q%=-<^(1+JEQI$]LIC9-3, L2DDZ. MD8B0;BJD-QD@%C7UE5>UT^VL9+B2WMXX'N)/-F:-0/,? &X^IP!S[4 ?/'Q4 MO_%>L?%316\*ZC)J-M<7ME8K:VE_/ =.\BZ;^T7GA5=DL3PG879@0RJ%RQ4U MZA\$M;U+7/!MU_:4TEY]AUC4M.M;Z8Y>ZMH+N6*&1C_$2B*"W\14MWKO)(4F MC='4,CKM8'N/3]:CL;&WTVSAM+2".VMH4$<<,2A510, #H* )Z*** "BBB@ M HHHH **** "BBB@#Q7P+>7$O .KWNJ>(HO%.LZP%G6QU>[M(+-(KB26X5 MH8I%1@(X1#B0$8/').?I>J]GI]KI[3FVMXX#/(9I?+4+O"&\-:S^OK**]DQNNH(;J6*&5B!R61%);^(Y/>N[GACNH9(9 M4$D4BE'5NA!&"*;9V<&GVL-M;0I;V\*"..*-0JHH& !T % $U%%% !1110 M4444 %%%% !1110!X3\*M?TW4/C!XW_L/Q7J>M10VHAFTF_NYYPUY'*_FSHK M_);I\R1*J;5;82%P QX>Z\>?$"]T#X2ZA!I7B.^M=0U6QO=6OM,GM@DT\LLB MRVDB23I)''$%'RA-AX!.5(/U=5>ST^VT]9A:V\=N)I&FD$:A0SM]YCCN>YH M^<_&5UXJ\1?'#0W\.ZM+J>@:A=6Z.+'4+B :?90I<1WPFA"A#O1KB\WW$ N7&&N(XYY(XY3[NB*Q/?.>]=Q)/$FEZ%)= M NH7:0F0!E4E0Q&?F=!]6 [U8 M\*>//#GCJ&YF\.ZYI^N16SB.=]/N%F$;$9"L5)P<=JX[]H7P7J_C?X?_ &#P M]I\%]J_]I:=/B:98/W,-Y#/(-Y![1' [G%>4_$WX-?$6[\:^-M9\'P-I[ZQ, MR12VVL_95>%M'G@RR 8#B]:"3=][]WG/8@'U)2;ANVYYZXKYIOOA/\3M-N)! MH5W. J1S6\EYKRD.2Q+73K()1T^4@C8 ;OP5^&/CWP_\1K+7O%U MH)HHM/OK"*9M2$SVR/DO'XFD0+=3:G/);,VW^[:RJN3G&S;V!K>UKX.^ M.%\4F\L;.2_TS3-=%[H]O?Z](6CA;21;D[R2R[;G<^,DD,2.>* /HW5=6L]# MT^XOM0N8[2SMXS++-*V%11U8GT%6Z^.&^"?QAN-*O+F>W9M=71M6T[39EU[: M]G)<"T>!@X_A5XIUR*OA7\6-6GOFMK^XC:34))IY(=8,0O;=M0M M9H44#_4M#;I/'QP=V.0V0 ?3M94?BK1Y?$4N@IJ5LVLQ0^>]B) 95C^7YBO_ M )?^^AZBO%-:\"_$J3X#V?AVQ4GQ)'J=TOF/J["2*S,TYMF$O\ &R1M -KY M^Z?O$#/%_P#"B?B'>32:R=.M[/Q*VM6^HB[;5-_S#19;0S$# )2Z=9-N.0O' MI0!]:45\X_#7X4^.K;Q?X-OO$9U>+2[.UO9;^UF\1^>J7S-:&%@D:('BS#<$ M*6JQO/ IRT8?.PD=L[6Q]*^;_!W@_Q9:_$; MPOHUYJ=XA@2\EUJQ>[FG6.PCOY)M,9)L;?,8!8G4DED5@>QK4^*7PU^(?BCX MC:A<:<]T?"\UU82+'#K;6Q:..SOHYU"KRH:6:U.,\^63VY /H9F"\D@#..:Y M6;XK>#K>=89?$VF1S-Y86-[E0Q\R?[/'QG^*8&,>K BOGJ/X,_%36%TZ?Q"D M>KB%M%NKJTN-5^=Y[5[?SQ$ZX4HX21\.N0X.&(? 2?X-_$W4&@EO].BO;E$M MHS-<:NLCE8O$ O0"Q7)Q;*H'N />@#ZNFFCMXVDE=8T4$EF. !D_H*BT_4+ M;5M/MKZSF2YM+F)9H9HSE9$8 JP/H00:^5[+X2?%6^\4VFIZY8+=6EEK#:A! M:QZZ6\L/:WD#M&Q^;[TEL_S'L< 8Q36^$?QIG\%K92:I,OB#^R(8/MZZR=OR MZ0UN]L?5C>;9O.Q_M=1@@'UE17FOP/\ #/B7PGI>OV?B+SO*DU/S].$]^;QU M@:W@#@N>1^_6=L$G[WX5Z50 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 86E^.O#FN>(M1T#3]=TZ^US35#7FG6]TCW%N#P"Z Y4 M9XY%6+SQ5HVG1R276JV=O''599#Y*KNWRR*C')PHC&.2Q/E^H? WQ]XD M\&Z%I]MK&G6M_H6N-=3VNK:9).L\QU)K@WLW^".A7^@>#+J.^B>TCN]8U*_L[.1=K6UK/=RRPQ ME?X<(X.W^'.WM0!Z!1110 4444 %%%% !1110 4444 %9.K>+=$T'4+*PU+5 MK*PO;X[;:WN)U1YCN"_*"=4DFR0HVJ3DY) ]R<5K5X9\5O M@[XA\8>.M2O-/DA_L_6+31[9KEY=KZ>UEJ7VMW5,Y(J]X;\=:7XFMDEB:6R>2[N;.*WU!/(EF>"1HY2B,< ML RGD=AF@#HJ*S5\2Z3(J&/4[.4R3-;H(YT8O*HR8UP>7 _AZUR&E_'3PIK7 MAWPQK=E-M4\*V=S]HU;3+:*ZNECPR1K([ MHJE@?O9C;*]1QZT =)1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<;XT^+7AW MP#JD%AJ]Q,D\D'VJ0PPM(MO!YJ1>;*1]U=\BKGZ]@< '94444 %%%% !1110 M 4444 %%%% !1110 445QOB[XL^'/ ^MVVE:KW8BH[KXQ>%[.'0I7OG:+ M7=3&E::T<3,+F8DC0?GZ?F,@':T5PNO?&;PWX=\7?\(Y&>JT'7K#Q1HUGJNF7"W=A=QB6&9+YB63@?(,"NX^#?P/U3X8^)KO4;[7+'5[T%PR1W$\RR3R>8P=SYY!(502,\9(KV&B@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "O*/BG\"Q\1_$%SJ":J+"+4M'&A:E"\!D,ELMP)U,9W#8^?,7)!&'' M'RUZO10 U%$:*J\!1@4ZBB@ HHHH **** "BBB@ HHHH **** "O)_B=\"5^ M(GB>YU(:J+*UU+3;72M3MV@,C2P6]Y]JC\MMPV,2TJDD'AP>"M>L44 %%%% M!1110 4444 %%%% !1110 4444 >=>$_ ?B:Q\:>(]9\0:QH^HPZFA@A^P:; M+;W,,(8^5$9&G=2J!F/RJNYF+'L!P-E^S'=7VC>"8KKQ+JVCZAX5ELX!]BE1 MK:\@M97='"%24:0,-QSU7!!P#7T'10!Y!KOP-'B+QYI7C'5S;S:AI;?%3XS0_#SQ7X&\*6MA_:?B M3QA=SV]A"\OE0Q1P1>9//(^#\J*5^4#)+ <:(#?MP7 /-;7Q'^$&B?$O5/#&K7SW-CKGAF\: M]TG4[)E$MN[H4D0AU97C=3AE8'. >" 1Y%JG[ _@'5-%TS3'UOQ-!;6-W=W^ M(;J ":XN+F.X>1E,!4%7B0+M"X4;>10!V>H?M7> +?6_#^F6-Y>ZRVLZC<:= M'<:?83RPQM!#++*Y<)AE41,,KGG/8$AVD_M=_"36[>TN+/QA#+!=%?*D:UN$ M78S1J)"6C&V/=-&GF'"AG"DYXK L?V*_!6FZI!JMKJVO6VJQ:@^IM>03P1M) M-):R6TK,@A\LETD.Y]N]F );U=-^Q7X$N/"_A/09K[7);/P[IAT1)'N(O,O+ M'[1%<>1.1$ 5\R"/E C8!&>30!;TC]L+X?QZ3;W/B76+?0+BYN;Z.")5GN$: M*VO?LC2,XB 7#F,,#C:7&3CFK^@_M:?#G5[$7=[J[:!'+K%UHUL-5@>$SR6] MPMN\BY'$?F.B[S@ NH)!.*Y'4/V#? FI::;&37O$Z0>1J%L/+N;8$1WM['>S MC_CW_P">L28]%R/>M?2?V,_!FBZ]I>KVFK:\EYIUWJ%S#YDUO(GEWLJS7,!5 MH2-C2*'##$BG[K@8 +/B#]L+P%I^HV-AI=Q=ZY<7MMJ-S%<6ME/]E5;.%I) M2TOED;U6]!_:T^'%]_9%EJ?B*UTO7;VQM+R2RV3/%%]HM6N8P)C M&%(:..1E/&X(<#/%15:;]@_P1,T3KXD\60211:;"DD%[;HZBQLYK2W(809#"*XD MR1R6P>,4 =9#^T]X!_#7AS;KEOXBN;^RGO%9X7T^:VM4N0KQ.@8[TD M4CIPP/(-3V[1R32V<5FYD"P* M3F*%.A'S9/4UK:Q^R3X1\1>,/%.N:KJ>N:A;^)M0L=2U7199X5LKB2T ^SJ0 ML0DV*54E?,PQ'S9'% "^$?VM/ >M>&K;4]7UJQTB6:.ZNFBC>6>.&UAN)8?. MD?RU\M286^^!@Y'.*U/^&J/AA]LTNS_X2;%[J4TEO;6OV&Y\TRQNB2(R>7E& M4RQDA@,!@W3FN"NOV _AMJ>AV6D:G=ZYJEA9K>)"+B>!9$6Z>5YE$D<*L$+3 M,=F=I*ID';75^"?V4?"O@7QYIWC&TU76[K7+5KYYI+J6 I>M=K$LK2JL0Z+# M$%";0-G?)R 9%E^VCX$N/B/KFA27L47A_3M-@O8O$&9/+NII+J6V,$493,A# MPOADW X./NFNCF_:T^$T%]=6K>,;9I+:WM[J5H[>9XQ%.B/ WF!-I\Q9$V8/ MS;@!D\5PG_# /P_6YM)X];\31R:?Y']EC[3;,NG>3=2W,(C5H"'"O/*,2[P5 M;!S@8[.7]E?PM-_PG@?4=5EB\:1:?!JEO,+:2#99HL<:I&8-NUD7:ZL&!#' M7C !ZOH.N6?B31[35-/D>6SND\R)I(FC8CW5@&!]B!5^N?\ '@G3_AOX+T; MPOI+7#Z9I-LEI;M=RF678HP-S'J:Z"@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **\A^/OBKQMX3O/"%WX(:'4+D7D\E]X=E5-VKVL<#R2 M10N1N28;7:W$$3W5U%;1R M0K&-@'V;82WS$[N&VG !].45\\VG[75I/#:SRZ%Y-I+-9)+=+=>;';K<6L,Z ME]B%EYF$>[&W=MW,NX57N?VQ+:R\&Q^);CPTT-E<*;NSC;483-=6BQ>8TBHN M2&4<,&P ?XN10!]'44@(8 @Y!I: "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**\$^/'Q7\2^#/%5Y::-<"S@TOP\NM)"T"/_ &E,;V.$P$L" M* />Z*:C%D5B-I(SM/:G4 %%%% !1110 4444 %%%% !1110 45YWX,\6:GJ M7Q9^(^B7=Z+K3M(73GLX!&@:'S87:09 RV2H/S9KSMOB-XL\2^&?!7B/3O%5 MOI%WJ^H+/_83V\'DO9+<[;CSI)!O58X%.&0J?-8 D@A0 ?1%%>%_$[XVW6D? M%KP9X3TR:\L;&\U(6=_>1Z1<3I<&2"4HD,XB:)=C*I<[L@X! >N_P#A#XPO M?&W@M;W4E0:C:WMYIMQ)$NU)GMKF2 RJ,G ?R]V,G!8C)Q0!VM%%% !1110 M4444 %%%% !1110 45Y/X'U_Q!_PLSQ5;7?BB+Q'X?@M59(!!!&UM>J[>=!! ML 9XT0Q!MY8ASC=G('G.I?M(:U!IOPON&:ZM3XEU"QN[Z2'1;BY@%KHKY_P#B'\1/'&E?&C0]&T]IUT'6+VUL;!K.*WFA MEB,5P;V61CF1)(66)A_!A0#DN<>F_!_QE=^//A_I^K7\:1WYDGM;CRAA'DAF M>%G4=E8Q[@,G&<=J .SHHHH **** "BBB@"C=Z'IU_J%E?W.GVMQ?V6[[+=3 M0JTL&X8;8Q&5R.#CK6=>> /"^H7UO>77AO2+F\MR6AN)K&)Y(B9#(2K%<@^8 M2_'\1)ZUYCX@\"1:/XH\/:"GCCQS<:CK3S-&@UL(L4,*AI92?+/ W1J!W+KR M!DC@1K=IIG@^'Q-K_BKQSI6D+J^H:/=S1>(A/]GEMI9HT;'DJ660P,..5+(, M$$D 'T+8?#'P=I31-9>$]#LVBD\V,V^FPH4?CYAA>#P.?:F2?"GP3+:-:OX/ MT![5IWNFA;3("AF<$/(5VXWL"06ZG/->">&8=7U#PQH'BS7=:\8:%X3UK3TO MHK@>*C/=PO,T0M8)(!:@&242CA';:PV_-G=1;ZYH4_C1=*_X3_QLVD36]M]G MU*/6F9VNY;V6S-M)%Y&8V6:+823]XX(&* /J&*-(8TCC18XT 5448"@= !Z4 M^OET>,?AZQL@GQ7^($K7D$%Q L=S,Q99HY7A'$/WG6"7 Z_(:U_#MQX+\5^) MX- TKXK>.KK4+A%>+&H.L3[H%N% D,04L8G#XSG&?2@#Z+HKY6T?Q1X9DOO$ MUEKWQ$\;Z!>:+J%U9A)-99TN4AECBWQN8%!8M+%E!DJ7')ZUL1ZMX"DALY_^ M%O>-8[>\LWOH)I-3=4DC1&D<*3%RP56)4<\8ZD"@#Z1HKY4\,^*O#6J7US8Z MS\0?'/AZ^_MN?1[2UN-99I9O+9$65U,(,>YI%7!!Y[GK74:':^%_$GA63Q%I M_P 2_B!-I(N19QS->R(;B8OL5(E:(%R7^48'6@#Z#HKYLO=6\#Z=;O/<_%7Q M[!%'#YKF2^D4HWD/<>2P,.1+Y4+=2M--MOB!\1K;4;J[O MK6&UNK\J[BTN'MY9<",XC\R,@,>Y .":E\2S>#?"&H:E8ZM\5/'=I=6 1I8C MJ$C,0SQ1@H!%\XWSQ*2N1EQZ' !]%45\M:OX@T"-O#":'X\\>:W)K.HVEE(O M]K/%]B2>:6(/+F [6WPRJ$;:24;D8YM^.KS1O _B_2]$G\>^-Y8)+F2#5-0? M6V2'30MH]U\S>259C&@.W(.&!YZ4 ?35%?,EIXF^']]=:=;0_%KQV\M\Q2/% M_(50B=;<[V\K"?O71.3U8>M2W&N>!+>%)#\5_'DC2O$EO%#?2227(E,@B>)5 MA)=',,H5AP2A]J /I:BOE^/Q%X,U"WTV[TWXK>,KBRN)E$DDVIS1OY+V4UW' M)$OV<[]T<)89V@JKD'("FS8Z]X#U#2XM1C^+'CQ+.2=;?S9KZ2,(66)D9MT( MVJRSPD$]=XQG!P ?2]%?,VBZYX.UBSM[B3XD?$/3%FF>';?7[(8P+HVB.^(R M$628;$)QDGMS5KPA>^#?'>H:;9:+\3_B!=3ZBCRVRM>21[XU )D^:$?)D[=W M3<,9S0!]'T5\Y>)+SP7X3U&^L-4^*GCRWO+-HU> 7TC.Y>:.!=BB$EQYLT29 M'&7%7O!]CX5\>:M?Z9HOQ2\<7>H6,*SSV_\ :A5U0DJ>#'U# J1U!�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end GRAPHIC 17 oyst-20191231_g13.jpg begin 644 oyst-20191231_g13.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" #, 90# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#LO!<%O_(GK?\ 7Q_^DP(O,N/^>"?]_/\ ZU,ANI+B M/?$D4B9(W)-D<<'M7GWQ)^-6C^$;J;0;;[5J7B"2%B+?3XA(;8%3^\D)X ^ M;')P.E>8_LI>/8-!^'KV-_XJF\>Z?_:5P1XNL[/;8H[,"8&(Y4J3]XC;\W6O MBUAJCI^TM_P3]1_M/">TE351/E=GV3[-[+S[=;71])>9"?]_/_K5,K!E#*<@\@BEKD/4(/,N/^>"?]_/_ *U'F7'_ #P3_OY_]:IZ M* *EQ=7%O"TGV4RA1DK$^6/T! S3M/U"#5+..ZMI/,AD&5;^GUJS7,^ _EL] M64<*NJ72J/0>:>* .FHJEJVN:=H-K]IU._M=.M\X\Z[F6),^F6(%2V.H6NJ6 MJ7-GGZBFGW6LZ?;7[_=M9KI$ ME;Z*3DUK4--;H+A15"'7M,N-4ETV+4;2348EW26:3J9D'J4SD#\*G34+62\D MM$N86NHU#/ K@NH/0E>H%%GV"Z+%%07E];:;;F>[N(K6!>#),X11^)J"/7=- MEL7O4U"U>SC^_<+,IC7ZMG HL][!)Y)76.- 69V. M H'4D^E5=)UK3]>M?M.FWUMJ-MN*^=:S+*F1U&5)&:=G:X%VBJ-YKFFZ??6U MG=:A:VUY<\06\TRI)+_NJ3EOPJRMU"UPUN)4,ZJ':(,-P4D@$CK@X/Y&BS E MHHILDB0QM)(RHB@LS,< =232 =14<$\=U#'-#(LL,BATDC8,K*1D$$=013I M)$AC:21E1%&YF8X [DT .HJAI^O:9JLA2RU&TO' R5MYUI"DBOST^'?_ "/&B_\ 7RO\Z^Q_BM\-_''C^UFL=#^(J^$M M*N(_+FABT.*ZF92,,!([X /LN?>OT/C!*684U)V7(O\ TJ1^+^&%_P"Q:_+O M[1_^D0/*/@_\2OA_X3\"W^I:SXET67QEK_G3SPWEP&DFBT^X^XRZAC, M'0IT*2BU!6DK--OJ]6KW>M^MSTSQ-KK^&]%TB#1A;^9J%['86TMT&:&#<&.Y ME!!8 *0%!&25&17':A\7-9\,^*HM'U2WL+ZVM&F;4]1LHWC6.$1QNDJH7;;L M+_O%+'"X8'J*]+FT.'5=$&G:RD.K1NH$PEA 20@YSLYQST],=:AT_P &Z%I, M,45GI%G;QQB0*J0J,"3'F?\ ?6U<^N!7AJ4%NKGU:B[)+0\JNOC1XBL_#\^K MSPZ;;Q2::US8Q&VED2XE%JT^%E63&[*/^Y(5MJDAN.>OM?$'B=_$GAZSDO-. M^R7\5Q+.)='GMYL1,G"AK@[+O'WB/1;V'2VL-.7,Z5HMCI]W,"LD]M J.X)R02!SD@&JO@/YK'4Y!RDF MIW3HW9E,AP14U90E*\%9'#E]'$T*/)BI\TKMW\F]%LMD>6>%?"6C_%;XT?$: M_P#&%E;ZY/X;OH-+TK2]0C$L%E;M;1RF98FRI>5Y'^#7,>-E_X4/X M\\6P?#Z!;*WO/!.I:]-HELN;>WO;=E$%PD8X0R;W4JH ;RP<9%>P^-O@SI7B M_P 11>(K75-8\*^(UA%L^K:!=""6>$$D1RJRO'(H))&Y21DX(JSX!^$>B?#] MM3N89;[6M7U3:-0UC6KC[3=W2J"%1F( "*"<(H51D\5Z2Q4$N9MM62Y>FEOE M;KWO]YO[*6UM;[G&_#G]GWXTAAN[WPC.US-&@#S%;J%5+'O@<#/2M#1_V= M?#NBZS8W$>I:W<:-I]XVH:?X;N+P-IMG<$DAXX]N["EF*JSLJD_*!Q7:R>#- M/E\<0>*V\[^U8=/?35^?]WY+2+(KBH2;M)N_-^.R^1$:326EMO MP/,?VM+?[7X!\.P_V1'K_F>*M(7^RYF14N\W2_NB7^4!NGS<<\UY+\0OAOK7 MAOX9_%OQ(OA'3O 6F7VAV]I;^&[.[6=)[B.8L;F7RP(T)#*GRY)"Y/:OJGQ= MX-T_QK;Z9#J/G!-/U&VU2'R7VGSH)!)'G@Y7%=1\/ZIYO M]GWT8CF\A]KX# \'!QR!4X?&^QA"%M$[O?:Z?>W3L%2CSMR\O\SRB^\9>-OA M3XLT7_A+-" M=,\1Z_H.KWJR27.C-.UL@8>6WG1&)PZD?,-K&O-M2_94\+ZIH<_AZ?7/$_\ MPB3L6B\.+J>+*W.[< @V[]BGD1L[(.R\"JI8BA[KFDGI?W4[J[T2Z:6_S[DJ M=351?IKZ%&/XE>(]+^,&H6?B#6O[&T=(C/I>D/I(>+5[9;59)'ANPP(N%D\S M,9Z*HPISNKSS1/CY\2]5\/:9XUMK36M1-]Y5X/",/A*869M)&!"1WW4RB-@W MF$[&;C: );O6==U#['.UU::3>7WF6-M.8O*,B(5W [2P M"[BHW$A1FL>U_9M\/6K06::SXB/A>WN1=0^%3J'_ !+8V#[U4*%\PQAP&$1< MH, ;<<5<*^%2]Z.MET72]UZO37?S1,J=5[/OU_K^NAV_CSPOHOCCPS-H7B G M^RM0>..6'SS!Y^'#"(D$$ABN"O\ $"0>#7C7P/TVY\)_'OQ_I>I>'+'P:^I: M?:WFF:3HK*]C<6D#O$UT64*!.6D1678N%" M.:.>UE,4]O-&X>.6)QRKJR@@^W<<5D> _A+8>!]8O=:EUC6?$VO7<"6CZKKM MRLTR0*2RPH$1$1-Q+':H)/))P*Y*5:,*$X-[]/FG?MTUT]#64'*:DEL>2?'' MP1IGA?X@:C\0/%/ARU\7^"KZWL[749F&;[P\T#L4N8._DDN#($(92-WS#(%? MQ9>>(O"?Q>^+/BG3O$*S)IW@.+4;6U:QC*G;]M:%2_4A64MG^+=@]*])\:?L M[>'_ !QKFI7USJVO6%EJYB.KZ/87_EV6I^6 J^(-6U:6W::35-,BT>YMI"# UM&9"%VX[^*2U3S$Q/<;MZRN%)RN% M0D JV#7H?A']GW1/">N:/J!UKQ#K<6B(R:/I^L:AY]MIP92F8EVAB0A*!I&< MA20#5/5OV9_#FJQZO8IK/B/3O#FKR2S7OARPU'RK"5Y,F0A=N] Y)+(CA"2< MJUM?*U^HY1J2W_,XCP3\8YOA7X-TFU\0F-]%;P-8Z MQH3*@5I7AMXX[BUS_$^YX67OB4_W:[OQHVO-^S#XCD\3/&WB"3PS=R7ODH$1 M)6MW8H!Z+G;^%5_&WP4B\3:I\*-%6PAG\*^#[@7[W5TX:5;0@8^8,6W MN<8_= =Z]-\3>'[7Q9X=U31+[?\ 8M1M9+2?RVVML=2K8/8X)J*M:CS0G%:M MW?R>GWK5CC&=G%_(^?/'GP=\%^&_V?Y/&&BZ99>$?$VAZ$NJV.MZ9&+:6.XC M@#J&*XWJ[ *RMD,&/%0:]\;/&/B;QE?Z+I&;;1K*R:YFTGPP^KR3W<\" MS%&XVQQHK*,?>8D\C%>@67[,_A_=IT>L^(/%/BK3M/:.2WTO6]6:6S#1X\MF MB155]I (#Y&1TK=\6?!K3_$GB.;7K'7-=\*:OS:VO;O?SZ==.Y'LY_95CR76?C#\09?!?A75M5\_ MP!:>;>6^M:RVA--J7XB:W:>,O$?A_PU M%HMGKNN^*+?2H-8^QCRD3^S!=2W,BJP,S[(W"*6YRH)(!SZ!K'[/>A:EX7L/ M#MIK7B+1-(MX);:>WT[4V OXY6W2BX+AB[.2Q+C#_,<,,UC_ !'^"44?AJ_' MA?1H]3N;K4[349;.6_>SFB\B%84:RN$(,$J*B;2V0?F!X:G"MAI/E2M>_16W M35_\F[=--1.%5:W_ *L87B+Q=\1OACXR&BZIXFL?$FES^&=8U>WO6TY+>Z6X MMEA*K(J'84'F9! &=Q!S@$GAOQE\2=&TWX:>*/$NOZ?J-KXJN;2RO=#MM/6* M.S-Q$6C>*;.]F5@-V[@Y. O%4_ /P*U77O'EYXA\466L:?:G0KK1-VMZVNH: MA>F:FK5H4[0LF^K27GM;Y;#C& M%G_(HK?]?7_Z3 L^0_\ SW?\A_A1Y#_\]W_(?X5(TR*Q5G4,!N()YQZ_2E:1 M%C,A91&!N+$\8]0_\ SW?\A_A1Y#_\]W_(?X4J7D$D@C6:-I"" M0JL">,9X_$?G4U )I[$'D/\ \]W_ "'^%'D/_P ]W_(?X5*\BQ@%V"@D ;CC MD]!3J!E2XL3I-*K!U#*0RD9!'0T!Y"9;^[^M&6_N_K222I"H:1U09 MRQQR>@HEE2&-I)'6-%&2S' 'XT"NA=S?W?UI-S?W/UHBF2>-9(W61&Y#*<@_ MC2R2+$NYV5%Z98X% 75KB;G_ +GZT;G_ +GZT^HH;J&YSY,J2[>NQ@?_ (]1OD_YY_\ CU24QI45T1G4.^=JD\G'7% QN^3_ )YC_OJC?)_SS'_? M5.21)"P5U8J=K;3G!]#2M(L>-S!A]*225(@"[J@)"C<<9)Z#ZT!=;C?,E_YY#_ +ZI/,F_YXC_ M +[J:F>:GF>7O7S,;MF><>N/2@8SS)O^>(_[[H\R;_GB/^^Z0W]L'D0W$0>/ M&]=XRN>F?2G)=0R6_GK*C0XW>8K KCUS3LR>:/<3S)O^>(_[[H\R;_GB/^^Z MD1UD171@R,,AE.01ZTC2HLBHSJ';)52>3CKBD.XSS)O^>(_[[H\R;_GB/^^Z M07ULT:../S&=5CQG(_[[J02(7*!E+@9*YYQZTV:>.W3?+(L2YQN=@!2'=;C?,F_P">(_[[H\R; M_GB/^^ZE5@RAE(*D9!'0TWS4$@C+KYA&X+GD@=\?B* &>9-_SQ'_ 'W1YDW_ M #Q'_?=34V.19%W(P=?53D4#(_,F_P">(_[[H\R;_GB/^^Z(_P"^Z/,F_P">(_[[ILVH6MNSB6YAC*C+!W P/4TM MO?VUVS+!<13,O)$;AB.<=O<'\J=F+GC>U]1?,F_YXC_ONCS)O^>(_P"^ZFHI M%$<;.Q.Y-H_WLU)110 4444 ?G'X!3S/&>CKZW*?SK]&(%\N%%] *_.OX=?\ MCQHO_7RO\Z_19/NK]*^]XR_WZG_@7YR/QKPL_P"116_Z^/\ ])@>+?%#X<^* M_%GC:[OM+?[-97%G%HLCF51FTD\QIY ,YW*WEX]>>M4)/"OQ%DT+^PC;S"SD ML8XRWVN+RU"6KQ-"1G.7DV-Z<\D8KJ?'7Q7U'POXP32;>ULA &M5Q=M()KGS MI"K&$*,$(!SD]ZPU^-OB*&W+W6EZ;;K-KAX2T_&?X >/[P'O M7S<'7<(VBK:6/;Q,=G=.?,4.OE]AN],9YJ.\\;ZW-\"[?7&UM;'4I+Z;=&A;VE2*G&$DDU]K5)6U3TU_IDVH?#SQQJS6R7=YJ%S M%)>0WDJR7J;872^8KLYX @VM@=P.XQ3M \+?$R2[VZMJ=^L#W\!NO+FC4-&) M',C1,)&8)MVC;M7/'&0:I1_&#Q4L-[H2V47VJUTMR+V5V\\R+;"03X/52QQC M'XGI79_#_P"(6NZYKUMX?O["+[3:VB7=[?)N"-$\:&$KG^-F+Y!Z>6WJ*F;K MP@[J-MS?#1RS$5X*%2JI?#N[-]GIK;5WVM<@^,7A76/BAX%TR#2[ VUT;L3M M#?! 8U"N,LI..U87_".?$"VU2U2T358;6-56/_ (F,)@CMQ:;5B=,[ MFE$W)89!X.<55\2_&#Q'JT.H:;IT-OI]PTWEJT)D-Q8A;E(L3@K@&0,2NWT/ M7K6_\2O%5[I7B2XL[GQ+/X7L[?3%N;&2"!7^W7.Y@RDLK;MN$_=C!._-*"JP MBJ;2Z]WV[&F(J9?B:D\9&=2ZY+M.,4[TJV@]N:-][6[Q5UM*WEJ95_\/_B$VES1 MKJ6I7[R)!$UO=WL;QNKVK"X# \'$VT#TQQQFEOO#?Q&\C44L%U:TB\VV6.'[ M;"ZFW1,2"+]XI5F?G!*@*N O*M!^,7C'38;3^UK<7$JZ2UT)Y$*V\RR7$2QS.5&1Y:M(' _NY M[T0E5G=)1=K?CJ/$4Q@%;)VEE)#;6.#C!KD(?CYJZR6.[3;"^2:6^B/V%Y&:CB,K]ZA"K.3JN,==7T:U:U2OK>Z:T?1":EX=\81Q60\-Z)<>&+, MJ[0:?9W\*I;W!E!\VX'1D*9^1,XY]Q7%Y?W4-U*TI@:\0) M&4OHVAV#/RCR=Y_ 9YQ2:I\6=4\+^+O$D!U2'4A]N@@@%S\MG9QN^PB3:H=7 M4CU(8=C+Y3M)<-")E.,^2 I<\9Q^=7:O&TE M%?\ #^NIS2GE55U*56K43LTUI9*-TVE%6V3\K:+L,A\,_$>UFT?_ $S4IY2D M3M*U_$8H)?/8S>>IYD4Q[0H7.,'H>:YNS^&_Q#T'2[E-+CFL!--4\9Z1J.L1ZAJUOIMR M+M[B&>(6YB%H5*K;@[O-,A;IG.XDRC28]3MKJW$DBQ+() -Z ML.2I3=@>N*X7P]\6MZ:6XMWF\F M6.&.W?,9QG+>Q'6B7MU:;BE:[%1EE4E/#PJU)>T<8ZM]7TZ===WU71(M-F2>^N M(GB@NHF0R,J*WS#(9B2 V=+AY=T4DT#S#.!R%"8/ MJ3VJN:O>_+'^K,P5/*W!4_:U5JU9._\ -'=)[VE;7=-K4K6V@?$I_$VBR"[O MK2PCAA5Q--%.H=0?.\[$@W;FP00IX(^[C%:'PV\*>*K7Q5?ZCKD=]#-)I(LV MO+R[BG#7'FLQ:)5.5CY! (%9$/QXUK4+J&WAL=.BEECMA]DWRFZ+31Y9T&,% M4/)SV';NWPY\:O$-O#I%G?VEI=W+6\'FJ3(+FY,D15K/\ !$=O\.-2_P"$;.E?\(1'#KD4 M:K/KWVR(_:V$R,S#G+ L5Q>:/I*VI2UE?RY90P%Q%(R#)&!M,9W'T(Q6U: M_%S4+CX6VGB0VEHM[-=BSE9O,%K;9D*F5S@DH .HX.>M.4L1'1Q6K]=7\Q4J M.457S1JS3C%]%'W8NW2*O9OKVU,G1/#GCVQL[^V8:A%J2Z>T5C<+>PBPCQ B MQIY0^8.&#?-C&>VU!=-M6N5A_M2]BN)HE>&$8RA/!= M'JQ\./&VO>,O$FN7EVRP6$&FQ^1;P[C$\F^0&9-P!*L$!&><$5RG@GXJ>)Y( M])@M-27Q*=12S2>XOX-J6-S*7#Q[HU7=PN['48Z\TG&J^=6C?K\T5"I@(/#U M'.JXMMQU6O));K=INVVO5[75^^^$^NVXUR#2K'[#9WL^IS-#;2QHER6\O[*) M!GE?];P>F3GK5;4O!?Q"U);NQN(KZ>"2*=)M]]#]CE^9# (H\[DVJ"#G'([Y MKNO#/Q!U?Q18>)C)IZZFVFL[.WGCL[M(II8TDD,B1%C MA6P5.3C.3@Y-0>,_!?BCQ+\+/#FGZA:RZIJ]OJ,=Q=Q+) TOE#S< M)B-W"L M@/8G)K5^'WQ4U;Q?XTU+2+O2(;2VMO. 97/FQ%)-@\Q3_>ZC&,>_6O/_ /A9 M/B%;>\-OKUUJ4C/RNVMSJ[WPG\0(8]2AT[4+B+3H+.)M/MQ-&D[ M._EB:$D?*I1$<(?N@R>@K(M?"OQ M]3BUA;;4))+4S"&&[OX7N6MS=6SB$N& MVY:..3OCL3S1>?M#:W#I<4L>CV+W!O;FW>3>_P!G CVE4#G 9V#=0<<'C/%: M-Q\C@1X]X\^&.K^(_B(NIVS74-D[V.ZXM[I M8V01F;>5!.01O7G_ &CBJ>@^'_B)XRJ[O-64>8,L MWR_,%;KG(QBO;:*YEBI\O*TGI;8]J60X=UG6C.<6Y)CDC(R R.K) JV6PG4(=D"JQ^TK&_!][J,W]K#Q!:S6[A;J\CGMK^4R;&CB1.4C8,.H&,#T)KW"BH^M/ M1.*.B61QO*4:\TVGU5DWUM9:KIKY;:&7X9T^[TGP_86E_>/J%]'$!<74AR9) M#RQ^F2<>V*U***XV[N[/HZ<%3@H1V6@4444BS\Y_AW_R/&B_]?*_SK]%D^ZO MTK\Z_AZ,>-]$_P"OE/YU^BB?=7Z5]WQA_OM/_ OS9^-^%JME%;_KX_\ TF C MPQR,K/&K,O1F4$BD-O$RE3&A4C!&T8QZ5)17PA^QV1&UO$T?EF-#'_=*C'Y4 M-;Q,^\QH6QC<5&<>E244!9=B/[/%NW>6F[&W=M&<>GTJO::/9V-[>7<%NL=S M>%3/*/O/M7:N?8#H*N44[LEPBVFUL1^1'N8^6N6Y8[1SCIFEDACFV[T5]IR- MP!P?44^BD59#&ACDD5VC5G7[K%02/I0\22;=Z*^TY&X9P?6GT4!9#0J@D@ % MNO'6D\F/;CRUQC;C Z>E/HH"Q$MM$A4K$BE?NX43'M*^6NTC:1M&,>GTJ2BG=DJ M$4W)+5E%]$L9-1M;YK6,W=JCI!)C_5A\;L#H,[1S[5;:)&969%9EZ,1R/I3Z M*+L%",;V6XU8T7[J*.,<#MZ50U;P[INNZ7+IU]9Q3V4HPT)&!USVZ<\\5HT4 M)M.Z"4(3BXR5TS-T/PYIGAO38M/TVRBM+./.V-!GJ6FY1M! MVC('I4E%%V]PC",5:*L1^3'T\M<I)-,FT.PN+RSNI+6-I[-F>!L8\MF7:2!TSCC-7Z*KF=[W,_94^51Y59 M>7;88L2*[.J*';[S "BBB@ HH MHH **S+O7H;.X>%XY"R]UQC^=0_\)/;_ //*7\A_C0!LT5C?\)/;_P#/*7\A M_C1_PD]O_P \I?R'^- &S16-_P )/;_\\I?R'^-'_"3V_P#SRE_(?XT ;-%4 M=/U:/47=8T==HR=V*NE@N,D#/2@!:*HW6N:=8W$=O<7UO!/(C2)')( S*HRQ M ] ?RINGZ_INJ3-#9WUOOH)KBVM0I>.W +G+!>,D#OZUXS_PVOX2/ T36O\ OB'_ ..5 MT4L+6KKFIQNCQL?GN6Y745'&5E"35[.^WW>1]#T5\\_\-J^%#D#0];R.3^[B MX_\ (E)_PVQX2_Z FM?]\0__ !RMO[/Q7\C/-_UOR+_H*C^/^1]#T5\\K^VM MX39@!H>M$GH D/\ \K0M[2-KGL9?G& S7F^I55/EM>U]+[?D:]%-1MR@TZN<]@**\R7XQ3 MP^)-8T^XT&X>TM;O[#;W=MEA+,>B-N"J.,GAC@#FFVOQWT[['$]QI>I2R^7N ME>S@#PAA$)6"DL"<(=W(Z UZG]F8OI"^W5==3P/[>R[K5MJUJFM4[=CT^BO/ MF^-6C?:(HXK'4YUN)#':RI NRX(D$9V98='..<5;7XK:9=:'KNH6D%Q(='M7 MGN8I%"E)%WCR6.3A\HGJ=$H6Y@N;1@-28H0BC[-),3%U+ ;",D &I9?C=I%OE9M M,U:&1&<31M I:%5$99VP_P!T"5.F:O\ LW%:6@W:JE9V=^C[?UV? M8]$HKSO5OB=>Z7X0O-1&G13ZC:ZK_9;6ZLY1F\W8&&U68Y!!P 3VIW_"Z-+M MYGMKJQU!+I&,("096:<% T<9)!SF1?O!:2R_$R5XPOJUIY6_S&\YP,9VCM,TA(/M5_P!F8OF^6%8 \DDB*'BD\YHF5QNZ#;G( MSWKNJXJU"IAY&Q='&1']75&L-;T^]5Y M_LRFVNDD!EP3Y?!/S8!..O%;5?'2C*+M)6/U2,XS5X.X4445)845!=7MO9"( MW$R0B618D\Q@-SMP%'J3Z5/3%=7L+/.+KX;W#>3%:Z#JEO9QQSJ;>:ZM;C<\B,AU/4;F.V:**WGN+;!9F0L,HV[!V* .=H'>O9Z*U=>I)#^%?">EWC: M?J5I=*S(T,JR!EZC!!XK[V_:<_Y(IXA^D7_HU:^!8+*XNE)A@EF&X)F-"WS' MH..YP?RKZO)K?5Y7[_HC\!\2.99Q1<=U37_I4CTW0O'.AV7B/Q7JIO+R(ZJ; MKR+-+-70[V;9YAW9V@,3M&.0,Y J#PMXQ\'Z=X?L;/4O#UO>3H%%S:V(<,0 2.& P<$&NL M\0?$;3-?T?5!ISZGH\&^8SV5K;(8;WS-H629@<(Q(.>#C/RUW3IVER\KMIK? M_@'S&%Q7-159U8J24O=<4]W=_%+ROLM'97=T6?%&J^"])T_2;W1VL7U".VD( MAL[?#*SI%&%D;)W,@,SY.#G;Q3!\2O!,3SM;>'8+*012K#+;VBHX8LZKDYZ> M6RY]^:;:?$;3/#7AW3+!+#4M*F@NX;F.SF4,%02F0SB0A2S,AV?=&1[5Y3K% MU'?:O?7,0*Q33R2(",$*S$@?D:5*CSZ33TZW'CLR>&:J8>4&Y)7BH[.V^KO? M3LNFB&Z7_P A*S_Z[)_Z$*_21I-M]C_83_T$5^;>E_\ (2M/^NR?^A"OT9NI M-NJ,/]B/_P! %>3GG_+OY_H?H7A=MB_^W/\ VXZJS;="*GJCI;[HJO5\L?O! MG-X=TQ@0;& @W/VL_(/]=C'F?[WO7._9/!5MKG_"."TLEU#R3.;58#A4:,QD MDXVC*(5P3DA:UO#?@S3/"=WK=SIZW"RZQ>MJ%WYUQ)*#,RJI*!B0BX4?*N![ M)JL.G6LEFUK((;=O-F4@[8Y3OVO&&.\ C(^8 @,:[:=3 MWFG4:1QSP])I/V:;]$:-OHG@5=W<5-IN MD^&IM#U.SCN8Y;?7FDN+GS9%624SJ>W!'R\ 8SA:YR?X+IJ5P][='2[34"B) M&VFV'E)#MN(Y25RQ.2(PI/'7VK)L?V:M+AT]K>[N(+Z5X%B::6U!8D- 2W)Z ME8 OT:NCVD6O>K/IW>W^1@L)1B_=HQZ]$M]_O.VA\$^%9((PPMKJ]O(?+74& M=#<7&V(IO##J=C-R!W-9G@_P3X(T6WO=+M'@U&1)?*N'NV5V+2JA\O( 7E43 MA?[HK OOV>8+CQ)'J,>H!;9;A9EM_P!Z@M@LQF"Q".15&6)SD$=^>E=%/\*4 MC\-^#=*L)[>T;P]-;2"X^S\R>6FQB%SMRPW#Y@<;LCD U4L0^7E59Z_U_2,U ME^&YE/V$;J_1==_O[DUC9^#KF/5_"\\\>J-;3M?:@M\"0)&8.69\!P]1\J9(]!7,>(/A/J&N>)-2U,:G9PP M3M#*+(6K>50JLLEI8 M%)+=E210L!W_ "1GS"2/7>?X^)]HGK[9KKUWZFOU2BER^QB]+;+9;(ZO3?A] MX-CURWO+2TLGN885^SP(RLL2B1V\Q5]2[MSZ^]%_X=\!Z#:WDEW9Z1:012![ M@R!1L9\*-WIGA_!&VT+X@)XA@N4%O&RR1P*95:,BW2#RU D$8CPF[! M4\L?K5*[^ W]H:I+-<7MB;;_ $O:PL5K+O\ =_7H6LSND=S#(Z,5=5D!*D=0?0UY]XW^$K>6L4,L]E.[W% MKYMQ;_9I1(%@?<-@;'/'!)/.<5S%Y\ ;]%\RUO[."[V65C'<6-KY$@@CDE$T MLA+'?(\,\B$8'4G.3QARTZD4YU=?,ZXQ5)M4X)+RT/4=9\>^'_#VHQ6.HZI# M:7,D?G!7S@(=V&9@,*#L?&2,[3CI5OP]XFTSQ58M>:5=+=0*YC8[64JP ."K M $'!!Y'0@]#7(>.OAI?^+;BQM;74K?3]!M[1H/LGD,S^:59(Y=VX9\M6.U3Q MDD]<8T?A;X!/P[T*[L#+"XN+HW(BMD98HU92C1]G=2] M[L:ISYK-:'94445RFH4444 %%%% !1110 4444 ?GQX&'_%8:/\ ]?*?SK] M9HOM%G)$#@NA7/U&*^ / X_XJ_1_^OE/YU^@:?=7Z5]AQ,_]K@_[OZL_+/#Q M?\)E5?\ 3Q_^DQ/"V^#>I:+IB7FH>)M.T,VEO%:?:[4- GE(LX5Y&9AERTX] M@%XY-9.M?"GQ+_PCZ_V/);ZO'?22M#%87LOV:UWP0QK,KM*&)!C=N"1^\;BO M7OBII/\ ;G@N[M/M5E9L9876347VP$K(K;6/H<8_&O.H_ACK.FV.JW6D:Q"^ MM&..YLK33966WM)I+J64D1%@IB*OCG[P1OI7#1Q4YQ]I.:3OM;3^M3W<9EU* M$G1ITI./+>ZEKUT2=[O3:VOY6-6^&,NCR-+<^)[6VEU&XE,EM?799V\#EI)29#'(6V$DG;'M.WN2 ,]\ M]!XD^&5UJ'_"%BUN5N$T)R9FO)W$DP*J"VX DMD$X/7-Y=2;--R6X9D).\ [B?XLC/(K&-=M)^U7W>>GY$UL%&,Y16&D]-+ M2:Z*^OJW]S?76]:_!W58=7T&YFU5+V+3Y+:4M=2RO+'Y18M''R%*L2#EAD8' MH,>MU!8V[VEC;P23-<211JC32?><@ %C[GK4]>55K3JM>:;\8+:73;2>\T M^:.66(R2"%D*IS)MX9@Q)$3<8.W(!Q6!WGH5%<'-\6+?,,<.G7$=PUQ%#*EP MT8\I7=%SP_S'#@X7/O2_\+>T]HE>/3;Z4E?,*IY1(CPA#GY\_AS[T >M>%_]=/_ +H_G1X#_P"0#-_V$M0_]+)J7PR- MMQ<#T']:3P'_ ,@&;_L):A_Z634 =%1110!Y=^TRK2?!;Q JJ6.(N%&3_K5K MY$^%OQ$/P]AO(;C1I-2M[NY@FEC(Q\L8?&#CA@S*0?8^M?H917JX;'1H471E M#F3=]['P.=<+U>:^_:*Z5F5---4MO[W_ /%GP5C*E.5-XY6DK/]TMFK?S=CX?F M^+&@75C+<76A7E]?[(862\ACE-PJQ.IW,4.Q237W;J$ MF-:D'^Q'_P"@+7=UP&N/CQ1=CW3_ - %C-N2M2L70VR!]*VJ\T^V.6A^)&B-QANK>* M]NH--N+<07=FLBB.4B,1ASQD':!T(&17L.&7M74Y7]/)?K?_ (&Y\U&KG"DT MZ<&KO6^MKNVG32W>V^KT-A?B-X7DCM'7Q!IQ2[D,4!^T+^\<$ J.>N67\QZU M7_X6EX7^WWMM_;%KBS0//<>:OE(2Y0(6S][(/%9D'P@T>1))I;R[O9[A3YEU M)(I:3)A(/ QP((P,=L^M0P_!?2K%DDBU34(7M_+6SD\Q YU:;Y?/Y?\'[O,M5LW]DW*E%2TM9^ MO=[7M=]F^QK7'COP[9VPN)];L8H"6'F/.H'RE0W?L64?\"'K55?B=X2:UDN% M\1Z:T$956D%RI + E1UZG!_(UC6'PCTU=4U.]FG><73VGE$,2RK!L.6)SEG= M 6/?:/2H+_X,VIN-+FTW4KC3I;-US,NTOM#2O\N1@'=,W)!XIQI9=LYR_3:_ M9^GXDSKYU\4:4+:Z7=][7W2U7O6^5[ZFY#\4_"TDUW&VM6D*VTT1@]?8U8;XB^%UU$V!U_3_MPE\@V_VA=_F;MNW&>N>/K7/-\$-#2U\B MWN;ZU4Q^0S1RC11] M*)0RW3EE+\!PJ9WJI4X?>_NW_'\-=)[[XH:3IWAF+6IHKH0O=FQ, 1?-28,R ME6!8 <^E78?B-X9FAN9/[& M-;6T$.KVL4UUDPP3RJLC@,PW 9Z':<>N*&^)_AD-$R:O:S6S>9ONXYT,46P MG>=W'WACCO7-VOP+L([R=+C4;NXTF2*%&LRP!F9&E8M(P'/,O&,=*MQ_!/1M MP>:[OKF8!$\R5USL3;L3 &, +C\36DJ>6*3M.5O3_@=/ZO?3*%;/94US4H*7 M77M\WH_UZ67-K1_%;PK-J:60UJT#R1QRQ2F5?+EWLRJJG/)RIX[5TFG:E:ZO M9I=V5Q'=6SE@LL3;E."5.#[$$?A7$W?P9T>ZF\P7=[ QN/M!:*0*P/G/-@'& M5^:1AQVKM=-LY+&S2"6ZEO'4L3--C>V6)YP .,X_"N'$QPJ2>';;ZW_X8]; MRQ\G)8V,4NG+_P /T+5%0S7EO;?ZZ>.+I]]P.O3K]*07ULR2.+B(I%]]MXPG MU]*X+,])M%D ML&LM5M(1'/;2ND4TD<4:JUPSQA-AWHHF4(I9?N9XZ'VVBO IXNK2I^SCL?=5 M\NH8BK[:=^;R=CQ2P^$OC*UTF2&YUXZC*;@2/#-J,B1SX1AYF](0R-N8-M^8 M': 6[TLWPH\:O8S0#7U^9+/>/MLA:=HH=D@WM$?+4MAL;6R1DXSQ[515_7:K M=]/N.1Y+AFE'FE_X%Z_Y^GWN]#0;&?3=%L+2YN9+RX@@2.2>5MS.P !).!D^ M^!5^BBN%N[N>[&*A%170X[Q!&LNH7".H=&P"K#((P."*QVT>P=U=K&U9UW;6 M,*DC/7!QWR<_6MK7/^0I-^'\A5"D4<[KZ+9ZIH9BL[1XY+EUD,EN"RXC9@P; M'R\HO/TJEIUUNU*[M_LFG);N('AV0[5S+&6?!V_O#E0>BY'7&*Z^B@# \+V\ M.JZ'87U[8VIOF#,[BV53N#$9 (R,X%::Z+IRK$HT^U"Q$M&! F$)ZE>.#]*N M44 ;GA?_ %\_^Z/YU0\,Z]IV@^'B^HWD-FLVJW\<;3-M#-]LFX%,L;_4+!F: MPTMM4=N&59TBV#U^;K7/:)%>:YH#17OA&6]C2_U#!%_$H!>YF#C[PZ9(S[9% M:4^3F7M+V\MS"M[7V;]A;FZ7V_ ZZ?XD:!#-$BWIG624PF6"-GCC< G:[ 84 MX!Z^E'AWXC:+XHO8;6QDG:6:#ST\R!D4KA3C)&-V&4XZX-<_>>'S>7,$[>"+ MB%X2[*+?4XXE)<88E5< DCC)IFC:#)X:U"&\TWP/<17'$+2/JB, K,N]R"YR MV ,G&2 !FN]_4?9NW-S6TVM?^K'DQ6:^V7,Z?)?7XKVTV\]_P-?XP>+K[P-\ M/=4UK3A$;RV"%!,NY>7 .1]#7S5I?[5'Q!UK4(+&RM=-GNIVV1QK;GD_]]5[ MU^TE_P D:U_Z1?\ HQ:^'?#^MS>'-9M=2MTCDEMVW!)02K @@J<$'!!(X]:^ M_P"&,NPV+P%2I5I*4U)VOZ*WXGX[Q[G>.RW.*%&AB)4Z;BG+E?\ >E=^MCW> MZ_:,^)UGJ.H6,MAIJW%A#]HN ( 0^X-@@AEP1UR*JV_[3GQ+NK47,&DV M\UN02)H["1DXZ\@XXKD_#/CG7MU2;V>FMETW\SIH?VEOB9-/;1? MV99QM,D%@TUD\:X"ENK$# MH"?PK&UCQ!JOC'PQI,^DZ!)'YN;47D]VO,LAC1V"$_*K"$ID;5^9AC-6]U%;LY$L,D78>LO)KECU(C)_[X6O@_3?^0C:?]=D_P#0A7W;K'_(R7'^[%_Z+6OE^+L#AL$Z M'U>FHWYKV^1]]X;YMCLT6*^NUG4Y>2UW>U^:_P"1UN@G[M;U8&@_PUOU^=G[ M28?AO1]6TJZUJ34]?F]JY3QQX'U'Q M!XLMI-/NHETFZB2/6[5I"'<0EI+8J.GS,61\]5*_W:]'KS#Q;X-\4:QXRU"\ ML=0N;+3#8,;=;2[\DR72K^ZWXY*AB>#P>^1Q771DW-R;2T_K_/U,IKW;6N,")2^P1I)L?HKG)^5\#+]8\&^/+W6+%; MB>]GMX;Z.XO;J348Q8RVZ7$$D82'.Y75(VW$@9()RV[ Z3Q5X4U&\\2'4;[P MS#XOM[C28K-;>2XBC%G,&*-6MKFW: M'5M.N-%BT56VF"W$;"&42LYCW&3+8\L'$@!)VXKOA44FFW%?UZ_G9?@8.+2M MJ:'C'1O'6L:]7QBDFE,%Y:ZC$EFMN;.1$C,1.3*)RC;MN,8.[C%-U[P MEXXM)+NUT^_UC4K%$8630ZJD=Q'<,D9$DS.1NC#!_EYQG[K C&U)XH-#P=X)\8Z1X7\4S3 MWDZ>)=2MHQ;RW-]Y^QUC*CG[H;H"P7G /:LU4LMXZ:>NN^X^77KJ86F^$_B' MHNF6L$-U=)>VT*%)H;M'M( S3)-",M)([$E2JM]Y?N[>9/!LGC+Q%X9\8C2 MI]6LIFM+2&PDUJY$S_:!O-R8S_#D%0.>#C[N"!7D\#>.;>/7Y;&WUJ""]EGE MM;7^W5^UQS?9+:."62;<=R*T<_R%F^\I(;''8>$]+\37%SXEMM>EGU'3+6W- MG:P>:4>\>6))9LL<#"%O*1@>F[/-:3FN5N\7L_Q7]??YBC'6VIR^GV?CZ./0 M[&'798VU*6Z#27DRRM;1QXDB^96<,QD!4C>WR,1GC V_!OA_X@6?@GQ);W]_ M<_VS-"JV)O)T=DE$>'97#R;59ONDGCKL7I7%6/PG\67&N:)J;:*=&=;Q;J:R MM[JW-M;GSH"R]2VP10X#1E7:3<6^1BE?1]98BHH)*/*[[Z=F53C?>Z/ 8/"/ MC?0[KQ;XAAEUFRBBMX[K2].O=1%T]Q/'@F.<1EMRL%"8!. QP<]->\\#_$:& MQNY[+Q%=/J\I9$\^Y!MXT:S;.U.!D7!&&ZX Y KV>BL'BY/7E7W%^R7<\(_X M1?XD+I]LHN];)*7B[/MD(EA5@GE9)G.^3H> M'_&TT=O_ &8NN6:[)!;)>:M%(]O<%E*RW)#'S(< _NU+GKP-V1#I/@_XC6'B MS1Y9]9OKG3A)%+,S7*O&@WL9TD!<;MRD!,(V..5QFO:J*/K4K6Y5]P>R5[W9 MXAXP\&ZKKGQ"N[R+3;N[@MM6@F;R4MF9H/L.P%1<_(5$A;./F!)(K+/PKUBY MT*"T/A::R>WMIHM0EM[VW675-SY0(NXHVT@29FVYVA>C''T'15K&3BDDEH+V M,6VSSOX4Z9JFGWVL'4K..QE%MI\$\-NI$/VE+<>:8_50K1+D?W".U>B445R5 M)^TES,UC'E5@HHHK,H**** /S^\$_P#(W:1_U\I_.OO]/NK]*^ O!?\ R-ND M?]?*?SK[<\5ZG>::VE-:&5@TP$D$,)=I1P,!L$#KWQD9P>*^HX@=\3'_ _J MS\TX"5LNJ_XW_P"DQ*OB3Q=-H.O+!F*6W-J9!;J/WF\;B68Y^5, ?-@C((.# MBJEQXYO8Y)'2"VFM-D*K/;2^:/,>21NT@?6I-/\?7>M:D]A:Z M;Y$K2/&LLT@(CV[AEU!R#\N=IQP14UOK6LW6H3QR0R0I'>(B[+5Q&\)8@G6;F[WVZA;B!D6.1V E7@ E4S^G6@#>T/6VU2YU M*V=$66QF$+%'#!OE!SQTZ].HK7KA3XI\3+&<:5;>:L+W#?++@[=H"#C[Q)/Y M5UFC75S=V>Z\B6*X1VC?8"%;!(W+GG!H Y[7/^0I-^'\A5"K^N?\A2;\/Y"L MJ^O$L+.:YD61DC7<5B0NQ]@!R30!Q=Q\6K&WGU6%K"X,FGS2Q,-RCS-BR,6' ML?+(_$5HS>/H+73X[BYLIK>07XL)X68'R&VEBY8<%0HSQ65IEQX*\0:Q)90V M&^_OHI+F42QNI.2Z."<\'EP0..35G3=:\&R:3Y.V&PLH)1*$OU,09FW*'!<_ M/G#C.3T/I0!M:/XRTS7;W[):/,UQY?FM')"R%%SP6R.,\8]:VZYC2YO"6@^7 M+8W.GVIG C1UN 3("W R6.>?\*ZB@#;\+_ZZ?_='\Z/ ?_(!F_["6H?^EDU' MA?\ UT_^Z/YT> _^0#-_V$M0_P#2R:@#HJ*** /,?VDO^2-:_P#2+_T8M?&' MA7X?ZSXSM;JXTN%)H[66&*;<^"ID)"MC^[\IR>U?E:A!F:"Y1A'(B?O X96#+C@YSR#[UK^([OQ/J&@7>H M^(/#=FODKOMKJY1XW@24J L:AMI"X7 <$COFN\A\ ?&6WCC5-(TW>J%&EWP[ MY,Q>5ESN^8A !SZ53UOX6_%[7])FTZZTG3Q!,0\S120JTK@@[V.[EC@9KW_[ M0HU*JJ3JTMU=\^OG;7MIY]3Y!9/BJ.&E2I4,1L[)T]+[J^G23;7;5IW9SNH- MXWT^S6P_LFTU.:U,%Y->649)$>XSI$0N%QGYOE7H.M<3?^ /%=]=7=[)H=T# M),S/M3@,S9P.?5@/QQ7MB^"/B]'IJVR^']+2:(Q_9YD>$?9PJLOR+NP&^4.SB:)90OFK*8U?=E5+J#^=31S*G1NX5*2_[>W[]? MZ_.L5D=7%652CB&DM/<>G97M=^;^?6R\#CT^YTW5K**Z@>WE9HI D@P=K$%3 MCW!!K[FU93_PDD_^['_Z+6OGG6/@#\2_$GBR?6K[28?.N;KSY-MW%A1NS@<] M ./PKZ-U:,KXCG!ZA8P?P1:^5XLQE'%QP[ISC)I._*[V>A^@^'668G+9XQ5J M4X1;CR\\7%M+F[_*_8Z701]VMZL70EPH^E;5?GA^T!4;W$4:R,\J*(_OEF V M_7TK'\-Z#J&BW>MRWVO76M1WUZUS;0W$4:"QB*J! A4 LH()RV3\QYKE_&_P M]N_$OBRTNK.Z@CTR>)8M:LW)W7 A+26N.W#LZMGJK?[(K:,(N5G+3O\ U_5R M&W:Z1Z#%*D\:R1NLD;#*LIR"/4&B21(5W.ZHN0,L<#). /Q)%>*6?@OXD:.M MRUO.ESF-8UCEU1P&9K9XBRC9M1$?8X &3SU(!+=2^&_C;4M:L#)>FZMX;^.> MZNY-5D\JXA2X@DC06VW:K(L;#(.21DD[L#H^KPO_ !%8CVC_ )3W"BO'O&O@ MSQQK'B"ZN-'OWBCDEE:&]359(HXX#:21K#]G"E2PG9'W]>.O&#%XB\ ^+;'[ M7%I^I7-SI:HWV/SM=EC_?/)@EP�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end GRAPHIC 18 oyst-20191231_g14.jpg begin 644 oyst-20191231_g14.jpg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oyst-20191231_g15.jpg begin 644 oyst-20191231_g15.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" #* >D# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#R>BBBOW@_ M# K6T7PGK/B2SU2[TO39[ZVTN#[5?20@$6\7/SM[<'\JR:]<^ /Q(T+P OB> MWUYYEM=8CM+.188BY:#SB+CIW\IFQZGBN?$3G3IN5-7>FGS.BA"%2HHU'9:Z M_(\YU[PGK/A9-/?5]-N-.74+<7=H9UQYT)Z.OL:(?"6M7&EQ:E%I=S+82I-( MEPB94K#M\UN.R[ER?<5] ^)/C)X'\;6L^GWFH7%A"VEI:073V#3>3Y6H&9$" MCGYH0HR. 3@U8NOC[X6-YK,6G:EO1QR+9-A/M)A-L2H'3]VV<=.*\ MY8O$V7[K76^]K?U_6IZ#PF'N_P![II;:_P#7]=#YKU;2;O0[YK._@:VN556, M;$$@,H93P>X(/XU3W#UKZ1OOC'X.NM+UF+3]2?19)G5IT&CK!'FTB6SA@2WMHIFMK39-$L66^1E,I4D*" M#C<2#Q5_7*]E>B_Q[>G^?WZ$_5*-W^^7X=_7^O34^88--N[FPNKZ*VEDL[4H ML\ZJ2D1?6Y],2UL]133&5F)NM[*QESRL18! MMHQG S@&A8NOS\KHO].GEZB>%HN^![J"VU_2KC2IIX_-B6X Q(F<;E()!&?0UV M_P /-8T+X1_%X7<^H+K.D6UC<1BX6W8"5YK)U$;(&)&))-AY[$UZ)X3^.7@^ M*U\.75TPT"^TW2);46%E:2-:0RM>^8VP_,_SQ M^M_\ETZDTU@,T-E%Y]PX( CCW!=QR?5@ M./6OH^U^//A?1K^*:*_;4-4#Z/%?:W_9:H=16&>9KN385^7,4B)R S;:H77Q MF\*:Y;S"[O9+*_EL)K%+Z'35W0+_ &E'- 54* =D"G'I@+5?6Z]_X+MIW_*W M]=NA/U6C;^*K_+\[_P!=SYSW#UJ]INBW^LI?/8VLETMC;->7)C&?*A4J&=O8 M%E'XBOJK_AH#P1'XFU"X&JQW,/V:U@T^]GTB3>D,4C&6*; #.\N0Q( 4XVG M KF6^,7A&]\"ZEI-G?MHL-_H]SIHT&WTKY%NI;H2"X\[)X*8&TMQM / !J%C M*[_Y ^'/#.K>+]6BTO1;";4M0D!*P0+ MDX R2>P '4GBG>)O"NK^#-4;3=]=AX/\ B%X/\(O= M:;9>+]36:.*R2'Q)?::;D&*-W:XM886RT43[EP#U*G. :WJ8BK&3Y876EM'U MZW\NUKF-/#TY17-*SUZK\OUO8^?^I [U9U+3;O1[Z6SOK>2SNXB!)#,I5U)& M>0?8BOH+4OCIX4DTZYT_3+?^S=(GTW50-/%DIV74ET9;,[L?PJ<@@X7.*N>+ MOV@O#>H:G+(K2^U"":P4.^GI;1J\&YQVD3H"-V.N#6?UJOS)>Q? M7^MO7_,OZK0M?VJZ?UO_ %V/GC1_#^I>(/M?]FVY5W'VW M,H_$5#JNEW>AZG=:=J%N]I?6LC0SV\G#1N#@J?<&OHO6/C5X3:UO89-6FUW4 MYM/NX#JZZ9]E+K)=V\L%N5 SB-(Y/F/'S8%7=>^/7@._T'Q%%%:QW'VV^O9I MK&YL7+7_ )LX>.4." C!.,L%?AAXL\<6,UYH&@W>K6L,G MDR26X4@2$9"\D9..<"O9OB9X]\*_%#1GT6#Q6R0'5;G5;;S-)\A+&V6V/E6O M!&XA@$W=LY&:XSX<>)?"B_#M-&U_7[O0;JV\00ZPOV6Q>X:6-(]I52I 5L]" M35_6:TJ7-R6E?:S>GX-F?U:E&KR\]XVWNEK^*1Y1<0R6MQ)!-&T,T;%'CD&& M5@<$$'HMJLEWX<.GK)_:4]Q(S6TQGZ(8@5'7(V<9S5[3/C)\/-$\41:Q;:E- MNNM4&H2JNE$&S0Z?+ 4YXJ MVG;;[_Z[6W^:+;1;Z\TF]U2"UDETZS:-+FY4?)$TA(0'_>(./I5>UM9;ZZAM MK>-IIYG6..->K,3@ >Y)KZ;M?CIX&M+BS75)9/$LD?\ 9/V^^_LT0C47@EN& M>4Q\?<62(#=@ML^E4FG2?]>MOT?E%HQBFJJ_KTO\ KZV/,[WX8^+--_M[ M[5X?O8/[!$9U3>@'V0.,H7Y[]L9KE\CUKZL\0?M#>"-:@\1(TUZ&UT3?;F%J M3YFV]A-O@'C_ (]TD//&3@U8NOCUX"?Q587L=\CO#:WEHU]+ILNX1O/&\6' M#JP0,,JI R5V[3FL(8W$V]^B_P >B^>[O;RL;2P>&O[E9?AW^6RM<^6;G1;Z MSTNRU*>UDBL+UG6VN&'RRE" X7Z$C\ZHE@ 23P*^F+SXU?#Z7PKJ>BP1W0>6 M\O;FWOI;0>8(7N8Y?LQ51M59D5E+* 5X!XS6EXA^//@C4M>>2RNX;"5[.^BT M[6DTAWDTHR^7Y491OO!0K+\BD+N."0>-%C*_6B^O_ Z/^NAF\'0Z5ET_X/5? MUU/G#_A"]>_X2*WT#^R;IM:N!&8;%4S*XD0.A 'JI#?0UHZO\*?%^@W,UO?^ M'[RVDAMQ=N6"E1"7$>_<#@C>P7@\$UZ7>?&#P^W[0=SXH^TW4^B7FF+IDE_% M;>7/$6L5MWG2//!5P3@'IG%5-(\8>#_!.D:GHUGXGU7Q%%-I1MUFFMGBM5F: M\AE*0Q,2R#9&2S'[S8JOK&(]WW-TGL]WOKTMV>I/U>A[WO[-]5TVTZW\CQW4 MM.N='U"XL;V(V]W;N8I86()1AP1QQ3M6TF[T+4)K"_@:UO(%+H:A86S?\2B^BU\W$+:>/WDD[;K(DE<_*>>#\IJ/7OC%X/U+ M3?$B:7J;Z,;JXEDE@_L99_[5C:TBBBC)88CV2*_7&-VX9-*.+KZO^7738^?='T6_\07C6FFVLE[RR)/JVC?8 MK4(I8&7SHWP2.@PIYJHXC$5(.2ARO3=/J]>W34F6'H4YJ,I\RUV:[:=^NARU MOH=_=G4!#;,YT^-I;K!'[I0P4D\^I X]:33-%OM:6]:QM9+I;*W:ZN3&,^5" MI 9S[ D?G7MD?QB\.W&EVNCWH>)M6M=+TJTDO]1NG\N"VA&7D;!.!^ ->V_#GXP:#H_@/PUH^ MJZE-;W6FRZFL1-C]H6SDGB46]VHZ-Y;A_EZ_-D=*J0?%+PU:_M">$O%1N)+C M3M,2W74=46S\IKV9(F5Y_)'(W$CW.,GDU;Q%:\X^SV3MOK:]NG7U)6'HVA+V MF[5]M+VOUZ>AY9XJ\"Z_X'FMXM>TN;2Y+A2T2S%27 ."1M)K$AC:XFCBC7?) M(P55'4DG %>^67Q \#6_B]8]6OK#4_#.I6+6FH#1O#S6!A*2)+&P1F;>Q92N MX8PI-:UC\Q^Q$I!NG^7AY!QVR1NQ_M >!]-O/#_\ 9^JW M$2V1N(!=#3V$D%O+8&)5(V@?+-M8J@QQD9YJ'C*_+I1=[>>_W?UDQPFYC6T"VS63I):O&A6:19,A<2,23@$MN^;!%;"_M#6= MCX2LOL>MW(UN/P_IFF"-K//DS07.Z8AB"I#)C!]L<5H\37<5*-+5NUG?RUV_ MKS,EAJ"DU*IHE?2WW;_UY'SCD5U?A_X4^+_%6B_VOI.@75]I>YT^U1E FY?O M#EATS7MOC+XU> +_ ,$>)M+T6U@@%Y+?;+&73G'GM+-OAG4@A4*KC[W*[< $ M&N:\%_$#PLOPRR?VCH#ZC\DP0*8F5EV-\ISU[>E2\57 ME3YHTVG>VJ;TMO9%+"T(SY7435KZ-+7MJ>:6_P +_%EU:1W46A736\EJM\LA MV@&!GV+)R> 6.!GKVKGM0L9]+OKBRNXS!=6\C0RQ,02CJ2&''H0:^AF_:&L9 M=%-A+JMW)$=(T:S,9M_E,D%P&N1TZ; ?KVH\0_%OP7JVEWD%IJDNFZ?-J%W) M=:/'HR2M?>9?&6.Y\QQA"L)"XZC;@#!-*.*Q*?OTM+]+_P"7R_R'+#8=KW*F MMNMO\_G_ )GSCN'K2YKZMUWXY>!-0U))++5VL=46SO+2U\0?V4TK6>Z>-XCL M903F-73Y1\I) &WFN:U;QMI-Q\(?$NM>7'-J;:A=:/H]T]M% T]O=,DD\GDI M]PKL?&.GG8%..,JNW-2:N[?UI_P>MA2P=-7Y:J=E?^M?^!YGSL6"]3BM/7/# M>J>&9;6+5;&6PENK=+N%)L!GA?.Q\9X!QQFO8?AQ\4/"WAWXGF;S^-=$*U6=;DY+15]?R_SZ_?>W/.C2A2Y^>\G;3\_P#+I]UK M\%1117<<1V_P._Y+)X*_["UO_P"ABOUTK\B_@=_R63P5_P!A:W_]#%?KI7YW MQ/\ QJ?I^I^@\,_P:GK^A^*E%=;_ ,*A\<_]"=KG_@OE_P#B:/\ A4/CG_H3 MM<_\%\O_ ,37WWMJ7\R^]'POL:O\K^XY*BNM_P"%0^.?^A.US_P7R_\ Q-'_ M J'QS_T)VN?^"^7_P")H]M2_F7WH/8U?Y7]QR5%=;_PJ'QS_P!"=KG_ (+Y M?_B:/^%0^.?^A.US_P %\O\ \31[:E_,OO0>QJ_RO[CDJ*ZW_A4/CG_H3M<_ M\%\O_P 31_PJ'QS_ -"=KG_@OE_^)H]M2_F7WH/8U?Y7]QR5%=;_ ,*A\<_] M"=KG_@OE_P#B:/\ A4/CG_H3M<_\%\O_ ,31[:E_,OO0>QJ_RO[CDJ*ZW_A4 M/CG_ *$[7/\ P7R__$T?\*A\<_\ 0G:Y_P""^7_XFCVU+^9?>A>QJ_RO[CU? MP[\,/"EQ>>#_ G<:%<75UXB\/G5Y/$ZW3K]ED,T2U3PQ9^$+_ %/4FT&UU7_A)8+IAMEEC1RS*?W8MUW[">H(SGM6%9Z7 M\8]/\,R>'K;3O%D&B2*R-8I;3"/:W+*!CA3W X--DT?XPS>%E\-OIOBQ]!4! M1IYMIO*V@Y"XQ]W/.WIGM7DJ,^>[JJW^)]]_TY=CUG*/)94G?_"ON_7FW.N\ M'? O28]#MK3Q% +K6=5NKZUCO-/U%)8+ 068G1LQED'_ .B7]EIE[H>LW4R^3:WUSYLUU9F$$W,J 8A)DX1<\JC>*+#3;X8N;6"TF5),C:E8T_[ M+5E!JUG WBS9:31706C<'Q@UP@<*S6\Q&'P7 M&-N#DJI/') /6L%'$1TC77S?E\^ILW0EK*@_DO/_ "-%/V:6M](UZZN]7GM[ MS2VNI8[6XLO)%Q!;R*KGYGW9;=_"K*,8+,-#U*VD&@:2MT M;6.4S-"CIM\LW#Q R+$"3N8=.*S&@^-;6-S9M:^,&MKEI6FC:"TK+ M5.UG;L9/V:<>2B]&KW5^YW.K?L_Z-J&KRWLEY_PC.DW$NF06::9G58;AKP2* MLL3DHPBWQ'AAN SUXK*?]G2TL=2TO3K_ ,2R?;[BVN;ZZBM;'>EO!#)+$S^8 MSJOS/& -Q4 $Y/3,FGZ]\;=.T_68XM(\4?VEJEQ;SRZK]FG$Z"%758U.,!<2 M=.V!BN;L=#^+^FWMM>6VE^*XKFVMVM(91:S$I"S%FC&1]TLS$CU)-1'ZQJG6 M2[:I]//7?^D7)4'9^Q?GH^_W;'0ZQ^S4-)?6Y/\ A(TFL=$EN$U"X%OCR56V M6>!L!B#YNXIUP&'4U@_#?X*P^.M$TR[N=:?3;K6M0ETO2X([0SH\\<8=C,^X M>6GS 9P3U.,"M*2/XJW'A7Q'I%UX4\07ESX@FMWU#4[BVN'GECA'[N(@C& > M<]>W2L?0?#WQ<\*Z=>6&CZ3XJTVSO/\ 7P6UK,BOQC. .N"1DG;7\?P72]S-PH\Z:I/EUTU[Z?A^+ZV+GBCX(VGA_P/=ZQ'K[76IV6F MZ;JES8FTVQK%>-M55DW'0#N//(/%<3<>$?BI>6@T[Q9%HC*R&R6VF$>TG+*..%)Y*C@T2]I**3K M*Z=][:6VTWU_X<(\D9-JB[6MM?6^^NVG_#':WW[-.GWOB*>W&LG2?M5Y<6NG MVUK9O<1?Z/:K/(9'9\ID-@9SSZ#%8W_#.MA+#:K'XK\N\#Z6;U9[$K%;Q7L> M]65PQ+%>XP!R.>N-/P=XK^+?@_3=3B'@S7M1O[Z225KZZCO"=SQ>5EXP=DF% MZ9'!QUP,<7!H?Q?M9O.ATWQ;%-_H_P"\2WG#?N!B'G'\ X7TK&#Q-VG622MV MU_I?CJ:SCA[)JB[N_?3^G^ OB?X*R:+\2O#_ (6M;VXNHM:6*2"Z-J';:SLI M*B)W60#:3E&([<8-=9>?LU:5IS_:[GQ;*FCR0V$L,T5DDTK&ZN)+=5(24IP\ M>20QX/J,5R5]H/Q=U+Q!::[D>'_P"U(O$&JRWNIKI^KW%I:6MLPA(M&>(2-+N^5MZ% MMF#QP3R,U/@KX!\*^+/"-HE]IT-_XBU*_EM8H=0O)[(2H$78MG*J&)IMQ.5D M]JPUMOC4FG7M@MIXO%G>R2RW,/V>?;*TN?-+<<[B23ZFH?#>D_&+P?IUQ8:) MIOBO3+.&QQD8-9RC5E"2E65VU;6W?M_6FY<73C.+5%VZ MZ7[=_P"M=C9TO]G'^TH]!N6UX6UEK<]E9VDC6^X_:I99$GA.&_Y8^4V2.N5Z M9J>?]G72KC28KO3/%<]U+-;17B17&F^4/*-X+23)$APP<[@.X'4&LRZL_B@? M#OA?2-/\(:]I4?A^>6\@N+>UN#*]S(06F)(^4\ +P.3W-5-)T?XLZ7=6<@T M+Q--!;A4%M):S>6\2S";RR,?=,@W8]>:?-7>OMDM=M-O^#I^(N6BM/8MZ;Z[ MZ?EJ=C9_LZ^&;,:Y1+VSB60L SG?'A@>H)(P<=: MIZ;^S#'JFIV^EQ>)6&I03V4&IJ]B1##]JB:2,PON_>XVX.0O7(R*SO$%]\;/ M$7B:36I--\5V\^Z?R(XK>?9 DI^>-1C[I'!SU %9XM?C4MMIEN+3Q@(=,97L MT\B?]PRJ54KQU"D@>@.!4+ZS:_MU?U7^7]?+6W]7O;V+M\_\_P"OGIJS?L^: M1=:-9WVF>+I)OM5I9:B!=Z:8E2UGN/LY9BKL=RN"VT#[N.<],?QM\#)?#GCK MPUX>T[4S?1Z](L-M>W$:)'N,IC)#([JPZ'@Y&<$ U5M_#?Q;M(88H-*\5PQP MP1VT:QVTZ[(HY/,C08' 5_F ['FD\0>&?BSXJU"VOM7T;Q1?W=L,0336DQ:+ MG=\O'!SSD=^:Z(RJQEK636O;Y&$HTI1THM/3O\SN?#OP-\)Z?->:M?:I>ZYH MD-CJH2%[(VLAN[,*'ROF9,?SAE(.3C! K!^&GA?PW<> =-U+5/"\WB.\U+Q( MNC_N;J6)X8FC4[D"9!8%C]X8K/U;3_C-KUR;C4+'Q=>3&V>T+RV\Q/DO]].G M1N_KWIGAS2?C'X/T^:PT/3_%NDV#_$&KIH4K3V5I=6UPL<;%B_!49'[P[S MCJ1SUJHOA?XJ0^+I_$]OH'B2SUV6XDNC>V]E,DBR/G<00..&(^AI_O+2@ZR= MXNSNEJ[VVUT5B;4[QFJ+5FKK7;2^_=W.GG^$NE?$;7Y=.\)2:79WEO:P3+;Z M9)=7$=P)+A8I#NN%1@8PRL0 1M[U4\1?L_6>B^!KOQ!#XJAN9%MY+ZT@:)$6 MYMEN#""#OW!S@MC;MQQNS5K1]6^,>G:Q<:O>>'?$FLZK_9\^GVEW>6]P6LUE M7:[( .3CL>,X/:N97PS\64\,GPZ-'\4#0B<_8/LDWE==V,8Z9YQTSS4Q=9-) M54DK=4[]]?ZZ^14HTFFW2;;OT:]-/ZZ>9V_PW^'/A3Q!H?PYT[4/#UQ=WOBR M2^BN-8@NI$>R\IR$D"?<( Y.[L*;I_[.=CXHFM4M]633YVTFQGBMK6+S9+J6 M9'8N!)(N?N#*QY;YAA:Y/3]-^,ND^'6T&RL/%UIHS*Z&QAMYTBVNB.WB-1JEZMG//8I;!VCAN02IC M ?>S(,%@RJ.3@G!JW;_LMVEUKCV4?BHO%-96UW9*EO$TTQF:1=N/.V-M,?(C M=F.X8!YKE;:T^--G9Z?:06?B^*VT^02VL:V\^(F&<$<=MS8'09/K5B*;XXPW MA+\?\QGB[X!_ M\(C\/5UZXUZ%M46UM[Z33&C5?W,SE%"G?O+KP6!0#DX)(->25Z7>>'?BYJ/A M^/0KK2?%5QI$;;ULY;69HPRIM*WGNVI?S+[T'L:O\K^XM? [ M_DLG@K_L+6__ *&*_72ORS^#?PN\9:?\6?"%U=>%=9MK:'5('DFEL9%1%#C) M)(X%?J97Y]Q+.,ZU/E=]/U/O>&X2A1JYTZZBC. M'DB95^I!KRSPI>6T$4UAJ$2LC!HY(Y!PP/!!K2CB'AJ\*JZ.YSXK#+&8>I0? MVE;T\S\RO&6EZCX1U>WO=(NI;34M)?\ M#2KV(XD" [BN?8@_B&]37ZB_LY_ M%Z/XX?"'0O%6Q8KR:,PWL2]$N$.V0#V)&1[$5\%?&C2;;3=:\BWVF.TU=H(= MYX\ILD@GN,*OZU]&?\$TM-N[/X#ZE2>'G]AV_X'R=_E8^M:***^#/N HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***KWU M];Z;;-<74R6\"XW22' &3@?K0!BZ1\0= UZY2WL=12XF:[GL=BJP(FA&9$.1 MP0.?<$$=:LZYXPT;PS<6]OJ>H16P+\OFLV!@$]>M=/+2ON1>1Z_H/B*P\36;W6GS&6-)&AD M5D9'C=>JLK $$9'!]:^$_'3'_A-O$/)_Y"-QW_Z:M7V;\*TT^'PNL6GZBNIC MS6>6X\DQR.['),F22S^K$DFOC'QU_P COXA_["-Q_P"C6K+3F?+L,Q-Q]3^= M&X^I_.DHS3$&X_WC^=+N/J?SKT30?'FEZ-X1TG3'MQ99'D2<@;ED7E<',9!3'.X?6L[5IO K:7?B MT2#[5Y3?ZM)P3-L388,\"/=OR).OT/TW_ )!UK_UR7^0K\\(?]='_ +P_G7Z'Z;_R#K7_ *Y+_(5,AHLT445! M04444 %%%% !1110 4444 %%%% !1110 5S6O>!;+6IFG5VM;ANK(.#^%=+7 M'3>%]=35C>1:T\L;7+R_99)'6-5YV 8/.,C(Z<=*32>XTVMCY>UC]C'Q7X^\ M53IJ^IVVDZ$99"US$WF7#H['<44G M05W,>_RU\P /@;@IR,]\5WXC&5L4HQJ/2.R.+#8.CA$U26[N_-CJ***X3L/G M+_AX-\#?^ALN/_!5=?\ QNC_ (>#? W_ *&RX_\ !5=?_&Z_(&BOMO[%PW=_ M>O\ (\[ZQ,_7[_AX-\#?^ALN/_!5=?\ QNC_ (>#? W_ *&RX_\ !5=?_&Z_ M(&BC^Q<-W?WK_(/K$S]?O^'@WP-_Z&RX_P#!5=?_ !NC_AX-\#?^ALN/_!5= M?_&Z_(&BC^Q<-W?WK_(/K$S]?O\ AX-\#?\ H;+C_P %5U_\;H_X>#? W_H; M+C_P577_ ,;K\@:*/[%PW=_>O\@^L3/U^_X>#? W_H;+C_P577_QNC_AX-\# M?^ALN/\ P577_P ;K\@:*/[%PW=_>O\ (/K$S]?O^'@WP-_Z&RX_\%5U_P#& MZ/\ AX-\#?\ H;+C_P %5U_\;K\@:*/[%PW=_>O\@^L3/U^_X>#? W_H;+C_ M ,%5U_\ &Z/^'@WP-_Z&RX_\%5U_\;K\@:*/[%PW=_>O\@^L3/W7^%/Q@\*_ M&KP[-KGA'4'U+3(KAK5YGMY(2)% )&UU!Z,.<5VE?('_ 3!_P"2 :I_V'9_ M_145?7]?)XJE&C6E3CLF=T)1]MM?\ T48>,C (SG'%6Z* (;2S@L+=8+:&.WA486.-0JC\!7P-XZ_P"1V\0_]A&X M_P#1K5]_U\1^,OAQXKN_%^N3P>&M6FAEOIW21+.0JRF1B"#CD$541,D\+WFB M6VBZ1!J1CCTV]-W!J$WE[WBDRC1, .> HZ>K5K:;KW@>1K?5KJ")-3DNI9)H MV$F$!,@5=@7;LV>6..0:XS_A6'C#_H5M8_\ *3_ H_X5AXP_Z%;6/_ "D M_P *H1U5O<>!KBU2,_98GXF2WN#&9,/\ H5M8_P# *3_"C_A6'C#_ M *%;6/\ P"D_PH W[#5]%D\,:5:3ZC:VVGK&L>H:?]D+W,LOG9:1'V\?)T;= MQC&.:LS-X BDVM%:RO(421K=[GRHE*S9>/=AB>(,[LC).!C-!KR^MG^S6(,P^9D^T)%% MMMHPBNH[&7>&*Y.!GOFDU"X\,R:#JMMIIA-M#;W#_=;B5F@\O8S#<1O$F,\[ MICL;96!5EC4$'J.!2D" M/+O&7C+Q?J'Q$U+PQX5O-'T@:1I$>J7%SJ\+2K<-([JL8PR[$ C.Y^>O3BF? M\-!6MCJBP7VD2_V9;WD&E7^MVLR26L-])$L@C1,QV$:Q!T38C^4#L+JORABN0 .:[8N@XKF[?CZ_U;S/4B\.XKF[=NOK_ M %;S&>)/VEM'TF:>72]*O/$&D6E@FJ7FI6CHB06YF:)FVN0S%2A.T#D9J&Z^ M/\MQ>V[VVCW-GI<>N7&DO=3^6XO#!#?VC'#X+YO[7E\/6:FPM/$+Z*TD%B;VY@CAA#2S" .K2YE;;A?NJN>7:)#+!=,@222.1"&7<%&0".K=E_M'2VUK8SWC0:Z\NEAUATJW>'[1>-?"U1!YQ!B.XX9''RG/)Q6A>?M M,"U66$>#M2DU*!M16XL_M,(,(LDB>9B^[:1B48QG./>B\_9FMWT.73K76TA5 MK,V2F33HY!L,WG?-\P);S/GWYW9YS4/A;]F$>'=/:*3Q,]U/)]K$DGV% ,72 MHLZ@%B<,(UZDGC.>:O\ V1Z_YFG^QO7_ #.P\$?$R7Q1KWB&R*J8(+"RU?3Y M-FUC;7,3,JN,GYE:-L^Q%>:?#OX^^*;CP3>>,/$UI/<:;!IXNOLMKHW^SH<1V\"%(HQG M/0,W/?-8.F_LKZ9I%G/:6NN726DT7D/;.A>+9N#8"%R!RH/ [5*>'5T_+I]Y M$7AE=-Z.W3[RU>?M%3?Z1I=KX2OV\4Q3W4,FF&>$B%884E:4R;@K#;)'\H.2 M215#PK^TT;K2=(GU70+EH?*TQ=4U:V9%@MYKR%'0B,MO*[G .,XSWK4US]G& MU\13S3W^N223S7+701WND7=T(YDO+;[7# [[%?*']\I 8]&![8I?$7[3$ MMCIFN26/A:Z\RWMM4:QN;F>/R;B6Q8B4$ [E7 W9/7! [&K-M^S#IMH+X1:L MP6\VB1&M$94591,%C!.(U\Q5;:F 2!D5?G_9]BN;8V\NN&2$B]!1K&/'^EY^ MT]_X\GZ=L4KX7^KA?"+^F=WX-\27WB*S22]T>?3&^RV\_FNZ-%*TD>YE0@Y^ M0\'('7C-=%7&?#_X<_\ "!R7CC5)]1^T0P0?OEQL2%2J [L>;4Y>9\FP4445F9G\^E%%%?JIX@4444 %%=]+\!O'T/A&/Q0?#<[:') M9KJ(N8YHG;[*W28QARX3_:*X'>N0UK0K[P]J=SI]_"(KJW($JHZR*I(!'S*2 M#P1T-1&<9?"[CLUN4**=Y;<':V#TXH\M]VW8V[KMP"K XSC!SB@!M%:GB;POJO@W6[C1]:LWT_4K<(TMO(064.BNO()'*LI_& MLNA--70PHHHH$?J9_P $P?\ D@&J?]AV?_T5%7U_7R!_P3!_Y(!JG_8=G_\ M145?7]?G68?[U4]3UJ7P(***X_XN>)K[P?\ #O6-8TUD2]M45HVD0,H)=0T4W]QV%%?%O_#4GCW_ )^[/_P$6C_AJ3Q[ M_P _=G_X"+7T7^K^,[Q^_P#X!\E_K9E_:7W+_,^TJ*^+?^&I/'O_ #]V?_@( MM'_#4GCW_G[L_P#P$6C_ %?QG>/W_P# #_6S+^TON7^9]I45\6_\-2>/?^?N MS_\ 1:/^&I/'O\ S]V?_@(M'^K^,[Q^_P#X ?ZV9?VE]R_S/M*BOBW_ (:D M\>_\_=G_ . BT?\ #4GCW_G[L_\ P$6C_5_&=X_?_P /];,O[2^Y?YGVE6' MXP_Y!<'_ %^VO_HY*\1^ ?QL\4?$#QS)I>L3V\EHMG),!% $.X,@'(^IKV_Q M=_R#;;_K^M?_ $>E>-BL)4P=7V53?R/HL#CJ68T?;T;VO;4VZ*\.TWQ3X^TK M7;2"YLK[5K6>[U&ZA;R"B^4I94MY2%^7!VLC8^96QSM).Z?%GC74O&OAB!M$ MNM'TB;STNG2-9D+F&0HSDX**K*F!@;BWL,Y.BUU1W<87S9,G/3BFG]L M77%.#X>T\'T,SUYS+XZM)/B!9^)Q/<++#-:>8GDKET2-5E.&ZN=Z&6!9,1E9/2N7^S<+RW^K]%U>_5?([O[8 MQSGR_6M+O6RV6S^9Z;_PV-K?_0OZ?_W^>G2?MA:[#(R2>'+%'7@JTL@(_"L/ M2_$7@N_T>]N[R&TLT()GMQ;H9IY"D(S&.J@0U@L%A97MAMO-G3+,L=&U\9OMHOZ_IG9R?M@Z M]$Y1_#EBC#JK2R BF_\ #8NM_P#0O:?_ -_GKQ?QEK$/B#Q/J&HVX=8;AU91 M(,-PH'/Y5BUW1RG!2BFZ23]7_F>74SW,HS<8UVTNME_D?0D?[8>MO(B_\(]I M_P S ?ZY_6OJ2TF-Q:PRD;3(BL1Z9&:_-J'_ %T?^^/YU^D.E_\ (-M/^N*? M^@BOF,]P=#"JG[&-KW_0^UX9S#%8YU?K$^:UK;>?8\!^/UU;6OC.>XNKR%Y8 M=)C-IIE]<3V4KR;Y29-.FCR'N2=JE"A(VQ=F-5O$OCSQ)XDL;^SCUQM-U8ZG M;Q?V#]@)GT^)=0MECFD=2#\RDEMQVN&(7 !KZ1HKYZ-=))..W]=C[?E\SYZN M/&WC.'6;JSCN5?4+>6738]4EL<[D^WP1B1HP0A/ER,>,#Y<],TW4O&GQ%M6O MY8M<4QP6VM7"1_V2AW?898EA7.>LHD;=[#Y=O)KZ'HH]M'^1!RON?-MU\9?' MCZMXF2!;.":UCO1'ILB+(]LL946\YC4>9B3(/SD*P<;<%3G=^(WB+7/A5-IC M6VN&XDU)VN[YI8H_-N9@L,82"-L*00I)AC82$G(/6O=:*/;1NO<5A\K[GA'[ M04UK_;>D2W]]9P6ZV$[1V.N2SVEI-(67F*XC/RW( PJE6.&)'(-9]SP"T^)/C"_U1+31-6A\2:9#-<2Q:M#8+_Q,1':+,;=2OR ^8=F]1QG M;]Y2:VO@S\2O$/B;0_$-]K,L&HQ65G!=(]FBR.DS1R--;[8P!E=J80DR#<0W M."?9:*4JL91MRARON?,GAGXJ>)?%FI:1'<>(/*M8=7TV5YX%A(FBGBE#Q,4& MT)YBJN,EE)VLQ(K0^*%QHR^//'@U*[NX=>32;0^'X[6:83FXV2X\A$/S-YFS M/!]^*^BZ*OVZYKJ-OZ]!-IO%[:%;74/]H-%<6GV2:&/]U=16BR MI\H^<;Y%5&%F@@51'O.X M$%C(LCC(QM9>*[2_L8M2LI[2<,89D,;A'*':1@X(((^HINF:;:Z-IUM86,"6 MUG;1K###&,*B*, #Z"HG4A*-E&S&DT]SC?@9)>R?"GP^=1N+F[O1'(LL]X29 MI")7&YCZD 5WE%%82ES2(&0.IQ17OO[- M>FZK>> ?BE<>&M TWQ!XLMX]*_LZ#4+"WO"H:XD$Q1)@1]SJ1V%=O\4O _PA MTG6+G6=1TUY1=>(K/2;R'0-16&TL2;6"2\:-5!#!9&E (4'/8 5QRQ*C4=. MU_3Y?YFG)=7,"T^-?@31]*T/7H;[5KOQ3I_@4>$AHWV );>:R.CS/.9/F0"0 MG8$R2!S77+^T]\//[+\<0I)J6W7_ +>C64MF6BE\RRCA@;"L%&UT.=P8C@KC MFO.?%7PK\/\ PK^/GP_\'ADU&[CO;236I+B026\GG76^)-I& HMS%N]2YKU7 MXJ?#BP\;?$JS\+7OA_4-!L]3GU&ST2\DTG3M-@-_L9K15>V^:6)BNW$F/O*> MM<$XT&XMWLU?Y?UJ:KF.N\0?&'P[X*T;2/$FIZSY]E+JEG+)-%TZUO?%EK8+<7+ M26]U-)+"1N4LLL3Q+NS_ ,LP",5>@_9V^%P76HW3Z7=7NG/=6]PS_ M &&2VMT/G.@0J5EF\S[Y4;1AX\/>&M"U[47\;1V^IR:M MI]K<>5IQM8R^YYAF./=R64C!)K.,**@WKTWT_P _^".\KFS-^U#\.[SP;K%C M)I5U#:S:G->VWAZWLQ$C;KU9@)7#F)T**":GA^#?PU\:^)+"UM8 MY;S0 NLRV$6G/@-LU%8XM[1@S-&$9L$!B!M/W"&&VD<1B,AD()=MK?,"%P#27U:^J=[_P!?E_PX>^>$ M?M!>/--^)GQ>U[Q+I#W$NGWHM_+DNHA%(VRWBC8LH. 2R,<"O.Z^UK_]E;X< MV?BS2K5[34UBDM]1CFL8;V68-/!)$L;D[%E*,LC$F-.(OV:?A]X M?^'_ (MU![NZN=1L9-4"75C?-=0Z<\# 6\,A6,(X<$99]K'=\HR#7=3Q=&,8 MPC?M^AFZ5%7U=-XWT6#[]ZJ_P# 3_A7Y]CJ(_^N4?_ *,2F+\5+6U\72V\DXET><((Y\8\I\<_\!S3 MOV@F#_!SQ$RD,IBC((Y!_>)1AZ%2CBJ/.MW'\T>;BL52Q."Q'LW>T9)_&VM?[86XM_M< M,VEYN$>+)7=E1QR".:9X$\8/X)U6[OXXVDFEL9[6)E(_=NZX#X(((!YQWKN= M)^.%O#=65[J6FW%WJ,%K;0O/'*BK*T4K/G9MVC(8#.,C&1UK](K3Q4)MTHWC M^I^08:G@JE-*M-QE?\/Z_P"'/,V\.:LNG-?MI=X+%?O7)MW$8Y(Y;&.H(^M: M4WP]\06^EVM[)I=RGVJY^RP6[1,)I&V!\JF,E<'K]:ZN?XQ"0OY=A,8OL,UJ M(I)Z,P01W3SG! MQD9#[?PI^VQ7_/OM_P $7U? _P#/W77I]W3^K;'&GP9X@6:2$Z'J0ECC\UXS M:ON5/[Q&.!P?RI]GX+UB\T&]UH64L6FVL0E-Q,A5) 7"80D88Y8=*]+C^/-G M#?WDJ66HF*2:&YMPTL1:W:)65(E^3 C ([9!!/.:PM6^*UIJWA6[L6LKR/4+ MK38--;;<#[*HBE#AUCVYW,!@\]:4:V+DTG3MJO\ @E2P^ BFU5;TETZ]#>_9 M-_Y*E-_V#IO_ $..OJ;QPKOHB+$_E2&[M@LFW=M/G)@X[U\L_LF_\E2F_P"P M=-_Z''7U3XQ_Y!4'_7[:_P#HY*^*S_\ WWY(_1N%?^1=_P!O/]!/[)US_H/C M_P D_QK-\1^'?$5]H=W;V^M^9/(F$40+%SD?Q Y%=A17SA]@8OA33=4TO2T MAU;4AJ=R/^6@3;M'IGJWU-?!/C[_ )'KQ'_V$KG_ -&M7Z(5^=_C[_D>O$?_ M &$KG_T:U?8\-_Q*GHC\]XP_@T?5_D8-%%>E?#>[\)+I%M;Z_P#98[EM1:87 M$RY*(D60K^J.=R^S;3ZU]K6J>RCS,?9YEMY;M-\,=P4(C9Q@Y4-Z@CI7?'6M!,9%K?Z#;ZT!;?VA>7-H'M;A0K^ M:(EV8SDIG:!NQQ45EX9^'1&G+/J<+2- PG9;LA0VV,AR"P]9!C*GC[IQS4N= M*\$:7X;DDM;^UNM3>RF3F4N&O*J3IUIWM*^VQ[M&G5P] M/EYH-:O?79?C_P %$'A>Z\(0:'J$;RPF9]QE74H0KMF)PBPX)(42E">0<=:Q M_B=/ILVK68TR;3[I([?;+_Z[-GEM M%>C>,O#/A73_ W>ZII$DLNZ]-C:?O2R28VR-(#_ !!5.PCU(KSFO5I556CS M137J>'7H2P\N233]!\/^NC_WQ_.OTATO_D&VG_7%/_017YO0_P"NC_WQ_.OT MATO_ )!MI_UQ3_T$5\AQ+M2^?Z'W_!V]?_MW]0OM4LM,\K[9=P6GG-LC\^54 MWMZ#)Y/L*M5\Q_&K6O"FC_%W59_&6FVWBO3[C0$L-/L5EAD>UN=[LZ%68&%I M T9$O' Z\5CVWQ2U:S\;6]K:>*(K2XBOX8K6SGU.";1H]*%LN?-E!RTHDR"< M[B0,<5\LL(Y14D^ES]_\ EEW MO_E<^R:*^1?^%@:WX?UJ>[M_'MQJ\%OJJ01VLVJVC)-:R::?I]_X]N+'2[C5+5Y[R2_A69(#:2F9=[X(7S0@SM !/R@ M#%'U*5KW#ZA.S?,C[.JC=:YIMB,W&H6L \WR?WLRK^\P#LY/WL$<=>:\"^#_ M ,5GN/&'B&Q\1>.-/DL/#P?3K>:YU&!5U)WF>5+C.?FVPF)..^ZO(];UKPYJ M'A'PYJ-YJ=I=:PT&J1W7GP6^IV\MS)=,626$NLD;/@;9E(^4=>E$<&W+ED_Z M:N$<#)SY9/\ #NFS[GHKY _X6KKMKJ)T&#Q38Z;;C0_[;B6UU2&1;:5;-X?[ M/5V8YQ[@,9"2!< M?W3TZT?4I]P^HS[H^P**^#%^(>H^-?!MHUYXPU2\M$M=,O=16\O8(IA>)>(7 M^S*,%E$ =B #RJ=\BNHUKXN>)Q-KW]G>,)3JPBU3[0DE[;?8DC!_T V9SRY^ M7/4_?W8XJW@)IVYBWETT[U176H6MC")KFY MAMX20!)+(%4D].37RMIOC&:S\8-#J/C]M5\.-JD]E/#?ZG;20R:>^GEV=L8) MQ.2H/;[M9OC+Q9IOB+]G?X86]UK>FW]]::E93WD.^WO94MTCF :2!VP^%*95 MNYJ%@W=)O?\ X/\ D0L$[I-[_K?_ "/KVUO(+Z$36T\=Q$>!)$X93^(ITD\< M3QH\BH\APBLP!8XS@>O%?'UUXY*Z (?"_B[^Q;33]"N[F""Q6STM;C4%N T: MM I(Y4D8'WN2:Q/&'Q)U&\UR75+KQ1,^M:7/JMU#Y=W;G3[:(Z?*+5X"#RY8 M@8Y.XG(Z52P,I/?N5' 2D]^Y]P5$MS$UPT E0SJH9HPPW!3T)'IP?RKXVT_X MP:K-9^8WC75&\+//8-J$\MW;KJB9MY#6:77V;[7<;_,<$X<0F,L.BDY S2^HS6[%_9\UNS[+ MHKXXT3QDMEXR.J:WXSOV,&AZMIL%]9WUM+.=EZ3;_*3M+M" REAAB%^E?0O_ M M#PK_T.-I_X&VW_P 56-3#2IVMJ85<+*FU;4_#:NTU[X2ZYH,EO;EK6^U. M22.*33+.1GN87>,R(&0J-P*@_,A91C!(-<77KJ_'X1Z7_9R:%(UE,&2:";4I M)5@1X)(72T+*3 K"4MU;E$'1:_0ZCFKZF M:W,FQQY+K((RLF!E?F8#\1ZU'I?@3QA;7=M=V7A[4)VA*W,1^QF6-@/F5MI! M#*>O(((]:Z6Q^.ESI=]:2VND*EK:0O;PV\MY)+\K7$,P+,W)(\A1GW[8 I(? MCUJ<.J17JV2@QRV,@C%PX ^S6IMU'T8$M[$UG>M;X45[IS_BO3?&OBK7]=UW M7-/U*ZU191-J-S);E?+9@""0 HVX( & N,<5I^%])\?>!=>T[5]%M;J+7XA M*\,)MQ/<6N O[PQ.IV$B0;&QG(..16O8_M!7MIX:CTIM)AD>"T2U@N=Z[ABR MCM'9BR%CN2,'"LN"2#D5F^'?C++HWC37_$%UI:ZA_;#J\MF\^8_E<.%8.K!U MR,"?$MQ#9M;Z-J+PWQ86[1Q-MFP,G!Z$8!.?05T/P[^* MJ^ 9KF=--FDF>Y%RK6=^]LK@9S!,N&$D)ST(SUYY-:,GQK@O(Y_M/A_+7]FM MCJ'V:_DB1XDC\M/)0#;$0,$\-TP, G-N552=EH+W;''V?@?Q1A7!SZ=ZJ:7X;UG6+Z;3K*QNIKB-OWT(4@1$'!,F>%P0>6Q7 MHZ_M#WLFI--36#IGQ5D@\3 M>)-7OK.6[CUV=IKJP6X46\N79]LJ,C+( 3QD9!Y�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oyst-20191231_g16.jpg begin 644 oyst-20191231_g16.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" #E ?P# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*Y,_%S MP,I(/C3P\#_V%8/_ (ND_P"%N>!?^AT\/?\ @U@_^+H ZVBN2_X6YX%_Z'3P M]_X-8/\ XNC_ (6YX%_Z'3P]_P"#6#_XN@#K:*Y+_A;G@7_H=/#W_@U@_P#B MZ/\ A;G@7_H=/#W_ (-8/_BZ .MHKDO^%N>!?^AT\/?^#6#_ .+H_P"%N>!? M^AT\/?\ @U@_^+H ZVBN2_X6YX%_Z'3P]_X-8/\ XNC_ (6YX%_Z'3P]_P"# M6#_XN@#K:\Q_:(^-T7[/_P .)/%DVBW&OJMY!:?8K:41NQD;;N!(/3KCO70_ M\+<\"_\ 0Z>'O_!K!_\ %UP'QJF\!?&+PQIVBR_$'P[90VVK6FHR$ZC _F)# M)N:/&\8W#(SVH HVO[7WAAOBGJOA6\M_[.T?3=!CUVX\1W%RHMU5TAD\K;C. M0MQ$R"BWF,XF1-[HT.SS%*I\QRHPI! MZ5\QQ_LL> )O#5SI=Y\9="N)9]/N[-KO[5;[M[W,$MNQ'F\K'';0QE?X@"&?#6@^&IO&'B_Q$T[66EQW:6D:PP*&FFEF<$(HW*!P22<"O --^!? M@JQ^'NM^&3\7/#;MJ.C:!I N1%/ M&7A+XI>%?#WC#PW]IBMY;^ZANK2YMYU598IHQ*K8^16#*P((/KP +!)=2L]0N+D:GES:26LL:,BB-3YJ.)"ZR+QM4D]\=[.6O@GP_=ZMI>L>(?C M7HGB'68=#UC2KJZN;NW4/)?M&V8E$F(XXA'M5.>#UKB?^%!^'#J_AN63XT>% M[JPT4Z+)#%<7"&2,V 4,D>+@(J28+$E&8$XSB@#Z/\/_ +2_PQ\4:A=V6G>, M+":>UM)[Z;=NC1886*S/O90IV$?-@Y'&:J:?^U7\*=4TB^U*V\8VDEM9+"TZ M^5*)1YS%80(RFYBY4[0 21R.*\(U;X+^!8_AKI6AR?$K1-671]%\0V!M[/4+ M6&:\.HN\@",\FU&4L%&[@]\"O-?"?PZE^+FJ:WJ_C'QIH7A^\LX-%32)M2EM M8%FELQ*&22""Z9BFUPI<2*2Q)4 "@#[/\8?M >%?#?P3U?XGV5U_;OA^QM9 M+A/L6=TSJVSRL$91M_RG\6YU"RN M88H4FN,EF6,S,Q S_$Q)QDG)K+U_X7^ /$6G_$>";XI^'X)_%0TAX+E+NW8V M(,5.."1[T >M+^T]\,&\-KKI\66RZ>UY_9_P T4HE%SY9D M$1B*[PY12P!7D=*T?A]\?OA_\5-6?3?"OB:TUB^6U6]\F$.I:$G&]2R@-AOE M;&=IX.#7A>E?#GP[=>-+'QIXD^+OA._\3_\ "1VVNWG]GRPV]JR06DEM'#&A MF9@<2;B[,3GCIBM;X3^!_!'PRU_P=J1^*'AR^'A_1K_2C&+V!/.^TW8N-^?, M.-N,8[YS0!)XJ_;6C\*^//$>B2^#C*S;$D@! MF7[N>A]*]8'[07P]_P"$HU/P\_BBSBU334N'NHY@Z1H(%W3CS" A,:\L 25[ MU\V>,?@7X5\7>,_&-\?BQX%M='\3:U#K$TAM[:75+7RUB'EP71G'EY\D75O*-W)#<3-%>PM&$E$DYB98\@;0BA@#NY- M 'T!#^TW\-)O#=QKJ^*(?[/AGBM3N@F$K22J6B5(BF]]Z@LNU3D D<"N;\4_ MM9>'])DN9-'@M]=TQ-!@UZ#4Q?K!;S))>K:^7N93M(9B>>XVX!KP6Q_9K\+V MNAA&^,GA3[?9ZI::GIMBMXQTR!H8986!1KLRKYBRDD)(H4HH4 9%;=Y^S[X# MF\*W&CP?%;PK9?:-!CTF0VTL$<0E&IK?O*J><< D%<9)YR230!]'6G[1'PYO MO&3^%8O%5F==2:>V:V8.H66$$RQERNW>J@MMSG STK0^'OQH\%?%:XO8/"NO MV^KS6:K)+'&KH?+8D)(H8#=&V#AURIQP:\%U+X5^ =8M4M+GXI>'OLS>+M2\ M2S>7>P*S)=VTT!A!\S@J)L[O]GI5K]G'P#X)^!M_/=7GQ'\&ZK-'ID&C6DUI M/'!*;>(DJTK/!--T--0\3ZO9^'Y9;K4((;=)FN MS(EI<&&20&-.Q +#'RY.3P36M\9OCUIGPG^'VC>*;>VCU^'6KVUL--*WD=M; M2-< M'))7>?BOX;F_T'Q'9_\?< _P"0K<&8 M-_K/^6?3_:]J[/7+'PY-\#O"G@;1_BKX4M+W0;2QMFGOY+6[L]02WB$;13P- M)S')C)VL&&!@T =-I'[2^AZ?X%C\0>/;0^!)7OY-/BM99Q?)=LBA_,M9(0?/ MB*DG>JC&ULXQ5.']K[X>K\0+OPW>ZO;6=J;?3KC3]7\TR6]\MX"8R&5<(,A5 MW,<$L!7BWAGX(Z#X'6PUSP[\7O VD>+K75KS48X((X1HMNES;I!)##:_:,H M$5PV[ELYFZY\*O!^N:3XPMKKXO^'+BZ\16FAV\MV9+2+#Z?,)6?RXW5 ) M"#A5 "Y[T >O6/[2G@^&\:QU[4K31-1FUJ[T6QM5G-R]W)!(D;$;%^5LR+E# MRN>35)_VQO@XBL6\=6(54$A;RY<;"Q0N#LY56!#-T7N17!^$? /@;PS\5++Q M@_Q/\-W2VVIZ[J(M#>0#G47A8*&\S@Q^5C..=W:N1L_@/X)M?!*Z ?BYX;8C MP/J7@_S_ +3!UN[M;CS\>;_#MV[>^7YOE^9C9O\ +^?9G=CG%8^E_M'>%/$@M=3T&[AU?P:L%U/J7B9)O+MM M/\F.-_GW*-P828W X!&/IX39? GP%8_$2?65^)_A"XTBXOAJ[P7,T;W4=X+= M83Y_"GB;6;B?Q3\7/!,JC3+[3/[4T.&VL-2U%;F,H'OI%FV2E <@ M*J@G)[T ?15G^U-\++_PW>Z[!XPLWT^TGBMI?DD$OF2#,2K$5WOO )7:IW $ MC-7%_:0^&C1^'W7Q=8N-?#'30NXFXV.(W &048@,&QMYSC!KQ"X\%C5-/T. M_P!2^-_@F;Q7X;OK:[T66&VMH[*-88&A*3()O,D,BN23Y@V'[@%.\%_"#P#X M?UBTU+5/BKX>U2YEL-9M]3:*[MX1+/J,JR2O"/,/E*H!4#D\Y)SF@#Z ^'_Q MJ\%?%*\OK3PMK]OJUQ9JLDL<:NI,;$A9$W ;XR00'7*G'6N5C_:B\%V=CJ>I M:Y?1Z'H\>KW6D:;=REI6U)[51]H>.-%) 5Q(HZD^63QTKS?]G+X>^"?@;JDE MW=_$CP=JSV^F1:-936L\<,QMT;(:9WN'RQPORH%4$$@L^(KB.X%GIC>9;F>>($F NR81^,[2-P7YL$5X+=? 7P3<>%],T?_A;OAM? ML?A_2M#\S[3!\WV/4$O#)CS?X]FW';.>:Z3_ (0OP7H/B2/Q1%\2-!OY+#QG MJ7C5=/@O+<23_:+)K<6JDR@;@>0QX/3CK0!]"?"_X@V'Q4\ Z)XJTV.2&UU* M 2^1-]^%P2LD3?[2.K*?=:O>./$Z>"?!?B#Q%) UU'I&GW%^T"MM,@BC:0J# MV)VXS[UX+\(=&^'ME\ ]#\'^-O$_ARZNI'DU*_M8]TC4KC48;NVN;>*))90S)@QNL;J^&'3 M/?@]UX9_:'^'GC"XL;?2_$MO-V6P\V%(7N'S.QDD,<:KP5&" M2.:XGQY\)-.\+?#CQ+%X>\>Z!K/C+7=;TF^TV;2+^&"/2IX(Q!)-(TUPS-'Y M1D+'<6);IS@ 'V;J'Q>T&'X93^.]+%YXDT-86GA.C6KW$EPJL5)10,D9!^;H M "2<'+OQIX7U>[\+6,5I;:A)?VX8.D7E-(@+G:64D<'H2* /9:*Y+_A;G@7_H M=/#W_@U@_P#BZ/\ A;G@7_H=/#W_ (-8/_BZ!'6T5R7_ MSP+_T.GA[_P & ML'_Q='_"W/ O_0Z>'O\ P:P?_%T =;17)?\ "W/ O_0Z>'O_ :P?_%T?\+< M\"_]#IX>_P#!K!_\70!UM%_\ !K!_\71_PMSP+_T.GA[_ M ,&L'_Q= '6T5R7_ MSP+_T.GA[_P &L'_Q='_"W/ O_0Z>'O\ P:P?_%T M=;17)?\ "W/ O_0Z>'O_ :P?_%T]?BOX(D&5\8^'V'MJD!_]GH OGP1X<)R M= TLG_KRC_\ B:/^$'\.?]"_I?\ X!1__$UMT4 8G_"#^'/^A?TO_P H_\ MXFC_ (0?PY_T+^E_^ 4?_P 36W10!B?\(/X<_P"A?TO_ , H_P#XFC_A!_#G M_0OZ7_X!1_\ Q-;=% &)_P (/X<_Z%_2_P#P"C_^)H_X0?PY_P!"_I?_ (!1 M_P#Q-;=% &)_P@_AS_H7]+_\ H__ (FC_A!_#G_0OZ7_ . 4?_Q-;=% &)_P M@_AS_H7]+_\ */_ .)H_P"$'\.?]"_I?_@%'_\ $UMT4 8G_"#^'/\ H7]+ M_P# */\ ^)H_X0?PY_T+^E_^ 4?_ ,37PGXI_;N^(MGXFU:WL;?1;>SANY8H M8Y+1G8*KE1EMXR>/2CPO^VA\8/&/B"RT;2H-!GO[Q_+B1K0JO3))8R8 !)/ MM7TG^K^,Y>=\J7J?.?V_A.;D7,WZ'W9_P@_AS_H7]+_\ H__ (FC_A!_#G_0 MOZ7_ . 4?_Q-?'.J?M'?';3[>[NK>#PQK5A:V9OI;W2(S<0B(2>6QR) _3FN7B_;0^-$UR+:/1[&2X:8VXA72)2YE R4QOSNQSCKBICD6)FKQE'[R MI9YAH.THR^X^[O\ A!_#G_0OZ7_X!1__ !-'_"#^'/\ H7]+_P# */\ ^)KX MC\0?M8?''PS>65K>Z5I7GWD,4\*PZ;(^X21B14X?[^TY*]15WPC^U'\9O&6A MW>L6UUX-T_3K6Y6TDGU3_1E\UE+!1N?DX!/X4GD>)4>=RC;U_P" "SS#.7(H MROZ?\$^S_P#A!_#G_0OZ7_X!1_\ Q-'_ @_AS_H7]+_ / */_XFOA&Z_;3^ M,5K/+$;#29?+4.9(M-D9&0MM616W\HQX#=#VJ#5/VW_B]H=T;74;#2["Y #& M&ZTR2-\'H<,X.*T7#^+>SC]__ (_U@PBW4ON_P""?>O_ @_AS_H7]+_ / * M/_XFC_A!_#G_ $+^E_\ @%'_ /$U^?\ _P -\?$]>=FAG'8V+?\ QROOKX>^ M))?&/@70=-#\JLR@D#VR:X,;EF(P$5*M:S['?@\SH8Z3C1O= M=R;_ (0?PY_T+^E_^ 4?_P 31_P@_AS_ *%_2_\ P"C_ /B:VZ*\D]4Q/^$' M\.?]"_I?_@%'_P#$T?\ "#^'/^A?TO\ \ H__B:VZ* ,3_A!_#G_ $+^E_\ M@%'_ /$T?\(/X<_Z%_2__ */_P")K;HH Q/^$'\.?]"_I?\ X!1__$T?\(/X M<_Z%_2__ "C_P#B:VZ* ,3_ (0?PY_T+^E_^ 4?_P 31_P@_AS_ *%_2_\ MP"C_ /B:VZ* ,3_A!_#G_0OZ7_X!1_\ Q-'_ @_AS_H7]+_ / */_XFMNB@ M#$_X0?PY_P!"_I?_ (!1_P#Q-'_"#^'/^A?TO_P"C_\ B:VZ* ,3_A!_#G_0 MOZ7_ . 4?_Q-'_"#^'/^A?TO_P H_\ XFMNB@#$_P"$'\.?]"_I?_@%'_\ M$T?\(/X<_P"A?TO_ , H_P#XFMNB@#$_X0?PY_T+^E_^ 4?_ ,31_P (/X<_ MZ%_2_P#P"C_^)K;HH Q/^$'\.?\ 0OZ7_P" 4?\ \31_P@_AS_H7]+_\ H__ M (FMNB@#$_X0?PY_T+^E_P#@%'_\31_P@_AS_H7]+_\ */_ .)KY4_:8_:V M\:?"WXJ77AOP_!IB6-K;Q.7NX&E=W<;BF3YG%?04\CQ56DJRLHM7U?0\"IG>%I571=W).VBZGW9 M_P (/X<_Z%_2_P#P"C_^)H_X0?PY_P!"_I?_ (!1_P#Q-?%>M_M4_&G1]12Q MMSX7\0731M*T>@P-?&)5.#OV/\OXTLO[4OQOA\-?VZUMX>_L_P"QQWV1;-O\ MIYV@7Y=_7>I&*?\ 8>)LGS1U\_\ @"_MS#7:Y9:>7_!/M/\ X0?PY_T+^E_^ M 4?_ ,31_P (/X<_Z%_2_P#P"C_^)KX4NOVROC78SM!<:)9V\RA&:.71YE8! MSM0X+?Q'@>IJ71_VQ?C/K>OZ7HT-CH\-[J=R+2V%SI[Q*\A?9C)?LW!]*O\ ML'%VO>/WD?V]A;VM+[C[F_X0?PY_T+^E_P#@%'_\31_P@_AS_H7]+_\ */_ M .)KXI\6?M7?&3P@VV:X\(ZH5W^=_9"&Z^S[6"GS=K_)R0!GJRVCFT4HCA0I#;23@_-CKVK MFQ>48G!4_:U;6\F=&$S?#8RI[*E>_FCT7_A!_#G_ $+^E_\ @%'_ /$T?\(/ MX<_Z%_2__ */_P")K;HKQ3VC$_X0?PY_T+^E_P#@%'_\31_P@_AS_H7]+_\ M */_ .)K;HH Q/\ A!_#G_0OZ7_X!1__ !-'_"#^'/\ H7]+_P# */\ ^)K; MHH Q/^$'\.?]"_I?_@%'_P#$T?\ "#^'/^A?TO\ \ H__B:VZ* ,3_A!_#G_ M $+^E_\ @%'_ /$TY?!?AY.%T+3%'M9Q_P#Q-;-% !17"^.H_$<^OZ;#HLTM MM%)#M,T84A,SP^:2&!7<(M^W(/\ '7/6NF_$^:X@BN=5>"W5EWS1QVV]@T41 M;JI'RR&8# Z 9SWVC3NK\R)OY'K=%6WCAN[F4SI-&9EB0(RKLV9Y8JS?2M*Y^. MUB=0U":U\)^)K9=7O;R]OIE($T#7%JL+?9V"<%2N06Z@GIFOT+^SQ?\ /)/^ M^11]GB_YY)_WR*X?[7H6M[#_ ,F[_([?[(K7O[?_ ,E7^9^?,XK]4_L\7_/)/^^11]GB_YY)_WR*NGG=.G/VBHZZ_ M:[_(BIDE2I#V;K::?9[?,_&AM U0J0-+OB?:V?\ PK]:?@U8W&F?"?PA:W<+ MV]S#I=NDD4@PR-Y8X([&NN^SQ?\ /)/^^14E<>9YL\QA&')RV?>YV9;E*RZ< MI\_-?RL%%%%?/GOA1110 4444 %%%% !1110 45S_C9KU='A^Q^9_P ?EOY_ MDYW^5YJ[\8]NOMFO/HM/^*JVMH'U,M--"OVEO+MOW+[8"P3Y?[QN%YSP%^IU MC3YE>Z1+=CV&BO/O!L?BJW\31PZW/+>TM MVBEC@9E+_GDG_?(KZZCQ![/#QP\J5TE;?Y=CY*MD'M,0\1&K9MWV\[ M]S\V/ /QV\0Z-JFN7/B+2]7U%K\6Y@NK2R1)K?R96D5,; I4EN2>00#STJY9 M_'N[LY;:Z;P?J%Q=11P91X2(W:/4'NST3@$/M&!P1G%?HW]GB_YY)_WR*/L\ M7_/)/^^164LXH2;?U?>WVNWR-8Y/7BDOK&W]WO\ ,_.FW^.TFD7UK%:>'/$> MI:;#:WJF;5R9;IIYI5GB.X+C9%)&A4=>6Z9Q7.^(OBM>Z]\6O"/BS_A&-2M[ M#0Y8;A[%8FS)+Y[3W#J=N!OD=B/08K]./L\7_/)/^^11]GB_YY)_WR*<'?B18:Y\1H]0U-?$_'75M6^'NJ:1=^']5&KWBWT3S1VP,,RW4 MWF,S[E+!EZ#;Z+R,5^D?V>+_ )Y)_P!\BC[/%_SR3_OD5*SBC=-T-K6][M?R M\_R*>45K->VWO?W>]O/R_,_&G^P=4_Z!E[_X#/\ X5^A?[!NE7NE_!.?[;:3 M6AFU6>2-9XRA9=J#< >V0?RKZ+^SQ?\ /)/^^13U4*H &!Z"EF&=O'T?8^SM MK?>_Z#R_)5@:WMO:7TMM;]1:***^8/I@HHHH **** "BBB@ HHHH R/%EY=Z M?X9U*XT^.XEO8X&:%+6)996;' 5&(!/L3BN4^&^J^+KS5KN'Q%#(UM]EA>*; MR1"BR;$WK@HI+%BYR#@8Q@5Z#2T 10SB?S, C8Y0Y]14M5-/_P"7G_KNU6Z M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKSGQ ME\=?#_@?QA!XQAGDL-+VW%Q'&J,[R,@/RHJ(S$G'3 R2! M2^*OC9X8\'ZIIEEJ$]QF]2&1IXH2T5K',^R)YF_@#MP.IX)P ":I4INUEN+F M7<[VBO(/^&I/!GV5YC%JP>-P7MS8D2K;E(G%T5SQ#MGA.3S^\ VYXKN_"7Q MTGQM?:Y;:4UQ(VCW0L[IYK=XE\THKE5W $X5EYQCD8S1*E4BKR0QTE%%% M9%!7E/AWQ-XVN_%%BMY977]CRW,BLLEGY$JI\P#/\K*$! *C>&P1DL>*]6HH M B6=6N)(0#N158GMR3C^52U4A_Y"ES_URC_F]6Z "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **9-, MEO&TDKK'&HRSL< #U)J*WU"UO&*P7,,S* Q$;AB 1D'CL10 S3_^7G_KNU6Z MJ:?_ ,O/_7=JMT %%%% !1110 4444 %%%% !1110 4444 %%%% !17S5IWQ M&^)K^*-<\6QZ;JFK>![+5+^UCTVU@@D:Z@B;[/$844>=D2H\C,<_(/E5N*K7 MW[0?B+5O&FG1P:AINDZ?"UGWN+!5>ZL7@FF%[-C&P!3 M;*-N 6WCO@/ZI4Y>9M"]HKV/JRBN&^".N:WXG^%N@:SXAE6;5=1A:[=EA\D" M-W9H@$[8C*=>:[FN24>63B^AHG=7"N#N?@IX4U+Q;KOB/5-/75M3U9(XFDNU M5C;1I%Y02$@!D!!9LYSEB01Q7>441E*/PNP63W/&;C]EWP\UO8V=OJ^KVNE6 M@N(5L4>)E:VG$7G0%VC+E6\E/FW;P"P#8-3^(OV:]&\67T\VKZ[K%[#<6B6M MQ;,T*K*T8G6&0E8P08Q8G *!PQ;. IR1U&".>,[?6*O\Q/+ M'L<+;?LLZ#'J%O>W&MZM>7#H(M2:3R -2C5X72.0+&-BJ;:$8CVY5<'->F>% M?!]IX2;67M99YY-6U&74[B2<@GS'"C:, ?*JHJCOA1R:T])U*/6-*L[^$,L- MU"DZ*_W@&4$ ^_-6ZB56H[T ,A_Y"ES_URC_F]6ZJ0_\ (4N?^N4?\WJW0 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %>._&[XZ7WPRU_2M$T;1K?6]4 MO+&XOS;S23JSB-HTCBC\J&3+R,[ ;MJC88ZA^T5IESIVG?\(YI\VNZCJ%VFFQ,"T=C M'=D$O%)<[2/D"N6V*WW#Q69K'[24]EX!\-:[:>'H[B_U32I=;GLYKTQQV]K$ MT:LRR",EV9IHU0;1NW9)7%=[KWP9\$^)KJXN=0\.6;W-PRO--"IA>1ESAF9" MI)P2,]2"1T.*6X^#?@NZO;*[D\/6K364AD@Y8*A.SY=H.TJ#%&0A!4%%( (K M=2PZM>+_ *^9%I]SRA?VL+J\OH[6S\,6^[4K1K_2&NM1:-6ME,V^6YQ$?)&R M!W 7?D$#@YQZ#\-OBY=_$+Q ]@WAZ32K>/0[#5VN);E9#NN@S+$%49&T(V2V M#T^7!JP?@!\/C8FS/ABU-N;C[25WR9W;67;G=G9M9AY>=F&(VX)KL+#P]INE MZE?7]I9QP7E\(Q<2H,&01KM0'T"C@ 45)T&FH1_K[PBI=6:-%%%<9H9GB;1Y M-?\ #]_IT4ZVLEU"T2S/")0A/

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end GRAPHIC 21 oyst-20191231_g17.jpg begin 644 oyst-20191231_g17.jpg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oyst-20191231_g18.jpg begin 644 oyst-20191231_g18.jpg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end GRAPHIC 23 oyst-20191231_g19.jpg begin 644 oyst-20191231_g19.jpg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end GRAPHIC 24 oyst-20191231_g2.jpg begin 644 oyst-20191231_g2.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" #Q EX# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#R>BI]/C6: M^MHW&Y'D56'J"17USJ?[,OAK3_C#XW3_ (DV\JVZLKM M%O\ ,P&R?F)&".U?M6(QE/"M*IU3?W6_S/QK#X.IB4W3Z-+[[_Y'Q_17NUQ^ MR=K5OX#DULZDQU2+1O[=DT[^SIQ +?;O*BZQY9F"<^7U]Z==?LQOI/A./Q,- M;_M2TM)[ 7T)TZ>W@D2XD1,6]PP"S8+@-MQC/TJ/[0PSVEUML]_ZZ[%?4,2M MX]+[K;^NFYX/17U'XV^!O@32[?Q5>V\LEG/8>,H=(M[$"5T$+ 'R-Q8DEAEM MY/&,=36/\3OV=?#MOXD\57/A_P 4V=IINCZW;6&H:?\ 9IC_ &7#&/%NM>% MH?&&L>)[N[2&*]N98K>TM[=PC#$9!+LQSDG@=O7H>+I\JE3]Z[LK=7:_6W0P M6%JW2_4\1HKZ(\9?L\Z%<:M)XAL-5_X1+P&_AZP\0RR7B/>2 M6?VMFCCMU5?FD)=&P2>G4FN!\1_!E-%\,>)M>L?$VG:[IVCWMK:QS:>"R7*S MH65@<_(5QAE(R#FIIXZA4M9]NCW=M.U]5U'4P5:G>Z[]>BOKWMH^AYK17T%K MGP!T_P (^&?'>E7D]O=Z]I6MZ386^L.9(HHTN8][Y0$C'S#)()^7BG7W[(EW M'J'AJ*T\1-)::QJS:.;B\TF>T:.41-()$23!EB(1L., _GB/[1PV[E9>CUT3 M_)]33^S\1LHW?JN[7YH^>Z*[:Z\)^'-!^)>E:)=^)(M6T(75O%J>IV4+QI$I M<"<)N&6V#=A@,'&0*]K^+GPMT-?!FMWVA^"=-72[6ZB72_$WA?6?MT0A:3;B M\1I"V2I'S!>&XSCK=3&4ZNZ MQ^SS=Z/JOQ!LFUJ&5O"$ME'(X@(%S]HE6,%>?EV[\\YSBO1_!?[/?@?PAX]\ M5:9XI\2V?B:Z\/:-=ZA<:;':7*10&/:5>1T92^%8$QH<\XSQ43S##PCS)M]= M$^R?ZK[RX9?7G+E:2]6N[7Z/[CY;HKVJ']FR;4/AG>>+++7A<26NE_VO+;#3 M9UMA%GF,71&QI0.2@]#SQFHO$7[.B:#(-%'C+2YO',;6:3^&Y$>%P]P4")'* MWRRN/,4L .!GK6BQV';Y5+7;9_Y;:K78AX*NES08FCW KO7N1Q@YKQ:KA4HXVD^7WHO1D2A6P=5"5>ZL,\^A'0CL017YH?M&_%KQQHOQR\: M6.G^,_$%A90:@Z16UKJD\<<:X'"JK@ >PKUS]@WXX?V;J$GPZU>XQ:W3-/I, MDAX27K)#]&Y8>X;NU?/'[4'_ "<%X[_["3_R%?!8? O!XVI1FKJUUYJY^\\* MXJGF$75MK;5=GH8?_"[OB+_T/WBC_P '-S_\71_PN[XB_P#0_>*/_!S<_P#Q M=:/QK^'FF?#N^\)0Z9+=2KJWANQU>?[4ZL1-,K%PN%&%X& 726OK?3QJUQH*7RG4H;0@-YSPXX4*02,Y /(KU.:ARJ325S[I2P_*I M-)7\CG_^%W?$7_H?O%'_ (.;G_XNC_A=WQ%_Z'[Q1_X.;G_XNMGQ%^SUXF\+ MZ"FH7EWHYN_)M[B31X[X?;HXYR!&QC( ;)89"EB,\XJO\1/@3KWPRT^6YU34 M-&N)K>=+:\L;&^$ES:2,NY1(A XP/O+N&>]"EAY-)6U!2PTFDK:F=_PN[XB_ M]#]XH_\ !S<__%T?\+N^(O\ T/WBC_P&C+ELKWML<1_PN[XB M_P#0_>*/_!S<_P#Q='_"[OB+_P!#]XH_\'-S_P#%UZ#\%_ GPP\<^#]?N=TF;5KYK&\MT@F1),!(E:,L#M9?O'J#63I?[/VH?$%%U?PH]KIFBZI M/-#H-AXAU&-+_43$!YBQA5"N0W&?E&<"E[2@FU*-K=TB?:8>,G&4;6[I?UYG M*?\ "[OB+_T/WBC_ ,'-S_\ %T?\+N^(O_0_>*/_ )?$7A MMM5MKS1X[G[+<7D>C37P6_DAA)$CB+'&-IX8@G'2LWQI\&=;\ ^$=%\0:M>: M4D&L0V]S9V<5X&NWAFC,BR>5C(0 ;2W0,0!FK4L.WRJUS12PSERJURO_ ,+N M^(O_ $/WBC_P*/\ P(D;@,]3T-86A_ OP]K6EP7S1 MZG9V]QX0U7Q# S7D;M));N1$"!'\JXP&7J3R"*P]MA]?=V=ME_70P]OAM?=V M=METO_D>:?\ "[OB+_T/WBC_ ,'-S_\ %T?\+N^(O_0_>*/_ MBTK59+2Y:>UBO;:ZL)O.@N()!E)$; RIP>PZ5O&6'F^6-FS>$L-4ERQLV6_^ M%W?$7_H?O%'_ (.;G_XNC_A=WQ%_Z'[Q1_X.;G_XNO?KS]BN2U^,FJZ<=/UL M?#RWL6N(-8,T6]I!:B3!;;C'F[E^[T'XUY#H?[-OBW7_ _8ZC;RZ3'>ZC:/ M?Z?H<]\J:C>VZ@DR10]P0K$9()"G -8QK86:NK=.W7^M3&%?"35U;IVZ_P!: MG/\ _"[OB+_T/WBC_P '-S_\71_PN[XB_P#0_>*/_!S<_P#Q==7H/[+OB[Q% MH]C?VU]H,;7VF#5[:SN-26*XDMLD.^UAP%QDDD#'0GG$,O[,_BJ+6EM#?:'_ M &8=+763K_V\?VTPM[:'-?\+N^(O\ MT/WBC_P*/_!S<_\ Q==#'^S;XL77=4L;JYT?3M/T MVT@OI]=N[]4TXP3_ .H=9L'<)#D+@9)!I\/[,_BU=5UNVOKC2-*LM(AM[B?5 M[R] LGCGSY#QR*&W*^&P0,#!SBCGPWD'/A?(YO\ X7=\1?\ H?O%'_@YN?\ MXNC_ (7=\1?^A^\4?^#FY_\ BZ[%?V=I8/AOXLUN\UO3TUK1-4AT]+&&[22. M;>"&M!U:\TW7;/4[N>SE30M4421RQ1LS1N73*$8')0@X M.#7/6OP \0W7@ZW\1M>Z/8PW=O-=V5A>7PBNKJ&(D.T:D;3T. 6!..!1[3#^ M7]7_ ,A^TPU^G]7_ ,BEI/Q_^)&CZI:7T?CGQ!^'^E>)M.(1;I-L]OG)MYEXDC/T/3U!![U^.E?1W[% M/QV_X5;\0!H&JW'E^&]>=8G9V^6VN>DFO>C^*-[_@IIXW\1>%?B-X0AT77]4TB&727>2.PO)(%=O.89(5ADXK MXT_X7!X\_P"AV\1?^#:X_P#BZ^L/^"J7_)3?!?\ V!W_ /1S5\0UUY="+PL& MU_5S\QJM\[.N_P"%P>//^AV\1?\ @VN/_BZ/^%P>//\ H=O$7_@VN/\ XNN1 MKU/]G3X6Z5\4O&>J)XANKFT\-^']&N]?U5K+'GO;VZ@LD>> Q+*,GMFNZHJ= M.+G):+R,U=NR.:_X7!X\_P"AV\1?^#:X_P#BZ/\ A<'CS_H=O$7_ (-KC_XN MO3$\$_#+XX7GA_1_ARMUX%\8W^I&Q&D^(+U[JRFB,;,DPN%BW(Y8!-A!R6&, M8R<3PU^RYXR\3P^'3%)IME-KE[?6D,%[.T;P)9C_ $FXE.PJL2'*D@DY& M9 M>THI>^N5^:_KL.TNAQW_ N#QY_T.WB+_P &UQ_\71_PN#QY_P!#MXB_\&UQ M_P#%UZSX5_9GL8+CQ6VKZYI?B;3(/!6J>(=)U+PY?%XGN+8HH5PR*XVECE64 M9R,&L/Q/^R;XM\*^#=1UNYU#19[_ $NQAU+4_#]O<.U_8VTNW:\BE AP'4L% M%/#FGW$=G)JVOW#PPO<."5A38CLS8&X\8 MY)KU&U_9?T_P/\+_ (L:MXYN[4>)_#?]#MXB_\ !M?\ 0[>( MO_!MC_!WP1X"D^"OC/QUXST?5-<;1]2L[&"UT[4!:9$P?)+%&S@J. MU=+XB_9)M_%VI:1J?P\U:#3O"^J^&?\ A)C_ ,)7=B)K&-)EBGC>5$VD(6#; MB!\H/4@9EUJ$9.,E:W6VGLV6H:A;Z[;W,K6*061<7#. M_E;A@H,84@[UYYXM_LD_"#1?C%XN\56.M:9?:T-+\/SZG::?I]XMK)<_P#"X/'G_0[>(O\ P;7'_P 71_PN M#QY_T.WB+_P;7'_Q=>R?$;]FV:^\3)HGAWP;=^ M3M=$O-;DLO$&MQWTFHQ0 M[24MS#&0),!_E8C..HQSR^A?LH^*-7M+&^N=7T/1]-FT.'Q#(6MYS/+:NEU82EX;FWF*E)8 MG(!*E6XR LKJ[L=3N=12YM;MX M(Q(8Y(_+#(&!."&.,9]B3JT86?+=-7VZ=_Q!1DSYN_X7!X\_Z';Q%_X-KC_X MNC_A<'CS_H=O$7_@VN/_ (NO6[_]E74/$-]IITAM/\/:9!X1TW7]3OKV]GND M!N00'VQP&0,Q!^1594 /SFL'0_V5-?UC4?$"2^)_"MAI&CW<-@VO2Z@TEC:[X"T\1:AK7A_0([B2\BL[75;MXFN7 MM79)E$HC,*'>C*HDD7<1QV-/VN&[H7+,X+_A<'CS_H=O$7_@VN/_ (NC_A<' MCS_H=O$7_@VN/_BZ[VQ_9-\6WW@>'7UU'14OY]';Q!!X=>Y?^T)K GSE79L MY4%@N_<0#QGBO%*TA[&I?DL["?,MSKO^%P>//^AV\1?^#:X_^+H_X7!X\_Z' M;Q%_X-KC_P"+KD:*U]G#LA79^L'[ ?[1S_&#X=MX9UV\:X\6^'45'EF?=)>6 MO2.4D\LR_<8_[I)RU?5=?A7\%_BOJOP4^)&C>+=)):6REQ/;[L+Z/QUMYC;W$4J@%HV# 'IP.#IMB- M0UNRELIK;Y_*C62)8B5^;.<*#R>M>6T5^KU*-.I\:OI;Y.W^2/QJ%:=/2#MK M?YK_ (<]7U3]H*^UKPG'IM]X?TNZU>/3DTE=:E,K2BW487]T7\KS O'F;,[S1_$FH:IX%)TS6=6@ M\0K>R6MS'%:SK@(Z/D*4*G'S9'S?2N3UCXUZEXB3Q];W-G9VT?C6\M;J]D4. M?LQAD9U\OD\9&U_X1&PU6826%C97L]PLR-Y2WTC2"/)O $EKK=PAT\7-S:7$"0-8#!E6T$44B8M %W2[I-R&$ MYP67TXU3A3=O97]+]&K?^DI_<=CJ2J*_M;>MNJ=__2FOO$_:&^)2?%/5O"6A M:%=MXB32]/B@EO+6UDC.H7S(BRRK&P#G(CC49&?E/;%4O#GC?7_!7A,>%/%? MP^7Q'H=O.U_:6NLVMQ!):2%6+,CJ5(0B-V*G@[&/8UDV_C?1=/\ B3J.L06M MF-(T^VN[?2K:.T,"W ,;Q0F3RPK;CO#LQ(;C&1QC1\#^-/"-I;F74;6UTJ>X MG=)H+6*>54MV-M$P5I&=OFADOB1N/(4=P*/9*G1C25-N*U\[N_56M\EUL'M7 M4JRJN:4GIY6TZ.]_F^EQ_P#PTGK.H:YK\^N:-I>LZ)K5I;V,^@NLD-K%# VZ M!8BC!DV')')^\?PDL?CEJ4S:]:W/@?1=1TCQ')!+!HZ6DL5O%);@I&8A&P+8 MYW D[B#D\G.3K_CO1=8\)W-M]@TF&_FTY$Q9Z3% R7)OFE)618P0$@"Q]>=Y MZXXOZ/\ $7P[I:Z1:OI]K,NE:!-;0:GMN!F)=: MEJVGZNZ['*)+:*%C4 M]UMO/?T(JZW[5FIPW]A<67AG2[,6FNMX@"^=<2M+< MM$T3;V>0DJ0_08QM 'O3U/Q9X,LX[^.S_L:YG$LJZ9<1:,#':V[S0!%D$D0, MLB1),27#",]CU%>E:_\ 'Y[_ $'7K70O!NC>%KK7B@U; M4-/,S--A_,VHKN5B!89( JW'XH\"2S"00:/;Z==LDJZ;-ISM):SBZ$SF698] MWD^6IA"QLWRR [,@YOMXR\%20W5I'?Z?%:R7"7#Q2:8@662*V*QX=;/&T/-+ MR803L7*89FK>I)5&G*DVUZ_T_GH84XNFFHU59^G](I>)_P!IZ_\ $ECX@C_X M1;1;"^\0"T;5-0M_.\VXDMY$=&PSE5'R 8 [D\G&,*_^->M)X[\=:_<:7;0: MAXHTZYTN\M75U6W68(&* G(8;!C.>M=-?>(/AU=-JB";3XK>[GCC$L&FXF"; M((V;:;; 'RRRYB:)@[-\KC:*YOX@>)O#&K>$8TTN.PBU.XNUN'BL[,(8U;S7 M=69H592K.J )*Z,J@[4P!44J=)6C&BTGZ^7^27R+JU*KO)UDVO3S_P V_F:] MU^TUJ5YX?FT^3P]IGVJX\/\ _".37XDGWFW"J%*)YGEH?E!.%Y('TJOX@_:/ MU+7HS>CP[HMKXKF-H;GQ(D+/=2FW*F)E#L4C;Y%W%0-P&.G%>0T5V+!8>+NH M_G_5O+8XWC*\E9R_+^K^>YZ7\2OC9)\1M/GA;PWI>D75Y=?;;^\M6F>2>7G. MWS'81J2=Q5 .?U\THHKII4H48\D%9'/4JSK2YIN[-'PZNIMX@TP:+YW]L&YC M^Q_9_P#6>=N&S;_M;L8K=^/W]I#XQ^*/[9,)U?[2/MAM_P#5^=L7?M_V=V<5 M]-?L&_ _[=>R_$;5[?-O;,UOI$<@X>3I)-]%Y4>Y;NHKYU_:@_Y."\=_]A)_ MY"OF\3BX5L8Z,/L+5^;:T^7YG[-P%A)T?:5IOXUHO*^_S_(Z'Q=\8_A[X\T7 M1!KG@O5Y=;TK0[?1XKRWU=8XCY,957,?E'^(DXSTXJ[J/[2NCW@U7Q%'X7N8 M_B#JNA_V%S]4^J4MM?O M?]6/H?6_VH-+U+X:S>&4\/:E=K/;V]NMCJVJ?:[*R,14F2W+)YZE@I !EPN[ MCH*J?%K]I.P^(GP]F\-P:3JLCS7,5Q'-KNH)?'3@@.8[>0QB4ANA:1V.!CO7 M@=>UZ;XMT7'@OP=_:&H0:;]GM8]3F@UM;?3YEFD,\Z2QA!\VV8PEC(-I09P% MQ6,L/2I-2C&]G??\3&6&I4FI1C>SOO\ C^16\!_&;P[IO@W0M \6^&KS6D\. MZD^J:5-I]\+8[G*LT4P*-E"R@Y&#VJC\0OCE-\1/!=]I-[IP@U"\\3W'B*2X MCD_=J)8A&(0N,_+CJ3S6CHNB>!=!A\/PZS%I.J7L]Q;IJ174W>."+?Q+]C&;GRN]_UUMK\SS_X9_$F+X?Z7XUM)+![T^(= M$ETE&60)Y)=E.\\'&;3EEN#);EDOQJZS@]=?T[FYX6_:PT_P_X8L+!M"U-+E-/NK"\A ML]12*SNGFWYNI(_++R2Y?^)R.,]:\D^*7Q$C^(DWA9X[)[+^Q?#]GHK!Y-_F MM K R#@8!ST[>M=]I,/@+4VU 6-GH6DM=?:K2V:]OY,0P2WEM##*_F2_ZU(C M=.2.,;3MP":S?'4/A+P_X7OGT(Z>E[J%A#:2V]K&+)+K37\.0W<4MQ'*]*TGP;=Z;:6DEK]LB?SYYHHTN6GMPVY761YF\V50$$:[ M6X3.A:P>!?'^NC7+R/0]*-W=RO-:27C*HCENB(W=7N8\%$CDW!&&!+$1&11+ MV=O>CIJ_F_Z?H.7LN6TH::OYOO\ >_0S[C]HBVGFOY/[$E NO D?@X#[0/E= M0G[_ .[T^3[OOUKB?BC\1(_B)+X6>.R:Q_L70+/16W2!_-:!6!D' P#NZ=O6 MNXT?P_X!OM6CM@NC06T*(\TUYJ#,S--<2,HYN8E*0P;%;82V[G#<@6-/TWP3 MH7B33KJULO#U[I@F-Y%)?:N6G,B&67R&C$NP1@(D69 -[,K!F#8IQ=*F[QB[ MK^NX1=*G*\8.Z_KN$W[2T$W[0&J_$;^Q)Q:WMBUH--^U#$&X(LY&,;[+EV :X:!54I$X56!W'<:DET?P1 MJ&ES222Z/'*L<,$!EU%Y(X6,4.]$3[0LB*)I)F#%95*\$IM9CFXT&DN1VM;Y M;6W\R'&@TER.UDOEM;?S(=._:*M[*XT*5M$ED.F^#[CPPW^D >8\F_\ ??=X M W_=]NM:_@_]JI/#>F:/I+Z5J$6GP>'UT.ZN-.OA#=!EG:5)X7*$*1N(VL"# MG\*K^(E\&ZE=7=_;VN@3^5=M-)I-QJ[PVD,3SW.]HMDN7?RH+48BW(-%UC4_".LVMG;A9-7,FHP MM;.SI*)G0J=S.^4"A1GCHL[$MQ'NS;V_DHA@0;OE926!&3GI61IOBJ?2(_#FHW/B*"71 M%DNM0UVSGUF&[N+UO.:-;66-6W3%H8(5#E-@\S=E1G'@%:T\/2J/X=O-^GZ( MUIX:C4>L=O-^GZ(^GK[]K[3F\5>#-470M3U7^P+Z>]:[UF]AEO622%HQ;)*D M2_NU+;LON8D#)XK%\$?M.Z;X1^'8\/MH>J7;"SGM7TZ;4EFTJZ:3=B9X98V: M,J6SMB95)&>,FOGNBM?J=&UK?UK_ )LV^I4+5![,YPH^I/8UTU*D:<'.6R.JI4C2@YS>B.?_:D M\5^(?&7AKX5:AXE@>.]&B2P17$ARUU D[+',1U!(&.>NW=_%7S_7VO\ \%1+ M&WTOX@> [.TA2WM;?0S%##&,*B+*P50.P %?%%9X*2GAXR2LG?\V?C>*FJE M>VDJXDB+#E7EDKIG-&][HL:C\6/#FJ2>%_#OPY\(Z?\ #M8=;AU-M:Y\YV;8A%VE MN5CDV B+;D!MS>:XTF[N+=E^>^IM[W%[C6H?"?P\BT33-0\*W_ M (;*OJ1FNG>Z*DW,TQC'F%=H C"J,?Q5N_$?]L2[^(W@F^TZZTS6H-=U"QAL M;J=/%%V-,PBJKR1V";4#2*OS!F9>$-/\ B5XSF^T:7_8RZ>]K M:3>0R1OYLD-O-)%&SM\XBDN) H8C*G:,8 H^-M/\)W6M>&]*M_['TN235)HK MNZTJY:>WAT]GA6W,DI9@TB@3NS#G:R;N05&WLZ+FFXN_?7U)YI6W'?#/XRZ1 MX9\!:KX'\7^%&\6>%[S4(M7B@M]0:QGM[M$,>\2!'RK(=I4CW!K:^(G[4%]\ M0M#^(&G7N@0VA\4WFG3PF"X(2PALT*1Q!2N9,KC+97D$XYP-R3Q9\//$GC27 M4-4L]),=W<6^H7-W*TAD\V75/.= -VW9'9;H2@'7'?&+VH>(?!_CBV;6_$=_ MI&IWO]ESJ8)IRDD<[6\E[L4M*&^:YNFA!"MM-OC>H(#2^3FYW3=_^&V^Y=AZ MVM+M)UJ]M[UA%K#6#1M"&"C*Q.3][U%;^L? MM82ZE-X@MX/"MOIN@W?A)O"&E:5;7C;=-MS(C^87929GRIR3MSD<\F MQK\-M-D$$7]@6PN[7[#=2K.KF".74+=&8!97!=+=9FW*[DB4?,VTXQ9KGX=W M$TFI:I%I5]!"O^%[> -5\(>'K3X8VVFWN>(9+N"YMF4+(F6 MB78?+\Y0 #N,@'&*U9?VO%\/_%KXAWFG65]-X-UZ.#2[2'2-2DTR[MK6T(2T M>"=5)C.Q3E<$'>P/?/F]O;>$]>^(6E'&DZ?81:/%(9/AA8:I<6]K::/<6]U;7CRW4BW=?K???T!2=M&<%\1/BR_CWXG0>+/L=Y#!:O!Y%IJ&K7 M&H3!(B"%:XG+,23N/ "C=PHKU7Q?^UIH^H:CXP\3>&?AFOAOQ?XJMIK"ZU^Y MUF6]$4<@"RB&+RD5'*@#=U%(99Y7T>X:>5M/@ M14M))6+$&5EGN6[$$X(7 5>DN]6LK_QGJ&GZ_P".+"X\$7UW)_9WAZQNA+9_ M9HDEDM!G<%M%WI!%R4DQ+)N*#R\,Z?X=CN]&U^2RO(_LN?WJ2+&4*R9^:-T<<#!XK?7]NBZOM;\537 M_AO4+32-:N[:^2/P]K\NF7D4T,(B)DN8X_WHD51O!5>0",$"N;U3Q5X.\,^& M?$RZ%/8V]]<6[H]K:.2DDXM5M #FZ-*2YO9^6[] M?T'S2VN=1X1_;@;PWF6;POJ,MRGB!M:4VGB6XC%TA5%6"\>19)+D(J *7?'3 M*D#:8? ?[:D'@6SOOLWA&]:XFNKZX^R_V_(=.NOM+NP%U:M&RR% ^-T?E[MH MR*P/$&G_ V\,: CQC0]=O\ 3DO$00SMB](BAB@D94E9B'DF>< L"/)8$(/D MJ6:'X;:OJ%]);Q>';#^SK^^6&,.X2[A7[,DRP\ ME_#=GZ_YCYI=RP_[8UW=?#.P\/W6EZR-7T_1!H5O[L]/,2J5CFDLXMH M>54^7E]K8&X$#%?.%?4MQX!^'UOS6&FVG@R:=P^H//*;J S:J8(3 -W, M:V8\]3AE<[^6VX7QWXR-X9CU#3(/#UG8VLD<#_:O[/G\V+F0^6A8.ZLRKC+* M[9#+D[@PKIP\J:;5.+5R)7MJSSRBBBN\R"OT;_X):>)/%5YX:\6:-<0--X.L MIDEM+J1B/*NGYDA3U!7:Y'\)(/\ '7P!X'\%ZK\1/%VD^&M$MS=:IJ=PMO!' MVR>K,>RJ,L3V )K]M_@Q\*=*^"GPWT;PEI(#0V47[ZXVX:YG/,DK>[-GZ# Z M"OG\XKPA1]DU=O\ #S.K#Q;ES'Y'>6W(VG(Z\4>6Y_@;\J^UOM26GQ6^,DTA MPD?B,,?_ M*O>#?&5MKL@N[49-M,"5)ZX.?Z5$N+I1;_V?1?WO_M3GP_ : MKTHU/K5F^G)_]L?#;1LO!4@^XI I)P 2:_2#XN1V7B+2[?6M3T;2[[R2%Q;2 M^=*!@GYR!C:,=P>M74(K?*?9;,1B1]O";PO!_E7++C M91J.FZ&J_O?_ &I\SB^'%@G:MB(KY:_Y?,='L;G5,/;:.L(8*I. K-@L#]>_>M67X"W&N:Y9:E>:ND7/*9NG[2BW)]K)?^W,^!O*? M^XWY4ODO_<;\J_6">UANH?)GB2:+NLBA@?SKDM'6^\-Z])93-+=VE^;;UT/7H<-JO"35:TEK:V_H[GYF>3)_<;\ MJ3RW_N-^5?IQXZUZ/3HS;O-/$GV>24_9MP8L!A067[J\DD^P[9KG_ VES"ZA M@O;I=0>-V#Q^8S80A_O(R J!E1R3G)KTEGCY/:.E^/\ P#Q998E55*,[_+_@ MGYT>4_\ <;\J/)D_N-^5?J%/HL$:O:3R7&HJ\?EQ6Q; C3=G.<]00,,>1@5' M'<1Z!>+]J#374J8626VQ]L>.V#?"#D/(XP!U( /S<,.:^8K>)#PVE7!VOM[]T[ M[?9O^#L>PN$.;:O_ .2__;'YZB&1NB,?P-'D2?\ /-O^^37ZJ?L[ZC)J/A?Q M"9@BRKXBU!V\L$*3+)Y^5!Y /FY /8BO5*^N7%-]?8_^3?\ VIQ_ZL?]/O\ MR7_@GXK^1)_SS;_ODUVOP>^%>I?%SX@:9X))WWW5SMXMX%Y=S]!P/4E1 MWK]]OP-*?#,8S3G5NNUK?J9OAWP_8>$]!L-&TNW6UT^Q MA6""%?X548'U/J>YR:_*3]J#_DX+QW_V$G_D*_6VOC;Q+X0T'6/C/\87O]$T MZ]>'5=+\MKBUCD*;]/#/@D<;F^8^IY-?,87'+!SE5FKW/U#)JL:-?D2W5CX* MHK[AM?"/@F]N)8(?#VBO+']Y181 ]9\.VUW:>&[;27MHP7N[ M;2X4C/ !W97#<_SKNGQ)3A%R=)Z>:/K,9BWA8*48VEO(TREU^T2K&)N3SM 7\@,<54TE?#7B:YFE\+?"31=8T:WA^!].T6.292UO);PG:,E?!/P:N@VMM?^#_#[W?D*DTT>F0!M MV,$@[.N>]>K2S6%6@JZBU=M6>^CW]'T,:?%M*=5TW1DDNO0_,.BOT>B^&OA# MP_KQLKWP9X?;2I&)2\N=+@SDKG&[;CJ",8K>D^'WPUCN!"?!_ATDG;O728"F M>N,[*QH9U3K\R4&G%V:_KIYGHXGB"EA>5RAI)73NOZOY'YAT5^I;_!SP%(C* M?!7A[!&#MTN '\PM84GP.\+!9[8>#O#\MJL;J)O[.B\YE88 &%X92<[NORCU M-57SFEAZ,Z\XNT4WYZ=O/R.>/$U.4XP5)ZZ;H_-&BOT2UKX3^&/#NCIA^9B1UXYF/P3\+-HMK+P_%>:A(RI&)K2$1 MDD@ $]1UZU\S+C7#03J.D^2U[W6NE]M_O1ZL%__!-;_P#Q%=']M4_Y&3_;M/\ D9^/%%?L/_PH MWX"/#M MI>6\BRPW$&E0))&X.0RL$R"#SD5V%>9CLQ^M14(*RZGEX_,_K<%3@K+J?FE_ MP52_Y*=X+_[ [_\ HYJ^(:_7GXU:+INM?M*>%(M2T^UU"(>#=9?R[J%9%W++ M;;3A@>1DX],FOG7XD>"])M?&>@+%I>GVUMEZ7X(\'7=Q+''HFBW<(4%#)I4"N?7^ =/I2CQ31EI&G?YHFKE\8 MJ4J5532WLG^ET?CO17[ :IX9\"Z?=&V?PQI,DX4,T<&DI(5'J=J<5IZ3\/?! MUW"LR>%M&,3*-EN?C917[2?\*T\(?\ M0JZ)_P""Z'_XFC_A6?A#_H5=$_\ !=#_ /$UZO\ :L?Y/Q,[GXMT5^I?B;X> M>$+V2XT^VT*QBNI;M_*N%TY6"($9\*$7]$>Y6:T58G<$C&6C#*=I'S;?J&QBN/&Y]3P-*-2K#66ROU];6U%AY+$UW2 MI[+K_P _*2BOUA\%>#_ EX?M]-N1I^DZG>-,(;G2;BRMV+DG]X2FTF,H,G M(.#CN6S7<:7X \(>"_B++I]_X5T:71/%TOVS2KB;3H3]GO%A!ELS\O 9(S,G MN)AQA0?'RWC##YE%\M)QDM;-ZVV3VV=F>K4P,J;U9^,U%?O%_P *J\$_]"?H M'_@L@_\ B:/^%5>"?^A/T#_P60?_ !->U_;D/^??XF/U9]S\':*_>+_A57@G M_H3] _\ !9!_\31_PJKP3_T)^@?^"R#_ .)H_MR'_/O\0^K/N?@[17[Q?\*J M\$_]"?H'_@L@_P#B:/\ A57@G_H3] _\%D'_ ,31_;D/^??XA]6?<_!VBOWB M_P"%5>"?^A/T#_P60?\ Q-'_ JKP3_T)^@?^"R#_P")H_MR'_/O\0^K/N?@ M[17[Q?\ "JO!/_0GZ!_X+(/_ (FC_A57@G_H3] _\%D'_P 31_;D/^??XA]6 M?<_"B;5KZZL8+*:\N);*W),-O)*S1QD]2JDX&?:JE?O%_P *J\$_]"?H'_@L M@_\ B:/^%5>"?^A/T#_P60?_ !-']N0_Y]_B'U9]S\':*_>+_A57@G_H3] _ M\%D'_P 31_PJKP3_ -"?H'_@L@_^)H_MR'_/O\0^K/N?(O\ P3<_9U_X1OP[ M+\3]17IFD^'Y+[XG?&:^BD0&/Q0L;( MYQP-/M3D'IZ]:V+.Q:34+:&6(XD=>,XW*3U!],=Z^?Q"G=Q3LF?7T:'UBA2J M4JS@X)IVL]'OH^NFCZ:G1^";N]\<:/EV\4>CV45W'-/!;PK\PS@KN_AY/+\].]&U:_MAH31[9B^00#S_G'O587$.G7ITZ:O)O6^WY?B>-3E1BE3HI6_K^KFY+\; MK"+XAGPL;*4N)/*\X'^+..F.F??_ KT-?L\UTDJJKRJG$F 2%/;/OC]*QM4 M\.Z18W[:Z-,ADU-2,3D'(/K_ /7JOIOC&V&H6>EM$QN9@Q_=#(55'+M[9X]< MU^AXFOAU*$8JVBW[AA:&(A2G5K2NKV5NW]?\.:FJ>'XM4D9G\EU?&Z*X@65" M1T.#T/->F:\=\02/;>#]*BLY[65])\Z_N[2_W(I7<=C'CYMI8#:,Y MSCFM:;YY*%S&O1G&FZT-%M?^OO.RAU^QU#4(UT>Z9KJ39MC#'6:FWDO76:Y^S(R74)FPZNN<,,]1R3^->3VNIV6B^'[33?$5E+;WZVZW, M%Y9KYDP+9.YCE2H^9>#V(Z'!KT?2]>LO$G@.*]FN ^IR0%)?()W2;W]>?WHS-8\476C,SF>QFNH"YCC7=&XE*;/ ME#?+* 6Y"\^QZ5H27E\GVNXGT_RKJQB)+>6JO(77Y0RH2&VD$\'G QFN>\* MV/\ PD'B#3+BUN9$:!FQY\6]8V&3C&[/;DC;T[UZM;V+:/:R>4/MMU,WF2R2 MH&,C$C)Q[#&!V %>/Q!R4\NKPLF^5]+_ (?H=64WKUJ=35+F[_UY?<<7XA\0 M7UO<1)H6IIX@B5%5WV0R>6H'RG*)@9YZ^E7-*USQ)?/I]O-H%K,]LU%XD\)^(=8NI[JWEOEADD&R&T*NJ?(H/RF5-G(/&#ZYYP&^ M'_">M:''Y_B&TU#5M/W;8DG*,(3SGY3,P4MQ\V!C')YK\8IKZKS.$92BI6^2Y4_70_27[V_3\3T3X4!XM?^),4B[''B))"G]TR:;8R$?FS5Z)7F'P MACGLO$WCBTNF+7)GL+A]TGF'YK"&/E_XC^YQN[XS7I]?JD/A6MSRWN%%%%6( M*^2M6RWQF^,R^NJ:1_Z;17UK7RI<:9P>&?&?B)]2N?):)]J0MG?)GH5'?M7O'A/Q/I'B# M239.VI*YC(DMV^:/KW4\8Z5SMSH]E<7B7,]E#)=1_=EDC!=?Q(S4NIZMK_@K M7KZZLH[(VWEQ^==S3 2RC ^0(1D$=._05X&(K33YYR7+UTZ'?C77P$$L353@ MV[*SO9MO5JZTNEM:Q+XT^#>C/X%UBXL;!K[5I("T!NIS&L!SDE.@ 7D\]<8[ MUQ?@?X+ZU'HKZ;8E.H;RY5VLOL1ZUQ'C;X1Z% MXNURWUS4&F2:U 9EC/#;:_3,-[!M>U;Y;=#DQ'UCD7U9)ROU-;QQ-;_8;-W2 M2X"R[]L# %H\$/R3C&" 23T-<1X6T(7EY-?PP3JEZQE2'R#Y<>6; #*^T*,_ MQ#D#CBO0]/6TU13Y?FPO"WR;&(**>P]CBK]O:PZ;YTSS,Q?;NDF8=!P!G\?U MI4:L8TWRKIQTK1T^^CU: MU6?3YUD656$6J]1+$3H8A0FMGZ=>^W3R/7M2UF^;3[O[196NHVVFW/WI;AQ+O$8 M8E&0$C"N1W)R1C'7EAXPT'6+619=*A@##B:/4+HR(>Q&(ZIV=]!KW@UM0$8N M[R/4_LEX;9_W,X6,E7()V%3A>6!S@ =JR5OA'=*G]DV\$+';)*UM;D1J>"_R MKV&3^%?B[CB,%!4\9K32MR\T6]K/7=W\K/MJ?=PE"LE.GUUN>BZM9Z=)\*-* MUBS\Z6:76]$>2>ZE,K[4U2WPH.>% 8D 8ZY/)->X5\^:Q>"S^%NM6=C=KJ&D MV"V5Z)U"8@D2ZC?RPR *?E0-CJOT9TUR'[-J5FEPJ-D)*O*M[=P:]'\7?\G?> /^Q4U?_P!'VE8'Q$\5 M:AJ_C*^M$F%C!:HGEK##&S.I9QO9F4G.488' Q[UQ8B*DKL^ARN?,I4'!2C+ M>_\ D]SDKKPZ=#T6QDTW1/[12&[ CL[7:K!L [FR02IQCO\ 2NQT;XC:E?Z? MJ$EQI45K=63*L]N6QLW'&6RA<-@ M=P0>G'4=GIWAOPYX7\*V]]YTLEE+Y=SYTCEGN6(R@P!\V2>% ZUX=2E5YKT6 MDGO]VG3H>9FE'$T<1:,$H26EDO1;*]U]P>1JDGB2&[-O_9<9'^E2"8213XP% M4#C!Y/.*[73QG?ZUQS>+-%\1:?=6U_%/9!6\N6*X3E&P&4[D++G!4CFMCX?7 MTE_9W:/*US' [117+#!E08(8^_.,^U;8*4:6)4%*]W?=?DMCY^<7!N$MSI*C MN%DDA98G$>-]!U)9+=9K5S@R0B&:Y=U[DN5E0>^TUW_B2UEOM0L;6T2W M^TNLDK/<9"K&H4$_+@DY=<#(ZDYXK$7XO/8ZQ#I5S T4UH52X>&6,P]CG<[* M>5*G&#C/?K7P7$6)A%T\/S-S3NDE=VVNMK6OO>_D?286,)7JPC;FW]?^#VM9 M'3> ]5:ZURTB755UV*ZBDEF5DA)MPNW8V8T7 ))&ULD]1]UJK_%JTU2P\#^) M-3O)=RZ/Y>M6C,P8B2VF6=2HSP"$*GV8BM_PKXDT[6M4=-/U-967][)"MN$W M*3C.['S<]P36#\?M,@_X0?QE=3W\48.A7>+=C^\8^0X"@>Y_G7FTZ56A2H3: ME*4)I:RC&Z:M=ZNZ[+>_D;-J3DNZ/7P<@&EJ"Q5UL;<2\2"-0WUP,U/7W1PA M1110 4444 %%%% !1110 4444 %%%% !1110!\?22[?%_P 7HB-R2^-[<.IZ M$"PLVP?R%+XG\2#P/X?OM8LWEM1;@2O#;X*2$D#E&^7G/)&#[TV2&1_&GQ:= M5S&OCB(,WI_Q+;8C^5>,W)N/17/HXU%0R MBM77Q1C)KU2;1-:_M@_V#<7%]H7AZ"WU.[A5+B>ZC#Y8>A# D#G&?RKC)_CA M!:SO>Z%+JGA^ZOP)-3M;01FV>?'S21*3E,G)Q^6!@#YV\474MKJVFRI(R1Q! MI'56(#*&3.?P)JCI>L7-O-=SE]XGN;W3\7U/K+PE^T5H_AB#28%TB]*V4DDDEPKJ99M M^<@\XQ6IX>_:DT?P[XFNKZUT:]ATZZ=FDLXV3'3AAEN&SG/:ODIO$%S-<&VA M:"-FO)+=9G!*JJH&Y&>2LT:OE MH^!R.G'7OVK@_P!DW0;>_P#A-'<%I89_MLRF2&0H2 4(SCKC^IKU:/4I]#O6 M1[@W6FHXC9G&9(R>!SW';UX[\D>OAZLJ5.%2HO.Z\W<_1,NKU:V#O+52BK]C MR#QQHNGZ]J6IZA%+&T]W=PRQNRNDT,:Q%&C)(P/FVD8)Z5N:)8W4EM+_ &6] MO8,+5K5VD=464ER1(@LXS'EC@%O:O.-2U MN6/4I=/N-,AU6]\PPV\'F-%;P8#X4I@@%M@(ZYW@9&*^HI2G42OLCQZ])1J6 M6[^7XZLZKPAX=^P[98Q;1VB2/Y:P(ZY(++T+LH'+'Y<9SGCI6UXDM;J^TBY@ MLYA!1WD;]SAV8J!C,3*"5![%2, MKD'->I:Y)!#IL\MU+Y%NB%I),9V@ M<>)K&&^U FP^P>&?(.R1)9(27& 0,1;Q@>Y'7I2:';PK?6IGU^WO4B>E?ASKJA2E"E'FYHMS6KY; MZS]Y66FNWH?H?+S--Z=OT._^&]Q:R?$OQ8+*;[1:3:/H]U'*/XU;[6@;\?*_ M2O3Z\G^&T8@^*FNHI8AO"^C99@ 6<76IAFP..2<\>M>L5^J824)8>G*G\+2M MZ6/*E?F=PHHHKJ)"OE^?4Y=%\?\ [1]] <3V\FE2QG&?F73E(_45]05\JZQ\ MWC;]I!?[TFE+^>G"HG\+.C#_ ,6/J*S31;9$G^V,HYBU F0,?7>/F!_$C_9J MQ;Z/I/C[7K/5=1M7DGM&:VDMI)24C<#<,XX;@J0?0C([#F]0\2V6F:A!93R; M9IN@J]INM7.CZI>6MK:17=Q>B.2)6=LKM!4DJ%(/;^(5Y+ASJTUHS[/'82C6 MHN,E=>>R\]3T*\UC2-!:=XU#3RE1WFFWGC&P:Q(LK*3)C23H21]W@CG(X!'M7C58U92-O(QQD>HQZM.1Y>TIYF_P"7;ZYKP_X>B[ M=]^^YPT7IS,=I=G'9P%4CV/G#\YR1[^E56N))?$AM22;=;;:ZO([NUN?LURJ&/)0,I4\\]^N._K7IUHR4%R+9HWE-SDYO=Q#%L?[/M7MD^JW>DWB+J,<5Q;9_X^8A@Q9.,LO.!SC(]/>I9_!F MAW6^0Z?$&<NC#8E0NH].C_KU\MR,='ZVHW7O6M?OV?Y>>AY'\ M/;.QT70KZ./5+I?$+.!%9PERKH$4KMCPV\;MP)P=O/3OUWA_5?&\#,8(;M'( MYW:PP\ =PQ]:]; MT^^BU*PMKR%M\-Q$LJ,.ZL 0?R->20Z@/!_A/Q'KKZ<+6WCL1:)ID+QO)>73 M,4B4!&*AF9TC7G)+D>"-#E\,^"] T>>02SZ?I]O:22#HS1QJI/YBOK\ MMDYX.G*5[M=7=_?Y;$5-)M&W14%Y>6^G6DUU=SQVUK"ADEFF<(D:@9+,3P ! MW->$W'Q:\8_&R]GT[X46\>E^'HW,5QXXU6$M$Q!PPM(3_K2/[S?+VXX)]FG2 ME4U6B75[#IT95+M:);M[?U^)Z=X@^+G@KPGKG]CZYXHTO1M2\M9?L^H7*P$H MV<,"Y (.#W[5U<,T=S#'-#(LL4BADD0@JRD9!!'4&O"-*_8\\*KXPT?Q/X@U M;5_&&L6>^2>76I_-6ZERIC)7HJ(0V$''S#).,'WNJJJE&RIMOO\ \ JM&C&R MI-OO_P ****YSG"BBB@ HHHH **** /#_%O_)W_ ( _[%35_P#T?:5QOCRX MCCUJSNMZAC<2VT@_V7.5/X,H4?[YKL_%G_)W_@#_ +%35_\ T?:5Q'B+PY_P MD]Y=*LH256D\O=T#[B4;\& /X5RUK.R?F>_E5TYSCTL<]=>*+&SU9-.EEV7# M],]*;,M])JEI:2G4+^T@B*V=O:L6D0="%"(Q10"!N"EL$#>N.>:U[P6WBC5- M,UN M!(%5GB8\J>X/N.A^E=??6:W MT>WBFSE&EE3>(UQDG;U;) XR.V2.M< MW4UZ?I* 73KZH:\!T/4K/3=1@%CIW]L/;MF*PC=8OWH.=XAA60+ MR!@R2$ \\=1['X)U2_OO$&I)>K%!#;A56-3DH2NX@MWP",USTZD:=:*UU?Y' MYOC*2IU;=_Z[M_>;U%9.O:\FGZ+=W]H8[ORNA5\H.0,DCL,Y-6])DNI+&-[Q MK=YVYW6Q/EL.Q&?:OK56A*I[-:NU_*QX91U/38M8U)(KB&39"F]9H9FB=2(?ASX=N+*TGN9DL]K[!)>7CD,QZ<.Q!;KU'-:>H>(-+T;4A; M3&;[;)'YFR"VEF8J20#\BGNI^E<[XC\5:-#-+<3_ &34DDMA;)#)-"DL#;F+ M@I*RD!P5!_ZYC(Z5\IQ%3HK"2JR7O+6Z=I::[K4]K!3DZB2VM\CM/"OA?2?# M6HRM;1W,\TSH#(]NBHI7."NQ%4=>O? YXKE_C,-)A^(WA.\\0W4Z^$K=VEU% M8US#'=*8S:/:-8\G"I' M%(RX48&".W2NITSQU9:-;S7_ (N6_N]8GG:VL].:T59;R38%6)(@JERW)Y4 M#);@%J^>IS=2E2E*,;RJ1TDN7H]59ZRMM<])JS=GT9[FCK(BNC!E89#*<@CU MIU*OC'/%M,]OXWMFC5VVJQ M>QLXB"<''$C'IV%6)KS['(L=[&UC(QPOG8V/_NN/E/TSGVKSJ[DI.W5'UF"H MTL7@)X:J[*=U]ZMIYGQKKWP]U72+CRM5TGR9-A ,VP@J>" 1R&)')%>0>,CXA&AMK&J:%=".T$<$FIR,8)2VXJI"L!P2V M,!3@G!;O7E3G4@^2%_+M_5S\?S/AC!8&+="I4=MKVMH]=4NF^R/)M2^#6KZ8 M(K*XT.W99AYRQ02PS*<<;CL8@>G-/;X.Z^WEQOX<8>8@C19%0!ESPHR>1GM7 MN7@'PK!=7"/I_P#:&JR7,<+7+01H# L@RC$9^IYQT-=OXJ^&FJ>%_$'A_5M, MOM0U287R2WDTW,4<2G<[.,],9QQZ\YQ7''%8JK>47[O?7YO='A1R6\>>3GOW M7^6K/FV#X$>,VL[[4H_#Q$,'%S-Y\*D;1G!^?)P#5K4O@#X^T>#SKOP^T2$J M!BZ@8G<<+@!R3DU]Y6OB*[F.PC1O]$M7<;8F[LW]Y^W< CWKW(815HQ5-N\FE2WE=6W< $XXKZBCAXNER=(Z/]?S M/7H55AHQP\=5:RVOIMVWMT\CT?6->BT_3VM+J2%8H_\ 1V\Y-S3.%SP-PVC' M.2VN?+,<>YHT9-OW,':"3N.XY(R,<'(ZW=JQKTO9^SIQ2T_K^M3%5%.I)O6R_7^M!NE^)M.CUB9A=MJ4T;>0\KX M5TZ9P@4 9([\G'T%=3X@M8[S1[J&7<$:,Y,9PP]"/<'FO)M/^UZAQGL#7I.H>*H8],O)/(EANX(C*+6X 4L.Q!R05SC M)!X[USX^BXTY./9^?X&N7XCG=I;W//O$VK6&L7$AUS4=E[:OA(X0L (*@ECE M),Y!'0CITJSX%D@O-267P]F:]M6Y:XND\DAE8 ,%@RW?CH, \]*UMY8$W&GRR0?, 0P"$$X ;@D#IQ2:+-I.K7$=I:Z?+I]U<,0MT-2 MEB* *6.?E4'A3QG(ZBOPZC&K*E_L$M4GS[*[5^;3^9ZV:=DS](=O^7B]#L_ ME]<:A\4;NZNH?(N+GPS9;H^.-EW=C'''\?;BO5*\M\)Z>-'^)FFVJR1R1'PT MZ1^2VY0L=TN%!]A(!7J5?I&!DY86DW?X5OJ]NK[GFS^)A1117:0%?+]Q,8?' MG[2&.KRZ1'_WU8(#7U!7R[<6LU]\1OVAK>W4//)=Z-L0D#<18(=N3TSC%1/X M6=&'5ZL4^Z//O$W@5]<\46.I+)M2'&X9]*@^(FN-I\D=LDD(5H"S&<>_2L+Q)HMEX@T_4KE[*VU&Y MTT[%@GM/-;=L5LA@V<8D&0!GKUKQ:LYR@HWM8^WQ]OJTO9RLY=5=_EY#_@OJ MB:=8RRSZO_:5TT3[ +:VE=AH(/3!KSG'ZTFXRLK6_K^D?F M5:K"M4:C.]EW;_/4G_X2/3-$M[6UN;II9!"K/(J,^%QC>Y . 2.IKD_$$,J^ M*KO5-+G6*\M;9;F&. QW<0)\Q7(ZGL/3KZUH:QX1U$1RV6BQ6MOIE^%%QD! M6CP?FQW((QZ_K6KHR^&=/U::RT_R8KUU\EU0-AMHY7/0D=\JN[/1?S='TU[['GO1F]IFH1:MIUM>P',-Q&LJ'V(R*M57T^PM]+LH+.U MB$-M"@2.-VY(R33DFN+F M69%V21^7R>W(.?J,5AZ-KQT_3[6WN4 C\SR8Y6D 9UW;595)R1C;DULZ9-J- MTSR7D$4$#+\D(.Y_Q/3U_,5YEJUTMGK.GW,UK)=6C+YW_ /5!?Q:693JMRSVDW[N." M,-*[-]X8103P :KV_B[PA872%XKTOVW6-PQS[ KUKE-0AM+K2D6[_M"46VP7 M%S:JGE))L!8/N.7 # G:I[=Q6!::;X9N[J*1-1U&OZAI*WGA.4B]@TVT\1VL^H MK>Q; D1AN$M9&QD%/M30<]F"DXQ7NLLJ6\3RRNL<2 LSL<*H'))/85X]HMK8 M>*/!?BF35Y5O[&XTF:V:3RC'&ML5?<-I).X]22?X1C'?E?B+KVL_$30_A]\* M[*YDMM8\3:9!?>(KN,_/:Z>L:^=]&E?*#\0>M?>\.QIUL#2C22BE>]DTE9OF MWUT=S*5-U*[BW\_+O]PJ1WG[6GB*5Y))[+X.Z7<%$CC)C?Q%.C*M!\/7US%HVGZI M8>&])T6\U.[N[QTN;D7<2EO+4(5W [CEB!QWSQW&C?%[Q)X@\7:F++0M,/A3 M3]*XMK8 0#S)$5<*",8.3[UVX^#W@U?&#^*1H4 UQY#.;C>^WS2FPR M^7NV"0KQOV[O>MZDJ4;J4&G_ ,-Y][G14E1C=2IM/_AO/O?_ "/&K?\ :>\6 MW7AGP??'POIT%YXK6>XT](WN[M8X($4R-(D$+R;F=@%"@@ Y8CI3_%7[5VLZ M'I&G:E'X6CMRFG07^J:7>?:?MOZA\&/!FI>& MM(T&?1$_LO2,_8(XIY8WM@00P216#@$$@C=SWJCJ7[/OP]U1(X[CPS;B%+2. MQ\F&66*-H8R3&K(CA6*DDAB"03P:I5<+>[@_Z^?8:K8.]W!_U\^QQ=]^T=J& MB_$Z^T+5]%M],TB&ZFMH)+CSUGNECA,@EA?R_)?<5*B/>&_$8KG--_:VUW_A M%=2U_4/!CBP.EIJ6GRP1W4<(>2:.*.":::%$8GS5;?&67"MCM7LT?P9\&1^* M#XA&AQ?VH;AKLLTLAB,[*5:;R2WE^803E]N[D\UAS_";X7>![6:*XT6QLK;7 MBNC>7,,Q$:LPR%3:,@'L*4:F&T7(V]/\ @]11J85V7(V]/^#U M,WX1^)O%VJ_%KXA:7XK>UBDT^STIXK/3KAYK6,R+.7:,NJL"VU<@CJO<8KV. MN#^%_@WP9X9DUJX\):;)8RMW+* 6F)+A=[ .,@@\$@"N\KDK M2C*=XJRT_(XZ\HRJ7BK+3\@HHHK YSQ#Q9_R>!X _P"Q4U?_ -'VE:^L?"V[ MLKZ6[TV9;F-G+^2WRNN3G /0_I6/XN_Y.^\ ?]BIJ_\ Z/M*X_Q-XV\3:MKV MMI:WXM;6'4)88E9W)0Q2%5.!@#[N<=QUZUR8AJ,;M79[&7K$.4O8-7ML^IF^ M(+6;PGK=];W5G=+#/,UQ$88'FPS_ #2*=@)!WECR,888Z'&3JFI6TU@RO%*Q M8J4MY[>1/.(8'80RC(.,$>A.:OZQX@UC4M6M;S6Y+8P[QON;-&0JQPH+*2?E M/=ATSTQDCI=2\0G3X(H3##>W,S$16S2LC''5F/0*.,G!Z@F V_F;ALW;U^5BNY6P-RG&0<#(( M-=#H+;=2C-9>QC42A+^O,_.91][E9Y]H^@/XIN=:NK877AZPFVPPV\*B-6 7 M#,RXP>O_ ->O0K.UCL;6&WB&V*)%11Z # KE_B]9Z[J7A6[B\/.RWYDS\APQ M7!X'XXKS3P[X>\<:#HD>I:D9WOQM!*Y=U0=!\IWCJ?D(:,_>;'2OJ\/@*>!P MSK\W-*^O?J]NB]#QX5'+$NARV5KWZ>AZOXF\$V?BB4R74TPS&(S& C)@$GNI M(SGG:1G ST%5]@420C!Y+;FD<%AMX! ')Y%3>#_' M6OZ[%*HTF.^\ERC2>>(V;V0A2DI_V@4&>,#K7[ M@C(R.QYKXK/L5@)KUC;0S7;1V-D5A4_O7 RS$(6"*,N2P! !>O1/!?PQL] U)O$&JW+>( M?%LZ%9=8NHPIB4@9BMXQQ#%P/E7).!N9SS7)?%6XGDLO"]FE@OGW7B#3?)8. M 08Y5G< =OW<,@^F:]A@_P!4OTKIRF$>5W2NO[K6O?7]/U.JJV24445]&K M:]X.\=:3X@%A?:]X4\LV]UI]ON6-9.>2X!"L=R$$_P#/,K_$*T_@;\)=(U#P M+KVL>+]*O]*F,JR6M_/OMS%"J(#M8@$Y?><$888..:X*D7->=CYG.9TZE:>' M4$W&]VULM'H[O>_9;-#?APNK:1?:3=Z$DB*J00:I:%3,LD*%EW*P&>GS*#R- MQ!/7/KB7VN:CI]RR1PWOF/)!+92IY;0@_=).>1M()!YYK)/PR\,:KHEE>:5< MWT6F1V2QQKI\I!GC0<9R-S-QWY)K)^"EKK=KINH7NJV^I1F0RBSEOL!O(&-A MD!.2_&.1T [5XT*%9?7J?(Q;ISY;:.[T>G_ /9=(TU=/L;&":1;F M[MH!'YY7#8X_(' _*N-^,GP]MO'>CV_VC4O[-%LQ.\YP0<>G.>*XS6/'EWID M-QK-]J MH[.%I);@1JNV-1DD[1R !TYJG9_$1OB-H-EJ5IJKWVFS9D@FA!AS M@D9X"G(((Y]*_6\/E^+PJ3I.*:VU;\M=/Z[GS]?,L+B*;C*$G%_GNM;FNVBS M^![6UO-/74#'#!)E9I!''/*L1(+H.2HP<@^E6!)&#T-4&8E6 M4$JC-N*)\JY]<#BM,/@,72J2G.HI7=_P]--;LXYX["NFJ<8M*UK:>7GY$OPE MLVTN:QMY66=+N?8]G*H="FT;77CKU)[_ (&O7-6UZPM4<75GOT^&01/,X78K M>@4G)Q["O)M,U*XT>Y6XM'$'[#5M-M[*UN8)HI[SR MEFB4H\.[+N6PV"2JX (QG!Q7-0WFM0WD,%].LMG''/+#!='>R1LKXB&YNF77(4\(PK_ *J86MO S\'=AS$.G' /.3D8J-KJ^AL[ M5?#MU>W.8T-XBQO=(DFWU,;[3G=P".W%;'A_5-7M-2M7U02M:,665)K0QJPV M,<%FA3;R!R&SG'!K^]TOQ.L\ M$R1R>._"DJ2-(T_AW42[O&8R66YLN=I^[]\'';->N5Y;HMS#/\4/"1@MQ:I_ M8.L@H&)!(N=-YR?K7J5?H.5RC+ T7"UN56M>VW2^MO4XJM^=W"BBBO4,@KY? MG6X_X3[]H^6T9ENH9-)DBV $EAIZX SWKZ@KYLTT[?B?^T0?^GC1A_Y)1U$_ MA9U87^/"W=?F<901D9#*1R/J*L>'/LWAB9[*XN-L M$VZ5+RZFP[$'YD=VZG&"#UPI].TT2:324U#,-S<);QEA$?OO,Y4,789VH"&&03CG'=^%M+T_X8Z!HWAX3. MUJD;@7DY"@ONWMGL-Q9B/IBO-;6S6UL!:W;7BP*Y"022QI#U..I<$GKQ$#SU MKU/P7&TN@_9+C38[.WA;9!;N2Q,> 0S*XR#DGK@\=!7/.,K>Z]3X#-,/R5?: M6MTVM^>K];%V+QHX:ZDBLQ=:5:N(Y;JWDWL,J"6"XY SS@YJ7PKI/VS0[)KJ M!H5AN6NK4$@/M))0OCOACD5T&GPQP6H2*-8T_NJ !65XJO$TV&&Y.HK8NK81 M9.5DY'RXZD_3^6:]BE1E&G&M6ES)+:RZM?E96_,^9E\3-XG')X%<3XL\36VC MZE%?QG[:UNCQO"O.PGIS_"*/&6K2^"[N^L;%X_+"EY@2 %W ' (#< M9/8=,YKS_P '^--6\>^&[K16TQ8KCSD\G;&J'"MDY[=!P?8YKT9PJ8J@ZU/2 M$6M7WNK67ZG#5Q,*=14?M-77]?(ZF\^(E_I\-K?_ -HOWD:M 9F'E7*D< ..Y!QCCKCVKCOB+X M=FURZTN"2QO-'U.^,>E6]K#=)(DUNI#N[X'"KQD?0]JYK7_B'J4EG+H.V/5= M+\\BUO;N%EF<*Q'[IB0O! '/]_'T]RC1E*"L_>UOTT_K^NWGU:JI-JIK%6WU MU^>J_KOKZSXXAFAL[J'3Y+R..YE#7$4*1LGW,,V74B,%54$G(]ADFN1T6YTF MPO(8;JPDNTD98T>!(<,Q_A4^6RN?/](ECEM)4T"2WM(G<.[^;&\,>QARQ M+87GG./4$S?LXVR^+O%GQ#^(* MZT32K![W4[EFDU>YDF5298[)=]O -JJH_P!*E@<#&3L;.:UOV:?"=WX)^!GA M+2;^TEL;^.U::XMYU*R)))(TC!@>0Y70J8/ >SJSYIZ)MN^]V_E>Q M3G'V=24=+V7RW_1'IU"%2 9)'A=549XY) M KIZ*ZHOE:?8XHRY9*2Z'S%\,_AYJFK>#+CP=KFE>/;'[9X?.FR3:[?P3:=; M2A$ :%$D+*591LXX P:Q[CX=^/-;^'\^J^)?#4M]K^KZOIUOJ%AN^T&"QM;? MR_,$0FC67?-O M#+[1;[P%X=\7>#M7\0PQ6NO_ /$@@EC$IA-Q$T)VB4(5 9<*&(7J/NUIW7P? M\;0^&["U\4^&-4\8ZB?"T>GZ-)9WJ?\ $FU /(0TA,J[2 T/[T;O]7CD5]A2 M:=:37T-Z]K"]Y"K)'<-&#(BMC<%;J <#('7 JS6CQTM++\^[>G;83TM'\ M^[>G;?YGRYJ7P@\4X^)>LWVC3>(?$S:3IUIIDK7LD:7,GV*.&]9 DB')(;.2 MI;& 1FN1M?@CKL>EW@G\&7MWI%KXJTK5+?3/L\$#-:"+;=>7 )F5"Q RN_)X M)YSC[1HJ(XVI%6MV_"W^7XD1Q]2*M;M^%O\ +\6?*FK?#/Q%]O-SKOA74?$W MA-?%VN7UYH-K*ADN8IROV.<1M(H=5(?Y201OSCBJ6D? ?Q+K5I86OBO1;B]M MK?PCJ<-M;3W?F_9KE[O?9P,P?YW2(@ \@%1SP#7UQ12^N5+62_K7_,7UZHE9 M+^M?\_R.8^%]GJ6G_#7PG:ZRLBZO!I-I%>+,VYQ,L*B0,> /^Q4U?\ ]'VE><^(I%T[X@:DI;$>I7$K*O\ TV0G M/_?28_[]GUKT;QA_R=YX!_[%35O_ $?:5Y/\5M$OM7U9[G37V7EG?O/&"< D M.>#['D'V)KBKI.R;/H\FNI3:\B2]UK3OMATNYD4O,I4QMT8$8Q5'R+ZUUS,H MAU&W\H>4M[<,PVJ!GS=Y1=N3PI<*F#XB\'MXJU#3=W;RT=HR-\A56=%QR5W$#.0.IXZX.,'DE&"4>5[[GT5>#K M0DFO3K_D=/X5\773ZM'%JNJ6\R7'[FWM[.W9XO,ZC]XB;5P WR[W^HQSZ5I< MGEW:M7A6DZIJ,\EQ7]]?WZG<9)+A MU3/M&"% _#ZYKZGVO-+EIZGBG(^//'7AWPAXH$$D]_9W]RJI0<' ^@Z=Z]B\/QP:1HMI;1)LBC0(B@YPH& /RKAS M7 8'$891C>$I-.36C;6VJ_JQME]3%+$3]JTXKX2EJG@^+6+[3;JY+M+IMP;J MUP0!'*8GB+8QS\DKCG/WL]0*Z6%2D:J>H%>;WGBOQ5)\5+*RLXK8>%EB;[3Y M@_>EMN00>O7'M7H]O,)DW 5P898;66'J*5][.]FGJGV?D>LJDIW4HM6=M5:_ MFNZ):***[QA1110 4444 %%%% !1110 4444 %%%% !1110!\F6MG-?>(OC9 M' %>5?&EM($9@N[;8VC$9/&2 <9XSBI0R><;>17MKH#)MYUV/]0#]X>ZY'O6 M#=-Y_P 1OBC9R!7MY/&9E>-AD,5TNU R._WS^E:%S!/'I[VUNRSVP&5T^['F M09'3;GF,^A4@#K@UYN(MS:GV66>UCAN:FKZO0VM(C@DT.YU"'5&M;Y7F188Q M@,8W9!DA@3RM9^K?;?%WA*1I]<%XEHZRS:1<2-'N SDJ79L\>G'MFO-H?%": M]KVE^'O#6E:%?!MIH5WI M.C>3+/?ZGFXDGDD7=A77C"\KC_9->'7]KB$U'2&W6[?_ +>A\-C\SEBFX36 MCTMN[[VV6W7='->$_B=>:'K4UGJ&FBWTO8$CB2Y:22$CH,-QT],=J[*_\:1: MEH=YKFE:[9/H\?[B:.2(N8Y. 4!5AA\L!@YZBO/O$T6KQ^(KP7-M#9W[6_\ MI+:>=*J$@W4^ %R,= M5 P2><8 ]1SX*I4]I[.6R?H?/>UJ4U[*S;E>U_Z_0B^-.CZUXF\*PZ#HMLLK MZE=QPW4TA(CAMP=[ER.<':%P.<,:\ZE\$^+M/\.ZQH5YI)O-+CU^#5)+?27* MQW=G(2\]O"&(.%?!VDC.2 :^C-)\,>([YA&?#4_B#1=3OS%+ \.X6]LP'F,0"<,.QZ?K[5^S4<\P5:48P;UVO%J_G=K M;S/F:>%QE*'*H*RU^?W_ "/E3P?:ZC:WS:EIFAZI)8Z3XMN#)I:2*]S#"]DB M(N&?&%++\N[C\*S]0^'?BV\TG2!J.E:A+;""_46<*+<26US)=NZ/CSD"DQE< M29.W'3FOJ&#PM?Q6+7FEZ8CFZE\V5K6$,'8@ EBI!WC !W =.M;MKX,U"XO9 MM/'V>2\MW43O',0J*PR#M90W0]LBO5>,I+J4GBK\T:?;UV?^;/ECQ)X#\42W ME^D^F:GJWB&:&P31M>2X41V+1QH)C(=_R'>'8X#;MU:UUH?B:/Q%/IHT74)8 MF\9P:U_:",GV?[)B,$9W;L@JWNKJ;6%LK>(D1PS)F:3 R#MXP#VZTHXRE/6/Y,B<<5%J$H*_KZ>?D M?.GPI\(Z_H'Q%DN)])NTM9$NOM5[?*$E4M(&0>8DI6YSZE 5 [=*]UK2\.6- MKK+1>=<-%ND\IE09(Y W ]",D#KWS79W?PKA6UE,%](9@IV>8HV[L<9QVJ:N M+I4G[[.7ZOB,<_:1BNVYSNC^'9->L[R6SETTK'Y8>.0K))G8 0=R,0<@G . M.U;'A'P3>Z;?7$SZ1::R&3;Y-L(E8#!R,.J9!XS@GH.*QM2TU/$$D<-[&--M;'5[>:SU2\U6:WW_NXA(^W=&R@_.( MPI^;KDGK@=Q_-^(OBY<^-CRQ3ER[1:/0-8B6-23L03:<0N3R<8QD\G KUZO'M)??\4/ $OVG M[2LND:T0>B9A7S59';\3OVAS_T]:*/_ "3CKZ5KY;U"X-OX\_:(VL4,FH>'X-RG! >W MA0D'L<,<5%3X6=6%=J\'YK\SCM6T6#2]6_X2*+(DC79KFE^%;#2=2GO;:/9)-]X#I4DEC?6D;BSN1']+CMC8&]N$D,$4.3&XVD@(V'P M;3K^ZGUZ7/0_['U>:XNY]%CDGN&CW2?O5CV* !M5@OF<]=JD \\Y/.QX3M=, M\*W*:K(-)>P\/7UIJ$0V-;WRAHI ,G<7XR>3 MFO,Q5:I3DN76WKO\ORN?GV;YE"K7E'#.\=+Z/?[M?0]E_M^Y>SM[K2K1-7LV MW;VAF <'M@$8/ODBH_#^CW%WJEWK.K6HCNG;9:PR,&:"(#&..,DY)P3Q@9XK MEOAQXVU(^+KWP?K6F6-A>PVOV^%M-;,10L%(89X;)_SQGN+_ ,6:7IMT]O/< MGSD^^L<;R;/][:#C\:^MPTJ?L(5*T[>NBO\ ,^<515+M&J8U*E2H*D8*D<5D MZ3X9M=)OI[F*.-#)PB1($5%] !W/<^U:T;B2-74Y5AD'VIU>M*$9V;Z#\SG/ M%'AVZU#4=+U;3WC74-.,FQ9L['5QAAQWP*\ZU+X_M%%;QFXG/4HQJ>7]?\ 0_X0^'YM$T>ZEOGWWUU('D^;=M4 M+A5)[D<\^_?K5W0_A_I7A/QAKOB=;^X\_5 !+'<3#R8\'/RCMTKS/Q-KT]C_ M &JW_"22:5=1OY%M8@J%E#(NUMI4L^YRPROI@<@US&GZ/JNI>=+J=[]E."%D MDN%WQC')5\NV/4';7PU3B%4\54P[@XK9OH^W3_ACZ:E@82I4Y/5QU7J?2FB^ M(;#Q MZ;&?SC9W4EG<*5*M'*A&5(/L58'H592,@@UI5X)ITT/P^T\^.-+UB# M6;6RBC@\3PV[81[1% %TJXXDA +?[46Y>2J8]Z5@P!!R#R#7K86M]8HQK6M= M;;FDH\K:%HHHKJ)"BBB@ HHHH **** "BBB@ HHHH \.\7C/[7W@#_L5-7_] M'VE8/BKPW?:7K%XUQ;ND;S.R28^5@22"#6YXT8I^UUX"(X(\)ZN?_(]I5N'5 MKN%I#YOF+(]M'1TMI#]HC<(Q M56/WU]N?F]RS>E6H]6M+I)/);[3LX94B:49]" .?I74_$?0].U2VT>]_LV!8 M1-+!Q85S%CIBZ2N-.N;S3AG<%M;N1$#>OE[MA^A!![ MBO-Y91=I'T-.KB*L&X);O>_Z7.XT&PUJ^U&RU6_MXM)=[5&N8K:1B)Y"HX96 M^[M_/CK771_-(!VS7)Z7XZC'AEKW576.ZMY3;2I&.9I ,KL7N74JVWMDCMFL MWP_XRU_7]7N8]/BT^=+:)I9;=5=GC8,-L.\-AG(W9P/E*C/45G34M_ MZ_K\3\VJ8:K%39Z+'H]C#="ZCM(4N<8\U4 ;IC&:N5'!(TT,;M&T M3,H8QN.5R.A]ZDK[2-K>Z>6%3:MXN&EQPVUOI\^H3QPB:41,BB-22%R6(R25 M; ']TY(XS#6/XOT>ZN/#NH7VF7EU9:BD*QG[,B/YRAB0I#H^"-SX8#C=DY Q M7EYK&K+"35!I2Z7VN=V#DE57-L<+K?QFU/4;IO[/MS81,Q@C9B-K-T(:1]HC M;.>SCBMCPWKVO>%;*'QO=RWM_I"9L-=M9R&:&V5R\5Y%M #>5YCK)A5WH2P_ MU:AOFGXS?M.6_P $?$%MH$7AV2\UU+=9;J47,*[5<90-,8&:5B,$YP!DHH8S[_);J>/K]6^OH?IW;W$5U!'/!(LT,BATDC8,K*1D$$=014E?F M5X/_ ."E^H>!_#MIHFG> +5K"TWK;K-JCL8HR[,L2XB'R("$4=E5023S6U_P M]:US_HGNG_\ @RD_^-U]E_9.+_E_%'%[>GW/T;HK\Y/^'K6N?]$]T_\ \&4G M_P ;H_X>M:Y_T3W3_P#P92?_ !NC^R<7_+^*#V]/N?HW17YR?\/6M<_Z)[I_ M_@RD_P#C='_#UK7/^B>Z?_X,I/\ XW1_9.+_ )?Q0>WI]S]&Z*_.3_AZUKG_ M $3W3_\ P92?_&Z/^'K6N?\ 1/=/_P#!E)_\;H_LG%_R_B@]O3[GZ-T5^",G_A)YO\ TWZ?_C7E<(U'X<_$;6[I MM,N[T7BD61C#&%LD$$X!Y&",#G.>Q!KS:S@I2YM^A]9A<8L'A*4Y)\KDTVE> MVC=]/2WJT7O&F@:)<:I;0ZGI=Q/#:)@Q0XMTG";5W,2S,<\$F,+DY)Z\^Y_" M'Q5X%T+[?H.F:[;)J5[+N2QAA=(3M4#"3,H\T_*2.?XC@=Z\N\'ZFWC*\.DZ MAI-C?7TDCRD31;9(RI4D'+HZX+ #]X<< 8Z!?$'[.=]?>++:2RN='\+7.Y;P M64TKO+(BLN)%.Z3@L"-K29X)^G##6]2&WHUZGRN8S4$Z^&A%J3[)3\][/^MC M?\::Q)+JNMG1KCSH+IU>XD\U6=7C';5]/TV.2; M4[YQ$+>'#REM@9F!(."-Q'/<>F<:EKX7\&:?LT$Z_);:Y92/'6#$;G 'WC MQS@DAE]:[KPSJ$7C1K^XMVO=%OHF$=S;[LX;! /(]L=!C;4MG\(/"]AJG]JV MEA]EO6RZM&YV1N?XU0\ @\CC -3Z+I6D_#+29WN]09Y+B3S);FX/SRMZ =3U M/J22?6ON,/A:E.-.,VO9J_\ P]][MOT2-XQG'26Y7DT6&VU95U2'<;IL)?6K MF$NW)VR;2,GT/L.]7KK1-/\ #,DFJ+CZU% MXIT^ZLXH[MIYI97AN)8)!$A#,4RQ48Z#C'Z\5H_8FOO$CQW;_OK=4DMD;YD* M@2U5575U_=&UFE)BE0^8);=>, ?,Q'/4#L*[^ M^L(IM403PQL\4)GGDC!&Y1D*HY]OTKQ[3?A7+H_C>VUN)BZEXY88=_4%LQJ3 MVQCD^@/%?3X?DC2DZL[-+?9?\,>)B/:PJQ=-73>O]=_OU74]9T3P@D=W'E=%J=W'8V,T\F[:HZ(NYF)X [DD@#ZU MQMYK&JS-.][IVI.P.(+;390D; 9R6C+@&LC39_$M]I\D6IP7F& *_ M,%( &?KNR.&SD$ FO(J8S"U(MO$0NO[R_P STZ:E1M:E*SZVU^>@RZ^QZ?/- M_P )!'J-G=S-E(VGMRN "59MV.V0#C)SWK0\+KHL>L*VFZC=VD\ZD/)(;>Y M!"*S@%4 88^;!)P"?>JFM://K-Y*]]8ZAJC1,!#+,\* J5&2%$6 XCJ]'M;2S^*7@..SGFN!_9NMO++< !WD,EB68@< M9).>/6O9:\@T=I;[XD>"KS^SQ91VMAJUM<^6Q:-9'DL]A#'DA_+7:_7?7[SSJJ:FPHHHKUS(*^3/$4WE_$;XY)G_ %NN^'$_ M*UC;_P!EKZSKY-U^%)?B5\;MPRRZ[X?9?8_8E_IFLZGP,Z\)_O$+]U^91.O6 M:ZH-/,H^TD9VUY1\1-%MV\2!$UB'2=0,WVJ.2/S99D)'#HD6WH>#MSD>HK4NO$%AX[U(OYC6<$96 M**8O'&T3G(YD".5)R."0.1UR:\2M[)))/7S[GT6-Q&$QL9X2JUS*5DF[:I)K M9WMKOU/0_@_I<*Z]:ZK-KLVMS36*K!=:O<#[3*K:[ JW3QQ*OERG>K*N&;*\#)YP,UQSE-)0A M'5_E;O8^"JITZCIJDH>CNM;]>_W]"AX%TVV@UF\U?PWHL27+PK;WSS7&TR2< M'@X;ICJ, YKJ=#M-5_X2>>Y-H^F64B[[F%Y%E6:4\ H1TX S_*M#2+?2/"&E MQPJ\-C$[XW2N 9&QCDGJ:U=2O4T_3;J[C MK96M?[K_ (ZGGRBH>1FWWC;0M-U$6%SJ=O#=9P8V;[I]&/1?Q-;?TY%?/?B3 M4(_#/P\\/P7X,":P9[J^OXX/,FDV_/&H.#\SY4 GIC/K5GX=Z]>77@N#6] \ M4_VI>V,2MJ6C7DA,0&"0B;@"AVC@C()7KQ7U\L.N7F3_ *_0\VGBIRE9QNK7 MTW7RZZ?KH>WZC=-;^4BNL32$_O'Z* ,DUGVNN;IO+A9M0C8L$D0!N* MY[0M0_X6!&FK-#Y]BHQ'9[PI5N/O^O3Z< ]Z36='9-/U2"PN9K]C2I4:7/'^E;[NX[7KC1O$5Q#&-9.F7,,^ M6N#&=D3;2NQI.D;$'OUZ=ZPU\+VMYJ$)3QK;NR2!P)Y 9)P/QK\ES&A.AC*^&FDJ#J-N5]'>U^NGF_P/M,!76(P MU.JOBLM+;?>=#XR:?4O!?B.RF:VBFU2Q3PY;O92F5)/MEQ%;^86*KD+YH*C' M0L<\U]"QQB*-$7A5&!7SYKNI21Z+H>ES:4MAY>K:&T4VQ 9434K1"?D.T')7 M*C&,C&17T-7T>0_[DHIWBFU'1KW;Z;[Z=2J_QA1117T)SA1110 4444 %%%% M !1110 4444 >%>./^3MO O_ &*6L?\ H^UK,U?7[?2)((Y?O2G K2\=G'[6 M7@<_]2CK'_HZUK&U[PRFM7%M*S;3$[E]^6?+OH;=Y9R:YX5U; M3;>W2>YGC2>V+RB/;+&=Z=>N6 !]B:\9\6^-D\-Z99WHB+Q7&#R.@(!_K7NV M@V\OFYBT\:BL:A61@<#T/'?BO)/&GA&WO-4U;1;VT:VCCG^TP1MSMCD)88]@ MV]1[(*Y?=O%SV/1BZI)#J&FVFLVT D9]H94@,A<,0HW M%?FVKG)'(QG*MTK4T'7-0TWQ#97UY=W,-I8A1Y]E J)Y889B 9(%P0".0V.W M-26VE'3]'^PVA^E'@OXA:3J\T5B)'CNYAE!)& M55V R0I/4CG\J\7,J%?%4:M*G)Q5MU_70TP]:G1KP51K7:_4_,']M2ZO;[X[ MWT^HB47CV%F9/.0(^?)7!(VKCC'\(KL1\4M2D_9#77#I/AE=7;Q2?#OVP^'[ M(/\ 8_L ?;GROO;CGS/O>]8__!0;_DYW7?\ KSLO_1"5\_\ _"0:G_8/]B?V MC=?V+]I^V?V?YS>1Y^S9YOEYV[]OR[L9QQ7Z%@J'/@7,UO&K;@QR-N PP' M(YKYSB^*GQ!U[_A'])3Q;KUW_9UQ%_9-L=1E(MI@=L9B!;Y6&< CH#@8KLOC M4GQ>^'^H6R>,O%^I:@]_#>6BS0ZV]VF-PAO+8D.<'F7'Q&^(]]I.CQW=O8^%-9U#1[/5K>.^:)XU#6^Y60J M[K\H^[@G/'.*]7T_X0:-\;?!_@GQ#XXTJU\)Z^NG:UJ-_!I5I'I3ZI:VK0B% MF18RL9W2$&01DE%8X.!CYHT?0_'GPVT#PYXX\/:C?:2OB!;V&SN=%NI([GR[ M=T$X?9@JN64]<''M44GBKXG7GQ M]2EU7Q5<>-;9/W-S)-%PQ MXZ8)]:NI1E4FYTYV\^NEU;[Q*22LT?15SX#\ ?"WX=_&&]T2RN-9DF\,Z;/9 MW-V\4KV'VV
XML 33 R44.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity Incentive Plans - Option Activity During The Period (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Number of Shares Underlying Outstanding Options      
Ending balance (in shares) 2,777,900    
Shares vested and exercisable as of December 31, 2019 1,108,041,000    
Vested and expected to vest as of December 31, 2019 2,777,900,000    
Weighted- Average Exercise Price      
Shares vested and exercisable as of December 31, 2019 (in dollars per share) $ 2.10    
Vested and expected to vest as of December 31, 2019 (in dollars per share) $ 4.59    
Shares vested and exercisable as of December 31, 2019, Weighted-Average Remaining Contractual Term (in years) 8 years 3 months 14 days    
Vested and expected to vest as of December 31, 2019, weighted average exercise price 8 years 8 months 23 days    
Shares vested and exercisable as of December 31, 2019, aggregate intrinsic value $ 24,757    
Vested and expected to vest as of December 31, 2019, aggregate intrinsic value $ 55,146    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number 1,108,041,000    
2016 Plan      
Number of Shares Underlying Outstanding Options      
Beginning balance (in shares) 1,376,084 1,057,373  
Options granted (in shares) (1,446,823) (318,711)  
Options exercised (in shares) (11,703)    
Options canceled (in shares) (33,304)    
Ending balance (in shares) 2,748,434 1,376,084 1,057,373
Weighted- Average Exercise Price      
Beginning balance (in dollars per share) $ 1.00 $ 1.00  
Options granted (in dollars per share) 8.01 1.02  
Options exercise price (in dollars per share) 2.64    
Options canceled (in dollars per share) 5.86    
Ending balance (in dollars per share) $ 4.59 $ 1.00 $ 1.00
Weighted-average remaining contractual term (in years) 8 years 8 months 23 days 8 years 10 months 24 days 9 years 10 months 6 days
Aggregate intrinsic value $ 55,146 $ 5,950 $ 25
Aggregate intrinsic value, options exercised $ 255    
XML 34 R40.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Redeemable Convertible Preferred Stock (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Nov. 04, 2019
Apr. 30, 2019
Feb. 28, 2019
Dec. 31, 2019
Dec. 31, 2018
Feb. 15, 2019
Dec. 31, 2017
Class of Stock [Line Items]              
Shares of redeemable convertible preferred stock issued (in shares)       0      
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs       $ 92,852 $ 0    
Redeemable convertible preferred stock, outstanding (in shares)       0 7,611,691   7,611,691
Common Stock              
Class of Stock [Line Items]              
Conversion of redeemable convertible preferred stock into common stock upon initial public offering (in shares)       14,193,281      
Redeemable Convertible Preferred Stock              
Class of Stock [Line Items]              
Conversion of preferred stock, shares converted (in shares) 14,193,281            
Redeemable convertible preferred stock, outstanding (in shares)       0      
Series A redeemable convertible preferred stock              
Class of Stock [Line Items]              
Shares of redeemable convertible preferred stock authorized (in shares)       0 7,611,691    
Shares of redeemable convertible preferred stock issued (in shares)       0 7,611,691    
Redeemable convertible preferred stock, outstanding (in shares)       0 7,611,691    
Series B Preferred Stock              
Class of Stock [Line Items]              
Shares of redeemable convertible preferred stock authorized (in shares)           6,581,590  
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs   $ 8,000 $ 85,000        
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property, Plant, and Equipment (Tables)
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consisted of the following (in thousands):

December 31, 2019
Leasehold improvements$105  
Office equipment45  
Furniture and fixtures50  
200  
Accumulated depreciation(19) 
Property and equipment, net$181  
ZIP 36 0001720725-20-000006-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001720725-20-000006-xbrl.zip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

/!5 U<[TZ$R/3DD];275F1Y?XZJN 122 M95"'AJTG^.I4FBX:Z_T*!H:%D0S"X->X>!^\I%M5H:5/_B4VN4 R*)B^>!7L M_?KRE^O]GH51W'ASA4IIC%.!5/I?S,%^VJ!M[TS VR>I,9%O+6U"R[T+D<,. MO,T8,9!V00WG44 T9U'QK!:%9_@__8=!7FO_UF BU^U?@],&_,^2"4ZQ/5=1 MF#NPS5"X8!F,TG\5P>KT0!ECMHU[W*!Y [1%KU\E604CIJ>U)#7E:AGU-#7_ MP9#FI1F]<;ER"0?I5*DQ5(TB/AQ :8\F'1APZ]Y[Z^V":\4_PORB;>G:5G%W M\,"[G>0?% O1GJ!5#9';HUVC\\#=9 I[NOX#!N9@ .%9!JZYC%ZSJ!U:?76GNPU$L,. >KW@,3K@RST1PI/'" MP^-RU25U=<+UWT[94T=3W?=E]B$>*V>FZL#@,N7# M!-IZOB6]BKRVP)3_)M-JV1F4\,2@[ (?=QT8QFP7^J'911Z8RX/08.X!L/K- M'&==NH(T40',7TRO\G4HIT"5E$5;TAMGD_%_9Q$W<+)!5Z_>\KA6L7IALBKE M])(ET&/1$=Z$<<+NNCO:,!-H*'3X8 I4N32JDJ.M&[&YUSF0L_K\]1PA*8-;&8BKP9B^\W6[(N.16ID;<%9,# M 3JIX=:">0(FBT5Q#YDW%_PJ49XR.C*?6H7[=K3'*:-?+S+A.I;&V.;YTM49 M*YZM,;$P/MZ&P Y/E(D[JTI83R8B*:-VL+S- MH@N!<,>1#RY%*&$;*]="4;CB1PP RP,.D)P1% M1/L+&JW>%$;W)VM.]"0_"&]EV!J9XM)V'2MO)5:W^2H6J7%B2B+7@<]#;&7G M4OF0\(IGI<=A3K,QE;)>&76X1VO>61(:AAG,+6^SUM"O&\2Z M=W3IPQB(PJ2X4NW%6/'XQ_'2,A9S&J8F7/K!55.6YY$G M<>25P4B?(=2%[J4P%FJ@321$&0\SOHFLS5!_9 _T'"K&QM%$. 2,I2J%W,8$ M5PY6:)(\9N!]%ZP)08$+0@-EU*P*45C*+.3NZ) @U#@W@!#]X*7"/?#+]=2D MKPE/>D8Z$: *E9_NYP95T-'WM%L__N"4AH;$V]"S=#C1S\Y@%!O8M8_BS.1?AOISP\[P,LY=:9A0, M&XEII8#E]HZ;'RP;3 WC1&@L3!#3DETQ)40ZR]KL"^4ZE[LW'VYLQ9XK\B J07%M$6Z7(-!:%H$@&D5<6+P2S2D6UX@\W#1W#6Z?'; M\ XX]*;RKGDJB'E QM'+,5TWO !;W6WX1.BQJ*+@F)CIK>(0\03\SK2D$;/+ M(@YE-9QI?*+Y :7RV",6MR_,Y( K9L#%_8M22*V55:E.1=(=W%T.;M,>:N5Q M=!9CW5SB'^<1G0RQ'["[EG/$]WK!^S2[36$7O,4'P:"G?PQYQ>7O(_(E2>Y: M"AJYEA]2%0)9[![FG@'J0TM- UV3A$MF ,?8%B,(_<_@XG6E,EM*94Z[4IFN M5*8KE>F**KI2F6Y5'[:J:B>LN89K64XRD87L+JT6([)QR6!LCY$I.3LIFZFT MR]N@&9P46!D"(XU[@WE90RIT>YHG<.AERNQ>@C1A03YHO-2/BV:1@DWRFM1M MO$ 1Q++*<5_]=;$>2XB;>=1%1*HB2^)BT8,]E"]"3CZ2TQNJ&5UF"?B6&]XO*O93T>QJ23ZEP,.R,8-GB^E,#C1B%_"@^=7$)B=CG49>Q*2V.+SD[A?XZH:A^QNB>M1L&T6JB0D#-J7 MA@2,_-0(>#&>1Y,JJ1>2*5R*7! 52GEM@J27I>(;(Y=+,U#CJ)]*@-F*R??T M8)2,<'Y6/YNL4IK L9^9E_!!(A J/2OE&ARWA2]:)5;,&@,&OJ15./"+3'K" MQ+NUDAMFLS-(S+$7;^E$Y%=ZF#H1^36NJL:I=C)*DS"?19Y1:@4CYVW4>!1T M#),SLE%>$80FSRG!5!LD%+YNW]L8,>G8#LC\B4U+JELP/39&P89#WRM1, M/ABYGY">B'(<-DJYOF:4&8P1AGQ>">5%Y"W7P'R9M-Z<6% M653S98L8"L$K;J[$0 ]=I8D4GMB^O7L7O7?5$;86N=9$("O?XT+0DI^31],H MSPU:FL:%CYOGK6=X?UPX6&K!U('S6BPW;#:)*O4IDX:=!4;YH K M\[Q*>.Q8KY-5;-:L4]4K=,DX*ZFJ8)K6W2KM>TS;&NI=;=E8:9ZR1Q. MF&(+G)N0*^XXI&43R&PVL8HWAV/]-- %B@%ZPR5>.+G(,$_,34PI5"=C=Y.Q M6_*^K2T+J%^0%*Z6 6F-\+3"XBI>.!>LT=_W@VNR51,$77NF&&[,AZ#M17QCH.6EQ MP!71QFW(S M93 RRJU5(J74K]ERT%K%"+P.+QQ-JTZWC-*UV+.OG_1D(G##OH7.6C^XM*8: MYD&:B%I*\C(^QU':0E*)Q5O6BV+9Z..1SD@Q_>;JQ)J5=+*!O(*&4-PS5=9: M-(?I$M9+;E=43!!LQ[C0QZNS5#2[A(25F;5NZ+%<+NA]\.4M;AJ6ZBORU(WG MT?C]P3*+,=7269GQ G$2(;.V9[TZR53 9JG!'Q8PXJ9UPUY6"N7OBC#D2/I& MLVD&DUDHO#9#+@IDVT6+H/W+_#A<.,HJK=HR?6D:NT-9,EH!:"^04*:-0=MV M7-0R'%Z3&IU"6M7?(O'@>!*F?.3]UAS?2SHIJ_+U=-+:]N=COLQQ MANB(C-^',W95C:EHD*'9/(P*\Z?M[K,K98?JU\C6HPRTZ=K'%$PREA*FE;$F MOS@&'&?&'1=EBOKL)!Q%8-PKYE$R)=TZC;I&C%;-B=[P7[DFNNO!V,W6^#&S MC4LUM/0.NS!9_59#:3=">%L_!MK72.+5XVZF!V&-2E'#;>BE*"(5 M')YOV=;&6N_:=\J-4]!WE=Y+#*#G=T?9(?'IXTZ&NK#=V,#(PK#>W6K#.)D& M7)PXQO=^\YRST5Q<1&= B33Y&2R%3!!P1*YGD$:S4!H-H4H6HWA6P2JX_[35 M^IBE"@]+I2YI/WB!K2"=B@L-_(CF6QVHSF]I_7.1GXS%ZS;V31M/M":2;@;Q MAKU(,1E\49[*:QHSLKEEU MD6JQNRGRDM3JSGZYALR,K$(3"63C4<7L7[_AQ]TC/ !DL4B]2 H[9MMB928> M$1[^/'X\C&:0$_H=X: AQI-<5GA"QGZC+HC^QX)%3E*"_+HQ3%M0P.^O/W\, MK5XO_$%;M^4>^_.8EOE'8EW]SKGLS._BG1>/?_SN["[.%IJ%J(**!A2[8>1# ML0^I;3SVS"N-J^S[AM:(L2^XN*%Y15^49,ZXKG JWX&/2?$^\,+A.WO*ZQ4[ M^G7L&@H"PAD$DIU3O-!U45X)5,B?]6$M- $D8:%+NXR9W'79KH==R.;:.)"O MI$? OJP^"6#L9=OUZ:=E)4LDD%^>(8P.]" M4GOI;-A0T*ON+V4-NM U;5UC7EA6R!3JU$U](C\R">[E5-VV,S1R3W;H;XSZ M%ULE&JWLI?T#F['##LJHLP15P3$UP_"CWK81&@7.]&6DT92!YTI[[&*[A=8A MU+X?"=&\%\\N45'+$VHL!=K^\)@Q[\*=9,0F1,/?UM*.:G\MVMV\XW06G/3X MGV;/:\&&F$YS:D'!U;@71J["1FZ![W\(?/^K3P6^_W&NH@0A7JC!P=!Q^NED MXT7T%HHD=%X1B=A)7SKV M7KUM0"(=A[D[=+W;Y1F()2BK9$AQP5U;HOA$?_-&!WD0T4!L="?/$A^>/('B MJN'V9+UL-'0)-\_X]G+ZJ0A&3J)WV;V^VOGUOD3;N*-,OMXHN-)T?P'/RF5& M;Y#>7N[1E6_AS-*VA5MPFA -JG42!#*2%E;07V_75&X]5(7W*N 51Y6W:1QG M3?E 9#OG.-W*RX9'Y;P)RG/Z^LFRTR9&[1Q>B=-*4QC#ZB"6!=J[$\ZE614. M IFB#6*P&._WH?WBL"2:K2CR:-J,_:T?,E&N%)&@+]2\WQHK19MO)%+L_.'& MS&1X-D@D]Y4G+IYX?=2]JC?I8@5C-K$I$;9Y;$;/3R?;C9^)PWC%!G&R9> F M0NW?5'*AN%CZI')J UQ4D@I)-H%I:RCC[+T9'E@4T]XS-#9" S =B#=>R]3K M3GVFK6M3_4*["/K"A!N.NQ"2/S!G@33@9YN2?#@BX8EL1#3?3P#];8RNN5 T MQSK>'_92__1"6-3^$;"7P8?G-0#)!\8'0IBD^I&;2;JYA:\RMK5U3/JSD3]B M :V&M+%,=]D,U0;AGU(X, *!;-TU/5+ KG1*%QFW4.M.I !(NZ6W%NKUV?>G M/O&R#[3M'9,NC7]_C1:.X@VZ',0MY0#3XH6B-*TK'UK2FG*>L)LK#3&K%^_H M&B\?&96@J4%OM"F[]=#Q_5;.FS=G^):499/7L0[0LZD1\ (9B+1@<7FS./QE M"ON>S[WWD@K(Q\9T$_)1F3G&BF\=$ASN>SO^!1D7.-?:*4*U%ES?/:F M((-CI"<4$KYNR]4XJ0@+J%]*4H-G1Q\MI%.-FI+%61_6D4[?2F/9F:I5NLKX M/&A(*Z\$UP+CC NT&S<^E];'-ORNCD,\>9KPEAO'<=I:*DP:/1DH>:0R8S$\ M>D<-V:%]>-40P.5^GO]/=30&9%JB!5?8FF(@*NF%' M=T\,@6%9FV1J>6S"W//,Y'HGI3VA_!)^A^-2U/'1V.2C,T>+ZDJ\$!W@P 7( MN?3-AI!B\ #BYJ9[&C=2MI>/#]Z+CL6F+:['$GB:/;ERJ,)#7W%A C29ID#: M&O!7:H-(AVT,F\T/U@_E)*N4LY5*R&;P)?L=$JNSQI+N;KQ:8J$C>J(K-TDB M4%:\]5LEII>LFFLY,8',P;4S7PG]'/3=I0(XZWR^$N?QT;U'=U9W[SRXBWLA M'7MFW([;E0GE,P<1EA]E: M'*)13JB92TS@'AQ0_)I/1&X;3] .$%D@>T(9R20AU?]/BI!, M$@K--;HC'N_:B?H:O[H&7%'_([0!"D?YQ.)GE)6AJP15663H5>$D)=3<6BN\ M$6KCG>NNJWK&B3_W["LU9RCV) MO:4O#-+/OB>GNADZ"GO4)=; %H%R!QS.2A^2H5"(?N#'<3.F=%;4FDT5SS)D58U;.4.PK$K(Y&1,@8/R M#!0BJA\>\7)*KMLU.'- M^@S'+Y8CC-\D#-= 1H.DM,!+"O[>6.SDOH:Y6E_JXVC->/_6DH^C6>-]G_M, M-P21R8N0XZ1,T&O3&O?$"X.W5W"5XJ2BWW>S;GGJLNP.B=CS%LKYSTWSYNYI MECVV)2-@JWWD ,"AE?!\A,E/W6JF;*=R4%6!KY$85BG%@ 0"2SZ? \KA%N4N MY@5G%/05:88]';E<+T4JN:E/Y"P)N? 5"/K3QA;S*1 FR-YL;RHCQPH*\19KF[P?L&J34P1L?-'L$ZRTKIV4+1%6Y7\O8?W M0K&P0J>H>1B\%"?GO4ZERE23:^#V[Z#^- 1)#T]& FEMR"G6/97@9Z<%Y7)^4D0SA"VGF>+7V:#19T M@905#TKK'$\W"@N5A*2FTX9'^1! X>2-K_=]?$LM@&Q!8=5S8TT=XZ^K5 ")M:?^,_61!)'X)( M^GI!)/W\$P^8)XSR4 ?GF:/]T)68[9M]S!>$)C?0V=S[MMEN3] Y0#_+\O6H2(0YG:8\DRO@X4V!.2@G+[]<0L*"4+W94=Y3((_D68BJBY/)_"4ORU49 M<)C)ZR?;)7BB0ML:HNN!(COU[I/;B,R1UY+LN6 M0/YV7/E*>6W&K] *:\G<\9R&R@X+BR=YO,6Q%$K8!^VCEO8ANK+99*(EI:'?!46D1Z%S7$M#X<04ST0 '#-%<&7J7D=%(, MQH$U P@F[M,/W'!._T,I/0X0%!IB:_9<.XZC@9"4#9E"G01WRPZGY;R]%PP_ M)&YA$@*EE&*2+!BH&T$H+'""#B&-4LX-FJV7GBBEDC)>=$B<:YZ+45ELGW A M8)^"'QV (DS;C808# M>^(7 [6MYU%? 0PTU/HY3RJDK&$54]NR,KHJ,7V@GK)+76XBOKULB&!!'9,X MY,583-"!R/ =32,V%49R:@M:Y\;.23RPK:G+!L@6'H?3#A'D%%1B/HH,]E9[ M,LOPGJ!>#(>*]9(7(_:S8$85$5(+:K ^&8,130%0T<)*J>"OY>W!SO]SO1ZH MMJ@QW80):]$.MT;M6_\J:NJBC^[DR@)C.7,6\%WA:%EX[+R?*/#8<+?3[" +9/@VT72[QP8,MVPR.J#' XA<^FX[]G20Y2JH&;2 _,<[[&N1HY&Z2< M9A#)<3&E!(@5G4\*:+^I#)/3OE/N02450@^5B^^.[ENE2>/XOQ."V?6PXXE6 M&KS3+_Q1D4H[S_G2TKN3U6E;6FY,='97I5;#@(7R;W*:/4M>UZ!G(U\$R!]# M)M6LSR2G$ G;W$;\.3,Y:\,[?<'C@=F1"J545JHATM 80JN978]7DE@B#^R2 MQE\/61 ?"-:U/WUK/+2BU#N3Q[GATCR-]E:0;UXHBF!,*TEUF/BK+$)1V.D( M") PIXR/"S@%JI/*,ON7*XRRU/9&LF(I]/D< 8*@VWFN:>S)!/ W M&#'V)_7RX\13$7-YA,FPRZV<2.1@C[&9]@#A@6>](5&:7@A;2C,8CLAZTE:=3IKV MUR'E%4R MVCZN0VPH174#:/N6.]<#C>>>ZA@2L1NPR"0$C%0EYKI,32O,BZ.(P%IHS_-GG,*/0#(,9 2"^TT1)JUZ__U6Q6LEG%.RSBGA6/]T^98 M7YCS/\=='?NET1>9S=&F2;-<*"YUEGDTLD1F%!J[U/$JJM'O(XJ2;YEGAHY> M'-U4X&Y!ZKY8K<5J+59KT6^+U?I\=W5+9 AY=ETP&)G[.#EFI(P)0WN2D1:C MFMQB51:KLEB51?\L5F7951,+;8FTE2%J-J5\K($DZ\_5-\KW% MW"SF9C$WBV):S,VRJV%7;>X,[%[-.LQ&W(]128L%62S(8D$67;-8D&57PZZ& M!CE7_HMP$@1S=0 !"&V(1C21;AS=KCNF@P&_I!##*,SP6S/X<3$UBZE93,VB ME!93L^QJ&7K(.L6GIDBV=7E5,DM3"VJGBA)F187FT=_/H'Q:3 F,XWL9X8W/ M"A2VEOERMYYEV^Z*-=ALF'I0&+]&,'O3R\=C7-<,\0]T"<"R&T"XP.ZWSGL; M_D<7!)FM=\I@0(.!F#RR-]S!P.1WREKHG[/._C&T9;=1M$U91SJO0/TH/05Q MJM SB[_),^_-H<8Z!>N?:J7&L7:/KE MOY)4:MO)PM_P(?P-WRS\#3]?[8!6ZXE1%V7.%$MTWS9.1$OF)@^#E1 MY(-W7IBC1<>\;HN-FWSZ?+T>]DK/(%?XCV*W_U9/SMRMG]179=M 7Q%G>-OT MPF%T=L%8?.EGD(:KJEDG.F[I-;DM<0\%U,15X_)931FTMR$=KF\DX!"$?V>& M-=M&B+AG:IFV;3'P0(=B14W.U-F59UO_<\?L9)W\R0M([1>3N,,.\B=CU?:M MUZN6BH>N*!//+>6O_]X5T=+B-=QZ0)\'=Y-Q)R*X,;17&294+=/[]AXLJ8$E M-; $D9]V$+FD!C['7;61T9DW9"=_*]=OZ-

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�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

Y7U.?"H>H$01EO.55O;#MSIED]5AZ9%J7$92M=4+/J&/C$M83%)^G) MK3=,+?H9EVT0Q<5PVBT4A3+[HPSJ2D_9"%]*<,M'JIWGLQ6[9\];"5=%6-#I M/U1,]N7FF61MU"+X^!B6'94 S\S<3Z\Y:Z[> RWINI:>\1HO56F)F!6>N?4N MGXDQ@'M6ECK%9HD[NX,>7B'4Q_:/WE0]>G%/B&P(P#?X9YD5S2[>+6XSLG84 M19_U8%()CZB)4CN+<_J+;KV3Y[:W=$[ICF(54.G[Y=?\ P]B)[7S25*_PKP:E8,FT^81!D63\9_+;V-N MTK!L0@M?X!.D#7QUA-P<[,].6NVK\R9_R6_)M25">=ON)*7V^:!QBF'<'+=# MS V (%A0-1PKM.S"W/F4F97NJ"UQ=UKA4SC\,I'7=34Q^8E@.#>A;=RUN]4Q M%A_A=:UJBKR(;(+X9H,E#9.=R--KJ0;<'7FX^UB;VU0?TKWCH'U;+\=52]Q% M\;$"Q(:'-D-.+TZ?&%5.B,'6ZJ;I+R .5:%S;31!1>1)=,7M ^>:("=IJ%6;5PTY^>@.@W#TWV*G:C;KP.4\* M91)R>/N:XLO%8 "I%R.W;0SR!G"+[JO@GY1LD6(="OUJ?CGH@MV>$3:.";>" MB%WYX[]IG+__RJV$$&?3GE[-Y?FL,DQJ,)5UF3"0B'\D MLD8!305S^"6H?,@1>W0Q9UL[@VB;O-BCJ0Z0)#XJVH0=^& BD[UU4%9NIAT M?=Y*L%69BVKOF@O$6==9]1Z80%N6R:4\VMM:!C2D83D)X\N:YE_^-G=D_OKR MQX;W;:C^B>\Y:@HK/Q!95;P-8P6.^\*N9RXDQ^,"THT@TM;]S9K,$]_UW]10 M?B&WV >Q!(UWFA^8HYF),M#.)VU,A5C.V?+(?2N=FB27\,$'%C_RVJ1>J*_4 MFX3=(2/7\Y/"B$6P"4^HH7N=@G.,6&.\'B$HN%#A17X M@[[W")V2L.2&F"48YI(OOWKABO%XVE+VV@K1BI7?\N_I*M$GWUMD1/E&N7A1 M4+Z: ^N;3:G"O0BXA!.[N,UU@@8?4^/7W\]\U+U/ E]+B 8RJK"AR< ]AN-8 M 4\G[M1V%[:E _P@9=Z4![R&<^^$6LGP"XN&Y<=KKK_OGRJ3,?*Y/9COR ?1 MP9F\>FM_[TH >WF^XM=3BJ[4/(WEE]^5M-&!@8UZV*FQLKEHCD7PP8I5H[[$ MB.4X9TU$OUR!AJUG8),UH;'B\\!&%[YF-]TWN]HR3GEGS>>-<_"5RUSY ,W" MH,7I0_\1K+!;-$X8I=_)S$XV@W;MT4/"+F9RZJ:HG6RNFSZE]9/$M]C(>G*. M+#+8W/>'=B0PB'6R ]"0SF)7ESLEMK1+B5:^J=9/A++02N]^H8$K^RKT+:B@ M0=]DO4"-(FEL3"]Q\@OQKFK_6'5R?9@5VG?Y;PL;FOXIZ4=68Z7UM M%_759^Y^#Z,Z7-J[/VXY)[PXL?SZ$M_U7.JV5O_344WA/;*]-"KZ>>?HML]\ MG7%<:/"8[$0YXSAWD"WNDBF(!C#RR%_V^MA)Z>C<"G=9S/_S+O;HG!UWF3O, M/@_!;.;E?.0ZB;RX'9#* N-NH?L2;W[.QX>8Q[AUZ$5?[@$!)AGROPZUY?W[ MO;CHY]W@<=6MS-M^[@$7SN_6M$"F]!A Y,&S?POZ-1276V+72&=_?GR*FH3+ MC=N^(\;\!I!E>+O.G5N3.?Y;2OBWPO_OE1E9LMXFTZ9=K\0$T;S$4Z-Y2;RV MU&YRHL(#=@]RHVZU.?W;E,%@=AV"+3EF7U["IHB1W0 0NQ#+ZR#X#2 !W+K MWM_2$WT#6,S&L4]!K3OCT?_BV4.W^$GC.80$JP8:3'C%,<3Q+EE,B,#V2X?R!XUJLWV5 M&HRLCR2K;*^=W\L#5_?2SREBEZI;?B AW4QFD=".J]1&7V_0.2;L=7@LW:8! MW3+^CX-&53$6,9O'*HR%N$D@E70YFTZ!\Y5KALN*5HV6\((EX?>LA1K5BKLS MO@Z'):'N??+=)2UJV.>8+%LS1W!/E>3)&PGFII-P&9>ZA?WQ7FU67RWMN *SH MK16W.*Q:,=A_Q*P BT[ZDJ\4E*^G'L[B05.G+]?J#AVY#')-@&>5_^JVFPC_Y[&N\\T=,/6+P_6S';39(88YTU MTCB5'G6D],'TKQN 8]K+ZB#M64Y[,EG=]\/<[TB%Z$TYS7[O]>9'Q:0[_R"R M=[&REO:MJFT,9@Z7?5?_"[0]3-')7D,"X@Q$1,\4K45W M%^=TC/ 2\TJX H>:".<9\+(>*QD=XI0#+::X G=F];ZX2/G4BM'XP*GU:;NZ M,Z1[LI)=@4G<<>HD82< 3>E](+F*LD6@%BKE(D+X%%1BK:&EDW"0\GTR3L4X MLXM%-^1$*MM2K0<9>U'.CRH\B/ZU9.%4&TR#'*SUO=K 4CG"$1//'EK/!=6X M%"3EWO^6X0GX=>WK4$$KM;K!1Q1I=@(J6U#DJYP#FO$F;WJSQINU0ZI;NZQY M,1TV;$UC!V+]CCY?^J1/)46&D" Q^<-G=EN@-^94?:9]A"$VJ *LT;31LO5Y MH[=(^*TCVF]22A\:"HE[@,<&P1!LK*6I[I\LQ=5(2RO%0[4CH>WMH@B:7O0I&N^L2UBKX#.BRQI M[3BRFHK:B:V6VND5A_0KK6PSX5<2^U$"LPD1(O%_NW2UG9M,U/3$M8?V+G>F MKU5L8S/9Q20AB&W[/4AU9*6B8U8@0CN#?8&K_)R8UX5.=1 ME%0A?O ^,YO[F,BD^CH_F'=F6T9BS^=*-$N:-$CT^BQ_0C1]3CMTAU>8-U;> MX?58SCHE7N*[QM8X2#7M>8*W6RZ8%Z.;8 97"-N55:C):WFN/CY3Z&BF*$L_ M%]>O2<"7OJW"B#5!!-JC)(($KX3DJ@.@I$X-UWGBZNV.-AYM:SY\]T.;7I,$ M[SL))O^L;;G:OE; XO8XID92=&\ 0,FV)GJ,=J#:*%9D!;H!B <6-0./\+CH.T%O*O-OLX)?A3J!M4?9=:GTS"56=.O MI[X4*@Z*;6L<[/G6_SRCHIN"D 4!*@J>H6.2/H>SW@ ^2?,+[R^>,Y/FU8>' M8Z<1!E8*1+WBH2<])[(,?.-Y\.OR-V$V%>,UT#N+VY4JY>ZY-O-:062)EKHT M!EH)XF"?-V+]N80'/03""'L>!8O]4 M72)&VA(A7?*9M,A53/1M'3U34">,X75%9@_G+#ES8;-7*^4-P/FS6R1.!J$D M*1;N)EJV3Y0V$]T8PPZO&>RC%"?&T3K1T WC[<7?\_B\!9]*66PLPZ4N7%Z& M^@-GG;8=L:KHA*(.C)SE;NV.:G3@FSRT*VE)R3U2J>/YFM])AL]B#UWSO#>; M#O?.DU&ZK1^]%DQ9 SK@%0O.(BZ^JW=/=58<"E;GABC[Z'P5J[_%/GJ/[]>V M6IMVWCSA-1=GPHO4W?BQF.'@&P0K-7LD'JK)0TE(UO3">O#Q(P[ C-R0YBJ[=[,^-[(H;RX[ MH/&PM5P_Y2@[MYB99\3MB]SG\EGZU>EF6Z6X7'-T\/0N0ZENB<5\4.6L7W5A MPTG8(8 PZ3&@+/@U^=W-UHA61_;H*[$.F,*69)%FDWK^&$!70=& M03%,NKWDT"=9@PK_$8%=5EWY!W0Q:C]0'#<8TB3I7>(LR_3^:FBC5-;@V;F. M)C[CG-APOU/E(\%O]87GY0J;"QY3US= "*?UN2[.1Z"B;%B;C'LR$S5:/6$ M$L;N:!$TLN>H9? =DX=$W+=ATG>Z=0O#"M.IV1A#K-ID,#-LJ-])0=BW=?:1 MVJK<^[)W,:8Q"TS\!ESR\0Z^'Y@]Q0[K^GI9$3&J[S6KW2A?=8@FN>=;.:8/ M+<3G.LGTB9:]B>GW&W^N^Z>;-?O2?)UJJ4QD! .TGJOI"@M4;'+Q)ZT[B,^@ M*WF_^\Q">?,&(!581Y6]5J;K+==W#(^P%-US@V+9)85@D%M\]&LK?Z,=2[DM-P;K8-Y[*1*W>0 R?F+ M#@ZBM1L_\/Y;5I8N%;">Q3_GT2WODIU"NGY<)[>F EI-F'M@/ 7S$@*2@-]9 M,3=##*JM>8]QCG8Z)?2-&*7DKZ:#^HV 6RP9H!Q59DFSF2\70#.',*UN:J#.)/;-BMN]728R7YF<=CRQN::NUD;]2N&(?32&T$_'=/K>IQ8IG+4_SGTH\WJ\_O&: M?VR9!E^^-Q/PP-W%)YUZ :U]WKW7&05;P4!J-+BN/K9\0K//?_1H&3=RJ M@&TP],=X(7>*1?ILZ)AA8X^J+F= M..74"M<+R7NB1]RUJDT1NM\>%W-V@WOE#GK15>=%Z+B59EK=KK($VZ+9+I^0 M@O'#_ 2+NHBS@T&?%:L+\SC"2'=5L$]?^2O4Q8%\(9A]M0L:DM8QFP7[,.", M2$N-LG!I&=UX>/GT1X>@#DLLN=_.J^%\C+-CK:7:U& PXZ2KV_M#S@G7_:EN MES,!GA2BW-]&O>8V3_^P?RTG_E#J]%1/'&*JZX1H76J%7DIL<&==Y;0*=B)*UK<5A%.'W*1RO ;GUU%[)L)*VWR2>P+LB8"/'Z2K3/M'$"< M;@!19JJT=J->U\3Z"*FZ@Q>U>S02;3*%#%4GX8/7$;&-_! MO?=+)-7L]'-HSYABMBHJ>:$!^IN'9.Z]R76(?,C>/R1]]N#2,N MQK/;O7Q;.5M,RPWVRKJ7_@!CV411B!BL0PG0FB]*96"E1*=("J8PO3I^]TA2 M4OFW1?3U-J?!MP [LK=U0':L%ZK\X?SGBI2:+68'L 7QENT:?)A<,,G?A4HO?+RLF<8M?U?&YNS-* M2+9%TA4EQWU0C#AOPM#5W_E2BGYXHE'/-*D@O3]2U";2G*M%K5DV7F"\K@E@ ML0N5S,3G-XG3,-J]+BUK$-/O7[3=_)P@5HT=D4")]0"C*\&NJ\-6X+7Q,K6I M\.I:@_FNHJ?3%7.:/'[PS*,35CW 3N89[?1?W+B-5$9'BVCK3'Y+1<'S3C0( M(XI<<-(6-1536-5++HK]KOV3,.1XW0Z1C:6[SK_=F#\9 M\E3WU1A@)PP6!S>N.G27@+WO/Q4:8AJ?,(3';+VHR9KMQ]A:,FR)]VHM8'H M6P7N/=(=:,AJ6IL2HT4*YH#FXJEX10E;HGP8D% M=RD(H'"D,G]I2[/N+=RWTF]K%86+_=6>':E'^4 Q:N"+'LON[P4ZRDVDYS#1 MW1VIS\PE3J5V06IO4_O?>4;.L2]R #S_FEFAA%9;XW%L@9:HBDB#VK ."MXD M%];#?'OEKK+$RF>*2EU<;AF>ZC1K!*+?E3S/>(GS&<[S4-7UU7FPN4VHF]A> M\;Z#6P(0[;G9RAX\NJB O/@#(0(W+'4D_G6^&FQ7?JK3:_?(O*>FO_]E8C_W M;+XO5=PRFS-_L'*@$>C@3B=:8C8 9J0&I"2&QYM&<\8(*&&".L,VFUH>OX@G MG ^#0PO\QZ=U:-74%[MQ6YU Y-@259/%NO2G\X;,*Y=%J"?[ MN0S4V_E+GPCL9,!)HM&^74F\N%O^5(D\U_"ZI,DHJ"!.1R=!;Z))56352F.5 M]$#TT)SP\QN6\<>VA@Q5KR0[F7_.:O"V5/\YS248KTV5^01%FBW= BN]I_F M&@2U[AVIL*>=QZ/+LV> X.QE>#K"I'IT(;>N.F._X4GZL)9]4#Z:;)<^^9%F MWPCP!3IE#1K%A&@'AC< 5%M86]V$= (K^-O*I]X^64TZW M=EY0: OH,&OU2\31I-\ A'R8RL !*>;=8LH.QO/ M-9D2$RELK)I0];+6>CZ[KOF8M)%A843Z",WVU7B$7MU%]6TJ/-C?WVH$GKBF M[J[K">4 +3&K<*,UNOPW&]^(%-1G:S<8WQG644QL>3\MJ6D/-^7HSAC3$<+7 M^_#!^:#G@ ?%I3E=+43:K/JBOJ6^:J*,7B?R18-%C71]0N!Q&^]J4G[+A[:3 M'W$_ZFG/4FAP]6ISZ3&S2]-0Q+R8K2&JF:J7=NU&U6($\0YO,KUK^R MY,]IFLC[U^VCH'^G@*B>74&G6X&P_TH!Z:4(4STVQHK?@OWB:] 9;@FGO'H# M\(((8MCX;@!^D6B(:9 9E>(JYRWW_\;&B_9>@3(N[5S,;D8[%"\Z';1,!T0= MHU@BEJ_L",*Z'Q?1KSA\,MU^E4!A?J]S$?REC_%$:4WEJ#Q=YUH/]"NG1=>D M*.7KCX0O&_'G6_2_PX'4EUX<,SF+61K&G8LYD/>( M+=]Z]W2'T#.W!\X^[[1J**B MQ3:9EXWM"M4V(GA#\-S$P"%9]^0<15:[+H,8Y9_>AXHGU#UJ5V?RY37]Y^5P]O,JT!J-LH3,-FH+=-=HS@A(NSWZ\'F!Y2@6QXIV6.7] MX?9FU9IZQ+(*_E671M;]CO$'\:2=-JYY%M-P>,1IH_*;,W-ACD@#D%T5Z.MC MEO9/*0FJ"X3)Q,U.!@8C0AY+3^M-CFQ3&M!F*Z3;[V+6.M*]4(.BIL^3 6WA M'4+ZB9"6_CQ,4>F0[+)JQP*;BXJ5ZETGTV-S/83IX&^R'B$B,MR^#Q\?)G>\ M<59PRKG80NMZ_5BCHGW[U@.HL*,AA@H1/U981?LOABRPVR[MO[W?[FH4,"2+ M3TAK]"Q5;87@N'2]W7\YCI+N]1V\:VR*!J2NO$[A-I]/#'YJ\ QOTBS/P+B" M-E?46Q9B$" G#7+T4'!K5R7:H;MO[[ 2)T.J7O5%W]%TP:>YL>4B+F27L<4V MJZ!"?_]B.8IK#'9ZS<0JV*$[]<420YLNV./NE?0U;J.7IS:6:L2$=H?&T&07 M9@Q=5'5@ZY%=8X_ T:,_U=IVIM/&5PLO#88=)!$?]^TEV(8DC:ZE9PW\:6&? M\&8H/_#ZK!/06Y"^PAO_B-'N&W]*9"/A2\@";:.:1O6/>K\?D?WE 2SDV4B^ M/Q>I5[^Z5C ZS#"MC730G'G[,$^R;%R>*<=*;>_:Q*:2!XAX17^_8[DUG,EE MJ+FF*;VKJVNL(6!(DTN3N>_1FZ>"OQ*$*Y'R\Y[3S1XQB#WI^E?R"]]5ANF; MXX$=$#(EON5K4UU]M5%AK[E+D;5JT&=P*#PYYE?Q/L"$!>+E;Z)($8HC&C\C MS=C3)W'R0?C2&RP.2/GL,@PF-+/_C>"I._2TSJ>%UA:7;/I?)B0KQ^MT >\% M,J_%6%/W^45%M/$3TA< /_PUQ=!08CGF.)^O1B:_>.SY7J_'G\L/V:Z,1'C? *C- MP6$OQX0/STI8@M*O--N2E:C-LM#<25G?5RNJET*#::K'O*\E+O03+. (;WEI MT$EPS)#PX9^PQ#LR1":O//#/]JP7W76>P@R$!![]\[V-(Y$J#)-*G.SAKEZ* M\EA%IE^\F:@PZG#Y5^2=;)X(Z8@; ""8I2^_('WQ_GCPGU^_1'##^&_L_ ] M!9?<;B50RU,2?I-?/4XJF#/BN\UCO6K(A+8/N_X%/[,8)DR/C,-A1\#]O>BU MUP0E8B\>$2AYQH-D]:^A.)8=H#V&+\SKF\J AQCG'.#R'=YCB&>X3>L"6VCS MG9C@Q5\8MZ,W?6P]\BNMD3:,R.#"HET%WFB' IM=8N_)Z;$#"0\KZ)-D/6(/ M72\O PMMPR]-/V:T>')(^'/RWJC]QUW5_ZM&O#;2=FO:Y^*5A*MK_3W@;],; M .J('I-[:;:VU.9Y Z WZV#_EVM^(_)_S,Z;$' M_$=[,8H_II4N^9A4C==Q""!"\SW_)WX,_VT3*-UM]?MXE0[PIAF15VUI_<'F M 0F"*-Q1B7'(A"X!AQ/^-0CX+U'Z'Q&?^MT?/DGC\R([KF/MYFIO=QKC$)9ZOXORV")I?>,PL+& M/[*J20XG#!\W=9WX',XD-;)*)FB;)#$S6^BM)(5-^H\2%/WS[T=1^*3P(.%8 M,JPF8J5-&>^BV/$_K/_.$BT1$3>%P/1[")P"#/Y)/%.CP4/O((UO %W3R-;K MX,*S\K\!$/3%Y^LQ; D*L5P"Z?K[G^,E_SF^#X9>;[*O7%N<6LPU.UX%ER;' M7):KHXCC SLQBN@OANR.P]GWSQK;$_M%_\1Q!,5H2UG!R2H_XO66M"(;E9S< MW%IPT\P,C+!I4%^U53Z=Z^HS[J<2;86"!O0>[B>N.S8/!G9MQFY9$!!1_BS4 M_%[/N^^GRK0G+0FH+ZNFQ;FS(-,65OBDBT,M4'2<63ZE(*ET(U.SDH[+X3M3 M@3CVM8-<,2>Z#W7/52J;+72VIOIDX6EE1]ZK.>7-OTFY+LGL\[S'VQ;#>J./ MNY[],=%# "%GUX'#6J,IRHRG/+3'-1?=(S'P14#6JC79CM$KYBBSE_"Q([Y4 M :)BKT]69:SF_3[W*LWBU4';(WA] ;(A6&7>_"V(HPK4%:'J2*BU^0T1O.RW MD+FEO"?XUV)E-9^W1>-ALL<&?>?^ &O+/9:LR!US-M -(*CU*-=JD?\&8.9V MICI>O[LF#+F%=4MNF.VQS=:+.=R55#\_'N[?BAK_GIK@_TE\67Y]?@-HB?.I MA:#V*#"?L261)8N2M?$8?>1&Z7)ST]4G >& */(6JTP6GU[V%("'PZI#)VF< MQDMX%9+&J(=HU#PO&;5V(H+MHVP=8I/%[&6.E8[3 M"; %R^:2.;O\GS4GG&Z2'/RX\A9/BI3P?;$R5"'ZK MF*B(^ -!&MVWQ.BATD+IQJ]VQRS;EW_#?ZP17WQ&$+YKF;@!A)NL9,/,=S^_ MJ5SM3/TH'$LCCGLHV7>N%&!VB^B-1BY9E>[? %YC$JX9:@Z0_?J2!5"GX!<7 MVD"[,?^G.$=96++KIB1L$!$Y=LO^F73M.]_Z]ELY&INBK%9^/ #YNLXR9 MI5<[QXJS(SR-32X/I/2,*Q\)]KO_#7W"VE9NATSX= 9E1]/KUDYA/4N>D#?Z M>H+RG12YZVN2S:FL8[=\N @K0]J4[)!"9['ZAY89*;G>$S5SVQ= [P1$A5G. MY#R,N>Q'V>S,84W+P,(0R_N]!DSW(S\>.,L.\1N?C"OQI*?EC=K'9AWS0 MU36YTEX52G0I*&GG"[CE'>BOB-X/[_L+?V*XI?>N!36$J/ M4( 6J::%JP\DNRR[Z]>^Y87ZG;965LU*:D;+T&F\K7S-[3=?YQ+&V.73(H=$ M1"NY^.7L*O3$\R88IDX=-I4HRSU.1;S<63WFCOL:6_ZUDWY_9BT3D7;PJWM^ MBNM=1JM0*PP&AV[ZV2R6N@P9RC@U'C=>-,/@65#)Y!:T^*H+>X?"--QS+0%N M:;X#"V(_=SD]M*CM1D4LP$EZU]?MXIH01,B>SO1.*'43=T+)+GE3 MT*^OC;DDXP;PJ<02).^B!PMT>1>KQJWJZ!+_$4 3N_P1P'!*6XALQ&F[?5+= M%W>X >0F-]NK?\A7=9ZL#A(9/;N.TS0H/DA/32GX7P)7S=I:8]@>HA QTLJ\6WWC9U;;92TC MY[\+Z03N59..]/.X\[N]?]=2$ =7OQ^X5X[50;F%!_. SX27C! N;V,68+GI MW?H53E$V4DG?Z93'$QDS&1;@]_^$P*7W[2MA3,E>+@'>9T 8M/?+(HN,4:1,;64@QO>S\8U=S7)C/>PV!@"U7??N@O8"Y#4 MJG?-=Q3+\>GWR-P 'M24QV3Q1+9/["(M+:^_6?4CQ'L*?TE7?3>SO3_"Z9%A M 3::C&79 J?=;GG-=XV37MW69MI0S5 9C"C4&T^B%Z&S9542U]MA9W=(7"O' M,2$2+!%H&ME.E_;!T2=YA#5_?8AU(Z4O97K&I;V$TB_92"ASC5W@CURYA0;E M_N6;&1%8@->1XPW BJT]GG/FN*/2BGNAP;<: HOB0QNAG.=>3B[I3I\)B?.D M#\/%E]0VK6WN"H_ZU1-S2,QC/B@RM9:"GZV)E*B!0,6[%]/3%X:P'YT*L50M M([5"Q W">$FZ+<9$ZU2]1VI;/=#H!F#4OI=3$Q](\7.]2UZ33D!*Q-'[.7>J MMIE/'?:5%!-R"U,M7."YCA8"Y%$LWR=K9Z;!\]0+!253R8;9SG%-\QZFC:;Q MTH^I'('0< $=FGKY7.*@IAM 27#6\W[S_+XA$E>,WPW ]%HIIH5J#,>]LRB- M+$LH!OE_.H?[#/T")>OS?3_WC3&]1^9Z9[0RXK$QRZKDKK,J$]AA3?HHOLE: MYDOIJR=YN@X*3EJN;RECVPE!J8DT7[52%S:RO@U3T*D(!3Y! <."122WQW9G MKRNW#0?(PT#OVXF^/Y/-X/)S\\ZB,@9: V-MD6D4!/:(WX15=*EQZ-O:! MU[[A-MSDZLR8/C>IB6/T?;YAD?#M!L WL._^U?2AGO2;NRKV_NE/')=I;HK8K-33V:LJ^F[H?9S(KJ72%6/SE/O:5#79-F MX!)%I*6OXF=+V/ M!D4?FC)# :BP7ND:=]3(JLDM^_VT"B&9DP"1#V-@933\&*VH)W5W9O<83DAE MB3_\^ZQ9;P1%*SZ<44^.-@J]:U];?^3I+FU+[DV-P M&DYGQHU?*Z+XPH&]X>YX<:RHA_ABM+"NFE>VB[_5"B05ZEU[3^.!@8T@'2*_ MA3'8,FCZ;ROR-E8N)7CM01E!5RMU#=-'2BKIP:EPV:3>Y6A1"^JGK:+(@OO# M=^W_NLK2396-IFCIZ"S)R8Y:J316] 0@-/I4W-+:KS.Y>Z?'_ M?'LAXENX]Y9HE$CI:O*=I]F8,YYU'NNXQJ3YJB]P^^6W#=J)_Z4,&5[;"97L M+)HLNE184#V$I6U M'A4CZU&NL(."4"/!K[+6LPS?R>JC^7O#[GW-*@'%J!,NV8\R&'.*(CEDSC-AJ/MTQ3S9%:;Q\[S"_+RG6) M(,)Q@WT\* M.Q(BEQY@Y5=!0I\;,1E!;*QJQCO%WHRU,F5\3ID_UVM/Z.1'@/Y7HC%""511 MJ;ROCK7\A5C,,U]4&&TE:UT*$=$8O(KD^!=F7T#JMJ[N@\TA$_^DG<3]5]I) M*S/N+AQK74X*^5<^2N+_+A_E#8Y]*NO0]O^7=UAA1I!RONN0S2H%UP8R>+V]1-) M5=(0>I<..J/SA-1^%]?AD?:GRHK:!O>K81YOGW=6M,,D;GVM-_V1[!WFWT5: M!/FV&AB]LL\BBS\7J:K\7'-:DOVJ&\_K OI@LCF$G1R5*9\YYQP)..QB6=4*P7_/EL*R9"9;.-$D(U93PJ\KZM.U7@:E&G ;YM2; MI-Q]]^>U9%P/6R',9ZHMD!Z=XHO2;Y=POFAXNGW2[SD5 WT$]N%C+:]+R#%7GHQE5@^M55H2_K'S!#K(SF]XL8?_#X)F:4)FYQ=JO1TJ;!> MIVZB'#H6)#O];>I9X&:I+[7/)3ZV.F19U80^NL;6/MUGP/=DI,W^&4B!CLO= MOIA6847E43F9%?P=(N&"XEA#'&2A29<*SC!Q\ID9P+0=!\8G'OU\R7 MT=DT=XLJPN,7[?%,+GZA^!XO/3I5FL(D_*5859MK'$&%6E@L\+SSKN-N".I6 M;=IM3G#&]#DP^%DK&5LV3RV?8A78(<)[]X4*/W\V:VAB@T8^:PLT05Y83YRR MXSO:<*&&KL_#BG?=YS18?Z>;BQR\$-=BB7Y0Y-%FKRH 3&,AF9MJ(< ^:9F$ M"0LWV0K43"Q:*0O.&=6E#<6,IC8U#50X@@KPAC4-??C% MD2G9/\C0F,1K'4) >-I#FS'TNU@C[0$;_ )H4[)PJ;+I)MN>S_;JA?_20I!_ MN>\Z!BKV#/-H[R+5I_(OB$GW],)0C;:Y.MBC&B;LT8=?(O5&*_'I'[)UZI^K M]6XDVQ)@X)I/2)ZN.]'DM.59*;7.^ZY :-[SYMM(0^]X-;@H_[N> MSFQT41/Z)E$J@YM<7>=,;N_(VGWD0VIZ<92N=&'##:!W+SXHK'KJA78R2-_[ MZ(+=%?V]=AO.=[VT*90U;J]D>O29V37$"[)P Q@-]V22^B&$ZD!YUM>XC,:D M__HK\X;VN#5>!/=0"^70/>KX R#B8I6SV0W)3/2S8[1;1*E,B3B#I_;+>+> MKGRD)F9H*VM2IBB5J8>YXHH9C8OWQWWJSU)H45GUJ^7Q-A+U\"JP=YPR1T,, MJ/? 2[W6W&Y)H;E!M^YRC)#JQQKFS]9/1O_%&E2/#=)_>VQV;]I!5\'V^7E# M8%)3U#2U'THI+M*'.J0^A$NX*:S+M[12WS\),\C& Q%26;0CW:-3D4Z(_#6*8G9COYEV3*7/=\NN06A5I,+PS-2UF MMBO]F3LW'?S"TFK&JDGK YG1J\=Z *$!![3G>%4\D"]@6,#_!@"<[@"'CPMC M5&(NIP=6"SO+J8.'%=(2A*O7JQ'EZ_$N7#JA0V76(F$/J9_>$1Y_:V;*\;'L M^S+39^G[( M!)'1@/.DJZ#VSEQPB?L %4/>K(_*4DZ++#JR%.N%D-J!Z=;^)#Q0[BI-?Y8!/Y?# MAUK+*=I:+#&,%IIMA&P_8R[U1E9E>UQL.XL+-.R]"T6ZVM6\I199']Z7RHBF M394G?>M-)?R>O-$O2:9X&(;!W*K#ZHGM5<%\B-A5+]=P?3)\VUE[]^W0$ MO #&*<NAF6;M22M/\@[ ?7@T5O7*$V&NNB_E M*;V_Y2/+I'L"C5)G*G4Y+1;C.-Y KWKDR<+LMH2SV9W-Q=[\\\3W=O&@J)C& M]\*^SUQD!EM1V:YU0Y+&Z"34KBH=N%&W=HQ3QTJ&\N_0]0_AC^50$N[MP-\) M]4RF]B?DXG^L"R6OH8;G6PE+.[@W9U&SYQ#W,UW:8_4:U(/S3\A#J(>9+M/T M#4#Z?J>_XO/I8MJC9!Z2G*<'W'R#?<4I[3"]:@@K_&@;)*#IQ M5(PO03)$4@:JMX]J4I(U5ZSSP4[B._H8!9]6)9===G,KCZK=7:&.&X##"'7@ MXR:$]-"#;M.+Y!FG:1GVMY-\$T,-O0?XE_V#?^@35;2XA$9>>@C-"T74\*D' MQBU-#"Y2;YD]4:,Q)0K_SV=;8V\ !',XT:7P_WB*M=_JOYYB_6?&"B>Z=3MS MJ9I4/@/V<+&=_>!#QM[^O^"<%KO+7QJCJ](C,99>=/XU39;VT]G%.\O2TU\$ M\R2$N:%+#SA)-]YH+22K,I6L'$4S^4;7'$AJN-VWGK4"_@VJ'5[=Y3]7((KK M_7O/GF#0(!D@?)=5L+252+W"MLBIH3N;U D^'GU(KU,+LMA*E%FV_]HH68[A MBR=V%8+07_.[#ZSR2Z&@)@DN]8]$S)H'B/CUK((FXC/' MKOR2RUO $W0MGC:52Y?[C]"V)IR&DO0-I4OY)Z@9 DY<4QWM".3- ^_G[NR5HLER[FSP@$V_TP7CV M:##9=H/RQL:>VRW1,5TS.2F*^!UGN\(GMW@"0Y!88U=\S \Z0ZM80 M):ZV7%3TC?[&\M4N M6H+"4-*FT-:!#>K@!KK[D('+//%!IF LQ:BQ&=B7=M\M&"Y/+RO9TJU_"V+F MKO5/RVD:D&[1(EB3LMU4,\)G_GL;>;+XLL<= O9]Q(0A;0>ABH@:=.ZU=>OD M#4![JR1J] 2RS\ZB\8Y'H4KD3[3!6*'A-ZJX3M8F\=?!K@O.+3^RP;5M+K/* M3]Z$6JQ_I6_28%>*_>N9L"@I +#-WFQ6,)]VS))]V=]O7$(62F'[RBOX7CV0 M?*[M23^4+. M%R\TU^3GN;?FC6O3Z1-4QEX/_9+BKX"G\R397PZ(7]8SIQ$!=M7O>\NTL*:J M4EGNON<"BBZN$C//S,![2ULE/3_BK=6"RT(_R@/QMJ]J4Z7EO7U]TSX$7+U H'J2XA.#N4MP*%*<$EV+%$MS=W=W=G9 47CEBSFT]D , ME\'ZZ5*E@_%:2Z0"C+ 2(,'#3"3':O/8;O I4AU6+.59\I$6G>:#MM@?UTBJ MGKU,RJFGSRK2T6J(S%X8,K %6P\J.ZM:IJ! M@=K!]/RN+/KW]RRQH:6'3/6)33%C+;=*P@)(@.3+)"3 OP().%/S;;=?&[DG MYFZ!8\4@ >'EG2-S,VO8*6,69,@]M/7.4G(9;6B7($M2D;"' MCECU*P-_P>"04\*3=:S-\[Q.G9;9KK3C&/"?.^%Q]*U4Z<_LCM6$;6@\5WAK M@\)6@DK-,(6U_>M]]X@/A1N#17L'"YL^3Z#DOU\Z!X$?@^T[VI;W%,>M?>'J M/F)]#\1ZO0=@\XW'CSM?+H(:@'V6W/(EE$LF=WUMKZ]K8QX,/E"PL+68UG&/ M$.CLS@4[Y?\W&+MQR[2Y7=F/&:8[6@4#=EH8V?A2EH=2'UTJLBB(Z8K4% M]S;4K8MGEI4[N"58"&C)-BO;]_;'\;*26@[TT^8;EO[F-[)/#S>T$?>"#Q[" MZHD$3+1KC*[5\Q@R390MM3383H8D#[,Q2?IRW4"Z&2@I&I /R1@5Z).A*#Y MR%F?F_]T:0>.A@1($/3N@F] JR-.)TX3#ZD7U&<@3=@9?95)JJZFATN:6Y&C MH\AP'P%M[;FZL50,5@"?5T^^>_GG<21@*G75>23B.M4\+#@>E*F_C\^VF0AC M>B5-)P1>_K9?LIIP)P@==4P8,4MT96N"4@3< E(D$]\52?8P.R2U$#1*FAG:&>J3*]:$4:! ML=3P*BAYR_Y<%(/F+1!N=9I[1)$?9>YXZGL(P*:_P7J\GB@ZKI!_*A9 M2.])6]>HRG9[.=!U,;L'U=$=ZR[*]RZP G9J0;A;DN(D<*ZL"A;X>1@ZJ4*G MYZDBDQ3KQYS2^E9AX9YDQ7NM%ION.5&_AKO/C94YY8P<)P#7599G51WW6V% M1;(ODWDA@W% 8NI@Z3 :=6/ZO]+0[X)Y*P0V2 @4Y&Z/UHY<[FSR)ABJQVQ* M">)5FX*(!@?D/W0PH'\&BHMH^_4(9'U-N/O%5CYS_.@MF0(>Y-*]77/.RJZ: MLR0*6)YC9W]15M2X>)RP\=K\H67EX^' XTQ([9?J)/%D&]BKM=[.ZY31F1ISXT\AGB[5;4U$0V M_6JP(PG\T"8,+XX_AY&K07UX*\^H0FJ\C>5AL"J(G.7[BQIG](KO)"[@[_7L MBQF?^-NZL:2R!GQ-+^IT5M:Y>&(BJBP%D\*(#C6>'*Z(%ZQXO22QEN.G6,_O MLIHUS&=W 20[I5T1@^(S[NK.WTH'UB4\9:H^%I21,IX=+!D' A@)8S'(CD?DI_=V #@N,EE\<.W?)>!T<,3E0.W M'"<3KVJPQ5[)Q>/^\MGZZ$>/+>O0>6?K'VM($C_JLT]#:H94=U>>EK7ID NM MX8;;HZ+9_1D/O>WXG#9G0[(^ESBK(*_5*FY/MK:(CYP XC/W MW+U[L\ \JB/Z\Y)#)* Z7-D"-4 $QHD^\E/:9W?X@XS._J4!Q:U"YS(_++I' M.6X;L?^L8E^9%%W;F-)0G76%BRG!_Q4&FD!KV9TU6Z)9"CA+6VLK%YT/?U_Q MKSSYC+B\VXH\)C!-UV7+/"42H);A%NT/,MV6KP .N1:B1F/V[B%^NFS3G)/; M^9B]GJXN:::_#;A80\27M2<2:>*#P)9V?^3U>6':>K)!":(.$I%X+QWU?SL= M2.,_!V'@.W(<]YR(+6] NO.BEQESM,9I_])75__T?)=%0"/GVG)A6_7[?>^% M& [<&*(VZB53J&QHGB$E M$8E^+E!>+XFF%]05X1QMJK*5PL[[+ U;84T9$[),<#A#*A(U%37U,['B,7%/ MVRQ*T\*N RO=(]Q+4#VAZ0\L?/RM'Z8[B'@AL&T]2",<_"#6*6 .[_EI245> MS@/:,+]6Q%Y6<#>1.Z:;.K/EEWMF- =O6>95EHPTP;S0XJ.JUBCW!M$FWJLG MQA47SDO$K>C[%>,OHY/8B*H:&7T4!]P=[:8!%K+.!D/Z%)?D=M+ M6D(CZ5Y.X]$+Q'/&I-]G", M?T_BMU3!I?K$MH431S:FNJ8N[9 ,RWK8-EU MB$VFPE)2K9ND-OO(2B9G(NW1:OBU8!DKFWK6^_DWAL2AAU3OGI#]Q&DQP8CJ MEX0Z&F/9(K:E]G#&$H6_&QC$B! O8'"]DU>^,^>^- 95B?]NUUB_:4T\B>[I63Z#^E-P!C&4O/_'55#DB4,D9!CA96FUS:+X/].)! M/,R_&C_I5-+RZC:MDV_^ZCN1K7" 5,P(S%,D--1P<=RVM6W%'R9R;_^),E[* M_;NHT!EOVK:4:-KU'JEV"A=^\4'?ZF^*A9@@5J8X>0L(W]2#8SA[?0R28/)U.CY_W^:: MP0-&&Q*0O9GYM 1KN$\I/"M> PEHSD$"UI_&OTN?(((5@8C[)TP36A87#N@8 M@PLXYNVK+BF4[I-^MR46MW7H59&E/296&?)Q\&W3]=WTNG5' KXM0!Y):^YM M#5*H3C6I[JA$*7UG>7>0 .E2;SYLW]Y^RIAS\[1DWX:!K3O(R_D5W5GN*) C M3Y5L,-^'WB^5&;_MW-'&FT;6?-LB#$+U42=LKO2 G8X*909+\PN^9IFI/4IQ MRP2VO#?VJQ^^O?P@420@PI)Y&G*8D^6VL>834VZ)8'@0K7,MT!EP-';9+[85 MZ;H7)_<##W0:?[03P Y,_T!@J_P8YZ5@;.P-RG/;7V\?WBK1V!X& B.X:#51 M0C]V*B_KU9X/R[&B>3Q2-O-&3D1:.?0)62,!94VI]7ZE/E7CY<@I01]WO1/RL887"BZO^ M+#V#;%)8<8,#;\5*)_B7R$RJ<0 CUJ#.E^:HH_9"2EG5,4[R8]0 @3)0UQ.% M%5LCA-W:9Q[XO#\CK,K?GQ]?Z#-\)4@>I9E,;34D[A/$#\$SC4FIA'AU.-X M>Q5'[H:__;4E!Q.6V]EB%>HS9@NF.D(HZ8(=&MP W7 MC,&2MJTFY)0K!=Y MT^5)I9VC@Q_%YQ*_.RQFSL^]&;.(!) B ;TU3SZ$\G>ASX&4^*%FUJW7O,/5 M]Y3J$5V3+IMCJ;QMI$ZHE.-1I607CI;94S94$B4"_)H0P=,9)_2GOW+-058E MQ.32),]S^&4FG@H[)*I*&,^V'#4E36: MX)9;ZKS^3;HO.V86K@"A7N9L8(-1>,O^]N@Y>H']"X0U83&3.%T)S,]Y#4M@ MJJ\QI.?U9^2LFX/K_-Z/C4)-7Y$MG MG+!A@O-K]>,?:UXE:3O/":>5$%&R<=:KUT ]=AYH2]BWVK"E3H&<^DH)&"< &""T\B7V+E#O"B"WENX3EIS>85H MDDS]-3QM^WV9H/9/]+ >9VX0R2*7WF<3H59,4L6'%%D 6TD2M?'AS6&8 YN M_DNGB?>PB4F)8.)N2:FWZX:XPSZJJSLM#*E#I\K=0QS=B?=1@Q[>5U%Y>9#K M $5[XLYI)("7&." 323D<:';"*E^<5T',J8/S%1\W2 K%5Z)60KR@\9C,R-P<_Y%EF: M)O%3Z%AZ=QH9YA->\/KK^:3-K0AD%Z+W(37NX]]Z<4;HQ)N(F3&8A, MNI79^$Y)?PIM*'L"![ $RV+V7^:6^#&\AN_;#3EJ_2*[=7_(+HR>,R:03LCG MUK3LO[*+V)(I4M'_JX7BF V_T]?Z=&E@T:)4>(9W5!G=@BU;C2Z"Z\B%+BU( M!#",0Y#M(Z#%'?1^G /26Q\]?"_-F:W5?[C*6@)\_EWCLK/B_HSCM;H3576, MXP1CN?"90??1Z[;ZRWK1/())UWX?=374CS]?\@V[X="@:XH8T$!!*>,(7K< M)$ ONAL'^[&>+^6]7A!U;)AGS3=)>8FCAP\D#!EN) #<#O6?[J69@K%*,R+Y MX>?*Y%YF36/6<*+?>X0LHO$E"Q$/Y=7 *F'>.;]$,\UG;$5U]G46NG*Q:!0;HJ<]J=BEZI*YC)T<[H)<'3A)E),C;4A^:^E$"Z], M7^. R&:O/1BS:X%_.\F]9YWO[I6 MNJ\2.AE\( :C.:QNQ"19V AL/G).N?TZH1FG!8EQBVXM@V>NG329+_+WEP?RMGX^\4:+@1^G^"6@V'N3& MU6/Z9X[D3[&033 MV6=0_ZK0%I@C;J,WPP@6?L-9[;68P?6)Z GJD)R1>ZKS1.1K)*@/#&/@NENV M4'$L7_!=S%)R O7)QJ]$>+6ECC9AL96G9C\X,2DJHM%.P7"94IG5NO*\$)4' M8SVY-_5B9IZ]J7SGUQRH']""ET8D%\)W=Y^_[J+:/T(4W&N*Z.'\5R&RS,-/ M> 1XVT$?]OLV>*P$3ZI2 RBM83WT_@B3+!K UG=]4RKBN,[6G4"?O/>B>OJ& MT'ZIGU2UDO=&;>%-SZ"/]>J]IE$].'M$N'T4XIG"8T; MPBRW?#Z WJG*;:4C=J/$#V=\'FT046]WH:,@E!ODLOY%O:JV5@FEE]68!JV. M8-0-U/7F-L&VL<&=S:0J?6'@;:<-)D!@ \9C9("]%__!V/@97SH,M=O_=6\! M,Y#*$RW#.0]^MH%F>>=!9$C9>Y&T4TF!DCYR5(X"Q)@R"]VJ9N0 M\C\!)7;9WX[;;/U8W&+TP#&?I#O*PU).L'CK7)UFR3;-SYIHSWZ-%:=0QAE^ MK]1XLA[3?42SIG@4!"TP=W>XB:T.!2?(HLBB"=!,U]O=AM?JA)<267(<%/V2 MMR^FE"O.V7R!! 3([NT"#,)3LR-?M(Z/VF%_0@* !R/3^?$(#!%;3GKEB-3! MH&2!I0*F >R01U<5 W'?#J-;382_3OGC*02N_NZQHI'1P](C"PGPDT$"NC1+ M'YN2D8"1E7:Q30=O&1QX2X2H9Q("@\N<>X 50NCL3J>Q7"F:FA?H$;A]=5-\ MTW*JX,Y#P3Z@5'?;4SID:G9"^P::FBSMLCB$@,7)#BMZPN"\#$&^NP2_D8"5 M)WC=I?(462/6#.Y?6+7<=/K"U3F.%GN4EQ&X2 #UX[\NAP1PM5T:W-+%P&E@ MTTD>KEV/1M/K8Q$+E7NA?WT6)_M)8H?# /$P>#I7&]-E^:O;*ND9HG6IQXD] MV.AR*% ^$@/3 6U>.:7;?F:Y:05!AM_>O,4O4B Z]_UO.'=L\MR]&/!(Q%[+/>D"&&ITQVY&0ZP[250*"U* M>@O,(P2=N, PE63"&_P*(E#'U!386VZ2'G-I9_&;%*6ZU>RB9)R\? @[V4RD M5Y0^D+N@C9YL[#T+D^E_3OCJ;GX6$Z/5!I0?& X>OC[G*O)D(?GH=K+6'(5Y MH^&AUR@8R0M^!_-F.]K2 F]*+C1,*PIJ]_3I7]1:D75KJ=P5^_XC+KQLRNDB3"CN,/#6J:*!_^_0,OU]0?;),X0#4L,,;0.T@4L,F;0,GB$@3;Y_4!V+* X]C)H".4Y29HI(\_XY[ M;-II"D.)B9]4/T)K]R$_10*"JSW9C+5()Y-(@R8'G,:)@!%A&VE#:"1W7K"D MHE7,ZQ)%Q[5N_]P]WJI=2D;$0",T1;AXY,/G/;+GS[JSA0T=Z;D"Y/;=>M\7 M&<2=GQ_=/=]>[FW(@NO:33J^_?!&'RX( M0J#?NG8("FMP1D0$XP)[6,?E764-SUTJ+FD7NI4W#K[VG9IWQ($J]P>E7RN9]@23.LKQ@4._VPIF[W0D M7K?9.Q80?[;H"DWARZ23DVZCD,^XBBTX,,"Z$L.5S)F]-6+BX DC?5U!'SF: M<(=YL'TB?@Y=ZH"ZE^V+A=PSS^G.D[G$O8Y KY[#34_O(/F1>?VN?_%1A+DL MY'3D\^B5\Y3/E&^A%7-;\YBW_38?;O4W.T"KADC]Q4SJD%K!"8B#S;;G6*/YJB*53F.3!>T8_7CZQZ&VOQ@#YI57(\?"@U!VCI' MJ $.M]#VI'+PBZ&E2R+Z<]_#['CZ'G_:Z"]]#6P[3&WDJ\Z]9B@_*A>F<5;) MP4G@/<'];/>X@8RM63&FG8PH?J\!ZQU:3*W.6R/!'>'5]:K(PCV72T1+>0I8 M.2BU=>C2\V0IVA>YB70 M.$G86^(1;Y4:L$)[0ZC,^G(O>SEPD*E"]Z\ZP(]/Q ==+DF4KR?8:XP+^\B# M=X>3A )_\)5PH&],F$3=S4 6X<_QK,;HFAN= M.Q2?[J?:G7)+F7@*?'+[N8"T.DA 4-/J+ZFL--6*%-MCPG>QT!2ZSLB\E*,9 M!VJR-,S]E-[[Z<2H#0XTQ3R]@^MK.W$0UOI"FST6](Y=;U0VF$=]4<$[J[;; MQURTILEVE8)R6C:#40_386'03Z#5POA\ _YLBDPL2) P;:UFS+IKJ+31%7=) MDMN12I!$A8!@+$:" +#YQL%Q.JL_J*1,O6#3,;#' --+TCY/>P ,MIL'Y?*V M'\C'?E4V6N=6U?] 33?Z#HV\D#)![+MM(\;Z"JD2-P1[X?4#"S_'A$J2XCE) MHDR"2@Z[7^P#]%M'3&K-)1+PG9)JXK#\*%E/__5#J,UQ;GUZPP#M5XR?\8C; M36S.GF?E;E_7MG^M84EX#@#3#HIR:X*[?.;$DM\'T#N26WSX@):\F![?+5? M-*82%YAP#WIT#Y-VU93=9\P.7^7[UYZDO\MZ>,TH?'!]6W3?F7M?&@,H[S]E M/;%#Q-SMV"H2<(\$*&^"KM?_V0@KRH0$>/R]$58M;U!.ZJUF-]Y_BF=+ 0S= M_GD;FW4F<]_@6X1(&/EGY]?_0!@E_4T;+(6'UEY\CD+6 1321'&?\0B\8"3\ M1W%B@H!#9AKG5WU;*3EXYC9#'0+=]C&ZCOJ*KJ <*U)HEB-?E,UJP+X!MPR( M):#6N!JKU>^#?2L%LPB.XFBUMQ*H3EBC/E"N*#]G6[?3:_@]H^8[UXW3MRB' MZND?"L8+=[S3]6S6RG,F'.6.*V MW =Z@CQU0]EW>+0.S-UM)O$#7UKQ/%#F'!=GXBS.VUZ6&[.-'T,50N?5KSZU M0L:;E#7.H/$V'%E38"J5#$6Y=6#O6W?'O7+F_OW2Q\. '(KGL9\(V)/66JX3 MRF.K]PS ]@)BE@_20R=5MF1>3/Q\S;6>ZGRWKTVT.X&OQF"1NXK-T; M=%\I@02 LM4[G%&GO+0>?;0+]I+#:BG"K[)QA5H8ILYAK4ZK8*'PY_Z1SZS( MRDEO)VW$:R0@=N )NOT):D%$ZLS>_BITE?@^ ;_>K4S?68D5)$":#> 3?!OF M:G$14W!!$)';,1&^/)WDDO;AWI=3^UY7A#\3JS9XMK5$H%'(D2KT"LML^)R_ MC+V4K13544+OBQ1K64\PR2(=S:R?^QZPPU]W.NN,IJ->\WJU87+]^VZ5^(M[ MJ./KP<*Q9V+S>.QB5)(ZDK^@F>5/O EATK^D9#.SII_GGG5;WV$P=5@C4'/% MR3-(B(.3A(VN!4W1>JO.#P#O=VZF=ISQM?+31'QI&MVH4>BIS=AB'9^CB?YR M8M-.M(/IMW >@@*+33C03V"(%A8B.)I*.ZBWTM/)D1-F<_)?5^^^-LQXMFD^ M0<.#*8;;R&*_&=HHD]<[(99$6KIITF""E6E>)DM\];X^!XA+--C"<5 1'\27 M(]S0OO+\2D]2<4JSD[Y#6>$$VJC!Z[*FBL&N+5D7R?GE+_L@8I)\5?) %5J/750NDZ>U(N/)-0O-V@%6-DJ\>?BH1=G@3WPM4$9E+N(T MNY#B*FC%DC:&H'$#Z84H>NJ9#4)S,TQ+.#Z6Q)7)]JHZ3BEO>C,K^(;J$]7_ MD$$+=:K+_5B"0M,0E=S;&?0%93.=W&-UXMI1Q^'/MMYP0'@'I$>?O*:QL29- M?\*HKDHZ;IN)?4R'0"61'>/.#IU!!&4(]W:GHTI!6*YL;XCVS6.VVH.J&?\I M]C7)FIWX2.U5WN'.K$"2HT/XCI-!J#[%&=I"5'0I2%"[3LX$GWV9@"148!.' M$T4DK$NRV$OI%!I>119E,Y1!L@%+9,S7='+](9U9*$#%!?!F>A!87BQ;&Z(X M=GZK*00^>]XQT8.64CPWK\B6V?0@TM4)>B_QU6>;K!;%P7$"D)'@LM+EP38= MRUN,76K*GH+]5]+35,93.,RU(@$'XW9Q2S@IKCP6)?R-SFM]N171(JY*[AQA MA/WL\5QO7'[D"%_TS(1'4X52DM1)C(+NK3>&M'Q=7GB$64L-$J"IZL MTAVH&U7133=XV\C%<"V/!%@MY,[_+,+\0J)6+WN:$E"+>B3T%F$\78H$M'>> MPF833Q!X;!R'I=1!9@^ZGMJM?5\<^]K0]D;D??I!AW^V8QRSLBN=.-[N9="F MJ<8HU0$3)XX5\[HG;FA?D5'%OYHNF;=W,6ZZ?LHM/]K_KGATK,P=?X:#3NV0 M@()+A'2+[3]""QWEW&1^#P9M^%LBM[WK@ANWS79T+F;<FM^C=NJ,T M"/KP @8_C4'IIB0* =^P M 9FHYQ,/Q7,D542B!=+V_"3/.EX_\F3A#K?O$5 E_ M' -''S2+EKUD1VLHE(32&GXI[8_=*3)O$V]5_[''53>1L%M3%O?CG$E]@AD( M M_O8KM:X[ZGV&*G.?_M5R9.')L/DYN"8J.VM9?0B\*H/+>5PXKJM.1> 6.X MD+;TG>-;V=2OK90;! MF6,"9GW;33,=Q#:I;9& ',+F)T\*,EC#N2?DAL"?Q\"93N$\IWF-8T-$(=RU M6U&!.:79STJPQ=$H+)Z#5/6F'7 *+@J==ETBIXKSEEZ_ KJURWS"FTFYC5A5 MBEU7E/G24MM4KQ"Q\VM[SB]ZB#27+N2,V"5861*B<]E_/@1:$VTJ=&L'/M@2 M+.KLQND6_V(E[(FGQG)*&=%PDI:$"^528#F-QD> E7\.9]?/;V-GG8XH32.& MN%]I= MT)SIC.V=KGCWAH: QI;*CN_%?T8)*]P]K6_SN9['='&P(B*J:J_0.R:I_03Q[N8:QA'^ ML-V$IHK8M/(ZC/;1+Z.;:\::Q6!GXW[T/KQZU[!E_$JV'6V*@V#*S9 MO\,TJEW/J$PSR,8QO+.85B$@_]8OT;H-NXAUB5IT049]]%%/5,-,6^ MT-<*)%C5*;68Y-!SWO.6\3<04^UEU##@W;' OA6%$E"G?.W1UX#S?,4M51"G M?8EWI3VU.^1E"8S(P:#'T=X9T_B&#]==59KD-:\=WD?U&.J&9YP@\=/HA">: MKUDW68-EQ3=9$[/8.\$L4=D_3GB'+^R]RKMY.>Q>IMV, MV0XH+7G^+U/I&#(BHR*5 ''BO<3^&U-GYGHQZGUH=/?0R.%%SI*5QD03O-2F M0@JKD\X]?F#Q3='2=S$^,::]V$ =4HYVXFH(OC:H/KCJ>L_IUC@8]8'6[K<4 M:2^1/846!C8P.AUER+Y>N;4%;\^JA(=QNU9AP1+>5\.T+/ 93.V^+.)':/B. MC&OR> MHPTQ[)"Y_JJ%VW%J>"FO4:')C@T5NLUW#WQNKDU2FZ Q]_?UI>=B_ %9[L8Y MC8V6EFOMD6\&3 F+V:X.1!$*O6XHQYGE"=36ZS_[:VV,($/@69WT"Z&B7EI[ M;7V26]MU@^?+!OJS4MG[559GD)H.IW-)BIP4BNN.[^ QKQU&EZW*.;(_3.H: M]1D+8(2.9>G](;M^>IX(<*TL*7]_;.2WV_SRR-<9LP23%

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

[;4E5C7GE9Z'W)*I4)V4X\K'> MFO75T\=8%S0?X3P;22ZO*]\G;5DU4>TW6/_ON]2P>),%BE1OHP'"!UD&L-D] L5YOQ,< RM+9J\2T:0'"=3T1_- M1Z_$F?0>59*-C@66+3BE3>/HL$X:,+X&?TT>H#_"I^=5O4WHDWL;H932WL[G MWE82:Z+3,T/JQD!2^]N)?S[FW;OLA=B9'85YE&R[._K+3'7;:1:5!GLZ0337WGY?]_0:8E7N^X>X%@9 2P2BX@J, FJ*L!]4610AGZ49G0'C_M!A!N@1H_/W"[ MO %PW;Y"E2L@V8/@\>C@Y7,0]N=.R?<']+I8852,[F:7 Y^MO)UX3C1C]Z<1 M*>LMB=/])8C&Z?KJ<.>*YY$KZ)9WE9:%88LQ;HK85J:LC!E8 @FU5_3O1(*Q M%;RQ-Q?$@*L-9[3$KEF=NPT*:23+]-35TZ?>D*U1!2+,C!;B7%X"4F;GOT"F#$KW!.S-B'N5=* !_9N' <_?R. M&-1^YO[X:;(OJ].LC]7;2TG[M,_7*YQJ$:AO7T;?-F&@W8CD&8XP':=@_COQ MA&TF;"*04<4+G'V;'1@H8/W#3G.*SGM[SS/3W MMW?E%_AL;D.KYC+W@26):26>['T>Y*1%'Q%S28=EZ8IHGTOC[A@=8B"3/WP= MC(J^N@T101GC.(+B&P#Y_PIH=O](&M,ZZL[[7IYV6(WMSENF]>/"3"N%RW/-8M!+ M/?/H*[9\[%FW-YP0:L54F+_\)'9US@2=('\?K[^)"%,!JLN#G]\54Z:T#)FW M^J-,PS?:.$>Z"!N,,H6\0L*=R+?SG#CL4;AI>T,JE,'G5G$;:Z%X\<#?#+,% M&% W"?.S*48]>D4G2OKZ2'WK(Q9:6[5;2'[VH- XI.D&X)]YH=*1#=1HJ(ZJ ME)OF*.BS$(GGW[P!*#B](IL0VR^I]-"\SMK,5,E4G17U,7X9N^S7VM*8.R@;^*8 [EWK(F.PZ^$L('%NQD?NDM'F7YR>#PF-=,\:DIT0<&" MQ[PUI.(##;S*:,P)GLP(\/?VW4XZQ1'?QFB!CC&K)@&,/EI:X\J"+DH^))1& MNIHG(VCLPK2QK7"YT\<(:.!BE>[Z@U(3B*BK'6#(34[/3A]\G30 5^,2Y0;" M\QD+K_)%!$BPA$N[&O43,BI.7_8MFJB7W6@(WX0P]!/;Q,[H*MX/_M!ZM+9/ MRI>(S/;7HA[9%$U%/ZVOWL+/T9*\\)AJTK_./C:4 5TGPG15* T6#$0FE&L& M:Y?H6 *DH<+Y6H1X19$!#6+CY@\8E4! M#YYJ3N;49EK%R7BJHMD.3J/='Q3RM<'@^IHMQM)5W';#"8UKF.ZP7'5H$393 M=8YOSZYF!BWPI/$V,.(5!O(&V+&'?1(:IWLP)@-D M6J(H@_?XGR"I'++/?H'M227;@^[L@F;;U"T:OMRE]<^GR9_\5CMJ)HK[TV^. M7\2E %H!6DGU/14/1LEA8/-3^Y>W3SPN$%^;^2>Q.1TBZZ23Z)?\MI8;HX^[ M6W@ZS// RT;P;M!4YE4'0GU-5C&@Z>3)QTKQ-UBEDMV'4?RB"/F@"4T;]H1M MG2]!XSRLU0;##&J7U8J)?@E@M^&7==@[!?/SPRY4T]D3)AVU$'5K]P'L,WOM%@X)Z_7SW,D]K@C[GP7[J;K\9#U" MT=XH$I&Q_!J<0L*MY[NG]]SBC]!]_M$8FH5;I/2 MI<:;?+JJ$J"=*[4-'#PMJV>52V M=E:7A6P;PSG/I#Z.BVS5CXB9T(B MXF3%CHZW"O4R5VDB\VN,2QJ,C>L#<4;&(Y6'+GTK^3)K;$=,#9MKIPYUB7L. M_!\CV@RG/:<6C8F:'+ZQL@9T^;R\C^[S=^VG*JT*( +/GD2YHD] O[%%R04) M%F#ZTTQ_GX#O"WW=IS:6=R4E^H0R M+\JP*O.T=U$8S!D3AVG^">:6W&\ M0 MXC2;=/Q7HZ=,DH#!+8>8.G384@S7JDKD28R]@]C9+P&X,(\B"V @!(GW>F*] MK\MT5'9V250]@N^.?OIG">Z:O$1D%7=BJ%&+^TG[W M_$+Y9\;;2^,=?39J,+U"IHIXS'N.UV&).19=Q^^:9"A5.!E;GPJV:?67PI&* MOL2C;CS:)';.?_TK?R7.+Z7TUX5F8UC!PG:CSKE>2GS!PR*/SZ\ =/L=9;G0#.*&T#U-_,+JJ"M^7_3%NZ\]N(OH#@R[9FC:A#^ MR3]4^1MQ+_Z>_OW_,>7+XNU7\/LJ2H_P9!_]MRSV_V+,-PO_!U!+ P04 M" "F@EM0=(_(,V!D !R:@ %0 &]Y<=S][G^MZ]_YC3];D6I,U:V;N=<_,_?TD0<^B5P"/5155 M% %86%B CY@7 #T/> W ?O#@GP.3<# '+@$N+@X.[B-\?#P"HD=$1(2/" F) M2<@?$Y.0D1 2/J9Z3/:$@I*2DHB4FH:*@H:<@I+BGT:PL#'WX. ^Q,5]2$%, M2$SQOYW0?P%D!(!^K%ULK&> !V18V&18Z$X ,P" A8OUKP3X[PGK 6:,>/@$ M#Q\18BI 'P,>8&%C/\#!_F?4F*O^F.L '#)<\J>"V46J/G; )?W(->OB(BIJ&EHZ=@Y/K.;>(J)BXA*34ZS<*BDK**JKO/^CH MZND;&%I86EG;V-K9N[E[>'IY^WP)_A82&A8>$9F8]#TY)?5'6GIN7GY!8='O MXI*JZAIH;5U]0V-[1V=7=T]O7__XQ.34],SL''QU;7UC ^%<0CE]/"-W=Y M\DPHD(!"/B&GLNTAJ[#V">4GU[%'5&PBJ^R(?TS[EV7_-<."_H\L^W\-^__L M@@.(L+$PSL,F P !IU^X0*)'TV-^G&7(Q)$/3>/G<\?E-?6R4_YL+&3. MU,"7OI_!W'T08R0V@E7^Y $R:]G4)V5&/W9\6"'TV>:OL_#ZW>5^ZY[BM0;$ MDTPIIP]32^E^PY&/0U0C11E3&N_B)&>:,2T;B%Q-G<_'2'H0NGC9VAC[C&;% MMG:'^[&7&]NYV&O9>0G-JB8IIQ*D:?\Y/#.*'6AP]>_RQU[3C,["1T#+;ORW MWL[' G9D66-)-_TR8\B VPE8^.Q9(0_;2_?AP2LU5-E5ELO)M2-[8_ MUO-L3NS)(<<31]7 B2M0AOM:\V94YUS OHES2_D]V# KN-W\" WP+4R!HP$S M%Z/7$-UQI_.76]6PP/(*'9UH1SD6H=#W;4<$P)CW"S(.N_3'T0$DC>,7/VKN M5Z+"2ICR?#TS<7Z*UP_RX(Z.* 7P+@E')^:",?50+[#W+3R M\N$?0QQ9ZDEO*JU:%=\_UY8/(A$G)Z4$&T.LO@@@#G=1X(!O]]HQR\>IJ\LS M-^>3UZ'$8D=;[7LW/':6U5"NZN$2U3?&\8%QCO$NYZ)ZK-.M/\8#@$BK QL3 MTS6';*C13N(>U5HO")8^MWS(/0NP^MYSQD2R\%[: W'6<;J+>@:B6EOR=_(7 MY'.\H)B@-8AH7.KO-CZMI,*JC;;!EL +B8*,]._ )HI2?V=1A0D(E:+\_4:R MFR57,_6Z;CJE=*/,Q0I^#]+T@ #T/[A3+/H8*9X@/Z"X3TR;5GQ_\T'ON==5 MT[WO9E-6B)33NC=9XA7]B3W1 %+1&,)5YJY5+]E?C<,)( L7FGHCSP=ZZ7V3 MBKTT"1%LLSX'ZE\XOZ$DO65YS$A,3%Z,"M0L/C/2,K>R8S5\S6-Z'?/G;N2L MJZ_C8QU.H)[1$\,G&AF2>59+-\MWJ1KY8QUC&73%L@8FE[4I:(#X3,Z9KOV> M;=VI;=7>O@.K78)&[8@[?F]550J!9C$@N[TU9+I5PELR%S;!JZ,8XN4 >0A2 MS"AA2_%1FT4#2!27+4)$ZWP09W_'56C\5=6:J"=3]KI';FEUW/51O0C%%]X_ MNECQ>@+R.$4S*I,/RA50P$W8Q88= R.QLT$ \W;=Q99?7L*^'J_[SQ;5I4M? M?:+1.87M!0D6@O4%:I>^BX\2%Y"\PP!II)DB+-(6,O]N"GL'8>8 GK,/T]*W M2:O8F-7;'-1^YHHM!L_Q0/QL3]]L;C^Z5..Y=N2H5-MQGUI\@ ;8*8G@?N#" MMWSDLOL5:F8$ :\TV2V?UEW,YP!U\IS72N]@+]$ DY&,*U+#EL*=NIM^,YF8 MLE0U"\>95 [!;&Y*;MKY62HM9.1-*8H.NXT,^?-=/5V9UXO[]&EBV4O_9^J[ M1-J"*<__8+\H7KFK>V?Y9TK*=M1T#DDP:F@ MD9PP[B5GT ]Z-9<:[+]X.18\L&O7Z<6;NT:PJ<>%%"'*C!/F?+9_[^--&B8M M7.H-TXU2&W/DF(0^Q.+!(4SZ*J1R &!46?$;FN&5B)XDQZ M0L.O##;+4\!8C"?PD58;-#\QU6K MUOP[^6??&?,5-"#I M@ MNMZ\.7WY$5B9MADRGC%WL@_FG&V*D9205W%1'3$M/[YTMME'Y)!SITC/V S.S?6>S,X&]&CZP?2/8"./#N"P1,.F>*J5L^=EZ)GC=)DZ724B/-_7H;BR4GR% MUQHU+2OJK5[N;)ZD^]-DVHM:_EEYLJK69<1:%KIJ% M,O$BNJ)GTO&"O4H-.SB3V%)6EK$]+791F\4]NC3@Y%0&"SIE&G\F8YDC\P MJTK?T!21.#L=[E>Z(_+J9M,.JJGB[ 7^94O9P=9@W0*ZYN:KF+I&0]1S)BT7 MHI0Z^W#.BKDJA=E< ]YX]134;@=+X:H_TACJL/0=,J[OMB,?Q.'_P21+Y] MP[]?(Y%--IV>-MK_#2I?MRM*FY98-RWK7,$Z4H$4'@9(>=.-KPUYJ%@B>!/0 M ,O[UMM;$7E1ZB"C4)^W?OY=B2SB'VM'"EQ-)9#051FC;KCZ\:5)!92]$5ZZ MGY!_>%UZR1?R4T\NMI1LCN2T"TRW)@$$=Q2F#! ,U+EQO_.CIU'#,5LRJ M/9.EQE/OR.[[1=&>Q9?%/L0_P8*B&8H0#DCB3N M9L?ZQ%U*UP2X&^GN&B=/K<&-4@_I55]_82\5TQ13?!V*!)2]DEFVEZ^4_*[%JY5U-'/+/[\G.G>V_-@#WXEM8&-153_BR2J\\\_%(9,D.S6&\Y M'LO?FC&9O;X\<7?C4+\9DE-> NFH@UQ[3%AL+S)C5B/NNJ%=;97I0IFVQJ=P MR_ QM2;_!T&:XW5W/"?9W;(2X_-:H](R7B6SI=_M5IY#]2U8-D.EXH9;SCX@ M5U=P)@X^5C>EN]D0+U"=B@:S)73PIX_R6H8 LZC0ZY]S_H@)$BWM0%F(J1S MCYA>56_2'EQ\MES^^4>KLSP_HJ*4PADK_[ M_09,T@^+ AH9H*UA8$\/+.)JR8EU.Z<_2D??7VAKRN:3R-B)#%'=&AI-5T(3 M=QW+X7L;W<*;\OEX;@14] M^V@MJH2P!=NZ7\ZH( C7G8,\8L3?AVDV)6[MF;!J3WS*,) 2YJV2'WW*1@)0 M.GB0!>A^J$EIHJ(T)^/OCH*5QIC;NC;XFK2(8LZ918<*3>9W+Z].C=08DSMJ M/B\(Q2<*K7_&;Z"EO9EL9 K[[?U3%SI^7JHB<$%?=+I2^\UJP_%)(!+;=/YD M>QTO. ])VF$H6UJL[NQ1.%!<]F;V/L=Q(XN=ZLI>2CQE%64*$U-2+<;O$B V M1(UFD2.TZA/7-2;(%ST8M1SO"EO2GEGYW"7T+BA?2?1M3#4K. S+CE@>MM:V M-'I.2) M;)5_%*V7NKY7K$8_%RVW0/2TBV=A3W^:M'I>LE>XMWH0T*DJYSK#PZ9 J^,9RO9G]^_OFRGWY%WQJ_*[K$9PJBNJ5*'./L)_!&'H@/*/R_0 \9_)3Q[5 M',HO'AR76]K:U'TWS_O\^<-ML$KA;NJ7H5GHG]J4TXU2B4A*WBX=-<&_!Q3D M_H&0/%&S*#/2B])#-9WT2]LC77_WUXYP-\$&HR[9UZD[32H[/OB,58H'X!K\ MP//Y$5(TP&:OCHPOH?ZK";',MWBC@8^?=%AMF7GG]4N(7!*R[)F$8/S?30ZW M88OWQM#@7YOE5@X5\_YHP%1<$C;VZ!9TOMUPW*[:GKC0N."[&,*D[R4'I7E" M;0\GL'V0 *\E>*VHR^R1]\]5D]"P_)Z'#3&@!_.B2?DI$#K*=(6DIRZLY!I8 M?$U;;91_8#6BF7'?REI[RA=BG("DN^D?8\K.-H9PAW?#/SV*[XMF=G0QE%;W MHN0:GVHR6!XP@4&$V4-_Y4^6V":?URUB)*_?>H*)61B* @GK,A2X;$WZ96)F MYYLI.T7[ZF?J,8F^^Y"O>UUXJ\/(1C"1/JAO>B$ /B[O^&D8 MTS>Z&UJ8K0.M^WMS_E(O-B7EL;)!Z^5-(;G/=!ONNW^8(?;2KQ'.;5]J4WUP M"XOY?Q8-_3;I\\CKR6,K]]\RH[5H.&,P?]0NO_Y[_NL+=:ZURN>WYS4P-30@ M=> NC%>,$>):6+OO?':-!J2=Q:[NJZ7?U)D@-U?47VNK\$(]*Z>HAD_'9SJ9 MY]1Y#(ZRQ,,/K'"V1-VOE?I5 *"MAO)_PG9/.S/YOJFQFSWHMXGMC6H@YT@7QNGV)$>GF M7+C\=E3%*?WKI+M+$6^'H9U%5S5MW WL>>4,S7Q"HD,$<@3'N\E"#Z8V-&IV+.]@(9-G7;3B&2WM[NSFS MY@X-&"A:=#CYH*7@Q:#D?/(2I<89!#O@;V>??,$.G)'/8 &=,XL^]J;#;:>^PE4EMY!CB2Y>P*'K"3WWYN:("\9P,:$'0-1J8#5]\AMU'? M#C$?XIZB 0B1_Z*-UQ,S.@ :.9 M%>"55C,41QQ([3IU*7AV"J5WQ9#\7[!B[+ 8+'0[ZDL'ZT>M)^8V+B,_R$IB M'M5+8\R2\H/=J3/_^Q!EH );9E^H_V6TC%D'C$CZN8L/AH@>+MCJ4>N9/CNY MGMI 2"U*W:>\9J@08[DF4MD, 2V<^E FKT&PD;YOH)I$!DAY-.#]Y$\YZ!1X ME3UH-W3.*H:A^OG];)W)[<,]@F%?7L M\(6JP%B**^Q@]20E9(=X2&J'U]8@*![L&TPY0X/_2K'?IZ3YYNR+OQ=(C_^HG<Q^NG/DA9&$@:F$4[FUA^ZC#V0)L^1 NOJSDA+7 MDG08>,(Y-?G*4BUAW"6&([,IH.GN[I9UW ,RAP9TB--IE/ZVK1Q& SZ=3#49 M&XE$CS@7JUU:Q[["YTUDJS+WUPHKL-"\Y3.0*S7XN\0[9R>B)S=8BU 2R,8) MCWD\.$^1Q/$J82ITG&"$LK-G%0V(^C/D(607P*OB]"L2[F7DTY;"A=C,<^DU M*8U[JUMJ?.>6>,V_Q$PCVH[_:,A9D,:/FF8^.+%$DR&>U+!-B8R1U<1O.76D MN-J=O>PW,/$,#6!5 %JGU(V+[I>VF/KZ#O%5%,1.KPWT43\VZBW9WO*? RVW ME^71\/7^!OGAK_(!UV>B1614X7*_['C<01;?!T?S"I=Y%Z1?]58^T-ABE"CK M#EXWTE^8@T*BZ>";!79YMIS/-%]LJ2^XTIPJO9VB9R:^,YSP4Q,(![G'4724 M#QH4P(P,FN?$/\_'RG[T#9Z&FDX5^ZH.?#BT<>K6G"MB4A50A'@$;+N5!HS< MB.64#OBR;]^Q2JEW-EI2V17:Z(2N0G BJSHW\@CJ.KW-ZXDNUJJR+]UK*B=K M6J0P*Z7*OW4-OG6SQV/$N.N,(Z3V!/ACN/1,^B-QURN0 .^Q7!4CK'7J\NO&*WWZ=0:K#CBL5PW17K\-9^<)NT !_U![K^9 MX#_R*)IP@I;+FPBH!;U\+26-Z&:,'JGWL3O#RG@RN?Z@)C]NK;PGQ$\IW\3[ M?2=UJBQ+^N(%L<8:?'4[14+I:(TE^B,3)ARJ]HSZR2#XV%@Q%U,S3=7G/Z^BJ][CQ>%R_ZG)/ MI^X $^Z#""M MM%:PF3&=M)/%E0)W\.9CBSCDX#YI=R.RM$A^/>I96@NWZ58#$M6%_<+L(%3A M_;V.*7!SIG'7?HE5E8W?*V,"=ESY^SQ%_H<%M1/^X-5VZ80D^RAH.?2B]>:P MZ$X0OAPP).5_'%Y41])[0]:6@\\7-9ZN M#/EJP5H350QO]EZV>TF;ZIJ^\%0)V4UHZS$F00.: MU7PZ E8^,;G<88>807+)%4,2JEY:)-K9TC[L FNW$3KL?O_NC.9;):SJUC8E>5.U:^> MOW3HL'N1R)@?_SCD^A7;B8QFN7JQW3*MQU>%H^RU^619O0'VFLZ P\&$%8NO M%8,=HTF1<.VR2>URRF4G5&9T'MWSOD8A_[I#E(U>(6KDBU(8&@!]AL KY3LJ M; R N-C9.3BVD_/1KI&+-+7J+H74?D2T24=/(GE6F!\AJ]O%(OR+7H/7^%11 M1OHYDP*<5>2_%&9K74MHTD&=FY:79:*UR,ETC\,@N'>SP5(?;]V+^RS_JIJ& M,S67X345V<*P//TSE5I#..J#2>-NP"(:4.XIY@Z;Z[E5E<';A*Z"K,I'K&SL M6(V.@/8I!N3>&O0H_6OU1*G-+]9%V9<>XQ4B/RK.1RA'/'BGQTS9].B?-<;7[_Y,E%\X> GJ M1_F07PZSQ_\AVO;S_O@E2+FMQ["H$#4HN)>>V9I*':%O_T[3"J\0\NG-B_L2 MCD1APJ/[([&5#0'CZ,AA!.Y5]PB9=[JZO;IXE^?9479O+(_/Y:O$["Q1FMO\ MSVZ36 9K,^O:\W8I:Q/=#Q@%DP\F>K.OB$IT5!&3SUF^8 >^:ZUVN/4 ZZ#, M9@:,P'HM+5%U(QB=!LE*KPX825>8CK'Q+_1N5&F=LK/Z'>A5^".9SZ;^5M*: M^\"+)VC^U6W]MHS@'>A$R(S$>[_#E&D"*NS/U/*L ^3K0L?F&UTH])JU\<^. MMR1M&V#*"$Q\9U032O-KO%F/Z',;8XT#8\U^%=?&&:M2(YD>DDJJC,90$&AK.$Y?2=Z))NPVEUA_D-/&J MC#DTB_IDL>>K^Z+:AY/F)=;FR6;E1N"14T'$:D3>^X8'EE2X<4LT9?=&FL@A MB/'/&/F>KIDD>IL: ;[FSFN!JXDBQ>/]I;35(GD9[^I)*=%T#(4MC([?O+>N";=\!SF=(4&!+KE3\-L MU)_U&->.@^[TQ^T-"Z:+\%)!ES(#7-!$RW?C>-V6ME.*^'IE$.P[SO$\Y&V> MMX#ASUN-R9Z?%_0Y#P7FZ*RC6#DW')^S9G]'?+@3_/6OC25<6J;$V!O82==H MJUUSJ9NJ.T/(X*@/PU54.B8YB\UWFRX1"$%QOU[;O=-T_N6=.&*2LJ:6Y^ML M):1<)>OU^-5Z*.N.'>IT/+@L<^W@**7BOU[[[61IY"-0SF*;0+4UYT3$$@S[[!8T.U_'X#1D.';A'/W%L]*E M=,G;JS-]N/0^6S;;SLO'^;/AD)5)12]@8[UR74*F-,V,Z,Y DRB;)(:Y"UN> M$_CQEFU)SV2V6\HFPWU$5- C245'A<=#X_X"U7B-056[.I7:XS&(.K BR\;Y M9'EU)$1:+N=.<@)*2FILLH2L4MNI$ WGSU>J.LWX%L^YP$*B<=3^LP@U["G+ ME3[%=V$YL0WBZ/8N+_]T9MF88NG)CY/('[#2WY-R'4K5( -41P[D(SUJZ'E( MJ0UM!RM"N^E]QODJ7-09@C2:CBY6 M/P3$*FH\5Q5U?BY?I3=O=.$,24DYY>9/SJ,=L,KJ:5'_D'+)>WK/ONY'BWN:L+&],)@230<-K=U6Z+R3F+=SKI;RG(M%"$% M;P:3GN+\@9M^@S&?T:X=?P6?A-_)F'Q9-PV!*D#K6I/>VDZ!W82_ORL*.-UO M^_B.1.,ARTRB7@'&FVM;>:O(@%L=-:%H>/ELLP!_ MYZZ*/4K)3U/V$4W7CI^GBP9GJ@K'Z[*V_RL )CKQ+T :&SFP1P-X;F-5(_?! M_\YHX']CK,M)6)K_CDR,V2;8I4_+Q/G?&>W?$8L)GGHFT(+_?PLCH?\3$P\ M@\&$S59%=P8G(5,S(1X_'6P]E)E4"BH3M"@D^MAB<0,*];87U"2&H;)Z_L#W MQ]Y.Y"%T&?UP5* "A5X/LRF%E@+@_UJ><:$3%FS_W2>R=PJ!&_7H,>$BU5F_OQKL'8PH4 *W_GQS=1E'-P$7+T>ITG[LQV>RV M&MI490+73>.1CK?@^,!2['88Y'W.T1HQF>.;*;7'-A,DC=+LB3VT' MQ2L%WM2_KGTE$T'+U*G79D8G\A,D;GC*=_GC4-0SB'$[[GF5,F=].V3?3!'< M)E(SWP3\>I,\V!:2N54GG?(35D\NP@;^FUQZ)+SSOE1>(J0U.^X"W(Q$T97K M)7K[W(17+_^]S-WR\5%ZT_'&>KW[,V$,>/*G_$T M\/=?T30J=3)BFS:H^3(J\',X-!QXS 3?\>25276GK97N.]S+/J=B=1KMU=C)CR9C^@L3 M2!\*_*II"IT84+U-\&&"_4)&=G1..WL4#5K%L-E:ZBHJQX]ZV/H2U8"E MY"J0:#\/-( 5%@X^8'5! _(,JR;23@^$G[A< #/IXXKO=KF&!/'6[]>OQX]D MB\X@;T;]? IVELC&W7OJJ(5KJNY+!\T2V87R>!+J>/_R6.#'.F@XC(35*4\( M&\G<):EQ-U<:$UR)_WCUG>OVU\%M,ZJ&Z#2F9Q+E[O1/8WKC4## ;L".U\ZI MSGS+@.E-1F"#I:D>OF#\>X8C9L/AJ<(3'CNOM3&66[WORWOCG]_./S$/EB:X MA+6590E.,SC.(A%Y-3,1N&$P/TQLTPJT0E_2F?63Q2B=[>W1Y5=<[Z"0>+ MS4.+2T&$65RSCI3]369M4@ZM)9_;$Y]4DM@>%P4&/*MUWL^_SC]YWRRW!9", M!S C]=Z>'(79UQKJ9CYJP^$9IO#B;.!DR]I(WYYH#^".=?#1#/^VA:L ]V)) M)1'7L& _8DR(J5K'A"$]LSLG&(LM MI!;5U>$%_H*9!\,WG2,SQ_^EN_)NJ8D7[_?O@O>? ,U@JRO+V. =QWI,^-29 M00/H\U!,Q"?BJ-"!N#M*$S"B\2XP-^[ 6-SK"G)*6O;V/N!_;C+NWWK=/\6+ M!%9^7EQ>@O7*5@I?W/Y;B\!_[Q+22\?U'X:P_%^R8P;Y'A'<#J-K?BG6L,HH M=\$GQ!,*],4&\L#/(W$Q*? +1 -PVM" 1*P2\*PG^)Z2TA]LQAE9 M0"=:H/&2PTO>>$P]A$++N #S]@KW/V=S[YY,?H /,P@S;J^FZ^S J*W&70:N1[0JTGP\DT3 MVEK4A2A224QRQ_W5^[LDA08DS'<"+\DP%HZ5FX%G.@.$D"YK33#J_:2VU7)# M6ZO6S/$WU?&ESQ/"6=;C%3Z\Z9,6\,DULFU\0Y<0*R-VOMCV6WWSV#N_7^0M M8/MK7E&I;NU/B#>38MU4Q:\(44G^@D3;695O.+V4GKCSU38I$AMTZ\!5?>\. M5 C( @T Y&-TT[^7V'(@GA866_J696R>5O"HS^O@^J-!1>OZCQHMAKBD+I,+S!N-=)' _X^ M![;_>_FK^(&H/Y4FD9UNTIY8+?Q+=^4>'7B.<&% (#,E@=F9F5-QL5LPUGYP M:(4@'SYFV']*H4*W>.3W^WO9G/>5><0:T5%OGP3-D"L:<%(F;8X1=;65:,!7 M;7 (\W\OM_[W,L!#;V8)K[FU%ERM'_SB.DUV-$&A%OXBH1N!5V!ED]%X<)3<-N^@#QT-",K@+Q6=J>*)+5"O#0V4=*:W(@:B#K897B'R\$Z\.8@G_9Q M1B8DH6^M& WHD)Y' ]K5G2'\U=5:@7G>@YYD97)C8JS7KP[X2T]#>>(!6TV? M=B0JG);C(!?.PI-1'?453HN--VB +@9!-.%&2N/6628"JLT(O 2[C^D%6P6V M.Q&X#6FYUO -84HNC5%)VM].K< !%U^G2[C,4%8J4X-+?LLDRBBJ T>N]D!OAS)T>IBP_CKZYQB>']BS5<);>P*HZ,_ M+.OI$^! /#7O%9!_M-:R9C'W?2@_/X>>@1D*A\TE-EN< @V82]1=W@)>?DBN MN\8LQL"X/-3$F+U>RD/@-P\>>K7L@RN'HOK % EGN5N1D->6&T&/8I7>[VH9 MHJ8,/;8OHS\C76_6CI9\]7_5U36$OO[,SV%KT8$'+V_PP3DAV()27_H$FBN' MUOKE1PX#"KN%Q RW#_9GD$(!#=NBFFKW/PY$[%A]U>TM;0?QA"[W;J73B.)_ M+_0\BE8A'+6AZ=*[Y8"=J*(!%C.HA^/>-NMOF)XAW -H0'1[ T9J43^<#O,3 MZ ^*B5SJOR=,F0V]JM]/VC5.C6SE\VYU/O3QD[$N;)_H%,BMB=?_.?^#-?3Q M^" +23F_%:C>K+$TR\T(KMGF;_86L56W=HQ\2[-WDT%F*%):TE5^7A&$/TQ$<))5-Z0I_7"I07$EL^( M"MXT6_GN6BWN3_ZX-Q5JF2IK:OF2]L7LD)$/6AY]%8/7>+IK/LW(O;AZJ[!N M1OA!;OOQIY>QM Q^1=(9NB';AR_X=/65@J'/1;GHM8RB@#7M1,_ZGOG\:#W, M_Z05;2-QE7MV:5WG3V(B-6.DK%,VE)@FLK-!3[3D-73VP&CP^FK;TV?H]:KS MW#=O+TW;?(3PHB8GO#/1/P30-9X[_(N*DXC5-#]+. L#F'-,L"T[5/<%&B#\ MYT2IL\]/"^(=VEOR@^5/U=3YM1C( N3V1*@T.CO-4&RDDG(KFP0EBRQ<;Q// M>H$0S;^B*5",-$4#M)IJ M$.XE5_%&HX3"R^;\ASZ)M9+#%9<[TI9P/((5V5&YPP_U4%3L1T]?S4M11 MUBNS!,:!_<%_#[6S&$V _-D^9-Y6[DNQB[*G4]N'E.(WBJD.JSR7B+?O%U]S M_+#Y%JY+HZW[O:^>A[A*Z30X487R=3NL9JQQW#WBPN3!9LYI3=>4J(.U0M"2 M0Z_6:/B ,T_#7XEAX26HZ,A<]TSG^R$95 -;TI#KC*LZ8Z[B(:MBI>!"/H,0 M=[%I&/:SJG/(G.Z,&H+T\C>"*)%&/:>F3LQN4^[2^YN+E3C(_]<#0NS@$5/[ MU"D?C^7M>[")JMG[S>I_G2G9+]?\29+W_>E/=ZPL'J_DFV^R2+"E-N ,[ZM^SU!IBTCQSM2E9]4J NX^ MY]VW?,THAT81[9J$(RMYDH#7;;V,WD/N.MU^0"0&Y D84F-%52Z8:U[C,+<: M.RI_*,'J0SV)\W-+/]@/*A(0;ZK8&:=DC!11:9B59+/]B-9-S M&%:S/^DW"X3&8J:/_D@,OW"+!( HB]><"?=:B:>/1/SMA\[O51=8 MU9R?XGZ7XH&P)/1797=7[:B+NF,@FHOL)NU_H5I8P&TOP!M?[;,O&;/1 4% M,[.9;8.PVRG-]],%)RRYD>LH?N_T6\Q=)!S[OR1V#.(8796O&R! MBNU 2";\WJ\?\IC4!&WUW^I"LXZU&D.:@Z(VGUNI^2B;I>([L%ILZ?:\5'E9 MU)4E.MGLL!I._Z9Q[#RB^;S1/<9:?HOVD7!24&19<6!@?=V?88TH$ZW%P2\% M?GUK0/B P9C?ZQ*[L1TQH8+,R=J]0YZ@-H;?G*<0#Z2S6\DB4JQ;W4F%?4K\ M;;6*B.Q[,?;/1=82_8%QCGKMK;(8#;G?";XD;_B7AI1+_+BSQOTAQO9,'WG$ MWO/IQ8=B-5)9W?G6GBIPQZ=]\+F '1IP=8U1WZ'=TVC CND$&G!\-C-24S)$ MC_U%MQP@%PZ;F) MZ;U>[Q%JMD?R]-Y!K<6QU@B8M@L[F84OWQ/>@.]17]RS:ZF:B*(3O5V[&+VY MQWL)[GA(U1#40T2";.JH=ZRSY^.ANJ2(>?L&>094N2^:(=,J+ M/,)%#EHGSK',H4&*\>@B)^'N2A8 MH:=KP*S4N8;6G>2G:*E2-99G/S$3+ZH<#1AM*4(#EK9 ?'7FFWX/V0^#"MO M#H>=Q&'\((R%:KAWV%-3B>DJ$TJHZ8WL_&)I#1/+00-,F&_7KV=V25(Q]#2O M>;.6?4, ^3'RV?U%279E# 0\>FM*.RBHOZVW_V0+6EZ7;?$W &AB9(@<]HTJ M[375=_\Q5)CF[R+S'<)QK9*DD2X=UL!I_YU+>9[:6M2HLU4:P1G!ZWRP/D.O M/A5;Y$Q]23K[,%LSPH/0*M:.41DHE&CD E\--P8X[-+Q;.>9L"7%+L]8'%[[ MC6152(/6)3Q^EDH@@D^U*]TGAGG-6D68&V^7Y2HN'LB:-*??,$7*U( 3\'F._.8] M$*D]<:7>:2Q&$AS0V'.EPMXHUGE>*X7F+5$F:[9>H.2CMNX%2LE%9,P:G]OJ M![B%D4/HFKH*_.BZ(!(HMO7Q3S&7)=CC5>48?VW M662W[$<%^JL1#,$&+G>& M")G6;._+:G50R9P!Z1^D-JJO@O\HAXJ0JR%1H2-I*T5;D>* )V8[+G>G@*Y/ M0:'[DD3/=^&$4#-"]@5LBGSBS50.@B.-:(:\J_3U1QA"D S.V[VH>O?U.LSZ M@L'&>4G;P6%EI!/R&/GS-8+XLIJ7+EI7][,)ZUQN[ZZP$JNZ<^T+/#U[\X=" MQ)WB$IQSM@7MVS:9P2N@D$$Y,V54TQQ$*7#11 ML*TJZI=U:57X3-NK]_X4,I!^P1P:P 5#)J_<#KEL)FE436[&VV5],+<.PM5B M.JM_K-];)=';/6W*4P.KC-*NRAK_W$T;W[W*D -7)"%@B?M=N)L.JH@I,M+7 M_YLR[3E6]J*#ICV7ZR_V#C>G-GG,=\?N)$VW&"0M^T'V(S\,U43];!ICB.*] M^I:6_TR/_L=-/*[7=RU]5>-QUR/M,7VNW,B$?QB=^3\"N25)$85>*VKHBU.I MSPISI!X3W:C(\F/OJB49GELI8OGVI9/?#A$X7>0?E1;VE,Q-8%T"V'=/QSVB M,FVT)DRU/-9X9#A.&;&U]$&\*M @M>Z8#X_;+.U> 4+P9;Y2]O"JQBAIS)Q? M@].*V*<&"35C G#&SLM)34-O=9L0&MDK6JM/\_R_LM>E]^Z<26]II@'B,P.% ME!EFC&$U5QTC!S &^41[(P\TH"[/0,W:\+G? -=JX)\R"I"[Y )-[*/U]+-L M2C^>$PR8P>*R2>^8:$7IZX]!;-/Y]?$JSIR9'JUL<,4'46Y4Q]I;+7IK11U1 MI/1^JM4GT..P"V*\D??96M5C FSC[H=BV.#*]#&=PU:[3Y^:7#AD3[.@;1*C M3GQ+0V:;]_;V#;%-G7VGLI7E*>(8_@(_?9#W8GNC]] M56"ECK'T8*LWU7Q[!'E^FF]8XEN%'JH< =B;"WB*"^"+_@8 MND"C6[=_6$MHGV."$9*UN<)QZ/;=W,9,[1)37349JU.+P=?DCA^9CYX/OY/@M'UI?QP)M!_!=TB_/X/;I\(MK^BL M+J!Q$>4UGN+I6NFV^'K.R7JS P?2_>)E76?KFV_D$MJC<1 M-?%.>-Y@B'$EE-Z.09'U:7R026W=(($QMHJ_X4T11B&9I=Y)^&Y_"Q@UE9X( MX/ SG6E6RY?I;/3?J3O=: Q78'6LBQ3C_;5"WMOSH/FH=1IVG]S*,(>L5H7Z MJJM_2ES6BG6@<;;Z(7*B0MZ]<6"@*M3;^6,B P_;2=UMZ=E]>@"S-_B?_ZQY MX# E&1D:TP2 QP):T16A#V5T:+\X?B M\GQ2QN,O/EIZ4Q/>RPK!QTLE& FFB=3;GMUS2^$NXC6:/+< -^*\XU -2FA 'OD/&"4?R,^$KSDIPMVGG6"[6[JH!WC", &SY2 ]<>M\ MFR_T(X\E5NY^32LL1SN6.TYJL>=,Z6=DEW;G2B73T-)8(MA-5N $%G+4;/![ MP,Z!KYF8@MRXCV_@((95+H5M_4_I35Q'IFO_WA*]@]EA2'W=K;&PG4^]4A2[ MEY420Y!DH?>3;M*53-TCE 1MWFP.(<(3A=RF/ H^L)P@N1$.TSDK+Z' >.=$E#QJ/6;_)CC9@/"CPMCDYNV[^HJ !'R\NC3+YU"_P9LG^6:%QXU2B, MSTK3\Q3\:+P>.5?4Q_XW2GT2SC/PL_1G8Y= *12X29UY$U$T<#4&3A[Y'M*[06D4N MB1LK_W4=@LD&TY3=@B-KO0SY6E-_[\YXN?B(G;Q%+!SZX'AI2K9U*[X^O'M^ MZZAW=WN(X10SO;__R'F/W2MW5'EE=S:>=Z!UXI.I&BW$QW/B*-7ORYM!->"4Q^VE1+R+$XKYGQ0^+8C!?5!SO]4(@&_'%?OF'PN-", M!F]0XM\'P#&Z>0,2B8&7Y0#E>_H0\(8)&N ,'-4\R'1#!:]C2"3ISD&\,X 1 M07D9YN7L7'Z=U/M#X3&O\0;XL23EK):9A']@U*JZ^(?Q\YHPW/KYF:,8O(G"?[GF[J4EK\3C4K_.XJ&ABL-(52 M)*;0*_ 3;SI)W*6:QDS%.8L&D$(A]1-^U6<*\9"]6"^!:I L]!):XLMUYEJW M$^ 76HN22HR]*J!U/8T*68:R\B:VHJ6+IND_O.+P&-OT_WVQ[9?OCGS M\R78GBU"P<*C6($0+)[K+6S?,-9P2))%\] MN0)OUX5_LA6<>'O:.N>%6Y0QSWJV^6%I*9@SZ8![RJ\'46IX4AB'\-+)[C8$U46> MW\9@\8K<4J;0,DUO^U;GZ'XTM\-6?-/\60JA?[E, 74 TAO!X=ZY/&KAD-7( MZ6%_C8W.:J\;O5V.-E8W-B=V*ZQ>U3AK=>'7',3,=W%V[#*\TVATQIPX[6I-Z M_79"F>,L75YCF9=HX_*B2V=:VKFL/+FBHE4H]-;P3/J5!;FIH6#5 TFJ085% M+[]ZR0&7](*@K%1,U$SNUW^XZP6[-K[EB+RF1E'AU:W>V_LV@9D6[$^,]HIQ M/*OM:Z.3#/N*1!+KI*VOS48S\ZQ^@/L=L ML!!K9>+\0JLEY%._T>"7KW#N?A%I73PWO"+]K3%TQGJPE^=185?+*DX74H8] M= KV%8(&.?@KK,;)JI*3X$^5;#9,?=28S MMWRTUR6O:]L_:;P\@K!.7T!([)G(3K;R?(KA)@[$>,6,,]FXK47.?(.I;PW8 MOS7VT1 M?F]1.!]#>NO$#IUZF@ J,!(/NY4Q^;%-C<7P0*7GBSKG&EY3H7W*C*N??/H1 MEY-[[NBBO6?YD_SI_*4C;-J'+,9@]_-]I[*B)Z \ M4^^.#\TU:B9"5UI& [//?IBRKU'?"D53:0$\6;#[B_PB]T0A45F<3QR6YY9> M?-]KYWM_^)#]L&XV\05XE#AMA#_ ^ ((]I0H]7Y8Y/1IR43D<- _061LOO.T M?Y]"65RX >O5!2=4P>.WX6P[1T-#Z!+Y*W(U%AVV\XV9?KASM'4U(OCU;^0] MU(Q$K%CF^\GRGN?X?^OFNX*B^KYT6P&1K.3<($G)&1$$$UDD24XJF:;).;6" M@)*#@.2?Y-P26Z"A)34"DI,TN9$K4 MWFM]Z_M6[;WV<\'\RR!_?R1%S]_RQQU[CMC!WFR/3P@G2#3SN<5B#B3,I<)< M+XCV*F36<('OZZU4/Q@?^5VQZZ ?C>IQZ[,JQ2;Q=(I)DB3(?=GI#P_Q64UL!,5T$<4)O MX\2)2-M7GCK+QV+N70:6I9*1R MX?G:PER>"HJO;$#,YB:=N-F'Q%=H[T?&HM3%Y_NO/>G3EEK.R5[ I.2ZGP@\ M?U3N&"\YSWC"'^P)$<;.Z6$[*X>H#X>+L7;#^7F>>0+I<>2:=7@VV*XCAS#SLO_VR'1M1'A0P7OS./IGF/8TZ&F#M? M!VEC7ST9DB@?^)C[X?,'O[R;8DC(H(H'K>A3AYB((L@Z^7C,ELLEL[KZ8BRDJTH@FL MU^VZ)W?PL74]4J"]!62Y]TJ++U97>E@]Y*OUJC2/O;#"S7]PO\S5)37E>F=J MH7TKW)GXW&S&! =)^VR*I@<"9G>74UETG@V\I.PR7+#\\G0,=/(HT74^=N-W ME9\B,]8:W::DI 0;WZ_9VR\%^0CV<>M41TC7OW$(=R3!<#=Q9R[KL5I:SUG/ M!H;HYWT3\;E[Q98A3[)N@GI*70;EB7@,*JG#;OF4+%GH@(J%+5#/S@[G!H/X M$2)6SR5%A_KY?AD4A/^YF0I,LLA]5&Q:9?]/GUA\A)3G,EV#18X?4)T45B>7 MMV.YHA92IHIN5T!V",^<+@1839R*U!@X,+@J2%NF'\V^YTD&4,HOO[]UT[JZW,A$-= ?PJAI MTW_/?MHUGX1=*:YXK9H^]^O_KX^"J37<+/,^8K.TO/I> 2U[6A,28Z+Z1" M_)O+6U?QHD:74X[H!,>69!EAYDY 7MFZ=Z423*X O%Q /__<1?!D!3O&J?PLX%E)\F7/][R"SV^ M/6(3)%PIP(48#W,IR5*)ZJK MW4M_)"#";AN2ON!D$ RTNA/D9EH$W:,+$2R>L-JZHV5_!F/VD)[J&U-3?_5 MZB2MC/DY-QF&6H6G=?1M73Z!(&N^*,*P(8+L-!<@"[3G'8W>.J:<&>L0$D^B M:Q,AG<6R+B+6^'+#A^ 4OBY>G':\ZM\SWR@:B2[JPD>:3-;OTBTI[CY:T M8V_(.%(%\Y?I6 \T$BY?M=*N/_^I!PFL M[SB,BHV,#XY0*>("\9F,04\XNJ^3VLA;7R:K;L\H#AW.LI"@6)#!%_]Q?VE^Y*$(ME92VT"UP'G^&89&Z,0MQ8N6WC^I;=#U*P@J6?O"H"B6; MXD\O-L*W/,*5P3)9L#.3F:K4)X-0A-S/2TDB@/(B^T^E;YV,X;XG6E*NJNKG MH>[SBIH:)X.I?0)I8"5'HT3IMYMX6 M\PJ[EA5N6'.X5W6#J0JS/#J.]VLA>[2@+HA9C@=5_*#!/N5\'N M(W1-T8&R]:B3BG=(;D0,. U.G=:^X-"WWX;+NRTF*PYG>1VY#($ZH0&/RS5C!Y(L8SX7X9'+W MJ9)2U^E6]X+5=L6B\=W5'^.3/YNK!18$L1UF:XIV*:FFCWVVS& %=/D3/=G, M7^5T7&J:2A+V_,@T7J/V]9E-;L3\IEL9"ZBH;>&XEL NFRF$WR M9#P6'EX\>/*%)>%C\>"9_UR,VQ=_N^/[?/-WJ^Q>&/H"Q1_VU;Q1[59EZ/4"DVP>\V?>R")ANN'_?@B^ SZ=8T=J2D#Q&GP2/=! MO)VW3S(=S/72I\#*C.2ZH#/7T1GOS K^IVI_P"R4WX' '&)\&^5NA2P2\ MV;JFFYWM)#:?4HNDR_!_/TUCF^M$!!P@^,,[NQ!'XD0 KP\#*/P5CU]TZ M-3.[W)(BP )CIA72DQC,8)J?:QC3/JH9_6N2?I[8:*UJ.B$[ S<7/R7-UF2^ M8T]F9SC<4_N$U2C^E.?#Z,R(MY:2;%C8&,)690=!1:"U 67'GQ/N1W-LN?.G MHF6JD"7VHCK4W%\5T>UMW3;WZC".G\%5+K5'YE;N4HV?#!*GA;W+4GX]!AT] M1_> KLE2!VE[_UJ5#VUX7+J?GF0),I?>*]%$%D6:_+F(/VMBE]UJ;4S7@2&> M'ZAB7R^10C;=8H@ <@.#:T#E+"?A:9*O);9#157?WG MTS3:]W.NN'_T&XJ^4,>.IC6_\;9>S0NR^$Z81\5//#T1$*5SJ$&(_@4Y]&," M'E:$WR8"1F?I"+2%T"1H!_7F-.1N36,FHC6IV^=/^ZY%$0!IS/T.JDG0'>*6 M'$R)"&*5T]' ,GG5!D;V! ><136GX%-"SD1M1;2'UP0\9=A3SM^Y>\U[6148 MI]=B?)J@EUQ6DQ(.$=%G*B- "@+%@U\8-Y[+!%=A/>QKQ'_.R?27SI7T]K$& M;Z11W8^4[L>Y7MWB[D545.[#\^IZ*+ZN.M+C+<-%PK"+%TWO>CI:A$V,E4WL M;3Z;\JQ^]0&WF?BH-=CAL>?#$8N"*B)@TKX##=4AO'\3YG.]5$7+6?IEO=_3 MN --ECH79:=\00$N*PTI!O;I3QP'1'R2:GPZ+"!^ M$.&=1',++T.S"O/<^MX57B&6R*BQ2Y6"ZWF(5'"+?&Q65T7[L%A<"DX9*@5F M\+7*/6'<4&1%(YCW[/2:GAY!+WOW]D7.?%Y<.UDL!A_21P3\$WL1?TQA1%EQ M/.73?KY5=\I&$RR7I^>@9M34O-/R,W 'S<]]9RI4C6P_CFQR^O)E<'36>RK; M@7'6EYR)'+^=&2$S;[?TMQ",<$5\U:T$B /##IV7*!U7PC??.'LD?4\R!4/.;JC:U3^S29C2EB3VB!A40J_OCYKOC;?-#1K);5+?X;-J1A.;&M M3E,V6IM#0>&\@?>F%^0>^J[(POPE;42>OU'NYPUBX^OG>7.+YOP3"91)(C(T MZ%O@]+%!*K+KUCAX%WSPKN5()8#6@;I$:NKE"Z_IEK:#R'RJ\3<3Z^T8\%XK M.%I,7J=J#IS2QP%/Z6-O#.'7MU?^89< /Q2I."SK4J7#^JA/RPZ*#,Y5A>R8 M3-2RZT2)?\ZR=+8W:(K)QYUNO6A/C6L( ,H>5*2!,06= 97T4['_>/M(GV- M3"7?[2>J-L&KR[8?E)5\2F?GL;$[>@\_@VO$)<2F2AZX@0-%XR?EBV^F5-')XFAU M1>'NU-LVNQD22KN6(#T!H1 M.&.TQJC;RO.@JRF]1U/& LZ?Z OSUR@Z26ECV#JK\RR7PQH'OUE2S8J[[?E] MG(*Z'UC3FQZ-DD71\VMV21G/2\I$YJ:"?+J) )I0U>41A@77YO/C%[OBXE'Q M]2_JGJ]W;-FO/$_)Q9^]:4N4,I)P '/\N"@+,Q]T!;(I\ZXL:*.&:2A61]&) MNW)_@UWN*LS^3;S7O&)Z_C7E+)G< FRV4&?1[C)COGY.'F1QD[P9X!+T[RH M7MB9TK&21F85DLS\MC+BQPJMY!GILTW+L=5,ZOB 2OO\@&GN#<-I2LB;[L+C MZK=%S6B?(%U-L*HN%=@JY*/I[X.,%GVS=@EB#GR#B3>!0?QOS6=-_1]]FLE_ M0-BHZ1U26>,R6E7MO@KQN55DCU%TL6NK;YGX&>*@;NR?1:=V,5/J3?ODH=P[ MO?A\LN@EPRQP5LVN._/$D([ T=J7P;\?U3=I"2I@N,]$=D-E*,WA?ENU7HU& M0(B'7PC?H/+T^(M%;Y7N[\SJJ);X._K1'#GK&[$I..;#_8:P"E?Y?)Y)=W%! M0> CCD\"1QI9\)Z^017G$0['I0_OI::3YN?*??1:FFH#=[H(P$-D9JWUG_JY M;4-^DU%\O.CP;G6G=K-\KH@?7^DM+;;?DRKW WG?M>NTRP=,O/U4,S6Q)3J] MO<[+"_.!X=^JVZ9Q67K8B!BNKG"G"WWP/:#L#(.XO'T7KG6WR#]-J9Z+BUV> MW.OA['LO&"M3IL>5ZB9SL-NEU:/H.NXXZ?#CESK?>5W@34DC_.)XK)J;.XK5 MG2K[ZY5X35)VV"V%7@3I5F6RE^AH5D:(5F,7U#ZY)[5M -#%D_@"/(ND MXTYO6;9E"[1%,YK6E%A4#CK^$HQ SQJJT;:EU&UVEXU&1MRN-, QC):$;#6) MQ.$==_2CUZEVXOKU'X_KT3];B1!^3^I5F/"/77[Q>C.<9IE#[\;<@@8X)"C\ MG+ID#2X5<;-V2K^N\/YJA[06?YKVJTR)MI (GX[2C3/=)-R%)1&P5/*O0Z_U M;I"-@24"7@)KW"J2O=O6<'%2&"MR^KR;\K*JTW^)NLDCZA$U^^>Q:F4]NV6\ MQ=I&\C\*J5IBOT$<&\48-$N2\IX0%UEHE3IYB9U)9I.6S;2X])I*_*%'=#AK MH ZZ(/*CZ:53K._#FN3$QV:RET!!UX3J=Q#A7V;8-_:@I_9MMU(K-TR MU6!)O0=[>$ MP?"V.&2)>\P8 PH;HH,ODTV:=PY.2)OM$T7Y#CF P&#OZ;YSLE7;!C8#3(0Z M,O36@75^W6'!SWP%3)=*28W+':OB2ZW)PMC]P5>@$%/+#S[KGXHEX3^+V9PA M'=+_I-G>>^/;QYBC44)')\:>GFU"Z\&WF\"R@K@&^!U7F]MM$1P<8+6:D_)[ M(+%GBZM7SYZ[2+5JB"0UX5SZ9:-"@'C*,U MROG#Y?2<-Q+;7<-K9$_*^X;;@!;.JC0$)E"R,PH\E9X.FSUHG&+-/69T5 \>1J95-['^".1]0(N%_E'= E->PHO6V//=1L[LJE 7P6/[5+E MO)G2#Q5N*JUF=Z+H7"T6\QX8@5NLLK3Q-V/OUT;038Y@!>EPR31&A.X&(F"S MO&KG\H*$0!%)!/"3O"8"ON\2 9?"PI<$Q*/?JHN5P?E-$A\H; *NGD'ZN3% MO'<2$: N$"SFN<31&+(0LA+>]K;,4BLH2-:9+YHWXQV_T<]+$O-E5*)@3HB/ MQ.^UW_?6(FM8JV!LX2^QPE#GX(_L-G5.03YVW"6D]*))+C),6IX^39_VK!5P M#R!J*#G:'$ 76(>!-MP\88E(;RCM."4XK!IUH]&3Z Q?\#$$= MDJ!L1P10N'>T-OJ#RW[?7%,;U+YAE#Z7+/]>\F;B+9%"##ERP8M2"3$ MJS+'VT)>J/\HFL.Y#Y-,<6GB\7_YG=RAKIJBQL*+H]90N<[BTL*2 M>IN_V^:^JC/7LU5]!7)=5-IGE9G;\#2W^&W&+ZMW5]DX&89E$H6_+'$D'T?0P6"EE&+$7BI_U#S!1TT%9>^V)@*Y,S R>$I6)ORPB,"(2 M$9LFDXB#*?N*M1TG((Z*0-%6DZ-];CASA3@DP\!Z6I1=BO[\T2H3:&F&R.S1 MR.CR7MS CKT?*0"Z,_UFN2ET8*YDFVQ?&2['3BJC:36"&_ MQ)<("##D)-CTYT9:PDLG6:ZIC+[M4)E7OM\YF^Y-K(=L_5D6/%3]L#%9XY$? M9C04)6[PT47YG4/6(->5/KU^PQY/!,GW#=G!!99.;K;6>@S7%XLTVRW^0?:@ M3!Z=+X&'5U@>T83X<]G0*/P3^07,F;_34,4*[;LDT',JO^K0CL(W0K%%P^WCDE/!QG MG;IK?%?]9OE/IHL;&#N"=F8\9%1"<:=;664T=,['/QK>:I MSTI&0W^]%OV0U1"?ZR27LP*,4;TK2_-LT'2LL5FI!Q:OQ!PNO'CBW0M((K7Z/A0W.(2$4"L=$@!S>;U/IIQ?N*3?%]+>FJ94Q M=&ZKFMC?5S"6ISS'P,%,H/#M;ZQV)ZS]M4 DZE7#,H7L#SX,GZM\0$9AB N8 M/X5ET"15*LKM#KR_\43X@I-]7Y:+!,V5],'W:D'(S/HUB& 6@03Y*(EC^$/L M\M6DD%F6OK>J;SN4#J'^LG9_Z8 7.26C96D81X MVI5D1C^ E^P&DS'L?OGIYI6?+11'6<&\Q5\D[IYGNDP$Z&%5K ."'N.[YZV& M!'J...&I4H[N\VGZ,T:UH1(8C6CP_K[F00+YMUK_[/&^\ MGXZ\ F5 ;>@_3BWOPY,$O;Y8EU;C^L4@J]MTEYN(WZ:[TY^) !Y+NLOSZUSX ME D[>%TK _4A,VJ$=PC'1KV+FW\@,W#(Y6UH##KA&I)S2]_.X#+MMIG;@3%] M-"P&,Z%/:U"](+F_B'=C3M]C.?Q^A*6X=CCL\(.[TXUA[\K* <:.XW^M=3HO MHY:BY70=N[K.L OJBUR)"WU9;LSR1RP1TE*(0^@_V:PHM>3"+,8[U1I\CSU= M3C&Q;08&L%,0T&NP9B03JDQ6Y=(:!C_X9]M?3_;1^_H&76DQ$Y1(4"WU9P=E MP#H?S(4VL5)!.N-"+3BFZ\?!Z@SN.C8$\UGT)IC7AUF6&!6ZYB]^):3E5:U1 MG_^$&I1J4'L>'*V^7IR;^3_;><39KD5;89G*=P@V*N521^3)IQH?&,W%$0/,R M3%=:$O6D*]%8>K%_TQL7+<,C!\7GL#:1KW^[!-UNLO]BC/L,)/RJE MG;^(1%K8)L*U(.@0D^^8 M>UOGGHLB3SF/T^?3U$>#G#S5!D16!P"<>XYBUD0 TH-T.YR_]1">_?C+C-02 M?S9MY6YXX,E.DMB:TX@0]Q.CI0VY74:#TQC?\3^*>AFKAZJ)H:K4XVH.86 ' M$(0YJK5WC87>1?[[T)GI% MB!1^P?FXJ"QC> IO:(2E.(?[L,B6A06T&E85RR*4M7I->2<'#,Y$ -UIGD+O MM&EFYNBL>IV&8^^]C*7=95%)@'?J ^J$M-0_;LOO!;$,A7(YVZ@O*+&^&'?Q M;\UQ5Q*[8F /#T[73D89SB&AWP&:7KDW$J7#7&,'C'._-,Z'MI$Q&I@Q_T=S M-43EBZG>M8!L0Q:<" 5&_JMQ#8A3 QY6P5VN&2?@D^JAL1<1T&.Z;879#YQV MDE+S)0+^SY<&_^-[3LP^\__7MEL2. 9R@N:M"B+@[2P1;;+6",V?>#&PFD MUR[P9"?['YUYV&["4T_(S!Z4D*@]7ZWZ7P3LK7]K[5\6X0XX=7Q6Q_T=X!VX M'L1I>7 G3JG&<#O0T9SWQEB)HPE;^'*D;6GZ10Z&@T IA='H*KBV*S2?W11S M*=W.-/', EO5::[96^7A] PSFF?*X<.DNEPL"*K7!<2?0AL MIN@9_&U4#!X?0P3$U59U02A45+#<2O9C\ =ASLW'@YZ1>*[Z<;4UE5W$;\HS MY9LW=JQ@..4E] SN(C" " #\)0+0V[TQ.,:"5<&J(*:2C+1OB];:_GUD[1]K M]\-NQO3+G4STKLN8Y#V4NR8BF9YHG:A(N+"6:N8%=XS'"A& >C:MPY+494AB MG\.+[ZUE$8XK0&RQAWA-I+WVLR4AC+$/Q_I6%5"\%:Z64*F6O,_^Q?) U<_6.WH'M MWX .BD.%/MM;1(!C)[![.ALYEC:4^'"O,&.+08!>ZSG]3X;\I\IOICRP3X@ M9S5X79XR.T8@KL%BKH^LLI?V[9UT8[J??\A71RRNZ6ME \@,V1CL1F!O$P$X M[[(" J4!)G9Z&K4.EG@:N[@I\Y3/7)-9O]HX-@_W_F=2>1%J-2@WCST@'+$N ML=LJ;V!LE/ZI_*6=WT M;PBE92BN,G5"NH5Q%D3 -PY](@#QG0C ^#EZ8!]H()5"=$ 5OC642I9YBR]& M['BT_'/E)Q#DY)&)Z;8$;@\,B! *5R("WGM#,'XURB9O=;V[ Y70L: +217IY<)Q0N/]S.=O 1)TYZERB]F M"5- "X:KT%7"$/-8D_8:"-_TH">CIQ5A0'=Q+F.S,/8B]= M% T3>].(R\56^ZP$SY1.N$+6>KS MGTY5:_!Y+CB3KE/7]3W^/FE\JIX^^77&N8TG O#4+$OG/;8X-:? N$Y41DWA M DJC=K[M=\ZSW^4,Y3M-/A>F.C60^D]KHJ$*2<8QGU.]Z6%Q<*VSW8JW86+ M_,,S+LRI(.).N#RDWP&S@8\YN$YGA=KG1Z9#)D6*7AQ\<;7=*\"D8JP=ADH# M0]\TD^8B3QD9V]7B#]_!R8SJS9_T:J.]?',@'3R@']%$P7 MZ[%7Z\=VE\-M(C_# JQT/1GHZG-V9MU_LO0 S+99]EH938U;W6IJX_ MM[ZWPAHG\^>'FUGT&$05R #\N^_H "FY[S6A8%56N.@HG%E%MGDL5#.NC @ M!58TF@OJ^MU+-% &L25Y]3MC4_1U&D35O%XWV@I'$0AM)X0V=@UK=YT55910 ME\I]S$N/:A0*&S*H%>$:P#QZ2W.V^D_//\\& EC%?7[XYGWW]O22DT"%/)DX M?>Q.PZ#F/XY"OWUS9/E$\W-A"\G:&W\"P3>3I-&NW3%4 1MSN*%V&-[RKK-Q M,">2S_IIE255 Z059;9JAOM1Q\Z_QYG#FDA.W7/#"KK'@*ZAZ[41&K=].E5] MN@.RI+NGJ[V(U%$42OOM+ZB)NM^UZC]I3,W$I(Y6LV.7]%.TXD) =R"3M4Z@ M^2I,$;HT#R/56+"[)ZXK)OJW-7TL@LPQ*[W_1B!0\ET8"CX<*S+^D>GA49\= M\_Y^/UAU]6B)T HE?!0YG^M&'$EL%9SNL!#>BQP*3A!4Q8B G4HB8/,9(NQ? MH+]'R"(";.H@FS<[G!ZC"D9.E#P7=*\ATO%R[W\-?/\QQU_0JD-E7< 9$ M$ 'CGT7.;1"4*O\]5B_=DE8+"A]BE/CBH/^HW, ]PT)6$%1;E[9QZ,AAPF*8 MQI[C6$G&K!V,VT33J%61(]0-ONK=K&)Q08B]K/PR97;4["4TL!_VM*COZO&] M38-%'3O1*L>QQ9=+*,JV@2I_KL!)BDE+OV?@IQ<^K,5.\)9G$H9K'"TB5>O8/*M M1KH"O\#/T'SE.9H1*#[P1RFZ-?B%U7=1Z87OH U:.+<:8YBQ("IM4A&7%(J% M%N+$8=B0BIU%QGKC_!U3L(0V?G?.AHE".5.XGFM)/#1>LF\HOTANV??KQ><^ MV:;V1^[9#0&G FVI*$C?&@+O9XN_;7H BX'\M9U0W9F6P -,EW7+<.&61,", M,1$P&A5^%1A 4,/+$-K?73^2A2Z&-*D6;/J_;7-T+3(P,3DQ,C,Q7V^\@/:$9(.7&?06X0$1,?(&$^/>N"9_Z$SX'2&A)Z:[?N7^1 M7LN"C,N%030P-N,2]X/29D;M(22/F*5KT&5R)F865C9>OAO\-P7$)22EI&7N M/GRDI*RBJO98Y[FNGKZ!H9'5RU?6-K9V]F[N'IY>WCZ^;]\%AX2^#PN/B__X M*2'Q?D%A67E%955U36U=2VM;>T=G5W?/\,CHV/C$Y-3TTO+* MZMKZQL_-+=3!X='QR2_TZ=GON(@ 8J*_'_]I7+2$N"Z0D!"3D/V.B^B"U^\3 M:$E(K]^Y2'=?B\S"A9Y+-/ 2PX/8C-+FR]QBVDA&2]\25>U._0_A;9 M?R^PH/^KR/YW8/\1US1 24Q$*!XQ+: 8'4R:\50;M][5.7%D4B%$\:W>" B M&P\$URZ:GUV3NX<'WAHHH.N ;=L2=1S31B#TISOR%X[J!1Y8_OG_Q%D./Z"V M,5%# 0-X@)H']7):N*.IR(E=UQ4?7>W95&=P5DM1P%'GB8%XI M.I#A 683LHZ"!E)41"N;9X1(&XAZZB&XR,A>E#[_.\[R(=]Z#'N'%&7D23JY M)*+R5PC[$HI^+BFCFG.\PJ5US3_V#VD5N:>F#XUDML MGCQKZ]+GXW74(X47<9L[01$^DJ =;A\^K*^/!J8,)4^#!#XZ8">^6/=)5S@3.2("?]<@4#^S*(.LU M1K\*.$ "ZW;"(%(I*/M MG5B\$6T:LH9V+G,YV0Z4Y&QV.4G-E[)< YMYOI CJ:06S8.^!G!L![ J,,M) M[N;_G+[XX9;2#^(7(Z;& 7+SD+Y&69M&7YL.4N1^9(/6DB:KM_IR8C#DW@H- M%397T,=I+Z.NHK8Z5?=5N&U;X>0IXUO!"Y?D&P#ASMW ;&]S;>0N++I!IL"; MSO3QP+.:6K8TDVDU!R';KDP)>7OI#W5=#6!M38A7-:@"U-IK3KMIQ([.'-RZ MFVG<6)CN&=6VH2MF8ZR6_/264HOT^X^WW@[7@-#/PNX>A<1LA:_HA*\]U5<)[.;4I_Y MTLO(25+*V.5%KNS/0FK*+YZ*A0-G"JUXH +1"F*P9_8T\HH4XDL;'_;;K':, M8F(Q^#K0^/'FI$K?V]@.^US8N2[FYIAXQ.[CF0[).&-#(>&[I]IA*E_:+2Z( MIGRNU:D U*Y&"[9(. 7A2&.62CYE=*,$'XTEJ@Q!'KX [QQ3&%@WW(UH>,,M MEZ+U\9M6_=N%"PT3+5#J''1MH8,O(A)BE^$=<-!/Q2@>5GD3_,(PIYPN1(TS M:/-S[@2YB6IV*:\B0 Z<*W2 *LB"(5)(37TT[)4'MG[IG-WP%OV.X9Q8T>N# M;\I:U9@\9_:G;I%Z^J%0>RA@;_12HVA[_"Y3*<@9-+:3P?G>)? ML,QP+2XZW@!LPI=V(*!%=86I@388%?VRU+O=DN-MO_;:4:$2BW"&Y!7>)"LQ ML2MBF"=J'6K=7QNA2] WKZ8JUZO:>DZ^1]-N4?E)]C M#9Q4+HD^]IK&[O%Q8G@37-J MB*S'BCJ(S3M^>?_=/D83#UR^5E7O@X4)29Y\_6"D!KYZ)R/I\U6UFOH[,BNY M@L9+"H$86F2O.=(S.X#?VQ7M#55&#$=:GI <-HUXWI+:^"$]$VG5Y*9(YUUT M,A[3TB2'X@@3>1O5GYCAX&R;*%7JX-FRI\9+"_;^.D.G2I04L.<+>GP<>'X? M0A"H=UDZR$-T9K^PCH9Z:%WTBTVV2\SN*S\XK]^!"Q'Q^DWTI=U!,R^9,WL/ M=$AU+G<&@MVA] [/MNE5P;LY8\*0RO<^SJ:LG8DP'E=F;I?VQP&7T/;;G1,! MG ATWY+#JH^'$_]<-U5;'^..,(O:H_C/259=[ _X7U#O:0#^1#2[4LAA)ZI9 MAZ+E]]#RI31!G;K+[XIY"HUX5<.=_+ M<&\;?#&1/MI^UNPDJN9;U62VKE,18NFS)[G(AC0&3<%;3NI8E-'=2YK54UL) MR6DIEM61[EUL+*^" Y7K1>&?R^(>J&8\YG]V40D\'S#01)S24LTF!V)L$'QU M$G7Q'M]#L!!M&R];\D)#89K+=Q[&#K4-GGA%D(I1P!"(VJGA)8XQHEW/QE0M MK\K!FCKCU3MZH5<]N_.%%.!^9['A"GD.C"U2O]TA8E).$#ZS=6A8V"WD4I1Q M,/DACO^%E/*DM$?/%V>'9@^1X "B<6'MX8WEQ-"F'_.W1AO4I1+]+I3SSE4, MLMP_E!;@Z]\_\=6%3W5^E[^,9H?>&]MH@U[<*E?)O9]EI&$GY_P8O,Q3]'C M^=2J0UU+)CS [9XLX1:NG M;1=:0;>>:I*,5W'JV!ECU0F@PE7-^=1@ M>?KR_/TM,E^4!LT239"XCQ>@B5K\X2B?@%XX$-Q\V>ILX%3FQ$LW'[G MN!=$K8&4;4F[.(030&L/_[I?45IEM[]:65\^2C=_G5U)CNK&G>[(U*\L+UX, MDFED!PR?<< 6#3#W5V8>+JJ9X33D!0UMF+L]NS(PO8;7R0;>%]SPS>\8[[_S M? D+;^* MU$@J.:W3L8]>UHP<0\6[G2#5;SYWO3+A[-*=[23YQK@\SXKF M3D=?>RTQ0(TQ0TK&+F^;&AUJ15_B?F=;M>GF^$&-4A)AVP/0FDCN&KZM"(I=X(.*V1K>?!7)(P5^OFX65#3,W@=A'C1B1+SO SU%J.)G!N>L??= MRQ2F6B5.55IZD='03QF@)Q;MY5FB/+"H$ 2&T-41H6N7JKB_GR6^Q1#DO7E\ M;]=1#N.#:*UVG#_MMR7>9)6_A[X 8L4#+?SS-\IQLYT8OZAV+Y\ I\1U*VL\ M(+(QE3JYP1B3@QN:9T!Q5HX>L==X0"]^9=;9,N-3:Z@'*W1'2YW^XI]E48OZ MOD@;D_=N"G(9R1C3IG;\"0U;HHCB6D;;[Y/^&&H<]0J:LY W@=D>C$GQ.T/* M6GG=HAU&(!*Y:'I"XRDOAKXF,;"E]]TUY+8L-5#K6!TJ"-%TL2 ME]4=!L*;KC::&JDFL\M>>R)<^4;UQ%KDKH\)TWF;X_1M " _5%.P09![IQC6 MP-H)]H!>($KT_ EN='"IZMMH)6-M9+K?)A,X[B,9IT#^C1N-@#^CS;D.1 B! MG-NK)XL46M"L2!.T"U C:7KY]HY F[[?/O!I.L^9)'*L'9LMSR8> /) >41$ M0>Z,/-CC6[%Z/PM?LU>$.Z&7ZE!FDP)HZEQ@/:Z(7%I ;]I?IMAT8F M W!Q5EF416#&3='+#=V4X:OQZU2A>T1/D>8M- ::E Q6JD9WL0Q=NO5MW'P ML63XWCRMT%ED$0_\TB'-QT*B9S)RJU_6W\B_(72;HF9S!KA(L9PP06XFF.S+ MU*_:;SUYK6I([\R^PG/EFFO>-8=/,2>92-/4Z+P"A\2AG[YROHWCL;ES/49Z MHVEC*M,N86V&#+[ :='6=NW;^(=NVK**)ZV!D &EE$QKRO[*UGG=&N MBO40!-]_^=+Y49)VR-+'H+L=?E<'R6HF<:,+Y)7"@KJCNPUV>;T6.9U.$F.= M_8S:Z:Z$7#S:AUXZ2- M]W0O;G6_"Q"KB&H.>$UK1N&!9&Z6XF >$8>BC9O8S4O1T,>#F(&*YD/_F&?J MK7QR"RM3U=?*TQP(L\([D69?FC!NU"-S.G'V4R$YFP+O,7>TB'!;/#:SN[B] M,)Z?/7#USN+12C'@?QF)6*8*;=<$?J8)C%C%L9L^)A*)E5H(;A;DT< -WRV# M>13-2Z/N>M]H#N!$,7R0&/55AKD$# J"12]EV9&_G4RM&6CT%FFYQKZTF_C] M'DTS3A*E$'JK)-M'0O#JK:JO#>1*>_?A\IZYC"VTQ<@]];R($:@L-3;M=4UH] MC%%WDNC;G3&X[R3D^E#PZ76Q'8$M\O@KMT0O+HJ*F?3NT4#5;.I1EY;G34=2L%:2Z7@/C@/",- @C5]I* MO?TZZRZ6KPA[&0\[54Q51*!?Q#Q.N]1&I\&MX?QCZ%3Y0:>+I7&>- "RW@(Q M5[ $L&JN- J9><<_-##R?AIE_XO.1*!46TNQFY5L_2? \\7-0)X9O=""4XQK:"KQ8+-;1 M=*VZM'(X))$8#]C-(#-%A.ZPG_V2/U99BIIHC0$P\3C[TO$33_UWACD2CPI]7CQ X?8=<737VP\/7/P& M1;E#6V:1(ECJ- X\T/P5A#$%_A\YZQ@-7PR[J-\A#[+8+52$GO@"31#:I197 M=RHAV-E!#!X(R\)=@5)#!Q$Y>&"1 8K1 \ILL"0;]%NN&"L"!X L@A9L"70 M!]0*.Q+9A*))07B WMC]V<4;&$[<53R0 57' ]_Y\0 Z66&)#+F!I3@SQQ&I MX(&V\3D&HC \<$DA5.&G^3 >0)(KX/ABT/Q]4U<4^@4O>K2ZB'PSE)] K]5W%!J4-$G5O#* MC9C'=!\O*%0*-HFI6? ! IUGI?^,,$;FV 2GP MA_65TWZSD">?Q$"Q*TP8&CA6L6Y7WV1M]R=8@.CJ91-)_?W?6U6^](N:]@Y M[;^[G"O# MQ&>/^AAPD)-FD;[+W[LGO_?G1*C\4Q+0,6V@RM!.$.6\H='\II$^S(=2I^7; M9IG\$H^ETE/0_JZ,X*CNPB7<*)2UX57&W#;3A!G5R-&V\:>*.'\=+"MD7+M9 M>6-UD1ZM[&@33V*'/.F@1_>R =^H4&:M]R"F\$?ZAWME#F_9$RQOTVH7.\AW M!M"(943'1['/>?']=7YG,AOBQ^XH_$4.JGZF4VK^>9/B?\)-<1T_,?V?L /Z M$_0=',.!MO_.KM[\#]_3FN:TU4D5*J]E(3S1C!V)8;,TF)YI6]M;M#.=ZUAV M90'(B%G@\DC$;@[*JT.>:Z3BGN0]HF.*TX1+3.K*ND*^+T^_Z _J=*%T[01Z M>H3-]0>1 C;>1KJFS%X\NYE;_E-_#4&46?7Y2 M"F*I*RU[HM"+'NX]U\8XA;::SQ2#E_9W\$!IIW_LZQE,7FJZ>2+4=$OY)AZP M6'X-$_'Q/1:0IHY4K/BKRG'4(WFNPL+!_6DHP2YS:U'S\E<)7X8Q!8PML,IQSEC7(*/S]:&IV \AVSOG!C;:LJ:NM25$O#IZ?:W'Z( 5 MQUI57?(0S)1!M5,5#6;(E'Z6+3G\E*8ONK$HA?FCI?-S;+&Q<7#& MMTJTCH4JO=<_4U*_L;EW$B5;=,CEM.H[Q]B-D8DWC%>K!X,-;T5U>%8K>O(A M$3N7I5:FZWKZU3]-6B@Q/(_DSPP'_KXP :B\X.,4!5:';WW9"RH""P.U&H06 M,: L_^E&H-%Y2].MX6.'*&[].':U=Y%"D%Z?SCI5YC6+49?HV][PB=P0R=<5 M]IH%%^)W4- !'CS0I.0//^N:E>%5SZDFQ TQ/ZNV.^R &^_B 1+,,HJL0]5# M\)IV#XC:.T2Y:9CG6XI^PKRTX]XKL>RAI 2>2SWUDC8) GU'Q8*PZ/$;ST;Y M*I&PL.)$_<:&QJ8D57K%":8B"O_4(.?G)?<=T].2X(.(\G8\(!>/.V7P3Q,Y M787]ZBH![?HR57_# ]WUF.B%G? )!&$CW?JG,)@+YH54&@AEBOXVFEE;-?*U MV%W5@^I@@7VLVL_PEB@SB<_3'\8QGX5=0)>;N-07%4BWDJG&8.+^WK M'2J%W$8;3$G>3I9BD1D@EB/'RI[+F1]V*^S'JDPMXX$T-3P "<_Y,JSE?')7 MUK]DQIV^>ZM6.6!&%UJ^$)"W 8YIOREW?5&33,TAUV2KKK&I>%V#,K84=BY) M$9)\R>:Z9*BHK!0QBZYTN\^O#B?F>8SZ6,44V-W?5/@U>)JE;RV?[MJP^#M( MQ"#3"D]:7N0RXCEN@!ESH'F^JG7BC=B(@RYPE:1Y/?V"S!]_ M.'&L2O9/6Q!#9510/2L@5F^Z,4W0P1:$40"5P:P=[#+FNH,7Q4D==EW:?\AP6+J^O4K]JIA#7!6U_R!OJ@@J0,6N;R?DM* M#,^(_K#<<)(.8T-+YZ D/ !*P$'C4W'ZR?6H&,>F*;A\A":ZL*HJ\%AT1(,< MF]-0[S3;-$E!<@IM<&3^@F3>\HB2?^67K>YY+R3\!9W,%)]I>"I!PQ:J;MKF1!B0DZ0GWLF G!M$Y1I,ZC5HQ),E)Z M\IK\><)JVGW@<+C$$.-77YXPO=D RC#X@=YBZL5"0K M'7_52[N*XLC);77PS06;)#DF^^08+LL&K;S45@Y6,3/.=3'9?]\D:+:]P-3 MO3R 5I80]*.B-G#D:+=\W2V2-C)[-[6&?=63>] 2\53^SW#ZXI9\Q^NYQ!A$ MLP1+*I1<\2DU8.&5^TS!*6II(8R);:/-]IA* Z)R*Y@W==8WM?J]-F?9@\?= M5V_[W+DIO,Z%G/HILVW@A;CF 39>VBO(-D5#==D:EQ<>':J\IA03'IVW$MO3 M;DY,G_G9$*F_"?H/"OU]'\^_+D>-N$M6-NY-'!QBPGV4'"1VJQNQ\R>'!YB! M#MC.-1U<8"("34GHK>89T&^.G_QR,/2PW:IX(]9*P]4HF\B,5]-OG=DP)ZO 9(;*L%>?4JZ2*G/2[SP5_(AV*D37'>K5 MA[8]ZQI?>!6\G-)]);.[5*J$_*:006V7-$L'J2^5,*!$N0P5 Z*BGVV,/J_4 MT<0#B;"SO3''-^3\F?_-!9=!)7::TZ!!'5>\7<\FM-/6FKK79XT4X52(:>O; MK0W[5(=W877%@7TF%C?KE4PT&,U M,VU'?O^!*/%!9J88GI8Z+\@9X"O03JE,6%XW[3\)/Z!!VVM>]/^T?L>^><79;'8R5F#F8UC[ MD F*>FI)1@Z'I*I=KD=]&^N5WLG]O&7Z'H!3QD3 MOUC%1@X)Z'+!>:YV[[A_U%)Z^4S_(]JK;5ZR'J44/F]H"K7J=>,JZ[99?5QP M" P?S7B_%0+Q7%ONR SC)!O?9U+"CRYNA] MCJB,T:@,NLRV=2EE!\6BI9(:*R 7V:G >:I;4SBQ4 %Z7^G$9C?4G&]7]Q1& M83A[K[BN8ML%S!./+5B->Z2G&R1-OT^7;JV/#(X>RG37],7C[\DYS- MN:)WR4)'7?YP);^P^V>1!?4:M6)BI5S%X>E6QJ,2GU[QD1J274&6E<8;;^1% M(8HHJ8B**#ZPAF4]"Q"]&<5S8Y",G)G--27C)-O.W62/>XO9R<8&R"DN/D =ZM^]' MFL@#UUT9/JC"U2"R?& M5E7YI^F^EFZRSU\N!+8R]0/DKBI:03(KLOZ6\$/Z7HY."O"YT,\[6TR_JMGF MBWVC$!#XH?3\",F4KQ@'UCV51*B=?I]8AW9XX\XQ5K+#V' M^@^\JD(_;X$J])+<\NP6D-%VAPYUT1F>R:^?4*A879LB:= VV>5>)5^K$O1O M;;=V %5\/#$C0H[7VRW]W!,YUA P=?23@3]QF9EN&RH2[>+FG4JV';LX5.^I M9J+O!X>P(C7#2DIN>=!0&S;VM0KVB0M8^+"ZA5@_R/Y")S8:I/(PW#CF;0!% M76-9?7SK>+'$QQ!5F1?Y3P<2;64?OV5X>9WTOA+G!4$/H;N5A*8#3V*"N?4P MGWRK:VB*'A]H93JO%%1&#+-M:]F.%7_L:S+^\@@26T;FS!QPG_CM%U^:5J>( M1.B5!L43JJ5-\2+O(UDJTQ+>6D/J[?0?I:1:L17<+ZMH-!,O?@6] =%$A97+ MLU1*KJ_L\GIUI\X8>FYX>H*M.EI59OI@ M2&C@TL?K]WKHB/W%3!!O AAFO&FTX_8H/L]*(#Y\:R6*I-R951/ZT7HG*AWV MD4[4N]-+"7@^@@?6-G#UE<:%R5!, QZ8\"QR![24&/[E>F.5WGX]2MU1(*E9.OQ;H$' M^3S.8F\$OZ63Y/S[4'(@0A\PQ$$TS26> M"M$+Y%SE#B\CM%6G,*U5XR]F:DZK;61: H\8#_/:!DYOF@D2QN$O"V>,;AZ_ MCERO"C_62G&M5]NK]P4E6M;DL3YH?*SU#LPT818S>KZP%-.&H$2?#:_/M :X MMN8*V0ZI$RN5&MQ^8I-_2K-FV@CI/6?% R6HT/,J:+_OF7W30U!H-#/]W=M3 MT-A?4]8"WC]XY924;&[-9R@QZ*?Y6IB99D#HV33?IX^MC>ZNI=K0JZ\:^"A5 ME8N2R%O08G>_*IZ. LZNFOE#BHS7\<"'G &L:\QIHW'A!SS0I;V!JU7!S!>OR9A>B$J MF+5U;/JUFCOM1KF6V3T4\TEX!=H_7[G<]L#$P*C9SJ7(1'Q91FA\M8OK48S= M(8A6]4>M">G5+Q-B4KL6'N!;6792;Q_;&]FW>ODX83,OA8]KD24>^D!^:+2( M)$:^!*7DFCB/O2SYX-8.>CAD$OH&XG\C6J1!Y_*P]?#RD(3R\%@)KXI#B,'0 MU/<'#R*;@&ZYJXLH4W\+_IIZT6I",\ZVOA'9H 5Z"Y'Q*NJU<_&[UC0\.$.$ M('TSP$-)N8H5C*U&K^1JN"VCHV'>$4MCU'N>RQN_8D![I[@SVK2WW#=D+B2V MQ40'4"&;BOR64GW'SU!C] /1@LZH#]]OLPJ)-3.V0EN0:+6-A2?N]U0;]R#( M\5.]?LR;)FL&>NXJ@-B-:;O/ZR%Q> $COPY8@7L@S>)MWHW+X^$.67'W)EHX M>,V9;#//=\H,5:OII_N/XCM!M_)^KPI>O]U>[;>K[2QU1=1E-M $#P0' M7#?V+C*H&UDIKRGW+EZNC2JY+7?DKFSY>?&=*"D/J$$^"?CIC@=.?0A0WM7; MRH7A 1&%X[G".8!!2^E?+GU$4O&.XRM-Q-77K?+I].9B4YB7J)R^+_22%1G9 M42;!%:'$G*"]B>&Z:DP0'+H=@0=^\C5)#^.!568;/&#"C0<&E?SY-!]\PZC:+[N=LG6@K-6ARE&G6O)=BD/02Y+A_/!8A?N_C9S"O0 ^:/=CE#GVW3IA.T4I)?'+ M-IB/<$8\,/G4"4M>6X>-I\"0!T0<*,#$:'[U+"PGK@_D*%@I',_?Q@.> Z<# MYAKZ/Q"EL+-]%FB]#68#GEMT^&0%>Y;7>Z"RDT2#B; ]"_A**!(J!L*?65,/ M#==CYN")4;GK?R0J,5NEX2+ &<9S_Q/)'DYA"7AY1@YL6?Q?L?ZB+BSXJ(A] MSFR/G;^]HV3K5W^K5YK>';8]LF]*Q-<$/]6AJ19E>]_G0JEGX)\$'YB?\:DTTXS!V4"T![Q\S5M1Z62_0L63[=Z5? MZ^0GX_'8URM\*GO'D)49>@%#FV_&7M1(=6M-LF.HX33;^>>CB 32;S](RH#. M=:+W%Y.LD,S?Z_S74SR8WH6L-V.Z3>$F@LUERW7#,-]Q4)/<(#U)U>'+#75;T>'L*KYVI\:MG@_M6TU?$H M!CUP=1$_(?6*D(?GZGB@VWH<#VRG(G!ACP_.CFFFS7'JDM4$&.[B@:/'^HD3 MVTE.YZDBCP*H4J%='=7HI%WS,DW,)PK$^44$+J3RA!?B=D+S<"! MV<'<4K_%9F%_^,@\]BR4,&AVE7' #RT(,C\ TI9\9$@;.RIZNUF/E<17UUB# MHZ5ERR'%09HS[4413VP'XV>B-Y+V43P.DI+,NK&7GWG/F8QU[LHL MRGH[\9R#CQ VIT%*>3_ZY(Q?6LDIB@Q<,8"1S4 M@+CD$))Y:P!7HT)@?_@Y2(] "=U]K L42S+1R6:."=HA%/(=].P2O*@+L;;1 M>RQ/%HYC4SCY]=,([H=-(^C+(QBN10ITQNC-Z[>P\PL/B&%!Z0V=XLQ(Q(XX& @@-,[#D?P8%S3YM@Q$KF(\]@Y/A!YCUBU M0]%@@YT4CC(?GY0U2 AIJ"D7UJF>-ORZ9DS\0()?5G)W(>L>(\*6/<%2,T0X MC#-(8\(J,J9V@?B@9'LIM*U GE.RX&J=_>:^I15(:/Z%\R+L?J1EDRO<"/L% MNG+>#C)VPI)NC_X0Q=RCE"O4B4JNUI]%'D!6F"/;.Z+LS(3E(TIW1[64(&%G MOZTD$8IF5X20Z!1C A,\\< 9KV#O]JB"'?14:'H!ZT8@ZM!-,W/SDE>(/?=& M6K2D!Q[@9EM8MJD,Z%8X>'X+#^RP$;[$-C'Y";6P$T^XT(-]7#,<#V04^X>9 M7X9!$>I# 2I;5PG]A*O+%]$7S*!E+N>OJO6\LF9O?0B^\NUC,V10NOH#*>_+ M:4]82G3-=KNK_.5J%$3^>MW=;5D#;)*BM7>/>*!5LV)#S*E#O1R=LG0[X,GV M=YOL\2_NUH@UJ&1#6^XO8774SQ\E0!TK$V9VKZQ C =+C@=;O$NWR'7= MQO$9A,JE!KZY_I3%646BL$W7*%>3YZEF!QXHSTU:>31:;5_-%'+^+.1XL/GJ M$$GXJ#&/O'$0>>&>QXVL*H<1.=F,&6_SUC/KJ%?K[/?DQP55(>.SY]R*$?&S MB]0.RN$]NC=XLFYDWE02?J:EQ/BY)_F_:U#$BARJY0TJ,*+*MWRV6; /^I^%A&/($#\1]6D:<7^XC($U? MRKS, AJH20#:X;H%[M08HXV9.LK[HQ2<)IX0,&BZ0O/K-1[XIIE84-6NAMWI M:EGDDQ&2V5>\MJIPP%!+((P6'I J\M &G9(3W-X$/QY(&:L#_O$Y#G]FD_6( M\7(GAH<-$;4L%9.C4FB6DQLF\6,XIMDEE-7 0=[=VS. M<>DM/?FDS":+)G0PBD8/M1YW%EQ2G-[^BC=U-.&N?S;")N&'.-S[T/&!P>ZC MJ&=7]V)5KX[ &XQ1Q-HH_:A*=HIBSQYAT0E=0>LJGT"F.RS?:+DSZ-1O&EY- M\WY]]87>@FZB7MB&RLA'_8$FOAKTVZ7)'>X(TU'3(P2)^KW1.".?4O4"F(!X M;/AUK]=A7_+[I:5+)DY\XMLF.(CBMMOVO4=,S =XX[;HDFR,GP1R_.)_M]G=X@''O/ 2XI6S6FA M72/+H'/R>>CFHT]'22"4S>89C+5=8>\;'F#^V2.Q;5X>@X%Z9VV#"3VHT4?8 M=V)G!0^ YOG/9J _16O8PD= M;+7< 7KL6AECGIS IV[@'@K&>8RJ[J>04CYGV:8G_-46<\T(LN M7\(#E2[0/C3W'$2P&$;G;:,^9@2Z#A?.^M)>[]G70RTV7^F0B";$R+/1:GY" M$XH'%!E']7N>/Q:S WDP>^>VA//G\Q?\*XI/GOU7RF"F1+!3\N8%2#E]Y! > MJ$8\&/LG/] L.(\';!"GM#<(O([JQ 6;)DV>K"$*O%_<%$[K% ME8#TWU8LP!?S)]*;WOB3+)SS,:,9L,RK4'EKT/XG1+M('^QQ0 =TN\$"MPL[ M3&M*AB=!_SA K"=UGA]K)J[&3(F"3IF&CK &!-5;X4#_[HM_)'4!#2;X%G3[ M([1OZY]G,TOOO XC_;?@7>NQ&][!HRV7M/G-]+VF#=X47E[2#9-?>!S6X),) MC\A$=M7H6735)KV$N].HNG4@C$GRCCW;K!(XVRXC MF6>NM:/KN^.#VUH#W+'-)+2ZKP=:>Q78C-$P'-W%%*V@ZW05Z:7?'[QQG*HG M4CMUJU:XP[I>>2*A\ G;$3 ..Q1I.&$3E'V(NIBZ;,SME6O:Z>-XM>-EC#3E MW;=IQUF&%2/EPK);0>'\V;?AL1!"L;@UWT-W! EF.(=.?T+W3R;E[$D,NOP( MJQFY#/ME (TX>L5V#)_JQ"DT:!U7$2IIUI#0Z'#B0NB8^PS^8,01,]Q!$@^X M)_8>RIN'0ER-1N:&I\>))( MJ&U?,2'=LE LW:>UX[-U8]R&^A#HK8WYP9UB')^?_C^9BVNX/SL09-*O\Z-& MYM6 C%:% Z'0(LPDH9R'G:/!.M7C0B(2%$671#B33T:GR4R[9$Q M";HT8*4O"!O&L#OEH/-T)JQJ:^SV1X425O/?O^"?>T,D_(Y82(TXL!VPW_S/ M65Z&!Y;X1J*+)5-.HJI=;GKJ:5\$] A*^X%5K5.CY8T$?R';K=I7R^RT7A8W MDV>_D$WJRZ]PQT:Z[>O_FYDL>;B\@(EO=,#5BA#&G8F)ZR@GG-I\)8%+B;_5 M:#H&9;45Z0 E-XL\4#[OW'Z 73K.:$*=#2*\_1UV!W[$6/X3AT60]3BU@1#$ M#H@&]T8P'QY2@.H=Q3Z ?2<4_&NO@/W" 7DC06P(NIB>C%XA:,X'4QC6.08/ MW&<\D2?4@+-HX6R9D-++\&AQQ"DIH8%.7"+((*VY?BRT=R!Q"T+#B!&'[NX/ M5IK].K]'T.$P!>P[1X4C >3C7XBI?=PC-4)-N%U^D]3: [?3J+_ETR"".Q5! M(OK^UAK:0/F_[VZ#TA#T"JLYWG!<4.J'-L.P/TS\Z^9_L/^GN2XXK,[:*??)DU"<4H6_@AZ! MG=Z=38QZ_MK]XP?SPP[YEG4U _$4-31\%Y\.C2X7Z\L6H46O&;??U:MQS*U. M:WO!PTESV^V@W$HVP%$%0@Y,_/?NX7/[CQSE9#O5!7PD.@0%3^*!%K%LPLAP MBS!'_+Q0\0MDU(M$8"*,-+&^A&NDDX_ &Q5N);8-J*)Y"9*X5T2P188$_.MG M3*1!: E>Q$N7H&E?"3.OX.#VRAWS3EC!F20-=IXP^A J6*+S5?!/;?1X#!*Q M+'+*!B%6/;XK?_:E.H0& 2P$ZXVAE"/!_A(O!G_]1G VH3\$#M M\)'*XM0$A@#7L+2Q?Y[:.Z%_FNSY_'%8$4*!\YT',!'7M_" )*%@$-3Q=<+/ MDFK\)\_P&"HU[%L?!O..BG"6A(+Z'O(P1C$@X;QEQ8 O&I E4 M?9A7YK*=M^V*EN/G?W=0."E#7&#I?V?(.Q3W\/?T"9^"'B78+Q0-\;I$'-X/]4TW?O,$V%J[2!T.&Y$@C"8U8& M_#(RKS(+Y6#C.D)134EAN>4@G]NXA['71""YXCS*H9.$(H\.%Z5A3$X MRV);:$G,DHO]=_[:.C4$5(C,@XS.W0ZY)YN8H=TRR GL6T+G'B3U8.S%$+0M MSFT)?D[6^ALU6X)+A1#78X5G>4A.@OD0_1]JSK7^RQOT9GXK?>9&%:B\4'#% MIH>JT-2[:@VG/+F3W-LKOK(\3[W*@AA>7< N:U*8VH177CY"4"_,&945MVG1 ML]_=(ZJ[H.(+Q\:70 ?]H4A2!71ASC41EZN(0 \G>G/TC(&&AM.$1MM.@8?= MVD.F6Y>JKI0JFGLTC0<84ZK*:O::11DH3-W=P))-X % !V/O=-E>B@T>NEOB M.&6VF$0[Q6P++NG]8A/]47K3+[#T]_M>-]GW8#G"O[4CG>9S T&.N<8)/<[L MWT1C6XS@@ Z$[12.-W^K^-.F(TR=.?T][L483$0='!ML@U,S"S7S0:K@E.;T M<2WE!/3!'\(CVZ$< 7D_)Q5^^09$'!#,:>W3;_\C.KQKLDCTT]*5>SH/SIGC MJNS;;0Y=^ZI[R5RMU@8^2QZX$LGIZVOE-&CU\131"959^16^Z8M.NH=29/VV MI375ZW;UPYSCX>>@A++;G"L?'BR.(F8^0 ?8!S#$B;]?4V3C)TX8/R9R*?I) MK^+@BS(V5>/Y*K1V^KQ9X.TO:,/W E"5)=)$1AD$Q[XSHI AP^@P_+MZ\S? M>LBF4J:/Q3(8LW*)IKMNU;ZZ&CL@O6N2]A:E8EP#TU(?H-@2K? :>!U&:0%I MC%6J>;GB+E"(>G^_*XFM)<.@&@@! MR$#1R4.99?S]N-FW..]YZ.)5!$;##4J[!S)"/BUX]>O=8;LC%7Y,<3*,["UW6R?? M S UA9;@P4K35ASOW5#STZ-XC* 7 >4,]NUI_0^*!"_J-;^. MF_I9J.P#=UEQR',0V5[W!DVBH>N)2S@5E46*K"PT]X.R^HK&D*WY?OZ MQ]^>75IR@)Z[TIRN$ CQQO7W6Y]92M[:B6)@V(-$ =4_A [Z(Q8$E*WL[[;I MV/W2RF:.W*<7B"GM[>;$ ^7F=R:]:=J^31IUG%W,+HGE^G8NAGSPQD]_O')5 M$,7=[FL3EE/1.,S75.IPOO+ZI*J-N2I"(+\->55RF$9%GV65[=A9NK#&TA=V!NE,2X=R4#^&31 MP?*FA@1F81:?8Z+FD3/5)[J;K*HU:\5BF9XF7YDK=LV85N-!IM["0TK$C8S$ M,0\[M:JQRNI3+M!_A9,&JY^4_R60WLASHC9:X"Q;\W=1C,=Y(94WBQV=UI)9 M2>N!'DVR9$+Y@Z568LX8*Q7.D0Y;"";OC78VLLB<((J+#8/S6SWCDB%SR:JI M_9L4'#][/\UA*(M@C6TC$-6)?0\$I?$TVA+7TW-RFMZ8MGQEB;[[ UR9/>!% M=BG+=^X">'%>JN5FRQVMJ+C#GXV:X<4MZ+MCK_1T/JW.;(Z=767>02REVGPO M\_ZX72>?D1>1\?KZ@OTNPBFE?N_MB"O.8P\/_&/A"6X,V$I.*%V2%6RTH)6X M(2K4(ITLT=/5#%+!*TQK) M>'KLV"/]%Z7?Y^SX04EF E@&_>O3C+T.:;(12BCKE$R)HL<3%A0:ZZ2"C4DZ M]BLBAS?G(L$D' X%^3QEU 4F;,"IYU-E=P!VD]Q+R82:#;\,7Y9E]\N+ MT0A>$]Z0J[_F&K"DVCE433Y^^^-*YF3"\.S1/EI5&%I+8/2;N-_'9H![;XS02E+5<8%&H;@+:K]?>-=>8+MUA& VV33*38FP\'%/&)[J M.)!#/HKX0HD'OE*W<@\%,O)EH-*6P>K/*H$?E(&N#0_-^_:%"*R9BX7*:!OV#4VA-\GZ,QU'4;#Q"]^OW._'J46\O9 M7.?[RH*L(8D;X6#E+8-)P^X0Y:0IU94:3IS$\3V?T B_S ML-U@LVM@$F9J_54L"S$>D!LM ^ERGL#5B<,*0E+9\^+]Y<9QB[6YR= M>B3GA*,5]L.],8+AB+IQC)OF%W;V(;)>R\RC1]OG$E^:UUB%>=A/BFQ (J_# M%U)6N$RW T"E(T?UHS%:M;?5);!?2PLAQ14WR975KG5])_G%..X-,JM#B82 M)=@G+:KK8G,,N0(CN#[&Q@'W+>4"%,%?/#PFPP'B-A4 M+T]R>M_I0 3ZC\';_I$&C$N@)W]*C^V?B8):Z(23>,>T+3!4@E74D;@"OU<" MBG2V7U<%)L/N[TZ^-?/' ^3P#NB1@ ,(??'WJZVF$ -T5CY$MB9.5>A%W;<( ME?JF9$,IQ^CG_-]6J?--3ZI=/OC;I0FA)ZBC= M"P'WT+"072/B]6GW-P-)MVMED3L'V0D2*BJVX@*1"&[73_7I5^M>R#OE4#B7 M0*N8(1/;*(KFK!Z,'IWK??-^5VZD2F2YY3(RR';F=^XZ$MN=11BIK,K>]L;D9^OQ!!Y:/E66[@RH1)AQ2-'+F=KH99:/ M6/UTQ3"(8NZVCH!S_#%3L'\D6M'6S$?:^82X&II'1O_P7(4NX5\]_RKWZ/,4 MII;5/OG%K&W2MZI$57;1$QR)[6*9CO0](<@G^DF"3/'PBLJ8L+:='JWX8&Z[ MM31K:WSDN:YKE6 J(V.;]]OE]9BE1L]MC8:J4?)2[3+^AUSBVG4ALKW5*_9-W[9]2,= M&AXRR2U"Z;3XRLF_GCY^^^:ZZ[=9[D_1^H_4+I'M63^2K;,(W!-4'NAH HV* M" L+>S3*+Z_OBY+G[Z0/:4-^^M)''\N5 M&6<]&AEC9] 7 ^?B#[G2K ,< 0 6+I\2(I(VP!% MNY.3&[;6O/Y_$/&&Z";7<69$I*2P_DB#U#YV1,_O3T+:QLGVM<6YA,5^5FGS>-7 7::.HB?>X5>846 MLQ1(URMP)[ 4,O)MMMAUNS?EF2NYU<&CA=RC_%2'UD*VU+$:;*I94423X<_% MY%4[* B.V__F=%Z;",7/NGB[L]#W%?6":QW;#A$UP_>_6 D\]8OI+UM-M,K] M^?-F$1O\NJ)T)W&EVR%$$7D$=5"M=%#OWN51S:NN3'H9)VE'8N7Z]H/4-Y*T M4/F0 JEV.%EC0]PT.E1S-!SH$&3_F/R 0F!5($W9$$J<+,,[>2NZ1-T[%P\8 MLJGA#MYJZ\NNF(-L$30[+^K']XRF+V+8GR%4QK0HY>X:W MH;P%^U/F;"'_E'QG=U RN/@S>[>U6]5SD:7.I0P?^UR+%C]:WO(LQ=NWZGC@ MS.5M_&K''JH57#HS45-KN<5=I91O//R%L;'JXK(7.+U=197!.3ZS-^+)"O67 M+R_-=6508SSF5GUAE4@"#W]6%#SC,ZZ5VE:ND6=XXNU++X?$)B/-C 4L7.(6 M$N?5<)84F)B9^>BU?3OB,-WPS"%I\S!KOP+.*8T_I336+OJBOC+I_<.\YOI'NLFQ.SLE ?3>3X[-)XEJ& MRC7=K0^JGRR:O39PM9G,BB]9GT_6B0*[;?\9;AGQGO'_M?#.WXQ%JWJSIN2? M>%L\6[!]:$;+\96V%DOOY F7G34;H**@976A,B'&9L/*=ESTA01Z?UTO5R%\RF<^2 M-;F[>Z5K[Z([6D_#"YLLO8JW[YPP^8OOS,JN M$\Y)<$F8*Z%_:H'L6:8G#PI_7G0M+3Y]8V=\].34L\D[/[P_Y&M^N.K9_)6W M[][9LZWLT5WEVMT1C HG#[S^??DGU[L5BW:JJJM7BF?G5+9WU?$Y/M*M^QR8 M&^0A]7"[Q#4!AP=\.U?K?^B27L]V<&%]IL#$.Y[F_NDC$.< M8>^.AL?*FWJ @;RS=LGO>?.U;!8_^-)/4+:4W]$ M_K:[76/Y,2?J3-25Z^/RN?9K/ M]Y_]6^-W?3APQ=17Z=>K3Y%IE_66[6QA#66O"7+?\*"$6_'Y>F:3P!B;3[;1 MRG.O[>-[6?7TVGJ;Z^4:MR;%+FDL^[,_H^N>VG'9UDW)?Q^_C0O^,/_PQC\> M5_>DIY>7%^8G+COZMY=WUYL<1?,$N[>+52J/]#QILE0W"8P->:Z?:EZ[]N?, M+3LGOBJND;ST[.K;K_S;8E4FW.N^ZGI#O*#:_?;E93F+Y3^H?3N^X*)KT:F@ MJ>O.ZB8LZM)BP[>$$83K_]\$ %!+ P04 " "F@EM0(.F(X;TQ ![/0 M%0 &]Y8?X ]#0@#^!@ M8__Z8 HNYH-'B(>'BXM'1$" 3TA"1$)"3$1,3$I&14%*1DE&3$Q!2T%YG9J& MAH:$G(Z>EIJ>BIJ&^M>/8.%@OH.+=PT/[QHU*3$I]?]Q0?\ * F!*6QR'"P. M )L2"X<2"]T&L $ %A[6'P7XGP4+&V,C/@'A-2)BS( J"@ ;"P<'&Q?GE]68 MI_Z8YP N)1[5#1%9_.M:SPDXG*GOO([+).24*V^FT?YYP'7WA4O0-2):.GH& M1NZ;/+Q\MT3%[HG?EY"4?Z2@J*2LHJJCJZ=O8&AD;&YA:65M8VOGZN;NX>GE M[?/F;7!(:%AX1'S"^\2DY \?4[*RT=G5 MW3,\,CHV#IN8G%I<6EY975O?V-R"'QX=GYR>(!@_7OY#_VBQ/B% MC8N+@TOPRR\L;,]? RAQ\6Z(X%/):A$\=[[.<>X#^K MI=9+!FVDPHL&K\7*:+=?+%:6W)R9F2$V1'9[!!'T?&.0OH"IF[I>*GB1ZR+2 M#C3:YVA_/N+1'1- 1CJ_NN2<;=#HF[A/CQ]XNQAB-X^]98P&6OM9Y]3EP/,L M8*82 >+G512.:."IIU\H[S+S85X#QW0G*W-]U:CC,]AQ]V[E&K^OJ&?<5S#E MJ+)L"ULI__(NZ%0,/BHC$K2G=DGLRP(R^BCZ;;%6QK+TPVG-HV?F(71T+G[9 M7PC$!A%.IV*(T P$IVY5I,+/[#&=QU]^3DFXWU^+U(UF:DM1T9,9*&!RT"G/ MH[HM)'L_PWKZJ]_#@WJ?QXS9B!@5]7ONUA'PLBR*KJ*SB,8="JD%N);7X!)/ M*!)GP4&^@W$@FYJ5M;SF4CF4YK#]<4&8TSNX44NXJ5EGV^1$X. MBCAV8#Q[5 [';RCL?NXL:9+5[NU$-1W8J,U_V_WE(C59AH%;4P4DK HTT:F& M,'DPFQ8347EIF'+-J*\ZR\M1>B,NC$$DMC ?)]"'^46@>/)IVX%[:629V;8Q M3X2?L$R,@Y._4%JIK>+4FKUMGK*VS?MR?9.]#.2/,F?3+W,R!ST;1UN=;<:: MPQGO6P7/ILT/.6.9J:UG*^_Y6HL=#;:38R%M$"<'G1V29$V9"-?6VZ9&D]-& MMK?G4_/3+;Y'&.5YG_(J]RC*=09YK\"DE@#Q-I$+^XG;\+Q_\F6^&R+P4Y)6(_&1H\PK+ 9. M[/K]I?S _6.VL&16^F3E$6GU)1,U@X.J/L^O\J_<^44L7EUB[EPX]0Y&*_*44X/BP2S63%-8\0<4ETVK M*4ST^SL2I2JT-CFL<>V>^9*3BEC0VQ7DKZ9Q%5$;&-)B-JLG*B<)K>:?>)C?UN4Z0UX/MUPB'2Q6;)JIXX@_28DMEY!M'4Y%=5644 MMA#S\CBR>TLO5BQK2,A.(@_V%])+%N;?0JB0O$FG]ZS!HR>^[V[-C<%Q-6?> MK H!6!+2@??+6!&02XDM&7*$3IF79TG2E[:+NX9(AJQK-M MNY^[&FDTC::*MWEQMG$ M&C.Q?*=GTD\[4_XFV)/O!9L&VB69WRO!.K8VF;D1"B1Q'%VX84K[X,PR"SC= MSO82'^@%$S28T=@XAJ(AI9/DKFEEK&+'P1/SHX^RMXH2"6R8 8 ^@USY@&>7 M9M&)R6XJ+\[9JJ@'7BQM9O92J;O_HR5(E7?-OO[N_@[8!L2V1_="]8%9>]1 J@!-'"]41J,Z'P*QT_- MM)$L&7CMM'C%J50YFKZHZE_']'$UW9SQ=1P%4::&7[HME#* 9%+]4L=+OL7T M^M?J\H/T?'-;_Z5W0N.C.93R>7U6E0/ 0ZZX,9%/:3DIP$7+8(Z$.]7MEWP72XW:7Z^BD0HT2>$"MS9 M4&SEPV_+!#1=",]3?OB[FL"3(OY^'(U(+4:/U'PN2OM,_?,21]QY&_6DK;!6 M-IY/7Z_7AG9ED%<[2OLOIJK?'-&%MAGK2EI.OZRICS\5"[$Z5A(, ,[9@]>]?[IVO??ZFY<.^5Q%#$2*H7%?HNWG&KF1 MW'"V<)#U/+&7L3IY:\"M<='*D7Y4JMNA,5AC)<-(IO?6NR%E0=$,4Q.14(+'2WFNRS90]B#)$H++SL" MV$;PTYW$^N^-VN$2WQ6;L3W]='QX&!"0G><#ZZ*%5!BTG?P\]KV25Z_$;':. M5V*5FG!H(P<<9XLRM\A85(KQT+#+RHB^J[!'%UO1M?UN>]-7SW="+]?4S/ 0 MPEJ,L.#DAVILU2HL-<'Y1SFN@F4?H@>@];B[O-,)443 )>UR^Q1+[LQIQ;:D MG[@FO_27;K<(>.%G*X&<%8"0*STP(E4-3I9#^J1.OFF9LM=?:C7R^6<57Z? MB^/UC_T4X,2,Q,_J(#D<*9*WW:I?,UPL)E"5?%K\<[JA+<"<0[6P/RW>H6<] MGG#!K:0=/AC*V*/6#L=/ MC*@VQ#P:06XT,O"\7:@>@UF,&U?>P76N>O]^ZN>7.0GD=E;C5:R8%5Q7;EII M:/G@&]PL].1CY8*NW(&QD1KI3Q&'J;Z![>;+5HD,\EQWX8@ QHJ?[H**@SK5 M,/5W;^PTK'-F%)Q?G2Y<;Z 09P]\Y<,X<[ ?)B"ME[$Y-9#\JL;',=.)9:QR MP\MK5IX/&586Z\=Y*;8%PIUN00E\&ZZ,E(*0\T3RC#,] ?J=\:8=OX;A/>ZN M4AS*#Q[ \T$#S=!@R;&FG9$%#>+Y[92:X"I[,+U%NKJ0KLHBC_ *54\K$;V0 M"%(4:PMU!ZY>]AK)4^P5<<$?ON-6I.+DR%GU\/##LG9_EAI[4( M7[SQ?*SO]>;Y"'T0O7*O(U%#9-X)H:1?YU2N\N$JB;=T- MQ:0?J$0A%8":=C^'3$D/$4P9"\>("KJH2\X)*LZ1/KD8D-HX+@J/$Z;ET?Q1 M:32#B<>89?)WK%0'UL$G[WS\]5E41Y23[@N_&%Y5"\_TC#/7LR1MGFE]$WUR MY%APR8FHT42<%&V7LCO<.6HSFSYMO!&I3:EA [4^;&-5#NU[0=X;];&.4/QPVFRRXN*:G9KR@9$=0SHK;%I\[?W:Y?L9 MY'6E]>!LHTV?TDRA7$=!T<]SX'4#\E/+1W/3+2M!U-8L]GW'H*G\YCF.@\'P MDT@I=6>VUHL7VW^DW]2!:*-X7'"2V7#TKHT1>#)H\6V:($5^#NG>TQ MY+9G/K"P8OU!S;',L<;AY-M^O:?W,PQCP3\*=X-Q$^)5># $?7-XT4GP>1K6 MM5O\@3X+4:.C7<_5O+1Y818VF7I*S_"!_"'V?Z*BN9!;=B=9PEJ]=+W.1.7C>BIMM=ZU;".KAF@R5 M7M3/#,II5$F+KCHOH#%<]^F\O@TY%_@.S_(BC(-:FYJB67_/5 MF5WWDQN6%LFKVHE7\:>V")?Y@9O'#<0/#E [CZ:K "ZV;B!68_LY]E25D%:M M()O=I/V!VIK)ZXK]P3&E?M9 M+GT'X2"L-6'N>!]WBLV/+,%>??$.76RWHO/3WP^O>U(/.J/^IRM@AAV=XKX&V>'[=XO".#7/2_-OQ?'&:E$R M0T8@E$&6+XWS)O+49:IE34D*#9!L+IA=$)A"%H9_,:+67SL,5!;VPU*4HDO= MZ44[/C1$#XKWQSC*T^EQ0@WGWP2)=#'0C(SV" GUDYU-_&LX>.B=C[R;_QJR MP>*-!MZHE:$DE/[2-DU6 /[_&?0DYM3S0-21P6V[+\;DR08:V%4]3OG/+WO^ MJ+4QX6B 4JB1=4+6E2S9WI4DE-R[8.O+YGCLIP5^Y*&N\3QZD@?U+/[>\3>-8.*=@%KLOS18&E6?@UK(=. H+J&* B]U[;F4+T6 MZ;M*#S1@%2*E8F4D>^>I]]E-TKBC5B%QSVY+9O?2X=-301D<@>\1*[R$N1_B M7P'8J>ZYDZ:SX*1A5P#F>-@T:G(; ^LPOZX@YY M-'"-FNUHUQ\-!,9#@MD.XF31@ QL'G&-!Z%?0HW5A:AX.ES%0K:N.LHQFOU& M+UJ-;6:RRZ2F8Y+X,-TC!!3LC 8.@KT>5*EKGU>B 0IK+:^5).J:VF@Q-^WO M[V]%.0YHW.=)V:_'X/,&B 0R\1@-;(J>#.G_3 T:*;CW;>4417.0^&Z\PMG^ M^1*_Q]C+@.97Z7HC>2T#[8E@=A$A[\XCB5U1"*WM,+BJI%+RC7]8R??B).T0 M;4I#G$34-A_2/J>8G S29=]N=DH9@P94!#9GX*2OQ'N7LB;-H^09>:Z" M!=# <9;D\=:SYUU7ZU=^,1S1#OKNG'0T16IEY^G;_W1;:8YXQAG^^0H]_/VY M 1_\>H=031LSBN.8ZX:I_:*F3Z=#19+! M$HKTYIR)9S39O_OFS%:!!I#AXF:G%,EH0%;UN J-YY) M]'5.!=3P7RS0TW65Q-_[.+WB9W7+:QH!$NBQ"JBEJI"_#'&:?-6*_(RS;N*Z M)-[< -&-T?P&$\-R9\U*B8UG,H()9!(D*<=\Z'Y'7U;(-TA#>A:#HIC9;)H\ MG>,>*]XQ":^MH1WI2PC2/.1Z]T4VZGD(8:]YB5\OVT75A4[1L(\_ BWNG7'^=09">F[@"VRO6MDW*C;WIQC'A0C;RRNKX5XY> M"KSR"B:LWDL8O?1+OEWP\;E_E7+.WCB4DQ]%Q0M:G[I$ UA<:("HW+RPTY^3 M0]Z9 4K3)RW6^^&-/.\E<;Y9.![T)#G%#I%64M5W#'A>%TTZKQ[RR):G.=J16?W M*6B7)VMPR8EL4Q_GR:B0X&*#VGAMQ0B3]L.NXBP)P6&;'/90GE?W\;Q+OR\R M/55:<) 9]Q=:5@/K'IJ#4YV^5D: HN0LXK*9K\9?>)5V@[?@)W?-F.[Z:2T7 M(?S4\VWK7O;:2STN?+G//F&M<9N_RR2,F/[I+G^2U0).E(%#,:2@&@V4?6@Z M%M%Y:EOMF: DV%Y\MY=MQIN3I/>8RUESFVW+H6E[3?B*Q( A,P#C,!FDG>WP M^D'GU=M!5(*&"9XK"B,<8J$AH)V;D.,4GXU;Z5VRAJS,F#Y81-,.)QLJ'CQ^ M]@L-?(F"7*@XR4V^;E*@UHWBS8H ^']CHLU;Y]6P?5,(;'40%>US M>M@4H32P;M8:6O! L D9(JIQ262$X>1';N\Q5A_2_P3M\%FC@5Q*6(W.0G+F MT7VGY=:Q .N?NEH*?BH7#[44J &#R("?9G#X(O32&Z4%JX3]ULQ/0@,-K1<; M7I.=R,AMGX#\."T%F@M*1/.^V5_#[@@TB090CU+++@G5,'HZU\$4SB46L]_#N55?92PRM5YZ F M4(!GN&K#3\I9IH $?VMIT2'[F5Z7XHXO!^/U-;$<'=QE0HO"Y[WE;4V(E(>'^I#DI[REF31_4=<4P/2[? M?2K>&ZOFR!E(4*KT9Q ;%$:7H_*F48TO,(*PW861;@,#L77D7PYT ]!2S/DU M!":1P:!');\TJ&#G+G+NB@>STQOBR5(> D_6K@*=H8&.]S(D?D>.WYXZ\ M[Y,P/(T&NLP?87"?"T6]5U)1<\(8\NXZJB4)IY?@QQ3ESTNNWL%10,K*I@LXLO;I@LB@SR#M8G! MLY3TXJM.833@FHVB1RECXG!9JB4+,R;&%C(#ZLG]7-JT/&5V1GZ80=YOB ;& MRH:3XD$G]L>Y95.+!]GG'65P[JU!Q:LTR$HEPG43HZJR4AHWRH+1P.^D?-1X M PWXFBV:I8*>+FJM^G_>"T3_OOD,^7I-@8-CU^3O7GVTXGOR@.LVAREQ-J7ZB\K7PD<&@=?Y_HM6LD+'S(A5R<1Z)!N1I.FS,?ETH0>%*R+=( M#"2?W\6@< 0F:\1ZX^>>V//\;GNWI&1:3Y"-8KRP"/C,\2UEK8?K?)7!/1DN MMB/ZD="KUGG,=NIM#(\J_I5^E2;\5*#G)+;S"&$(ZH&^-"A[9M/A<[^G)\ML M^\F/6JN(ZU2E'-&W 8'9;((R'U&5+?P&:BW-V[^2AM^1GO.[C)SN0?&Q2:5! MR%ASCG_GYV'MWP/!=%8CR#2T;[$IAESO'*J (3(XSR:6 K4FEJG@I0*DLS,$ MLKM^KF0Z\GLS'8PZ(]_.7+9F.Q0NV;Q(5\"$S(;2,D%#P"!F.JY9R(2 M_PA_'P:):."U?KPHYR*DBD_%SZ;?$?[KU=:?F1NY'P:9@R$, MU@9A]W50"OM(C4-9C)%];!;46@K WZE>9;NVSMSYK4RVV>!K),:Y]8UZAX]V M5CWOA+W-*+WZX3$P.]%<.K* 66^$7@#C$>T8TTYD<,7#N-<)@0!@33^ ?ZV; MV4#\4E66NS/HN-R:9?2B<.M+0W!#U'"SLV@SUSEG_#V2MZ7[J1D,_6[SUYQ. M?,L(IZ>W?WH])=^+^:[6UZ?[RJ^ A'?5OJ M0IIG*UD[N%I;Q>=1,3"T#^X/W;O'I^V7<6Y$%$A/X7+_N,'\2KWIRJ\=#61& M-.F*Q9S<0P,G1W2H$/ZHH:8_]EL/;M[E$Y%B-Z? M"Y[W/3LLLE38FOP TE-LJU*3(,$^_3I:ZU=A0N M51,D7Z!9?P]P#&6M^!-E&/17-_DNL&&](X>RN7K,4=$+O6(^V5V% M4,>D#32%DFO[@"'G)#;04VK,L3\* M!H;T54,MHG2QSHM^B6SM82542<#[JLNG,M20^V,HK@:CC?F*,F02E,Q?"'2L M8S!+<]"T@\FU,&""JL5<48^=*01XMH'V[9'\1];;G_C0 ,<9BN><'6/E&OE7 M3'0$_ITJ37R:'G>2.DB.\#C9VQ&5P$V)W+KG([B7M>U*J1PD\3$'?!N_?K(#8E-%[ MO6EFQ:UI.EAMHSTK@5 +67GII1&:EY/TE>]Q\9Z'+7M(M+O/D^V?..@T&ZN/ MUX[O%ZF0;;^QV]C\SL.<>>N)2%I.U#KSB^]"IW(B^&JZDREFXSZ#K":#HHS!3ZV]I2R'S_Y!UIO76G^NH= W]<1)3* MRUU1:RG_;^E HQ\:>&O65EU#%XX&"#MR>2^?[GU5/%TU,M:WY+SS)HA0.N*" M[!N4V2O^Z-%05?*(PV05DXFD?9=E[>LI&&_.KA4+8O,3S)3MNH"4([]K)$UP MB-"MNTY/.N,A+: EC0L:,;/++8P-,;IUD! _I7M5.4X'XYE.U#[!E_I'%\V80$]Q M@KJ@/Z1O*41'[M/[$1\?2-S,3P6:5=:A_];7_U1?7[]4]:K?K#&^]_KSQMD4 M--2=--[$/T0J'GR](SKZ.=CH'U3^EXKK^E3!J:8_D7/FU?<)$JBL M&D>V8LO#O#N$SV9%YL66(8PR1%MF#-*6.;+.GK301=\'=[8D+&\7']8?2=M? M5KV0KC8^E%9R M7*3='9@$3DH__WP;[[=UI>QBG[GOLEE-RO^TV];1P@:9]S';I .TEQ#S?7)'?VX&V M52&]1U!IE^XEXXX<7.(3S3;#Q!:G8\"S)Z]$NA0.Z)9*UH/\%"RL*T*.P.EB MHS*3DH+]@US?KV7BB.#'3>H=KG 4W#^W6PY]8^!.*3U8?C)<5_[CV9.[S?D& MH4@ZA/F2!AGBT@!VK[;,84!F]IUF:KS1 ^GE9H^8@[]UWQ7YK;JXV[;]"U;'>PRARCHLY M:,$*)A,.>!MPVQ>V@P8P?>JPJ[?<&*VIW7"G?O 4@D'ZS6U4"Q5&S/&9?C1+ M-0?-V?E4G#$W70W$(,S_. FB]HG^%&1)_\@1 D%BYO\6:VQ*PS M-K4E%SU@^DM\-=+]-5<80(1>[4*" UY>N0:#5DPQ2X\&N#!ZQZ_Y5/8_ -._ M4@EB4"/#TJP$PWGA0IS?8O2#,QNK;=\8W>LF^/1(LZ=/)+&C129@UEY^8?#- MLX/!0+=OHG01PC7U!N+OQ*'L[D240=Z%T3G!@WW9\5Z;&'V[:^F<]]2+[?&P MDU-NT-ZEID)U=<@6/T3BK8O++E<8-E\K(]%F?PY2X&"VJ*X+/G6H M_RA.T? 3OJ(ENS40(DVF(C8M>+O79#)Y6L)$YP>K(*-)5=Y':8C5&U/)-ZW> MWOPJHB_6Q.4LNKGE0KD-#STNGEU$_RDC>&J;_=C1_6E:-D_!\<78@S_%WY*8 M\,]_(6/Z;W;^3]E9'IZL-.HHK9.Y1;X(+J-#^/#S%WD75TZ4F*Y)A=\C7.'P M,(L%YMUK7U*1NJ$!,C<0I6T3F9^(>6$_7DB) S/$(?I^W.N'&GNHQ[S^M7CO MS5]QO;+_<)7O?EE&BL#OV(/I)JNC@?!/_+? <[W6@GV^9B+%Y0J_&/E,SCQMZSV6TGBW^)K$Z^J[]F M#=V&7G,?/+8868Y6?E[7%$]H\>F.XI':]7;^_>X;<76N5\U1(5=;H R]4F3\75A@V,%^S:J6:#OT/-Y>(S5443FFZI[6%D MZU?Q_W=H[DT S/1FQ8@?N67>^11X2YR.P_UKTV'?5[G"WAO!%N>>?ELYIP8O M72-V \@G9M0.4EOX'9P=\@L?Q4M.9'4S8S1SWA-%0[:/KR^GRPVA;#*DVQ#: M5.68QV-N)??&1U76_6L>1R]YF+_+XS-2B:27X'_3M?+B.QK \O*!$"+$E7_N ME0; 'KRK:SG#5_)?\9Q9*4>JE':KLAE$Z8ROV7<=0E(6KOOL_M$;LK[11^Y^_V(S@Q6((*K"Z\9"!Z[30Q[$B MWSZV/L7_I#23JKK#WC9)CV HD2>E'WZ:5K#-2@#;$;6.?F"\U6$C:&IU*Y+S MAAY7X"LLL>4+X9WM,@3V^ "(P"NMF.XQ.[30)OD6(6#2W+MC#%/^H%ME6 MSI4N4G_CFM)J#GYY,!KWQ MQH7#NR,E]IKH%]O9]>KVH5$O62WBN3_C=0R3E(S7Z/+-SF4R#^_X*]UKR#,^ M3W?,MJ5+0NGLIQG8FTMI2#-[%)5W?8[&WM[4L]E9,@H#,KZMQ^^:.",#$\_84*SYJN@#C5)-MC\'2[/>ZK5L96 M$CM*SG=RA9_I :PA+$.]M^R[#$]KJ\\>O==2>*;Y1^(J_BMQK9RD4&&ZL=&* M'P@2S;Z,/,XM*[&ZBI6FP77B2AEH(%'K%G0GU&/3H5%BVXE9\"[EKHDQ&Y]; MHB")$US!2WAP1[HXZA*V 1\\L.4NFT4#N,CH?*+E57&NY;)4-,#9_I?70ITH M5M1 (]4!)+S$3S['[B(]T]7"XIV^_>><,!'M8GJ!9RO6>?83_"L5+TVD'6_H MYE:5E/5=UL=@&0BU^#*.-TR/K&""U2M_*/AO'C-XUO;&?A>)6;D-(V#)ZL,, M[*^!Y'OS[,C\1HD21EX<#/H7GVPGT][Q/K0M@/C:"D&]!2RK!1S9B> WA^B> MO>5]LNP(CO:/]G6KU26[0S/6\4"VJ\#F;[VHPDX9OO5%NX?^&/?0=FP12M5( MM V]CN(=+)B9@UAM&/L'%^NK7P^X,-(W%PVY1WZ9D/A(2"\<=ZDJG[[[R&JVUO9WJO5T9Y6/-R@T4%.;>M1+=EF M7S2MPK4P/;EU.ZOSQNOX:Q:6$=CF*LS?M.K71-E9W_O)(?SA/.V,(1]94RV] M[852\XR5\NWNVHD43L_(G\*2=/O!< MC'FS[\=;,^A+F@A-8VFH T](V$SWR.69)SZ56K%XML!Q:/]MT/@7E8(4_:45SL-EU):P,SP+.4^MAF\!C7M\.2 8 5HOH#\.">;W=/ MI@?IKZ&!2N$HO)SZ)/%TE4!S*2C?1^FO^V\'^RM="+ CWM\@E.#+7R%2_VYX M6L>;5=O_MS;L3Y7,MR.&KVKD6;1WR?@:BM["WIO$43,AEIXY.JV /,CA%63) MO!BR, Q!":4N7WJ5^DDNV<1K?NW88I%MQ6EFV#>UI[?2P.TCE@R&_9; MQ^%@!$0M@C?^?G9U& ='8"$V +#4%HV VU^)"*BP+X=J^C!'5.D)NW?*NLR# MT['(=_&6B!NH_(UYW>)$:>/J;-1Q2]Q]^NVX;;->(2B+XG-5X\(FZ'"CK#3@ M1>U%?LF#!38'5_&M6B*=JW>GM\KH*^+O+^NF!?4]CETT@)G>E.=]EY/6- <>]RGK!UZG4\K/J[J>D&76#V7Z98+H C&SG _ M$Y;@&7TUZK5CE7QYXI+QY!6U3C7%MVAW8BM3V50?RD'(:[9 MLZJ/YD2UY_)29!+21RG'\HRLJ@42@T]0E0YFJ:^/W)=+O/VV:YR&+HA9\= M<63GU$M;5T_SG*WPU4=HX$7YEW0^"V^W\[U$O;Z2,U-*MMGSFO553GP>1/<2 MB_9\F[.Q':-BN>OB!"8D@L<3<9%6,M8>(C,I V6^,'D_]+B$(EJ6URJQ@U @ MV'D?NEB6L?F.2EQ79SY.H]0X05NUISWW61D!O+-MD'(#)30F4"+(DR><%7>MR#-(*2Z?AN MA3U1_HE*!/ZP[".E#S8R,G"RJ@4H8_^](F9QCR2F$D=+DW"<6#0@P9L32,B\ ML,S"5RUS^QLDV)3SZQNPFKKIG-&SFK'\,8NZ($WIDA&E5^:SY7Y#.;LMU0%5 MVRE"[_(W\R!?#:>-SP,)#I_KSDALOQ[4.1\/FISNI A_]NX%\/EA( EK-NO[ M$F7KE%#95^5;P_< XH/_#@YX&=-":AYL!57P'I\R$OCZSJ?#(DJ5/BVIG.3N@G?H>"E"8XDG4EIV"8H'MMMUH#)5 MH5G)5@]2-A?IS9\%);![^D];O'OBM<[LG##K1Q,DAM!:U"[_?,>P\VYL]EI< MQ[KK5E]?6WI.O"_,CD.!_:VFTA-)G0)MD?=9V3-4#CPN>=^9Z !QS*-\Q-,FA1>5K/':52RJJ3G9GFKIY4]2 +7 M@ -$&VWI"HA=1C%4<1+:&#)?K)[54$Q8#PE:1J)C(D;7 Y[OWG).,"TZ^^Q M\[-]"M':AN*\^G "H5 J[K5?(BS>6P/W>E%\.SQ;E%L&8H$N!A8EL>FME.A\ M<[C9(R,Q%0.Y5*7O26!AP4?V7 [D^\3+7(LQN NN)OIO<'#YB!&/VF" JWXWR2[0ZM))3/B<1*3.Z%2? M3?D$N+>0,"M5(VUET@K^.NDZ\/CUQ*L,$IQ!U=-5A:?/'_[X\6-W4V4U_XRN MR97N:W7Z?W$]7.GUW-=I:*I%SPMD%GS'KG M00-U=JK44T]S%"3<)GL%2H*UIV-N:*>#(286P M4V8 !4 !O>7-T+3(P,3DQ,C,Q7V=^ M=\X]YYYOSLP?,_,\W[>KUC]5>Z^]WMIKK_6NJL+^P2X#*#55-50!.#@X@%>W M!P [!U &X-ZY\]=YV_!N3WPB?'P\/'QB0D("(E)B4E(28A(2,G)J2C)R*G(2 M$DIZ2BH:6CHZ.E(*AGOTM/>H:>EH_U*"@WL[!@__+C[^75HR$C+:_]L-VP&@ M(@(TWV'&Q7D N$.%@TN%@^T!L , ./@X?VN _V@X=VYM)" DNDM,PH7>)Z1GN,3)Q\_ ^?,0G+B$I)2WS1/FYBJJ:NH:F@:&1L8FIF;F-K9V] MPUM')\_W7MX^OG[^81\_A4=$1D4G)7])24W[^BT]+[^@L*BXI+3L1VT=M+[A M9V-35W=/;U__P*_!B+AXA'_APKGC\U<'*CS\^X\)J)_I$;YVIWD@^H&(5BDQ MMZ;S+J>8/I+NC<TOR'[]X"%_C]"]I_ _D]<< I+L[MXN%2 M 10!5]EG0UA LA=*]Z8:"QC_!?Q*=PF^LL,"?C6ABS%_P%MKD-_$-\+A[?/K M&-X+SN-@+BP@( %MLM%5[R+'6KF3Q3+E=:4M&1#'K&.GU3R%._0IXR!\L]7& M9*R]%@N(;1&V0_12D?C-'A$^'K]CXR7^&_J4KSH4VR$Z[XHJ ->>4Y WR]%+Q(C1V-;AF4M M)W,GTWK\7\SM(WI =TPO/-49W R:ZLR,A"IW=.;;&3K8683.'O97U$O=_1: MUV<]N'T=G-?I;XW,@-PD*.)=U9HRQV_-D.( M8X:U*H'=PRN]8>:F7AJ@\4K.%K^I3D[,H2OQ 5QSV2&G,H' =[534M19%0O0 M0\9M-)YM ?6;XP<>:\"\>;[YY^2OC-KY902GNHT>Q_WN"V6Y/> M,9D,;-$ZV _& F8\UYR@I8XF31(SLY!]WA\___SP,Z'Z JK(3:E64R+B."=H MBXU8D0J;?%8[_@K$1,:G2[S$:!/P$*Y7STG# ('A9AIYVF/W]9VD*(NPMI^J=C,#3U M[>E6K< <-5Q-+7399;#V^8EU<9]7,X+]SBY&H3U]J!MNU%?I0QK\/M'B0\J+ M#S_7XD55 GACH96$?7#=<#E6!/VX>"\,FOG42EW0 X;*^ P;M)UK40M]1_A* M;*+1+=3ZX7@+%19 0N;56]\:'T2NI>Y2E+*J-8LW$%@]-#" MPEO8N,I*!ET M_U0XM^DFK- NAA_QT:E/-&5U:1VL.+3VCHT?:=^\;*7NB.&8J*J+@3U[T/T^ M0^O^5L<)9]C 28739;L&^M/ROFH0H5[#5%TEG4N@0+7%-L.]%)"0PL2+DF3- M>&6ZBT9CKG>/3101MKZ$SU%V+?XN&'8F%2P@CCO@R(4S$?QC<4)@N0[,9?]T M7HC<TYB(1 M2>NK,8RFJU8C2T]Q>$IPL]0T+VL[%Y\@J^*6KXPFH:,4V^;F6TR%F0?9@M5, M'YL^ANHQ5V20N-@]Q)DGD.[/]Q)F\+U;=R)8XNOM1E(SH1I1,#=;MF3Z.X&J MT6]NB*SACM7,!+ CF ^9FBV4 B:,E)-P%6AY9.-ZJ5,( M8D_S*Z&09I=4C?JF=(>$KM.E9#3/][+4:@*<<$'VRE'*SBB8?2,PUV3_A%5I M5Z5U&E&7I"TYHK[RL]'2)6IMI%=AT]EF&Z@][SO7P8^L,Y^O_^"7(<,Y+/SA36?AF*)\/IU@ 8$>K&!VA^7/" M=0&OE&7Y]=B)W2OUUYUK-!/-D-"F^@S$@F=?.GUQ>7?>4,7;\R?R]557+24\ M0@5B=(S$G<1K8/]F"J+YM]9D34SB&-F)TTQ_,O(5^0='1V(*R076+66=G Y* M=Q\R"[PL>:-(5K92K).O*:7U:WM85&&M]NPXSKHX ;\^V*C M4J-P4;FHNT2^8/NU>!RMCS8C57,)_A=)$74\6^\!2!'4+2J+:DRQ7NB]12:! ME;_6 I60Z\IDOJ^#';EPX0ZK$Z1KI'E+:K-LF0&;[]Z"LE18+U61BX6YVR; M-%7E(C*EI,Z3T/5]QSJZ3S +(?3;+G@.@(?P.RG='D[.PI$8?"S@H_<$#(-Y M5(= Q#T8=&;_VGAT"->X+^RX^?35=M<7+0N_Y433IYLXD5?_NM] M>W9QY6CJ#J8T9X=)X$G@#"S)0J7$(J99]3.I]MTWN3-S?-U(2,7I*%N@0D9? MNI;\:'CZ/D'.^V'M!QH<4 IZP><[U66?R,Z5"?@\DZT=4=#7J+/L?* %.D9U MJNI: A%)HP]Z(L8B.N):8&P:HO(2[%N<0RA'7&:Z/?7=L/2H>!'CO7T#?./T M*E='U#U;S*K-9/?&]#B!Y)H=51Q7%U;VEHVY;?H];N^:?%&< :VKD:HZ1YC4.N]4-5\ M!FU:*LX]$BWU)B;08L$QGV&C@H$"-;/8,G32Y4'KZO2](<>D<7'EIS+LF0'[ M]87+C^3XTNO,JV+<$O#F'1]O)ZL&_Q'NZ4V,G(V;>QPEECS1#*2ZUD3&C49F MZ$_)J2#V5<=VFU3ZHEU H0MF1 O:\\D_G\YIQGI8\-[;[LI2R$O)USX];)U) M&QUS[YAT;RD3RJRO/;[PSV:S-ALN7M1U]F16=L>+HZUI,/22ME-8#C/W5PSS M:J=T9*HO+]I.7G2$OWACL1L9PN\:(6V_64QX!"D\U64+E,M ;%1_KD_P9$'M M/#B#@-O@:5*I_%R/ [JYBCJZ,)8(^>*&$.R\/*O/4VS@F M;8*8-=KK?EC\G*I:3Q7_R*\>6U.K6M$9W8 7:SN=*=4')L,"$#PHO9B7R/6B M["!/O",K@<<11\,_*KZJA534',Z_<*QI\.RUKV4J4SCE!6<'>.^]/;K4L=XW M0%C$E.;-V]=J_6*RX,)CYS-6I?CLQR[DG#\3&(!<=+OG2#J) M=GI::UV?'/BYO->^$H>^Z[VI(1Y% _%<]&<-"2"KW 2Y&AJF%N^^)1]71-B00 \$]3!X_P@1%L F6'7:]V6\5,*&M_^/I@B]>L "DHY0>?\ MV30IL5);'N8O''CJ'7)K)_-T<76RFFA M-+>142W.7B\L '=WD3Y:0P(DY(P7O[WW?:AA/?.I?6R(?T@'1D)+>\SM-,9* M:65P^N#^).)*9;+T7K1\IP]+UC<.]UV@\0X[51O[@N_1L4'ZE7JKR?!+YH_GT+J35)$20$!,[Q8P-W-,(E1TFYPE5:1=L6"K[ZT!'Y#G7KF0>HU M:ZZ>4D76TYT<=S-E5K->3P,?[\.9H?6EF@*DH6&VH(I=\(+@S.9%"!B-A%N>L_$@7=)9?'P, MME!FVYI?X(1RI<#'#FLGD6".IRN9M']>A7&%<<7 M"XC X*.Q@%YSP7I(@:\Q!@MX\5,?9:7$8!.BSF77^HS]DP?<(<)+T'[G"#XX M?L!;&VI1'CD58A-]_]N]M1,]J_8/URK%V[?[D,O11RJ*/+)1 ME47!R?B^[?5A:Y/+\WCTN05(J;!,^N.+]0S5I38T1S&V(^(8:P^W3I3N=9Y-"@PN5 M$2I6;L^_;ON/I+F#O/ >T2;.";S@?5-^S_:BIM%L/DFLU_>P2Y%I[FW34L]/ M,'2O;KS"T<3=7-N/Z>M:VC!I3%)<;-6>MUR H3*C<8$=MPZL_GP&J+.HHD6H M21UKI;5X9=$ 8OU.=3T06FQ6)W2"J!92TA4AC,QT;H5 M1=/+1MZ"]JQ2=@#GS#O2F)JJ(5IY)L9X%RJ,34H_G0^YX(Y\H_JHG>+T MD&PID *)B?-S1S">\LMK'CD*!NI*]-ASOJ3+:#1A\%'@$&00 M)+R^O3O_KG/B['M2YC0D7ZNRY29(EEUFE#1U4H.T1-_T3W[I#I'T@ZJW_N2Y M*R!]5BG-NJ1+#&C1JL5T?LZPIG_L#ICXK%6Q-XLJW("(Y*^\8F:8)Q U!ZB)L01^_BS"N4?*MQY;OK4M/3LOZ7^P]?_>^M> U7[H$&,V<+6_YC+NR MY_/OL/L7-ATG#^A>&/D9+$ M,D:$X!NXU1-XWX@%_11$@/R57V*M0"-1R'<;;L,[SS@\C5CLS*08M(N2@TV> M#]W5>:1AJ"V9EOFM:Q>(>QV F*UX,!7(7V*N!7XG**B7HI&N+TKUE/<[[H61 M 3*ACY\T*9MB@6@U?>7.6@[SLOXDP,>S^M$O1A:3,2HTI#N8'3V-@-!8[%@3 MUTS.6"1I950R:44)L=VEPS@^SREA"=5<#O6MV%=<.4N ^(*[C.%GY47S]]X? M4C&7%-1%/?>A)J!OX2.E'[UW&.IWIS%5C';"B55B' L(*%RRFRF=0/K:PCWK MFYS:FV=T#HN5-X0>0HJANI2^2M=HIWO7SQ"RNO@73:8-DVL3@;M7JL_9'?U, M^;XSD#4'B+Q3?<*TY37*Z,MV=*6;/F.$G%<0LN+5JX=.%4<_ E4>Q*(R/!^9 M&E$N=,9BV&?>Z=I98@%T6 !%)M1?,-@A/,#"UA;"#3 EP43SQ,-O #T\C C4/7ND=JTRC>JWEP5[LDK9Y*D./1 M!Q7:ESC_(7?*ZUP83UR*#*U: 3@2)9#Y!)NY>03T=-VBN+=40O M91*IWP,.#6T20RF<5GH#7(WVW#:=@0Z@D\4969'%H6]7%H&'H.FS&>=4AF7K M1(25)".&PS<+2*X;4&KEF*IG-GM3X-J0/)3JJ(.H%[EV3^YUQU"@WRV*H#\) MAU>>:MFX4<"YTPRCM'K7E"H.^J=:776/J=^H@6MXT'G,'"-JW6S5XG%27.:DTAG[K:[?[+ XQ@_R@@ M.=[_CM56'2GZ7?W/;O1ZP@RM SC&&G94G[8?D*E_F2T.0FXOW@@'9YZ)KZ!I M\L!.CANK?3'TB>5PN.4V-7>,_,+LS\1\HR-<6Q=;T!K-AP3S0:14)P/*I'MFA1 M;OU!'[[0A$C:ZYO5M/4O=P =N]9!"&#D9U_%7O@&Q*9(UGR'WB=5#S[ZSFI% M8ZR$YX7=X&:53"%[E?2P;#%(@14#C#MI3]2_3/_"5&LRLS)W.5<9UWPXBP58 M-TR> /D=IP^%H"0!&19IZ@^@%DH?"AQ-0VC#1W2AAO5H_-7P:>%]!MV&^JS> ME;C"5,R]U<1U;92 CBFA4$M(<:%7/1B*-[F-N=< JR,Z9:YDZMH9V*$:+'7G MU*PI&RE,#!TL9XKK83ERUN\_JSN2TRK9.?;U7X];\RY#"A68\1P].#I[417[ M@Y]< W[/=GD9%CSY.-HY41X+4+2J -8.K4UN.KL-309D 1V1SKTFP[Q-*.L.HOYTN0';KR[!^B$/Y] MWT"N9HO 3[KR"@C7)-'%7]AZZ6LM2^-3//I:I/8GE46VJ %OYOK'(751!NZ: M#QUT_3M+M#DS"@*ZJ_PW=Q8OX7ZX6H6Z_"YV?V@B6,+O#[ G T@I6.3VB>[*;=3YA)7GK07,P(Z MF5XNU4>_YT:Z8ALYRMF;/,U 5XJ^\T"K.;"]136T-N%E0$KKQ[D,!VYCHS1O MF&4Y:=B?F2)?D[/(L2HH2$RWK:ZE%KGXK=CI [/)E&UK4[K9_B#1\V:/J X M3I^'OPG%BG#\N%,693NR+R,'"[#?FG"DAVL7>%@QVGUZ\/WWR/Z'UF]?XT4 MO38Z14]V6%JAP: SYV+=UO2IXM#:;*E?_D+;I[MH1JTK131<_?TVC7;#Y\5A MLJ;G:=5UB1HB/'0IRO;RRX'-->GK7MD$3ACVB9,;)S@=K07<]6D&ASVNU")A:>NZK^+>JG$-IR MWIM-S=[+1M4P-AS90+ESW@3)XOK%LUPZ&PLF7VS='L\2U;>&/1)J]RG?/:_J M*B?E>G/S/2-( 0M0F3QP<%X!SUYV=V&($HR;8*?X[Y=KEF$M/0BFJ+N]"[N?5^#JD2GY^'M#$B M/:$:TAN0[7;VBO>*=Y=,'8.9L[KUVB9UOKU+W-%Y#\-7JL,"[#C9''%E1D0U M($^1O/WLI+Z0E[?)C$&K>/O=K+-W$[2PX,CRKLW;9?5OT_E*/^Y0!N_7'U^; M5LD8]NO%))LLY04U"6<;_!!'&A7D9=8?-"^9'&UC'.+5D!1]DXYB3OQ%RFNJ M:=1X4HEW[2@?F[7\''(-RM!Y]R3(6FQ%XTN MM:88C08E:)#E/9>G5>_,/A$G2C(["%1P47_IX@^MLUB'VVOUI9&K*NCGZ62B MC +-4/MRNLAZ8:+ZR#F8[-O4C8/#?7[GM5/GH*%6DE52DL\X'#A6>J5Q&W'+ M%8MMFIC6BA$S@\ZCP0D?+5TIN_7%K75QR$=K7E@+KW#DOD!NLDX\HY!W1@G, M)UPLBMLTQLW68.J#^9.&#G:6K;/J85?=_3U:\,I6HVYH6E#>, M[*S@;I@Y>,]LVSQMU[#$9&5%U%*@;VK[=86XL4\L"]JWC06PL@UI_JC!#!A; M@"F 6VP.W_T8]!E$5]F[LS)1FA+N$YJ:_)?MV4D-D,_KNOCT*VM80+F?7_,E ME?*5%'K:M8+Z: (V2!)3'N!H[SQ@";] 'V49DGTQ'L5;Y8W6P (<=._50RO^ MF%K G>X6+_YZE7;GZ%[OVJ]?ZKB25JA00]OXB/0#!0[,&!-=?&,Y._&VEH]" M =S">B?)LC'^?=W1FJ%Z=&C$;TN:Y,GHP9BSN DL *I_MME%YO%^WQ5,^7;' MZTZ[?=/7 MHB"5\7)J;^0;'HWC<6%=G'L J0975<:$]+>O=QF3-W#\HV&-Z!NO@.(6!B9] MN2-?[\UG279I.+$S/-X9]U;Q$NN;K C/2C&_IB$0.^3UA."@.;]%/SC2GE*I MQB5=2E55=2[I*:E8R'1!FG+@"NH^USU2J;I89@!S@'2TU5 M[;UO-AV:[;-O2M^Q#66V)71TY/*@4U5GR8+.*G;(:ZDA%6-.#RDMBY(]E^LY!M0U@;5OEX;[G'+&='&2^R9O1*-F5%IX>'K9A^E(+1US)[ MQPITF?[6#6MP)O](%?T'U=__*- 1<>.@ANF/[YLXLJ#X\?%K8WWH!$^T]"_. M32Y)+7>+J50A(YE7E:P25Y"9F>+??>E=?=GB"^M5V4%-_EX7]"WWD0'=_OUA M@6+EN\%\3>.NURI@R4P[6F^V0/X'HB6.S._X"GYND>DGG[FA!EJ2B$ZN_!BN ME*Q$&9D.I'M[4#7Z)?="_1V*E?AFPC#B;YL(/\K)%.RT43+MST0<%DT). 2< MA2L^'JRFYC#X>2T)?J.G_UL6L;"N77O"@Z;@1XX8_H0S(=VT&M(P/8B3#H(V/6DZD/1MLGE MI]+Z^FF\.">S\$W#H'CO4X (9[;F&7L4>ZV,L45PI[=N6%*OBUZ)\$*>@F^3SX,/H C M7/6#X*^5;E'LS.)N46EI#>U_3"X5&@($A!HBS!+W*QL'20\Y(5)."N&@F%,\'!=)+_;NL^2 I:Y0$'=[+?VS'P-$.$ >Y+DN%!VH$5%C G=W? MIG\1_4/D>M^/,;3E5=N,92E+(OQG\VB8 F^84H9%_*#DI.'@N$ :E>#O&JXB MGI37"S]+W$.?RLTX4.S3V>3NT$_X>G9I%<#;&MB:2RH:AN72DOI,\PCX[G ( M] /8ZG;9X4:W21IW_JU&KOBD8OJ;*Z.E3&>:ECX]T9X=3?6"91<[ZS7[VMB: M<;B4B07\;+?AU$9##5=PH2[ >F:[_=3S2]M-]K5GL97CV:3C8T8(CV2G3;J,W\3 M 5C63,!EP=-#Y;O&/N<*+*F^PT,+B^;SP(L:OTK&IV/WM4L,:UZ9/B;(<+LR MNG>M0EX E\S)LOY&G[&A4L8N Y-A[ P:T'\Z5ZW,R]X=+5]E W(LGT-==<_: MG6,XH;?5[\_C9N"'+/&F20F2M0DZ_>'-.$32!G>Z >'E(9_\7,'=^2HUV,\G MYT4W955-0HVX&N>J[^JWN)[>BJT@%O!\6"U>=DPL3GYIJTQ0>>G5Y*S M^+>/HJ(W,-N1NZQ1+$9/'A;:UK/.S3_,BWY#_# O1-$:(Q@HW8"N71;4ZCHW M2=I&6N\MN!.'V\$1/PGCIX\3KF6SN[& $^D=,)J$'3TS,V6R>B^PF^YC!#?C MK-O830)5&J)&?[.2I+4IFP,+Z&Z\5L0"E.-O?3JD!@N(8T<>@"FP@+'54BQ@ M60"\"@3J60'GS"*N;\ >6 !GVA4S#A:@T,Z <1A0_(>N:O\TL]X-]"MX=.9< M^(ABSX7P^O(:>/%OSJEV!GM]6TH!Y]L'%&NJV8]W4>"-P# L@'P3B07DH+!MFS'Y_> M#%V'_6^,_P;&^_]D&.^_&+?4"?X,MGFEN#FS@@7\OB#$L(XBL(!+%B_%:_R$ MZ[=80(0G&HR)8-6]+4%ML "FR\MHQ?I:BHM+S#KFV4U<"!:0#8S! L36V-$^ MBA%8P);[%!: I%=$Y?]73$9Y*XF*!@X>O1SV#$/(8= M"\CM-\ ".DQOR4D"VD?J[_5 ("7Y5\XBM_- #H!K['_^4%R#_;8&PH8M1$\?/4<^M\9!LL7(6JQZ;:\!3/Z8**U MUVJ_ER*KAE;.>XB"Z:X?HZ1B>'0?O\]@%#(6&_].^B#[3:_:JF7VWCAR1!=P M+1>A-_VK"946131].GNA MK65-BAV^QY>RY4MR_S]YUB42R1?FQGO?$:5(V>:>76:H> M/*765",NN_LY;-IDWH3Y2A@S0;_XN*D9#5H)>KD0J#+F*E1QP&7;T1Y_5S*J MD\65XTAQEJ<)$G7FFC<'35W8!T6="[^94F0(=$=*&==.M@FI.);[6N\8-32@ M8"E4T=*9\71N][& 5#/%OG:A(/XMZ36-?#-..]\_!,8&GY]M/2MC>X \RUP9 M)L8"5*?W.=LFA7/?"@EN6);GDU*"1^E6V7\L%H(1M:L4G_Q;I](:@@G;U 5< M[5U^26:(7J06)GB4IUSB6!ZMEQ.*5\ PF8,PH?X6/16Z 5,]8/*M\QZ-QK8O M(@\Q)!980+S>+1$50 _=')+?1D1H.WH]H/W/GVSAEHW+'@H8,?\1&,-FADJ[ M6F3% CJ=P:A!1<1Z-B.X%;%T3=^ !;#D7S'3K)]'P#B"J_\=Y>Q_TZU0@WL: M&GV=?>O?J8%VF/,(,-)\Z=HC >WGT <\]/7! O KL8#^AYB^GHL@Q&DD>P6M MR1KVUCEJ5X7/6V2Q@% 8%K#Z!=P]I""*!01TMZ,%W3 R:F>2O$.'%!5/;U[E MM?-B ?]@Z#_BJ*E1 /H&O2'[4/PG._\!QTU_+2X2XDO=2565$$U,M'WO.^YMLX?M]_2Z.K%TK;=L8 M2T]ONB74C5I_L>I_+67:E8X[YY%NH.[9% ;^#=(NTSNY_<@U2M4@QP_>T:JO MHLTBC7"YLD)+V"D=W^S _NP8AZYLXZ4B+W;;[&2Z.49,6=C4) MR;=_/"U]XQW_O/9;RM1R*=&[9Z>0<,($.:T/6 =^6WZ^_ #C#+D=F<'CP,! M6$"7WPKP\IZ7[C79[2)&YV-H1JEOTV1W&7C9)?O:2.%EX_DI'9+BFC>+^S:0 M11C>!K)91729(D(.)7Q#^J080_ +"^C5&V10P.2UW:;MC\<][2HE]K^^R#!:7_H^+Y>\$YSMYO7Q5D&EU>K$', M2N!A9IN/'+051*P6N;XQ#GTXIR$.MN^HLNAGAVY&SW2(_4+HA@=SU#2G+ZAD M04K,&05M] D/O7-D0U@^C*'@;1$HG^X,81I?L-E$Y:(\E[,ZRDGJG44_U['J MCE'X)IX#(>#SNR?D7]'YRFBK57 $1C(;,=_.**>[O$1I@4+('%:]@"M4VN<0 M(8B6^-0SB5]=$9\CD[H&TV-7?5B]W :OA(7%ABMUJ1Y92\B8).D>WY(.#P7\ MF9.@@+-0M'<;2RB"IGM2MV*W37QZ_@9BZ!#)G,CUBJ:;K"3G.T['CC/0=%*! M[2V80NS/$K5<5&'3D3(ZI\E)XY7T2N(8<8ZSUCY,&GO+UL$24L1%%%G:1RJ MPB>LKK(D5RDC3U,)L #3A2=%GE/I9ZV9?*G?N6"IT$EMZT,KFJM)JP1)WU@K M,FYMK6&K8'I0,/_OL>C1$H.P;6LSKPKVT%3O MI/[EMW+RE8O5$9H3"DMG^S8&7[)3'XX#3&T6XHZ\7ZKYG]]NU4U$T"T/U,4; MN3S9#EBY\3_2MK%LTFV:T?_^Q>!FZI[>"6^K[]>!EWD9>17I]5>[ 0C(FA^^;^4%EVN=_3ID>YK70P!2S-1_FM1O)/?T7V1!WZQ#-VWZ=J1;> MO@N[7;/GZ3=!D 'A?[X6-=*^:%*\,ZI&@<2GU;/&F:+54P'\*Z';L.9#^Y0! M=\PQA45?J3?UTA>E--A)Y'\4O [S%Q6M%9Z.0-DZ^]IT2_K#DL^:&UJ2_'@R M/$EFO[ASXG2XD.,[@[M("L&3AQC"V\C5"TM,#FOB+O]VEL4RXVH_C8"Y<4[5 M-9?8Q 7Y;7'%@VH;<[ED$3"RA>NJ:X#>*HE\_+:J:1*Q,'R0_J/?H[)$HL*D_ WMP6,- MD5B6R]AR=AOC&01YC63A>H<^2'8_;W1_T)=SF(KQCM+SQJOY$9\,33&7A0?GQ@XN@LP,%!J$.L #7U13E<.AB3W>=<")0'L"Q*] MCHMD4XH-PGM>LD43:1H-4E)B++_6^X]67Q$F]<[<.RT6#CDETZM2K#[DA(DC M#;DZKR&22LTMU7&_/I.7B3VEOE9"RK%16)B$:T&/[=-QR4Z49"A2_QP;XOX& M33&M.D-KT"8K9/H;PZYL1-0(T1_#[YA?';THNW='?3X_NIRAFX)2\DWIC)R]'M/OAO@?BD$MBA IYVR*0[J6ND@ME_]4,]8>\XJ/HH[ M3<@Y9+_\%79*-PA99#?'"XZYS9[]+<"#A'5]0V\L '7(<)5_89B2^/KO_J3X M3['L[Q$.;V-"ER)FW^O2.K[*2W*B2.>^6!/K];DL&GX!LTZ/Z.16JS M<*XV)"1<%YXP-K(G=FCEO])@'N>"T'RM#A<(&J M.0^U5TY6BEU9(K4PP3?-Z5J[_ ;%!2;!WFSJ$_:.>&%R/\)"P9$ Y^)=L;VV M-;4'PH'"-]ER$L@APY\S@4.'U+Y-^][SZ&2K[_.+TO)&IB@F\(\<]\X1_LGR M3G$P#CI)EQ0:6R^J5JHAWYAJULWW0Z#QW0@/=Y_,LK#F*7MXDTYN'MIAKRG' MKMGBV]?^EI:WA;^,8I-T?MLPRER:R&WR):3K[!4D_=DIR8O^D#U:2*L'+,OB M,(1Y>^XP?#:W>#XY/Z]>HT+MY?/F3LDYUX>7L,.00X[)0"]$,_5-00J7O4">& M&B75,ZQTV&^N&.4BY[:B]'V#!S1&5PB/4LVE_QSDYZS-P6?1O9CQ_(M72O[W#IT"M= M W=">.R1^+,,/^K'%QGO9%@,Y=(: -U* 'RJXPC'_7/7K?#C[W[["& MB!9G9(!:$\I_%NCKH!]W>E$\97Y))'C+^^'3CUF<7GU.,6L9C_1^["*E'")G MFW;=#)X9.CA@&_91X!B_EBU%?W(;^68GN%7=X-P,>>CPZY,Z&6< :<)(;?G> M+CC2FF(20[4T]Q9^^.EDGV"SH^C6M6KS=HI-A4C7L^V/F!E_@0IL<"50H2=T MDZH59<=6YCV:?)+TT0^KDBCRVY>SL( C+S8F+ !B,7I#[7QZUL[QWUQLXWV" M!?A99Y?+LRAVW"8M7T*]D4 5F%"+XK*5IU[-9Q4?9Z>CGG5ET"MI:3FF"]K@ M"2R \IWBBCL#!J<7"^B9F5YB:%_[BL[ M-ABC)#>8;F+OLE&T$EQ=,O57/@L M;4#(KS[_]"N7\$_$7_ATZFAJ=])LCH-Y>]^4K#@:=(]H[MK"F]L3M\#(O_2" MMQ[_A]IQ+(!,&$6(":,"+[, K[7=,5Q(^@:$K*DKE-G0PJQ I #Y(IGW*X$F M=0&B9H0?=P@TYUV_M^HJ RD*I\#7\U3Z;GZBUF?X6XQ/?SW3K'AC=ONVPOF? M3^'7EU$TOW..-#-_;M>8I1(MOIW*"PCP?-%2F]ZW$^#WN:!:W>:S%W''M*,S$;\'A_6(WE-A$.Z(0PW'+==\(7^/>EO91^1@FX K%#<&# M6^HLW8Y./R:+=?]DDQQ/Z _E27%GR\"_.!INF1#7J'\*]%B5L<[QD)%_>QE/ MYJ:IZ('_S9[":?)VW+>M]O\KJX-AF^N*#W^MYIR6PXTC BJ#2F8[[.BKY:>* MI>>8;-S/^U0H\,.BFPO9&_$\!;ITQBLE;[6,OD-KH5;[LAZBH_*VS5.+6"]@B:#N$1(R63.9'QCJJ<+M& M+YA= DE6^-^(U*8X-BJX5MU0WI:IQ[RS+.'4WKO7%(,P]\WC9Q6!>DVB'P).53 M8HTC%\[$\[5'_26$QR\=Q9>BTF'?BLQF5<8SOWEO7FQ2 MOM:Z& L@C2L#CW4Z8@'!Y@EH6Y !)OQOJLV)CG8IHID.TC]7MGSF_3(X&%AQ MDEC0N9DK-'M6;';]KO5\?:4'1BF?F"QN/P082UK.]UU/+" M/9'8Y\L.A\)5?H?6MT4D:)J;XJ7) M^@ W$X,3]6K>#BZ;8R8"[;Y!SDM@1")4]_*>H.+AT$M%VZ"7E& $1QT6T"ZH M,L;^8NX_J8,!)U!(W+KY*>WE[W_G)1?NQ4G>YVKK8EKH9>D*^_/=[!\'']RX MSZ(*T(LKYWWUP:Q :LEDK\)[.:D4]QW>:W1__ZG

% UX$.._- W49)YV%= MO8GF7H.%,*+G6TQDO01L6= M1TQV)SDG.T&>]+O<-[7L)^A]N1<3F^2>/HX&HHXUI]K?.EZ[K[@[YZ/]ZIZ] M+G'T(3^^J7]8F201+B H8/UKD#A/F7?C0$A^\_:^8<;2%$ M,AB@"/OCQ!#AK8_')&2_O?"AH"8);U!X]I4L)\0"0.H0&E1NL\*PAU (>U>_ MR *DW&'0,YW?\7FY>_EHXH_%LP11]3!9OP^>R?&AU7(4J*;SKG;6%70FV.:F M)NCL*N.BDK3O/N>+'X]PD-ZKOU?C.TR"D%C *F%8E8(PVL!06P%,N.T=]ZX) MV@>M'"WM]W3@LN,.$4XE3C66[C>(7:DJJ*%*$YT5%CR]../V:"55#Z8*=$ 5 MQ3CGZGKZ>18\PR^ -0475I0])46E-82+)YY=5'R/[!C \Y^10H8A!-,2H&#: MSA56Z]UNXV#62>XI-Z[PT7T:"L$N43^[M._9UM/;3<#];,_"W461U$WUYL9) M+]!;)]C=XAW0:\&&U#;+E[5\C]_V.#,M@SA?==)MW$:T8''EY24:WVX#V D/ MBK4A:J^XMA5JL='@HL7A_?J1B!/,.H8^MOBPU2/28-)$-9W^R]1.P M2RQ*UI_6GEIAY!!IH3_^VA/Y4S9,?4*$P]#SS6J=6]O9!0C]*7?^*++=?HE5 M>X5W0J'[-4LHC+^G-5G_@\M&M-HLLYH,"-+8^1)GY%F)Q9D/:NV)3GF)I2.5 MF4K1J"=(P,3'744\Z9:30TP3,T1=#AN0P_YVD/W8U*;UAF.^Q?*-(TD2/W_$*.]Q\H=FZ6%%QQB,RDU@U]B!GW"T H'O:&<6;4*/>7T: M:]OWP&P9XPVIK)D1J[$+%&Z3X&K*/(&G)5W :"\$7G:UTAYJ-WX@/M0L>S4- MM;A(,TJLF!MXFM/K0HLO&**S$'(UTVLW;&90JJQA(@1QDJX$[Y6]3Q8Z< MQ%]_ZF9?+X*UD8 G\]]%#%_7N+>W -I 6_(U^ MN\I%[5O8F?BAT8,-!?[B)$=UNBHW8$_@3;XP%I*J-80&UU^7Q1=8W M22GRYDN_CQWMQ\\.Z-['S WL*0B#?SU&2=WX_KHNOZ6S_NO9X==!>3O^'T/Y M9?VT!M:H 7"U9T"G0,M72R37FL\&)*DIU8+YE^FN\MIB(I;+7CMU[BVTXZZA MR_+SXW*-90O!C5FS""P@+\R4(J[""H_U%W4\=RUB%1-S(TB?.%H MLYKK@_&U!LI"*QYVN:DY3>M,[4B?VK7"[6V?*<3Z_=#]9^:G8)M?$**\UIDT M/8^-VU2JL_E;8(DR9SGI],*B+6(,IDC3(LL"WJ>K/E[17<-"T- M&KWM(WR)B"%"0)GK'F)LWE<.?>+]%#0F;8+9Z<*@\9>T,4A&R M(B@K=^I]O?M@/9)O]>!2%[8 V1[;*_ZZLJMJ\-&@ 6+< M!&QMR;;(+, "[H% +L*(FNET3A8FS=F/"0>B= PJ.M*R'G!1?'A,JA# =[1MTPE+9*4Z6J)Z5">[-^,0Y M8W4V)D_6VG4G+C'1$?S#N3:3N*-^9;R8I).4\-08^_R?&/K&K.6 M>**3@;)1BP\R#E@ ZJ9B+%!> C4J?,\\W=8^F3XE29L+;;8 ;,I4E& XWV8C M(T?QVVI9X[ZDXYV1Y%0VVUH]Y@W>L\%C;_U^!B')J[3[8MP0)/O^ FQ%NN@5 MZ30LU'IYC04@+C-O21SP@C^+&0NHVL0"GCI=M;41HSG]R")Z=2GF+0>KNY*3 M)F0ZV!]!ZA413_[ZVHB_#SYL"%TEF6DQPD'4-<*EPLH:SU%S6$_6=VH>O]'G64G]NE."7F3Z\+/%D9WQM;>Q!&94"O;\<4O27>=5Y&X1#Y?H6DQ6@FP0 M+6T\SG,9WC5)X%J1$*4,*:%-S -V3@ MJ.CLGR-BH\R2S]EKZBU3%/-N NS>GO6D';=)"*.-U5Q0;XNXT]?N'21=5H;XQP+]GKZD,_S,-+U?Y5AU )P<"W]8L<#1GZ5Q:F?GR0WJY4@@=S M[Y@?SCLT3%0X80%TXF2RB+/25>: W))M^D?"AX*=-WN1&V),:QXOPNS][5LH M>JTI478)7:W.:I,MC!4*K5XKC!+#DI<+^Z.S5=:KP[%M7"/3C/J+*6/HY.[@ M!QG+3WQI-)"2A2QGJ9\%:#0\W: ;43"EX0B,I+[NU32[2:&7 VRNLJE6*J+0 M%RHH#((MF(TY+=5)W"3$5 4J@A# AL7M&G.%?-?T+WKS!]]P5^ \G=\YY!+C MO[+,Z$GUC5)L[5=*-OJY%7:_+B/CD_\A/J%]/\ZVK]>JL[HGA;&#$4*'SEP& MLUP;-S4E7G/6OIC*_2A\5IA9OO-$PXBY;8AOD#@Y]OJBD[>!CB)2CGF5G6)' M>$5;N.MR*KWN"6JZTI.6P1FZG[HP\9SFDB9N&U2D^Y,53;2/VAC MR227*]E1T;H)W+E]GK7@- M\:C]W]0'*J+NS%BBXLL1R]')<^9S.Y*U_!%:S68?[JB<=)<_8C_(.CUV" EF M\!W51?;H[2C03N'/-Y&7%OR(:+ J.D"LFQ$=2\-9[K0U5LUT&"L(( \3'DP7 M(14JSN!NX?MRL@R'^U._Q^O/TVX<%JYR @XJ=EYOJV@HF5Q4;7B)G+PIR.6' M!I>W1:C=QGTX\6Y/VY/V,8$3$HGP(;-L=;\JB6;?8ONHP=K"1MD_;#GD+9Y7W@-O'Q;1=*U&]7V+\E_>X;U_A_5?&=84\W6]@94 M1)H@O44$17H3Z2"@5 $!Z24\@F+HO0E$>"A*"T5 4$":(%5**"$2>A&D%PDU M]$[H 4+R<9[W/=]USGGKW_?'^C,S>_;LM=:LN>]K[FO[%T8BZ19W;^ 6C<9= M%)B_3J/!3G5L+4G'K12B"^;VTT/Y"QYU9&\]6NZ5J&&A[?3^#FV(NQ.1/D;7 MTAU*T#J\$I;7$FRJ;[:=?':>ECOJL"H:=--PRZ[ DRZKT^_*O1X10NNC>'WI;9:!U#M3R%K99D[9BD]X(^S<@L_Q)P\_/\RD&URR9;3<'ZM-"C69:#9IK&R1\OCWOKLXZT]6;5C_MD8JUE::\\>/1S=(EC%G0Z7I:1?:G3G=(VZTLLG3EZ=5MX/HY/G3!#[],'7Y)GO]M70'7)6!=.8Z:!;>PJSH(9*0O-HQLJ!UJB0J\.]R><# M?N[5R.A]PHMI=;?I&MZZ7EX0%] MDD4FKZ<4KU.A,B'CTI';4I;&HR#C^MK/ [XCEL)(+H-H^I+P$+V3*P\MFS0* MG"?2!,%JW2G)@WAUG/9$3*XUI;RUBLZ&N.#<^L,>O_OLRJ,#E#=U&S;TW#5O M_VF)@+X]++O5F2'DN>Y2-%EVA*QV2JTCVY*H;.#G%2^A8FQN9A7NU%-A7$B8 MUG%+9JAZ;&9[ZFS*,[B0W)^@SD,O$ZY*BK+"1=0+=V9'HO &:#G0C' M2Y:M[1;U7OV5^:%2BW><;I;_E5AIG]A6.GMMH6O#$6#D0MLR?A:41ITWH\/K M#CG8(@PWOVKPI4%Y[>2&QI\N??:P,5T1FQ M,T7'JI90M M;*JO2UJXFVP0Y6XB[/OB=1W#?LMUVCTF*LE8.JO=,&].OJX1&TNEM <>%C]3 M:\6[!!GC['UY>P5R;O\9JSFO+MLOR-XR=UW!;I&6?NV,]MCD6SZU]F)O]*9! M57W\#+N=TH+OOF^>]])B])8W>#+;:$SA93"F1)\9XGOVX85,DOP[U[*E^L2Q M3[W[:+&-+_L]K0N M?BNT!G9OY8[*PU59/OD0JYO^)3R8K"0?2DM^YZ\9PX^ULMN9_!Q3JW[JK,R* M]=:\_/!85HA]Y?8WTJHF.CPG"@=C?KO$@EV:MU76BXS;B4TN,AZ:A*>TC&NU J34?-L^2!NV/C. M*/[9Y_GH5ESH_"])=>10[DB9%$L!(NOU2_B^/825+D&PLTJ@6IQJIC;I&JV5 M\V9VM4/':=;2O0J;SD.H3^EC]#9WS#7")2Q"-,G:14T7)^(/[P M7+[,[OR6 6)XVS5CR.>J4:H@?Y1 ^"XE:KE?O'Y1-I<^;L28I/!W]2(G36^; M^'H:VBVJ;JW'79KZA6 ^(J7RA ]T)^)P'RO9N;)I_>',NGZ/\=#"-\5.)$WZ MG8\FW-?2/E%XV_AF*^7-H'R@[WF8Q$^Y!,%LV+$+[I,W.E\N*]'K*Q%P6$]V M[$-$M$8DW7]G:BS_;I:BQ2:O23!A#]P&9O&GU*W],5'SYM>]?GRX1LH$S93: MEGNI=NTPNQ/@[J7EJ3=DI!M98LEN0XT]B70]S!0_$M0I^591+G5%HLO_#EV7 M&Y6A1@0ZX)4GA2*":GRYXD\D9Z-JP)9(ND\$A)5G%#@7B&%9%ORX>K/95$+6JK*^6S6*.\O7=M7H%QU_%GI]; MV(_"6?;L"\55Y_9'S[*/H9F!3 V8CT$J16:]GEYN;O4UX#D^5Y+CA5ICU?O& M),^I '+2!H%7],?:8D,_\+"'J48@UU4CLS+DA9[&PAHE%M7>3$7[70OVLXD$ MC!#<)0(Q<_M/@W0O29\$5 !'$K)6\14S,/_\Z((V;I'V) .,N5"-IFB^]R/9 M AL7^0FKMUX&K7;=N5T/S[+$+6ND9([%=,H7@5-43]!=/X*%'?=R%[+1ODKR MM!&IW+H=>'Y4_;ZUR+&BO"$>O6[QN;RH%8D M^B-":>R@8U;ZDJN#9\XG[";SWK8+4$[^LC#QA?BB+(_3"*3G65)\[PN36XX) M7.)\DY@?;X8>ZNWW18<'B\'C;/9 +GM-Y /3CJ_&ZJW;&7*GI,1?8E M=LT^5W9,/=?#B'4R_ MEQVRHBK/H&[2LD07>W@/.?N#32K/YD;^0X?$=VT#E,;#69L$CMTFLB*WF!". M*Z0*!RU$P'MB!OHRBN#?102"HG&F\Z+XE 'JO_U3C@A\8;LD.;3O4+-_$$!C MV45_)S Q6]^)P +$=A-U)C\@PAD:?WMT=3H2_(2_Z8YR-]53"Y@!+HV7A[9 ML$M"!+H;0!>^GXB .MS[P>^K# ::I-'WO_Q71JN,P"4&$P&*E-DXR!]VMVL: MHLEKZYOV*PK5G[_*8-'&+#Z[\*,Z=94+33_:C4$SP>R@"A+P7O32?GQE-[UQ MO"&LCOI[G0X-8H*)T:K8MX"'[I? M2!1\VG6_(HZ7'$-5FJJX>%X=W.XY5X XG*^ 9>U5>)ADTO66H9# M58J+%F[1;!SB%SF[/+7P\*<3K]9M^+G-%NF9?IORNL@.%%9HQX-CN9@BPGJ" M)4 SD3-.]W_;#WPHV\>"R5\K9!0LH,(7V\]J"P)]0+=M'@U^Q&=.>5' % ,V M,X::<"&B;A7E2I/5V]*U:6^"D-O[P&G@P6>?;>W1&EK_)' T%V?DL'QD8[(3 M!>N0K2>VU*56/?'1SZNN% _J0'0/.NM_6/(;;G"*6"/*6J83S3MY)"29>*A4 MMWG)AD++3:UP=R]R2AWE8J5-)'X5!>?*FCZKEA2"\%R["G@DU2MPL2L8(*6C)%T;T35CX M7.)EB\F>9]SI#P6%HMP!JOWKAR4$:BSU:N26CQ-$ZFZ8?'?J_=LCQGG1 XY5 M:>^M/T'NAJ*5#&IL??ANG&.X2BIL5(*_.2*"+.(^J]@V?O\N_NG]E7>854,B M(+&L-*^HQ8TPTDY!NSTZB?^"UQM4ZJ\*.$B/_44"9QIF'4M1^RZ^Z-Y:5>L1 M2[>IB6) B@OJ<8^.SZLQ&,FKL=>WYSQ]=%/6@>JZ00]>(,9?N3VNN*,#P)RTR7WA,V:_#1"3G2[V&3T/#.H66FL6M0H_R+3?>7ZJ81 M:;N"_*Q4BN+]ZI*)9G/8FIH *4Z1G[R-26\VJQV^3U75T"X'?.G.)R6QNAE, M@-L,8&8ZLL..7.Z@SZ@ES@T^3BMV9KJ^T/R]1?*(NAZ?6)PJ7'\0AB1)P>R& MUR%HZJ5D=A_@8L :_N/CX^7OQ"D?;]8W"&G>WE$\2-12SZJS&VU7D53J/SW4OK#VS3_5BKXTFWZA<)Z6_V@H+T1O)&X?(!22J,9:V6JH,\ M.G?;/M('7']R9?MQBD2PIURTM1?F5U/#8IER^RVK[.J6EU(%'9%]9?WSQJSQ MT% ;VVO*RX5PSW$HF?V(=QP=LV'MF)2NPLQIFEQFB805Q=*LEK&[<9JSK=>) M$8?#G;0J"/B,4(:+F95WPYEED%E/J7">?.:CHWM@4-W>]+I/Y3-UL>5WOOHC MAKDKN)6!SD#K#T,O!'N<,]+!6.]I?0E"%P2/T)A6=<2H+]D9F/KUD8AP1B+P$J[8XB!MG;:8G=7YJ M=YW[J?\M:Q%R-#D?56\;C1=&5Q2*9C9*HP9!;ZUFL>R_CJPNMYO)-:DV9POH7 M" O>]\QY/(F 0KB/6J>L<-874P]S_=3-A(*0PH/U)PRF&WS1C#L$T$6IE#[M M[U^%Y5'4G9^DP\DCLM ZR6W%3]_[%SK\G-=K+N*(ES8--S ?+;A1/&+*K]5E MAR8"F"+1W>41GC$%\4(M.XC-!%P0)P)0C@B"#QHI\/911>9: MJ0U3\CJN\J#[$!9!!)B$\.1E3LP3:*FQ]HQ06L[Q]\5*Z7[VF-Z0C2HT8V=LNDIU2B&M2^F @I?1,[L M+\?0RRZNH 4*H@H,#K2<-EITRV %>-#Y,\@M)QO.R$T5:U(CFI@"QXPE='B: M>'!DJ^;2SZEWG9,<[;)7%F_;?1,95W;>;(<[!4MJ>GDY>/C0V7IA5@:/L9WA0(,TTG6S.E+4@+3?:F[ MKE6(YBW./"K?:IIPF$&R#?QR"U0LHDXQ=D0@5 U__W)3F.[-X;&51* YA\!X M.(>643X]!R%Q UN?VPA!.CL.R1H!'M3(! V%]U01YHLFW&;??B;))Z)+52H< M31"AJ*AG#=%']=(4@A2T>$K9"H-_GI !VB:(VR7X_WW)8'"+XH;&[A.A"@E+ M@[3I ;$H\.CV(D(3SEXTO+;B8_Z1 CJ[FMV99_WB@J%X=EK@8SLOA24[2;?- M#Y+MORY__^NU,S2A0HE =N+Y(!&H.E ^/5)NR#+_YB1]UM9Y016JT?^A_PD27.]%P1AVI5OOD@&/PL M2L1-$)HGLL_N;F+C&%S !6]DJ'[8\=Q;=N(X MH3&>3)+[U0VQO&^\H6N2OP(]>[@9IHH(BZ!2I:X=4;Q0]F4U&1S)O0QS*X@@ M ,.9*]$1@9S")Y<\)EP9;QPBX7@9?>\XY98FY;'<\5=IS[#]R S-2J<@PF$F(>'9?#OQGU>JW!3("]JPKWH[?=&E:7+AB,;U-"8EE<=_WGQ/0A-R>OMX M(5WB:=*+JGED/;Z[U@64-MC/DJ:N]QNY;#<4G(K!SD=D22!VBJ:$P3HJ+ MPN?3&^97B)'YI+%="I?>.K]$5@5Z:3'&[&,;$"&$0'8\3# Z6B0PZ8=#UR!# M4.P?M'_IK?_%$2AN.&A2PZ)RQ'4'A>$97,J8I?CJQ)AD)"YN<4GP*1XUAM.P ME\O[5"CBX/.-;E$H.CB*!JU_=^Q'>&*NKAC)E+.!T1FGC^ M50SU[#_1H_]_7?J /RWA23<1V*R9.Y,JR2FWZ&T]:TJC5'&H$#(YGQECZS$K M7Q&.W5DM,R-T[9%?4%UZ>?['94:]D&,3S/KG)N5*O,IETC% <:)@@D!"'Q&( MS=[7Q$.(@*W3P 7]$4X3Y1&2_5R;N7/ M6_O7W-./I7!]V3XA*4>GH!:C,0Z6N$&X@^ZHJW>WT,BZZI_9%G&V3V+/O9/5&/_5.#[ M^G>LY]22JS*Z0F.BB2K($$F9JST>V+H1N)7M"!_9Q:2[P!_&UH0M0MKU*ZT^ M8TFE-2X3[>HCZ3<=$W"+\HV"KIOT1)UDC?UCJ]&R=@$" HD^A4P_.)Q+5V% M;ZLMN(7!?Y#IPMKI-IB9.V=JOM4X=9:U+XW2,-]D+]'>X)B.X+=K.OD M]&K^CE>L&CH\9WE2PS1B(U)5!T*S&V,L_6W4E67%$1\,]4Q?HU'"_L?9>V$C M+80[PTM8YG#,<)DP%RN7L+G=:(5(?CSX@7A*[C6>9O!T,6=>DKX4VI(P0F"O M:3K(P2KEW+*8^G4MW8>K)L:O$#F"'.F.'^]K[ DNGB(3B*?1DOIEF*GQZDLF MJOSRA#ACRM@)4.SJF&/5X>VT]EU#9KU.=K?*EIBVU,J2;\U1"FO8AH)'%0Q* MK38092.S&\R\#R;H[;P2.?D$32AC!^D0 QNYVMH+J-H[&%QVW_C>\ M^>]&XT=@G(A07K.XW"K71 GW8#A3&X;+JNBD>7DTLJ!P&6M%):MI'N8/76_Q^8D 7M]Z6*/6LBDJI\P"M?57[HW_S\(HO_1; P6*I@WLT!CR$OJ"4D\;%.$EY4( MV7Z2S9#I7J(Q5&VW/W2&OH&9?GV@.545[>?I*3>>D!0S9J5KA1$AW!;)1\2E M,]MP,>U\N\CC^]!+:#!R7$HHJ'[;)];0LVZU MLC:Y>6YKH%3Q+L#-,Y#CL^ M5O$,UGG>Z8\6,(U7P_#R1,D-T/,\? MGQ<7 R!MN$R!JX'YB:SH7S7'Z1]JSF4Q.:_;2R9H@>*4MZ@#B$"N#8KBUD[% M<%,>#XYO(UY(;\WB3/38!QS M]$OBYT-(\.8SR3_:IYTQ;F$!7*5,#O1QS-05L1:*:FT3] -.XE5FXYKYM?66 MBH/O8)]_-O>+:9/F'S7?-NT9-94>@S;UKNXK96 OHYIY;>+XW1ZAPJYD_1DD MHR"C!1*@N)3A'W);Z#;BL1OW?ER/(:]=4"*%W-CEGK8)(HO8 M(FF>/YW;YOZ"TV^MPKE.M&6\6)\(S,S=3$O(;-D:]Q_IA7/#'@MRLE'M;O99.>J6LM44;_V7.EH++'F:"SCK.)LS3+X#U M2U"VZ$($K"9.;U0:'Q(!W%[M)4!TPD>85?R$.=_/C0;^)R-._C]02P,$% M @ IH);4&2 V;Y/,@ D3T !4 !O>7-T+3(P,3DQ,C,Q7VB\" D*H@O3> M>T=%>I<2BDA/J %"\L7[GGW/WOO$6@IK]""P6!*$#T#'2T##2V8]M>7$!#A/T-\ MX>*%"Q=I+U%': &HR8(;@D(C@.D!(34!$38#K B 0'"!X#\NX!\7 M 2'>1Q)2LHOD%/@'JB\#A 1$1(3$1+^\QM_UP=\'B*DOT%R[*TUR1=V8]+HC MK8!?;"89^\/R=O#3822'H(F3_T5R.GH&1B;.&US<-WGN"0F+B-Y_(/-(5DY> M05'IV7,-32UM'5U3,W,+2RMK&V<75S=W#\_7;P,"@X)#0L/BXM\E)":]3T[) MRL[)_9B7_ZF@HK*JNJ:VKKZAH[.KNZ>WK__SR.C8^,3DU/0,8FEY9?7'VL_U M#=3>_L'AT3'ZY/177 0 $<%OUW\9%S4^+D)B8B)BTE]Q$1"Z_WJ FOC"M;LD M--+JI,:.5ZX+^)'1/HS-+&^_R"[X% DV<1HFI^.XA^!$_0KM/R+[[P7F__\I MLO\,[)]QS0"41 3XY!%1 U#@_%E673RJ%K$7!XITN2QOA'[?C0.ZU7$ 12/B M^)QJ!H2E-,$!2_E$-5EU<+3! JCUI]L0#&E*CP/ \IC;N\$+!V)64/3=8831@" ;6R"PH>T,'+#8PX_E>2-FPQN* P+G MD&?88#M2'$!R%X9Z#NO80?O@ )F:MSC@+4,KN@#8SB_APM*[=^Z>LE9!, S_ MQJWR^M2MH[W/'FQZ+,WO4O@X."?*?T6E60692 M4SL967(_0KTP19>G\\Z5^-[SEJBK3>1'JQR ]R^7P*JN+[-#YDOCBV"6D"#A M._(,Z/Z<.\K,S"^"K(1#,YH4YU^)G*]%B2ZQE^D/"6YPPZQP0-#^QLRW%'$- MFUJFQUI7YNZ%;-+U47'=O&90X6D91*;XK+T BAQ;H(25/WOF0!."\.H9#>"W M?/#=)T?VQXFAHIJ@8S0ER;PT0VF:'98((SZZ@F)Y#>N!@M91!MWY)4F>]B;T M1VJ>7,G7K".Z+@M\%N:AR8M3&'B)$4=K(<_:)6^-'D[[WO*P][3#X+&^2#2K MV^3XR&CKQE!/8ZY;SYW9]W&J5D0_0?3>WLC:("S% $K@F]MDD^10SQ'LQ>HN M1YQL&'>\VYT!]@MK#/<'9?2%J\_4;+$$0P[\&!_DM[..H/E=M1"EAG?N;G&R MKJ(A=6F7??=NZV3-?C E_E%_!B/#W(9-5_O2S'NKC;!Q?U&F*KVPJ(RY:ON):@@A5 MWLHQSN'R>T-"PDTT:0^UX0]RPS+63"YTA9_#'1TE"@*KTC[J7 .^LEU-'7UQ MM=P<(+RXJ7GC/+>%269)68(,73)>S5S/EQUJ&B474=U!6OO5SXT[5L(3_P)7OE>;#1@8YVAT>5;)>W>](M1X',N]'PXFIB#@M22%2!WUE/0NJ-MB6QW42YL5..89Y8Y MWL*C>D:7]?4W=+WN*<.:/H5IK_+?7;CV@NW>3/:E>",YW\$C.*B%HK-8Q1EU MI>-U8FX!A55.>G=6M=%M8O,(87,WBQ-\TDE> ;0$I4CX41]2J\N.]&'3F!D; MPYC0R9H!OW*]>Z+U8I0#[S>3R\2,C/?[U,<+<\K."R3I;'152S]U+FVJF^;* MLQP+*M+FBR=S4LL+V*O_D/O6+O-1BZO8X[AS-ZB54IR9+?+"9+<$_=/:\B M,<2RTG^'.>(SS63. !A_?.E,:IX,D(\ MNJK3WZ+RC#\V[1PXJ?5E*(*$PT%-]"C>)?I0C*PURJ%]QK4UI"K5Y_K>//;S M!%;!-'R >=$]QM/^4=X'MO!U*;9]R#9H419%%Y]AL F9/IW/9FV4MW0F#E]5 M%/])WYL91U!3 %Q_%4PS'$V;PR8BKBA*$]N%+EP-%CN2,A$?Y>YZ.5??5 M%DA@"8^]*CS ^X=K[0L$^AZ;LA/R/6G7U]2&=UT*OXCR[["G+UVS).Q<":5L M?"A) 8_G?+\2JTV' RJC.P>WYBQ&'"+F(5'W9R9LQ6QO1#%#J_2^GZR+3RPY MI49_O\Y_\Y4J<(]@=Y[[O-A;Y&.WI7-F)UNCL7/V1DK>S$J]<"C%U(F) B=5 M8/;+_K=UYHY]0J.ZV!$CD 5*%AYD@0(WL5VM2^>5L:R04]CA"#57>-SH1F+^ MXCF-B%MI^@TT+W)^L[,8K\)@C*"MNV/NIC#]4VW/NX]&C$X\8Y]\5NN[#O$, M?;EGFY&*V.VT#>42\-88)E=9:A;I^I:U=!DVS!<'XA+# 2$WW-T&E8#C5D+O M5TCYKF:;8R7D?#-5KH]-D&:DJ0N-'$MFW/7/Q"$,X.\!$<VZG-7? MTSG'7@R;JR@_&=W.\$M'[5Q(Y4YNBQ0@H\I-@G!+J'A:;N'[#21H@@CK\*^4 MU=8&K=@X+H"EL.9%,3?WLV?C%)YHV9I16M0K3K9/X#$01.( >71CQOKQ:W!Q M;H/1UZ/)RX:WR&A[Q2FGK#Z DJ5)/X+ /["L:'D$B+3Y8V.&MQDR*G*96\@V M4IWIVP3QB/&560KW,-Z[_'W"D;-OS6KUH[B)9F[!7H( %13)6:>[[CO-&G\^ M 0,1;4UKNVJ"UQ'#,9_?1Q""G;;]]%,YU\]9 M('PN](6>)U#K."<=(/"R*/&0:6^E$N==SEY20^N^9AWUR3;\(#5Y.8)5"7'C M*NLO;"T6O(\R0(^,9B&+9\)0A, ;2KFS@2J$>*V=O\KLW=6@$^7S(0\NH:'O MOL-0$)^X6C[:UXAF]F-N7L[NJQ;]=.T[/>;)Q*EN@CFFCE+*!#,MKQT"C*CT MVNTR8!WSPW>\V=)I]S$_G0,;SN33(K%-=AAG#>;%X$Y.E&KK:S@MYH[+@.SN M#EX3>90;;5,++?U"WG^)#&]^;TS$LEC#3;2P!<4W>HJ-FM+2Z6_QWM!@U90C M&!V]F?_]I]I#,F49%KKLKT?'4TVH-] M>GW'2J[[.3 MT4TIWXH@C&VRMSB)SJ,E*$?6'I75H#Z&?K+%L@]MB_,CP@V$A-1+9C9?V6@6 M,M]A>]YSAXFQ1WZG[_X@<3IO7OS11[0Q*/C%1&HW=:IU24Z%-MV,JFLDJHSD;6O I(S/MZ*".VX6ZJ]_RIN=MQ+6K&&SS4%] M31()J:!VO/TSJ82$PI2QI%=S>*M:15X.I8SQ1+:C=M(X-XKW=?5\ O3T>UD< MR-LX+NV=*'W>VIKNNV\(D%89^(ZT4FY5\]K>]#9Z<:-NE*22^:9%]):<2(RJ M_J5,\BY,W'V&#:GB5F*,(3*I2P*D/EXE87#[Y<$$K]>/+J2B70#HK"M6XQWM M-3]V8I:PDSP5O"Z%JR)+0\7QVD*AIARO-B'.:XG(OM;X=B T(]%:I]"R)8B:B/T^W2AI]%5VY+.N]FXN! M(N$1+6S=YDO0D%.JP$(X2X!BGZOL-56RN6\@\(SB MXD+P4V^UU!X(LKI*:L_6KN@\:?O.XI7<2] O&-OI8ONLYIJPI8MT MVC>D.9QN]IFS7XTVX5V"7?8 =?@RHAU<<]%>2[??EMC$HZ]YD[(X&[;9DM7E=8L^H7\^@7VM;]C+F$4@W.L$[!MB+F+/AHQNWXV'PTGA<$:G"M M.O9/M28 [D9TOEQY'6DB4F.W77XTCQY>LA]4:*C3"3#IMV?IJ:R1_I[Y^2:+ M#VK T\$?![P<8.\12;$K&[HQFK*IWS)JX578K5%365--?^/\V\*A':,^Z*AA M?"&$&G,=%=PNH8>H@2_;D4J/[!3K,BN^&&./F>YO_:JHY;R2$$/"*"'K^2T5 M:;EXGMY<.*^&$E-*&7R*U$7+%B<>@>_&@V+Y1FIV6U !#+W,7D.DM;J^8S!* MARJ* 1/(E9ZCFDH9HMXCZX"=?4)CZHYGWOY2%Y\6R *ZSK%9UIH5F]U2S-7 M,M5 SZP;I7;%MP**OAW#S/7,@^WW;V-0DULF2G)>ZJV[%='H:,BMZ\=)/G_TY2[[D*NQGB$8'P4N8&^C#S'XP#N@JE̝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�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

!]OJ7*8"A)%K?HKMFOIP-* M17(,M:J3&TRJ6[$1OL+::R:(ZAQ;Y.)>9,RQX:]ZOKD'\(R%F0_V7>?B/EZ= MXOIK.GBE4K'@$52R_QL\8*TX\UC7M FPY$II_'B9%++!CZJ$SR]RI$1V!/O MN&-;DC19T(G_)_3[P8M+WBS?>T!<$.!3+Z441(=?]D,=P%M"JAO]A(M*.S=!72X+,7 7 M=@U<,"=^$\SB+TZT^!9:>L4TVZ8\+WI%'] C+6576V.(:S/3<3(@'Q6GXTN> M3IKAVIO@BS=L\C_>\]J[%' )0"!.HZ4VEB\FEPYU-)Y8PDP^EA'$L/V-4[(/ M,GTH4?5O]AQ>#Q*H%*L-#Q,6G?M.O2HL-,-_D^I'?'[H_W__F#1 -=X#TFSE MBH+CE8T"P%?G)^5>YT3#/.89QO7>AQ3I,_Z)D+WV/V:Q2WHRWV1 P*"U/Y/: M6DR-R2GUM"(UBJ98R&NT0 7-XZ9U5?%@/W&F>T @MJ2J67>?ZP?; &-\H,*5 M+M[SQ!+ 7\J&M>S(][[&8!T$HK[-NNW9.K>7Y$=GV9>?"".25Q_*4V_Q71&< MY,#\(J^]@R6R2_;N_H8[>9L/0FOGF\RR?MON($2#]O;W[@%'=[\C?;HU,L-B M7S7JS238S4INN^NY-JI62B[,%+X8R_9U^K_8>^^X)M.N6SB*BHJ A:)4%1#I M(DUJ1$2Z(%T04(KTWFM41)0JTD$(2N]20PM1Z4VDEP"AMP"AAY!VHO/,/*/C M/,Z\[YGW=[[OG#^]O=K:>^U]K;V-]^TQ+HX:M>^P'PU+O@5WYKG=D<9.H5\G MTWOK2%+12^OL#F:A#FPLM'ZDD\+=-2J,&(*G[.G;U,";V865]9(\1G4U8%O/AY_L@U52E V6N268 M*M4=^_3P8S3E(F>@\M+"+R\:A_L MGK9:9<\Q?:-T'Y#CR!\1'P"_+U7A@3X\>B0UC8SP?-16$_"QQ([EXM.0;=-Z MR374;/>ZJS\1($C80D;.Q\N-P8?Z#AZPG!!Y#Y ME>!CQEA8:;Y8G+V5<\4Y93]Y(QE1\8KW7<)%&89SX!K$?D5M*SYT_OEW&?HZE,.B6KT^99>I>PG>@9?2'IV$'^Q,MY.EZ# M;RL T?(=0BSG >E3U.W N;Y24.P)?]HMH?G4 0S/.ZT9PE9:SI[@Z/@!+0$O MM^S6$TW:.\.\U,VIK9E\,<'6FBKL43T#MVW-GI0W1&6UF2[5)>QU8FKCJC=1 M8V_J7,"7E2 F_G:6Z*=B;$O9%1IDC#FW*9+,*=D+S:QF;13U*\9VGXYF&D)[ M+"''9]ENN1>$->:SS;^65P=8^;I J4UHB( D@6;"XI[T>G">IUX7+!)\I#9P MVL1HLB:]NC*XC?4YW'66@_K^ZFKR"WB"J@=V<;4OOJAI>OV<:A&/G9R&YAE- MI(D6NPX-]6[,YB>5SOHQ5[J>3TSCU1_:Z6L_C=3<[KNQ"RFV,[/D[V):K'BH M8WDQ*_#&DR*1=WHK8H5%*,?2)](?[+OJ?(3K;LC)7G]ZFLJM2.\0^.7ABC:" M)2M7?L!]7-N*PX@#/+3>8TW@'*0&\<"3?I\E8S$)CRG9?=DZ:.:2:%R;T6Y1 M/YH%YJGBR4UK5>TOF\VYD)V8L_C8P&J!"'"HMA;7BUD1[1Y_V#Z5F/F*FFGL M^:S/03I-NK0@36UM'KH#B.GS5 _&;L]52<&T+X7+TVX?ZI=6CFRUO#8I<](: M&*_75O1T*7)N 3==XUB.E3Q/*,*1Y_ M?+KLINQ]_3,:!;ZR4[MN9AWHRDHX\*J"-GGHB@=:;VG+$A(B M-F<(.D!&PF6_6H07TY"QG]LXL^_6F7R?:&_'PI#+F\$'AK1K?>UW533Z)G/+ MEIC6+9:F(E+S\CC*T1)&YZ:HU&;/O\:N&1,!G;ABBB;I?14SX9X6#CWMS"3N M.*Z]8^Q<>];O(X(E)W9O]97 5XN^^W0QFGH,/+W8]E,@ZKO:&W?>)I3(M?.>L/G(] M]?N$M')]E\5Z\_6-1K6.OE[@O]>/+BPJU;;3Y+EO? M2X4\J!F%;_9 Q'SXU=J H<%/R1FT(C]5%7?GQ[2"Q(!/L0*85SBU56M?8R,B MX#-C.D9[6N:DWZ-5F?HW8YL+-3S^<^C'8WWSJ>+KY? 0):>=A)PS;%IAS_)L M;'P^:#\Q([O9H^QK](G^]>-.K.GJ$^9EF8?V'T?/*5M7A9M]IC^A&79VB4K[ M=(T:F39S '[T[02O WNUV1E[),650]:YIBT7,Y[0/=5-2])^=,SM@S:(&_B8 MM0.(>8.[OT@]KQZ$T8/#^"103!ZWX4:AU96I=#9^O'<-*!,K!<,CT]I6"Q;, M2-1V54EM53*4YU %.X0?OII6W;_A&_NIC@A87;CB:#Q1":^P+X,\;[[IP?$D MD3E/IU%'@\V(3S9GV6:GQ+5LM5*RX [JB.&+@Z=&E_/>M&E4G,A7C@H!' P7 M.?*6OIT(B$5T-+B!N%8;^B47Y@<_$QZ,PR$U1$!N3@"-2IV,3-L[@J&;HX5] MB,^YJPF$Q@EG'AX[J2,W4E2+C9A%E)KPGV3RBL5Y7PY(&-^=B_"#H*\BW$IF M,1[2F0LIQ1^-O.+T3@E*J%K/L9'MV8@L16F>/+X]OCM7'C#C520FD&/ZO"3J MU.FT3"8;4SF^ VF<%]\6!O;L=H#$4"&L[/D2#7,LG)B(;;$&GY3:@;WGOCPS M"&L<(WR\:5/.W,/A>"1_-[W6KKO_#1V+*[&)=M%\[&[:=Q4SLZZO2PO'OLJ\ M=DG 5APK/)ZN'S!_H'QG-R6L$O,OO-08XZM]6AW[&DLXU MEE**.3%D,; B.Y3PHH0V\83'<,9*RH?!/=ZLA6B;Q='^*Q8N537*8T\W6LMN MO>KBJNY(";8-C1=WM!\M6!E3L+:7?ZHT79E&D1"G>ZRX+D;!0D.>$K#,!ZW& MSU6KB'2U]G;:;/=R11OQY"6512R?:=Q VM71;1&4H7*X>B'0(1D>(D!,.G1C M@6/L(?6N78#*3$VPU]K:'.: _)W@O&8'OKH*'9J$X_Z!E5E-7$1M;-KV]F[KF4+=!+[[%6:EEPI&-#;*Q?'&^\D(@CV;Q]+5,E9.9 M&>E)A^3ORH@.KU9^J!Q>>R)]XY7@LUO\EWVMX?*YA=RV*085XO8"R%RK'!=Q MB1,6FGK3)9A[64U#O?;-@<>EFRSVH%%@KC M1W>;^BF PJ$ZCR>D0260..Q[=SKU,[FL$ MM@QF.';!X6/C38?#D@8HT#)U,R,*3M']6AWA37(&_)>U8#> MVVBV.!5YEQ):'(-N]6Z9@/8N6#VPKAX]5.Z:MM?X<5G']8XN-U7A^>DZ"2.9 M#2M><>^+T//I;45)STX\VK=DB R:!/>F^PDK/,M[KWHG!= M$D-IZY(4\Y<:FBR7KV 5/-U!\J:[M]6IP6]S/GYXK08SC"U. ANI"7LM6;[) MS4A2G"PT>'0X^*7W@NTLPD8L!69V>@LHH.[2J]_:EMMK^^SEU11Y]\. R;@# ML8\XA*-I)BJS)C!/CCDH?W"?LG8JO&XFG\9V0M94EN8LDU7CDZE-:C\B@,\X MB'"'40_CX^=&,"6OA\Q++H!T/6_A$%B>(G3 &9Z**Q62D?1W86+=*G;@T68U M2,T0I3JM$2T'G?L$3."P7$8';V>.=ZD]8=(Q8&',M1G3>O%34Z7W_1 NCO#8 M8;T&I3'+>V&*O#T>62]ER?C&)NSIX-?>JL^0LT-NHQ0.6Y14)>*7)? M8P0G(3K-)NF&D=0AT%K6-OX:@@584$825[6X!E\R'AXU$E0;8-Y1^NQ[1A*" M1._VH\8'U.4BX=Z4#:_@-.(21\VQ4E?U+#A;M$''0FRL\Z#/JA5>>D\L.,^K M%>]#93ZT#\$M&NE/MCG/&/JKYB&9XMHT/\C1FG+O:RC6<^E1],%3=RKD*#,; MXSN#56P5Y:^RLL0@1$ R:[-;U^Y01VHTP1;,6NDG M&6W5D;0\$?R&<&^/LF\31EF?[^3E8XGLVJB]ZAM,7B5FS-X_0\<0'RLHKZE& M&;-^IT4X0U*]\EZC&5SJT)8<+A M$:?GN4-E63DU#L64B3*;[S$-FE@YA+?HQ"'ZD[G3S^G)W@G/?R-^-\^**W?Y M F\Y4O55CM,,/UK2J$E4LH/?J%H?HEW!9;<)6"[EUA3BD#W$ &@,;*R@OF-W M!JY6I< _PY)OVJ!A/-$C&^*]Q)(NSNY>7J\R"]ILV>/;.+-0V;I'!. ^BHEU MKH5AS/I&BJ![N;C:TJKQMFIG,*LKMH4\/J.H:]:E=B0?Z=%%Q>;R\/:M/)\\ M/YH->>6DF>*VX]Y##--S*&?O[F1Q?K3_[//=E!F[&B4!L?-F/K;,9WJ,_?CQ M]6TD$.I>],,WUN<#]R)Q^;[@>6"#>CSPJ@32#H,X&7A6O MC&MXNV(_HE2Y%3-RW(>)ST' 8>C\,W'KY:2LM*#M(^1CSETRV> MNQ&]:SX@[2L45-4G%.\JM^JC""WGCU!*+#=]9SB_>CHQ'T*5+F4:>EYEG:&)8R/@QA:\RR\0%+#2_'7I(^CZW<6;LU4+I%^+"Z71EY:,\ BUIL M\;,CW$Y6GX6"-A?AM5KS#\<"O7 HY!H*49MN_]G=6$'HSN>H[?G^4-=Z;H^< M\6O:$U?[!UN=1HZQ^X$"STN5A^JHGOMPA A8:QH24.B&T-_+Y.Q=*8,WASVD MV)&17"PZ5:X1\/9Q7OZSWN$EG6(>>2_L3:>U$(-%1;63*0P'V$*/#SYEH9&! M:M.*Z3F.?ZB'-+]'=L768U6$2L2H%C[.G4<6AM9 ,OW<)%V=YIPH4EI-*XL$ MQ.X&OVD3Y9J3NW8"HX].+Y_,OVYZLU&G43 M%J5$D;F7XAB].H/\WF.!W:FO$E)@5>@C4UFCC""[-3_"9D&[]N22Z$,*^P4A MQO9T,?E9D2HKCS@Q5JVJC(X[1^]UJ7*%;1SF&+B^6V08ZL4WNN;[O/?S93.V MJWF'I1CO7K"RN6PK-]=K_L3Z$MW2.:$SRGY-H$Z0I0+ZRZ^V^.J;,%N;U&4U MYUS/I8:.057ZL UEGJ*&WCMTZUU#,SR[ PY'HEF'J@OKS.'B]F4IXQ2IUDN' M#3-*994$GZ6Z+NV2+Q0[>1"4ABO'41]5X+[YY4%TXCVR5&<3=7*6EY.LK+AT M:2T6%ZR&^3T-.Y*O$BB:SIDJ+[=.EA]R_N27>_O:8MBJ<Y5"*JK.-__4X_=#LY6S+]CY,VU-L^_?>*+( MD[GRTV7+VK'5:4C\I&?L*9/N=V6 ,86/ZBRA%]_5)2F91HR'O3!XK*H19;!^ M,6U6VZWO&;PVWKG?/&=W8G#<\%4MA9J187*+_7@)N-M\W4V_6DIZ%1$ M07&#ING"MG:'%I.2.F?6C<(6R,/J2HC^Q/3\M1F7@W'N&HWKQY4.O-@$O/*K ML>9;B)H0#HN_HRD-V%H.6!AA1)I5TGH.?D0DGUA3O=^U6HP:;!N7Y'50%=P M3V.]UOQN7[84?/#PA@V77PE@6>5NT)*]KX7OC#_MBM">?29._+0:)8XO+863 MB9):-W5P>OB6PT7NL]IZG3X[26J/AZ/L$FJO&E>M//?Y9*D=7#J'7)VAO]=N MU&C3@QJY$EJ>*O;R$9,N+?NZ_Z(#HZ\Q*7'QW\[IL;Q+Z_]KG#@2#4 Q#2 03_\KD/ MV.]>"M8;^1!%.3!DV&+MP=+0/2N:BAV6C*>HV[V-;)1RGJML7H''KL]=D0RD M9^]1/V@N*,[@EG1Z<9%9OC]".KNVO!)67O,.^MBB-%4TXJ9C4,\'7:W-\R]] M7,YE0)*XIDTY;IV@?G,DC3"1*@DLESQ3*WG&TV/! 74"=G_7 ]\FGS"1C #N M@IL]631/^--=2BV%K7!96<5.-IM9+_68/A/6?Z-!3L^[6NN *!LV6/75>?L! MFB)>!7R(5XZ;_\!R=]8!2S8_Z95>84CC1> M7>$AA9]G<[")%PV?- Q;OJY^Q:(Q9X1.F+]8^4[PNI=PX3)"=F 3TZO%.O:Q MIX6F%\IDBSJRNEOO/0>-?K#P;+8ZW5=E;HP!GZ'9Q]YTN?@LZBB^HO#ZB19E MI.G#X&B'NJH:N.8>NFGJT/')2^"@V/J3VOVY-/V*M!)ZA2 K7^"2:SCEPDQ:I*/$)>JYPPPV\6-^'!'/\\?TUQM M4O99=F96EM7).W8GQ?Q,H#VNMCL ;^\)&0QU+@<*-'@?+Y%0^O B@6P,8+,D M0DNF(9PMFYEDE!XW]^(L'[^J@PB#P)(GUX.HS*"S(2(')GV&Q1ZL4=8.X#UQ M91LF%!*U"\V[>ZMJG^&20B6"1,!1KH!+;1OJ7M*W&&(62A!<0M)E=^6A7&)4 MZG)M=W5YK!ICM_JOO)Z[.7(FS>IK:X7<0]-9 MNI7I'$3 \4,(UG9X!I>$*^;)'8^ #]E(XYB5UYRZ'^!&EA71IYXPC[P8KO6) M=UH+J ^WJ37@FS.4DU)=CR6%2!T]<7!1.4D&X<7!:' G2=&23T/QBHNZ]C8Z@PH.8D MWC]+,Y)3#"4O=SM!!%SKA'Q27=B\N*<20WC@U3T%XL@+N#]]>S7$+H#\3!4G M'%E66R-36[#"J]M+4>%L%*A3UDM7G)VNK?UJOX=SZ^UK7Q563CF4@EA+:Z_- MW$:%:%C99CR!\@;MIL<;JFAU5#(D3G_\C4YG.VRO--A7U9AI@.? MDAZ-6N<<&1A,2]TLSH']^7=X1L&$,_#!<96-K3O14^>K0W>A8J#08=%F6"V50!'?P!/DS9P(49M':3FQX6JW,LYKA[1))5HS M9\9-U8XKFQY6M1K5?ZF8>[]Z0#8SYO'[JDNQ:4&X:1_8#+J#^A&"O-YA1Z'M M.<'*7CT('UA2SX1KQEQX!L>$4+I%B/:67'42 M")/ UH.]KI)Z/GO*Y["V?/S)'5Q">PKX,9++)X"_7"UY,,;;\31MX3F-">Q'UZ%V^:334?T9-]6=93ZP@TKOW )5BP/ M)L:O&E[;03B3L,?7!7&Z*S!_6*W?':G%39YLKG=VO:;&&JNOMOYK9];K;A]IUE>7UY]K%HA?UF"S[\'XFRH M-X/ <:530IRV$YAN@CK/3!?ZBXK1RS,?/N%>/;ZU@9",R\G.S(ZXS!;-%M76 MIL6EPS!AVK)C,M+\P5T$(8BEY&N<5SK2XU%AIB5?F7! :_$PN=K:8LFJ5&M. MN9O!06'^$I\*S33P'TY"[OH$(N=V4$]065*L@M M7XJP+G//VY9\6I%@<4.=N^H)?CR:YSY=529[DQO6:7'^K+>Z>=FN@N-"CJGY M/ C!?6AJF$;GH4;(@5Y +WNAR+-/>6;I\="JZ 0+>$+T0]/SA4>BAPN-:7-S MM9*LFY,6\D+V"DW@R>H8$!'PT7O+G[Y'PR\,@5584&C?Q^?W8G@G&.TT'7B/ MG*:.B;G;&4N%'%>G&X,G^@=5I!=VF%T5"9_*;#5+-VME5Y;J81EP[3;>:ZAS M9)5]P-]MSN)4,'Z*=4 M:#2U,0BDX=-TNE40)?< /P#&"%; $HLW[5$VQNMKT"_?Z>* =+>QI!7L%6ZR M%M; [-'!>O:X^9'H=[6,=@MHJKZW!043DA)^:YT?"[F2L@JFK$NJAC*+\Y2' M8A[M5F%\0([^O2.,%N713B41@P^\;7F['7FXN,[D51\4.]ZK^]COEC?9Q1BR M]#AZ$-0CN92Q6(&$7 %EA?-,K)&WR6 N3NRJF*>[ MP2W_2SEJDFXA;H'.XPY3HV+'#.XE8TQ%A-\>OG]8_B@@)_=&>1G(YI%JC4K.8PO*>^95"[[!DO&F-4YZ3CO MP#.-^=-/=QB95,_F;U7(.\==80@1<+0]8K5I?J>($L5Y8$2[R>]WYXPBK'[4^F-X9I'XH,ZD<%OB_A,)S.RA8^IE:X M25VWWX )(I$G9EV2VL]"E,!3*"-@KQZ5S!#DK!\69NA8O2@C:"J8 "4"E*\F MM \F%3H9RC&![<5?/;&R,N.CL&;/JQK>M6^)(J#ZC$?RVYRK*@J>%8B\=V0J M?_C43*M2_BR=L/A2<7[-$U1R$M=1JYX19P/:9Q>S98)>8(:DR._(\!$!Z:LS MI.6G9."AU7WV#E0#[40 +RC*$#D3O*^D3V^[QAH[PBO0<@]W3J(\[@*9PSG1 M9G4AHYO6G]7)A+J4ZQFCK8ENR:)%(H7]LJWM21':S%/4)&SX[@^ M%Y-N.7M[7NF DIW:8V;7Q3FY\0:B[U5OW<"+PZEX=>U]!31)W MZ\4TO4S]!U5*#P*\GPL\X0AKR@%,522% :[4N%OG)4'/%I,U506XXQ*7BE^# M6LFF.8T=1GFI%="PQJZ@^+7P H\)5@X=V#*/3YZ?_"':ZH)PVEMFI]3+DNTY M[%G7,;GZ_>H7-OJ@@(1EGYXPJ4S,R734L: M0W(91K0! '0\+E(* MAD!. Z0!I@#6\U1]D3^4_;]^Z[W0L:GPS[\PN/.C#PK^ MX4.'?WCPVQH;I)T(G%_V>D<$A!,!ZK[_L>) _OY!_;\>[(%)DWP0R2!2:$U+ M?WGRY<_O71W42;6>R?]FO(&&@T\)",\7(L]!:L\,MS>NF5P08E_=M10D_.J$>>&@I1\W8H"+40ES#PCK6YJ)@^FY@?&7\/!2>^Z-O,*N!G*M MQJ*+Q?!\%1$G>CV%8/O5B.Q%O^8Y4@6QM<.FZ9 2!XH%M]6W%[:9"Y8WN,Y* M"I1C)]SL@+ M[S%$!.B!L_@268B &):KQT]YR3)QJ6K-W2XA @3:NY++8+%4G((;"!M<7]=N MW#PF&U'BE]=&LN@^:V0UZZNS:[U-:$>SK".1I5;83]QY'L@J#X/[,]KI+S*# M6?F$ZD.4ED/A*7'SR+$V4P2_1Q"<;=2>$.:0M6B0$';*5I#1A3IT>@]VZLW] M]SJQ7(6EN26WS%2BW'K!)^'/.Q.*@_-UY$_X7#O>/Y"KNP01&?.M)<=MND"C M^TPZP/574XJ?[Y&]_NC7!=\V, MD'@ZR=&DH!?2]M L3%/N),TZTH4O;]#1T@R.-O8O,2J!5-C29<(-D4<_K')2 MGWQU[< E-0LCC13Y4I^A?B6\Z=6FLNX9O#@U_J4PA[OB45.*ONL'TSL/KQ7+ MH35T<4F+W0LF8W >D4U;3S1=)PHX]Q"*#H'7]A57'NE;*0R!JD"UK-Q%$:MA M'GUPKQJ_U.W16$F(./?L1&K$O9C$D.UIV M@E6-Q2V\,C;2AR1O&+6=JE)L#GDG>Y9[O"6[L&FU6' LM]Z:[56C]#GM:[V* M:MH'"Z #USK"W&[LMY3#$AWF"5H(\EH8YOJ'P!7@2V840CH?!DP@8#[:3[SI M\G@VC^%X/5:JIW)G9 \_0TM'?::<9VM3C>6A_OUL,"LD^C17N/2)S 2S*ONQ M0,6R#V4C^A_HAAB%D<<-\K2V5?P,%H-6$EY[K[?4K8"T\-TCII(9J%X!Z?%3?G M+'9-S =6PVLK+)NV;^NY6<2#S%16"P(N1C)#9D8PHV'N=X),-V=R+VR=XWBJ MM*96/K?HS38^83>,.7WL_%![:1N-\LI^T8WBI[X=IT?[KQ1:=?:GL;L9.KMC M.RS+P,Z][?&C*B('CK*9-J=1K?%>!O33O28W9/:((XPQBLT6[;^?#A @ @1E MUO>(@)#%RT[]T#OOG%B/V0+CCVPOO_" GO02E1==^63/C#"L,\N,G;JG\?;$J]FU-K&[SFJ$LL_#EX/=<&7XB?;M:.C;7K+--KE(B13MS$(:[V84Y M+@E%E;D(WT_914Z8;OJ-SDL?1ZC11\X9*IK$I1Q5*1TTJ-,.^21E1<5LZR8.DV\4)U@S-.2 M7BHU&6]QJ=M>K\TR$!7,G-_^ER%B?W\Z:Y73P9 $IGFF4V>KQ"4N8(!;((1) M1H2:G1N#?XH99\\$/T/O=5 O!%.3B)^&$P%;=0U$P,*G4 (,6QS,B5V%/4 B ME-R)@,N]H#KPECL*14=&\*P"X3 ](%)N"UB?)1S!!Q?[O N<4,?4H-&ACD3 )S0U$0"6$-C'HR:8P*C*[&$?=*\1J%T8C.+$ MC?MBFQX1 2EKK$2 C)O)#A& J!,'(NR_;@?[?CNGW[;#?]G.\2^O]!\.OO,7 M5WK\U8R>OS^>JX M(=S;MA\YSG>=M+P_9$7:=XF?")AC4$='$QR@OW $^AM'T+]QY/?@J/X([L]L M^=-S_\B8EM]9P./K2@C,UAO@#F*"-.01H6&H_A6*<(NU^7T59BF/M$A>/%9>8HXGC6$3[N'#,.7;%4F'AVF![ MBY+$$!^IL#MYW:=5M>C]8&X%@;LH]'Q,G$G6,Z9C>8266 M6PF;2\-:+A![CR4IQ^4W,40 MT]J\CH^2F9\+(:QV]&#V1@QX570X,"KN_G! MD2'LUEJS UV23:+8$4G7F4UM3#OO2@7M5<6=J$\55)N2]!P)R1T6-+LH:^DD M):NVC.;6<\?7>S6>9%K+9H3<-RMD-WSJ36\I6J7X!C0=?*)/3KAX[S8X8="7-"'CP[Y ME6\H&;?S6K"-VOK'VYI!.ZPGVIB7\#-B."SZ^<*0]VJ(["N9\>%$X%IT;?AT1>/*P0*V%*.[::L6$_ MZ#6WH_&>T ..)^UUV;.E3:9G]81?540WYLR(=&)PLK.VX[$K^* QR6R?!\F> M.@K"(I*95["1SN8E+]?.O:,(OSZ9%"O;]\AM,!:PXPWWJ-:(/S)]L]!J]'EQ(36X.U(6A [^EK8K+0W1 M>]0K2V)_S".^O^41&)7ZI.,(*=:0OXLU7O+O8@1'ONN.RJC]78A\M]>_@^T_ M)(B=KPNQ0+?C33;#.;$DF2QF3%A?)?W]Q!0I*2W(D\H6/.KKH7^4;.?_G4>_ MY"/+;U=2.8<%N_2O*//GYZZNMMP92.CL6)-RU%::\+?ON/:K> M_O?-$EY9\P_HYBS7#^08XT6F#)R0!0JN#FJP@DB M@&+8^YYNXT0%S<.8GOXU?(IL0J"#@TV2G/R!$.51ZPFA0SZ*&YE0_B%KZ0$H M#FNG#CIZ4=Q Q)KM2,6Q"YJME&IN48W[J77YU1EJ!WF1%,YW"KC>Y.2<%>^& M]Z(=<% 4-*7LBK]S&4'?\W8O$EH<'2Q2*7II$)6"@E2FCG9H*6[VZ:WB+K&Z M]?1,F6?%W?+J330+$3-M?QR.?P..$Z7(KRY>JW9H-\30J[3N;I358)X]O*'/ M*M$?1:*J2OBFL/XKPZBSK61&!W;(6G%[0U(^2MKH^?V")LX7^9Z MV$,YRE)$GQ\:;,NB.YEFI1O3=XI"?S"A-X:FB:N/?:VSE(WQ583->^0;D4+% M+9%N>*JT^QV$[WS1[?K4XCK/S'OX6^5+_:X#'G&3."YL*IK]O##,VI&_&Y)33U'^_O" G\_-P.9"V8U:D&Z%R%!>A4QV MH99;P:5XVLC)/:P?%A3\:.HVV6=W_K)9/7-S:T\HE<(L^0/SR[Z2/!'='O:T MG@YK/NTR;=T/9M.33Z6L)#.K;E=XB^3E9-MXD8HSX;Z;PY55 M$[V*E2H6K\:5&V\*!IY^=R'N*EW.V=-'#0X>(X_4?3@^>_?4Z%SL4L[I60:& MD,#F8*"#3XR,FD<58FNW%<,Z,E/)76+RWJ96V_,6BCE1Y_$ZA\ Z=PI!3 Q= MZB72/Z<)JR6Q.[IW:D\TWNB$M0:8G43Y8 M[^]HO#&]M[_FYSB=/Q1T;6,J(HD+N^!W9UK4 ?$6Q;-DJBF\, M57Z];^S2"_V/09G7 "0#N_7.01$1@&V:2.'U22$P M1,I'TZ$XUJB['D) K(9O;#I6B$7:V#.8IX\RQU=AD]WFQ-8^9X9?>F&]FXK, M&2,7J603[#[O+"L"?"E)WZ__J@G";U>I*[0:YWLXP] NJ_CT]2=B,D6/W6#4 MC912-K*EY#;HH<)BY>_U:EO,!6V>:>,IZVP:CCUE M3T>'/N;I6/Z!>;3QHIY^U+V;7(H-02?8:&BNNX4;^34^6^8Z[I$F?JFK*8&#%2/"70,[:VUK7>,5'O>JGR./ MR%^UACCYO@IF5-%WX>9F?A,!Y)U4NI0%P*JY=R1SX*?7Q,9@UC*3](IQBFS> MPKTQ@^U*-,U*:>];;C>)[IP(."3@\HX(.#I(O^N$(W3+]FGY1:RT=*)2FHF M"Y*T:%:K:7K'W6?3#I/C?*DK7?7ESQX[,8EN -#TL+Z/98^/*(O,Q4;7G$ON= GOU4QI2UI:FHRN3MD.!=D$LL]&"^C'G7A2J M9@@LG]$R\JD":PWH.T28\O.?S6XPLKQM&[+>!;R_O:0^"N;TM82^??]A L3F MRU;#55DNH%YI+6E8B3Y"2(=OJ)##57"7(ETMKPJ7NY_1.L,4G>??&/6J:(42 MF@WW!EF-J':5V>D.VG/E)SQ0#/5&TVC<=B$'>%$52R4WM=YQ05\]T*!;F3UB MS+IAG'(]#W-J> >;.&POT98.;XZ/E@U:B=FZ-#^:6QLP#"]R*G_3ALE'>M] MAW/H$XG^\2'IS_04]U K.5];H98T9C F:*UQXS&'65.& MD82YV?R]T_X^ Y[^=^KS4ZP 6@@=LD?DK=3G)6X^%!N0F>ZT@%!-3[RH\J0" ML=U-['8XL3MW+FS-4R@J9;E4/&S0C,U0*ZK#PH564[BLOU^)O4^Q*27TM'_A MLP'[Z9")B6&%@Y=U=(RX\Z[0:@-HK[\' (Z0JXI4K$1\6E?^U)P1:ZHDI<1N MGIK\G?1W\'(!D05\RO_FHMVP__:B17Z]:+]4![ _*PX0P9SKK"/?"7&^+T*\ M\S7GY1QGZ\TKM3ZIPR^]UZ/?A@?V1 M#OU17?S3E9!_JFA_1EN^;VK>+R0Y\*^2_\>]&M\?]VKPL&G,WXLTX[\0:5_, M^"='_I[7WV/_O@-%]K-@_'?E /IS._]6.?QIM^N77M9_)NQO,?2SN/]#>/RP M)/H#%_]XGI^T@]!_RONM/TE$I3]K4?V4B)^^L_1]X'>YVO&'M\(/J/KSMN)? M@?[3'/SS-L\/,OZ?#OII%OI+$?^#._'?O5E$T ][L]^%V(_[;N]8O[NCQ;YM M\L6)\R^.C110M8]6ITZ.5?L7#KZ"*ABLAF6;66PRNA9QLR]3,U+R6MHM3KNTT%,BH>A0K+K@:IF<&W-SE5%]3:S_K<&_A[FZ]K\6L M)Y=G3E3&F,NDJYLU^'6;'L\Q6SIKVMF'NB>4T*LM#T8]GS^ 3(A*VE:Q[=%9 M:5Y_+7.RW6W]K,$)]RI6SPK^P2Y71LCIF@]27E&[J6GW";*[=,,KWK71]IX3 M.#B^2]&Z#[(*K0V?LRN.CZ[(.U5N69A^V1(1O(X':I?-M/&*^FSW@I+8+&[7EO$P*)WF0XS M_2;GNWT#H[;;,;5A.^JV"Y4GO/]>GW-/$F]-W\UGK MLC36=5@T9>5&[6"+O1>;B#H#3;PZV-J=W>_]ARVD!ZIV](BA;M5S%@GWXN+L M49!,0B7"5&T6:94/^MV;3)A*EL'E*G: MLUQ5!IJPJJE"=3Y&6D'$PM\0-A5(Q5P($>!^QLG+*!HE?SZWM]&V1 :%K8$C M;\]AZX$3!L)>$PQ[-=<6-[B*U4!4>7XU/4:=39.TKQOR:GR7C&FSC_=UOSD@ M8X@N,#+ ,[*VITY'9LR^.0M9YD Q3TM,3L=*R9T0C4?'[RG??VH<^>Y4R,4Z MK\+58W,IS]?8O*6J+;$(W6+6I9D-=Q =5*("I%Q3[R\]XVA,WN<5#U13MD+U M*6LF>3EAG+N9MH\73<+S:/7$@G1TCN=5<]/JZ-#IZ-Q]I*/!"YBDMF1A"EX7 M"6CH!?Z:C0UQXYX_$*E_EM;F?ZP/N[2VG^0.6^,L!H((C(^]V_?$V\X$MB0)$P,I;DWWJ#)-:4<2^V $$W2 :X"38@C1%"(0:++(F K @B@-#.002D[:/7NFH)X>N@ M3R)?[@DBP()\VA(_C6YQQ)_VMR4"AKMA((-J,"%)D@C 7HXG!"(1M1XHTI$( MZS 2W)4TG"H14&>\MTH$O%4O!&'/H5%(/2$BH$\!1%KK-!'PV=\7_7"<"+BU M!UQ@^'HYE 9N"!$V?&<@A!DG08C32A-#LC]T?Z"0"MGM(T3-R$[;-:HP?@8!ZZJG107_=3/\FN"\^AO4% M&!V*8(9M*^T4$P%F,GA20(#VK5#_"HCB@%4X;!%!COWXYS;J(=F(X[]AH]]1 MB91&+,BF3?#3J!83$@+K7Q&D$Y)4?D5@\BV":"+@!0@="F,&;2NY9_\*(7+? M^M>8+B2LP$$D"+B9KP=2)Y#..L&/(R6C'HY!\"\G2@(N9?R9TX![\20PM1LD M8M^,-P#]XC.K[WWV#5E)"6Q:[U\@C'X( O$W010'_$^ J/T>A,E_%<3.CT%\ M2R;0A@!APW.FF/""O_P+F2:(@-^Q2>U?BVWY)-*1TW@C#-B$B8/OL M-7U?,HT/*=,HX(7C_YUI[&&D3$-P+OX2/IQ$P&D8BCY @@A8?(54_R6 NEBW M>TW^'3\D-4\*($SSU[P!QI'0U1GMD:Z2MRJ%P%_RAC"H3^GW:0/^3=KX'L6/ M0N(G( )^"H)4U/P>!>IW*!!_!47Q/X*B^+^'XJ>^4/[_@B_^-J-@_T9Q!O07 M0$S\WT.H;U'X_@Z%V-]UQ?\Q*/[_X8M_'@7JGP^+GQ/JV\L"^7]@:/_MH/C; M(/XGLNP_']K_")W^Z0OO_XF/_[(0#/C'X^+GPVA_J=48_]]I-8[_O./V>R+]W8[;?[5_^Q^]_+L6W&$ M<>S-/-YKVNR;]30UJXFV]S2>BYR)-[9+F0D?36;S7%M%E%9N5^>B]2Q6#++: MS"$2FC]AZ+4<9F\NVP"%R\JCKK) MG4^[2\\>EOK"T3.CK&Z?YEUUJO-9URGN"MK0RX5&?OW;%W&W,=T]L"N?B( / M.]O^0262>CGY&_H34XO\&T@<$:")!NOT+TSFY,/=&6OO.UBQY=K1S;_-?'7/ MP9!9).!BE<+%!NU->>X+GD(N'AOM6>V&\T_\:^:4GLQ/Z"1-W,\*?WL3I^S4 M^L'(2?GS$]V[#B<1/#0*2KI)44,J?/)6"L<7A"^]IE8XH1B&.NMV];SFXEGZ MZ^C/1K(UP;WVH$)H4(X5I6#OBX[E^1J,S[ZN8\PLKDU07S0K'7WAR-CQT1\NTM%3[B5=E^FS5AL0T7L":5[>L^($,$=&QGN[D=-L<4#)[? M6?"?%/TTNG+V8L- DGZ9T/1N'&IB+ZAA/L;;:I:V6>GBW$S8Q@JPWEYP96C5 M@@YE[?>8ML[PH>?S9=I>B@S[7"\Q>Y[WJ?&C]T3Z+^I6OKH(HGC$N'M086O1 M?E>]-[5$05C(6^IJD\ SW6-7GG!IR"L8YTA) M='SSB5W3A,SG^*WF_KCH8/X M!JCHL]Z662%&&9_74'L6,LK8S.8^G=EEK0ZIT+/>YG,OID<0*PJ<+L\V5NOA M50ZX8LBXB4C3^ZLJAUS$*2X Z"QXK:XB/C/P%1H1Q_4UZ?=&W'Z2ZS MPJY3TAU]*O94)J7EA!F"!:+S)9S0?&Q+".^X^\"7D< I#,JN?HIU7T7AK]0J MX%\U$ '7MT^%)J ',SUMP9@.3HQA;@D1<+5X_F8 K)-^WI(0P_F !;2%ZH:R M.N"AQ;B<9-*LIB^S+.DP4#'FB06"BQAF/YEUBY-@MH#$O:^W .\09'>/$0&^ M'6.1;D2 (G]U<1 0D+ M6W2BL&YP AB92D @^@B#$W@"I!YA2;A>^ZLAS&@'/KP1HR9L^Z30;YTCF%HB MMQ#SQR [J"[\-@&\X;&/S=U%PU= K?_>X_3=Y[2Q,$% M\0.UX*4=X0@B0"9[ C:()=TE^P\JP5B.4,+CQ8\7EGGZ8PFFH$ZAQX3NR X$ MGE423004U>/\H;/4OXU;\K-Z%BN+E8@#=RI@@DX"%R0)1D1 ),XR'$/8(,SY M]^$=J\D("?;9_SK%E8BCE#S'"1_Z,P@/$)WG\0$>N!H@QEALCN0V(B"T&$HR M*/H\J(^2) 9'>$VVJ572*RHY1=NPY)K3A ?@SK,1 1Y^U4 DNAY+!+QH]_?O M@<)F&2(Q9*O 715Z/%EO?UD9<.,T$!W57TYX8-)Y,A++#XXCW3^^0_XDQQ$! M\=E0:D?,D7)".FF&VI<9C>]*FNS>$@'>S(HF\Z=P[V$H"1E#5EQ1[2(1L*E) M(+D+%T@$J,KTF6#FOB"V\_48LS8\"II0P-2\@G4R8AX9$CJ2YPJ)@!:HV!#6 MP07<-P'+8?HR1Y0DLLU[2$SB5RNVG8;;D>[Z_AC"?3"0" "*!QBP=DLOU4=B MR>RR82S79YFTHG;!V$N_;'&[]Y9'!^CK17FW#_,8AY\F L1E[I*.Y;NP!"+M M%>+;LTL$O+0F KAE?MV%-])BI/70JBCBRS]/#;H3[IL J?'=]!W\"J0KAV^+ MQ%@5?>SZ'Z;QJ$5; #=;*G]1V!D"6P#,#LD<#9OOB8 Y9P1P11UWCY"Z+ V; M9951& 6M))$"*C/_W)6M!!6GRA&[] WKZU1P0DSM0#]Y>ZH1'7 M9UGW'_P*2G.3\&&A9!3TB21.Q#3/+*"[74F\A6[6XB.]2"4'.AH"!6F('\FJ MB_SB>^$OOF>;FS!FDZ0$XZ;5M]Q3 @+\2&>OF\ 8DG13@Q_K+NN&*QJU3'X> MC.D5_4)'W#CW;<,Y4DJ2P/\R)3' '[?#!DX&\U#OCR/J*8F G>P=3D3D>1=* MT)SBKU"4.J1(DDYU)QXW]P:EOH%I>BE,0$L+SP%M= M7\@6,W=;=VLNGQ7S$3R/O()!;37B ^S]\O8W@7T.:-;;,N!&_*(+^04MIJ@* MT%<;*$?'8+2ZXWB!"\=!R06!"[!N1I)U[/QRI3:(@'.UOJ Z(J!:/8"0MDD% MG#WUU7*@;6KUXLN;J;;M6!!N\BLD7[]UDN6&,%H8(B!I! K;7_AR,'+2P?() M;6^_!*9F';A="I0']P?./_FZ4?&GC18LJ?#CIB;H=I$TX!#0ERFP5;MXAY5$ MGE(K4A8",Z6TD8@2J^60C?L['LX&5G M3X+F?B,.15M=BCI&>Q>%Y23-L6"5(GB )FS]LH$8 _27.="53>H+3H0,>Y.O MX=G7T?::)'55XTC9R7SC"]="MSH6+/'SV>V.>&9?DE0N"MC!7Y\EF;T]ZE?B MJ'-R;-Z=:6=TQ$>W$!Q*J5.!)" H$1DM4#BVV(<(4,?>]=V8I;I!DLML-O]" MDVJL-/L6-*!+)Z04\2)/HX]GM M?TDY??FMN)>@!;514E[ZLM=+/Q1F (/)W(PF A1T_Q=MWQG65!=E'45!5,1" M4:I21+H@O45%>N]-0.DU2.]$1$!:D-ZD]QJ1$FI0Z4U*Z"%$>@DA] 0"X>-] MYYN99_[-G_E[ZS[[[+WV7NN)S76H@[QX(C]KM:T^?9@LEA9T"$X>$E0EP /)06+@!E3.&Y)]?^G:^3 M%IWSURM:IU:-T'^3'I-+E+TT%(@3"=$%U^YD;_9>NC0MY7S[,L;!B'O_.5]& MI'P/UG,A::/S)(7+BG@T>)Z#SF:B/O8*T;FT*CRS9'XC]?F["M-8X6?8PBPQL-D89:S1?WQ/29AV^C8W M3;D%-5,T3U4I^Q>9A[0<7CEX)-#-EY>W'0[2_!XMJ5WN]UZY1'77;T7'P%N2 M2?^,[V:B% IY$@Q^+E!^@I^(:1-+BW?VL9N"1#(CL]7,S6D5/:W6M]BLF0WX M4J,. @6E1OL%>+D9;FQ9&4)>,:OKR;-0$F.P4SCLVJX+E%=LFOOIPM^;'&4R M\;L#Z?<5-?17#%1K?VFYM[>@SEL7-%)6;>?6.*MW 6J87T7@-OEVARQF>5] M%2E6(>V][4K9_X.&6>0* ]/M'BR"EN?2XQ;W E=S';&H5?/O/@OTM:=&[[>9 M$;4SM0 MK2K,0SNAJS(E8JO" U&NMLF^OPMV,W&'7&Q M>R ZO",C@/-CW9LCP.2M J&K]:(OG:B18W%M/7ZZ=N'+3]NA+W]_CAU-R-2W M#V6F7!AL ==<59Y3BK*1YW.*YW@_T1?UQ)U1BJS<4)[1D<-X4^R4-3 _3Z37 M8B-R!_>ME+$#KG7D^_;,=R=D\[(GHX,9]62WMC1._2(M5UML%IP\B2L3T?%+IZNNXWP6[CAY*:TDW%_30QWR)][^(LQP9K1;H:-4V:)YL(O,-MB M(WF58YKFY86:56#5:%7(!E7/LC-M5;QH8W2H)NZ>-Y7D_E]G=<1 $,R4&'RQ4#; M)./+S8KK_1R[ ):CWNJC'DGV5)%4+A6V!#KEE;BP7C:)VQ!(424[=Q/[)]GM M3Y37M(]V9.DA/2?L#:?(%<$>-"1#HZ/I!V/6RC"U]S3V+4G"ZL\"LO8P9!J) M+)7+^CIIP[WO=)*IT4NC;^FLI2U3VY':3S%FA>*,X0%[V\(/%C/$/H<2_*J^Y7RU^U/!\.TU#L3X6'N'G MQ*:2E\F]F'2H=CN*0VN+=R/A%GM >!/0TN8-+PJY"R?S.2=H:>>:XREVUR5AD[?, M5#[R3YIAMDRO;"M#K]8)@?BTFJW3H)+0H!\S+D\CI,N/ON[7&D\H,0YL#]%^ MN7(/0G,8X]X1Z5*7>NQM?9^61D=7[;G.2^6#]^NC!IY> MT.3&3>5CDIXTZ6L@YIUWR#QF/9=1[Y5Z5K!PJWR3[Q^#@UFAMS8EL=H$%@E. M?IZO^;'X/[J-LR[7M]\NUEN*?8?3UM?)-%_;*OS%L$F3+U6I^SQ P[9%Q5\H M_+BR3(&W0N%EAZW!S/3^Q@YE@7#]5>,A#(/Z:*0E3S>[%$6]B MF-LEE/09U2(;ZEL7U3-\TR!FN7KK*52D-L;A\Z?V06B):KA'-$/((L]D:MCT-'OU"=?I+]^?1B0V4R_FV-!A\<^9U'DQI)K!L5LGW3.MMQI# M[,]24$#F.N,X9 IA\"R+Y.D"33,/K=T76MF5"/C39=[0(B?A5;..DKB95ASS MW=U$-KL51BLG5$([TT*Y^NT+'!L4QJ)1VX;T-TK#^LYDVG,RD4VZG4W^[L.I>CD6E$1"^(W%N0:*:W>U4AP\5#.% MET/877%?P(,7@$6W P !\Q$U"_W*RB(&ZT4GH3E]F157YXFP6CF=0]+J9AOY MP(E9&-J?Z=BN;2+D6$FW/"W./B\ M8BOS(4S,)Z;X/J_*N$_@TY<5(F%251X)\FP#VRM[F_F.S)"Q]^U(>;6R,5$-'@,Y>H)4(JW(1Z!L M45 [S /']II^JYKM-&O\F4I[\Y58V]#',0XRSRI*,L\T90+$Y]0LM();^JIH MYWL?LGU6>L2C]?LAQ0?-U&IN[9=.7F1!>9BK!%H87CWB MZ6UK!C=B%R90PRT>*X%%5$,\!>*)#I_$QVJG&"B4.**K'V[F5_-^-0??/C@0 M<4=:,OJ'?,Q^;Q#%PB\R]LOT_JMJWE#YU\[ E3\CV/CP)G#,)8WWA?;+KNYK M@F-0"#2M9!/V8?<.B1 EV*AZE%&#Z7JF^Y'+@+0^&H$,A&7GFDFE;"[\9209G[QSF M,)=F-RH=3G%IZ"?$GZO9KEQBB!)^J)Y6J M S;C#=0^4@5&1__HZ(06:YF]A_K.7\ZT==JU:9 MG&%0"I8)/523SLCJ;2<.[Z[9+Z><9W3B(:0N1W K^$? M_]@Z06QUZ/@M8O#M[)UE[W8-0_*1(^Q0H:NJ8U2W=K1 ML%<8GZS@/VA?AZGC1I]?*&^'5"-AKES'EY3YA)GQ^FK-1+$(/*2=ZG^I&!8J MF:B(:F@P&>B/3^E441NI,.W)7H8Y)4/*UCM#X9\-O _2!P%,W W;P3.%UXUX M7C.,GC"XYY_X'U5\4J9@+^M\$2D9@>SDC9,\["FQ_6[5DD;XO;A2$?!POSIV M_WRCI]W%]4:NTI>!8E&G:X&P<,'P98+&7R=$1:1FA9&&GV%&*8-]M9.YJ2B5 M5[7,)D9+\UL[;/*_#"WA_]7B\V>\N* &919_O='AA\DW.52O(>@V'$BE9MDD M3A4D445^,[J074>#UM!>,KDQ9+6$[F(9:S\S%0G E425GV3QAG8&ND,OM7E4_E*H5$?.9(/G D%)_MZ0 MTUE4?!UFM?Q3F/>V[,AG%!'4&,"=F?.#07T'7=.WM&5;5";/5)%8&_?+L);N MN.#X-]&UR5FC9\ LL!B0G/"(R8BMXN<]G$DW=!<#MXP[T3![- I[)W=$P.C-"OR'MH \Q8M"3K>8+0&5I M%1C/3E*+R^V^ !CG;T47X,5S0K7]O1;I&T=8(-6G'^+/\7);4I)A@Z7/<.]) MIVA<9,LI)+:P5&^Y@PG<%0Q$DF2G#S;&6=/T"DFY9B0!(-TI.++=?W=C2H"L M/.HGJ]8QZQ[KMNS&R:$CN7*IYCU&M + 9N#W8]>0L MU_M@X[>@0'$O"7;9?P>3VL\QA<^:[I1PT9&^>9Y< -Z3&MH)ZX4/1^X4%U?Q M@_&M%P#+W7643.U8OP>+OAA]XI4%OTXGE1ZOKX?W#C#7KS!.]%U%C@I M'&#&"J#6-=KU/ST'=IZ[[>)Q3\8)3;>/^,&79!2(@W\CEBWJC7WZ -4UVAN9 M/F7-OP!'.&Y&)VW0[;+P +LAN(XKW=1UNODCHX[ MJ5RZ1B3VI!.\I=XXX4"S#HH@B5\ :/&UXPTCNGJ;I-YS-RAB(?+!^ ;A3EWU MOYIE\+DLYD\[KR6L"D,B[I%.2?@U*>.,4JA)]\_U@_-+CX*G\#M9\3^Y06,HPQ]R6%;%'PH,)N2$'S'+-(R;)%X!N MX$S""0E^%F"8@7EV ?"[ "00=Q=SDB&R=JRXCB59S$B\*GVDB5)[YN'I+H;M M G!)RY;XY)R+3$7 ,8+ M &N@K%1#'B:=*1X/)4 /R19:@MPQC\_BJSM*EU'P8"EX R;]--BOENL1[A;1<1V9[KYTVDW FS M)!Q*@N).*^L^\!+NW0BP=NM*099FFC"YK*1(!-_E:?J M9B*EUO/]G7_/=W>84C9N!C_?^,LL_ ;]Z M!2!0K"S>\1B"4.4#@XZ8@[T,)-L3OI5%M1E,O'",JD-RR8S)I%<5.93+O"]( ML2J/=M#+65@.]&PE^K<%,Z,QKGKZR/DK"BD4"8_&>-ZI/!*E8*MX)7.(9T7& MH9'MRQL[&#&$T#\LFZ],YLO9_9)K"4G:'CS%QKD7 '>TSO1_9;Z^Y1\ ,C]$ MX@*PK'@!2 -? *[[F@4FGE== !*GSB\ JLPCI-'5C9C+$^Z7Q]9K6 F$#]2N%7[@U<8RR\7 &/%.\+ ,.E_^]Q[2Q\W;B=NC3L:M%^PHVN/>,B*G?-Z>8]@H,J0ASUE/6:2,5G3M6>]-'6.,@ _.'5;A'1N!UF@ M2A<8X[V70IX$9:(U9F-FSD4GLY+8$_OL/\PX5<I=& M)_+L 9BW[_=W["R,'' )F7:UC7BWJCV0^VS8UA#[VBK'!L#[W#?Q'O=+6X7K M,2F38P9#5G^8CW_W"!]37A7.=^)IMKKMI/E2I/)^%_?/JW$Z9JMKW_'!/0!P\HYK(Z:Z5CUH#^._,0EB27HX7SS$H/FZ05 M2=!/TY!+WI)92Z0^:?!>6,MC//!FC MP*1MC,R3*HK_'BS42&.3?G?HE_>+NHE6;]B,:ZOUCID[E^>806+5N.J9PVRE M?IA!,8T^[?@C5:TUC1"+K%IPUI&3ELFG095]K9/[U9:[L=4&(H?Q)C/97'<4 M(V12KB4G#:KO#7/<-Z[0ND5KR],=7+VJO!1([33Z<8^J([V\[":#PH=7^= \ M(/LXU8"2&L3>/7*OB@)K0W$F(:-T3WXLE+!YUB$G=C:,NV2=A6TA^J[#W2@O M"6AV%K(J &D#&B;"R?LVM[W%7QX^U0.V!L#NH0WW@ZY*O^D9QF_W\<85?L"7AVXG,)9 MW8;@2MWH>4K*7'#KM/G(-"N'[;8Z19_6#VBF;?Y)='-=_^+YH_7V(JU>5X\"\A5QVGM0WKT*!4IHYKM4H#J6H50L@E' M89OGG[\"(:AMR4GH8"5JE]A1GADS:H=Y!NDIK2= MENH9^-G&HU:I=WC =4W6+23B5AS"ZM,V.+HI7:C<5%_I5=D]#=F_%K]VKE[I^]+\YU/AP9'(D"/RV'^P3IS)C5B9+B&\4M=-[Y3,UN M:7TE#-=I)93)LLXPMGKL,&#+[\@S3=QJ^OMUB"W@FT[9S?=K_$2?E9B%#VN2 M,AIHYWGL'90_CV 41S%JK9%/B=#E$%U'ZZHH_$PS[=94YN\IA'N8"_+O+5MW MF@(OO9>%RC=_&M4G14-HKSGRJ5UCO@>7CEDU/",4GE6UVDLV"TLOG_@?1_@& M7P">!\\SNB\^W4;%[#F_B.D]HRJO&52_QAC#NK\/?=%(I."^DKU0P%R:5)IM M8,.S%CB9@QCT"1K<$9ME=D>0-5SN!V5A9!?C:,[3K"6M/ZC56>"07BU,WX;Q:7*X5:(!,,_@RO*&>IB&N@TF*;#2JM&Q]?J MX\T_!_8FNH'E*I:/7L5?5E@OIS!S46SIU0 M?V>P:Z/;_9'V]M\Q*JVJBO52 M5%0Z\M;8@XULD%;$^:N]%TN^^Z>PO"22@L,J[#YW.4,X]TI)W,\*="9, MTWX-Y+LJV_M;IOHP*R-ZTOI-!'ECM']>(J>!N7!A#V724D!CRY;LD]0!M!OR MN'U\5F2'FK_)OISS,R1TJLKX<_[CF\?1 $?3.'.3/>BRV\&U$]NS;N LOI?+ MPV?DI2_F2,GHD)RXP!AYKP$N%V0":I\-C*R0EJ\YIF,7#S=E@@5.KOSP;T$= M./*65)606%7TU)M@<5$PEG?H9M;49OK3)*$&I%O5&\3;GFB+M8/N!+L(E4>F ME:"K/=^#I#1AAE//6G@9S1=P'M)=-P_D7_!P6R.9R=, 3'3+E@*/J=Y\KSR# M6,UZH90.0#'5K4!!5+9G+,DFE^,[DAHF3KZ="[:#[4S]=H44=RX+/Z*Z .CI MF,B=2;S)=Y&1+,FT3BKIZ=992>I?L<+YF6[BY;0"B;0-':Z?)HO#M15KI54D M;>]]O.;-I0,)>V55=%7*,Y66CGG,VE4[IF=\DL\\2.*PV4K%ZG>D06!3+$M- M[[S":-9___EL]/]&:7L _6HYN+XH/H!:C]VV3$ _DDIJ%O_#Z#J^O6VWA9:V MRA+,+)ZK-Y&!."6Y\3O_4"9$NS1:5.0_#M:I:KCSTSR^UJ)W1 8]:)AH[,+4 MZ>UHMT_/S9BBNW*=7TN7]I7/C%=T7T8AC)Q&B%O2U M8C>A>J^R\M37/2@( _JR%1H]B\ [WUTZ.7@.=L$?"&AZ++X[PKZ#.?2C?]&UOOR,4 8+ MAQ>PZM54)B*[3M=L6?WG.ZDO+WZK(B)\_5H+((]O[-<"F9SZ&OH MW:M^U,@F0V%QI-@SU^[]XT-M8T,WUCSCBC<[$5V8']KOF^?9%[(3V:=]&O;Q(3/O)QI8Q#/VFL_:US4T M "4J_7)%*]]R/N8F *_"&8(:Y\W OD&I!-2D+*)%K(0N& 9[@3QP0=@)IP== MU_!<6>_2,93F&+->[5-&/*PQZE,S79_]T_WGV_3@W6&W0>+1<-%]L1)CI#+_ M2QZE:@#KUTW1M5D8^JL;__W7W%T!AKEU.N>E>5KMP#3X2%\0#\J2/(1MJ86X M= '0.>Y9Z?W;JIGD\IZ7^TGI9ARV]9FSG/RRF,)UBM2O;=@N3C;+91[GS2J&](P7[A=;;#%[XJ?VU5F*^]3S"0?K'YGJL'T&?Y^1.^=%1^W?QR[>QT=%AKZE;7?@3GO9< !1%&95([/764(+>UM!)WC>"4^+3($"BY;\M+;6;V88X<3]_N-V M!<"7; ]>LIR38(J5]DZ&RC845 UIF'&LQ_%H\*ZK>GD$ATL)_2^WODVSKUP MB**!:B=P7_J ,Z6*/IP&:LSR*EP,!.DA%'/4ZKEVI**T,G=P7Y.E.^V6?Z30 MZLC7MR)LM:V!4=LRL B_M?Y'[M[O=(R&=_QF@)4PEDFLF9)P'F3N(*!5N>:2 MRW\;='/2?]'-QJ)^L M-)"GH_R:::3S"V%*#IDYP>PCB:N[7-0Q.Y;Q%P Z'_N^D6AS(:0?RU\<*&%! M>K D1/DL'[W.*@=>&B*.4,U(FT8N;X]A318'WP\KF&L:2>LDJYJ228^.T(RX MMJ4-+$UG=!V^+27QAN!7Z&!*I)5- =R+]96X/J!P 2/O,=WK[AI#'B MD81_K[(4SMD8U]F2F*C\,XF%2OM9X?3H9LTK\D!I9*Z$G.E9^,F]R=Q[K=)E M5_;/ YD/"A*-ROR? M$]_4[/L)IZ4JQ47SC!DHA2@S"P3&=7YH:HD$-2M;PY+D7W!],:FOI"73W02( M4DK^57".)F [OG9P!2Z7BI<,GG@W2F6!CNU[NRN<*.SA\5!:]<.F2,_& M^,.MZY0Q1O&_U]KTVE9'3K;%#NN=M(.O!.JV!ARXA@PS-8B1'W=%8G M-:SUKJU9!5'R=*16K,-*"]'>F$ZGCO3V=='#IOZR&Q8HUXUN1O<*\\ISZ/4Q M==H.G"'>MX'NJ;K2VBHZU!/&_&IE+$2D*N!\4F=O:BA-]>_?H-E)_8&:[;_- M5Z!:SA#Z>//QZ&C8:FRT*/65R;='ZWT+7PB;NZ4G.;X7@*X+0/3#^,] L19! M.ST0.!E-+7Y'5L_%!;0VB[Q9>XK\L"1F\6?02JKN@_>Z _:G?><.ME0CMGA! MQ)U3P6"K? 7RB YOM>!+ AWC;=8LK(.7DZ%/N1T#2N'&+*^6RA,5' V-,T,7 M,[[][*H8TU2>6AOO=4.!^/+5S&8*KX].%-F+2%T!<%3Q37ITS;S^; M@@MX91O]R=E&=3R2IJYI-'S .',!8 NA\<8;@&1;\HJCC+2"X@>/ M+5Z']& M&GZ^6*EX/^QZ>EOLKY-JA9/0FQ'5E4*WN?/&-=E92?'+#'P\_]23 MMN&LKI(/D?1F#VMX;U&>UP<:R:["K ^OV9(5(:)B[X/2/']/5;1DTD)B*UY$ MW?Y,=S6S4F%)P>&*H35<[ZP2G2L:XK#H0!0L:QE M:<^&D,&3O>)NECKWJ9FM/U% L'DJ-[]D9,==W9BBO]TU%59=L^POL-J2E_T M5/]L>-;0UB'U]95)4F9[ ZVID2PYX<\*"90=L^=3>1+N0C6V9^V*175/2H80 MM]"ATM!*F)Q3'3="DJI0[&C&&+NZ'W-O9L+DIL#A,/81-\8V.LE5 %G2/]1T MPG^_W[0RU^EXH#-=B=UR#B1LKN3%7SROZZW-1;W8K*;X.;[4J&)BP';T5K4& MS<:\VPM3JH6Y-=82AX8OT0_T"0T4$Z4Z6N'*VAJBM.4W10XIAGGEE?Z- MR] 61"E%++;UM!N8#&9I1U4F#4H\3 M@AWY;L8T4T1QZ""NO#,TSN+(N(?19.9'"JS!(]3*:?CXV6]T/V0&C-+=IHG@ M8(B-O4S)#3R1W,OV?[3>EB]8";J_@+N[S)-N)P=HEH[I"T#\T]+-7GC4.:J< MU)!E=';T]@(PB9@"$A,N )P]1#"&1E9'W3(>/TWZ!HYL;CL]O!4V6/JP??30 MFR)-4PAL67IT 6#UVEBB%OA6N*ATNK#EH:6H<^(M!>PE,%X VH*#)TZ]'"E2 M)(XDY7+'T=M 9$CP]$BA<9.W,+#L\DY\+F&ZG86B4%E)\YX'>.KL7)#$1"S? MW^B7H-8L+1WU)/V\ ,!)<,SZ6.Q;J=2TRT;[])_%A,L[ _9E'W7_M"YW)AT< M+LW'$V;QA6.?Y2/U[J^A<[>",842;2WID>=X A&?JWC/':IGU=&(7#HY;)$K MX:R^;*8O %_P4%,O.)#OZ"FP] A&W)'[1MRKIE K6+0H+B7>\NPECI"A'+L. MK5D! 8F1H6[EI_&]1$S@[*97$(5NT@;%2C 0_4$"7^75(D=6]1-]OG=I%SJ" M7,HX6]420V+%7 #,+IW;;BTK&!]I,HV.5$64,)N2%RP3SQ507H2X.^7 "B\(N=Q61?,,])J>L;X&6+H^CU8M[.JK"%86?$ MYI0MOL*^F')*X0+@%@B.9,64A;LA.1S'+%9366)^!@=,0 M8/$%H!,%__/-@JPJ# ,"+OC#@-AVS#IBL*Y8 /KYZ 5C$*55#1RY;O7SZL_]8%($?39XNH3]I M 9=[B>AE5&2ND:;LA\0WT9*<">//"I0N>9\M1&)9@6]?NO;FEVA*CET*KH6? M?"^O%AUN7/M*H[_+[')R%@-.G789<].H.VBM%R;V5HAU^83,T".>C?Y\H/:. MN?R(?4R7GN<+P"9HPYV)XIPDH?)81.'I$T/!4EI9$AYH'\@(=3LN>]?6NG>E M.>.C%\Q+ D)&N@ \NM]'=4_EBT&,(Y)]X?%1Y/E__3.BDW9>7^L:M8#T_1W1V@E-:' K2:<->-/K>D;LY(!E9P;UD MR!3O[.++B&U4L?W>XE>KS[\U&JUID%,!>4I10\ 4U>;=*^&O]82BFPOE,,X=DP5]#+ M6)*@KO=Q^;7SJY<.CK%WN<<[+P.+/_=3MBOR,/>Q#[@[) V)&E,R-_B6OY > MEZ^BGDXUEESZ? VO.(Q,DS:S!T:'3/4]W_;STX?6 S'DWW#4Y4W M2L-M6I,<'W/'?*72 %0 M&7Y)WKQAAV*E@TNYF9(&!D +&9CSSH0=/IS^#@A1/>"Z)5411VR2$H8]2MC< MAJ\GC#;JMM;P?J]/7+))7$O8'"VN)W+#UC1.Q\0(U3#'<>DW&4^N?+G'_Y/- M6VOQ?H349D]IL>+ 6,Z2/*AE%5&%X"^]96EZFSI5ZJZ8EM'1NMD4;@C2.3M# M56H^)[W66B=]OY(B/B+"=;5CWR^(!=T'.B-V7>FS=WZ>Y5%+-AFOV7M;.^.V3KA =V:.BZ-N MB%TV&3%R$=Q--3WJ=P&("8Q?QAFNR]&\1N M76& DXFK?.N?,/AEKKAK\$MF9Z^O..KI=T^W%V9N;D,?W-)XX4V%FDR8]T4" MJ< HU;+KIA4O:1]N GE<;JF5Y]3HG3@_W]J:7(GNIH\RL MA>KEQ \7>K>86)8'P:SSF/J]UTPUVW^^A,R^D&YU-U0Q:8)9&#*XS4$*V0WT M1-P#:#_M8;.)&3"2?7,T#HRR:\F@5W664"#1Z"B\6GM==FV]TF1FSOC-D[I0 MZ_C1$'N.E96DI*Y>7/4G' M>&]&Q'C>YZ"XNS>UI%R5?&1LL?R^H]6MYT2_ :D?83NM2D(XY)7D[:SV[OR$ M9;O=["2]-RJQC8F\177:3#83WIBL6](]<375B8HOO5(!FY.JB/'Z1X]ZU8&, M).8@2T+XEWD)R[ALSMH 2*ZOX;B-K[?/7(_T#O^L$22TW-VM1=S., BR,:_R MI21AN1#RXX?#QK*OL0'9=T&WL\FAMPB^%Y[D.%'$FQLOUQNN](]&7Q6H_(.RUDICM7A:DL(Q7M^_(44W;G+7@-"?GD*X!^*[TC]87#;4IA"&+BT3SH;9NMU;7,VB=:^.^0CVV,>!J\[7VKBK;EBPF&94;!J:92DSO M5E@R:FO%$#OT'BGBXO>O*D-_%JH*$G4LG_2.1 D%=R*"3?8IJO% +;S=;Z1L M[B1Q/"1.Q7A^!7MZGG M;EP+N#=F@+%<]3QK:_&!!AAY1W;=^3HK&APSS0@K\YV8X<_74/>U-,8-^'&+ MI_8.5ZJP&;FB^C74$R813;P\910S:1_PC#DP@WKSWDRWI\8"]_V.9+TT'E5Y M"!8^$=5;'0MB9$&X'#GA6Y2,6W$R6494OT!RK MCK/8#DJSM!.+&.FW*M_Z(.W)/?DH2"ZP&K,G<@?.HYJ=DH$\%)4XU@GP=[2V M/6>?\:!">S6V-\^[XHK4-E.U=Z@]*W,3UH& MRR'Z[3],2@S5^-J-&)L:=4ZKZ<7Z,\_F<<[7-G;^:9L>O#OB^AT'HYL:%RM1 M$#77+_E>=<.H1+2,.A05.NX\#'6;O\DX:.!14M# ).N@H,3$$)L3 :_8%,C; M&#)<_.4U8K(-J?H%JD88M,/(J=]AVRPF?Z_@;7W8;X56C6A\Z=33M2[LTU\\ M7J62;G,O7BZ.-8NWE<[9:\$)OQ+#-@U[BNCO7525TYN M8WU#G9&:F5?0 5@&$8;1[9_H;VL=DXY+\WDX[]WTC<>M-^*Z1W>*T# M^@4P0X#\FF+@4J_%T70G*&^GNQAISCS>#I7;0#.'SFO!^M$IGP^%FUO3-$O972Z'!BY+#"J_E^05)#G!<3-Q<8T-[=]80]^I8_ MS;/PB?NFBN7O@EINHQK7O=L'WSNVB+9Q.R5:22Q4C;!E8BAH=#J+2%,G#_9A MA=+4K7)T07-8/KJ=/[9P+A]\WTALAUB =+40\98W*#M_:N\7C&CIMD/*&%C! MRPUTX]$:4SM#8LX/W<=58)Z$N;ZVY,.#7SHTD+^*LXF'!=X1!#?/9#&W#&_0%OE&*3Z^C MA1"FSA1- )%0U22+%,87)\E'ZR;>(UT+'05SX!=P.YSLR1YO@=P;-[E?F)JH M+E =_1 MCR-X:8T%[(5?)DX^T+DQ42A*^<>#7H>,JR^AM1VYU9)#)PNT4]9#2O2[&Y*MA" M,1<(27NB;,8R.F"G%P-UP7/,XXDB1R6F.V#>T;CO_<6GWJ7$'%U4.%:PX0][#Q\75ZO\N?"3^AM^@?U;7==.$NF=13-A[L6_ M(\,SV?+$BFRMV'UM#/4>FYL_@Z$*FYH=[D^YTWMS<)^ZEL8Q-+&$?Z3HR_FH M<[;:0H9%U)H5D"RYNJ+$ 3]+_S1NTK+24;';]#!+7ULGWY#-8%7K3V 37:AN MZ)E[%K*\0QHY*YT=.9UTL]RYN]#8@1&+LVQM\SQ**0Z2E9(19,G8E;%\<"K: MJQYR_EDEBS'!D40:E0&:GIF6DZ;CW;HAU3V4B^41#)F.!66E9=&2?W,H[QO; M1^C?5Q 1[C'AB'[S;F! ^?%\8*PRC^KW)Z%]&[MW7SY>KH(?_6_$>IXFZE@: M@F"F>=K!;3>GEHJ:'@)NLAUP[C?#XU#V?=<[YWP[^( %$^,AH+"%<7JA-:.A M/N&JQO"R/K2KQH;GD\E)5,DJ?T=*R-?KL([,]>[)5.%>F@ 1W3"M<'/3.&?5 MF_IY:K3F ZZ]EIZ_:\=S?P]-5CL2FK3])[X!J+%:J]"] YN@GA/:?9R+E>-> MTMF/S7L3EH\#4F7D9+:I+@#I03CTJK1PR5U=4ZKAU@\",_.'0H]+AFA5^R,7 M&*(J;N]($H-:5X/C4T&<=N=(GZ>-67I^"<]TZ1Y+T"I*)< YF,.^/S.D=V@T M(V9-DJF/T7KE%=*Q%>5(7@WWTT]=TE"%>)X8!V57$./([]B2 MP?E@U\;&4Z^2V:&SO#ESK:3?!G]W97GI^\YR]I-8,S#5S?%ED(_Z(PWT'OKO MWC]$),;FMNGPR2U[;.&>>[KV/NGF$J3?XAY$[DC*L;_^HK;RIL1@% M-'HE6\RX/8U],/MT@]Z%]V7.73ZZY%'CAIL!-:%(?1I30,OE>"M1YX@QHN"2 M-_50G]ATMU1\/+/:WF#+:1WG'@SJ"W+V?B\UGA.=Q-\AE10XO;[)&Y 6XO;- M1XS!,!6>ZS7^=TC;<)FMM*;$I$CM!S&T#BO=O?X"R)TAF6PY[.WVO#6%ED%7 M&>+W.T'$/='8\7E]"O<3&R>J>9=I3[-7[[)RLN[=5,0L[-8N)NXYNNWB+\;(;:*7FTN<6]VJ?'SW04.5YV.JVSISIFMII MO;9C(KYK\B++T>K;W#"#]DJ:CO4XZ\/.XDZ4Q*:]7X'@_-H_D"N1I\E6S/SCT,[O-^]L4A(^91.LFOKAT&8D-<#@P8ZX28^ M$[7CTIBTV7=^=AV.YC6)'D,%#:^+(./D)D[<+QO(5*Y^/@OZOF%^<-FM"F4% M5@9> +Z'B/A$#*.EK7^TX.M]&$I,(6F>KB8\9P_O],V(IC1MBSL=V2T50G.R M7L!XUR-R&L643-[G/+1]J<3O9ACX=)&#"!F\3D+Q\=-\[_^DLVD8K?I"7OCK M3=6\'RO:GP+$X V)6Y=5S91[LH'WYNCS:U2J-Z::RW4=E&FKN2>5@DH(#^:) M2HOB![H[=R:W7:"#(^FYO*074-.I5Y/!*D +;!7H)\:%9:,$LU"R=:?RU[KX MU'I.F8UOC6E+!1S*G=B_PNLTK1PMH?N":W]:$DO_=A';,PTS%I@>: 4M+H6) M+"D)J_;99CIF6+]\%DW[FJ>,O&CZ6F!XW JCX=X'A!_Q DWM?4!Z=3<>N"IH"B;D?1B+G"'Q3Z_DJY97.%//Z_4(OUTF62+<: M/#8RT:IA;7JZY/T'G.NU>&T$TO2'#]RXA\61/:I,1UJ?0L^N(Y6CO@T5V^I M5M]S+9;BNC^97?+5?'D6CFE9EIHZ0NGG&6;D@2#,(S")N!QS$I6Q517A^=OE3UQ0F^ M['&85<\T"^Y+T/ISBZUO/UB>LZB.3._#<N78KN.*@8'&][+:\R<-XBQB4KXU M8R;F37G=18GG_7*3'H)B2M1RGI9R%OW7Q.2HL$.-X\_?>]A;6=5K_WQ$V>27 MTQ)HR/Z$3$L#E.5X/M+HLL./I1\?KRN6R!*B16:V8XB2& M/[XN &VU6':\UH\YKX0U:HX@9PAG^@_YJQO<:=+Y.R(*OH"SBGJL'-@B1,_8 MKNRPM;:<$((^[:;6UZ,GLN)CB%E_' *NOUI%Q%KN:>'1&*++WL8.>J!-ZD/L MN5S'MAQ\2X:T 'D\+.49OP&Q,4)@A4Z VZB]92@4O\?G MZB5M7AXI/=/;E_U'36]KR6*EOP!$/39;J'SKY4B]R*P5 M._$6DES/[5U:V!S[]I:B5!>Q=PY\I1$T0)C2W]ZG"%MC"P44VA$5DCPQH>-WU+:WIQ:XU-- M,*Z]HUJ9 W (4"ZM=W6B^,R]E^AV!/XP6 !8BV()U)V!=' M3:3(@+^O+[18LMZI@Q)QQ^@]: A+,*^613$7$;=)ZCUSPUG8>#7*,2M;'L$[ M\ M_Q7/ TEMY\&$PW()O:K"W*..*?I_Q/1;7495@X1_EQ/D)#95=Y>G7H+18/A9 MX"Q4J]3$Z!S//H!\_BR\0-ZBRE7IW1(Q//UA;93_X U"5(NAOH2 M1C#$VB5JK3MDB*JPTQ!P*1#'FNLEUR[5%K!&/3Y]&LQ_2.JP]%V2\@_:FY8. MD?OFVOF$1PFQ9<[*\ M!9P!=P6BH9K^WGVL!-3EQ=2][=[ONX[0IW_C";G#'5-X7%WE4?0E*K(X%BD7 MA+.8V*2D2A1$BT[LJ["GZ"M/O*W]>\5S9^#6W0J>WE+VZ^G7KR4&S.!/Y"X MSRB)(:[0_<'5U,G4K/*_J3$?O#K400Q<$85UMN'C4-H95%Q499Q-)'396V67 MX#\J9A->6:FCL!A1^:A]'9_M8]NZ0M)JI?!]7#P\P/3JKG(#9-?-D\T]P%RHL-:ONFNK5&]8-&[S20ROK<:5?/^E3 X5#; M4Y%04,'&%OY&X1)P] $5><97?K+L]B6J<*Q7"7(DJHARU5@<3?U7_A:D[$/7 MW/2#E(LP+52+D=N@OFW2ZKPW4JNXA;'(Q^4\$B5;E]5I#7'V!'OY?#-('V ( MNC/\DQLZ;/>C86;^*5N:O(%!U_CO'Y0GSLEX ?O ]8;4!32H/E8&+TZ]:/:[ MRJL$5LBLB:KMB=Z7K$D1$1'LF,]#3@FQ2?]9^1Q'7AK@/LXCX9_XDL4^S_?= M!4 H.V8NBW[E)1(ENO_"+BB*L%Z;Y8_3^G*>,-6$;=_G<3&T9$[.M=VARFH$ MMZ>8<=7ZE.SV6?$XE@FG!_\R@ 14F#BN9U+VQF8L[/,OH()_\"';/R.9#W^+ MM$?K3N5]$JV$AW*H?_PTL$>>7W;[2J'03J5H0U>EL_#;@OM6ME>U^JZ^&BG\ MD/]W4+OS1/!8'.0K^-L\;KX=U4I2PVG^QG[YT!Z6.W06\]N[D8S6( &5I>1F M[^Q$DK$^76:,BQ:$3*8\NHK\8#/YX]6U' T>@U>YK68AT_6>P6N(>E/LGO%< M:I3A9+'55>DR>D5=<,]'FC0E^YOZ_X^]]X!JNNOZ!8,-"T5$1$% !:2#B'0A MHM)$>I..]!:07@)$04!!>A,0$.F])_2(]-YK$B*])O1 ""0W/M_S?F6^>V?N MK#7?G3MKWK6R6%F;??;9^[=_9Y^2Y'_&#]*2L%Q-",N&.OO^.$VX#O="-D]> M>MBG\O1W%RF5G9).\:[[JTOBW:QUQ^OH0PAM(+>_YI:!'QL8-]JB9WF&T=M[*]TX=*QI&]L1^FZ0J;JN@C!L!<)9D M@3VUOBJS;<(-[+>.>J.(K_-QRNPP&,S6^O/2]:JG50-97X4^%7W2B35TF$G= M],Q8X.-#7YJ]\DJ$6\_&7#JYSFN=@RDZ2>T'75>QM,IR9MMV,@MP5VC9UE7K MM'3=+#&!)5AU-WLI2O$M)J,.*Q"/D#&#>%JA3#7( M;A3A?M]>(R=7[TU*^O.&AHHL[;7\QHH6:&5SG8B\;#GUP4BPP)MB>R:/]>\7 MTN6;'>QTP(1 $D"D/!K"!./:9\4*Q<4<)IMC4.29H<<2GM2S2?R!;.:*V33I M0WA(,UJ<>CAW_UQP9ZEO(+[<1M4F_LA@&8@8O&J-8BB6IQ$_]K?52+:NPNW[ MKUP+E)N%LA54QMW(]]SE4FXOOA*G4GXEY:V*W?3C8W46__LE]>YJ$67YHB?F#!\8OD=KA5J@/U4,T7V(]8'<]W9Q<6H)P\B@ATWL51$F\Z'3 M*;W$PDVJ,D<6F' CK(+Z?!?T47W_BB)GQ/?.>7A$'[V^DL/\6Y6[09+G$V7G M,5%33HUS7ILFJ^].0%DKFD^R5&Y&-6\5,7QVT%>W[V&XX,'5$&>'R8N;$W / MP1A;X5UY@0+/FW@E#K5+4_'%.VE+^K_X7;Q.%X#\ZT33;^)RN %UUL!=JW034[ >@E-G7!7>Y=O.K]>./=G]"CYPI6]K:[UQ1&/JVM_>1Y M]?[54 #,Y$U$Q/ZC]&ZK^Y=B;E9:LRN/)@Q>$;WP94)EP3MS_U:7/V\71*)W M*"[:#+JQ^V8H3M)LF<#VYO#[N@,D! ]JO:0,?8R MX\;%522=F&BEY=W6A*,CH0?* WM@K4: T7N,76-RA%"4RZ_8A2>&7]A>V[(R M!M%K?#D.4O59:RZ'R<\J"I_)C>2\,O^1N-,T+DI1EG%FK-B6P;&'(_["[Z/3 ML^<(;91[>\6_@9U16>V@UMTIF6HO106<'-8/?@ .1TL/-3=.PFHJT[Y:^&6" ML%0U=5*@:E5!5&%A;KN>WH1NY\-5^D1.NBW1J25G1:Q*"546TO[S?*34X47LW[ M\3$<_^%5I?S:=B+P"3Q% -C.6CS;7*VYT^WL$BSMN*+8TS*SH1I;ZRV(0TM2 MG\TPYQ6YIR\Y<]7&G? ,!64MVF%'-^U:('RG+80BAO%<[EZV*+1G+"' MC(%'L+:6X\+UTH[9KRR-\M7KTO%OG55#J@@N^01MSNI*();>#CO05N%]*"KH MPA+-Q7;+C$V3DUN),XK[I_]N#4@,U$=8:77>V4*4)D?%5#,^4JKJH=H)KY[V'Z&[6>IWII;R>P)KMEP^!@B,^S0=/=/V?/B< M7^QT&H6: U=+AB!CO(".G@.JUXD7FX7W.Y[P:=+=8'CX^X. $PXA1@)@EI,Z M@&(@0N"\2Y.Q6I^;#5-VW!R*(?Y7J.&1PJ_0,)9+SH8;?0$9>+'U_ \8RR\^ M;U5O/RUQ+$P&T!'D*0;H-L?0@BVFN#!W_Z;MJ.#B8\S'S:%0]+T6\=.GQV,I M@.*P([M%&=I\H-+_"AVA%VU%+ [.0&#F,9)T$GT$/WXGKLR[B+CY4YXA(,TWG? MAQ_:@\I=!@:V<)V/H:,#4]+YHIC1/?G)75^!CH1U MGB2E&62;I\5+GSI/$+>6$LJNA=LJ]WJ #/)6FLYUS&CD"/^B?*+2Z-6"(B6? M]Y<[=$J5+[VOX M<.?YR=F=O7O4+ Z!WRKPGUF$U&ZIVI>7% M'Q43S"33MX_3]>H*V\&QQ$J*QK\0=X1CH/67O;#)#7K#;1/!- MI/VT5K"1ZH%VB.U\_\P>W\J1F#$B+H%A]!]J B'*'_?)#GA715:87?,(>9O= MQ=ODM?-#?)2_,+^-E_-19=DSTW)"^D)U;=+L,$>ER9EBZ)MZ]^^%5(-=A]2. M14WR'N-CN;8N7F:]+JEP=DARL_/@,07Z##@"9R.:+$B;U1/$ETS$#;>B?OU< M^KU>MCA3A[3Y->TC^ LU0S77EEN .O&^%&"KQ&K/_?U[>"7K#SMZ$-A;T"VJ M;>B*YR".$=R!FQQN92A,4OIZYW=,"H==#'^^XGK7JP\E]=HYC \SMCWJ9F>\ MBK]FA?\6%LI2]:BX][[_%G10/Q#:'U;<\VH[>TO,7$BZOG*9?Q6Z*LS?Z,4-H9(HAHV(@&+4#/Q#K+ M,/TMA-;3F-R^>3\7-TP!LY!V!;>7!SC\:_\Q-W=0D1Z8WF3?I'GPR'U QQ6 M*]GNSM>OM^FPP1(,-:BT#SCRAIA5EGQ#O= M\YH99H 8^X**&-?C\(_GNRFBH TSS&;,E3C3X9DW#DQ.IFRV&/]+4QV6W$5\ M&VN[TRCXYYSVX>%176L'WKW$)^,)-9_ONNGT";PH"F:OCE,3-37N\?7V]!5) M2C*X,QU#P?FUDH,;<$-5"4 KIQ8FK%#1<5.)N^@[Q1H@/P/B\BK:OL']?]W3 M9S>2 FTA]\V"@-)$.6?UN+-U(=]\:^>22V,(7[G*1CU0,0P2YM1OMN,O/CN_ MV#IYS$4 [IQ$D M@.*$RZD" L=% @19(LM5&_\\N'XM,$;H@9-*JQE.GJATT@VV TKCKE!.,-X[&*^$5 M28#L(P[@'/3X:/OX84 OD05&[ D[HQS+3A +^,B;]VY:.*15&*L']AHB<+(=,.H3"S%F.^BC,ZEP"H,*V#A+ CP2P+ DFWD"=5C"N:^^%D:/% M:9, ):9G),"%KGJS-BADAI<$&#;A-HGJ\'$D-_C+G7H2@%^4!$C(3* \"SSK M)0$.(^;@OY./N([_N&-VS>%JR9D?"/<"UP+FJZ./7E'L];*\RXYL@:$(OY#":;#+ICTGT MOYC4NSP5XD<.[E%F'_^U@*&>0=G,W8RJS#-+,G2< =U_0:=/#%H_Y/3QC('\ MLH DV9WH^*>2 "/["60(N)HAK7Q8N;_Z%3J[.-;G^F GWX#R]*$XWHXV5[VG M_(SMCCJQBIRW&QE+EC 0"5"E2P)\;_ Q0PI1 ZO)*-%SGM:$C68O=1&C_?-) M ,9 O&*NALP[(^J]1]57V_'6E$FH*T!(Y%>Z+26D1RTV5DTF!QTS[;B-A=6 M3I2// 7-//X#J)1XW_)\]MEJ23:17O*TMNM<]E(Y,=HX\X_=3>(5(=>N>01D M*P6R)IA^MZV.AI6-,/3'V3"\4_GH7ZJO_[@00/BC2@+\FP^>OIGNIN>$CJ)Q M?BO ^2?P/E!@_&D\&835^,4SEZ-K9/25P='_BKZBN'-;6 AQ!S@T)4P"7"D@ M&F43M625R33>)]/\,!D-_QUWQ/8G!P__Y"!,RH7OYPOB+G&(3.*'U7@7FHN* M/4)GK 9 8A6!C)SIX@F9\:^!:X+?[NZWT)RCQ7?^;;F<:'R>;%F);'FW!W*8 M3$YN[-^&R?15BPI$AU&XD 27?@3LM]BD+Y/D%[%'MHS5DDA8A4Y0#*!V;'B M.YA_L9[.NN!^>0]& GRS/#US8]M),UON!"ZS+X41HZDR_\:%S17^%RQO20 Y MC]]'7%^GWO]YJ.R+TS-W1#^.EZ\_9_&30LK>/^(Z, M4C_DESLP^1T)X'T:3H9IYA_NW\<*_X-MQ=%@R?%WM\SVWT.&3;Q)@&>K$$$2 MX'A[CUQ;%4W_=#%)'LL<,IU_E\&+8YF;\X-M.]/D$"C(<'F2^_ )K__T\=G MCBZ(#ZI4!F6@(7F87&8:=##N+C_[;N,OR"A!% CP 'GA:04Z&_K#HWQ"=Z()_.P92_ZW>=-)AN'#)U.ED2OD@#WB'\@A=3!_X+TT9_Q"SLA ?:W=S D $Z-G/%ZR+ T ML&^,*'T:]N>!H+%D4(%_@?JOG"@E6Z %1K>1!\.,Q!\+V\0/LT13^"YZ29SM MZ,0->&9+!I7]K.,?H$[ ?W\\.G_L10+\%;0).9'2D+YIUU4\-7EZR2X%T^0>32F1W6G[_2Q>/_NX"131%JP.[7FT_T MN[!Y!/ROU@WD)N3>D@O_Y"WTOQ<&>4K2)_?O9Z>K_<:KSLQ=#JD9G#HTN"QMI.@>K=R(S+6V7^>T7>X."L5LXK#$QA[RZLWQO^ M:)0\1XL$=?["MFV4WJ.__X+CT:=EC7<>$AQ9#[(UL(!T#B8Z#Z4(IJ('10^X M7[ZDT&5X=K7H^]^'S[_WE#GB,[+._?E;_W]S5V)N[WR MI>V=ILD$B_5X=$Z1U)%YU.?R'QG,:^(2EO::#ZSLNN[&M"8PG9M^4/O;_F>2 MQFH1-!E\FHT'S0+%8-Y= ?N[F65>^6V@S5V1;"]&9Y92.73SD-FT$>+B3%I? MA?C*Y"PBPM6R8=L&U)34U[4 [61G-Q/3^N&'3 QXZ6'/+RPQ9[;;*#T)F M.K:TUIFI-"J"7?F9!FK.<<]RA(M[O."KB,TP8'@.* @W_'B0=#D?WI+L!5:^ MK^DT7"2A@2D,=GC"I71!@^>PO)L9N)P[2=C.AR>CVTR+,=259E4$QO(6R4.] MT;E&%3X!JAF!^OIW8'66%TEM4RI?2KHMY M/,*5QK"GB'<__8"72YV%,#6^6(;] B:?Y2?BJ1\=+VK#]H#LLA)'@\>(.E4X M8MH_V1C+,E!=W,A81&"".8^MNOH^O?3,6HRH8-CK6\BI;+\!J+>>]CVR6NYV MK@]%.*V+DIB)[>YYHY*4X./2%H+\B.(&7J3VA7%@! M+@VY^5.BV#C$@E8;"7!'6 NW$^UO-"]L< !)0#N !%N/=Z>DTX14WH<)R (E MFRIG>/U#GHGJ) I+E*>N+)=[LM,(WJ^![@8/WE8Z40'=L[%LE[I_N2(3W#S1DU.F%'<3]WJ'V%W+OH9 M.-/,XF60:)'D)<5>H>7$_54?#Q*@LWEB]9AKEP2P>-LBM42NR.XD $UAES71 MY.BC4?S20T2R-%J[PT2 9J#]Z\,NI]//]ZTW6:MN0A&V0AC_/ 2;$#BX MZD6#619S2'^I&P?W93Y;EQ\SOQ#F3X8TCJASW_ [?I\S*BZ$7<8Z0\&PT$=4 M#D6INM7(0T_.3IYGNNKG[&YO,<\T?TC>)!:B J)#-V7P,RF8YEH'D>.6_.F: M:64"I==R7(I5]JR$4O6=$K6Y:%$#_0<_K0K+0^/8M)M^B I@KR.V?C0C2TLX MD?=A(4NC-C&PT CC1GNMV6<#Y^)\*+2'BY3OW']\.24U\_*B]C(1HE:@,N]L MN21X@K^8@85_@_015L(((FAV'G<6(;&39,81!C8FV5NGWOU3^D,OQL],XB.: M';USCE]-VZ^[,?=YY &688(>680W:X7V]HLI]65HRZH95X[39X[FA_%D?^&=?EZ^RU!DDP/7DA18A M+E7H*OY\Q%R^5WJ/2=,>BN7U_0BK;Z]L%I#[MW.O*3+K),+U>S7=JPE5DG$3 MT'WA9B,F^.29P<6.1L7Y=;K2UL),LU#+VZ(R#\6F!JJC#,3V?.8N?QG(/ZC1 M5Y6;2!H[=C2T7=A:4R6^;4Q;*G?WUD,=IVON@%?T]HC& ;Y?.O6.;!2S[$_> M.ZM_38N^^34\O7;DFFZ3=+:YM5=^)Y.4UY[S1KOP,LSJH(OVKL?THJ;V&X.> M6TW-,!#CTW9?N$-$1C[',\'7L_RQM909L:W>/$R..6Q%H)B^UB4V_[3@T2S5*9A8QY770LN%GR:Q,H:> M0/A5\\#@HS*F(],OA-/ROY>4Y'PO[DT5357,BYT6'Y).FN)>;C&=<;DXB*Z9 M/G[X[C;'6,^3^,'=T*MSUWV?*!C(F:<6*K (S6)LPE4[]^8]^MP?^?D6%?%R M2\J,&V;-R7LI5=%%:<)XCE^TKEN1M%W:%PH*F'Z+BX._DV^+:,]OS<*-P?1K195 MM4]T=(55# \:?A'8,$\3+1"Z4/R ?]^M,2ARX^2=1=R"[Z]T_G4J:X_VR^SM ML<,W:&(?-62F-D!2=_USK3; M=HDTF1@AKTX6;/M,FV;' X*3U^:Z^D&1,R^:_>#W$X@7*9T.\FVW&F8'"F?/ M/%7KKBXZ%A5.1L$98JWSR[+S?1],IJ5(BA_)HNWA(.9VZ4S^H?N1S@_TG\=3 M%+=F\ !\K'E%B^)Z>Y EBFH&S@\77H \GZ574TI- MX1^]SXZEF4&CPFH#SY_>GP,*X<0ULO6&.9'$66BUV_>8-]V593P_ M8SSU>X-#?1CX'8F.$P=!T&-1( WX75^86YC6!HIM>)2_JS/LZX&U=)IJ]AU.Z;XNGI= ;%.^4#A MLV4:32*_E*@HLBDC?_71%[:Q%PQ2.# )536)OUI08N+[F)?C-)H];H[?.2C_ MI9, [$6GI*7E-'(5!SX]$'^&I4U ^";I<>K=* 994KX7VKD"*#VSZ MJ38F@W*44BV97V\_^9#R()R#UPK$/7C62W?IAY_-"5'%6P6LXL**3ZA0E9.6 M U1:4%]Z9__+:JNV M.RJ;Q0YD!W5AF5AB55K&>+TN63IN(V6]&6,1A#S>K$_=%H_?Z<;?H7_!(([5 M40WV(@^LN;?)ELU1DEE-\N[,B$:&Q[?7%XH[>SI;I6N13!NSOKD<;NCQEY>(,[1D&!?3IN#<^+"VT"BV2<'C JUO/Z!VP M-#53WR"KHSHW9T;_D^==Z^*GTG;-/N9'O(/!KR,,"^_A/2S[=%<,G.Y_7H2! M/W\Q[QU_:;[,NY7UR?!+3%ZZXK'R/J%(UG-1?-*HL((0=FSZ"VE0'&_MH;M[4)'1U)X2E%^JN1EDZ$YI OK MW "LK6F(,<+]1D.N_;VM%_=YKPF&)#3QGFS>_U(GKR45ZTL"( (6$3W08^^4 MA5UG"WV=4@Z6<"M..>OAN.00,Q,KX>J/NNS9".S3#>G_A9=Y_5/P_[J -/[7 M_*+C>@J7+B\F\G@+#9B%D "T>47O+C]C9MP@-H.T)C,?3 M-J7Y;K$.;C;W9&2R?4)+LF1'Q'I%N;#)R\A[T62[Y(ATQOI$UP>GXTJ[4J"# M6BOI09-&I4DR>;.#Q)/'2B3QP&3@KZ;RIQ<+AV>SLEL;28_)K< MZJ(J=\/RCM/<'18*;ZO[:B.7A3^*Z !G*B(*8$O(N^59MDM^ MPBAG_NL%[ZWX!OS/^!2+*(N(KQI!Y8&%E:!V4>]'*"NK+D;2<;7['DO<7 M@^5SXOWOO!12LO=K=$ MKI>'2XO\CG;>5H.OP1.!5Q>&/-"^'H,$Y-?(Y(R"/O,C&A=V5:21 DN?=GAR MX"'?7UBZH"DX1VJ9.X& [LSQS0UT6-E$I,^GXU6$LOR^'QE7O: MHBRYRI+#_DV9RX)#&"5XTN3)FO,\6D9RIHX&/L<,KV&NCE]<5M69[NC'?E$; MV,(V(O!/;=\Z4U&SZ-"I'4M]":&^:"DJ8USY^@GX"@F@1Y_L#%T]1;Y#4(_",X&+RT8OVO<([ :9W+M"':C@N MMW5/?;@0ST^#GSOC/!V5LO4[71CP@!F[",68]6U['$R.HXS8I-.SUK9@#H=" M/:_++9?]%NVP@3WY;3;:WC8-Y0&+;K^B:M_&-1ZKVN?=$!"J=,)!C> PYMQH M+GEOF=*DD_@&I2+G"R*&ES^6Q3J87'OBG&BX/ME0:!K^XR0M ,?7/-Q>@C,4 MY=D:KTKZ/J'06S7^32_XLV$$NJ_+[7=C]++^OA*>:[+^JDG7*$OTWOG#)?\XA-R^Y+FO0*&=;7AIR9] M@<[^[-%:A6#"C]KX9_$=IQ_*N[HC.XIX.P]6K*E3=NW4-%>S1+N T ML"]T?TE_DE%++H A=+;G@;"BPJU;X];6]XII'UR^=U =7RX$;312V61. 6W_ MJ$L!]0)KB72AK*0'3&'H6_FF(!S1Z"A2S[OO>0?5 MH?+E!W,\EW+:G'1T .1 G1D[9F=;5(VO7]L74%XJ?\Q*T1[MN\A90&$T] M<4'^@NYB$0E5K3>^O^3WX%&*8WG+EZ.TSN03K:KU:'RIDBLK[W! F@1X5-H$ MAJ[R#[\LH+O&5.6PY8_?G ML+Q&P_IR4GBC5:OV7??O#<(:M]V$,%;2 6?M%F_X;7RB M4[/IHK]>\!@;NF"KTO^A^LHR-J,*PD@@3Y%2=Q1 MO\3B1@($2I[XMR%M20!>RM<0'/,VNL'[WXSI7>T*RJBWF^%:WZ=TRSS-/"'K M50P%GHTU0$:@BT17.+ZA+E3[U\.SL#)3@:3 3*$C(#$,)4KNS;8Y< ,%7$/\ MW9NQD7'&K6WB'F1@*I Z%8)U\58DAC6+_U&$_P=%ES7LT#4#X)S1*P_6C0Z"OSM\V: N(->V43;UT"V!6%D39/_CJ;+D?,B",; M7#LP2%DWZ%-G^F6QTWXKZR@#B^\=V+F\;KV>FX G>XHJRI5YZ8LA2OS/8[[O M8^J=A'Y_Z9-)Z+F^;V4NTL:A+:-EQ#Q]O4_T6^'M?TAXX2.L$"*DW!VR:FL* MP37BXG.:P6=TJR3 ZLF1.-'+D_S.$?[G".*?PG\*_RG\I_#_LT((:>*OS>VS M(S=_WS7UV#=2U+5H%,\$"P*VJZNE;U&!JIQJ5*]PK2M:CY-8*>T8=6Y2T[L+ MLAII+]K[R1Z;^(PC2B85(XT]JN@_8GZX[6DK?57D!5_[&[\;7VK9V#5''8OY MI,??; M8)E(4T&2]E_WQ??B@>'.P9C,C>_8KYO.$-*6U9U)W&Q[R<0O;,CLM MDU9;F>']>-"5 '$>7JQ\8N.K;"OBR0/8;T+S2PEV&9QK ^W+#+DCTS4"ATXBB=GW_]\>K(\THL_<1 MF!W/L\H):>8*QYV#.>_")U\;4%/!O1,:HS(OOV!NJE56Q[V*"_@*>CK0#[[: MF\9* H!MHAQ^WMXOEJ[TMMSH;X\+M#K(D\@.%0V_/?% \ST $/#> MW",)D_%U@^9DYI E8([%8"J]K9*WF,=->VMN:";-.P#S^;$.JUEESUW6U2ZK MW6SV%RL0J@5A?L/!4$;9<5 :=+,*)8 ;JE=W]*,XIV1E-Q?V:?PC$YNP(9ML M6AT4UOBES?.<,MV>^>W -M-$:14[D,P':$6:D 4HH+$*ZC7;U?H9D:9N_U:X MT04$.M7E7<_K?/OHC9_#4U,^-K4F12HZ12;:[ZQC)B8F9L:JWF!WCBDWL7QO M"VS[+G^_LD6 ,E<^>[B$I5)6I!;G30 P/J>BJ8*U%P,%7/F-\>%(G]B7G.7 M]2Y?8@/-[QX_?=.SZN;I6S+WTG+7XZ FJ%$DI3RCK C$^BJ\<"GI^>!6UQ2C MN+B;SY0^+?^LCH,7O]UWWO X589GNG)@?5MB# M/SC#1)7_W_S&N89%SZ)MM]Z">;?&0&*7]O"DE7"L;NO#YT'Q#R<^1Q:5_E"F M5A60E=N=.$?IJ9O0>D_+0[3,,E:34[CB\V? \'#LJ_<^-WCYUC5-9>P>)_'> M=KBKF.$3.,N:!?'U6CWZXD0"+!ZK;[O^8ND5@^T:LFW?003560SZOWU* K0/ M7K>:UF:",P8/^OO5[F)) '77 Q) _S=P='.D7'FD+'&L*&'B]7JI?:IVT?'G M\E^33PWU$@.$(!,+;Q6+O3C\1 M(AF3TS[_SL=8E:,6_[K%DL],5(9&G#$R*S_.(?QSCE+6YSNHH*" >BH1XP&& MYB95SO8O#+IR-C:6SXI^Y,0I 2BTWDD5-RA$&)D8ZZZ2YW?J M>?#(FN-ZP/K(@G>X#M^#N,L//M(%79:\ZCV>M^<_',3KA04]/4K#I+O\: MS>LMS&8UF!ZTZ)ULAAVH;1&+LM+]IK ^>Z??9@E1+R=GHOVE3&)KDK6HFMF0 M>T]'6[MO,;;)O7UMTMK\ILD,:MI8V3[ D4-<655I0S/DV9^+M#3D&.Y<8$T+ M?Y,OGW2'8?'IU1BYO=;;BU&IKB;YD[YSK:AFU9 MEN1D#$MP*"(MPM]S4-S] M;;%WR_#/;=H6:7V1>J]:&:N4DH++Q>^:6"%1GO @_M1;@F M]>HB5FS>+/&VLL2E_JID>E/J1M&5:6I@8<_*&7.'\5.98H;BM-QI5\&Z+X9- M[?^Q'TG\)X%_+W#^U7&3M=G^)RRLN$MC0G*=!(CF-_P1EV$C<-:9<,9:!L.250^RR^0SK!.DCE+DC30J56Z\%X] MA))N=8+3$CJ)?/KMTO5,@JZ&V=D*K;LC4CUZ"G*4/8%K6&!<#R8[E#7)LQ$M+[@@1H9LT9*'@+$4S2,7)Q,8 @:1C3('UE$<0F ML!W2& )'XS)R5*MJ[JR;*,+$<(GLYT-/:( APV?*)$#2N;E9<48&X"*M^D'7 MZ1DM%/=.GCE70 R%(&_E?K01A8B+W" 2P!"8WQSP\I"((@'FHE^ *?T$[A+' M1H,R7/O,^RS_](RJ9"F>K0!=B3X>:F2/"(%V3+Q7B-_+IA^ MNXW6=#7#H,_6_NB)EHP!@+HD@/WZH P\:/'LUP(E<+_TQRJQ@E ^_B\X$0.C M2U MBFP^@$Z0E($GR*71P!@#+GFP"$I_TL,\7LQ#-(_B_?6EA.("W>01I'<1G^<4 MG8Z0< K8$I9F7&;M:^O0;(;RB_@(&R$851?SDBL;QG6ZQR8Q)X4I@2?O:Q)] M#%,N:"6'?"](HPB8Q&60 #%"@2U=)ET\@P?A6KPCPD/!,H_NTH;L5'$79%_2 M;2WWE"F"+_$-E5=- 7G)*MI)GZ/\[Q2^_^U/&Q(K+W_[<6D]("-;&MP)5U8GI>QR1NV]$3IJ>YLEJ8]VL")WLR2V!-$])6B.G15X_(=+<6 M=K7BRGWU:?;EI\9[GOR7LMRIX?8H;YM8L>:JA>7A<[^XYYY_G_SX\5)B5FX M[6MU3Y#3>6,DAX./@WGM68Y?5)S/=H(94S4#\ZUDVCW:7!%ZG#]+F.[D^F<, M2WP\\TE:P?J]O93/W:W5;USE<+BW<3LO=<,*^_U??379M, MMFR2<[*XL1$J-Y\2>7^7-ULQ7)Y]0M7VFFF!D--0B$K!T&<3F;9&I6)MR>\] M^109+->,'-TP ZNP=T9PV]6=QF)[[!<%Z7>@TB'8XP2#9GC=.\EP);?;W^9H M12(S\ED2VY>Y>=E3,_*N<(3:I9O<+J2YH[LC9-T3]W#516#:YRV!M_83\ MXOT9=/G>]7=^@9+LB3?>?'OB1'&!*8A&[H)Y\)(?&#>DORYJTH0+%!(P^-#C M/% ;-6@)'2<,W0\I&UQ8?SS.+)N4]TJJ=,8@JJ HJBH9I*WW=ID9+ MS0%^9WUM:CBXH5HG4Q0U / M63BMW"[?*VW1^5>NI:YJY84>&^-/1FOW\LOEO#:VB6'3C8Y.+C+;J'3%:FC@ M83@/SGD+91);[86;156HJC XB8"^8,U$%".&Y 5NKC^NY:\*_3S1E1.\U8NP MG"MW%A3@QX$+G;.>Q-[@N3,\F;Y1]&J)#GG)ST*E42E;V;HATN*MA@J =EHY M:T'"[Z!\!DRP\%)C$!RZ[^:7RO?C1O+TZG!S= <5TSS(KT!ADH:;C7BBL!# +U/Y2Z55#>9[/O MZQ#^VEF(1?%J4IQ]CM*(?,^1D8I*,>$K?PDH)W5/[^JG<(.9J'-%!1SQ2X!R MO3BE^W59',[M=\JGSAJA;6QV M"1&.V*>O!W>[8MIL*MW'A_5'4RP\!)@K:+[DM5\7@KP%U\X9@PB1.3%F+V=- MQ;7*\D<2AH-?K_:5*W*X?8_CH@KKMS(?)K8%[Z^#,%SZ_S.?XTW^U_PXT3%R M[^C\7F@\_J=+V=:Q=WQ!_Y%0%WJY=9@PV;C8\N*^8OBTF6##E,">([S FP1X M[6S<\>9M+?@JE:!P,93&A^]%%-(KM.:NIXD&_11?7U\IQCII8D X9+8<1OC: MT7VAQYJ[!BH\6"0K<<@B3K=K5Z3=K/B,@"Z]V_4DB?_IFZU%BX]OISH2'D]] M>B)Z\U(.;2*#R=M]]FSI>'RXZKZVI8YUD1_Z_&D:6,@5N^5E=/E1>FS%7H#^ M7HD^SEMWN[G-=4U;F",E.&3-S@VY#]\[MI0]K M!G")O?STPB%<3C3C:VYD*),D!57)1?N@\^>R^P*YLNW@F-$8&VN$-*D#EY(@^]AK?US^O;:EII MZ[OL+I$1TWK:V.64&MF:N,V?U)4AEH=ZEY,FE>W:79E+T4FG(:\-=NV]1?B" MK':M6JN*[!=H@&)L. QN%8W5?H[A?J_<>>/E@K 6DV4'^P-)X95[ M[\377T0[>FK$^,MF7JI-NJG0*_^,+=81?,_LF9SNJVG3['9_H>/II,&-DVPKF(I;R--/ NS7?QZ=D[HQBV[N7!:%QCVX-:)$ MO>MS'@V%;^/$YZ&UVXC,IX$@%?4FK^C76,'<3B^:%_C?PQ"A@-B4.92O;AI" MVC;+G8U5F"7,('[(0C@MF3IF")M>GE!:W-.AS:(KHI?J4X#2XO(^7UH>5_]2 M-'<2X^(VR=?3Y1YKF<#7W(NZ_5Z/NU5S_$*6=EYNE;P41]V<./N"_(5/5>GC M"!Z^@@O"#A?"RR]E/:S]WI7_ KQMEFE2.3<3'822V4NV=MJ"=[!F;@RL[G6M MA*X?XVN.;I$ 6]A^[$;D>LRF6O-&V>=H8,0&)CDX=X:@X)_TNV^\)];:OF!M M;7U2H;#PPH^A.-Q *JL;RM?9P!R)S8L:;!5,9P_G<[V=9%#V)"6]2?$:$P#^ M.>73:+/08ZRXN C(JS&\9.=!"J=PT.RWN/?WM[(TW*CE[NP57$&?P??::@*I M20!QH4]GJ&D3[R \[<[1CZ.'1MY'BL:'[PLW28 X(!-!.\M[Y1@1WS7%G.\V MV3=A=!0 .JO,0#"'<*B/!L MEH^Z8I,#A6D@.YB)1?=VLR,S)"TX=;HC?ZCR7UFG/IM8(N@+@\;4?N!FSYD$ M>34\=9:GD."GH)3)#_&;GP2/X4-TO1A;X<$F^GO!I= 6+G<20$@?SS6#PB0> M+\+F;_(/-!1:E!*"=N MT;Y[TWKPZ7*]&W+O*7AU5-Y9$*69_B-QR9=CYU15*C:7PB-FUK+0,*,6)+AA MYCC[%JEK4M(>98"=;LI M4:*&"J6JE7V8B5TM)-=Y"I:)9'8W-Q#8[)&3N'32KKL]=3LV^>%%J-&GR3>+ M(1><.&(?>-K:7WF^JG2S\))P7SW6&LM?-GG-;MGCJJ91^W"'\L/:9TI/[NGH M\R&0UVWA7Q4'!O=G28"^:N=3]]8#M-K15(_L.MYZ=V@IXUK5#CZP8]I$LRE0 M$(3]V8K+.)B9D&@:1/8Y?W,>0Z' ^@F(.EQA\/&2KH=.XM@83T$BM?F2L_9, M_FI:Y!FV# =J&>W=F,ERO1G7Y3-2PWV2&)1LH"=II+X^@F(H*-)JV09[$HJD M%97*;.+LIA]O,/THL.!6Y3XOP7 OYOJW^)&,S;E^?,JNY7*YW*D+7AO%S+<< MK>M?UXDS92^23KLV[N,/'7?A88BM#[2=SZ1% 8KI? M?+%T6DTU 0>K:S) M[F(=]_(6JU'*3=C'1B^/?KC!U9\,/Z^\;'[UAM)BD4^>'O]2W?,LG0JP0T#O MD+E)[[7Q6]T5;X[AZ3(80!.9R+RXK7(FRK#9[#9O?798G MEW*M@UW&=/2&;LA"M:@0]1PN1F;W,+3U _3&6'""^RTO'XOPD7MQ!@_"YFGG MCS^.ACZ_23]2@AB=56\:-+_X( B5]-[!4MA:0YT^AD_[PZ^$GD\S ?*G*&B4 M=QGXO)?_KV,X,CH!961W!.E*'8KR%2S99*FOVCNLH-Y(IT7>IAYI &N!>JJX MK;S:9#=^=&O;IM[CG6)>;GHIGI9?>Z1A]F9VKVS1/D]\1S!D.%4_5FZ'^./2 MRX\\.K0_KSH6. M-W>B6/]K-O?[XB1 "#<$,0\N)@&N'W5].%PD/DW-#* C-$'&2F8AJT6KQ+*, M[V5@$B Q[ QV9A%6I-L92SR (&C4C\&I;$_6S_)W#NJ^-W>=M&5N0!;4HL M8O]U.]V0.V\N:5U>5YV(3%JU]H1B]3[+HJ5NQHDSZ&LO^;=2_MD@G^>YX-EL MNPU2%*V6Y%U47E*:264^B+ M"*&''>**J76(DI[/#_8'WL]M$C0#NAG19N:L@3KIZS?S!>CO'HMH4_P\9KO& M&Q[^R-J8YLAL-@(KUWQ" .SO?=M6RI6T^[K:FOJ5AO+GL8&.CF8P+R*SSKW M^W^G7?!_7Y"EOM(8UFT3Z$8"\'U]AZ;'Z0^\[@=[KW[.60LX2]L$P=[W_"1< MR^YP7G-".RZ(@&6OEL*8"J.X@K$V^YGTU$*^Y0A)RXCX@"[[^E30#R%Z4&F_ M(U]5YHV%SWFW#+B)5DQ7;?N^0X0O@1#F5V"E8PQU9V*\%.V^G*W&KEG[\Z,J M5=Y16].$B/DA/>L6.@]@F\Z66C+1P1/OG-OZ]@12L7_FWRA>Z)6G0E?G!Z_V M:V/X^'/+?6;Q\2$XG,I3(HV36?ZBI4B;6[%+36T3;&6@5_!=,ZKI6O,W_JVQ M]JKC^#KKU#LIJ>J4J@_X[4)S)0Z-"G/#5*L#RN[ *3R]_&YT98L15J"R MFMYFJSEDJME[LOG%E(3_BBSU%%S\(JN:7]/<4MBQF-"="*MPWM3>3W'L?1DJ M%4A\&#+#"0G=#:S<9Q@H$R\-[! KACCJ^47J"!)8>CZ>@TAM.-JMW)$J\F.NDBM]9O#2X M]7- D)WS2_>(KCPU?X9/Z>"E@83F7,&# MJ7DAPI!$ABJ-$=W7\&[]^ONNNJIW^[1?-:\W<3HP!?4:&O*8GBQR*=B5Q; SO]?F]87,J+K6&BCZ+K750O? MKAQ[5-!?GIX$O;DWH/#;KQ-#4?992JL<5^R&%<'W139QS,P&BS:-8Z,^G:B-U MEW#FSZSN#4=)KM^]G*P89UFO^4"FJ2'8^](9A_-O!YIGDF7/GOJ)FST@BA_D M_S1+9CLO^])?9MK(:!'GN&3;>]:\2[LDI.4I^##>RM,[X!!F1WXYOQ+HJI?J M7IG57AF0XK7*6A8[/G5^OS\6 N-LK86+!+3]W2]_8QB%E$X/G-JQ,RS'-&K34HC#YS #3ZEF?( M!.!:5C!3XKGW/(68,3WS-ZD >?75-MB1P@+10&9>!7KDR3J>EX\\XY3="(+; M68HGRFXBM(],6SN5H1S9O9-:VHO9R:*Q665QWZ]\B=6H%5'0RIJY#A:0J877 MI8D8&Z:\Z7IW(THC.\)7K>&],H:JIN.:0ZG.^;)WRFSFC3M+H^B[!>7T/AF)1F6*P+A\M\B)^.]ID>S+ +/9X8D0&-$,"\!)-)_T#$ 9.@PLH MDX$T](&,[I2)Z.XFH4]QRDC9;9S%-[EO=2\Q45*"Q^)FS7C%G=Q4W2:OIFS; M&E9OM)=1Q%?8M9ZWU56,@EE:%S\-\!])497G]'YF*GBNEF?YBB;#%IYJ(%:L MTA'E8ZGG^_Q\,O\SNHP1#=J4_=_RM\]OTV9F2@1*^-L3S65 C0Y2T?[^0\PH^SHOBD)[Q94_P)IHOI1&LZ\,2CCR;#G#1\2;=Z*:.2(H3E1#OC'/NVZ=_.LO:Y7"ZB6[9/_[3(+JE+D7FA MJ$!>0E/MHUXL2O&R45\L_])X3,.S^?>\[ZCME+FFLH9FQ%_]G\Q(I*G_FC,> M!J1M)[^I^$K@+CXNK4M T-''WWX:R&P[+1#95483QES1*%XAS9OFU99,Y1:W M_%A4FFBHS#-]^0:O]3L5X8HH-8LD-:W:Y1<.+51&'Y.?OTI_V7/3]>;8K_<* M3+6EJK+C#SHN+1&BRL?M7GK@+_%3.RYKOZ)H'_^F(?Z33$I@%$%_A?<=]9[SSQMU_=O6:U;6J:G[KJQK5:](-%A)%^\HJO@5#AM3Y ME-5I,QZ\*"W8C#Q:33AKU\GX.#LK&.#CQ2\82DP9$EQ0-TY;7\'/<1>WX+. M0,M[/\X#VMAGL@;$G$4!"CV?%,F,G^5-J3,G+,H=M>\;UU>[F-(V5!X_WD=6 M'_C(B@Z/&9.7@KN].TIJ(BNX1:S"9+>+4JNU< M.\R_[56OI2\9Y>PB8)C6Y(')D*J)^\%0-D?,'+Q0(.KTL#>#+"':Z^'E@R=< MYL7;Y"#J:HH L>5>:"/9EK&D)M'*;+/5S07H KH+T>8!,XR2H M_551C&%^VZ$[MG_HO*SLFV$@=(>)>Z'ZZO%I"\1^&0(Q=7[72Y(/,>F"TQKL MM IXA[]4,":WM-_>D3$6W>!_/N_5VSMFT[2.LER?7CRS;OZ3/*TX.]DEI!8U M,?008OFMI)+NB6:^OFM5I:H)\I/2AZ0&ZH*E@\=OH+Z2_82/*6X2QRU0PUY*]LED*E1NWO&B/8_E1N[OI=(_T7XZY%:S>9V:72#(6@?V=;R M'$ZSZ,8@XKPWTA)?N'0H)2474A@F*LY+*B-'4B\7,P/'1+JY^;4MZ4Z,B>]5HA;;0_4FWPJT^,J2=:@:3C_>:)WU<&U2:_K> MW4!57JG4'R<=%P0'X=[[)F=Y%ZJ'X+6*C?/T(_R.]ZO>A;4\=3!IEH>- M$>@RT5"PU@6>.9V6^>1S0(O'Z9*IF D&[&+QL7$XGYA+MB;*ICCWA_1#^O"T MO;TSZ_51B_5SM%BD->_; MT !R\]]J9@UWMO%$O:F56B(K2-\-YKG&[ 16O# M6XA6G5UUE>B?S'Q>+B:D97AWAZ_'+BI%0/=H_2=R/XKQ97.2AX>NV5FTV^46 MU"\HZ(+R*,[3_&QR/[TK9:G-RG3F-7MZ2VW5B2YUH5SNB>#&B)3]:"S([27?'H;#U[9F!NOI?18Q:.Y M1_" A\;Y_F%_ENR&%HUZ=13N /5:Y;:B0[Z]S;\5A99?-!IL[.)/34(S.7+2VE]L[7ZV.^KR\F.MI93L?ZTQ&I>QFS M.Y[>/A4^F0^^(CD1N5>/W56EK='3)_5M$DTBMW(D5FB%O7+&EM/X7RSL2T3QUC7#/QA<+2Z9KH' L>2BTD:,8"\7U]$A%"_E<[ MH,!#C/]E$KSF,G9WI\1OIOW/&%C[Q.EX=,6'%R(HOM.U<4#7K+*-?+=NZ9-Q MLZ?.1"H<9XR9RA2$O]X_P@)B"/I;!*#.6+,/P[!1B !:2]/>A3/)SCW/O ITIK#B% MX2P<'/\O0"B?R2_*CR0W%'AJ :O,&W!J7PL._5@0N?[US M)SL+KT9&BG]$GA_'=1C*.+3OC'RYWMB5PKN2+SR M=JR\-J 7:CDR?<7HL[]L>F]+O5I[?L>K./EUHXM8)QR4N[[:\"L1G>:T[.;QZ'-B MJ3%-.!-;IR33I-RJSN-HX\C$^?J%I#;KL-?]3(/"VT(EO].E(021,H"\XWX M%GBUS>MG%[B'V$A"&'^9--9N/+OVH:]KP +:;B&Z:$&KR;V=>?:S=N@^^#O& M 54K@L%AGY0F\7))-FY2;\HAOWMA>3RHKXQX?50J!1: (T=^T/4,\B39Y:?> M"0^@+T>:A#^P3#Y5>/QM2A+ F7D*\WC"?HZ9:LM)#;I#626%DW<[$;C[,*R* M.=;@JX%'XVIN^S_0@"Q$?(>$#V;E^?'+O;L1[>*55>W *;I[Z3,"S/JJL5$B MU#DS*K>JQ:&QP9AZ )[R.2LG3:A%>-^Q8#%,_%=6 :^6195+7W+ ,PI^[B'^ MHWWFO1]C2&1TR./ =)M%E$6==;>'"<5]>1"S^9N\R+(T:SYB%G-FA]MX*(A2 MJ=B1[5<02T#7@]>T;.5KQF8N?$_L"1(4""CX3B0>?^27&&'B#PEIE+'IM;K6 M29-;(Z;$>[;6,^LFO>9P_=996-\G.)SEG556$27L5M1M6M8=D\1WCK9#;J?? M=_=<*AL.AMU+/I&>QB!#6=].4U5G H$Q"@I[^=*90X4]JV ]$XEB+$!VM<2< M[\.Q @%CQM(]70FM)=(VK=1/EE8NPH.NC6Z R^/YSU;9J47,,=D1?K3':0*! MM5-4<^6?"X*2[S/-WJ/?R]?$7]JG?CF) VW&\7&RV;J_YHZ%7 M=:@/1ZV7F/>,0BE4 @T'&[:Q;R1MB:'%$8LLKLDSBBER7VNHL[9K.XQI1M9\ M^,H;-'*4;0D9E)=C[TAO="_[?)OD&,^_ 9F4V;TT7UYKJ7>"Z*VEIL1+#?/QL'^!+KW:32W? W&BV1R?>@1[43E\T]5TX"ZE86+757IE MKL D0_;MH_+9F]D8*&B,+U8RCB=$BQ)B&*KH5O1< MG\0W4S(T9)AA<#M" #J$1BE&U[H3R)]Z:*X)%O"\.)O8+8GJV:,JSH/[-:7! M>'L2')\))\K;G,:OIU.R#Q9P;<2>OT]W],#1^"#/U@KQOP:9U8DIDH MO=ZZ:+YE_UW08%^+?S%9E\QWU/7HD$"L# MRQSVX#X"Y["A&;5!7!?GG4W-%A<5ET_/2Q= @C0))7SJK.C<9ZSL)H'UK M&TW>' 8< E5&WRPU=@KUN EQ)A\*",O?*\P)AZ\8ILFO!=.:N79 (@)L50J5 M);=%1<)B- AO,W+/?,4"O#N(V,;](#&(Z:&"#U[+FZA<"RUK N6IY1W,V-5] MF8Z&*73,EKUQ)YX.>6YSGWI$']KN>>3\VJ4)GGTE\-C4F=K,'P1[D")*"N^6 MI^Y[P7GI3'R=N7/W^Q)!9&Y/=D'J#G)F8@/E)/-U8\XT-&RKH(U_-/5B:HJO M(F/'5.7*H*Q,%-4Y: M-7>2FV88'I*[OO%?V=:+3=U-TG3>UHHV>;YJ M;5-L?4%]1"7CW = M?SA@OQ(F'_MFJO]L_&/4U(C@91^%!HI0,,)N<2DCX M32PA220<\;$%MESSHHKRD)DK6XN'8S:DY0L?1?;D1V&@I",MQ'S6+7']XGTU M%DBJ[/>[.F!R-H?(;N1=,(;"K^PB]\26YUI,,NKS4:"$PQ"A^*P;K%6VLLJQ M+WGQ(X%BP> '(:WM(4A>*R[AK,]9Z5S(Z3C#T6Q3SE+3WB(E5X$A,PMM6W[_ MAT[0K7AR_Z30T@)&WV9M087:?I@9P2E_UF-<95F![+NO$RNHF;=K!T".=+U?3W9%+2H0SVH%/'EZR M?1-]FMS'7FZK':"NK*S\T)J!NUFCW\^0QO)>HF MI7/X#)B?!LI_(/'6M/&$!+C+]T&GR0/S5]0WC;=PK6, S-7/W%#W!V-)W)3Q2>NWM!-[9WKF[V7&A!X:! M9UF]\QT]5J\^8P%2]"R:3T(5*1&2WT8P \[O6,FY489,7)Y.J3]@:-RVD'5V M!C%RY2G7!IR4Y_QY>2JA>H8%5,\V89S=)Z)5ETSY+(+31%< %@!A 0J&T^/C M+>?WZU-7$JN7_KF'6( 2;1(LX&\L+G4-F4K#S"4Q!.GX&XM(GW2<=)Q?@0LQ MI-['6TH.8:[;U%/1WB=;9Z11%"4"QBXL M\%M'T&<951\\!4$9A=;FZ8J4=UN+%)A5TC%^W0_-T7[7,U M5P45N!J*$7 -WG1KE*:?>J7/!-&\#L8IO51R)(54U7HY!)M*7%6&EUIT0G9*H MUV"G GU]ZY,O2)W.D8][(CK']7WFL>7K/3_RPU^Q@EB\;GU^]3:HJ'L-1STC MM1TZ^6=G+(L'A\UQ_0LR0G*??D*B4SF7W&1)I"P\;M8T2UE1 M%9U6#/JL)1//TEE$33_$HC I6 #L2+:T)Y*/6>*'A!TFVUA_9 ZPPHL):))] M$5'S&"?I5NCHL#FDSI HAGCQ5=D;99R=<)7),GO9UU0]#AH_[UO[00:Y-Y%[PK5S/?<[=LS212O<-:MLI2]NSC*'MB@CH#'%5KU:%ELK MA+>6L=P7RIO^^.[V6S4J/G6#TJJ:U+F>V(W3S:;8U.2SHEMU=P+K)2L3%(28 M3U*0'5_U5.;WE\;W4]O[%O78KT?/!5O%R;2088^X'I;2!?]RNMI.6M)T%Z-W M4\/LI/=(">A-]VLXILR? M#!>')#61?D:,]U-=_LAZSW+ZE]B)K'P\P)JS%#G"UE7HU7[OI )USE$G#GB( MO_*@5KE!EN@KMW&ADLA..>6((2=VDL:%>>+2H*4Z+-#51F?AI3$'@OJV$1L3 M,2XTZ6USW&,6\RU1J'O#C' QB#N+I'YU(O73YWD,C0$]X MC\?;RWWH4T-G_7#V;_D$'HG/ (U.W=//47SB;53TL,LJ-.BEZ24!K(W@:-/[ M).KJVA1#ZN$&,77W<]9RZ[.?VS>N;&T^QIEMTH9C3-WSQ>'O:M\+[)%?C? \ MOU 2N0ULWQ(Q=0&E8M*=!-OUPHZ&?--9$LGXJKYZKMOI2N>;JA2\?O[Y5MOC M.//W)+.)205L2"9+N4FZ>Y0*[,J$DW4CL@HK.%LRVZKK^VFPJ\-Z?S7?D@M5 M&",OIJ7L !--,%E/]]<$JYZ;KGQ/J\LJ:0N:VNB441LYS$!"\A/^^ND\=/A, M,9?%])(;FDH5Q*#YQ/UP], (1/VH8\@( JI#4M\K<*$;X9M[2)*G;YVR$&'[ MDZ>M3&GPN4DT:S@K8DQU;I9[NPBY7ZQ_?-_2TO;7HO?YTO MSYO2?\3TO:SBAG\1[\_(=?]=W;C7KDOEKOL>*?XSR,[EPAG-J,;#3Z=M9WGD M_ZW0VE2CLD9<N?$<7]?3*8OA!G+-7.\JDM9S.A;3%%L;FM+ZUOGUO/"'!]0F_BV&SBF^)YTG,[T3"L*\VP:[WM.2S")DL7?U8I^_5 MSN@;)[_DVY[)$TXHMU7[3G@10"QFRTJL!69O95@^1Q^1EHL\6&.T M<'_IG"GB1;J6D+&9TI-A;C8GA;\#4. G0,=]WA#E2DQGJES:]I>96>%0Q MRS9R>6,-**9JDHX$Y*DL=K%;C7^!N?&$^9W2X,QS%C M53SZ/QJ>'/_/::SK(MRQ '=&PODR/'UBUAA.:=V]8,QT&%[6KH#B@I:4&"4* MOKQ.\-&L\LZT/W5:6#AO5BR?R=P3G?T];\ =SZ<^K;6^4[J^ZLU8[G-*?E%ZH((7Y_1=RHL_KW$" M^)YZ0<6.Q_9NFV\LINC6U^@.AI8T7W>(H@4FNLE;U<57+_,E@\V'SCGCPF:! M&?=3&+T?KH(^!$U@'?&HQLR=:KT?>6JPF$B\R[[^L_:A=_'EX;N8V/TTY0Q8 MB_A,'6J["6^R_07KBF#\7<6""XCW;E"B8.2W4YR?S+Y] MN@$[T&TEF!'S-Q+%JO<8*3%Y&+QVQJ=%Q+C^+-/J]'IS<;ZM+13>)-8"@20N MCMBXP#0EUFDX1XR_]:Z5?*1(\^$S ]>5Q_(7%(\O"3HPNF4Z+I:_5TI+;_9$ M0F4E1^A*DDQ#<>_C6%TJ$LLE[]JY.#-11KE:W\K#O_UE-[!KD\2S/J#92D;W4J.KGL9B&"$RHWE/018Q. M(9<=Y>HY#+JI_=FIRC#"D!%DA4&;[;6" MO9S:9NHP!!^LW=^L?[RO\])(9DZ(/@Z/X?> 3K[1ZXG8*/NO7ZA&V55D,NA+ MX] CHRN>[N6C&_)K5@T)(\U,W:4L>**F%/(&+ 94XV\2G^/MMLJP;&Q:W=?D M;'Y"O[NHQ\TTF,J'UKK82&?;$O<"L:O&^3TXE/!=%1"80(K#SQ<24'NG+_QF M:GC)'/TNHH9.K1^&Y[,56R@JPE?3X#SNHJ>OO?]8?;7<<61CC*S\XW/O[Q[<9TGCVG!8A7 M,DVQQ)8.!$K:LE^B=G8ZBXHH@;!QA9V7<<2:XWX@*.(%VY^0E=XC1$I9 2S3 M6N//E4LKAA0;%>-G> ;WSPU)N@^IL@-^VJQ#I/% ;L.I" M!AM>F&\GV:%^O0GQ2+/.C($Q:A55>/SZWLMQ*,&D&J;"_"(,3Q MT)JIEF?WD?!#&;MUZ["LPBQ-,I.",RVRLJC:4@L0M,V864UN)-18[3FL'*\K=K"\'QHG#>HY"U M,PFBUM+2:R*/L5_*JX>0,N\=QU\5>^=]C.;NS\ N^]\W<;ZF$UH6+ M5\Z8/P*Y>@S/TR MO%K1;>YX^7XN_K*7MP9TYHJM;8,C;TE7%CSDW ,A:RJ@D30A7>3G810%Z1+$ M1 0<7]1SM6E62B?EUB6Z5),,T;G7C"<>1I?RNV'M2]NJ46UD]<*:FSI$:R/4 M1N[1O\3_P)+O,U=G*2*-'=XY'6 M):\PWFC7K5T2*O7JV C_4@]'+(IB/AG0FB]RIBRL: N?R' S1VI\?37-(R_/ M[B86A 4FD>[5R/ZIOENL2=UWS6STKB+TF+5 MB0JY%&'1CR;X*@I*-&0FE8H)\LV&RV(^?]8(FHJ_I)%S2!,Q80&/L&YK7J.8W"E&:^-_O#6UQX/OXI M.>Q>Q?+/][5"RA-59YNZ.A;K]JF*7I]F3D":=V4HW['F*#0-Q2*=W;^=^837 MUD./>DX_\\K>CG21F-DVITQY(S]%0&'.I'-762LC?'2J<8RB=X-/?^F:-BIQ MFJ\PV):C,#A=%">KG&:]XL%ZNL?0H^<&YFBYKA^,NOO^(U"?70<4?=^,7^GW M7V]IGE]PBMY/EQQT_E9)@%B9M=T=WDVZF'1TW>X.=?"6[+\O.MT-" M2 ]+G<_P8&]H=,2=UT;@=_9!<5YOY34:M7,?OL& MR<@8)NF7)D'2$TT_]($K' MT:7'=S9KHK/& GX>%LNAV8PYC.I\Y1^_%G$:S+"Z\>H41"CO.X 0&W%'6& 5 MJ=JY-'*.G(3+!"#]*J-V&;]W" ATN)M!H@TWFD.>RRC)S3==!VR%5O'!\^7F M_8(:E&6>O61L,L_N14*;QSAFYUB$:7'I7*_A'QO.?ZPV.,_I:L(4K1NJ?#P4 M=,P4(IV<<#V?O88&I3X=>8P6/E8U*-;!RLS+S3'B#>TOF M@^QKW'1%1^^X%8:U/G3'L6CIWB,Q*I$"<:.,<.@56/_K8JENXY$AH[VO*A3. MTA8LBXM3"FNZYV\?5O%0-E%AR?;7V(>'2UV&A7RP@1J,:P-/(KRAH\A+FN6^ M/+K2A5XTF?)Q/2L!20(,&07Q.4RQ WU:#LH>N?U4 O@,&Z[RUWI_8CI$E/I_7/?IH&QHMF":259.$!B>IYOS.P$ZK41\ M&&%5>U!O@Q?!Y,'L(TWBO^5*C/(\-P^**APJ'2$,UM>MB\?$>VR[-XA:*).B3&8Y?!6Q6>^J%^T MIW8_B]X;4/%52F&!4?$\)&,T8DCWPF[\]&RUTZWC^.'Y:L)Y^"%Z)6^(1-!S M8@.S7R/<17L(:?#^90>]PUJ;1OIDUJN\+V50ZW94(KL?A$HAGO-A9?UB9C,( MMM\H_KOMA%3B":(<.;/9'03*2:G(2OT\+<^BERNEX< FE;B=MNM5YJX M\N9)F#!EL;LZ79:U#D"FJ<:;1X(?C+Q^>>F[($'A+WJ"[N-J48B:W+X*"5A( M_O.G2B+49I?[I/.X!2+XV!H3V=,*N3VC;Q3?'2?F9SG)H(?Y)A3NV[IAC'9# M5(Z=STR//,$-"/!1!^<^#))A4,QR?593%]8[223_^4[X.X#=,TY*DI]< = H MI"=E&/#6_@?B;S[<[T1]L6,IFC$GEB# MOY%PC, H;CZ(<0*,,,TL;##\:V+XPC4O'W)^13"W.W9Z\ZO[PK)M9YC@7H7*XED!T,)RK"E L']")=3J\O,_QVLSDA>-NC M+_LPB!,L$(E!%\I5>;F]5-.R,2\)*QO>&RPIRM7DK7Z,IT;X?$N\_;+^6?R( M]^M %LG5V9\2@X(7;W1]DTM@F<_\515[H>5V+VM M2PO\J-%?/:8P?7^$QM/,K,;I&;5 'Q;XV>J##EG2NS 0R=!9-_R\./BS;*JX MJ(X@[,EOISN=HD^P0&KF;3K4?JO=X.'B41^'$?Z&#IYURD=.' K6D"^-3*'+ MI)?3YX*2>7EY?9,:XVH:4Q-J$YI="G)R"O=_> M?BM)20$ N$MD(JU1D_(]>>8*S-.Q'Q6>AXK;E+%Y>-&OQ0S)=\A]=%>=Y5S'>D7[!MJG+YXKPVE%\6^% M-+A+J%D(G%'G'K0("C:5'J6%^&E.C\\H&^*??&'+^D9@$UDAN48BI!E?)HB$ M) NFPY+CG& "QTZT$3PJ^A4/922I>.YD1TQGJD^(KS9_K-VIV2 M$=)^Y&&] $1OOSP&BF'"+-="$OL7/I-GE8$>[*M2ZX=23BV MYWJMMQAR602LOH>_;_+DFA2\U5#=,O3H^T#VI Q[B11?;FE %SUS4O)MJJ3) M(5L99-,W!:HL^4,]/!00V)U!6_!*2L"KWB>P6'!V&]Y"9^F>9+1/OUME+S[E MMW=5VG8VN@P78:\B3JUZ$#3''R'R(9/>5?,7B/TXLMSG+ M.0&G%ZE&^\_MPK=A8G9U@F?HQ#L")GUPNGT',T'__=2"_*+M;"C&@3,A;\1F MO:A4FIR3F3SI.R7U>V?W!JB@PY!A^*YRS8HAC12/?$S+4S6M73>-4JFXH@BW MPN;Z,*T I>19Z]_YGRW.;MF#N9I0&6L[])'U3(@T6+TWPF;/JU8"WN^1L7U3 MR3HC%3Q(#]E;!0]HT%2&; K??,<.O0FWQ:??V6"2+<-5ZJP>-D ]#(?BK&P: MC)0\'Y@&Q[2(I^+/Y$N!A.7M)^,?SX94BLW4J8=:-LI\2[5_ 93;*<8ISE&L M&KENMOD\KVB>LQ]K;Z$&.Y8'UK#I))1X))["7W.6UMO--B78IOIUI5=F=;^I MC_C]UN#]&K-=VU6]#02!HN:P>F_%APZNB^*S^:3"IXU7O1GA9F<3?&=XZEWQ M_FC$X6FZJK]1P9@/#R!2@\P92I M?"+6-HSHG_+*L9R[5]$<'[[(Z-I- MSL#\Z&?]E&92_+H2H(;23UHQ+UW,(!9#K3X//IKQO#*KTKM4MM(ZL&#?V3%) M3"1C#N0,C'??A:>J6&RHF!O76@KB+SV[7]\]]8Y"Y&L0+=LC^T'+F'0M*BWC M=[9$SA"Z9&NJ!BK\E5V5'")/>ZJZH00S9?"=XGYFM;GLS.7-P?2.(W21]9ZO M^Q#MBP8OY8)T=]=.V%9 MQ,Z2-V!A;U>2R_[L,%N5[VCQLK*9\VN2^J+!T+U/G7QNA'P/N(K6U'[R3+]/ M"-(.Y++3*.D]$]E*?4OA^C&JOB+)A$/]NG-4DA^8]B$^J?UG7]D[\9_T5U_Z MX[0R'XD/6$#8R*;?*6X7F;]TE7Y0^!LLCY8A[4U'1&<7T8\U0.3 OB'0EO(_ MNR+?*X.CS7V_S.MYT_+0/>!05]95?J:AP)J'<2OA)UM[SHK2H;J>&*AQ2JJ! MZJ%@(]WX&P*%GX= ]MLK18S%SD_VTOE?.KNII+J2=$ 2+A*<++X8=8'H/@]I M3'LE!$#B@.4JFH-./CS3RS%Q1<>7*1+$_@QG?>KN*K\*SS^U^+]WV^!8OY9K M:N@]Z#\=_=FS_*&E\;8+O"&0291]\66].F9B)O\/F#+;2O8C M[M=;:H!ZF]& F]U[SA_]#=?"YT&=C\V^/V*CK\_W^3Q8$P=5M%A-,D;>(SU^ MNO-BMO<"]X DW&]57 )MV38VA06&/%:CCF">)-!M87BM L-PZ85@RP>QIH[F MELJ5!;$0 9X6J[GUK=]#ZPR*@P_9&#(4 C@0^YN9,8+RS@)B>S#^]8XOXKNN M4>,JCW:IOHW+O6AG]IYUDV6-)_GY:E")AEZ0SB;L:/@ME;(=B!(WDC%BUZQ. M^,YCFWK# U<][['LYL!BB>^"7<2[ ?.'R(H<)++G,-,%"_#X3^U<\AM+.#AA M@6\^F;6EM?!-S1;!BKX"L;2XW58+RVVVXVHU5>;DMN\\9%/,6H<\1=$N2Q"Q MJ:514%W&R5 3M,^]14NCZE7^SALJQ-N/C+?EIRUHS7#'LJI?>$L[6S=<5M;7 MN3>3*S#]2<6M_/7"+4#.:RJH0%Y=D8&>5$+P5>9@.!X",2AUS29]:$J*$"+- M8*0%-\8CJ$.,-:GP2!(939QJ=F\>$6_J5:CU7WQ>V?JM2-0L;F:G7&C- UN4X#.12][WRN28:B6T!ZQKJVOV85-S)YCWHW04?\12/7]6$28X_3*6]]:32:MNG9^ M]M&A)M01TK\3-M"X6-^:MO>Y.&:P*OBH_RU?W)NGM[_UB+"[3K;IH&87C8Y; M\FL(J)3>4.B44T"+),L-QX8O3GC<)'1.4#87$6!.9&?LKDGE$"JL8UVH&;*" MNA*>C8(7YX<;YKFIJX-$G M^3+M9B>?,J.@L;-#E"";DU ZTSCSAV9FI8U8L<=3TE7WMA5Y 3UR D50N9G? MKF4R[(;6N74G3I)^X+;E+^P&A%4?XK[3+:F MH"S&M BW;+0NVM63>C4)V:SL.^OJ3NJJO MUL1PK!7TS?UD8U]+%'IXYK=U? ,CCN,+J/$%4U/0[NDLSJ6#P]<&U=N*5!DL M38=$"@]XEJ6SI[-<]2$L$!1GP4:5Z"%SOD5LO/T@%L Y^I075*"DR8??XNWK MN0AS\#XAD'7F3*K]V/:I%N*LZI:X ?7SR;@AL82CCLKU&0MZ[RJ(K#=<#-:N M:1.@Y\V-1?9LIX+!MK1(?N/?B95[U#^A]+#.D54*"!"[ M\YJIL'$UBF:2->9I&+/>:A2_5M3KB3.KH:WEXBMB!E7^E?N^!3-MA)2XG_P%@N3Z W"FQBN M;.UOD!YE>OB6+"&815HJ!+GV871T#MH@X[C@7>^1#CF%Z@\=G;8V!9D?03\* ME O*(U*L2)_@S ?5S!/.Q8BAERX>)(&:/@Z9US4VA,(#Y2?Q6>:KS_5(A?T^ MF]0L.EWDA\?A1@KYKT]HSQ7!X+]#:"58<1<> _ MQ">%&"=WVC-N+!"0F]QZ(7<#D3Z-6* \W9Y$K>YS0)*&?^>UPMW@4W)3QYK(]:$UT[@;NS4:)@E^C;[#94%B\H@)_V:<-W\X M/'*0BXZ_^G+MKW/W4C,/DML#E,"C>I?! M>-)#E88(\#T?$[:X/TCV7#_M^] M\,/D%%5U, \BQ=B!M\3SGU\^T\TFG[TP/KH/NRX34[CBQ *BIFW@3HEAQI,! M$&)?E_&T-I>F[7+)?'DH4>ZJ#G%:6TQTDR,96U9_?,LN;H./<*<[EJ\$;#K MG6)_K4$B]CUNUN07HT.75I>'!!CW-;' [.A7_R(L\'7STF#>+[P.DG&.7(*C MC&L;>&*L.82[/,?W7CB-P^NUP"V1N?"7$(%90<[OG9JS)4-B=\<>46;?UMS] MVNIDW.*W=E&!!4"M-54+>WL5^M8?Y:&_>CUA5 M/ZT>_XR7X?9=JT.Y21&HM:52<'TAY'X(@BWV074XUF+&K?*H6TGI RXC\2I(^@#])4[-TY5R MZ;=#^F[2LE+H$_,D^FW)7^&T6=,T-J-9JR&5DB''C\Z59K -3AA;K38)3T4 MUA:Z8,KLD=2[X-.Q)N'AO(76=7%6T.P0=JX\*Q=M20VA;JCR<::L:IB5VA9 MXC]GC,[MH27J8DR!S\.^>T$^;*BZ-(E953<$.E<'[_^LAT3DDCT*>K%G M(*LV62O"._6\0+#ESADRY(-KRM(ZE%-#(3^]F,=NVA:'2(."3)*[B_X>XO$U MOZ_;><)1TH4"BC3*3V:NC3&]](*[_5KFC1"I'UL=H? MSA![/' FQNF.W+V4!>6/#'TON>9]4W\MK36IN&[(^,JY=6PH8U.Z Q6W]%9@ M"Z6EV//K75+B3N5]?K+[L<(:KW*[A-GR $KC>1@2G4: PKPG/U\WE,QB-8]; M+>R!*U(73W]P>WBB<%)GR 2Y. A MQM>YCRU-Q!F.4"CM_&"ARMA[@ 64"P\OU5VYV+N>2BW;;5-F+:1.'NPC5#$_ M15+J#VD?V\XLXJBQY3XLS?V\E7TRVKF%7+B\V8>)C.:3'B^[2XP1$S,2XABB M?'\)\"LHLII:X;)@1WAI;:^\:8&"_FM:1@U[>A,,IFJILUIJ >=02BB&+0A# M]UA??Q-HAJ.QBMBWYK;J+E% M&O&3_58SKE+7NL_/[B'1M>DV$!+T(;@4'KY\RR=6.+TEC/5 MYODNUTRMN>C8^D.0/O&:Z"".9J.],+[(9RS]=,;^B:Y>?!!PNY1G&F?I_D417]96#Q;@CMZ@G@,3@YOA^G-> M&=&9&UA@@$+$H5!@TW&_O';.A]KNO0O?@O"/))_+B"5]]DLWD\6MJ,)L#'3J M5O_'EM@F$B8BB@2W!TKOI/I]8WQ&0&*G)QX6\7LX7JDT2_I&L;G;2 M@MS$^ M7L,NA_*IPC>U[ 04IHSN@][$*O7D]]*B(.VN^Z.]\6JX]TD,OK[$?VQY;=3F M/-EF>%@2Z.R*Z*64-%S?\Z)TQY(P[[0T]MA0@;JBOITP$/9;'/%BX-5344JYNDX MQ![M1.8_R3"QD_\Y70"> BBLVHD]'<& 2\2P5]8U"=II&TTNH5C4-O0/J*ED MD@XL'GF!RR+.$/[D>X9G<:KF[4^J3"7![BRK+A_,##5%KE@_=O+3/_D&5!E, MJ0.W[#0 !F/-+F5K8]SNIPD%=KT)JXH7KD-RLU<>T7E+R7^(@VJV;$6>=K E M["FRBY4'%N0AFD37;WN6+SEHB@H26VRBH9GA".+4[_F '96]PO#R=*2W'Y5TT-+N;RL(#N MB:[\B3\OY]=MIQ\[[5E=-B4]_I_(9JY\ZMSQ>7F-2MDYG0P"[5:X^9H>5L4U MDK^+.G.G7L. /RYY1*[(%\#1#FG%W]4-[$PT4:N]S_W1=I$IL*!ER #VR M5Y;7ODMX,7[WI.D7LKRIX8!/1-<)>?F,P&&559ZEYUFCEXZ M)#O@GA_+W=Z>M]R]U9]!#CYR_#T]W?N?1%'H%S-!XG_T>]B!:_@$\6P%-:?LM0 !V9IGU%?O\NB: MTGQXW.S>5;F^P%6/IAED>,80_$"=Z[AS8D+7HO@5K$;!CAY-Q9[$&%\<(.S= MQ<=&_+:HA$H.[]:2R>-ZK>;O=VCJ7*T9Z,@)+<<9E,(I5-)>AXZ,HGT:U%.^?F[ #HOVB9.34>B2M1@;Y65 MD>NTXK!:8%#F?M>K6JOBY$.S9JWF6\4'#PW*W5PGAHB,^LT]9@?U)G[H1/VJ M>\'/L/KCQ]II-<7[A&Z'"9.@7_8Q1AN.D=8)G!UL^:? MDTG:AP3 9K_1+W7W(E",EC8F96N,_'7<*>_HM:F@0V(^M"/*Y-+6(.W_<$E=XOO M^DDR,29)"]9DQ)_^I[T ]_\\P;OZ-&>GM4]ZR@/??RX[H*F@X1SXBV,ZYEOV MM7IW/E5K2J6%$,9G$%3TR*0$1%&4Z#%':#'+,T]3.AX9J3[B->P3*2.GG,WZ M7EZ0[W9WHB[6=?JAUE2T%G>NL'P_4;FM78P)G[CV\>EN6R=$X&RO>_JWAPH1 M<=,'[6@%3FOJ#^9;GUZG%G.?UEVP$[*[+-"PVVYZOXADUORE3QAE&S,[G!4I MY2)65BI6-_;H5YT5BY[6?5NIVUKDI$7,;IN1S!JQCRW%WVI9B)*.B?FP0=RO MG4H)C5,[W]>?3)TJF6+R.G7!ET.J>F8PSB_%I4&Z%?K"_1:VK-%'-"L MOU)E]JX3P=U"/0^REK=V5:!6^BQ_KYY "? )DN3CIP0.Z;URY5B-<=CMV3G^ M*KC'8]3'/5JN)5P%S?8CRQ=@F+SF<)\SG9[$6+^X><..\@:G=02=L*.?H>ZX MOMY;#+TPO;:D M>3'Z*$9) MET)!G>7MI/RH\4(44A".^K5BV$*_L4-7*!EQ./14Y#'.FUJ.6UJL !L?@*-( MTL:2\*.H6LGN@6Q!%J4&3KD]#@5^4V6EHLG/G:5J9&2Q>!=2O&D^/:FZ)"-5 M,3UEGD[:>9^S6.U$%R.8Z81ZX:]$QC%I=![^YIW'"0SJ0S_D N.20<' 8FV_ MRYE#H8*4JXM?!7R/,RKYV]J&K>F^D&F9L8X M'9T=?VA*/+I&Z:,69S)D;=Q%15)"+2(L3VVSPV[K985JRAIU-25- M)FFRCS%\$5JW>G<=(%;ON+ALA;!>HOZPM3X5_[UNUAI#9-^'Q0UJNH23.6J<-SL)4-E) M#JGB4#Y*/LH"596NVP*[.7>TR>MS/A,4XJA*3:Y"Q=/_R8H1.[4DM-O^UHN% M#!F5QDUH=3]IJ653DG\ MH7,VO>X4^PLL.BZHL8!HQSLLL 5J V-N_X4B[5A@S?3RZ(H7"V0WG&*!O0=_ MX0L&"\2 CX=.QJZ#87-8H$KU+YSYE\I_J?R7RO_35+K"=6,O9&N^2-4VD]C[ MW56:/9-[KZ&ZWN)@2BRAHRNW"MRB&_CD+PFI5>);, "<45R)J^K=+KU#JB_J MBAQVV*365!7R!=]C 2DF[JE#7EQ343RFBU.Z\\PATHL5?]$;,R?V,J^G&:;/ M?6NQ %L2%C@.?OD',>4-841/2^R#L("DV_X*F ,+;(:>'V.!7+D:,$;-!QTR M)'&4 L8"K\VQ0/F5C\[J]9^0*V3'%DG;I>HZ^/)0@@%\8GNFB@7L2?T/+FRN M-5_>:+AG>MI1:;\(1JAA@3;(%+XZ=AW)<%,I(*7VEQA?8(%! M*RQPN1Q^#3E%&D9C=AC1#5@@2WCWWZT&_YO15\M'8Y<%IEA@E*9C%VPRTX@% MVK.P@(_S']P*+/"_I!M]*)'(F!YWN(D%9*,MLGI!@8>)S>YSQS$ O\@__^1Z9D_]V42O"#BYLO1%7[,J\>BL5A 6@@ MHE5<'PO$#]THZ:*^?X9L_\]ZB&75O^4 M3Q)N\J'[T@L+3.0N2%P5B6&ZUC,OWG5@@1_:" M5M%1,5\+E\V5P?PTEW\^_#^ U"J==16?@@7&8=XW^X+P+R;GAP7Z M.R[6_SJF41JTBP7FG__%\=!8X.F-@Y.V,Z^((3@8\XM<.S& MS/SCQUDSJ3_W09V05;AWI9Y%27ZB=YA>B5EB05P76NMPA&Y,&7W',A#U1(=' M>E.&A1^GB"@<4RUWMT+KJ_WX%/X/6]_MS9DPX9*F-V2ETN\>NF0?%V;J7\V5 M_+>^J7JI@^UA78+0O4AC?CP\"O(9'9W9,4I.%A8^5LO4G(("CRB:QV'\+T:' M*26;Q/96\>_=B1URR^K).>7PZ"=\7[WW'''^7-G_,9.=M:<:\\UQTY6 M-YON(]-;9 XCDN/13,515/L\:[53J!R+' -P5]UERE7"\<:H4H4@S.)(4/QQN\CRC(!UA3*ID@D$<<\@80]TZ3L;^(@<9:UX_95H'B5L@- M1F;?*U.-XWGUH\?ZO](GNZ)F91-4;"L"?(M#)PN /98JB()':T9V:2KWB=>Y M>6"$M@B.<+;=X3 CO?"4)97="DG4OU_!_*@0?C?:[&A&4>@XCHXK.)-Y<^FZ MG:GSK[[,;1X0CZLDR!OT$C0ZA%HH*4@7C_)+7':*>33K_E91$X2F6,"K)&J*-P)DGRQ8))?;2KW6OALHC]U\J M_:K+?L89;/\?0?=_3)MQX9ZEN587;7VM5NTL..WZ7AF(2+]=7H?UU]BDN@+= MN+RJY/@^LU+?DS3JFTHB35%O: >LP?<2B=[]2DB\L?#N7O'9D1=YB/"7KKDG MK'\C@865Z,>W)UH'&_8H'XW_"K+U'-$[=TRP!"?N.6;U;M6X:!X=Y!B;PADJ MP.2 UM=39Q%N;4XJ[=@5EI;WI&Z7Y/1X#]%(N>GMBC6"CS(J_S*P5W+2KA_D M,LL2F;J)Q?Q MBT1]@U]"L36YJ9[D5!#BN\OQ4EM<_+DAFL8@.Z%WRF<^27.HJ?\^R6?U!RJ[ MW#7U([F2\1$ZW(Y,EL!FBTW=^#Q'5H-IS/J.OP&@DYYCN&+=@NC=NG2@>V(I MG&9]O: DA#.]C6]6IU?(44K_PZVDRV:U'\K-_)F:^?1UY<4 MWO;5/=/OKPB%Z/F\U7+442/>+=FO2OU_C=:X.%VL# ==G;5S\?[C=I".K%"] M\#M0-XDK^;"FH3+7]WUN']V4>R/]-$Q+[J#WS',[K-J=;_N!7(_O%3-_B_J8 MS2SPZ,O&OCRK''=-;0T@*H3S7K'8/LNSL]A"6)'N)IV.K!9M_ZV:P:?S^/F>E,U)9<,DL5&IT31+:6Y)2&6Z MA1I(J$Y1ZU:.01[UZJLX%4U-FD! =IQS7I9>*V6<,I+5E+[J8(I]SBS8&9P*H5 M.8?(_Y#_Z^N\N$#]Q^$?Q\E@GXV6_XC[D-S2] 1*%53D"VN_G")E3O98>,#KP%)VWVQRZ':ZO>_5]Y1)@!Z-_[S\/]\,=7CXV,C M8\/Z^I)"]3+F" D5)]XJ' M!J\2&YPDF\M?G,4:%E#H4]$Q1QR.C'N\[WIKM MP(P8FVC423Z6R'=1XE]HJ(5Q1-R,N5G *FMFYV< M436;%I1,NJ X]5.7.:#'T@LO8QC?YZ&%S83\W'[+LG6!+WV=R@P<_D;G-/8% MQ7)P$6VMGH?Y@8I(CA"8H]F#+V9B4U'5G!W#SWY]]C]M ML*=W MV\!OF?;)Y\,U?&7Z?T=01JG :;I<86+9B]C"V#HF2O:$#2['')7R_/WZETN. MZRM-P!P)HJD@S#=@]%YBL0*JT M-QWRV.*^,=A':$C/KE?^_R=>CMYRS?2(BB?%H>Y-%"(;*.?L]*V (HT6P:7Z M1G7-FQ U"]=F^<2[K0@@>+XJ2#4/ XJD<#O]E#E;>-6,25 MT^#OIZ%3+@)(]G[? "/.P?\?/_7X]ZYNNFV3C,2MUGAP=MKV)1;W/4TCOKSX M6V5_B/_:\X_M(_84CU.Y]="%EWVCV MI/\0H4W:DV<><8Q%.M:2K]Z^Y3MWZT;#*:1]^3E5^V?-O!^"KX/*HVT<-3>E MG'1*Q).<(>"?*W%+UX .ON2):X!,+:X,RS^HON_?4L]#KL-3V5[SIUP#.LD2U?RU4RV9U3#;!WX-7M8,5FL5.5*- MJA)@H'-"HG-$Y,Q;(XIZ@^CR6B6?/-]/1>_B&R34AMMV1#'ZPLBCZ*SCT&,< M#T^ :Z6"F$7V^!]OQ_'.YM< 3>]@RBNE:X!PY0(6 M"..8%KM@ESD+PC??Z9^=![_YLI4U/"\5F# M<=?>,K]<8,Q* S\/BXU-'N]C MBPW)LL^*;K;$'YK<$_ M>%LSL6U@:HET<%8J!TMONONF0,F74FY^,9N2":0VFIL(T>E%@."&9 M$OF4*=,5QR=YCS6YW/)F0QW$-SFIBX0,M6$H-&&7S2+M?V(><%&]OA-KS+7$ M,#@[3XT&@KI6XC_.D+N*W[ M1OO=B,?O5%G#5N1'B8WY+CK1PS ?Q>\Q([],@;6>IJD'$OX044,[A*@MF*Y0 M]/X$!EUQ#+\LGC-L.E' ?JM(%:U#,/S9W(J1UX^*V_$\37=/+KFMN[X$>H0( M:$/N2"\:'K!?NJ/UNF\]+:]6*!_[*9G@J[K01,N:+I:@5U$H9E1I2#ZA:S;C M>85K@7VR'<@XZL,;DS_6J#/N+!^3_Q?NT5=+8NV)UANCJ]#GCG+*V*Y*:.E% MHNK6(KK-TP(=]TZ04$VS"VZ<# >DS(66Y"QT??OWQKHC$C[W-T$(]:*\OP>V M<35?O^_P%"T4)\;QZU#*TIC?&A'FWNNG!M5Z%G8$H@B! P$)36YZ$"K8ANO^ MIP$^#[#,>B/\Q1-*L2>+B=\D5;0FDB.T'ZE S+2F1>G',%>6RYG=GO68*M%Q M3,'3+V:+)*^Q+?P(+E.!R#(&+Y]0JAA"FIR("_J7UOD;2U^H MORXN3L^2<=@6LT\4N0P?SCCK\,*Y\8&1P#^ACWV?[W]A4]=)6];7!687CPGNK9%O[KZ/X7K#N?%UF+GQ=4YW9"&' M?:+\2 %H6$/HGZW#&O8#&:OW)& %QUG!JY/G9VPSYJ0OQ"NS?9>?HSR3&E%F M@5-\CL<^9L^M-\TRI8G*E #5R(]$3$P.F>)\/<-9IL+[$HMM M"A>?IH.!T*S^,X[6D]BI:X!Z"Y>,%=[?M,R:P<4V)3'/T\35Y<6O M@[ .@)A)-LB3'^H>>6@J:VK]AKKL=R.-U[@.(EYZ=BVAVH,;C+LY1G'W6 7N M\S)%_'S:62ST/#[BV$+? T^K;<@.R++@G&ZN,JP\-AD$_00>]1^,:9^;Y] M:>M+&1>+=&HDAX%KYIEZTPG#$<[X;6XA;921U([(KQE0XP";;(G0C$GHTX+\ MF'L;VDP^WE6\_^'*E M>0VX.V7'SE>)6F(9EZKX%&L"'S[CKT:Z;>6>42&@/0[/6RWT!UF"OV.'7T98 ?[&JIB>^C0D-LV5M!NCUCO"<#T265" M/O4/U!Z)T82+].'!@9DS3E0+5M="J?I"^Q\3%/E1(7)*B9CXMF57_F3^$LE\ MYLB!5W$P//LU..8:D+#9OH\ )[V[R-MB*.T?KD.*VKA> \+].%M2FB!![4-6 M<'B5X^+5&S>#G%X;NRXI'EWJ6Z4A<*6E^!"QII68I'ADG(]8U(]V-XT!;NEP MFK%.)7,O+4YESAJFV<'[=R)/E)Y8]+2D?+?YP]/'%VPD+:OJ!N/VT4_-/$2XKXJ(6RT'D-5+?TWC;5' G;\EW&A6.]X*7;M:"_ME=^5A<6I!F0) MG._S3E*SBIP;_3YZFLX[->J1&VVCE?^C1Z-X]L[GLAMJUM\>!NT? M8/'01R_=5-%XT1NA<&1D[?>)6S>CA+X8WI\ OAY)L7CQV=O^Y!K0%QL^DZ:. MJ\[;CLTJVVYI^3@X.>+=F9E6IU^[;U@.F2C#);]ZA:!=[=I*;&.**J*X3ZR= M9I;67$KLWQ)Z/*>YRG7J@F2IGN=MYXXDF?K ][YT]%[_Z:RD.!<]*_R;"]W2 MMT),+[8[F"1V&0)KJA5%P//% MMWN*0A8A>@ML6N[V=W_RE;4I%QG>H!(T=Y/>-B/H>V@>H9U[$04UQ*WD'DR^ M>>DOOZ_<4=T696PLZ&/-F8Q MF7)1K[#?_8,*L(394R?63[P++1Y\KL&5E19&IN:?&]ET0J][R93 MI-V$*^I]XRPNW[IK^&*;D(--T#R]A;B_+K9S%>&XY B:(#,F6+UN2H5K\3"(Y>3(+[&\X\L M+3)HTR1B-Q6>:"5^F")$V3!QNLAUQ'9%;5*Z$OV":T)8Z+"!/4L[BCK(8'EB M5H04LD+?X>[C>C4[45$I9_1;G%:G5.D/V^0[ZDQM_B+MVDVC0RHW@^6??R5T MA>2O=+- -#@[)Y V*BLDAR>*W_=)U@&6*J!4N7@;JEYG=U8.7-E(R/SFZ):> MFZ47W!NJ*T&M+>EKC_^^DEH1)!P'QV=F3! $*W;?]:/V<&GRDO3.=2>K9^U6 MUX"H!9'#:/_;LT'6=VA?SP'VMRJI2GWO:M;$\5E3\X3H0:#4ZAZJ\@R*PCJC'Q#/ M8+"J$MGWOSD-LKK_FQNJ,COD6)HO@P^4?BQZFC.*Z+_=,0O?;(X(#@AN#RC2 M6#RS3\"^XD7,7(JB-AP\,(+TLO6(2EF:1M%N)[>+,%/%.+(T-1]I@0P:'2FY MT2"LFE8_PXC)(*. ^0'E?"-.%NFFBMW[)P\NE8-*E[9I6^5!>Z ^NF+GP2(8=X4LU2_MCM2]S+7R8.H'A@_=3'IR M7B^-*.Z OX*"GU^17,QNT!\EK,=,S 1RQ)_V?BG> L?"(@2;Q$7KC_DLH5D_ MBC$924Z9W#,D&#RE:7)Z7IP+I^TKYM2*=^[_^OYKWC8C$]@X M0'07+[H9D L0_UN[J2G=7_6G%:@U8:?21/Z$WIYV6.6 LMSA_C/:FQX3SQ>N 1E(&Y?2F)AI7-N,^0UH MMXG;X&!=-68^]TH*//0=R\A\#J.:IKG0(Z)([EZMG1!&&Z/+(*PS/;;80]\+ M:1)X%G%:L9E-^*BF(($',5]P/%/K2M<-1LF2Q]#CEM\5I'2\_;Q5H'N?1PYU M[T.6LJ>N$GGZ_=6E&5/$&1]D,,Y^535PDCK?87N'.8R[DI;C\A M4N9.X7]\?RDXM#L@DN!NUHV_!O" )82S M13//#?R,AB@O-_*[W+YE.BYTNT6H]"'+^^ #3BS,FC1M&I^)I\^(X,C,K.&, MV$M6R0K[!T&'VM:B[S3JGW2#:7[55FRB"NIH(WN2NIP*'F3]/J,X**J1UCD9 M[GH4)\&U% ZD&*'F3<0"4UO1/NBG+\*,L@9GA-/Z8I)B-TF*OG3:'J 3T2]D M>=0HK(659:-^/J.X65CJJXMT[9>>=_V:U]\\,S"%+NMO[/5.F#7V)>Y\\_S- MBRQY6SG0,X$O:?GQQXX@)[TIN%0+1DPQU:\N;0>JG^0!RX\=Q7S7D[XU*RDK M&=7^1/=]GZ5=HL(69^EA:/: 8K4_H9PPYG8BH[RTV6KIK6_G(ZHRRIUFZ,[LV.2T.^CW:Z#0(A:C4\.>-[EH6M NWKXWP\VV M3Z9AM1)U;>)\8F9XWO[B"'_9'8+E%,.@"XQR736^>!4&1+QJ R6I016K-;_Q;C_B?WN)#TVO_'A1I8 >[E_?0^-DR[Y M-8!%.N D&'I1M1'W=V6[>#4X>PV@1LL":QQAHF@G"5$/V1E#[F&#K9A+^=KB MXZR?51UZKJ4#DADQX>8R/*:Z_#J3HXK*GTO@XJFZ%?T,V"W@70XPW4C@OU:V M0H4/M&[Z:>_%= O-@Y_BMB?# M=6X7?Y"D,%P)[;-),U"JR$WX0:%L$]]<3'R35'>!6&V.ZGJYX8?EZ[C\C#TKN9Q&.>]69*I*?68\"1_B,B62:VE( W-^KI= MM\4&0U84 F%0W-X2T0!C@^\-(R1P74N-BG7-XLR8T+>KJG[MP>7\P\5?70_IAN]SA[7V]YY#WY ?A!R#7 P#HK_^?# M()K$5Q.1?KJ2"=]X02TI^\X. 4YGP'TO!)HC%^&X9=9PRK97YN=V.3;U=%7@ M\F/;2835\;#=EA1RQ,!E2)L[2+K-177:($K<1-BD\5PMVA.K*"Z8KQVL"%1"R@1U)%?JNQG?Q%I+4I:T M(U8$;S)WF17MC9WW&Z"J[DJZ9; 4-3=',[LRKAOQN)=%_+2\D>FYLIV6VZ/$ M;.D@42V7V*4SKRD9ZM(KZ>W M5I(L-WB.9_P=-7,/#"I#LK+8H_G&"B/4=M2?UB0K1C\F,E?Y\_G4:PXG()*.>CDV:W4Y"ZS9W*84O>& MA-Z6U;MQ-FTR5^[DR!I3$9TJ)AJX>Y"VN9G54F:2G^\)!9XG_W7#QN_;OG M\G%GXY^>"\^^&V&0BM!\ FNH3P3"M&[9/:'OK$Y3J^.*T+LG^2HDQ-2&CY,W M7D._T^P*G"Q#=][=7"I2C@%R->^E^0?VUQ7VR*::UC4CPE<&MP+Q8?G][73\ M*WM?+C&(,NO\LKW.":$RN@HZEY_D#X:^(B^U5@,QJ9.[)K)$)=X@$,G'\[LQ_*YV(D#?1+LKL?.GYH\N,?+: M\76G]TH4&]_$B0+M6P5VAE?;#\Q;$*D*VR>;6?LX8Y$BF%B&>TS< MWG9V)2K8;8=G+*$BA+=ZH".EXY>.E<'M:.]!*;,<%2M0AE^J&W*U!3G3*KN" M:?GQU >I^%QY)>[/B*3QF'!_YWN]!>^^5WK$$*.Q+TV+C*6T-*VF59X%)XGR8,Z'XOMVI4;;#T\*[\TJ ML\A]ON^:):_PTC?NF=!])D7+7P)C*8%-JR653<&))_3SY[_B>_ZM*VZYLB;D M*MQ"##+G44LJQ@O?[-'JH;]W#6"XD@THWQE.S&8268:9YR'BNMIB6JX!S>>R M@EG%5Q=V,.]6AO17^E,;L;:KF6-N4>N4U?]8%+]707Z2>01S5]2[''6U(;KGY@'I M9T\Q&/OZ\[HEJBZ2M!IH< _O!,:XK9:K#E>1/+"$RBL2AUG:0(Z?ND,8CG(Q MM%#(=M6 6^!$7,?"RR^]+\P0M7YLQ>7Y1850SVW=E1CXC@/NK"X#7/ELI4S, M^CT;JLS$!#M0V?M007/T,[='P4G0!=B<0/Z8K^K%UKO=C$S.#7UTG/B M:\UW,IPN]A^]_E"=8UV!\M6\3*P8X:^KE$'"] M&%85,EF>^UI>U9YQ_/.>Q_/XH[^TJG+T?]!J/1):I5!^)OAGU4K8"OC@T<90 M8?0JA[LWN+M16E3+RD'B08TXT'8-=J=JY:ZN=]?;5\YE)SYZQWV]5/K@%OP4 M!E)U6@@%CRWNN?>3L,F1^]U->]?'AEB^!KB*!BZ=)]3N8-)6"[T>BGJ6,_]8 M7-;EMF*[L_A\U6/AYXO$MP^X)/V=W[ A.0B.S6[7@/&8I$#LL'!].+7;BD%0 MR.**$R4_&9&DUL!21Y0.:RBEGL/AKJE;7)+,2[3,"M3]PN$4V7 E]IJ,_S1WO9>!ZYMJ+RR.)Z8W.ZEDB*G M#UJ2XR/DE $EO4!-CJVO$X,GQGEFICC3USP\S>3BJ,]1(XA [")O],0:'Z[QZH6A)3BN"I'24=09W.U(&\A:+V M4/5_6I=:5U8G\\$!D5D*]*TYT\QD$R8I<'MJ$?W]0C4[^B)X'4/+0(7RY>=>YJ;^K_6;:SS[W2B(N^34 ME(3KW* P+CKN-N/W1DPE*_.*@?AI]).$N^%O3_LJ89PM=)<3^W=7%;;P_C+1 M]"3O3P_X/'VR=;MIMUY-X& ?)"KD(-PL):KP'P &3/)$SB ,J/=;.V0C?#Z5LGG]Y#I5G^ MLDWWPSWDSP]B9B-C=V2U+@#I(E]S21LM._-DGK5]V19]4V,ZITHZ[WP_U%2M M^H_ H.1VS$./[D76P(2Z7A9:3D[XGU>S\P-<*/'Z@)6"L]1Q8RZGR8L7FQJ) MN!*M49J8GTW%L#$63-LZ:?9=_6I+G-#I>;,P^^Z0:S.$A3ZZ8A]D75L[WJVC M+ZE*OCRY@U&/AOZM6O\G).*#L-GU=DR[A M*(0S;6?L1*Y4C_MH,MWC/E<6^MT1V[QAO!$=EVM/,S2$KV38-X-](5Z=A-A M-)EOOA89"-0>) M/IK^U#)L/IAYQMRB0\I96R= L"-94TZ+*D$*C;X]! EYCO*0>ZC2KWWYL_[M2M>G_C83E=CQ+7R.2%G_6E;1-? M^[_=K[!TQKO_.-K_[1@[62G^*)TY)G=9!/T=!YZ8]K3BV&BJ#T5G#:D]4RK4 MW?*QW1=!N655I8$W,KIO%9[ F_ZJ'SIS/X*9+LJ8RQJYSF[A73D3&L;/F[<[K(QO/K_@LIS[Z^2GF?B\W@*MA\6PPP[+>]H2I^?Q>Q+U/Y= MZXK*!\C,F"H;AFR;1QJ#5VSY7$]\YPZ]<6!$'7J2CD=P#7('6]RU(FH;!'N: MD!_U\2E%$*^__Y+DA+#TO8>NC/B+N'Z@/L^.9/O0%#(71K^AWHR9]>7H2F"> MD$\[NO>CVG,T.4'E-LA4[9'6U7P/MJK!,&6PI"@EP)./1 M- T;7)V6/5--1H6]^U'PB?$#ZJE^M$UC;S<+M:Q.JWBY)PJY&IT](( M/ 7=U0/MK7D>V^UNJ)7$ M?8]++,K'^A)IZAT6EK%0<-?6>TQ.Y);O4!X(5T[8MI@9;8V8*]J$DE!%?O( M_O)-Z'E:G^Q?[/K< *#FH)% Z25<.6;;8CJ[53.O:)-,R_>$;%'TVQY+/(?C M\Z-WL^^J 5]^93+GB<3U#1+& @.G",Z+;5V\*1'>)SL''&=>>XOJ:0P+6+2$ MXU?$)):^5P>$/;OH^]G(E5,!UVA6&UJ*(C;Z*,7M0W[XN)OK.YD]>GFPS@^+ M!,:ZKI;MY&*:S,&M>T**K,DIKG%CS,F7I*:K8OUVM8_S4V$_C^5O].^.:> 'ZK5 MON%4J!'HIZQ1_$R]_):TP5;J"?CC/+,$(4'G3LZ*> MIU=Z"/1(+W@.\WI1-7V=\)Q*A:1T>M(S2_@NQ$X\?K;'+B!/ M=EJ1KS2PO&[*>K;%%V_.=5[4)EZ4>V6+SXH96&R5B\%$KP\MGVY27K3CL?;6 M6YD5B?-^095;,6G39Z8=23G%0UL#(@K(^VFYO;TDQDMLA>F)-#:?/OLT[D]Q M[$BV-!_<9<9NWV>?9G'.?AC/^>(^5VX_4!%$2BT&^$CG9M+0 M2QCF TNV]R E0J0G_P>^2:DO#Q>)+:5[Z7F;Q#(@X&Q!:R]O@?%[4-@TS57T MC%0FACX0([%:5RNMO/UPZ$'A>5NEB+WSVE[#F4N6C.NP;)-HUQZ.IKQ/R_)E M/#%F Q \8IE4L>]8983"=3C3PL;35QAIJS M+CSV^1)H@CNV_#7G$YK8NY=-%S-0'T;M@+Z/@OI[W4VPU,5K0/=L54*&1&! MP.#V1=%;"**?(DWM=>?J\]HC$#J[$GDU-V3-$L$6D?K"=*6PJK"T,#,7:M!! M%31D)'+0JWY+HB+V)VK[;9\2F%*X.<24\SRY^,G@TQ)QUB<5Q *HC8*W4UE_ MY5$O^';KIFV-&SJ^+A'X\Q/X6:I*BVYIY.JG\6S2-[2_\K@J*S^SFZ_<'+\>U-1_U-V]-=\O Q?#_?RZ01\7U@,^YRWXD_5M!JWJLBUUV82>\@>-3ZZ) M7AE;@MS$52A-2"AI!/T>ID@*E1!S)\%(Y?M,(J!>K6YP GSY:T8=JZ,75Z3Z MSXF!6J4$MOS7M\/LGM0]HBC@Y^3W='X-C$MN(MM>"\#Q0'EZ_03ME$97]1]G M1)=]LDE@5E5Z_X!X@,6.@4O%6I>MMY+N6+-G/@/X8&5-/L#@C*^F5LU1H;^UB50LET)R:44WJM]PW. M(V/X0GPYK?2JSJSCD0QJJZ1N*ZKX$5YNNX9/>+=0;MVA(4ESAF[E" MOCB@68$-6T4'7.R!Q_*0Y>JV3@N.#$93804SSGE +HB.>SS\^ WS*^TG%/#8S23N+12]+ ;Q!209_MF(6):/B6T=7\UA5J,V8F MNP-"2IB6*#4)EW$XPFONFCP\\N66UOLHR"Z+SQ@&:7#F[!%7M:".%X>_ZF.2 MYT3M5XU38U\5<0$0(8Y+"N$O\HA'U81?D?4".Y^^NT&=IZL?C!]&B@0LMV+9 M]] R@B:]=!Y#<@]<;XWE"O&K4^LE6JA^X$YH?B,,>)SL])7AYQG//K!>8HI_ M;W[!;7Z#HFHSJ&5:*@'7,C7_$6H#T1B,0S#U3QX5F> 9VJ;/Z.ZLSL$([A;5 M22N;]ADL8SKZG8#;N$#ROHE%/G:![!G'K %4Y/!VQ45V>&U?:Y] MGU83'4%+4>30)\7W]I7.BRG^5L.952EB]@XKFT'V:YCHG3O;JPX\KBX7PG = M%UU-H22U*KIW>8TQKQ43%2=>EQ:@[+9DOI@2]D07I[R@5 -!!9O/D6U&VZYM M=>>+9NE;M*&;65>].P.Q#V[4./\9@VDCUM91\CA@V/.#!#L@.W_]H0]%M:;Q MHQ@:/#+1S^MK$]IZ^HS1#RT1.*[).@^ZMX>G9+-/9KQW"N5XZQ39G6U5>@U(9R!TG/"I;<6NX-M",M<;T,/5N_1R]?.D)WQ6XSM77[?H%^@]7=7" M88]:/6F^P/A*.05U^1?+#L9'\.>?7>5=*+1':"$.BU1@AE$#S9J=C/"?M5ZD M\S[(V99>B?373$WAG+X?:-DT;_Y^(<#*;4?Z)%ZZ/"'H $\?2F _:7218'R) M/Y$(+,,F->7?!'ZQ&K6Y-\+I2T5[/X')^J5[&-'&]L:PM%% I R-?U!1T)*( M*=1N9[ =#='4.Z(RL*ZM-R"N[,+/#6.3@;(6KAQ8,>$ "*Y+SZY654261: G M^=4?CNQN+@46WXPD/_OSJ99*',_^+'Y$EN?GP(IJI.LW6=91![,UBS*Y-^H: M(*<;K')?,_IE)EOPD'4P?,HMBL:-UY[3Y(WK31KVI+&$ <&R%]DY)=X-D@54\9$C_&)F>LWIK!=_OWX 5 MN41LKVO_,7Z%HMQMCJ+(??#[Y3/!+KF&.+TT(AZU"(0GLN'KU*.7W?UH^)%S MHRO!=66TX!?"YQ\=79![_Z^F^ORIC*%"X(Y1:BE?0K8,;+BIU> HKEL]9<_+ MSA7\V;3AD=F[8TV(+B1H,;K.T^?2N>8$SS!8,(NF8HHHFSWR]6IJP[8&&94V M:A.?R^5UZ:I2J(8.]TMC78",'-O-(X'-FGZHF=.N?[KDQ.QPEA>)(,MGKHQ% M]T!LB6\/GC\GUEN),&Q>]SW6T$DACUR/CP9[/R]V[MHP2W.^-W%)\6$] M:H/N+G2'M&, [W GV&=1!''8,[I0/6ZPG%L\#-*7NW)26LK0+#B>=,Q\4T E0FJT\4W#0(25 LEG(R=Q7!1_NO*:S& MS&ENM/9R/Q^^617G/:4R_(_]%<.J,JHT6"Y''B7\YH_P#UMID.B!T&E,_94N M/NA;$AL21;1R;&UQ?**HCN9'0-X4VRVN>%_5I^UD*SNE.?JFM) M%!ISQ/6.K# GQ7,<^#,?06VC9T&P1 61TL;*EM6P]Q[ MB=TB"&))(6^'Z9?/RO@;.DVRI(K75%LU4&V[MEC$1/KSE;Y/U05(CY>).XCD$FE9%%M$TM]MNF=/(,-4/7&=6^3,"R_S6@Z'AN;PB$ MKVS[48F;/3/=;)/@JA7TW5"YZ)2@JCS.8E8I+37Q?FJS#Q(8&QDM3@SF]CAA M]_P9?D;8A,Q7K2!68BIQ=DV^\9*#E?)1SY_I,048YEN4#LDY$$FD\SP,[ VH MLFP-(N"0F^NN3>;.2,-*,]9'@LX)5E'W*"+-*1W_E@\)M("AU>BW9%N/$H-9 MS[-;(?9O J9_>'^./^$=GR=D%TK4?=.'+2!<[:Q+J^.W*[]OQGZ?D;@&L#4> MP*QE9.OF EI%V>YHET:PR,N_"WN6Q1RZYKGBIC_G%W0-^-)$[-IQH6"@O3&[ M^V,TK-&+3E"6FXL612/4]<=:3\%6F/,-AT0JER?BH/_DHKM'8)N\&DZ.0C2_ MK,]QH^M^.*),W%49KLZ/HNY@>?G7,E5VG]V^Z)&6/\+S]8+CZ*WWK-T.L[;R MDWR\VS1/]#3KK+>',)N6K(GXRY',+9(J4]+O&Y+#=@N_52Y$I-4T_.E\I+R) MF$!E?R> MY=8:@#15 -IEBZ$0\Q:K$N)55K;' M#],DG:\!$"]J23KR@ J7&'=K[QDBX(XQ"P8>P@,%K1I MF?:> D/2&7[[,P6_1&,\CW%\7CX0LJT&80^A[@A_P+W(4X9D#1CA"-73FV?\+&?T;]8H5 MWO@8'&\N$O06Z)4X#G;*;BB%12T[E3GE] DL9 [ZI$4?WY<;FU! M- M74V@EVG4U6\7]9+&21>^O;Z?@YKZ\07I2@ZTU%$]U&;&RQI&&(3.,)5Q/GIH MP9F^)[;S>YDK^.7$ Q4[DB559L>D'SJ/=2UH7RM)W9Z"GSV"(RZ3#P:'UGGW M&HT4O6NF,WR,G?VZBHUT7H(I#9^J99%]"2D##-V_FWOPYJ([R&3[JGF]IN%* M^HAAR,)SS>D9,;V2GEWLJ1A2U1KL25O9JL2Z'Z0_%0]EDM12J)*)W0-\ B:R MD-V_V5V>!'QL,TY>\K0?'\$VO9TQ->E%<8%MLN\_1L=G/<\SY-B;>_:$Q5/. M2NN9P5$-?QT1^[<"]?1C]FO -FGZ:54+052BOH:^?X[>=0P6[;LLH@^R%OPB MR6@)QC4@G/9K+8[-.+B,44A>&9JT/NW3]04_3XH?(K7W"T9CR%TSW/I;O0+# M)\"^QQ*W)_85:K$"$AT/>JATRW-?]7.F)\FI['$V,'-@1'!) :L$DM*Y?57Z MD(TS%D,W&OJ%L.4'I7I:=+8IZLJY;+XI1O%O$%5#?],]]S1!=5]6JE&: 1IS M9VM[/@9-5(6,Z):LLF3"5Y@N,?'QYR-G5Z$](6TY(67R M'R^5[P%NA2:TDWE#":FMHGS& 1>+'IKPR/6#Z< 9O1<:[;S:T*1H?]^'.S MQG5ZW,QI>DP+O= G16$%13ZD56$Q(<76R-[JO50DP,4$[8S:'Y8$)YDH(8$F ME,.T%4)-61L2D$ MY>P>3->]X'$Z>*2H_#BOHX!>1SZF.!DTT7/@:YDM!H:+ M/4J\_#,CYM2UY(W&X=D3TO7.?4)E1M.L0>JWTW)9-^)KK[[1/KX]/K;#X]G- MY&G>8LS!/:.),MT^3E(Q^L>*-3C^8Z/E=2K?]I^_=WA-I6.@EIFP#RROQ4GL M*BXQZEV88W S']?G#Y$8&/RCJQL^9T\B%W7"ACZ @5U'MX+J,#Z'&6TRC="K M/UW+X1*/F[@#=&N6-IPV.)[WQ-"05,%/#*#9[DU5/KB"E3.^UG32\+!"6(P2^K CKU0.-*V8]W#3E>?A+ M%6\SA]W?O@8@/2L7>B0RE^O<,&C#>Y63PB(%UC'3JJP@LE\RT8O,G%^4&*@3 M#/V-19&2Z $@F'.;[D.36;\('MT0'X6WUG'2>X4+K977XB'R;65U*+5\YFLE M;_M''H->.ZL2YAW=POTC][73"T?69_6"+6Q_JPI.375$8F\N/ M.YN-V'"=;T.8B:.W/9-9B**Z0"VLXX>@@;D7]MPHS&4F":Q^=B?C5_,G [:# M[@=&ZLQ$?T_X+E#.O4^>!4RI:*HRJG#G6P$4%ESWH4HD0_W GZJ&ZU:K[X*S MME7-1LAPSW;OZ>:X5,'N-2 O(WV9W0"9,JEI\)(^J=N!A6SS\'T@G:TAHGO7%CIFHBZ@] V]\?A'B38+ M[] -HKPKG>/2N9V4XRR'N>/ '7?UGP6[3!B]9]915+OIQI_LE,EIZ%Y%4:@D MT$#B[Q#E?=@57241'7 KQDG ZX ->["=,@DNS\-K@ V?^;8R,EM_351D^B/0 M7+,%E><[OK0'RDBJ.&DE$E1,Z.K74;]M^C)=125,4 ?=R(+54 Y2G./&DREG M@)OK8UMX02/22%A.G4((4P<(5I]"BC*@BP[(=TJKBKRFVP1.'QUX<9#KDYW)-C9 M.EQ^9ATOTJJQDN6\6G8Y:ES1B2V=G8U\G'1K5E)',N>'PNT;LD\E8V$JI35_ MKH;A4FVS31)POZKT':0R+_2I9YFS\V\F]OO-,E3=R:^4)AR(J=.6(7C.4MPM MPOQ9]$7B-!K(7RU@"IP4O.C;G(EFD+/!\FGBJ8DK$'%()N'GT.)1EKG\7'R^#ENPH9^C%#KS/U9'L=_0"V86S"@?DY/C7^1H M5$HLYY4JA9B&7K9YKFZJYP6C5I*@AY,(Q!71G$2^*NLH5G/!E_]M:)CI8[3$ MJS?Y7&)0^&7#M-]',+8)->8PO]UD@;L4KJAH>W\2NT[6*X1\^J69.N?MZ[\< M_>HU^0O/_K K9TQEWF+5(#V!@2H?S='22OW+1;+"3;-(5&05&TR/KKL[ U8& MU7D9$_$;TDE4W4\IB94,Y^#X6 JOS7N4GO=N D1^](3??VD&([=ZI8"9-?V! M23V93 /QD@FU(!PX695U&4DBVED]WT>SNCB4]OG_E?T&9^@$Q '[@FL_85.C M-/4^K;FQ<(O<)\ZI'Y:[RG3?F'N!Z9PI4@^!.\O(X?D8@EGTB>ZE% ME%_-_K@BQ3)K]8JYFU_N7I-Y,E)]_."-'N6!"?<#9S].+OX8JW=LB*>.S$2L MB;3QK,1=[V.[_WGB(;JC#YN'E8(#6O&^$$[SOWJL9%KP-/P=$Y'.WT+$,)S_KDK M';K>BTH2.]^#28N?Q1A2:[]YJ"W$)SDZ4,L9GD+/$F/-5D_)3?Z[S&6E]=W, M&OL2U^.XBI 5'K\-\X\2]F55IZ,E%/R9/_N] N^,LU8""PX>,6KJ&Q M5-=(V.[AV]3NW))<0JI$J& M5(=BK>OR)RG]@'!UBXV&4M\CYS/FC24G5,.J\2+@T$_WRS0+Z6<[<)NTVS+T:N(T>W(:'-,TGY@!+7<@P):+('8>4DEQ MIVL3!"]?MXH)Y'F'D\L0JA"7$IC2#-T^5J\Q?1Y5)O%&458Y"EYJR+C]K>#= MSS;>?7)CG_E7VW5N-?OE2+O9O@DC(IC$3SJP9**:]6/%APIR% :9:?GW +\, MPKZMS+V-!J/6Z"=-)Z5UX5L80Z.RUV![W[R8M43ESU;W%B-[0LJ>UM'O,Z3D665L?&BW>^KIC96TS M9P](6CP9PLZ,GUYF.2QWU!_1B$NV\+RC:/ >U&1YCO,SCQ>YK$H60SIC3U0S M8Z\![EDO++D>0D46;X6>&OT9DK_>-@RJ!CG>CY^3#RYT?M6HB*I.=_9ZWL7C_\8YWF?C;\\UG MO+,/3K37KQ(WSCY\.&IIDPX(K.)Q%=+7L)VSC$)Y:R4.ZD2+)CT?<%\RSW Z M?$9FH E&=(;52@$'3@@/:%%6WWHX6;\/A:>P1RJ9W76:>E 74UF45<%9--)Z M.#WA74#!>6$3#MJEUO"U]HYW$Y<@G>K:$N4"-P21G^[O2AJ)W^<*<#^L&U!< MN[UWV]X9K7MJLRF2D/&'BG6U?&0%^;H*H"L]>S1\>GR] 0PW0;%ABQ^B?@WG MOYXT/DM@X#$'=S-H,6;KTO_>22[(YQ:Z([N3W@%?[>A1,%@[6P[4<64R65K" MVWD"9*R51L=:7%K-M"X N%+RI*.J55-ID:LBP#9O7QV#==J%0!VWOQ8:^+9Z M>S7PFK+JER&?>MA%<*+Z,'.7B7U9;7!=8<<4+G=F\7SLR'G&&EC0$]I^A$=3 MEEC7\6U"O7&E&R%"N5E; _P#';LE-YW MY,E!)P)PJ]=Q&)%WT&;=*XQ!JK@YMA@Y^CF;1]]M_TA]0/W]DYK)Q4<+GX>- M0Z;^:\EMUMW_:YW,H\T(>I"F]7]Y& -3 +,T_1 MN5!K;6,_PYEE@F9(1<5ZDKIAWK&_"]8KV#/KV .:5@]J>&4 2+@:Y(Q(^Y8C M[?:MEV.RJI>C\E[B)8[&G,C@$=@A$-X%"TZ#E;7)=2*[1=5) 0\7803=&V[X M8AJ6.(,ZEMARS6.H/U7UI;Q?B3X"B M!RB_MTV*1YH5UV&M@99&#Y1[I1*'&G#78?2BB^)/OS%DWF>U,HP*YK2363WK M F+/4M:X(H##0L,[P8G7GFHP<55/(Z[RE3(%=L#S7TI2ZPP;D/;>2UE<"?=,/"W?T1O$>D*!LJ?_H0; N@S%01&4[$#=:EWO M(O(F#P]G< M,. 92H&MTWF[?5B4? OZ6+LP,8+_V9Y1H6.J1EF.^\>RIZ_FH:\QN(Z&?>&- M$5/I;_L@0B[H%_#F<^U',7E/4XV!U!*,POHM/!DWJD\R6L\Z5TG6NH MN-U@A+ZW[24*%7[;#VX).*3Q&<- MC02L^B'#WWHKE>B.(T=+HXZ)<*Q\XQJQ@-O41^A; Y/9FRD#E0L&%A'%'Q&( M]KKF?9/U]J\=MKI ^!PQ4]IKEQ_U%G0_R3.9J5+7C5]+[Z(L-_YOWJ+4E4H3 MOAPA6BF 11&;T/>EFU^Q9T1\?OW?O(6\Y+TD3NF41$@Q]&Z"X$D0S*SE3+CK MQVZ,H2D9&Q$1]U#IY93@A+P1?31@M1,(9Z5XXX*1V'\"E-O? %5:@X@@)_;? M:Q_'Z3C\'O_%AM^?.U.90'G4B#&L; M@P0D;>][_,%1B%PB6Q-M6D[;T^ 0 W[7BL\%4ASAUH<4[]7;_F?U.!<$[BJF MS:I)B?9;-RN.\8XZH\K *M/3;F[S.X]A4MO&SO+7C_VQV%NZ9.7YLQYHV!>O MW(P)R79I&GJ(CY72(VM&@72W+OH,Y^<%@L#9OR%-@EFW_MSL0-9)!F^K$]O6AHTJ E_,PG <7,YQC\"%IA9E$2.Z$S8$0] M_-?27GPV^43VS0?$N>^$?7"GW*\2XVN_S_T(F#-)?!O><.^+G9/U0LX8 U<.]+H(=N9B$_ M*K,C)*DNQ-,/- B3KCN9DP5 #U4%PKUU9@GTS<;''@D=TU U!\&YE]\G-$RS M,$9=6DDQ5S0EM!"WO:18ZW)D QQLO)4(=@]#UFK_G+F?SBO:_W_@W.(!.IKQ) 954HPVAD89)O!G8]?K=^0OZ,=IX&J_9\ MZ^QGC\67BA@#267S$RLVN:U^^$[KO]'.:88;ON%:WN?BOMNQ<)74K6>\D?I) MDR7CEL4 9^DX)[4\'(%##*MI-Y[U"G@S%.J1[[G7-&*OGJW4NI5;S'1!K*@& M?L6F'HB&LF$M298+G,+8\.4,1)QN.32&C_;?*@-18[?,8ZJJ*NHK<,8?(W[/FEP[?Y]PW1EM-EAKR<>#$WTS/18\#[4BIM; M;(SH=SAY1R\H(#E9FZKRH/@R=4KJGL"$YHW?$ S;+-"R=LQWR(]H23SO]87* M2>F9"]KJ.<1\V++6W.#2CWWZ/#I^A*-%XF.=:NX/]B'>8W\X5/=VZTRMZS8I MAG!TEH0F7],""1;\VI _N H%C9+RJSIE$7ZK%4_\_.S\LY S466LYK6==U.+ MRS]GKXRG]MTA,Z>\KLB$OIK^M@&N^785QH542=P4NN485*;"'5A!]<&"*WH M\^K-[?]Q1O]V###Z?SO]I7SZC>F2BZQ0+A,#M-TC"N-J4I\Z&O)UU]7.(#1P M#N!_NP4Y$:2_#"!SHW\!*"MP MY5S6>W5":D/:M3 M*D5NWZ7(_I6*L-N(H:'UBL?)&$:,57J0A>3Y>QNVY/<5Z'R ML3OI-<1:YP"<5"Z@3)"ADOPHTZCLAP5X1J'CVG%51O4A,UH? 4?"5/X" 80@ M0SF97ZO2,%9DD5>AXRZP91^S=@UL>$HW;\T\4\C>D/N':G6A6WMQCS$8!.HI MW[XQE#:9U+1ULGFCHAQ.(@SHNY*CQ#DHLWH3>F=GK&KX$?H]8\$[FJE]C.$$ M/YVOO*VFH5UM(%V$%ZH=[,MU\2YW;S3/1^%- RFVAWXG#]Q-]'*R-?]:_)ZN M"(9T?T84!,@EHH1W6//-C;4X.8S&>>9<[]+("HZ^-#*2!X"=:(&?\_5%>W9Z6$!>KVT@M_ M+M=*H4F)Q7<9'#J/SHR!UER-W:JCI24<:; V&I@7_.TP!%"=V[,(9!WO=0%^ M:4'D>;X9<#%%:4 M<'U.$RGIS![>J25JA.C64VB6I%^[D#M-P83335#O46[JPMT?3['%Y>!,RW/1YW!@9;36'=O M")#V.R#Z@R7W(/H>QE/0G:E/OSF&0W3J']PMH+5WJ9TR\3&<-O3=L>7H'ZH' M^P#/3@73T$=# 8HV#KKVSI#;>J;>_?X3BCXNTJIJ(FSBW.@GY57N6X<'M$(W M)8[**U?*:G/:OJ;--V%".^KW;RON+?!Y4YI-H> AI-!*W8_WK7=^_JTL9E.! M@A9O-?*SLF]<2W"D9Q4XK_$[[!UD^4.%"2WN!.W: +$\/T6X7U-Q][Y;+"PU MFY*D?G * M(T"XIZ= M(R)'/.9OD1OVA4@;P9XL.]SO]<,D*P>12_$Q^B5M&49168]C3)!W\]^"WB=^ M.7=E?=N!K%MDMP]]_7$#]+>UM7?OS,= ;Z_1[92'U+D<"G_+9(TN.:*8Y\V* M1&NR[L]:EJP^ZEKSK'RR>R#Q0#.F?,.SDJ>LE!OJW<+LLM#N3\(.CMLN:#>V M8OYNH'*'*>+,*FHNTU<7?GA*0A.!%U_$J3PN<,HKS3A,@6I-!M2@CSF# MO#;_]_K PS>25"D%!6=E&XK_/'BA7NJK%.5A / M6@6CH$JFJ3JN'J 9^BAY'VY9YOSVQFO1.**\ T&FD/BUYW?ENA5 M?J6W'K'JOR;M+W_XAPKH]DM9 KQY-TO\$FVSWCVS*]?TX^M[+E!-QOX661]V M?I=[_.D/5990#1NU2R+^A?@U^Q]8Y0O<;_0"'V!NVMVA5:][KF8?>KF86(/= M3^P,\=[, RT<.VKL(JN M5:12%L5-'W7]>P4G] X1O=S?-+MWV80YR+,F:^'ZR_<2IJ(V+5S1GW,JF[F7 M';38B%HOKKV@1>&"I:"WO1>QA[] <,=0[EUJMUH'M(?&76U)XZ>9"3&"T!8A M:M:+^(;=V\?1IZGS4.4:5.\J8V^\:N\6H6>3]DSN3'N">>)^PM2OPS_D?K$7Y517$WM>HD_OC!?OG$5BAJ:R#S6#0CK M69M?$MF-*\\6NORK_^Z)0W*5)O3W5EX$QZ1$$[P>VK1?!I>K@T"0?G^HGI!J M6G%8*Y5ST<"[6DIR8JKA627\XP5G3.N/HEN$8>#IVXK*OWE,RP&4%M>XNY\,Q!N)HFZIW2/SE?NY V5GH&UA&3?IN*:L&-/S;^R$Z)Q^)&G**8C?2%NK3+Q5!F0;>3.)D:FPJ&M*>]&[8LTQ M1,9Y"A%L?4KB/&"B'19F+]X@"ZGG;]&5O\T[T@#"=BO#W_A+6AK]P.,9PPXO4!0 MI-V=W3SK2.Z;^@'A6<=CBWV[T5L>&WO-]3-V&T_V-VCTU.C]F[Z;O;IP@\ZO M4''>;VT.8R)&;-02^B"FU@:[1160^&SB&U7%XQC-+9YTB8GU<1M#\L49V"': MO#X-F&KN)0.3'ZSWN53BJUI ?<7C03JOOD11J=S)?23=L@*D#-75 7#D1C7( MX"# @[H>VKC$;Z.+6Z('K9KHB'GH LA%S+AEZB%3JT %0H+2*./^*9$O)^.1 M,SB]_E%AUG'C0NCJN@F6/'&>OC,58M$1?C4.=2DCN$Z_Y#'=PF>(05,W<& MN#H]9&R'2']F%%+AMD=C3'^'&Z![,PDC-RI3%@*?)VX3M=/\\'"\?"G^RQM; M9MN;D?#6L<6O?D[&L%F,RLU(+5&[O]IJ_*]NF:_9KM%.644!D5 *H6J4PK] MD,;;M[@K8J6O2J@!%EMZ(Y/[S:,%W1W2W'':_KO%C"KC@!:*K[=3\7$00&00+6I=?#=O#]2/A\9E'HV8;G0,3>A0;2=A]TE4[Z/TL$!"0\ M;HYZ-MM>FP$SB5%FT@=]6+W62YN[5USNSZK;[F=^UL*Y"C_+BF J3]7X_>7)?#M/28?Z MO7RCNQCZ=T:&7_G380]-=[FBU16BXL6NZ2G^UXCV/OH?T_5OPUGQ*(E3]>&E M3^ZI&[IK#1WPR0Y ^[E9J.L\EO.QN@]SVHJBX6_TR==3V#"Q@I-BE:%SR7,- M EUST:T$CF59,YF8(*P]E^R#A"^'P7 ]?BLMH*."Y8]$)8\4)H_]JN.R.8HRDF==,=\$,-NM$>RAKR^N0_9(I MW+,8%Y3WO?[KK*5I_5,9IDKMJ?C:?#K9#!&N\>O?U$N9=5LIZ2Q=@X#.I_.U MJ_;M4984B"/3Z,/'SH;>'!'V'V\\28PY+/0E\\E\R(*$V[=8#W0% MWT0"1"QY_%I?=*XH**[,M._3]4XN!1Q^ M*1YPY/^[/QZU3./?W@9[Y]D(PW,J7_%PH.#2PLMS^29MO\M$IZ>4U/++U5>< MRG8OO79A1X=]GH=9$G,SR);XP8KK]T]'SP1??4EX!=\M:=JH\VAZ*3=?5DS7 M3M%J$41@101("%21P3V!XX]2#:+7VF $"5B88J3Y)S:GM!>"%YMJD/N/L\IQ M@2@ZURD0?TD&O_1-BN?-XPV8!T,WID[,[0]5#$.H9XY?*.)7/GM9DN\W$"K/ M1Z@:&K\TZ?.<^%%O\\BS;&GDELSR)"BW=IV>QI-M^5F+#347\.('TRYK188@ MWQ&VRJ@/QR&GL-P:^,XWX!#AS#7[W!9KZ <\=N>TSD<6'RNU(?W=0 /RBRT* MST!A/?[%=8OS0>N]!O95TO>YQ9S]+,.3#24%Q88DUNS3<&@3Z^GU0J!,.$G1 MSR5A,U3]/ *0S2G:#V5RVVU7G1P7%'SE+L!PZPL?'7W!ZAZ2A) [G=$F)\8YN^4G2>.FU.M5WL[H?,XWIZCLS7_O]MC4+-1P,, 5OQXOT M+\3GF[?).HKGXZ'LHND;H./-FIFV&?"*U*U3;(#,2=@J?.D;B5_3JH!9*+Z/ M:3#,RY\KQ6C"6.-.#D3$7TK!'G^,9K.?K65/)UM^1QHE&EM6:44O__H^VJ9, M!WO1S^7' S,H$6N\Z%(S@L.G99$3O3]D@04^K K-[PIG<&:8K(TO/3L5E1 V M^KZ:W.RGQN'NS*\L(*2)<0B5/9;/VDG\=OQXC[,CI L,(G0=%7:<2XT&=MH$ M$EY?F&$U$,?VTK7Y2@*4'^?BCEDQR-TIC(K@W$!\>2(:WE!DX:^E<=EH,\YG M/='@72:<8+I:8-L>U8,-CCH:DNC;MW)+2&E749_BM"^GAHGI&]W[FI\=*]1; M(*.Y\"^<^%\LM]L^P\09X'W70%)]UH/F3GRZT>5Z]X=Y[\^"?Z4=1P!Z*Y#[FGS7D* M&H(.>)(DU.>Y?=SZX@V+@2.%\@VXMD1R_D(JXLH:3YM[ZL)FL9285G6CMKS] M[@&=6@Z7]RWS"R0CA_S;^9&_TB!>UICQL\)?B,# /U36WHE9/^-%NM=FPX;@ M392="H! D53S[V/:E!8$W8^FH(0%.,3DRV"OD(T(0%EP#T&84C+5-:3OZF'% MRIQ@?%L6P 6AS4@DM@[!V+D+M'[<&K'W_&4C3[,;0086Q_6*BFBB:F+U 3X< MWH@#(H;*"H'"M7 LL7OGU-)4'?2H/=D=]G(Z@;E7;,PI,B)QRLG9>< S-%3P MF!O/SD0AUZ+*5D"S@X=)4%=9U..$7J!UI.G[H^/Q!VPM"[F>D-Z6$ZS+4%8A MU)D?P>3 ;RF0/;"Z4EE7G9,7;1>1\=C9TEO!#_UUR J%]+)J$ ,RAUA==,J2 M7)W0I>FN#7X1G:Y6$?IL.9Z?+WQ-6-T8OK\N\#>-2NZ1MAK\OOX-!G*_VUG/BTO(B2U:%$W %ES;WF"/%N/)%N>%1=Z'P(&QGR MPAWW3 JQF21FBJC_4DOOFI8S+.5QO6V\7%6<49SB6!'Y,.4-OR/!9L'[V#5T MONV=EYT(D=?<4*\R]3/2[.)UD_LF5!%&R=3+D\$8+/$/E:!WKNE38/R5LY(M M?E-^S9P,.VIN,^._T,!-:>3E.\_3H'.[EF/6R :*^*JB]EB@SK?A'V+FYX,; MI +,]DXJ?O7#?$OS5#JS=_"*'R53>&O+XUG/6B7V-YU6ZOLA7?76GV5_ M&X),)M9M$2=R6&N !@Q]!]VCR4U/[9DJN,7%Y\Y85I]1@$+[ MFBW0@/;;'RKW58']#BO.R(BU5:[Z%O<+5Y:,$UP+NRX?"8B_B8KO4=4?]Z__ M0Y4I123B=D"0GA-2UL]SN\F==IZ5HS(LQ?1:_=S2:Y+D/<&V;SA6"CV&PX!Y=[C/QWE9+ M]2\MIVEO>++QQ@%R+Q\WEEK@OM?4Q,D; 0O6+;9A6%T1((H[6'RC $!Q?R!N MVR_[5F)XH*IHZ3%M!O_T&K=LOROK192N0^A4[CIB*.$/U1CJ#U45>'K[TUSG M;?B,XS;;W-;0@>4H:Q&LL,S/.!"%<03%LUFRH\&D'W/!@14ED7:YW%KZ2146 M(4?HI6>\[Y6#6_V8*(%]EI"GQ)G4.0E*VE>A]M$X3"#C(^K5A,GO&_P9+I-W MW]66)Z8.?!/ =R5G8FN5L,!Z^]M+,N15&J"H,^\YNE5HG;O M93VB-X2K[?DZ,U75((&Z08F;)!PG)\VWQ"HO,16NTT MK MX*W8'E$&2#4.,YVNA&Q((]\-L.QH L95E38W,J'"GTGDA6@:9]1Z'^BKY M&VM<&IN?INKU+;KBM[%04TB*N^L;36:C%BM-<,1*#[8VIIL4NUC>P_AQT%?WCJ^#WK3 M1+6G;GPJ.?Z&P4$GZ?G?\OB9O#.0L)B"RSHE*O;9'.O\^#XZYNCAYH)]=K") MAF]]?=XZ#+^N)S7 47S6!>+P,%X1<9#ZYA!N9")D2Y M6%TW>7/-/M+39PG1ZCS[?7E-QRDN#-NFT ,P28 /H3:R4F\U'="-E%-=N;;E M7E31^]*B[D?20$W3[C674\VM\[FC(238&3Q- L;AGH&V-VA'D'""35(+E-?/ MVTOJ?"[94;I#R(JYJFZ7\N;K+1$N?M&6 TU>L0DQU9<1\M]6*(3 SG4AC#/> MH>,>5LMK&J%?7(&(>);S,/"E4J)#AG".M=%&\47/1W^H:MEY;?WAB\.6!1AD M=Q W'#974UNL9NA]V5="W"/Z'7TW__"_L4=KW]^UIIWM9]D"2@0*!B^.'!!V MCD1W,8MG/-8*2YEP-PAO+W"D@ZR#(VV0C3(DGYWD+[-!?);WTD\J\GATWEFA MU7%%2HQ(LE02PG86J*_2ICPHC4JQ8O;+;.AF@17Q44=_DG/E;/C)YW>GFS0T ME4LD4\*GZ"W3Y;J@;?>_(IY 6?3[/>@NO]1G$G\!8*>78:L]*MS7ZF"T/_B MV4G.%T"A%;U8L4V0Q(W2#4(E+I>W,?S53"#:G[D-[B*.*!DAX;\V2S',%0;8 MNS5F#] VZ70]T=!\P9^WV)>']B:#-%911S*I2P\=E?U]4K\Z\*IJ M,&%?N@O6AG(S7M@ M/&N5*L7ZG673/>KDEL']3:H+2AH!HS,<'9?:XK*6"(<%.EC'%C>L9[TGV$'I M'D-;0=AS*KXGPCE,*X&]BS,O7!3$0J'S\B(%N%G\0CH6^J%YWY!T4U6XBE;) ME-'NWXG]$68^CNH(^_J[C-#GPZZ;)8-ZCH MX;N[/[ J_SNR$E,)69#;YV+!#LZ@#EJ*O]YLL/RH:C=X4VKTBX8=/:NJ6-># MRS=3;-Z^_:5\'7FROZYK#$[<"$6/'Z?@F>.:*SS@>?"PV)RKC^:GE%9:L+$#AA!UFE<]Q^-BO0GW)41K-0[Z< M$527U03]L[(]JW0JGW+=>>!TSATZM:,IE#;)+JR@$H#>/2(V(G2&<)2^ T5# MDE NEIU7S=I5%)7F_@, \B)L#WNA.[#90OV1G_I(3&$-KVP%N$5+(S29-%;B MYIJM5OORVLG8!>Z]J5.6$3FQ7O9)*R[8H8)8H_KA/*>&2Z"JTWNB#;3K7RGG MGA/3/-"G=@C(IU)B8FEUA;O8YU-!?Q5L0@BJDS(7QC+O2!HH\%2S>'+\DOW M3J#&#["IM@570$ @_^9S+D-! ."C@CJX]AKRE^(S@&,-!-Y-TFGL/WCX4R=V M=HZU;!IE"5HOWPLB8I"W3@C&Q^A17.Z6S[)?(8A;?'FW]>75->"]3A85ML@GY4-K33YBT:LZ;,EK%%4ZO!!SGUWOX7 MU;.=Q=?TH5 93OGX&XUJBR\9\!RJUD;CI(-BA;Q[!VE'CONO&V1[XI;4?$]+ M-\]Z=S7X&BB*P3L=+=.4NDM[G0CDZP>.9:!Z B#">M%TFA*""+"S?V4"]7/D MHP6IQ@^,31B,2*2FL%CM]UFZ_,2M-^R5KEBMEF-8="5T$5A7R2%EB$ MY^\VE+\ITH&8G ;7;"6E+G !OHJWQL!GP%Z=B10UD-=I.,^GV#JWWO$'X=^Z M322MH29::K9:V=;KM[%J-^^$-1H^=3C)5.<,6G,CZQBM@FRE2,+PXQVG8)J+ M7"?PR,@K_#>.U/2Y-H5B#3_J[ [NDMHK!MK10)PU<9_0M]?T_T.?AEK#+X%. M9WIM4_&\[,Y$9&@9-'2T+[3D.X@1^U"ZE]A^Q;M/ 4UZ/SKLDPHUZRM F$H9>,;?<5WNR?V&^]"D1>X.X7< QK<9@:)%MW#QF:E3T.UG[ M E.,Y$]U4E)"!S%^)V0DG?T.A;WV\+73#FO,FRV;U2V;C;]KJ4_@;:\?<&<0 MJ+-.^M442N1)-(%9L?Z0#F25('B_>:TQ%<5JYKY>=I6O] J 4<+O%-?)^&2_ M%ANH,'&E:P0H6?7)"MM>='GL+7^SG[)(5+S1AG/@Y(/)Q)A#8;?5#3AUFVX^ M&%MQ&"W,!G6OL;ZWAE^EYHF_;ER<^C!4PJ%,2Z#V8T\SU?30N35J/UA[WZ1N ME0Q9AL86K\U8_CX?Q24'3H_4;/$+%U5M44-ICL" RFF4+ZC-X2N1Z6Q&Q3JB MJE;46 M?\T=SO=QZOKC6*^#V_L2(1TI#=*=&.'(I!HXV/."<2L4XA0 =LA=L04!\6VV MNGJSK%U1.$JQ](0E'6?[SXWVA^TP$783H&""DN[+;DU&_([-9'0=@K8SC4R' MTDED(%B62)F0?B2XC?4@Q*+[J]TYZZBX7'\B=T(.2U2@K69^X2N0X+%O6$Q MU >=[>"Z=GTFOY#R02NP$4UUY]=VX2( >)K6,?ZWHNP_J3JKL,%_=\0BU&@ M64/+TY7ZEC"M;.*K4K!)$]^!MY:E=H[-]P2.F,<)11*#YKEZ]1Z4K"74RK#M MJG.+<\[ X:8_MRJ,D094]&+\8]V[5!W/T7\#PK\ [%] Y8%5#3+R8@93Z,V< M=5/M_)E=>!GB_'FH+1&9M\;$6C%FA#]30L%!NG>-;0W1HOBIZ>1MZO*?54NU M99^[N^.=@CU>CHZ0[Z C1\-L"+,R%5(Z%FO$#."*=&Y,D^A -55,C:OX/:7+ M\.HK14SJ%76W"F=E:J04+-;._C&H_YK=&([W#5[_8V(.L4?N^^^JP3R 94:] MT/P-?-UNUX6+0& "UMSFTY SVO:@SG"B_L/]&8JW*-OJY\T\^-I\ZYW6/%5B M;4].98C;I_*WC-Z'^6=RG M@G-:0VCJ=].]3RK*.E$0J]T^YH[?IS,=>RVG[3-/Q+1 "&I4P,PU(8E81\\W MB0>I6H%A@M_+DQ\_RKLIW-M/SH%0AV.Z1O*U =+7G^$3FU:@O>,KA([7\\V6KUMD=V20<,EP MS#R>MTDVS3J[D4D XV M.,ZM'JB9\7&.+'9="+=Y>++NS[RVX,+\'GANT M5%F>)>:&3J\2U\Q6S;F0J:N\<09B#4J/=6E_T@9Z7+X16WA=06)%XX^_4"=4H&E_$G ---0D6^6ZAM(-<2:CM>Q_'_:7UPWH-LNBW*9]R:K@8LQPEPT ME6I4-W)NO#70'\'-,#[;IP&-6F)8&RV50%&N]W":L%U!+?($I^/ M1J-&-Y*O.852XRUU 6-S(8E]V(.& Y%AD71%(8&/<2 G^S3QB.,+*GB)UIIL M-'6+]$UUA4 M*&F:RE_)S+:S>9&;=IYR7HH(:-\-I)4UP?_X]=L &>,SWV(0D5X;(O#@]NHJ MTD?Q3KAB )R]K0)>UW<[KN-=/K$V=T?PZ@2L[$HLX5@;,VOLOPRYU=._]HKR MP9Z4D#*;,7MS3:;Q3H>V'%'"H%O0)YW1FI+I&3B8_'55.IN7X+M9/%IG?R@W/#TIS=9?PA<"UHKFFRIUO& M(ZJ2(K[4DGJNAE;ED@3>&'GADYUE[_X$"N',>Z%0#*I8OM\4(,^S"4K?%$G* MU0H&UG;T[%AOO:F9H\3!(3V.KTG67:UDG6WKW(R:'@>WN^Z[1T$"FUR&^GKG M/M9M^[K\1%PGTF^'$VC:\'G)D=&4,56%:XA>I[&T7>NF6TKO4F5[DL'>?;V M\HFQ\(TAN0J$%W.9\![/3!@+-"E*N%;$*4HCYUF^LU80[,$89U*W,20D,[G\ M\I4+SQ\WO,Z4!OZN,PFU[@^8\0T\N-U?F !@K#]!/,XG6(>E#07400)MG;SA M"]D@] + H5#QUAXV97'_=]!I(J](7'_8*FV@8.7N/W-GZCL@A?5MU/GN4,-. M+C?&[_.6+^T7]<_&R);6"/8K+C$#03KF-"4I?3GF#_2J'G$IMU&*&O>O[O]+ MCZW*3Z_1O$EY517HZ7M9X<807?JOO$9&#<%X/N/T>ZWX/U2W%/0A'WI' M,K TZ'/E[1CR3-]Y?6XU.'%P2^A#&O8/%9LL@/YQ'U^??7VP53?X=,$2H6B< MXNYWG)<02BNG;SAA.#ZA3'7+UGF$I11S.M1/R13:PW_!'J(:Y%)QFG7! ;-= MC97=]&Y4=[_'NFF) \3OT50'+Z.:3N-J/)=4E61H7-"Z= MU@S!F'5WSJK"Y@D[&>3GGX)2E>C[=MN">",,:AG,M"0O":AQH(ICI2[AJH;@ M_Y98MIT,A-ZG);Z5NZ^2Z#(C@KCY%YTCL\L?OO(3D'U6;,UTAE\]6'Z^HHA$ZD(2;[D\+K@SM?H8$+Y",IH52=MR1634UKHDE/I?DOE% MX!M5;?CHN/C3H3M[7M6^5(_BNW:NT;1"I*0=Z]IUZM;D$$R0;052&8,WUY6[ M61PD$RZQTRA[" Z/B]/>B!6J^Q478/<:5K!TQ&T\:W:C8RIO0V%F,V/;3>KP M1:&WDO5L"S/:XQ4&V"_6M&*1QH#*N-P01FA[]4I9^.-%S^'7S:UD$RSNV>$< MPSB DVB:A5^R?'4U$RO!7CU@X[ N.>(CQ!(?KJ%?$\>KM*<>$Y8_BI,,W[A M@4 UGP4BRBU@J2.P(YR/3.@BWE#X0W64,F_M#X=R^@:Z?-NLW=E*7)O/_2 _ MT=&I/1T0^!M%$Z9FWBS^H&.G 7#)72FSNCCQM*@;9:(1=XRKVUV6$E&+]F#7U]G[%9Q-V,K\X>HI=,6!8Q MJ,1I7-LPRAB'>F7J;V4QY,G!/=20]T[0*,/BB4-R9<-E3H&(@4F/Z\>OHSNF M")WL4$ -VBSTW2=<1UPG(G%F6SNF%0FI\X7RNH5ZXSN",["4PIK<*M'LD_SN M-HBSPAPAUZ60UU1JI<]X*$-,^Q5&]]7Y4YS<>H/?'RHQ(+2,UV]9!6[YE4NL M=+#'W-LQVT:F'?P\I<>&E^\3O?[#"Y2L@,'_X-PRGKW_$SO\@_V*../;=?1? M\EUVND:RGQ9&;NCFM]5^WSJM>PTAJ_U ;E4W*HL;OSWJG@94.9(2CP.D%;SNLR-(JVAK'A1=. MTT%M+,, *CQE&^-\H^V%D2[I4Z81]S2D_M?9X+API#2=JN,E&,"8B^YW/[V; MC>ZW)DV/JJ_7N=+N[L4M3PNL+.@[A%VKW#7]& 8R(CCB.9NU MXEQBU5W?]E^7;^\;&Z*[FU+S8"PRH-ZDJ)3Z'Q5N_(]J^;>*_$?]_$_KNF'EWYWH3DK%35A?),=_!.8G:9X%^JZN"P 5\C8;F MS*T7.QO%B:ST9N1:;9[WO!-3F>-:26YZLA1\XK@]SY+B S%%W-GIPS6YNJ?YH,# M8ZL,N:>^8DH;4P&SV)?\X7S MK%)RBET.&;2O34/WR7 MU70+2"Z>="WMM3@U/W;/.7:=5A12> 4I-';UD*544QRK=^59)P&W_1=#=MP- M#N_K]%0R9X)(0&SK'K0,@&P2)[*31?5M;^HQ!6T\*HE@IV\-=&>&\%=A>$NR*LQOVFGRB_T"A-F$I%/!1>W*KMF0\. MB0>;,'D@^8^\:8T%=X=TWKX++1JZXT_RBTNOV[N M!URC?47+@M4?VLS5/=[,\/F_9$%36A(W$&&NPJ"GU/^5WW_;-2ES?(AO;&1; M=2XVNHP'[K[K)(^$$&U3V"4 S)6(<,_*PZC?HE9 MFZ_;"9C,!?/VM9T%YG4_8*SWC]^CF,.L=E6QD/38AV65L.(YPM90.P*Q=[8N MN,_$2PLBB$1JJP6[?0 MFK;A#]6<[]',GF.QZ&NV!D_S=YLUN]A\_79(;Y]-Y-8)(L774L0[1WXK82MQ M@C5,[5$9]B![TP.[JO)KD'7SH=7I'_;D*^J^(* M>8I1/X@>\EYF&:AO,DKMTTL-D43]BYZU%></Y\X=#4(C3]:QF(?4O;M X9TGX-Y*4^9M3AA MLV&+,U/95E+K5O PV?$ZSQ6XSG'7SBNC-EF+:B/:EW^HOO,_*4A_H?=$H7^H MO95BLXMA&6NRNF71VLF8'"=SW[DE2T"M5,[W$8PGYKU7HU1M-U"E:>P_=N#T M'VO>VGG2IY(7VV0Q>+]X/.JOY62F'NB;+R]J8>B[^?>Q878:&\.T6C>@=&UP MPMKQ!2R[N*SRVC5?[T&;P=JOV_:&$ZB%JKU64-U61ZU_1G:\R306>ZW*S:=U MH#HRT-FK::NJTL7]IAM0I U@!1BJ(D)9&OSP!=V!<.R+\6NP3%&=.KF1$@'U M/9Q<;7GE&WUZ/:-<#,EDYM:^!\6F5U"NS;G!&@@?DWB[6CIH>F-_\,380@VV MN.H36W[EOBJ_T4'G@W";@#H'R"W3Q4Z_WXF\5= _5*]=*+8!@>0^A4X""EU6 MCC(-CLZM1_0:K!WJ[&!3UWY19IZP[X;DM^08EWQX.J&E;7[96%R9R!4ZUV]Y M.-?8/0+@6>39@6.YV_W-A^@=E@@BVPZM&@YA0O?.=EW0@OAH(5I)6?,D+MW6(,%Z LR,JS*U M*$>L?D/O.]IC4"?DZ4+'*%;:>XM_=F_?PM+6RP0:ZGL]L(1=2T+,6$.O1_;% M?67C;FA6WH$S/C=Z88[4B6\-KR$\0Z.W-4^%C)@!(:Y22&\K*<+('::H3H$6 MI_[%*'^V1N%LN_MZXISW:A_<]C69DL)[M\X-HF:;DK MV&W(+,G&@BO@6V$]P\#Y?A)XRL1& Z20"M6SS?<#NI+."0K-,#+SU8ZM@I(L8=I"-<4*$ MG^( F/L:*7A)R:;G?I.3S;^Y([[QLUD4XFGK0+ACWI/.9JN11J\QJ^\JORO) MC'<(3Q*#V-0S3)ZE\C@A;MR.,B_(D'V)D$8";+!M>[H'4+>V0J>Y3\CHN UC MDK!]AR'++[GDRLJ7*>+/Y."[V_GH7$ .,G>B4Q:P\DP#*@TY52^8X_\J*^B[D.A!G)?E\_,;VT7TY[48MN#ROT&*S"%*I7_2\ZD?,> M&WJ9<.W8T3'\J5B7IA*A%4B1EA\>407[)J@5?)CXAB9S0Z>T%L'$?IGN"H IZ$9[S& 3Z]++\%3]\?S>%D;#;G M7S]!"X)5,;.LJQ%;)[5%!)0C7&K:._#W'RK_0,-U5[R9=B=RXW#8\3H27+ V MB_V,K$31Y/5H"3;?)Q2(<\CY<354EC0\H]I0,S&U^*V&L9IH5&ZPWOOP#)C)*(?B'IG\?CB< M@L-:N=UMZG%22WP)DS1*Y?TH:SR5,4 =\ MMC1L[/(.*-L7CZ(MGJ*\6]U1[YV&&G)'/%38_Q+PV>5U>GYD"_@@3%+SQ_XL M?@PI'B;P%I=;S/J*K_%XW@NH'PC3V"BO6'\<09- GB\^@-9T\H"N03(L8'4! M$=^>L-RMN>E;BN$0G6)1F;QQQ=6Y5X7,O-/"90V"G^:V2NWRMPC9;%QYK_,C MPW57@S<&<+2-:>1M]N(VF'+U#(]58C1T$ M+!(L;W,P]^"&=B$"9>CH8W3&;"N__?^W<]S<;<+\'\'1JJZK#:,VV1M4L+8JVMA2U1>Q6K1*)F=BT ME)JUH\2H5<0(12(B5%$C5&N3I&I3$EMLM\_SW/O<<^ZY?\+SX_=]7C]]SN=\ MON?SRX<8^7L-^DT5\CBU&BCR'BS3>+6\)RG=/FTW'22:,2$,%^+K\4!4'"&2,]48Y8 M$XN'M(3U.?>Y6QLKH0?V$U9,$*(L?[L>OCY@HVG[TDK7%J>#,6D@338517)? MX2UX_HYZ76^EQO59K7%P+-C>==%IU4RMIL/@@4P;[@#9-+;OB?-VC.CIUO^] M*)OU4Z+GM(WAM[6G%=R:(@6^BW#'H1O]-I96R<> Y'2R%'2;#JUJR#"G7TJQ MZ+U*4=$:K,6%GC2W+1/3 M$?"# =/4N(_[V3BU$2L$M5J;2;R]VA8ZG+B35PAN[$DWZ30\+YBT7VAJ:IAG M?"_/54=Y1!GVIG*;1K!+OF01:TM? [MA9_O:*E>% >RQDCQY>LJ_TDH$8^ ZK+*39). V_.,[/D/0 M<^,6UD^6QPA++QT9PL^,9DJY*KD:'H4/F XH=C!_4R=EC7RN_$(IZAV6]UHN M\QFYIPNY#?1T%\LO_.@7\[.+K8PG(*DVS6&P_/SCRU[SLLNQ53G&<_O<>(1& M ^2#4&V2 #X,K*&MLL9>D'S7[.&6@$L_J=2R<-/HB8O/2 @T8;9FXV5!(\&V M!A^H7'=O/R!/;L1D.2N2O 0K;O^T..X7PX+Y2;@AZON$QM_Z-MG!==V":WQ\ M&:FJL5XN_4W J/C62A#!GYY[6[BE-I;E4[\V4[2G:.-&]7LM&1L]C80'YTIB MT#$Z,2-YQ;?\7B9F2'[*!YJHH&/RKF@; M66Z*T3%1$W)*$R?>[AP#UMUG0O7IF#CSGKGQ\F6>#ELX;&8\^V^N#ED^()YU MYZP.%&VH@8/A*[93OH]#9++H ?%UP#E2"T_J)BD^[)-YBV:QHA>GE'5?3U91 M-^.'-^3;%'OFE(+XN93O'F.R<1A0Z1WF*WW=$B P+5G/R/= ?J#<8D]CHXF/U!C_-PA.LNV>\L& MB;DL^_*E57#J?/RXS^'$H/)-+':-$@S/HI(YF?1JMS&0Y<:YKY2'>KVU\F^Y MY<+2KZ7D2P_9>[.EFGZ?NA"E,5/L.I=C1E$(=)MM\A]?<8AU=WF2//7]:;+# MWUFA[2[:$Y>LY>B4Q(5>J[G'E1:S:53G;2!*YR%BO28>0WW[U7&UN=J>SH+: M,G_'D ,NS2D^^6E/>;^ Z2.WGC.F:4+' $BH1--Z@BR2>IBW#H8A0O:IRHI' ML@?=5*4<&+:,;$A2[0]49\6N4Y^__FH$BQD/>L(GV"XD_ NIC;:-Y;ZH5CXT MZ"]L)S'28-W\6].Q=KUV&!5D30S& OG?"^8U)&4[.TF']5(L7YQ<2JS68U8Y MC;-=7%\-$Y,H2/M41\Z?73K\_/# 4XB%$K>D)!W' :.9 #BM(V)>60*<"1/3 M[@B^]8Z@3SNHT?UK#HA#L.U/^!WG9=M),OF=E\^\IYLXA_/]>JSI6%[M_>LV M [6XD>=..$F]-7R <.DU8P?AHM+B9"F^UPE2WEJM^Q&[P"PL.6-;%@^)$L+Z M]<^-.YMJ^V2 DI]^,I]FY78IN F_U7#.B_%@^7F]5:I_'Q2?:V>%K ^S&3;SPSIC[L7"(PH'^[HGJ_?FF)LV#-RLV!>.! TU[ M*178TRAO)[='R-XQHBF956H4O@;-CKADX 6[6*GNH'YV4YO#[6UO2EEG'4BC M)U;C"[@LPID8& ^:O%6N#_V:6Y)RN<1Y%1N#\$D;H =\ MFS$(+#31.U\9$!K(N#J :& 83\IU7=MK^Y%:%OY[Q]>(PFM#W+JRR%;TEZC^ M?L)W\&M1KR!G9WH--=-GN#P19R&.G+(E4*RFRW#ZL[OL:ZU.=$HVS$2@.H L MH=KH268*-H;JQ&6KT0(.6[3J'L8@8BY$8-[GB$DUS,/4)NB_YT)<9R&+NWC0 M(\<8O_[N;?-!$21<^L9+23:_16;VQ+!652?T?B5B1N*(SO=JKA+:7'G> M.P5-1_PZGR49@:J]/UZM>?)2J;GZ;30*<>!;#"*(?P?RC' M!K7_5BJO8B<[/"+O?2ID'3ZA%,^NLKLIO.6NXA1P#)B9Z&[:JZ#L]'P2F)%E M5?TYB1B2E$2G"]6ABK$A,V0%^6Z'V-Q4+R#R0BCN:7=S8J*JV5I/ M(BRHN(N"YRTHW+>WY?#Z4IYK(OJTP10 5E%CT2Z595O ^,V9RS\QGOEE_?YG M?W %AKG3G#WECZ,VI\X/]A]7(PO_".=G>W=NGM45V+AV9OVE34MT<%WL3CM1 M\6R90V]T"4K(*ID:7%#-6(>=2G/MJ[J>&/B[6(O& 31ZRW%NB)E62<.CNDV_C+57)ODA(?C77V-7 M^'^,]>8SCUR6)O8OC2 ?SD>+2Q8;*ELZ2-\H&%9QR8^/Z1RZ6?FIY-<_:&"S+71.WXR(RD)C M1($/M.W@,F_V^O.B2'R?3^GRN!EKE:+_0+6NE89PV.T!9SC!VW=LYUY5$_4& MFR](YU[&5GY!%Y174,KXKE6M*A%N-$!PZL-"$JY8,>;?I<"B_9B8+BY$>G*A M0N/&S/[?[06V;SM_ZLE&8#-V5O#+&WX?*6XM@2*@]Y ^^@R7R_P/WX#YQ=UP MI&\PQOM-KC]Q@NR5_$)%?X%/. ZH\WX>G6T*XE+96-#Y"QQ0OBD3G](.BH>%Y"VR)I#F8LO&K@F3<^SJ Z6/2O)>Z+A8]'-0V*2D)>I MW4Z0'UEFF$&*PA8@$:"K7.&E9AE&:D%1"^(KN7'9[?+^ T'Y.]7$/9+;-A:, MD2;JC5NQ$K:1[G"XE*L;$9_9"^.-3RXI&;=X]H0^1EBQFY67TW/Q>E !/N/( M'C@P.' OABF.G.Z/<;!YO9XN/THE?2XB6:M*E$?SMEWMC$HNN2H&%#0N]_RC MU0]*-Z[3YN5:7Y%S"W]Q5.H=$4\A"/I*>)[&)@OZ7M:]?5L'D&2I<#O-/L%8 M+KF\(0W=46CV9\=[G;GN2/@@;Y$^OWLEG&I3LV[O/E.UN>7'D@#"!=PI7'"5 MKK+W)#POESOE5,90G[QYA:BEAA- EG0Z0ASN*T2)MG%:;#1+NE%FNP/GVDE> MFC4TXW<%W7STF7#CC1YV$S @)NEM?* FQ#;=PKM9#5-^Z6/ 6%;P0&SZJ:-NY+7I9H:JIRSDPY%L#$T\]P6I(30N<[O@ MB/,Q;T!_C %NO;S$NMMT\<28?\XO?:VC4F9Y3N4F6T;[X(,%"/Q=ZX#.G].N M0^C4=K&<\ %OC:M>4EL:%O7XPW5&DV1>L:Y5^1.^3+"A6)D9VK _K4^SF7?- M>0ZHXP1TI(VSWJ81C /<;^O=:*HH4=.#9BS#SO87?O\27E>X& MH^*QOCECY=0,]/*P&&N]7:0X%&[5MC'8'])7K;3A*[!Q48[[G>(R]]O&#H@[ MCU"%\WL1C-EI\\F]W*ORR?)7\H&"?_<.LSQ0B4KV+B%I-U*,MS4;R_(59E^' MB[DZ7-/.!BX[*>YQ:!#-W<4=]5,@^:FV,ZCDPN"MNS5__[*]T>=<>V)V4$P2 M.]N$<).T+Y,G@]4D* XS5CU;ZGM)%^?;]])9'D&A0:-!'T!]M)S.\<#M9XBI MR)BF&)\RC?*/F6?#!+<_'P.H8BRD3/G#KTO(I6Y"17Q%7?N'=&TCZ,6[W"TB ME@*M@K,:M($F)8D8#X9.A]=<_#' HV&V>[URR1X"]702ZC>U;#VIM:I3 MI,!4N*WBC,FWT&/#PCY*$_$A7R)_%IP@G;MC,JGE(ZL[&B,(! M@DSQC\O:-!;>G0CM)';(GI'FR4)+RX\U717Q2FKAKRN/ :&T/5ID:^JVQ)=? MCV)ZO0-E'D25/>^/$8,_K:U3=4ZQXD)$, %@2K_YZ!__Z!8X%>BXISN]& M# <-8+JS:U(>X*$U%A.!2_6H%\;&QX ;%J\V\L-]A_(8'SH(+!'J^:([J^XDJ\VIAAS^^N!N2T$T_[+**1@8$9-B7=I=IK.Y M;TF2Z)>F/Z\#9;S<[D7JSMMP$OC9H7'=SX$1 M]_17M6G@Y6!G/Q"M52Q0T+(AQM1,;#.1U0B)#NK'F[0.$)ET*F *KS=&&.M>D"=2' M?_LYK68,>E44J:49M)@L?[J,_261E9];L;6^@>Q*O[L_@>_PVM9G4&65,%)R MS!#C9=NJ4;;/TPO2'WXU_I'(X#4#"T6,/>1Z%H!#"25V.JR#!DS-3'L$V?*VZ3X-&)M;4>/WD'";G$M)9(>?2O*A$2_0O?C'UVY- MM4/^Z :1LFJ_Q@BHH!$(>'N1T\M=8;WO+BW=5YHF3^N54SFV-"EJ3;C[N3,RW[YRAO/)K5O=)%UL+A M)Q*LSOW3^E_AS7BZ*$TX$@CJ&"7DSFAQ3CT/]L&V_Y%*)9.]$&9+L)$EFQ'" MOE3!/G/5O7H*ISWL?6[Y%UBCY"@UT?DYCTRM.:WEI.K[;@*_X.;RC\]E?#XS M\5]'D)4*?>D8NGQ%_J^'M_?\"]XSE]@Y^=GC6;FU^3)WW%:3^_@+#"/,'BUV M<<=C)"C>Q5(3%'4? \R# M!#M\5MR#+*@H 9^;2WUQH9<9ONU99A323UT0?F,IJQ?.H=%0YAJ9,1=*('?7W2_-O:>)-KIN8%3G3 M9+]8\FSJ$C8.]N=(O7U<@\N75C$[$;^. M 8+;L*^[ NJK*Y!M3BC,EO0=WD&2BK7:QWF,L;00-=F=EE9"(\B,4OFF^]S- M<@S'&6;0H-M!;1J\OG> ]U6 (JATM4N4EM7,K^1U#!";@#TJWY^E5J1Z".[# M#^1Z2MDU$*@LL/1]M56I5_@XT<:SBDJ+@T(VF/3I^9#GLX$T4EIN$*'N\_O3 M*!CE%M;Q*5J@EC*%C\CD?!.HV6,'^BW=#QPPO!T$V@&.V82OKKRBQ\0O-36T MSO!QS\X'!#4O2'ZG!R?$5D[4,8^2:P+L7Z&/5+>"F,YH\RK[P3_-H(-;WQ2B M>,$QL1*7(Y^*+@R9%J-V&:YD_^'M?B41R5V8'G( 1@@;-[O">O;AAXJL>:-C M %LV(,SL$F8R,Q*,T>29[$.9D;_CD)X6ZKXD8S0S_^TPOD%N MPMQTSA+]1O@ER&6EM)I-177N]8Q7MA4CA5JT=[_:UO+6[FEJ^*>8B'RBN/JST1?*Y[^M7%'@+:$:^DF MLVQ\IK8_PG'V=PA.OO3XR@V/YGB8ULR=#14690,P@93/XQY-<(6'2E,+E9G9"&N\>#-T?= 2D6_1W3%UP>+1.22 MA!CUNWM#_F44V,M@K#K?+J2^+8KGU!7BR^X>G\2OB@P &RZ)UU(RM$X?PN#_ MD M-[&BRI$O?9@*TC?186+Q/O@ZT_2UBU?D^\=V4 8F>1D+H#^S$4I3Y[A'% MQI48 0@MJ1L3O.IX7.7.SCZ>H*242'TI$F0L1[<\Y!AV$$[PIXSMJ^= M=74^-#%G>U,A:1]C%C;F],>ARK)\GY9 M6J7!W4.*\3;IW2D@M-N;DE_^A7D2 MSBL.P<]HR5[XOK^#7T?!-VV'%VSQ].\%R[W%:7\H\R#?H(E[>SBA,3SL2UE? MQ?5C@&YJ'5E)N:XDW?>%L$[TW:JZ!P91'TC7UU4&U[IHG)(;SB(6*XR@UH9E M>2PNVJ=F_(B>_<(\#'Q@@]3PGGSXT87];?C#6U&+K/^0X^XC62T$-S!VY-^R M]I\RH&WJS8S9U8L_+K?Y*,'OZ#,,#&;WU.VF",Y,^*.'6\K?*@B#8T&22V39 M-&)KX[[N*TE6YHAE-&T[P[WJ';=57;67A./Y3[X!8Y9Z;C>"5&DK@:.,>@:M MVR9[)*H/ .:GM6\L?JAL3< MHM"7O\KO=VKZO7*?"M#HS[*T?B6?Q+F:4?6/[_[WR,Z/?Q_9^>=[)62)&OB? MX#\!<>3XYW]:XS_!_]\:8_\%4$L#!!0 ( *:"6U!N6#)O)UD &M; 4 M ;WES="TR,#$Y,3(S,5]G-"YJ<&>TN@507$W7+CJX0PCN!'=W#218",%= M@P09)+@S00,D P$"! @0W"'(,+@S0+#@P6&PX PZV'!YO^_[_W//J7.K[KE5 MMV>O7;M6]W2O9Z]>N]>S=S_\>5@#/'FEJJ$*0$-# ]@\_@ /BX 7 QT]'^. MQX+Y>&#A8F%A8F+AX^!@XQ+B$Q(2X!,0$!$_?4)$3$I,0/"$\@DI&3D%!04A M"14U)3GU4W(*\G\Z0<-X_ \F%AX6%AXY$0$1^?]Q>>@"D.("QM#B,=!8 .BD M:!BD: ]] "8 T+[5\%\)^"AOYH(S8.+AX^P6,#R!, .AH&!CHFQC]6/]:& M/M8#,$FQGCX35L(FTWV+P^))+A*>E(?+JES;3:$W<<(F:NL5@8=/245-0\O. MP.3LXNWCZ^?OX!@4&1 M4=$Q'V/CXI-3OJ:FI7_+R,PO*"PJ+BDM*Z^K;X T0IN:6WIZ^_IA X-#OR:G MIF=FY_[,+ZS#-S:WMG?^[NXA3L_.+RZOD-P#L&QA!MV^6.:%/Q@E. MZ]2$'!25L0)7^VH^W?A]$1;(BZ3/2RTN )MPB?L>*^61X1"MJAKOEVD^KA M>$@+N3RSGEV^+.A]'(4WQVWP;(]&]-=O< M^TUD$X8>XIKRDHX+1VN0E?<=/O%9'1ER,ZDV>S3J#JS,"3'@YV8\>#6'54:Q^9E6K. E;- />>=3"Q7"V$06UL'W\2-H'B55M.'LY)^[#9+?X[!EQJS< M+)PD8?7II^YO-;F&&7S(B;<75?.D3N:F-)!&^Q(A)25W[WP.T%4A?Q1CU&_( M[=OZV]>*0-@QZPCC.WF_':D?!.3ZK)G24.I-4_1:HP6E;@:EJY+?:"I*'J%N M 9.55*1O)B3F*24)=6[H?<39] HG*F#[+)+/OFXRP;Z1Y,?;IZCA*;'%1R^Z M'#&[>RCM!8A]""4W,*;262B^WDH@'Y-4[U;;?_YT0K=7SI_T8[Q**HFJ,FX9 M%R#_RYYK'5"-P^($.,Z6?5PD;RCN_G.R?UO[OQ4T)/!69 "ZL1J1 M>*\(.@!;0\WZ-YQOL XG0Y'\.2KCI7J@HC".L%'>Q$3&1Q_7'-\G55PLPAU[ MY$GP]'+8H79[D!DYNZ"7A5M@5 *^)7(3H%%WLA8\.I8:[7 M(:G-;QV'VUTMI?'-99. IOM^)V%\ Z(Z-/4?!3X_59$!%I M/@H%EMUGR;DIWC&[V<$7E]'E36O8G:K.>47=G"_]%G^R'- M2C9_[82F=R=+W$UXQ=U"_8T[KIJ7 UI-S2&'+RX$&LQ.Q M?2[+T$OW/M3(4H!N5/) *YJ(_Y,Z!HJ7YO*VF^&/"/A/EQ3UO[]F>M\5BX1QE_*5. M+_HP>=46; <8\VL00YIK#1VPV#5T5'GA9MKFD;\['BI4WS(EX.$0 U\13_?1 MZPK7L/H0]^U[$/YJ5GKJ[2&HF^!@.@R?AT89Q0> VH_)PR0@,Z M$Z+C+G U,F.1QO(5_'[Z X5>KA]IQJP;:OH+2=)O5@V!>U#M!F692TVZY\=3 M0I6;C957)31VJ"M0= ^ I/I^IHL%IGMRWKP(V,)LX$X,+CQS+2;MI0ZM,C:: MW6K\3IOX>'R;3F_23H_H\98@><4;<2K9J5"Y%>_6S:D%3VD:.+4S?( M%2_KJ)SI^JWVITZF:CEN>.B< M4)ZI-'66^^:&H$"A[H\$*L'/>,4OB)3@D/ MS1"K5+D5S\D;\(D:W+CWT+Q;HO8O-YS(QBFS^)/C5TA[]'IJ7X?.M9'ZY[?0 M4B9N&^_^(,D^[:C&,-GIAF6718-I.5$X6-B4[V*4_PS+D+6&D?"N^HO*4=0115"D-)HPP :_:-&N)__;P">"]]?]M-.4Q7G]]S M'.UIN!X>60&+(IG)R"V$U0=T2L*;-B;++._PFR,% MMT*).2,/V=#K@H2 Q5]^T^-G7A3H0L>6K.=GS(>!O('6FS+O/:?2K1X LR4Q MNYW$;9*(^ $X-.X"J;!<7EWB[5"\IR?*U^+Z1(GNN=LX-@O-YPQJ-JA8#ELN MBHP$'376(3C#_#0@9L-TXFI%X@7J;+O>3J*C$'P^YHA](P11_QV^ M.#51+=&3&&[+PC.:U'IFRZ9Q*]Y]DB=_:P-2GD^?9WT,6.ML3)M52Z1+M<1/ M%H6]=V'"0_J1X"*M-7X?VB<#W20F>=4+L^CF==$C_@ <,7Y6FTG5V*GJ)!Q> M'P)!QLV5N]ZC&N<*9D@/^'BL%0!)F",2L:-B3>!T ][VD6CP;VJ#H"92';XL M>:!+*[SCR<.]5M58'JB QMV!$'0P1D[(24Q) =+CYR4I".^(;1([=]?MH((C-E-Z*2?6\ ==7OHG.=('?5$%VS(01 MS\5GY%3P4[Y6IKC-0XJJJWQ7PQ+OZL'2_>Q3;SKGDC9W-E83C^18?UCOI3BM M$)]!++6U9\33?Z;=P":!@5%^)QT,K]0$QUY7!OS!P9Q-!(?)(R- L;3C,0W9 M5G.]C3>$$ON>I8DDRRX]-WLF1GJEK#:L<893R9H,2S:$.<6"\VE$@EV[Z_)D M,!3KI%@<[8E5\5\!VDO9DE6>08>X#M=DS$A"24F+65C!"9_97HGN26+\!0C+ M8MP1"[SV4UV M26!'(^L3ILNG.<'/IL%/8#XO7 )I/O,DGUV(7 WE$FS!G*Z ME&,V.S=\>F&=5W]B-Y"9V <"++C<-'Z]42AE3UO8QHY7GUB0Y-V&L:&U00$R M1S1H/P,IX#E"2/WU!P#AOA79R5%,'=":\EC\&R2C[96J('.C>1+[:']OY&F? MW3(^+,QHJ1P'A^EE@&B/T0K.R4PQV-$[,)">[I.E"UG&$4?2G]8AUIS*D;Y+ M^C6 $.^(#\G\L-[):CP$'#8,_Q@W>VO2:MYZF;RH[2VQVDJYWXGBF3:;I=O':0V>EXSH,7K*^37C6O6W>=FXR\7JQS"A%/AJSZ*E^; ;[25J M!>@\2;7B5F+D5/AGR1U_3UT>6:V-HED(E7@ ])$A@^%4<6V2'G""W1H(K_D+ M-Q;9(?"*;C*'T'="=V42[W'QU5UK$A\MLBYAI P,C[]!ZF!AR"[!Z*FKS0N& MZ^6FS>SYL3?.MBZ39>4N5^;\J9#.T- P)2*AQBZ&AEO#YH>^'.X.UG['6=7&'3HL"@^?UI<>ZM%+*^+XSFA*0;_/3H M M+N9(56.7MLZ<\PM>T-3<=_ YW'_KD@:L*'5,'7HBW?^ #@(UF)<4;9[NKRJ/B&8>?]% M8O*]Z(?@)(N2/C=)N&HZ_#B:%)EE]OOB4&&C7UAR@<_GJCYY;,ULZ5"G6.TI M3,G]S2R=F@7B;R.H'I6D&-.F68S\:#1]IUT:$&]2/"W^":KN+MF?R-S#8FC2 MEI^7XK1V-JK_Z1*4JX.@BH'D/@VX[;/B;#K9@J\X_UXF<'JK1_KE^A.YYK8P MR3!4SO/S]WZ9/T$@H@9+Z)7>5",T5"&8@FLZ[0&0FVN=!"X.\9KS]2!!>JC$ M$TBAGED!)YW,HLN4;:&WTH*^4I;S\YO1#CN59?O&G4Z')-H(A;*33HT9-];. M*?>V-W'RE;W<+/>9WC$,L.>*T18GBKU/=>,@I?Z MXD,TS%1O:?UD;2PNJG/AH%YV9(I'_L&<. GQJM/5?JF9M7,%@7H=IGVWJ>[T M9^D]7DF]5!G$^PFSPTNW0!]SDC2O2+TY%,YUCAN0F%8_ @ ZZ_];J/;$EX*##>RMS7H M;_A"GDSL;3'72T(?D-YO1A+5]FS-W(V@>]''^A"L>G; +T8Y,>3)Y_G"PYW! M:V1"?63D#\"'#;&[,->= B>AV5V / #B?8/!5-KMG_0:3_9Q%48I1C0:)4SE M.L6XQ@ZS3K2M7YWETH3P3"LP#J\K(E7Y0C38.U)+-$H> #U*ZQ59WF7E#1V. MJ?(-@[:93S68/YA2O\?6R/_^5XM+=:[NO$4[>.$!D-!J;9.N(45!U78J*)Z:7B$9 .CF0M>^CP#_=T.[';ZR9I0=IG:HT^[TX1!Y;IVPP>#OUE-MH4(Y^NRDW M.A?@?N$48EB.S(!4R5^T ]_,/$LT:$T(54+U-Q2,_2)TL:R_;0#P1&-@M]?= M=EWZHQ0FVTS.QJ +OJG]G]^7,9JS5=$)RSDRPX0CEV8#XK\%0-]PNU5HUO L MHE8Z^O7!:L>2]Y:HCVHJY,:?_;#(=9__K\+T41&PG3:\P1FU$R68F9YAV@F") ANH8+4'0-@X)2Y/CF:ZWNS ;,%#=J?)Q'HFSIA>I%38-=%#G>[-EBP]+,M8J5UE MF?^![*2 Y4\5L9MQ.ZH(CV]>9CFRS..\2CQND';LBNXLZG,-M$ M&>UK^.JWLM)_:^(> !W1C#ZY9]V=QWEZ$\]) R=!X]C_=Z6^[O,GU_^K4F\[ M[<.SL\+'VT#T C%EWOL*1*TJEQ4].]>_[G^9Z"UU:O?_S72_Q^ZE+%T5(#D M_3E/$!<&0O$R]",(EHN;:/[HFA^0L!DS59;&.#4'IE^=U(J.WQ"(^AZFBQO% M<^R:!:[.F9+?QDL(_W_/#22*VK_GG[DA%PE/R-V@&ZM^, M&_9[$N=;T+<(V,I\Y;+$V4":#']"Q*S,IQ0@)OI:=[/RP [;UM(I35?LYU/O M?N"=,D(MOF$U5GCW1FL$SP6QN\U51-30EBX ;@O_'EV= JE_#9=DE5^6!,2&-W(&17C91/C-Q968/M;C;=N/.B12&H M_36]YXS%_DS4]\R%W>7YA;E=C^XC;QGWCQM5Q [M]0W3G"T)L\+43;$_8^\3 ML$)_?"' V :0&%F;_;U3JD1>RO-JR/#NG2F/2V9X!A=S-0O@7[L@2M>E/;Z% M?_=244*HP7*8)T. -6;."]!Y%L@$:L+#?8K%_4MA85V>\B1I R.U3?CW\\IV M'+A@?)NT;[! F?]]89<<]XXH?P.;-KF5ZT=WY5+;OL2@@\V:V"C>EO?NOX8K M6A;=TV]OM;V#'M4JTPJ&A:".(HJC/QG9QH9WN98068*=;4 M-0I33"EN+H"/PP&O5>AHKL\XK7X$ZR\:(',6BFNQ!5A5[.@=7"-Y:C+C$^DV M"/V>]GFO2O5;S76([67*2:R8_JXV/^CQRY'>$K9,$4YTZ*2O"T\F*66\\ WC M=ZD'N6G3TQHMR_T:T'2VOPT:(/\@6[?AP9O&]-%L4_-I6<7ZNEN0P#X*9[_L M+S0\U51J@Z?,U-H8DKNW"%VJ>@?I8.$_CNN@V_,+$EQP]T@+.,2,IB'\G,+2 M&M+$'N":]!<86=^"0,45_&W44:OB5<'D>6(:USOHCMMD:EEG:"C\\\J"$=C2 M@DPJ?7%R2O+T/H):8?E]A:L =_[Q4%D@G/L)E&37:(.+^_Z:H+X*DU KV[F M&BPSM#$'T^ARZ[/H+P[?LP(VKTJRSY?BPQ\OIX6FMDNH<#7:?>=4//9'CF"A MQA3@HB$KERIUMF;W]F6'T57$84?I:+H>$@QDZ$WKR*'[8 \2Z"=LC!7X1?ID M8&SE#37&]XO*48[C@1O+H@:_V9M&]J8UPY3]UJ@=- &RMZO(F6_^=^ ,Y4GCI[ JP M-$0[<$-CM-);JWBQES29\QT@%;;\PQXR+VG'4BTP@'@X;G;"5:?4 MZ4BY_XG4&*.(^71XOTYM&V(E!4A1G>%_LIHD%BMZD]MV:^H+.9\'UHS* MNQN$@DVF:_!GV@>O6B=@=QV7X-W'.J F_=)"31_W'3_M,L@E4*^])[ QTTG2 M\I+3?JW47Z'13W?JG M3>!M^I37=M_HF5JZ^;*5H./$+FC\%Y?*6$K!,&>T&!.9TV(A5$O9O#33N3%D M<8&ZT*[C]>$P6@1)B'Y>!S+%]Y*[!%BA4[M0F+;[[N/(&7NJO=\^)$V8[@DQ MFKAW3X?BS)UN 3)7-_.2@:LZUZ,]AR!F:\H<]@\:RS*9K-GCU^]C MY',CMI20HETA]?=^+^EZ:J\B=/@ <$I>VRGNW7]3]%J+768RCTB_8]'U < $ M6Q4!TV.S&)S\[)]ILW#KN&DZ#G8N/Z@Y73N&",:F6Y$+6X)-^D66688CY#5H M6%F;6'X**$CN#7N6JQ%G./#VU0<:P=5$%JFW3086L*5(6GD3WUR4P)EH@,;6 MA!= 6%O#;]]/LCMU@1M>+-[TK>JJ[_W2,-"^V9"9&)189Z;X%#"%FBTO[J4U M[EXS&+BL4\@I)[#X"FJ5^%QJ5-'Y:1U[=.IG1;=9YO]9RF:9LIIJ4Q2?E_C= M@+YW0Z\L]>?@%6QRIVR0\<,,.%@/&5EFLD=K",OR8\\9VO)K_$"MG/64T&7M M_@&@^(,>1?%*\/-"=>:[52O08Q R#-=6 MZ.FGXEI#EAH@>XGE4S.NR\9AK2#;7LX^&N)<^:KB(I]94NU+XVFWEX+;6:\I M'.C)23X47LB/FQW*D50$K+=)\MV ?[8ZI.FC,LC,EZ[?HJ'I>XQH'F%(;9#7 M(/00'?1_,V^4'!EF\[P:)X??6_*[Q?$1-&\>7GMV=_-)][]U9J(3O]=P.^JL MJV2K,PIWETO_TGI=KT%[;;J6N!PY7N5M$,-*]D;SCY)7:\A44,AJWK)R,0&6 M&/N5HV4;0<&C\2:*/ET@[6AQO[CZ/FCW]UD9 M'P.M3JJ]SYHZY4L9RA%50'2_;!J:OP>:[#+AL3:Q,>HQ;E?N4@9WG.[_[B"[W3&TQZ@!LU%$_43=B MC$&&FY;W:XQ4H5\+U!YZ9F1*13V?F[ZG-EE,VO?K57X>T75-2_,\',=7* 8;X.N-@YJ5@]:6S3MY,;!A7M M*EAX:;C3U6PWX&#+/)HV"0';N++2JWK[%EF-H_3Y*07&-&B=J5) M<3K4]7>^WQFX,)! >3K$KUIWTF:4S^=<"]<9CQOMQKQVI_K!M $N1I8%K!*+ M688^JX_?UVFB/-7T>IS("3M82Z=^=TUK:\G2 ^+_O'8#BX]36@6DZ[6\]0!2 M1*DNS,I]->[+2-+ >-88(?HG?O07E*_"H #SQ^%9BQ&J >I&TV 7LQ-#F\!1 MX$LE,G, W_(O?P HN"T:J\CFXNY1K6"<8.K/6XO?9R_9;E%L&JL/>BUVL7Z. MVC=U?@#@S7R=G3OC*'5H;8#-5\K"P8SDN#OH.DVNH^TCBOJ+JHE$DNP_TE>=N(_+EK0$LV<< TQK0C0[Y]RT;7N+E]Q^E+XVO;/L9!I77D[ MAM>/C6G#1ZM7D"NK_9<25&7![%&@EJPQB&'CK524ZY=7TB(94KP7&^TV 6KP MZLX2I+%&4Q,>G"#;2+NN![[VRJ[503GVEM1/@""96'W ;%^.#*%I@)!,@! ] MW=&,65A8+GZ^S_PT#]RS];51W;T@/$'FHK1OJJ_;R*L(AR'8V;Z@Q)(_KQB[ M$;^@E\NXM'@I>-]OQ]E(ZVR<]?#&7,&N]%DW]0 MR-C^>=3!"CS1J.!O;!4_7WF7#Z74I#WZF<"A\#J^VTNT9[W^.V(2(JB@X#+; M$@H;%1G3_'9!U7"&&=456YNN-V;"_0XFQ4J_Z1B_'Q"BOW4_S9EO=LW64M5P MYS_#&.+Y#;<,A2J2-Y]ZM[EXR[]?OE\$,1->8>A H)(\@(5*)5:4=.S1.U&! M+,+D61.;\M1#]9%C)$7&4 79N>*Z,R93EMG3,<_+87;H2);#F<$A/8S.:3SO MAG;& ]Q2-NOFEO5FZA S>8# U.+-JO/UC[/7/\*AP^/#K7]R74:@]S\N/D5- M8@;Q5]8M49XA./K\GD:=PM_9$ "\OYC0)_;(IPEHC;Y=]W?S.?.__C,Q-YQ? M\,;D5[6PF]GDK@-08+0Z-ZW=O_O^!-YO1_A<^1_^ M$45JD&,?+Z*BAQ.5JX:*F+F5I+IIN,&_ R(!WY"CZZP/ .W(!X"2R_W73_=F MH5BAC4KA>=Y)L0+5U _, 5^8^>>WD>(C65NIDJ]\.CJF3UZ@)A[?"& MP9):UN^&>SQ?-[.G. S6V3:XBC.>+O0TPI=>YBA7=S.NICM1P^2Y[6*D:NO$ M7P,*7,*[_BJDLE-(.GA5]^DNOJ ?YWD9QWM_98B6M1<\050IL3@B-$#JW=S( M19=8-F"6%B_0F^K'0OD[CLWS**]F;,$-CVT,+"HOWPE/D-URM M3#P'+]BSVWI),-TE*:^_,&KK7Q1*&!W4<4>PU#VQ<*6VE7&<+,=IV*XXU"DXH!"\$9!4$&9* MHT1TP;!GQFV9^JN5VHKM1/43_ _+1X-:\]@-MU\4&;)V.,XTU!O8D&=356YK MZG:-<2PJ^*5/; 2X=>>YQ5B1@E5:A0XG YU(@F,G]_MP? TC@XK&N?LK1VB M%J\97X>]$=XZI//Z\I=0"7-1H^O@DH1/GP;-1E.\\OK48O_K.UNS _D$ M#32N[K6ZQEB8[FK-CJ'8/8[VY,+FPH(*:5-2T=?HK8R6G<6$U+!XZ^1'=[Z=>!5-,P_%I7^BGEU,?)QKH M'Z.QJ4>H!](;W :*N8<)@=FE%4F1X=/$$;DJ5'9;EK%VD AVW"^P^*HFGE( MDW654M'?RR#^C(;Z\+-JTV_U9/E%":['))?%P$M^&)9UM%IIPM_S2NC:D!DXA0[8Z6V5+[BAQ.0CMC9]##I[NI/J(D> MT=<>D.NJ:"BID.N@_4=P-D!=8HN(E!Y'5"[./Q%/]^^(#T 2?T-VK[_X[XC_ M^.^(7Z4&_2?@(]=V0BBT$:C84')=:]S0M?]I[\GKI'C8IB\@_P?JU0GWPM:ZIZ\6LSQI^@'6^?%<@/P"8&R! M6Q4+KV>W#8D\SRL 5PW@OKB#.R!E_:CL1V^>]2>IH[R,+6SVT'[3YWORHP$U M=V+0/L4;HAH4AMH#H.\WSK*8\4 .#K(;00:#RD19GZ29[<8YNKI; ;-,&NV\ MJO$VZ'_NG(M7>&\P?>:5+2IN=O83JJ*>Q]=@22ZW>$:S0-.X>4,+N&F)OY9\ MC8#"Y$T=,^=,ZUOJH!G/TH[FWZ:*^*4TA(_][DKJE]F'Y5+G=63BBK?2E1IF ML#0E#N*)QO!NU3#MBY1L_2"IY*J)?@"L%X4]2R!N_/$ F*L$W6D]NR_J>+;V M:.@AZ(16$<7Q06&W_&0X@R$489)+# %6!7>U$!<$M^G\6#,35FMD#H'_EI/8!4-+] /B1>0_Z MEZ/#7H006X28GS3_H[\#A[7UHZH4(CK./H-6'U.DR O'G27RX_ RE.0#H+#O MGQF '19AA\R"T0I&NKUMGA.7#158<98KW6P.S 21&0P M)9W=^:']A3:0&9*U>/?4/, YQ+ED(-C3U>VP\L)$\Z=1'.N9K4JJ,)?3V-1O M;%:*O?43I,MOBPO:] )0B8=BR\(U]>UOU74%+AY^S*]G1?L)F$+A@A9]F=70P@(T1Q'@4R8NZ%P3PQ2^O+>^=*D2,1C;^_K.G5@-]R_ZU;2G0ASL/"4R^BX_D4%&DRN3 MZWKI^ J&P5'=ENILT=2\, $3.1DSHX[T">M3.X;'(:H%*\"J59-]W*H6UL0=IJ4R3FF,2O2ZZ31.:;Z@RSNQ&SX,*W;",(KBID04B25]TFZ MT?2QN[@LW9FO ]"VTZXNV,^3^ &P^MK,>)7W>%BH:]REIXA>C)43OVV\&.S[ M &"MRWXU"'RMANZ M6L9]:9?^.N651BV&)VCOHRAZ[,I3OBC&MU/UK9[R[ZU>[ JB/CBO_+.AR%_S M 5!CTGF.]IQ1LBQ >>44=;GF8C8ZV *T#5M>7VQF%&1KG/S,2JTH>3;F;15= M%6(P>2[%G&G.X+"1[!"UH=&L1T"/+JF*MO-3^AR[50;(4L_-@Z?_17WW_ =) M*LBU&;-E()H>&ZW*D5DD53%0)G*PYOO^W^/%%Z@7.92/(P"B_?/+*VU'4MZ,;G?-ZYKI(3\):=/;,%= BU3[$HRDB *%5U_0A F:I X M]VJ%"2X5M.S/:";K?96HZ^US3 GEMBLU_5E:R M:G5]F$>KCWBN'VYIF=CK9JZ7##\=-YD6TY6^E89.,XP,4W,5L2<)B9Z!2]68 M_7X0@5]T6W&^F\:"QF/]>HU(?A6-QX([?(RN@%\A>-/1A)$9,]X;)C979:U3 MCPAJBW:(<=[A)W3]4:;S 49CDNY:"XA MDI5KV:NJ.9U3#JL$^N'8YUB\1DZM;#PPH)[/6TWLR\\^D>8ST@Y7RDB&0#TB M0$#W(!MC _A*BY\U=.HY4QX(]P&P^0UIC>I&@/ZR5 7^Z?P&FE)6-*LX241I M)#X^TPZ8J% 1W&#!.RT!5=!6 4@&L'=H[F-;7![D?930],CJ,CLZ"P*(-4)$ M654J1X.=W0AXREA'LDD[3NL2J$^5,*J JEE5>F)3D&7('QC$4/5[.<0G]7SI MF*LFJZ9#*.3%;X^U"!1L;&^[:]2!9[$BMGK'$'J_D=W&)4KO-J!Z0_ ./G- M*%";X#!]IUBT4._P]$13<7YMWL]M,]FN_IEBK-UWQE#@=. ;EB'8&,KIU,@S MIE6O!9JB$)'?X3L%CG M@ )(7/8ZF$.4$"31%T[?Z0PS!WJ]79)WM[6^+"T=JU^FRQV\3EF4IF&I3S.- M_3PC;2JYW0+JK6F;E*ZF]5E67RYR3W2<.P%Y'I ;#Y^&305=)@NZ%]5#GKRJ M\"6Y+,G"%SI='VT#/C%?Y,X3@-DG M7!T<$N;!1#:2&JZJ-"Z<*D?EM. ,@"CGM=5#\S7U5 M8>W2'Y/=QC,S9WVAS]I\&80!L:T?WFL8TX42Z2(D!SHI7S!49]_GVA7N,0$I MS[1O=VXU-!$853^Y(T_1!P*IB9)TZ2M(Q:GHS(SVERV:WR%=W%V,V]P;#PYW M_X;2J(1L%:"F@K8K?F1-%#D_LY?87*VLS](D$1WY99&=L217>Q5P#]^\$IX/ M"4&D0 Z79-#;7!.#+C,_?NMXJ=OK^NJEH8@FS3?PZKU+S<%G/3>QU+:YB_L@ MLGM(I+-4X_'F8VSN3]^HQI^!(E "KBUP>%;5JGN.O&&JFOSUC2]0 $ M$')TF?7VBDG>X2I5 QX9KV5&"/Y$GS[8Y* GGJM2Z_'T@V0P-X(;"A^((;F7 M3]P$7HP)7CB?4UQSGAAZ(LQ[.5$Y<]>T]Z[_SG>.:4"=^@\ ]+OYZP'TUJT+ M1=@#X/Q;XB-K6DN0L!42JU)JWRCHT09O-FSAL.&[A\Z MN41[_E[48$]:^G2WY]C?M#A8(UUQ]LZU::]/OS- MEZ/IY*(C!^JOC=F?U]%."*?!D6:UKQRHY:4JL@TH6$N,.SQJLRYS\D=TE^^U M9%KMSOG5_V)K?)?T(H/5;BO58/6W/4)G.00/,;PKZ?<^(%X*[FT+8V__2G-7 M:B5-Y?DY]G<]:S3^4HD%:=R%=GB':/-,FLK2 M]' .^S.)S31IB[GJO2(%7TMY60^@/$BP=VJX1..4*Q@;<@S54E0NS[I!&"&! M!G3O]TW11067ACS7#[(AV(GVU%)Q6LJY/7)?C;P$&H=U/(J@AB\-H\Z:]3 M%OP-F++@4N=,O=6<3(V,PI^0RM;SK%';_9L8VO2$1<7=FY,#=ZK#9"$>NJ"N M+<\/;]Y(=;$J?!U'FM%2M-=D!XO./\G+L,2CK^?YL(PG2XW"_B"SL-5B.4I_ %C5@OZB9\$]KBDO/&[.'Q7/Q0=Z$3Q$Q'26HK<" MEZ=.?&_?S^Y12\_3\ !VF*7DY8$N!B[&Z?SB?EYP88/W/_6K>#GS_OH89V@@ MO$[/3%NGSN_IR)0OR^C]#]D$A;\VN16\O6WUSHG"EJ^8 KY"NC0%!QL"'P!= MH+(T*H87=*,'[&&6C(FMUIF@*;4O=UX3'0Q[Z3>: :OZR3T^\4HNM;^&FC4L M!SX$P]L&4*1,'ZS/A9= :X^$ D&>VUAR%]/&_PCA[ 'P5\-::N'5%\L7;''; MJ@F50_=K)"R=+WX%6!,D=DWU&WS_6A1*T2+1&LCT"4'%](Y&P9-OT+BR(VJ(D$(5HQ*P)V6+UW9KSJ+0=R;)Q#..]9.](0#9/7MCMLA*D-P MI+?Y.E#A8N=FIP],N3]@QM'JYNO+,C]H9'NY3K/NY\?=_3>^6[[?P0K9J]IT MTADM-E_]N-BFKN6<7#3O.?8JHM.\8B*WHI"CD/2R>R11%48M M'MV\-!S)3%36?"DO?[=F->-Q]6+:UW@.3#81"?9U8,X=YT583E&$(3D P91E403#%GEI4B"WIH&9M+^QV=GFIH MF. ' (;9Z/M9BN&4M*('P.'J&&QRXWN(3?GM*WHH=*%S>=2[_0$0I;9&=4]H MS(1\\@"X4^&\8U$$=/ZU>UR+NSX^ ."\PR&^\&.BO14Z*VRW9"1=RWO"\RW3U/_1YS1A@L(/7;>OFMC&>1N$.Y'K2D M+RPE0(!!9+4GZ+696'$H-_\7L\$!]H*!7][GU5X:BG!//\7=>I!,ZTDD2L,_ MNO. B005PEUN8C0;2#M,K2[T2%%A7>N=%84 V+ PP6.#U*<]]4B5V M.TZP5%Q68>$T:XIVY&;Y@F%58+2RLJ;5;[GHC08U37=IB:-84>T,[_R?T=D. M_@"@,J0];6^];9_K;CB6DN/=YS5*O3^+S4HT%MOY*1MJD>LM3L4S;^,%>4=, MJ1D#OTEQ@X>A@UZ: *E+\2$GHPZ<%M34A(\ET+!ULLH'43I>HTWH_^MM_(;9>17PH3!4].MGU^XE. MV996$",LK0QF!K)F)0[T5[-3['L ?%PX>+FTE^8]8 ,_OF>ATB6/5<4E+-BA MFPZ?V\8D5I%19$#*]BVT@V<@P;H0A5%2D85^O@ANFCC8#(.IMI3>>V . M BN]UYK,Y'IN8>"HNH919^6MD49;4[HWM_57G@$R!]B*DC31V&K/,!/!'P;S MVZ>7P$^]K/VAES'/U_/33*Y$\J-?IX8 %V8^!FJ3SZ*Z+7;_'DB"L6:B;\KX)2O-UDA/^G\&.)VZCWHSS%/^>#9U M&G/#C=]$?J;B*6]%#2C"!+'*6QNA MV'KB?M;\5P([3C/JBU_Z)V KG=P;\;OGV7J]?6:6C7DEXQ2'X%^!25I,/+^" MYV@DN_FQX;.'[YHZ,D_WG*J+.I,VG%\CVJKK#KFW=D2E%NO=A= _&[]=OR=> M[#7C+TYW[#RX'*I]_9$O.%F[C"T7UKP73!=VV'J=-9"#0DAD%<[_O0F1H)2H M-9M7SF.-8,>/+_B!7N7&&)$6O^,&]3/3X'V&'OT74)0?_^*_W\NR=Q!R*' C M@:B.?W*3=_^FZ-IW=*]#=$[F'RDZ!*7::<+R ##*5;(.A5D?-SP&=*=$F&.7 MP+6O-:+SGH/U;WX\DNR\NRJ[*J'IT((XY0& QUY5:71,<=.;1L 6[9#VHK4R MJU 66[%%6YJ5'C]'2] ".@/AYH>W:$H?R<&J? !W M@#N*KJ*93,]/FT/%J9)KQS&/UZH1LDUCLN(2>0#U3WH=NR= MH1]&YE% 7;>G4C$N4-%>XM5S^HD M*(I"2YYU6'5RR6;]0+%:S/WQ<3[/%C1X?$*'&NRI3JN'_=ZKO>ZC'XA9#P=R.S@+0GN[';)+D7AL_*9JB/N"K_ ME(TA)G'U9O9 ';$?;_X8*9 M7' N_<9V*XGVR6+0OE5>&;5M[=9E]NL:!&0WP]0Q.&FDJA\ O9VG1$S'F5LN MAR7@, *0O'NDQGT/DCK ?"#=J=-<;U*]UQ> M0@7!ON#>^/D#__K&)KVC@Q)<,"Z'/K?WYKMSV-;*K*'NI>E'=I);BFFD!TIE M61#5;OL ^(T%> ?J$2Y/6PK1#M"NF5\;1X6;WJQ&^-Z_XO5M1( O"@9$!AV> MJ&07E *XQH)L$)95Y&BG'P]_%(E[X%4(^U%.10R47:=D7K<;M&+IF,9U ;R M>YT+B]V95_$0#V(%<(&U2QPA&1_8&4/]2=IKC/"!%U;"ZTP?%<1.CN,;0O4\ M/Q;JUWY[BBXM/B.SZI*RJ%T:(C*;9A"%9^C3*4XS/#B)9<3$ M[+4W3Q^!NZOSHO ;ZNU)KYF&PCBM+,BN H_!CN'=VVEFE! M@32)3[>>511FE,)8QD(;Q]@XVYR<^R8K"HBP7+@F5UX=&$[J(ID" U/K_!S\ MI4,8'"-UF'E!A*,YEZ6#( Q*C))[Q><+5J5+Y#P0W,(RQLP0$GFN-V_QQ'M? MS]KI"OV2/7*]N(H-R!H(M?X37P2;1Q=*I+[6Y!R^,YIO@:A..H0.W$OJ@@(V[@5 M7#\J\"BUL(B=B4E#M/GMQ6LP"_P>998G><,[IKBN$["!BN9W? "A\ ^%_?[5^-W>=2_=Y$!%@UO9UG;MZ3P2Z&=K_/Z4HV$8/@+B+JWM_T#:P M"&EIYUD<(G.R5;3TU-RBU^ZI!F&Y85+$*:X\D=*X*/5#'XE;B&1#\JTT' F3^HSFL$8-%UB^8"'44%\ M$2TUIJ];# EFF.&D?>^=56>>*L=TLCW>?97N[[EBN;J\7#RTU<)]AKK4T.@I MQ=A.[00H0.(\3C"Z+QMU%]4G]^J7Y<7[JQ#A*J MEK8R\U1CT[R/1=P.HK'S.4CJ2)UOS^]97^?&<(O M)GS]B4[[MB]-^^!6JTYU'8-CG--)"ASFZKX_)L4@^1'U]&\'?1T"*[IU62&K M6E/NJM%-V-"9XYV(2-WZER^+ ?+D_D,2E6&\2%']EH25J7X9K;[3EXXO$P[Q MG+K8H%;?C!3#SPMG%#B1(+6.VIC@?LHKHZ[[SR'BI)(LMM=_5"FM/I M0-3\8D0+(=LC<:GHFM[78N'7S#H&+"3HP2.1/HB2_!U?P 2K0=/R$-O=8*#( MCS8L] QF)!=ULSA;;KI),I&AC@F".Y+!>R.I8\R5%'TD"0PXE#--9X& MQ/=0'_)7'>4<:48]D7EMPC$[SKFU<[^^;P0A^1R&->F^,'O6OR .Z2EO56,_ M>!M1%Z,_EV>D?RY=L QLL Y"M8C6YC>%:L-1<05(4%\0 M9-HXCC+2KS']?:6+/5\_N@C1'YX>%>;-]V\\XW-?(5O7^74&2&*SF 8"]FNEHIQ*(2D?L M= 4U).<'I&M'\4_4QVLX",ZT\A&:\+4OO8R052-?KNDB#V?*FJ79;!?#FH/- M[%;9:')=DRRFK]8X@I)J9TG_MFMYR[*$8Z!LG?@#,33XR%>MR M3U"%]H^:S@W%JSW0FG66HN#)]2I_Q?_XA $(^T'1OU_G,EQAB4NG:_YEXC[. M;6.T0I"NK?NK@JH]DL*_5] RM.;@ #.5*(GE3<(-*:GQR0]2 MLK)@5QA&(V2GM+^>VH1O,O!C!IH%%VR%.GP.<[:H?R?V6?T$>FB^[,?/]W4O M_J\^SC(LRJU?XX,(B(UTB0*"DM+-@#BD*(WD; DI >EF%*1[$-D2HH3D,/30 M(]T- ]+=,4,.3!WVN\\;YSK7.1_6I_7I61_N_^^^U[T>LA0UX-R-S/F,A*X\ M^]_8=-WZ9BV[47SYNKAH?P)7MBA4]$YJB*P79UT=WJM8Q2N?.X&B2M0D%T&K MP7A]8-VV9L,-P'F\:+-1#=#*F]VY-[\5'U=R;1H3H^Q''JM<=84]^F,#EX]\ MX(Q!QMNF>Q6-PA#%_!]F%N:BC5"7ARG>:SYWP1SCXB#Z9J^Y+@5EN@Z>+B(JHB^N\G\DCE2>O7VI_OV5T[35YP97S?' MCXX>:\A'LM-U]C+1WVIY<,4[8P7F8LR[M!!Q*FO1D;D&(TS,53VT9.KC M6" MUJ)$BZ'>JUY=//5S^Y,,$%@3TP6_N#JJX_X8D5 M17NVUWSO83(^AB;^7IF62(B1I8RY*3HXZL*4X!A8Z%_DL$,F6.6JDN@X8\4RH0#'GI?3TUYQ( MQ#>-CHZ*7@TC)9%O6;Z3@R0 >HZ#G@38?/B3!%ALXA\&+F:/"LP_0//#^5 ^ M M)=%"OPA.*3Q@B!%N,^!X-B5:&7%U4-E9A@SH%R[+O1:CZ)/*9B$YX]=,[. M@/XI%(O,Q[)J32YC*).]O/Q/EZK&1Y7L41"QGH<];;2KS4I;7>83,)451%?, MJ_MSV)<*:L^==LP,&Z!.Z>JPI:EGJQ%O6\C270*2P,*_?7$=]QSJ@R-<2RR" MHJF>.#G5.LH4C_:V^:D?& M\_SYG17B7QM57N;>=Y!67_>6]?:>7J:"JZLWP;#&0O+(6="$SN.=$8]4GEX. M0I"PX^DS=[+0PW.L5C" 23Z-0$!MH$=M3FL__IB!1?>V#\ D[:;%0E%S:*!\N,"NQ+L^II./;#^ MT#@!KAN!]":Y*RK]=3IDEM^(-*J"9:T;\F*,&+-E_N(X MYPRF)@'*##@N $5ZO/A7PLB=OZ(;7GIZ-I!ZAPD/"2!VP4'%*R\AHS%7"^_> M\10Y:!Z]:[!YQ;V3@=/$*Z:,<%3 M+C.@]4QGZS"7I83"I>1M8F*4&RM5@C?P4\6'MGJH',H@=T6Z:A=W*E5(+RW= M8Z$8P5$<2(E&U17,]KJX<'K70;>^?TSD8[P;U^#6NCSW7K$J%5@Y'_:HW4?R M;!)E7-8(G9E5ZF9YJR]06E<63+K#@4/?\"U'= M950ZKN^KJ9'W+'O*C=)A1:<;=68'E M>0F-V(^GYV]UG_#7)M=I6$[L%$T6MAX*91UUL-9 @45^5$H@WHM"]$5]53UAC = M1II4X[B<;OY$Y:LTPS@C;608WOC-8J1S+B-T7K'PT<"QJ=>VBH?X"XWS1X^4 MY"*Y;=W)5CU+%*1:D+0_1IK')0(V3[(/0712J5L"NJU666_>4Z+>K]])OXKI M8LZ9025OI-AZSA.#(%=O4$3$^G&][)EQ%808V;?A9#;W"K=5#T\=%FM'G8]K M;ZB;!I6GB&JVHRUJ.G,_GAE<]XE"V@4(:J[W'FA.N(@W; I/[P[^T- YTWB/ M4YUUN?E!R!W *U-R!_LL,$"R00*OZZ3C4,ZO=JMI'4Z7.J^5KB*J]MB=#I$B M2>VB8/P@NIXP%">>/B,HZ^"U/LY["*F\-W_B=H4U?![![287>;I:NDN&EYGU MBGNG!74K23_W1JS5I?]:DC&W$"0$+!S)T1$RCN5>OY'T_Y9G%W2]8\VR<]/& M6%_&KD4O%SG-/<2T:LU4:$7(#!1QSF_Z?,>+O0'$K>1B9&MCN?:T=^3\JX/\W$ 2\V+!O.Q-UUU( MM/\2>KUH$L$0CC':7A^=5RJTV>.[&\_R?#:$OH45O"[D'1LB:HBY5^EU1H01 MG(_$+[[0VQ?L$2!@].W,YEN@PLU@H;'J&$+2SF2B.MR1\DTT#4LK4OI!^6&+ M#)-X03L[7_V):O70?SBM:*1_?;&X;8UI=_LL0< N6018;78B1:FT6GFQ4 M@E2FZGR9LG@]Y/2H^0>;9%FN7G'OHZA(H7/S$+*][L[;@9:,F%T$S::N4UK" M%$QPMY2WT>E2%;^I@FIC!KA2##3 \8<%3--/5*M=S#HKC$D ;F1/8(3 ?>8& MS/@"G_H+/F<$8)$\&57- M34C'*W#CXHBYSDM)\X,S_19?/JX>V1BZ_/B#385(ZHAUK.IOBM MN^7QT^K[-'-6]_J21?Q4S^S[?1]Q) W.:TQA W)]Y[L,YF \.:?@742$5\>A M1M2G0=V4P,G[U@_U9BKH/I G=9AC7L>;%>V\1!&1Q>_LV)#4/C@8;N'BZ&32 MG9B*%M88KN8/4M$>=RTY$-RSKHI^_MB[J#4Q-*1V<)SC*UP3SH+^%KI2[!0G MC'-4L/**,^3TK5;_%1F5%3#W)*FQM=M:SJ";\AIK@&XYVJ>]..K[I>O[EI-_ M;A0_IC#_'9I[\2'N0](S**C./;]/SM\]N\ZQTS#K@"_?NB9.UI.^\-FDPF#T M8O"=+<7'HYX!JQCY,[W>HT)$_"$(^APLJ()OU9 68OI@A@1M69SXG7#^X*7; M]^HXXI_"P[&:M=CDI142X)46P>E$\N\K23=TGAN&M>U2>8^1**3N\M\!GT\G MY&#\[X#/;&FFV<28V S\[X2/_$2I5,T2!3]&WOL>,U1;B5/<0,2S92^%;U@C M>-<& >]6/65*ZZ,!1PUP%L<1K0#>E+49L8BF= M;^K;9EIG<@OUE1[*3R'60]ZS:N=MF/(2+&><]/'(LY2H/FK?JQZ].6<8KIP_ M3/4P9\>T'ANZZR/"9:+-'2[&WO D[KE;1>P&4Q^0-V,2#*(#]"#'>XA;1,-6 M8Y__B,0"WRPU9-T3_/1>H<2M3;9/>)I3H/][:+4ZKNZ!W5;TKY%FIMFM^\SC M52-^3MP(J:>S7.(OK/O?P8ZN>!PY;TJS%P_;?[\C"PY#."@4LX.X/S(U)G$V M!K@/#K I2=+?QDSRKM$'M!*IQX\'U#3'X5ZT$NW>@ZF1J^5),S]EII^*=.^$ M[G2Y@@#T_ZRPF,/^#9?#5[#I1%"3&;'IT>6 O277EG4H[ YV6$D?GC2?#GA MDES_ 9208_*7Z 5\3#V8X-]! GR_#ACY*>_P4*^WQ&#-72QT^\FQ#E7K)9GI M(L^9Y6E( ,M4\ 6;UR$\!"\K;[%,H%61XK!A2=F5#%]Q.1 .")N+C5V1Z70Z M9CPM02-;7]UUG&>'1%F*NUZ? UUM[15YGW3>;2*5]9556@XBB\8!R8+[+KQ6 MI8RRF/-KZL/:D[1O_V"I?RIS,Q>4J'P AMF<-PDHFKU,$*B#^A?4(.Q6SB?O M6&&^YKUXX6?.:BK#O0NMVY!%[+:5.IQ]<3-SG YL73+,KDTZ57OBD_B,BTL. MD?MB=H7]CL0PI)45XWBXHOD-PM"*?!OWMCQUSX26\4,#65A[+*?>[8,S#U0# M07'A%#)J()BZ1U$\S==Q^OXA*F19H:/FIMJ9>_O*>)9IFHPBN=KZ.T*V1-Z] M9S4'"',.<<=K!L &W/=[@#,)O0$[8)R,69/DW:6M,2*;GVN](:-*7]7"#6R. M#L8G1N(6L&,2ZINNBHSNG3.:Y9OESWK<<'/ON6ZU.EG9M17Z9%@@*Z84[DKK M*$O,#+ 5'.@8-=?P-&%YQEYJBZM;V=UK2%AB&G2:.HZ!_#Y2J?^R/+:"^AX> M\.?^/I>SX75S]5AF4\-#-):K2?:,2,?PH^AG'O#R.S2"V)H]/4B =W$C95>O MY/>MD$6NE'.F#9CS^H)V83A$4,U,$Y$$J%/D*)8V=2I&'HA/S%\@8"6->V?X MC>6A$'\2(-0SH,GHU(E9?,<[GJIB!,-T*/VOMP!O06P3+@3ND ?1R"8 MHF/T^3$=$,(LM49]7Y4K3$0O$[W-I^BA-H4$0%:CL+S$%AW(YI5LJ!BA,H $ ML$@_1QVT\6NSM"T=1,#P"D&$_!\=MBPFE@RW-IXSKKW[():T9P)CQ&N7#A$D M73? L58V^9;N%F;XH9FR,D_T\9+@J!9:5H'Y/85-H)X&-]JBE;.A"<'!0I5F]J?,+5)@UM7N/5OGHQ$1"ACA'^-F7IS.7YX?5.S Q M'!>R;4 <B9R%]MQ;?+#ZZZR#4G93K+E4)+]49I-*!M$(SO@71PD%G8''*_;Z=1,&D>U="H &R+!N M0E!@Y>MZ;1P#G1 )(*E9P,S+[F_,+]4)IIAI6SK/Q5!4@. ?/%$/RZ4%BECS M>Z5$2\W(!:CT33M3-/ BKJMV?&7A4*B: \B=> ^;N01A=V1)B0\M:2FTV!JH M69=NNX(4>_PF44IH[4V=NVCNV_KHKZHZ@15&MJJ:FA@?E4M)U^?%Y9\;4UO\ M1_N1[_H_[^"N_ZNV46I4#[]- G2+0YKMR0(OG1?G/.Q2V*&7SINR\2=NI?T; MPSA5!*R1MW!'[/=6F2;4!$_T.']?#@(9N3#H>(0.3Y9M,S@5O#:?;J#76+;_ MFEIP\UHW?B>S"EV#L'6ZU6CY^+/:=0&G=":-7TSL3<6F[I\L-ECA9K3Q[C4CRNLH@_^*#&WA-ZN53VW0VD<3Q51 J61B_B:J,XA_1-X$.H]HR7 M^SRM.%&C3POI>^%G6Z'E#,.($S*28VT.!A#I2!"DZ\!&/U5T(J]FI5'8%DW; M:13,.?YPS%/[ED#)*L^"?F.:0HOV8NP,_TOFGW\(1$F[G86/I*U4+; $ .D;.O,G7J"^W!1>#UX;XS_T9B,7+@W/9M5-GHH3I[Q#<9T MQQA5'7DBJ+9[<#.84YN,:_3'YYDPC;2NOMG7ZJSKTV*3?TCTXYTPDV&!%GDS MRDM]]H+!0_!M! VW$;]+:Z]Q'*SMJ6ZM77\K5#,TGI+_6R:S9CZ7QYKW]O%8 M$_QZBH4^)=E,C;5=-Y7 XZ/C 9U2 M4X9JK+ 7]T_=@G4Y>DD0=X+X9_.T]:)#?! >T7KK/D ?$L VZUQ*.(+CE+R: M!!BQJG?E)?(84Q'3I(Y*[4Y-2(!D=ZP;"?"'')C P%^E[A$D MB-&?(-K-CA+9@FA@5NE6Q>+=QN_^T-_Y//XX.QKP_RU\)]8*B0%O@D\NI<3Y M[^<(0UC'6LQZ! D U@+_I/E'CCLL/4:XR,(RK@]UX\5]>G<@DUW_#'*SLDHI MWB-IFYF[,/>U'[JP4%97X+3D:0O_V..^PW(?6-_/BB[=CD:EF(RD9;!G'<FX 52YJV.B5N(WL[)/SP?.?#Q"_"0V MB \)7ZL'],9^#2O#I@J'G?%1W$FV>G&GN1E]3'KD4*X;%2\*%D_@V06EW>M, MD7U9Z6 LY,B.]S28(S5)[176]5#M2^!CK-D4I_8O0#K\/[KU/]-*'/Y(AA9 S;;=G M@Y#S2S]PUE.Z'-T]O$3L N(Q$-SJR*D,"; 10P(L\#1$/R:/P+&1 $>77'J0 MK#:U00)\$[XDV[3]Q]]O<^Q>8LW07^^WM#WG.>)RQEKK4^02KAJE_/OOH>=C M) "%/AH8V6BQ/!118>_/D%.B1I&RW(N2A#]]9A,#V*-B;L$77WJ6L*S;>-O% MOZP2[:27\!5LM+/&4.1DY<=D^Z-[K-061%V MVP/WH,S4[K.Q "PV, (,A-G_WV4!*"]5*;FO'GPQW.IQ>[5<8FA2 ;_LU"\ M+D/<V Y&YNP(U][5R:D&N<627VS;T'M%+?M,2:-=Z O1H9=?GG72]TB^PG<3\MJ^B#COXZR/(#2MNGW^Y+I\L^^.-Z M5B4H;# 5!\0K5C8BOHSNLS/\?A1BP[?90JE,E>A4'\XVI^Z&5SM'Q8'N ?J# M=E8?L]=>KGW/.:_==]I]K=T)X\=,-<;XQM>_WOLH(/P@S $T:DJJ M2@ 1$1'P%/P!"). G#VS)E?O^!!#/Z2G",A(28F(2 V:(-L\2707.T!*=I24B= 0 " B(?K; ?S](#H#CI&4[-QY M<@KP@2H:X S1V;-GB,_^&C5XUP>\#Q#3DM!=$;E#>E'+E.RJ(_U-_]C,XI*RBJJ:H^?:.OH MZND;/#U=W1^[OK2_75H^/O(Z-B/\8GYA<6EY975GVOKNWO[!X?H M(\SQR:]Y$0%GB?[]^,MYT8+S.D-,?):8[->\B,ZX_7J EICDB@@IW1TM,E/' MBU=O^I^COQN;6=9ZGE/T$8KAV:M!2"Y!C_":OU/WG9:I.ZX@TJ:CWZ#?>J\.H(LVS)8TNOB#4)QQ@Z"^/@-7\: M:4+U2M\T>(5?JA@:^YD#+*ZSE[:>BZ0H,"ICEF4]WNZ9VVF?E".54<34975YH#>\ M0B=F6J_6- 8PC8Q)_JNLM,%J9JONH>O?)U:[[9=&/TCQ*5D(-IB>? MJ7(L<3P5NNO]_CA*>LQ?%J9F;0X=U>!']:<7<*0,C0P5'NL;8-[;XK\_T M*;"QL?M;VA 1J6M%F,7YV?8?S2SC:R>P:+O#)LU[J-3TD&*[A;K@4=6/U?5A M"U+MM;QLSL^73"L/N"PNG_UY#5X7/F/*;:<]\_HZIEE MD3=L[[*4UVJ-IN^&H]\,^3*[4[2G71NV3>]\B0G##W7=-[S.K"R9YJM/&18= M1-%_5_.V*.P:QF*^.7*7J"J=WGUX@30AV[UPU3CM9&QKUW JI"9NE)==@_BF MAW5'5]W=NLE*LY18V.WU.&_!1A3$7U;09G%+XO-P6W)B>GX;:A-V:Z)Z[H/2 MF6#Y5)F'9!;"6UJHKS(^=\UV:6M/J0@ VBAV4K]?(,[XQ6W32.WSL6-?8S[= M=O6/CPA[47:JY\TWL"4V681@;$4;WQT4GD]CYDX@:5!Y1E?W1(9>)4?5]BG* MIAL^SX@B33T#:S!\T$]K*8W.+M6SCFMEWUW97;9Z%D=WVWQ2B(@8\A:B MI1>#O8)Y;#/_35DM>J&JX9+"'7Q7;5V,DOZ2Y I:/8(2T/]1VMI"3W20&[V; MW>[+AX*\\7X\/YD[4N+\I.[T/A7;Y->X=A;7R(3O-^-$(J(BJ#QXVC0G+>YC M_'U8;3POY844ALQZZ%V]A\D!;]V9&; 9RBO$\8W#;F(A8\^7723KUIB%6Z-/J.W1C,QY6U?'K6J MB3IHYA@6.O Z)W9\)4I1\>;]P=1A"-6F^;F#Q.P&HN39Q M5)(7#MT\C:[VV*!)B-\\E>V[>O7^UN?AY,;92K?VL@4-R;N:M.U"F?DY#8:; M80J,:V,N];(-KIQ?I)X\8VD@/PZ&^R.IS%$SV7GPMN^HTVZOPM+"GFOO60*D MY'L_T3+3G:>); @4\%O=L2^Y!)GK;VMB^RRM4^[+K[<^T(Y+%=Q!-XI,31M- MZ7\N8"\2A<2[C@CNQ2?,A0&'_>3XL1FV$;%3.TV38 CEVB/+19TXJ^W>(<5Z MW.8(I0V'6N)MM]6BY^POZJ60UM'!KGB.$#TXS8V:N&V;*_8"%I+J GP<3P=L M]^FOTO2J^=$':(K/_5I*0XYT"VM? 8,;-4-;E2V=%U=HUO,>4H\5\/1TY8GM M<'CS8& +!(#6FA4+H7EC>=2!%F(9-: M*,3*X#*\R78-]7R$VUG7UR6+K-!+"@X"=_4D-ZTXA3*DBV(^%MSB(6T<,W ( MJD\/EF>W=,7+#]O:>3/E3ZS3>!@"Z=T!*@$,S.>HWVE>$O'73R<_0 3#* X1 MYZQIL&IE2(<+&&OX!:Y7=G=N]CBQKSP.;"65?3[C)WV)&EWXH0/&5 4A^^'^ M0&I3#&>O<6']I\V-TDR*C.-2C7" +SHQU9>>##[P9ZO*QQIBPB9@ 2[-.FJ M?&>"):DF3FG89JG(?C&K5W^1QF/6D1_5Q2U)62KZS0,1+GMQ#LJ&5:@9K4H/ MK]=&1]L5"U4X$%??@%L9?I)B')REE)Y3*I!G@Y"C4=E8(MZ_%1'"8W\FQI-5 M7'A"O2U)5#/7_<&RK.D"?//GH;KQU2_UN*SS-+)V*YM\_DFW^A^)C#8*=\U2 M-#-A>CJ2$6],,9DYDQM,GDL3'5 ;?WO!1?WBS*HXQNA7VPO$+\>)(5K&.ZWS MJ(JY[;*B&9#IAH4XOPN(G4(X:=O*PO6FW7A-2/>6J_W])_SD-!4PLW,$@,9] MQN'<^'JPL2<+=X#*/3H/$V\U5KU[DZYB;\X)9"SIIKEGH_/3E3'=A>Y,]U%A MUEL?I_0G9T1M;DS">M!!NON"@I><7KYAM[_2^N4I49>L2> \/,0 TM6-Y^K: MU7P0W5M75^]%H1(W7GK_R^.>6N>GY5D6K^(^[!$).&HW"V,T6P@ DZR6BZ// MKIL*C'JZW^[EJ*2!-Y.DCB"M0CA_;OMD""_%RUF/LH@!LAH"T*[F+0&CV6 5 M2[M>%;"C&K6@GO?^TN4S .6\.7_9A&SDUX^Q:0F*<.O^8++V_8V;[DF;Z)CI M3G,N-\;X+NEO?$Q!WHFW"4"C-O>%*4G;L7"0N,GF6"JA%]T?P2-IX6UDA1^. MGPZ:AC$DGB_]N*\_,QODC.EY&4NA*-^*9%<@0M4'A J/JAS46A^ M+)'Y,OB.;>Q51JXK$:NR[X$N%@0[2(3-#.[4"QUXP< %CD@7<_3IMT<37PV= M3^]),MU[#QT2C?.K>$I"MM+*1?Y<'\/_$.._4%V[^_F#3>8,INC^;D[JTN/L M"B,%ND[!H@(IK=.W3Z=%>/*O^LDYJ>%*FAEL)-R.=&:NWW%XGM=3J,DU6G&/ M\5P*5X?]G7@V&A8EM;B;?!I,Z'R,XX*=/16URE@CSGYEOKADR]Y.2+#=Z-CW MV;WMW7F6L96''N9+9TU82KVO8XQ+W.V-KS3S&]R+T]M(-'GZA(M*;=GBQ6?/ M3"-JHWUCTH(,K-B'3DF.J[!0QE?]!.#\@_2%3,L<>2N!3?DOGTAYLJ,_./YT MSZ#.\*7'WJO"%,P9RW2XCO8_&R-5L1=8LOMFYT@?23]XT3^U-$+4/X9H1P?/ MB2F'$V'(.DRXJHZK2V7F9W'&VDF+\_2UF,I^R< M3V>WJ;^0XY0_:[0A'1EOM!,F$[K-X>,7U2 9]&4N@:?)S81V5[E5F&C-;<(A MI$J#3*V\6:HN^'RS_H7IQJ6TJ8>]#=GN4R\M;SEV/X5V=)L$P8J;G)])"XO(Y)K]9Y*IW3Q]JQ;REFI0(5V%,. M0LP,X1OOBG-QZ?(7C PQT9IUF*2L>M@>(-$W3NUSCRN8W\]@(DB MMMVBY*S?Z;*IVQSJG^5NAE&:[>;%@256U+__QHXLE:@&MS!+&K0,$.SBV=,M1>1?D M>Q-AI!8B&?MZ.F"TE5ZAG,UUWZ_YW)RV3E6PC# M7;NN=NHWL]0'&F<[TVF??:^2XZ/C'"U&S'Q]47M#3%"*]L9RPB1_RJ4.9S&B M2:P49@HL2HA&UM#Y8^=333IW4UGE2]^35!9NWM>OF2!5A=TR_P(L^GET%8P% M>8,NLRW]-?X,JB9$$&N>NQ[_4]IZKK82R'B9U1"- M@4&IX3\=A@C #B9#V4OQ)0S5[,M! 9FZI 'P[];+\^ F Q00!Z*^$'FUJ M_>$I'=X,<@(PCD;N;U'C3NGA__&0=ACO&>0_/@+R[X\P/ L#$/\[NSG>>(3+ MWRF1OV7LSBA(IJ$G*'Y.["CJ5%==0VW-3/&YDXW#U:!D[ND AI[4DJ ^(N!H M=O,4=HP.P>/"H!5;\-4)R"F:_W,CQ:F!NT+G#$?=]QV[0V'J;@>[ IA'' M#_@><\D$L8PMEB5$SQA75,8(E,EW;(9^T%LQRXI5L0E=([A28I,[/:5H<7-R MTF- #$.W^6.HV-3P*YDKVX\!LMI_,2.CZ "\B#ML@2L72@V3R&A7JQJ5/&?\ MQ'"*],92;#M-Y-MUD2\,"S *I)V*M_GS?!O/Y9J0@]0S;:,V#?F;XB&-W[=B MK]':QXV8LNGR"+A=R@;5L\.I_!C>)Y, ()]%_\<<]](9?$?2+\A"Q*=T)ZIZ MRPV,-6UNCO_XYECQ)4I*B/N8'K\NGBC7/V#?97!H+/.P>J3RU'#C>MQ*WSIW M&DNVE#ZMG_E3GW.7!\[\'YL _S_I!A[TCY?F6/.V5%UL=C=,,%X,><&VHIK=+>OGP3YUOM;X=+SE]TPSP:>K:"YK6>7>#&P_I'5QE'G M::G,^@!UI5/QI1)VM]@=K95[:A+GYA9KZ(FV87\Q>-T0C!NZ#64^%NQ\2<%8 M4EI[)M-66"BKNBIY_9($8ZT[9^**F4899_U3T>=[*]6YN")?ULEO8L(E7X2> M!>LGSV[&O1>Y-%YA3E&3N.__L$F%.$HJ@UH'WU]% -(MX3L_LO^1=XW\B_U; MXHZHD 7&R'D;+T$RU\RCB$H+X):SI&NH M8^F^O$O!.0XNI.D>E%9/JN,,U3@3W!1Y]>GIHC(23%L[W2J)8'\%C#)%0/*Z!^2P'\O'GR=]'_JP>'XZ V\A0P#)@V05>9]9Y%* MN&UO4CE_BEFCQ?7^%8<$M8"71#PKSD9$*;7%P9C6N<-@*7CU@DC]]J.R+[XF M*L^#YFC.$Z.4.<6MZ:S7R']N6A:RRE?9E1KV"!8QZN6ZLW-DOEW9$1J/DL&^Q'4TY3:E\J?6CAI%3U+E7S M2@7RK89ICFO]T&# -PD2J!DDKJ%0%AF4";W-$J_9TD M/,\6/M*^XYBQ\+YLL9H*V=2H9*#\6:PJ"AKBX UER+;Q94G[O-YU2O9H3-"W M[Y'/I+]SN?X%BA1SI/3)>ABIM\+S4VY,#Y[A*.# <(OT6U4_]>3T'8FJ"Q64 M""]T+M5+8XNJV#OA75LUL0YO+U>K7!;>>OY[LXGE7MO50 M(KAE.L*EY40WX">RTB(T^_LA%5QOT @KIU[48[E=XEQ '%X.YYM^/>,D$#9O MG!IV-9?4H$H,-L'Y<)>LP^:2A(S/U?8[-LBR!^73 F-D.'HCG\P749J"SWL_ M*9&R.4D1^3/+:5)IP;[TIW(<*GJ7%?J.G)RLN]'J=V;>>>Y"><28I"OR=:'3 MU":[?)$N^J8JW4!YUB:G9_0'9"GV)BBCH+[4ZD^S).92?%;8BP)N_?4W=DBM9H?K6 M]P;)C+/7FE^B8%O<"Y:;PQWRPH.LU.36(A::M37#)K.VWS@]K(=E>X,Y:2A? M.-(%/R6UL7;.T9+D>%W'77>0RC O3XW+%*>F\[XC(>EZ8I*>"<^]-Q#:.)EO M,M61.:$-%WR-X.2[;)3ZGG*:C(1GRVZAX=V+TTN) >:UGXP-.I.EC"7>#7:& M=F3WUE[STI[*N7L<^5;&8]S4NGNBXU0E77_0"-H^RV+#P;?+%"GHPJ;.9B/( MIJ5.H509NV0%?14GY?J4=,[LK"4SLVR-P39_HI:CJWG>RZRPS!(;B0G2Y*,: M6QT&L^AE%N[4MJO1KWJS=W.:WYB?\$?!PO'4EF9O;1PW[U\\+;CY2K1E,KZ5 M+*J#XS7KZ #6/,<];GE^N-1W0.?*#;L+%0;FO_(.O/X M%2^7O6Q\H(GI/&3+W-OJ MWGW'S_V_[* UZ(EV(Y#EB#!X^<+05J6^;67=YO-A<2\5;U7&:8,)J1GWH4=V MY^^R*AD/)G _D%L_[-IL+YYRG\<^]&:RKXE>8&Z\9S?647AEGY;YG C:X9![ MZJNNU&R?E^X/^H=DO3 Z>2;L_=VCJ,I9)@,K H *WY P<$[6BU:WH+E,,]?"%F5Z=F7D/T<8T#I63(MND'V"3W4F_PM<97 MU?,ZFMP?-1.43]HCGI*?[(4!J/3Q:-#THZ+D3&:??(IB2..]&KQDW,I_[!A0 MQ*)GM\!^0;UZY=D#F^G\+#]RWE_MXPOR\SS *]4,DJPZ!Q+L0U1-AU*=YH6- M&^L.MJ%<1:SE,=&I46>)$NQ*@MG9.:RGHZ.PT +WL*.[52-;%B.;V?OV@EI[ M@P@6GAJV)/D/P8ZQ.O-<$S:FQFS?=6F0;(WG1C=N[3Y(>6:#* O>]^P)NG5B M^G;[M-:T7WS(LOG:D+?*T4:.M<1)Z*=:B22EB=L+UP.*F+O9[8F2.*L],MNT MIDD&\Q3IGU"V[C(%%;M$*FB."#U2Y1Z^%\09'3?WUOOYF+-6+'Y;9HQL;DNX M=88OQF#<,NF3@EN.P=1Q/+1GZ9U?)!NEVB=]:C*6]N>WOGF.O%B;81MR]GHO M)"#6P,\?2OO,PVYK2-+LX9F"RV9^ . *:!=T\U_COY)V::"DDLWP34E*]ZJ1 M;-_2GEX*$0$@TM8F 'XGHR6/AN"+(P1@HW'V1+QP2]UM)((W*^PVO98B\%?M MQ;JDCB_3@'UIWOP>2C>VC%YA:P\:@EZE&WPG,U X>EN5>2@;DVX[Y=W].W".Y#+A]-]-N7, M1AHJ^VTIR3Z/+,1VQ:[W)#JIEFYQ-,V+HQ"1SB+Y5A/BF65Q:'4_GK)[@M(B M,!DKB/OBE?JYL/7LJF 6\[A;V5&J;ZQ8GIQ9HCRCZ0NPG^C&8MDPWU!%':S^ MJ!J_TJPPG7T'WTZ2B$\\/$+MKXB^'R!,BZT?%Z@953W6[!U-57EB]'W"Y@L8 MIHX!FZPO$5&9"<'DG[YP#F5'#9W;TAF_$BF8(%M&GG&.B7DRZEV7=7+=SAL# MP9U060K$FJ==1W5RY'3$H*$&Y6=&5;5+(>[+OK:O9!Z2;, I?Z(K9#]92=SH MX?P8M3MYM>(F)2<=&;2%DPF2*"N3Q_PR%Y:C!7R^Z8IND_9*?)KT2+NOU;DB%8OF97MW^#PJ M+ZI*D/Z)GPXL5(Q95N.C:MZ4*)<=UZM@D\+=+^57"$!SC*/!V\1'>Q"MYOZXW2=RI,D6[&7'U%KO&EAD!#,@ MU8F#"B@]N&O>4\>QJ;:*:]6YC$J+MRFF>L3&%7QZ@;*L0FBK5[^GAF$!0L.@ZA8G6' MR OKR2Y58S_LA07-:Z(V7A [E3RD,G8E(LI9LXE?-?S+%[*ZN)9X$K#WM#< M<O=9Y* DQ0&3@^R3KR==C6Q?4 M+9_5!>"_$MGE>KR@\*HS3[X-]51^=VF!R _@NN*ZM.1EUWMM84;O=?1Y%SZN M"+^>V.]F+@RK>,I!;^VL[@PCZXI9:XX'_E0Y6PW&2G,S9,9#KY16/B\8ROIW MR7G*E^F,VD:II,&M3J]_PQ50+1^%"JZB4QB:#:75^&W M?M-9$\>R&Z DY]9B0A;=@J[OL'E9(VJ=7#):(!;.E"BI=DP1D5[OSR2'7HWX MWGQV6%R#4[&N9F3;HJ$./]@4=[W4G$[*O]3,\@YGQ+FO@ Q 9OUSW<(@1]%* M)#_GDY8B@_\=Q9LOG(.5(HGC2+@?5@]TL5.B2R^VP"_F[B;F.-@(O4=?E$B_ MM/;XBL6;MT%AM2W'FJE!S 2)%^H?_ MT;0/*7++/]75JAC,SX=^U'OH9^3W8$"UA2=/5CML'Q:>SB8@3V]L55V3;/PY M:^+UJUM[^D_X,A\ZI1NW5>6HN:P4#.O:?JZR=G>73C"W+,W&\N_ZN7\P&!8 MC8_&1Z:RC/WD)=&/*Z,R64&N>YG<6DC93YR7-@I1\- /G09VWX;'Y=-0)IJ6 M ]U7&UY(\J<@V!>AD=YX9.5J8.*NT%A+N>#7>S'%[=V4^<4L3]B=B<_()XQ[ M2^*R*QU8W (8)3WX=3$6V-B2:'(YCMUE:/^GZ[1+.C9L MQ/H(IZ_T=^\CCD[2A;LABKZMR#V3YP3@DUT7O@?V4?RXZ924 '1[1.-;:R"G M@KXQ8QV[3*='W1"K=@*PS3\"8@5VP^>R[JH;EEYF,22ZF15K/7C03^%>\V3 M^=B9V9YCXJO/FR&6;?HRCEIMB!]BD!5;30 "LN#=<-!^;AK6$("A#\GHF^\^ MN[_]6%K@Q5/^@P]N=A!.O%*44''XD#59(._EIJ(U'JSTBHS68_ACL=FT1-#_]13P!.'I/XR,M' M\LZ_6*1/;6!W7CH>S5O#@6,&//U_Y<:3?ZH!M3C^A4K/I-"LP;X$\8:JCM&^ M/;6/P:K7%*\HSSQ>$N&")+VR*'%EA.Z>YA. ,9#G!JUN_ZH8 .^_:/PK.,EY M9$F<*FG4-\Y"TI M&''>,:\3DNWJDZB&T0LU8DO-;K9>I/7&&(GGA M1+;T%I?,*E3<YQ7KO4=,[#VSE^U&KYWH3REF[Y[8$^)*%BBHWZH4C)ZO<1#2S;- MXCPJJ17//^"M[0%]4R5X]X3"AUKCTYNI:8^8[E<,$ROW+GD>/WQLTSEZZT[ MM5SK*=K6]BC P22\079B*.Z#:OHKW\_P*N5.6.AL):/__,Y%3+.=KE)=\'). ME9>Z>SM#T/L'CVY,T5"3(E4W]BCPYW<) (_6//SDJ!',2C?$V 2JPO-EGC$O M5T*]9T5NH+TTF.XF+$/T V'%*@_/,_/0K_.>28PG !P( F"\ N9#B:[UG\XM M_RC( 40BU!9Q3(UYC&^R1Q[<*EH'@X/^2@!B"$ 0=&-T@P HA#4U)N'PZ?U[ M%GV[U-AP?F^DF/>N2?2I-+S;&K4ZM$@ [E5Y='I"-\& UIZM'X^A&3CA, M\6NZ6.$]Z+5N K!DJH!5WY=?!:.\=_'HTR\G, ?#\.9AWSJ0$X ?8!TX<$3$ M%VU ?K]V.)6$5SQHAG^ \O0A9]>]D5P^#'^N "M'FVQ@WRO04](I^&;5B0+L M8@=L9Y;+)X^: -0B=$ ]Y]UZX ]+G$4]T3P6/H'@PEU_0=$)5B!^#*XKR3T" M$$< ,L%N:QP(0(ZD^-82 =A1'TS!1/MAT,V]8'W0![M\N:N,"PMU5Y>)?0O(.FLVADHL M6(3WWVXU^R$IM)C8NA5'ZF/-!L'@OL,W"@G S\JB*K4N/-0%?FR8+R4! M0(!+DM[.9/9NE;\W) M-;U1QG49Z=8]H;):UND*.4\ [#8,MY!)9]";O MP:/!RFKC_I$PWBRD"%3EEXF!RA. N:+9=3RXMH+OK!.!PQ@''.N):\$]G?W=>?V^_@Z0Y[\]0FNR&SZYA"< U M[QT: O"EO*9G7[F?X2P:-4@>U(#P%89DK MD.T$>!L!X-RS3<K81"X +2"8 RZ[%T M<]GOUY#&W? EF/KJ<<6>]P8.G]>SISP(^^2 37H'DAR;(R@6QM:H?!W^3*^[ MLHIXW)[RQ$L"BPO#7(#F)_QU1)C.:^(,FEOXW&.KHWZG/VP+V M MX*ULNE6O=L?.<8N%[O^-0=:BK[.GJT@$Y)!BD#75(Z) M_6CY<"U2*,'%=JC?:[GL!P&0(-V<>^X@"VF48K?(!F<>/:V,KT?@P]4:_ID\ M_80&_["?]V_-$8:J/B 9:50WVU-+1T5W#,WT/?%X;ETDC9#B(C5I,3O@2X ML'ES_2=X,.J*)3YPV&5XJQ)\Z3'* @?7! BG]X\ M)GFG@F M:7-GPR.C\6&>>U\/H>,.^ <76V8/L?"#QV/K>CM'!LAY>.QQ%!EN M.PF3M.);#"I33.8I+S@)HN.CWXCF)Q3+X(6#M<./$,BWXL>[L QS^';,,=YV M;P-.FZX,;Y6'+JW+"A, DZ/TDP>')Z>P&!A*,_I8.IH"E U-J_CX)M_FL7X+ MV [%\*&%#F0.3+3&L_F\6767KD+IA3NHC'?2X2&L#*=7$8D,S+:?1?83>7JG M4XB"/K]Z232P]G]!\W\*:/XD'^NVU!8[UG8O:H1- #/,$EW]+N/XFM7N9[[V M(AS 1EW%4/T?.2B#HO)/>R!.:5*8H$SO6T-;AU2^6UN"%BF&2H.M7)T?^;Y% MYG_$?7^>\CQLCRT]'$+B("ZH=&+3,);^4,?0'ZV.BF#F];YLG/WRWK1_7V>_ M6A+Z"ZCLR4"%CF;3Q%VK1<3;;)3W9@5+4F]9J^:Y52&_8(PVH!WFM0A3M>M% M/"4$H/=4LA7"+L_\0RXDY$#C 4K5PY4SU%Y@>SPG3?>SB>K%@A?K77MGFH*1 M,G@.$$V**#@N>!-^D"6-HT'(2+0,MSR)N%Z]C2C8,/-(-1IZ73@2IB%C]3,@ MC!=Q[N0V(@8ZEPW=NXX1Q2/SP 2R@<'&OD!06NG']%@6 @ ;!L-1A;#@(0#P MG(T3T2_?D%/6)Y#S8P7X'OC>RS10?2! U9.5UEC>I(DV) #QKU&2.#@$1W]X MDBB#&T5@8$N^S_T)@%<.GOLXO0@,I2^O[]=?$?7U(0"MNL@1K"0!\#P]5H"E M,YQ0_XYG%MCI1WGX!]GZV0Z+P=G?H;K$A+VXB'^0#6;\X8X' ?BX T-4[8^/ MG;8=X/1'0C!@@4( Z[\R_S^AM%*#R85+05LK318.%OD:7MFOK;8:(\M52O7X M+S^[>>'S9\<8T8' VY^R4W/X%WA;^N&&"PB#3I,9=3P!T%P] M%EUU#\$K)C3#DN7=$/!)N&H\9T-H/RK M0WQ/_DL?N0<_ROG9YZWE#X5Q9^W ,5K>R<$+83$OVV%:;^#US\Y MN&7E;8F#@H)Y/WOT;]4S!RPXD/IHG L,QYC@6J!' +JVLT%5KPLR3PY@_.>= M]A8"8!M]3.,-)0"FE6!?-F''$LWEN'+HTAT4 < %@SFN6LJ_-('C!RWMJ^.* MW6U^$*(!!( Q;&"C0?MB#P5+C1 R2 MHS#1F ,<]/%:K0)N* ^#O/=+9H<>F?[&@'#-H:J?R6!JY;&,8 MT/,2_JJ5 +CFL3RDC%"6Y4CE1S2#J]6N!@[UU8" M 0"=*SE\K&0,'\+@HPD3\!V'[4%0>3C/:?A/1]T:D+Z0P\?X^\*CQ/=S^2W-2_[[%TO'8*4XS M:2DZ"_ET]EA8!$Q%"; *FR.&6+$S?T;Q@GLX[G0ING*> !PQK+>!Y?"=? S_ MWB2>/!3$&B@]"$"9_2R8R/8VA]>0@LBY_/0]V 'TE'$+-$RY*TV-Z;@U3]%T M6A2$8VP\':4./1;BX 7?6<.0%*$+D+K#"6*&:/\&L_'D(TDW& M!8R6->B)""U+QH'>&IU;5Y9C0[Z._[S=TK+(\KQ/27SSCZQ=.L+_ M)U;6:^;Z[F +K\C\)+$AMSP0V%NGY*)5]B.%E#@]Z9+7L-IVRROID,@J8^B" M=M_[%56A!#2+4?[P1U.'&S?>-#\5O;;/];ZUZRL9,9US,STF^LGNM?!\]4+1 M7KN=- JO L%>T@7!V$\^M9".WJ9;DX%QYV6@%KN2H 9;@V)(0-'(42B]O!,J M)L>Q_]"FA,^E.N+K<\:X@J=2G[V'H[\6*)U0KQM6#DR%7TK\E H4_6OW7$ZNF$!HP>&DYZW[2)X# M:R0!8/H;H\?*;_+_;GK'#O?(L/06>$4H*7SL *0 09OQ;@(PN^:)C]@3=3AB M;0YIU035<3'%@X#E;Y$.R#+,-ZN-FWX1F1=! MZAYXYBOU7>6'%ZB7'XV)YV*@F_)BWQMO'ZF*U+]68*< -+F\&YJ?^K[JO,,= M[ ZP4SXD_?R?; V=)3_%*U/QXYOR\%:&54&@6.$,!@N$"4@68B43!;:OG[HW ME(:#O' +CK;^YYHB%P-6QD>K-Q<+=1GA,O!]7\?F)/\RL.>.%!,,%@5WU^Z/XN MU1$;O^._ LQMY- ACF7IQ>RVN _UZXWO(%L@CV]IGH6/[8+YKFFB_V*'FK^/[]K1:_CTXS,F[9A8C72U6K./'.>R\^" M+P_BORX:]2'8,PSP_=\-9W@O$[X-=+&;(TB%<5#3,W#^2],.2L^+_] -7A[" MISAH^E)_Z@+DF%'GV-?R^,\J?C^R?;2)#>UD2@ HBMI3T/_*N4?7_Y)TKW&; M_^J+HW8\.5^+MS*J5!/;]F^^7>;E(<,)^G=Q'_Y7XOZIKVQ7/[;][^+^S7]9 MW%>!RYQ] U))&A)'AGW\$KZF\,9$$>?P;& M:>T^PV[B(1Z%W?AEZ,//[K9W,DL1@+!_4Q GQ>V@9LYL5U]47O^5UJD:I%>>WY[7K>'PR7LER%%ZZ'\1$58X]>Z[K-U]),0#/8?$J$J<,'A M^)R[&[X-S\H#L3UK/1WU2+P M2A#T^K^V# Y_L@SQ_RW+ /OO6X:D_]PR6/Y7+$/-Z=$ORW T)6?SSW@F '\% M:#+\^6WX(M\?-MEP,+E4>*.PYDBJ'MP/[ MU(:-8'4JVAI;GJAM=H,.5.YOS M#5UDM1]O+$0++BNG'Y'8@7:!:V S)S8U\_A=XBU7]K0\8!C^20"^"HI69"1> M/%L1>,5QHQ9@Q58Z=17OLR9NFL6K)W*4$]J$C)3 M=PH),J$?/L!L/A^TF^F^V&-H=:1.8[1$%:&&\G3\3,JOMV%W3_A(C[A[^>-X"?M%OK^&@//BT\KTO*=N?THY__$VV3I2EIZK:*X5UKC[LIYWDZ.A,Z/RW37M;-D6I;W M"1P0:2G/&W[-LOHX_M9*468/4>N&)HG&[D*/=I&?HS*3EH%'N MRK^Z=9O#9?>L.HHCW>.C9*@SA?&='6Z)@2FCR?,=LHS'[RNJ5%L.>J@-6NJ' M?2_H8YYIV#7*S1]?C1JQGQEB4S%9UGY[XS'SD@2U9HEG<-U\JFA'V9LJF7L- M;Y0%3(S>3SRZQSL7[<*E(S9+[GW=Z6/U>\>L5K<7HPN3/?77'M)<:XWLF _8 MK77:,7Z8GQ5G]UXM.;Y!I15U(1YU]&2D2F$>2?U#?]IJ^VG<^NCTU>>)SI<9 M9,KJ)=@7<]Q@?US( M"AD:S),]4WI&M4G\H8!>D\["CDM7CZIHG!367+?SK2 M7D><^QL_HJ.V4U&?4^8?B:7\CY!46A9__6/NB+=@E0;P[./K$X\Q>6UHUIR1 M]6Y*)C=75<=/2CEHT6:U %5R:49;%_&UP^@%X?-K)@(U-ZRKP]UH@U4DRCB7 M8X!I:C+_P.\TYUJ+ K42?KQ?'DMCPG!;9'?EP]OXY\.#G,AQ:1-MYU_HQ/AE MQE!&6*0< ">Z=U#[[7#JY<;F#^TFC.6#]L\?1HLWQ4W*#E1<*F:YH<^2?:O? M9QUNCE9OHIO8FUV^(N3_]KH)D7''UJU%3G9' Q,(*NW]O&N]M#<5 MTP3$:?O5C[-V]9([8'\,8+: [;:_C0I4?!12&/ M9!Q:L4A6F>RUM>?G%'HI\N-$>YWWK R>]A2RK0H"#]2L"T603M=ZX9 #F523 MDZ&%E4MR&BTJ9F[QEVGWJ*;*NB&1+N*Z3X8%J\+/%V\O[MOE,#MWLZS*-74^ M\ESGC!KR?CPW;LTA&X2PQR'8.[9D>\5>*9 MOA,5\5![05.;P*L?HVG?2L<8REUQ&F:>3+%G&&A'];?K[$U+KVG%NCAQ+PU6 MB$0NQ[-UW]^Z4AT1\1S!/BS6'RS//NA@9R^&D[--'+42NEI3\RPFU*A.>#DZ M"=H4<^$6U:9(R=I!;94$?!Y23@#27L%GCZ&80N@\I R_E'Z$U\3S@2E$+HK\ MPX5HC/(FO(X'!QHRD+1+6'G/!F%B,S"/QMIJI*/?5(:*V\EH7IUKW>]M;5Y9 M-IY*D5KK.U\*TT2%M$[?L3 ?=G9OK#&G$,@TN%W(YEFZF="ZSC\J+G=S4J_< M2[T6^X.]P+P;XA)X(6U.AP313DTQ_G$W-_I\L!5WH@J7P*Y(3-SMICVW,OCLM?2TR9N2 >$X#7OEUXC^Z_KV,A(@3+DNVN^W2H^&JYWOP>[57F M)QJ;2T0#YN_BUS7L1EVLI:..'+[7.\^K&M"J#_3][?73N+^,E,;]G7^*3BG/ M C+HUX[..2S3C-! DGY936W4K2%%CUX[_F(O/\$!,SH?(H1R87)B@DVQ KVN MX_GG89:KVEP1TC?,H?YG*E^GF.6\,F?@?A'-4(6!H?A6OGH%SC>1H MAG2<[V+7[G/QGV@(A2Q_GGZ7!6/DV?$NI%WCDO8HKT]'Q)'""H/;I& PM978"3;"V,GV7(K:8N,-C>)36OHW%MV8C=, M#@LM1SV'[B9]$FQ3X'E7B).T,U]R8W[!+%_5WXI*;WMI=3TGE?'\)AU)M:%7 MW/#ER-OD-Y8B(B@YLAE&R!O+U-\CE!2B&MBIV^'!T',ELH^23)A0&KG1A0H4 MW218B96K/6UJM($6?(8V7JLEGK-83C1TOT\3U$@\!(#AB:SL>.><2O3<+CB&ZM>Y0&E!?(6YELG43RL\RBHG\0@%?__J;NX#W+ M0J2+$IE4GI8^_;_ZB]L_MJ>2T6(D+QX7WE6+R[-7^7)+UE_SNZQ=II6G7'61 M6Z%A>]Y4;11;L$.BDE0+['$K-M)Q0KB#'C7S@3%)/%Y=L,#R_9#FV_EHSJO% M"G,5B\+G,4::+N+)!C/BI[C$!96/YO*6$^5*VF_Q*+/HN_S9XYU0KV?"/[8J M4[T>C&6*6HT-F'1(+&>\;+%_V)Y7& -G;3(17J#VDW2R+I,/+#1<,W#6I9U2 M/'O/1.6K3SJ7BNHSPR_>*0'>?:JKXDEHGQ'RGQD;$C$49!P.XZ;FDI2RZ0>) M H9'JU]MRQ=QIJNE-N.//0M\B7I/.4:>P^T*QN]X6,FZ,59D==,/5FN/!-\A MJ[TO3./R+=2?_[ZV>X,59NH]7!DT*E,=:,_EAL^_. /J6\+_BP:9S/V><[2 M]*T1G\G1VD]OM.[[9R)#R24:2J,;OJL6\$5!"O6H=?42DS[BJH2G*94]IW7G M*&GKYN8"HQ_8&$C%60ZI3)M($B5\7Z+Q((:H[4?3846^;V\?-D1R['T>K++! M;.?N7S%W9)T4$"JZNE<\Z>'8-W3[\K[Z G6@:]I5Y.!*JAW=I&9U9754?\^+ M2,;KDM*EFM/F;?L_G)+WZJZ8%QPP^43?JZ\/_CIC&+JD9QJJWACUDN%V][7L MQN]VSJ=20ML641268UX]G*9//.,Q8]]FF%'>@UB#&M2;AJ@%8Z%IBZ;F1 DZ M#7M.?V+RR>BO(BV<$6D:+M&GMPK'/U_^+CC?.$G7_>J3Q)H(\6!W^@?,Q)/G M!,"HJUIP\+7=-^$6H_ZR3>G/-7D8W\X=%YE)'_G!8"UYNR#?\2DSAU37;_9\VL;K9UHPU8Q(3 M.<6C:.Z@WB*^A!#+[BDO2HMTZZJ<]5&#Y0BW1":1Z8GNU/*.<3(R8A\G$T-( M:^0#S0OK)T].4I/#>RCL1+AJHNY=Y7=-6'C1;N$E]E'^W+$R^TA/?^ 8ZUB@ MG;.Q^L,HITO?1EIUJ+EL5KC"WE!(K)PSHM&+W\/Q]SJO$0"1C6FTW-W,RL: M$XCTS)-DP=Z&@25SO0*(/[$OP[YFE"R;<*"W:::E@??H-X]B#9;A-$N]SKS& M5T4RN9" U9V7;G9:75Q'8^D56\5C_4X,O?Q\P30]7+9#/#VVG%+]VGOLJZ,* M.\G.3^/L#8_)1#<]KQ4LPJE_)@LVE^7;Z$A(:[=J!^^MS#\/N]N20!3:RG4& M3EX$2M)07[K=%YGH2TP=]3I%7I^ZT5XR7Y9]LEGL"E5;OF WVI#6Z>,[AIBD M4UEWMY83.7Q:S8D=KK+?*9\IBD=O/N&"1%%*W&*$Y[[)XU,F_!=Y(0SG[CM, MO,%W9YDBX<)BP9O*+)*=*,W99-9&]M,,12L'KILO:_=H^ B]6AF)R9X1DHB[MM$'O MS?A[K0E(UH4HG$A/K679N#N(4QSY9^OB\-NKG+[>PQOG9Y M[,\JQ/L#>3HX*(%$GH;0M<.EHZ6HOB#X^[],V^ M_U&^G?!E9(WJ5HY^IJ_./2FRE)=P\N.*+@[J^'88C1B=^.54#" M,\M0Q8\ ##__]Z6A>(^6>_;Y9/9Q>4UCY7LA07M._6?)H@G.I@E/O0+.B+6I/D=DN5&TDZVC\^/3G_^#[BT9$&/]_ M %!+ P04 " "F@EM0_E2Y8H5- "'60 % &]Y("@B"%)$B-2#2'XQ(KU$101 1Z0@$44"Z M@(BB$! 0I47I/4I'>HUT"" =$FJ E'?<>Y^]S_;9YYS]ONM;Z_OC# QK,OW)-0?E!F@!.&N@:Z !45%7 3_ $HXX V0'WLV*]?<*,!?VF/T]+2 MT- RTM/3'6=F9&9F8F1B8F'E.,'"RL[*Q'2"^P3[24XN+BYF-AY>;DY>#DXN MSE\GH:(&Q]#0,M#2,G"R,+%P_E]OE*\ ^W%@Y9@ -=59X!@[%34[%:49@ M%2W57S;@;QO5,7".=/3'&1B9P#>4GP".45%3'Z.A_C5K\-5@\'6 AIV6X\Q% M+;J3)K?HSWIRRCU)S#HN?.7+-ZX;_3B12[OH&AJ9FYA:65M8WC':>[SB[W7+V\?7S]_ ,"GSX+CXA\'A6= ME/PRY57JZS=I[[-S06_M;VSN[=/.#C\%1<50$WU']N_C(L=C.L8#0TU#?VON*B. M^?UZ SL-[9F+=!Q:)O2W/$^>E7MRG/-*8M:7;PS"EV[@N&X_ZF?D%I&?%<7_ M"NTOD?U[@87]/T7V]\#^$=<8P$Q-!=X\:G8 "I!,WU;1_YTJTO@YO"#[J](+AWQ&L4X+W]/0H0+@\GW@U5UXC>9B-<"Q%# M]$N748#&-!GR)3VB&/0D>BG5!C%KS$,!^#+98._KFL@GD5'3.T9%4-R'& H0 MVT\!&'J;-P]%1Y $4QT*T.I"/;B$DJ4 SQ:Q?B2.51CQ_'L*,">/:/3"JY*C M?/+(G/T(?!JP)DB X'UD'Z?3-#+MO.J:V M!.X_#]+A'9AIB-:-N5:>"C.:/:%_HM;=VEP32 PSP#9$X>^F8F&"70.$IS/Q MB07M(X^6%XKK=$[>G=*U2(+N0GVBST WHMM'&H2F_"-AM25#(<"2I2+&M,5' M0NGY;9K.4U?$)]A/2%@HF+4+/XFF\U1I6Z_'&O$297PS6,LC^-;71$9V#N;3 MB]9PP.M=4))I>I_CJR(?P M4N^4<4LW]KFAH)1 $^SYUW)3TT, M'R U1[W5)<'=@)>0QE Y!7B.$"*ZS=[3..L*9]V!,_K[CIN5J=BVL*=9_Q&^ MD26C[[&#%"08&0W6*8M.=NJ/-&KY!E5F M]'/I=[[BN!5_&;#,";J"4\S".^RU;K=, SOJ@1OM7&%NZ!/-]F;O7HI<59(. M&'NDGD_:BT2M&'T2[?TZR7UUZ,:8*CB=9Q$G2HJJZ6A/:\>>H781O*AYBKOH MR&6U!AY79W S0W!0IDS2UMUSYVC\W@-H@#222=]\WJ51$9LCF^#;-#%XE_1% MS2G;:G)\ATB8$(B*?'Z;EMR7ZPQ9J>*@4PW]*C*_W:V-IYY=C*YSFPV&&983 MC')=*I5J@AM>86(*;2822KX>O7^2G<11Q*L\%W;IA58F*^P&J93HX?C)WO^6 MFF"NO7_-M$W=P/B:J9V]C9RM;9MD%7M6LM>E=6J(>,]&1 TJ?IJK[EYA2%<# M%UXFPIPH6.P?30&,RFKB9[_W.N]%#2A==<^C]VQ="QY\<CD4!4-B%"!L M/UPL(;3>J?UE^V%&1NQ87@M>?FX6!IT3,_0/JL=M_&6*BIL>8D(?5: MJGWE4"QF@)00\O;4HTM7OOG)^KQ@5F1,[/8+3(TH+W)LJJD(#\9)ZM0,*-B. M*@B,&ZAILQL4IU?*M^VK*=]*;Z)7H$N=J3?2&5R[<%_CF(O%JU>*^XH5_2W8 MXZ'QDD^B,"1+C9M'S5LNQS;72$>:_D^Q>5%Y T':F I\\]Z90] M[<"^HL_EQ\6FOW]\..&C1@TW7#KACVK<[W>X!Z4MJV7ZN$.0?_D*PM[,YWZF M-YGM$%53&T]?[\4-8427!MV>DJP@@0V7(>R65T_N5UF3DLGHLLZE:7S8G.2% M.1>J_!@^#F].Y?^)]O"855>U+..WR/ODDF1EUQ7C[2YF5<%W]ZJ!T@.:UP0: M+MIXB9J0\0RQJH$=DB*FB9M'XU+M\/QG-VCIM-BHH^TMC;L5+G4+OO.T D\@ MBIXM/GL(1MIGF!*M(U6"#__6^9EW@H$\AVFMK8XUEM MG=PA=4BO#=,]XTEK;S<;WO#P+.CR4V3XG\5GRJEL*7K+7:5M/P;HSF2!-1M3$ M/B 9*(#;:HV\E%. L$-=VB/CTX]R?<-]GL4ZGWZW4_P==GRE1,0EY-B28>*X MS>A[L>=GS*W.?W/A4VR3/9J7"[]6RRK<+7LX7(0IF MI=+T76A)ZD0'^QRP9B\/[OC?WU'G;[*N=5$S+C#V1+G*<23>V\^E<;VAX7?^ M*WF#WF9G$R#XV1%L*I\V(JCE@YG6P__XB6DV.784LC+?DIXMQGB9;\;4G2A3 M.,9QB\#UOC4HIM8CM=D$D5\3O'^>7) 3UQG81\>S+HB'-_M1@%)DTR8GX8:[ MD>Y0$.S34O53HPR1ZHOV0/+1>Y.\Q"D>QMM0!2$ MF."&7X>[[W00==@C+IX8YZ7^3F;_6DS? @=V[=V^72=HZQ#4<_TMFTQ=*PXS M\AQO%7V=]MBRDHU]%3/? 7"?FA.N!Q2AX\)M4%SRO3';(#4#_I%I?;!5*X^N M)GW%?+W,+FO\]+NNW<&S!V="E^WS6H^*$'!25L@I@F)3:V#;,WEWHZO#J.)I MO23Q*8,SBF1KQ[-*U(]#?!3K9Z5L6X0D!XG&!4%T?9N[DVJG*QO>-I](M8\\ MCYR8K4A.F4S/2XSV:(;1K2"YG;^\;850[P>C[C2)6K>*BMK@"U" M@UVC@[=\YKZI)L 6N:-^@T5^RMXU3C7@TN1%R\CN*+ZS3I?'2L*W+WVC3EL) M,IA1I0"\-E.VJU!@1Y6P*1.?!WV#%:]4Z-",DY[EUN:\GD?_0M95%17IIU0S MDE+0>:1!\)]>]FSB>A>#NO)>-)*D/W:&T1?!JC4>?U&3">>\]PX3;^=NY%5L2LX6R,+@4X<_DTYEV0*7X_KDX2_[BY MX30:KU@/>5I6=+=G3( ",-M;3]X[O"]R5:0"_>6^4?WH6VF&TRJ)RPY9LPCZ ME0PFO +FN3PT=$PHM7 BDLW' \O[%%BO;F23/,Z[Y?LD8Q?F0/#TQ";PZV$G M+?="^F3J= 3:Q,8_X&ETT@<%^##?Q]:J>"\P\/(NB5.+AV!42 U16!C?!,%/ M5X/V2["%@'BRV7A!U]X?EN?H>,^,PIB28L("1T+01W;^F]\*?')6ID[B2(O1 M(C&Z=9\3K@WEN"E%7J]67"G1-Y58FI@_QA? -3)*$*( ,+Q% =8($2H$,?8P M,W"LKR5/AI9UGF[.?,JJX;G_6>/!07X:?9-RD,P'X[QE>.EBY-K]G[5AA_IS M>!JX?%_%DE4R=XCV]]C9QXQ YP#:=9/?+LA*B+L*=_72\EA(@7OFRKX%Q,6+ M:^B%9,>%!Z:=6RD3 &^DTT%]@?:<7YN[QRP%:(;Q3UJCQN1[J0E2/M-K%2_: M!$E=VV5N/V5IUJ]&?8G?7+?!.'"-R 0%\,2)$=BR.K&O]U*&!9I/'-2F^!8@ M)V:JX"\O"H3.\&=A>^D(M:T.\AXG7.&,A1L[T@CR(Y-LL>JU_#?&O@.]+(>K_*/YG?\;&'[_;@ V;3@EF-[2W M6AM1>7Y<,AT?+Z8+2(R@KRP*V'PJ+R/H+].2!FI8J08^6R._?&TW)T[GYH>% MOA:^^/7H*=DS1UEI>B*[,FN2Y7_R(53;EJV]L7#V(!:\:4L#VR!1ST_ RK5B M2K;2[ZK(TA46C.+7]5F:+S7QQ-T"%8]UI[DXGJ8:8_+;7&CT)O&>9Y%_LG'$ M@>B=LH&;*8Z5E;%7PDLZRY\J48=881TYG3XR MS[.D]^(-_ VV0I9%\!MN LT:5/5X>*2W,9,%@3K+85GE@AMKNIO8\]M,;KS7 M:T^RWY'NH[*;"95C ;SX>=;?8.$G@[3+!@LU(!,RD4G;L,%=:HD_/*06JI^( M.HO(O"S@2S0K4/P))-HY?X.,"[?:M#4&>[;&@:;L7/ELNK)H2OGY/Y32"K<= MC/C5V,.I9G3L:U-_.MMGWJT/A-&ZRA$:.UN,<4R:_*0DW5?[G:@K1;QQOJV: M)^8DT!))'2.*,/DE=[M0@&'O;89; M2]=T60!O"%.(H@/1A*"*37]P2 $,<,5??@1+\O* MFWW'OX7TANB$O4<,QHLUAHCA:=-M\57ARQ2([R1[ 2E)AX'P?Z&XRY[-J*CB<7W04Z7L^.CP\@]>)9Z :"I M> 0(YD,BIR"8!L[1*5M_HQG?Q*PF_Y5]R%V\R.-<"=FLU\T&C)>I+P,X6B#@ M/KK2\OFZ>Y"Y+YEK8%-*2MZHWLT@;>1Q>/3"S1I]13Z1..T(5E9":Y__8I&W M'[0<'E^HIN4S4YO Y"+WZ>#E#OZ(9EK@A=QC6YNN<&008+!6[4!5_!-6'U(Y$/9[6_ M3U!A&:R.?X["P+LRSN6KW_S_W^R_D!@,-?//_G_A-^6)#2%D#H!D;^M M2V3_-H,^^KP!R]?@B'^ZXA>>6+)PV4UTDYO9@U5PCIS.D(043:$$'<[K5+_O MYIOE3/;2 T8%XZ_=I;+Y O(>/L\>^C)C'GW0N;>7F#PC27L[J]SV^L/ !&3T M2F/?8;>_27UU>KR=N4=!7[H;/,5N#TFP=F"G %EY8 :^Q4*)YA!<29TP!="^ M!L[P*2^"D$]\_+YAFF291P&@\$D*0$- [Z;E$0_A""+UWDDRM^4SQ-*]?@3. MD8T"<.D1+Z".4X"^01#"9EHA9 FT6L@Q@N6W!A%<_50!5EU1(!PWE5FI$K]L M;]S]KF-!XI3L5VO]6['\*]*(NQ2 I;?(.&O2H?-#;Z;MV+BKG%6VL=J^Y0W5 M@I+9!K.$3M[KN_*$D<^"_*VPL+@GPZ\?Z7\]6X5X#F$L))[$&VGU MWW=WQLNK/)7Z&C;MT2=JYQ*/F9FT:]5&7!V8!6 MB7J\$D]D/3OUU=P>5O5\_^+6_P=PBN'1@SP::GU<7[\@41C#R[O"3' M'^^9RJLEQF]87'CJNBY:FB0G*]E2D)_ .H 2\C')74)W_2QJ5A#O3!R$@?&V MD\)_#]HB(Q$K)=G,(+P#4C$23:5E>R@!MT?%P[]"Z^*U_BBW^S78.?F^AP M O_N;AE'M"/EUPG@/)K[EU2: \-[,ONDFJ3>40US13$RB#QZZ#8JN>VWMTX! MDHX\*<#-<8_YX8T[!!6K-5A)0?E;-;MI'E/:B+VRRAJ]OFD<3B82L<.&@>+X MH(0:>B(GT^SL:1:HG0@%&"RA 'B?@T5]W1F=X,K#VB=KY&TL>H39SV;\N#HTP&[O M+2I(N!K7^RQG1*IL-#;.^5S.5^BXQ:*7P(=DIE>QR:0U]U8ZM]9XZPBX( ,1 M2:3^\QN.@P4D[!%PS)^-5.XYG/:_W?;F[-AYLXZO'9.ML"+NZ M4 \Q??<=U G8)=R7EKN%W3M4)6YM:T1'7$;/OM67(6A)=GE]6(>HO;)UD6B5 M;12CX1*7EMF-\&'/%^I>#AY'4/_.)B%J0J+78]346[=7U5LWAPIG6=Q/7:U, MTYSY>*OL&#V0(6FU8&5PY9%9KO\:"CUS=_L/,^?C-5_**@<]F@\K-O^<268@6MTE^["JD3331?=7(')6H_Y7H]S MW1=YQ[;R;$8,CP*R?WQ\'TT87#L6+9[Y/^Y5;''3Q]/ M*G1Y,2IOZ2@@3,:(DB'$,B:4 70?\T!_G?@J(7Y@C MO"T43:]K"%)<916._V,QL)A(U^O9K25&/+G9$YO;^/@\]"U(+:M$!EB[PL?#X+8JALF8M.4D)#OJJ1S MYC/J2=\#9S$N([)@AR/(%RT8,I#W"\J<^LU*"P,MS*&TY*MUJ<#D)/0O MH>8159/:R)$Q*"(5C"Q1[[;WF)1Z7^.8ZUA%+FNU9^$D_&L%!:@+OVW5I[@1 M^B[);<*ET.WNCRX=)<-;*>ZQ9XX,:?JY8DC.?T;9K&A!JLK;F7OR\(-!H/ZW*%G MQ:YQ\5P8QKQ9@.,ZH8R()4.0_C<_00GYT-E7(9S@#4\!8YV^@<";KY19ZF$N M0K?WX(^5R7D1X%TV.4K\=X:9[';!B*34J:85?X^#74BUD#GH;$MQ>>1G15#R M8?)?6(+/>19&8K!!D';![N!R*-"!V#53@-[1X#6-_V\OA=+O][9E8UVVJ+G[ MYAY7/-(U[++[C/W':%4J2Y?"?,L":YN<\5WW--,LP^3ZRZ)+26!*/RO]GF,U M4HB\2X$7,X,[*;1L[X;)TAENJ(L0/']%D& M$=P::TF9:VS=-KGF4OQEC_L6'W)GIUD)EEI#"@+I*LKNA44_JUZ^;D*_4M+_ MKAYYFO4KE76-8,83E$N5^:B M/_V3=DS),?1: /6GPM7-."'J(<7128=>1<.N,\E&M1WBLRFA6[6RILCKDBJ= MK: *\%Y]HEX>^[!'R("F(-/.@WFM:UXI.?'573'2G$WKVX7]S UI=S]%HAC> MAHW'E=^.>^S^)Q92@5WA5- CWKVDXTY7'LI=K,+!J"\K3%DFC09I$F[-CF.& MUC/<5:Z_%3(;]' TKK[=M"<(5$_H;!=BF $4(*P 35;0^U.*]/Z2(HCH!]RV?_R(X]- M@ )\_LL5LD?-R);[]'(;(#'S%%X@F@=D35A-ZLCS%-Q->E)WC?F8A3U)MN?A;!#S.8K@HEK\UE7[TZ?&K M%ASB"7Y37]EG[M:04>I0'YGJ=^0IY#:J7BAW%LJNA=UD6N9?*#EXZ*J8:"_B M])23]4E%TF419WK!%C?+U_Z(.723[^!<6;^"AV)/-S=7=">LVB=>A*YZF[4QBZ*WR-2=G5 M0/*3CE;Z:]LDWTYT3Y?JHR)QM3SG?CQ)YY5L=*:';Q]X6NFK\C9]JC>2S?U'+V60>Q%,*L$@&!]%:(HBN"4ZF M!_")4YW5DQAJL1:2QG3+6&3DQOWBK*KRVB.5=IZNDV*CMPN4DV&/# MM);NP>=2GSKJ^@T]Z.=T>E-6^QD0-- P#]C=7Q<^4G?UC*Y3]5%*&WR0 MP>U5G^CH^-U'(CIO5,?M6NSD)AWYRB/[GLT6"&]1T"7/X^X26VYNKV-LKYEG MR[7SF;5]27T(E5U/[N&,=T/A&NIYHH.4/[B=T.UK"7Z0RB1 FI^@&@MN@S76 MG?-(0)8^VZPB()OPLXH2C2)QIN\VS,VI;*&MLE.[X_Z6>V&$6XB<-DBDPH_- MLJ/K9R"C(Y8G]83H)T4=U>8P:=5]2?$OQT)B#0V/,C[]N0#-1=&M"0SV$SHT MEI@(:WM'3>_:STPGGW3$4"8Z$?[72,SM9%G_:VZOU^>&^3XD-AM^&'A(_8KIR^L/G&&:9S[K M!5D:O5_IX_,.E1GG._B._;'E\DF MM4J4?#CQT]UI [8^] MO-C%0%6R8G7"5K7&K\ SMNQ#>DO^Q(9XL1B9QZ\)?2A$5 (MK0MH']A *(YT M1"6HR4,WI$"XXS%=6R06!G56\T20+Q$\FGWWM@60:\UIU,KD?J?(SH.7M/$OSS1$C'#Q^=//O/$KLMF M_YNXDP%/L\-)Z5>)5F%C=<9'H,L?_M3U;FYH>]-DPI4"4&](B[T)TIDU,GB@ ML:14]W4/MQ[;0KD1=7\)FMYVVO.>);FROW7C,D?[]^%) ;O$9#46BLCEC MABJNSWR&JL 63P$2!BA XP8!! ;M:5 ,X-Q_16(WU8/XWOG3OFMQOZ]HAZW7A^$0,?_'!H,A(Q[86H2<>%S1NY@+*P.RUQFI M$\,">C597%R$Q/GWLO+'F)@*E 9SK>X$-*[Y.DV&2[2]R#7H=;;9+MCD#&(: MEG*8VF[68*R)&K6+*E>]J_IR_E1J3_"JGQ$!C:LTBM>_7^^3-E79_UWDM,VVGM@#1;%N(D=C"B]"=I/ M=8('!:#K0^"]$7]*O%XI0R:WU*,*'T4F7;\^X!8%!%2GQGQ M8V,DZW[;B5N\ISLZJ)Y/#L4>\^<=D9]$REM+V[\9=(7SUZGFN1H[OEE,77>[ M6_CDBBK7A+7UZV,%[6)#GFF;!2T_,0W41IXBRU@XO4VW2(Q(@G/A-ZH7'T_3 MC9Z>D+VF-;-?W*)Q.4C9B58M8#:IOF)EA !*QJ5TI3P1^ 2C_>AX_[\3L_5C M90H@^0L_7"6C0(B>!+U<))J% LR,L9&E$PCVT[]\XF/<-)DEDP)@E_:\R!8@ M/GNU3+.7]=*N6+RR"8/5K(QA%T3BY$)U2A<<,_AB0AORHHV-L'Z19>L*#UJ( MEH5WHH4]G,]V2I2^ )SH8^\D9X2>'*OVX C2)2ACPU]).;8Z<-9RV*IGYZ1- M2+Y.3QSU?^'CTK?XSLN*;K%5 M%0VK^,_$A[/NX+4K9M,5; M8:&!CY",BVQBDK?1BR->//ZZ>($\$?&'1*Q$\3+KD,D[\:]\ET^E3?PI!:4I MRO#)F,HL0Z."?YFBFG09F\'=;@TFDLKA%+G59Y*KN[! Y!'K&PN:,(V4M\^R M:P3[W?OO6%A<_]Y$:W6'?=F.7)WS8RF$=KBP;%7U,=/EM0>*MF/-7UJK=<48 M,ZDZ%!XWIV)J?!/4#H.S[2^@R?$SZJYEM.M&M(#2YPA3,IV,;= MJ1R;&ED*3SK)&?U6P,4S5,FQBOE"&,%%@&HI>N@9KOSO3A10"1.!KDD>"7:1H).5 ZQ*X>H0:08 MF/22/\#V85N9;%W!;&3-&@3I<1L%R(RN-RN#'AQ;I@"[FQ!RF,1ZR*A@(G'. M="[UT\[T&N@YA31D*$#QWO0A-6; ?-OOKX>D_W'HX)H[F62)V8%Z=2#F[;6) MXH;G75 B>\VHY]"9;/@6-PY*\JP!RSX;524Y"XI=<0PQO(Z- M@]0.^(KTZV M4X#Y6[#%@TLM/8@)"2):/LC=E@*P(>;?^^N1FWPAAZ:"-T?VFZ8/Q#/8P51, M1I)?ML'S+( 9N6-K=A"21R>9 M^9UT&51&-H@.(;P>*2*!'&U(;$,-(@FB><1$"G"2 OQP 1.?@](&X!]]/U8Q[C7YQ]EOB@8.KI.YX.,*.MDN;MI45FFO\OT M)>I#AVB5R=<>.M_BAW2^L8O'\@D/>"=W'_470-89 B34N;\$B6&[X?;X#U^< M/>^)5KQQX^"RC5$^X_WBF>K5R//B"R5F,^Q/WIVT;> [&D.3GHF2C33YT70E 8Y MF$?NMQ=[S6*(,?OPO5\O[=0$KD@:(D]R_(A9ZP-M#&A"&G0@?YN&A(WDQ<3@ MOPU#A5, %Q='B$"0U3%Q(?=*7,+!3EC#.BHR'CQ%@50,PX8#H2N M38+=,=@$WVT%E>G5M".[-E(/*ANJ!!:AH][0T;^>V=:E_3"94FWP',GD \[_ MF.4GETRV$Z02*2Q\%--R1S=T+8:@1]RU(39O88ZRMU"@Y1^7)!MC6A ;.A0@ MVP(M6[ 3ST'\-"C>BB\KYB?K "##>W^JRFA>F!]^@U_ MOE&A4$&HA\LPPG5: ,ADV]%X2DX_@T)6)&C!MU"22$1#,&H MA]S8(?',^Y=K**T$&U FHDX@;U7%GOV&!-R.VKD[Y?F.H""KX/0E/RZ M NPS>PPY3'+W58,1R#T!!\)]340:^'_D4>=Z/@"P:1GI^(M=M] #86?>=(0" MK+8B2-S#CM9?:H8NV BH7S&6>_1(6CC.+N&^[#>N]F4ACBH2H1 >S&>*@>:IHFGB MRVY5\K=DQ%)S<7XUA'W<3;'APN=A[VXI'_VD :. $Y,7+N24?(;**I_B]R.* M.)P'<5 3,=,C@RNR"TCZHLH19$P!$GG YO=$["@4IXDSQTYM=\7:M*HZ']&J,FVT XPV+:#A&:Y<[6KRPE>L4!5BY _8[!9!( MRD:2_D!N(![]T496"[('T68=O4./RBGX.?W[D:UWXZ1#%&HI9#&) K371!*NF^AP MS6?\L&P"58 )ZH#)'T*NFD0LF6 FN' 4@,CI1KXR!8J#8B7X(:?/QCQB2S9O MF_@&NPC=X J!IVDH%6U&HK=,U(0IP*U:-M+Y^,]NCVP">U- 1 M-2Q) 1A#$K:@,DT((60^L?='OOA[-"O4]=G*O#:?DM(_.OSS7D='SCPF3U3H?? MEJ-:\YP*A5C] _*LR *XWN?>TWRN:1\*BMH^C=K;:#-?UQ.X>O9.C[YQB^ZC M-O5K#Z\!10G,I'4XN9$#Q(E,EOR%!E%$>YX8*=@&L7S5!V17O"191QFZN@+> M,D/A@LCF9WLJ:>(@#LK@5LDZ1Z@C)E?$H;VZ#UQ MAT5%W>6#8=5+[Z.)L:09\??1 ![V)T#:W_L.MJX/'GZ4 MB%@:1G5)D(0C$)/.9)E^2(:GS%&S.M2"ZS#[")Q"1YW_2?*W3K!)^(G%_Q4P M\?T5F$##BE:&:OTJ"*@@VB/A0&53 #&.)"=IPS4P??#*-F*Z7QQZO9<"&( @ MY+93)P8.USD0DH+%'2)-$=] +)K_*85>X_'YI31(3J@.%.'<-/%=2R4I; .] MPPXO+-]2[CWJ[1"*@,S\6FX6_AAV>,BB^!V[M6(>-C:E^,K:;M:$T^GU$<#B M92ET[C,^LBG=U&SPCMR8L=-#KN=M5V^Z>=GAR&^Q[HI&+#:-TR8ER9O:GKP^ M2[H!2P%J\3JW'0@/.AO)U!BI"\_>\H]@+0-RY%2_Q,:6"N4!;%^OT\/^@30F M_Y!EUZDEO:[?Q_T*) MQ?UG)5;[7RNQQ3_)KFV/_UF)@;6R!;O_+U37!B,!068$2^V,!S4%P B@2(PJ M^X^@![RF!^0_\%[(?4:T3#=$X'?=9:50C]LG&XH]0ZPI@3V;>Q&SD@+6-E3O M )(ZBTZ #8J__Z@_Q]V]%W.3OQ\H5,F9X?LMDY,XX,[A9 M[M8MQ_1$=#U#C=!8M#$TRP/R=NP7^SINN%&#O1.J!U%U_Y]GXJ%D( MARO_2%JICF?@6Y&XUYRG3HM=GF@^<.N\Y/C.42%O%EE? ,[J"GR^C*K.X[=\<8J"_3HUV7/^;Q?!^D3@85U1;BD$L- MI-M0/ +_'3JKAB2'PTZ 'D4-3GSTI>&\?TSSF*IUW-DQJ_57/C(BQ^\FK2Z( M=5QG)Y;H4WL!=;L.Y72IV&D.5PCWG9+';L^)E_NP7(J%V2[/+Z9,O@2")OO7 M69 O!:M4\P^R?]CLJR B*_85R0*.?O<47I;"I^V>2P,<$@8^%Z*JCFF*6L,< M=@?Z=?Y 7KI_2X?3+-2R$5FF1'RUR0U6@ZT'222L8?5_$&G2?Q5I"W]28MO1 M.XC16K)17@1Z-6Z1'*6P5YUZE [7#?'X16VM"9_VU<$22436_2H1H?-'3HB. M&@**U([><<7\Y K)((_"MQXT@-ST2(;$7WX0#L]YV'M42 %:#H6W>T0I@']D MWDHCV@SA!#]02CB&^*&,V!&&IPS_"=PR0.[QRUL]Y&J"MGY:/LQ @?RR*+9T M1H?S.OU HC9SWD<>?V":;?%L4.F/="<)Q?C*TG5%&!91&%[/23UV:]3 M+*&%6S[AT:8K'K]CUX'"OY),>G^73%3@)9_Y\#F(8R(CRE2+KHX;^\UG0U./ M<:N=5YM[YSE2#6$C#""$@L2&RVW?ZJ\M*F),U!YV_!3['A=6>/ETK+=8?:"@ M(Z'<7$VX2"(T_X+S##.B4S&3Q0A!V(\A]1/S#>.GR>J@$_1&2"3]\W.X.U_+ MI.G%[I'-#L6IMQ\;X)2BULMJ+]_!]50DZ3%*RNS=)Y[(9-]WG2:>:0 E0I:' M#07X=A_4%3K!O7C5EOTI5EQWRQ3REM3P"*=(@Y7+K<[\C1<;O,!%Y259@]/' MW)BT"5%%*V-L81OA]05VKCP4P''83)*\[FLS%._[9ARDTM9;J&6I)C M$070P&"#Y*OT&,[-KQC!85N7/4;9K@SMV$-;6#XN5Z;YI_FK?0F@;H0?'STM M2S-WMB'\??1!H;%?=)'$@,7]PS5IHF![!5QKN.I?]NLXGW@E6:VE)3O.[I$8ZB3< M8Q)VZ84;H@GZV!*,]1FZP\U02F.$J;HXNR)"]4TH1]='ZH[XMPFF"8'=N-ZI M80JP=D9FRP88^ZN'_2V5=IB"5.@SV=& GT5;NVVYD1DJP3$7W2G S5H4B<9R52HH MWHN\O:67%4DX!E[N^,IE]*GE!IFAH*>94TTW^WK6PNUN7U4<^+BM?;[]).]S MQH VC10XK'2XL$%@M7^E]>9/@5>5\2N>:OU-"SB4&/[4AO+.:=_BGNT;98-= M5U96!!PO<<8:GS9>X_Q"+98<+A;_-:T-XV,DY?SUL&4$Z4>[6S!J1YLVII/( MROZDB3J^C*KVOU ]OWWP[=@)WA.Z6IGB#J%LC:]^L>I?]_]]_2?)U*IGJ\)R MZ*)A R_/(?_1'>&RL-7[RAS&LCWWJ>7!P"7:&UV:U^4,EL2IPW&Q#5(>?*[G M"PZF1\^R)0=>/3M=(95A;5*5?+1^5'/*,7HIZ-)^.>+HN!'Q5;EC3<2]G"C1 MN(788TN%3.+J#(*EU@[_6-L1,#/1 3C_T\Z%RUMG =FVM@6].P+>.8/3J)K5 MN>EX)"/1J3C(!L^=^\'_[I')YQI_(8&W7D(C3.X<0L6LVL*LZ05+)1*?*N[SV)TB.]1<_7^+N1JZ802\G64-R'D-,4 MH"\U'U3P$+*R_?Y7:'C#Q;X0&1?0=,T6K"O!*B/FC3P?.HXQ7377^SX_CW0] M)#;Q1&9PYSB:* ZN)(1]?[3F="&8;RA;)'GR0S "I,*%MK797^P;'?([Q>>A M*RR);U'1%& BA@+H%H7Q%2(_HXL M!0"M*]>LH)X,%D$U1DC2O^L6];XZ8F:B=>"DG/ !QQ7%UOG\6$,# /BQJ' # MR@)A("H-KPG-/OAY)-J5-%'HQ%S41- CS?+=#VDK6Q>P"_1^OFY!MA MD=!KERJA5\2IOX#33_!'3T*^YWQ<_\=2,_ [SO\3YD>"DO3_:>'6PW;Z_W;= M%BSPD%,A0[]JVXE00-:)WW;J.F85R(]B^%",R[Z4,J MU-=J-,: ?$#VV7W#/:P!__0M>DD.?0TQ\PJYI4>$48!;V13@?1+Z8L'.(IGA M'@40032#TIX?>GA>LJ\;+ Y(OEP3!3AQ9 CB\-\6;0ME> GV0;>R')8?3:HI M8BQ*;0U8F_WG.71-%YES7E2W?SL5[^9;JJ:#565C6E8*#"=.V2GB#!ZV/_6. M_YC[]G:\52C;L5#E348"G3%U2^ KE-K(]@$NYT2 28 [/ZWFMR_['1>?5LWC M@*^GUO^3TSB7/,=RR6:DN*S60,BHP.IL5>K\&3-]N0+DIB--_*A06<-_!P/: MYFDDM=>%[DUO8H0G+K& ZO-\TTL1'KZV[\<+=J[3O_6'P?%6R4V6_)NO1TH) M7CWH\ N&-2M"=X23&%JUT1WQBLG)XZ:S\:58]]N"P76PO(9T-9OX<2O#CR94 M8=R,A6P]U&4QM=7T>5IC_9J_D/=_BU3G*BX;-\*$;TB]?Y.5W!V7HVG8,% ; MV3!R:^=<29!.WOB]#*:1F;+*^#%(B5W'0N,32R_)TE.L"U%B$VF=^-9Z;)Q, MNSN;ONWG2N;8A&U2ED:W9/%Q:"UII;7:8]-:D9Q.$O"'EEW3 M%3Q?(=Q!K@VXKBE^(V4>6+SW.WN[ +U%<=W+RD^5 ME,]5^:'R@9X3>"GQ6W'GY ZQ2EWVG[D,]!42'K_ U? MXQ#G)?=?[@^2'_[_)Z%+%&?GCKF.E(Q/:28WB7B>4:SUY4Y3BEVJ"YJ]B>AUXP!XSQ_;9T!A9@XBTZC MBO*A!V>M[M9$RY;HQ_1=W"0]J;#(/U/EYCHHF\ZM8M'[9RE ?P'\ MM?FA'C,%J.DEPM]#U;#P_>>!(862?U+"!_;P?&@)BOBV[0ET[13ZD/T3%K$? M&(+.LKM$=,U ?EK9 ='Y44C8+\@)40WY_>G"& 5XCBQ5:O3@=[-!1A,M9YG< MC6ZDT*1:QHD]\X33!8&$Z6(4JRGIGDFLHZ^EG((W\&;#5]/W&@\56"O"[NFXELP9Q M$+1GTV_/-6=0X2;+PW<+2^^M!S,G*PE3-6X^8LS0N"G[F'_/$'^1\!J[^EA? M4M)'Y9/68-QKD)E_OF6P_O4T,Q$&NA<4'R@#;"W$XNK.%/HG%F7T6MKJ5E3= MRS+YV9OV@YH_4W$#B!N1 MCXD/0&!Z!((]W47+">1GQ#8_BPL^)TA2-VHW^G&T0-[D"MO\R?*WQ.2LE\>(?IR%CB:.UD M]STU(PDG)P[Y.[KM,\1G%^DORU-56TW]G3_MT$^#E+!%2FUCP^2"CT:>[WN/ MB=:Q/.K)_W:6STPD?$%$)%3.CK0V[R/TWU#N[[M_WI][[O'O!)G8!-T P9-G M*:'W5*PEH!>"[\#.R(7H;\S-4? M29I"HI8LP1;FS\M;"?SUK9!WR,QP3@MXM,*2FN1LD:5--5_EX+I3[0MG/K,K MS2$O!]Q'J6X?Z94,?:A,^SG"EU=YX>:;/I[GG\<,3WY/8KU<[, 6KJ)3/YSS MR3-X84Q[0>O!P"=]"N!]]BZ?_:A+ZP##>,=I.F64.L']R'0Y0ZJRMGIDC4>O M)%[RWIGZDI3-S,0%2T<&E[D#)\W0DBVZA<6T)7EXPJN0LX0HI\Q[-788?IW) MKCUV-SK-M\5G*VRC@.=QXUQ6YQT3D,*G++::AF/N%3U?3/"JQJ6&>2=0CTV. M+8V@[U165[FE/E=V8C6W7.C5"C]EL1X0DH5_[^\#$[2V]7==T9YUJM@^EW$G M7CDVZT=#P#C_V8*D@"9FQE6-4_Y-9&[Z)]Y0#B:Q08Q9N5%NA1_K==GV@T@: M]G:-9V:&[]Y7IY$K)=] MTK76O4:GGV^34>^(A1YSLTP+(@=![E1IO[SC=(NOW>GF<8UF/RZVZ!#>I0;I M&NM-8?^F!T=7KQ<^EGYBC*R?R$GB3&$^[D0S$XW!48"(]3IH7O?])&-_#(<\ MAH?GOI#!9"@M$F!]H@<\I 7N_0,9;MSH^^_XG(XM00WN-L-&ZY8AVF"1A#$H M>;6E/Q3:PV[D3K,O:$,#> MR6U6PDP':=1'&>+SGNYL"A$>;%X9?J4W6!P;\NCJD1&MS\/J'5%-C>RSI74& MN((F(4E;G2'Y10;7PL]MSGX*^>*W&0YN^]!GSF.N"DK;&JN^.$!E]1)LYSZD M8S>%*$ CU/'#1/DSI*NM_ 'CI)5IE1V+<7RZ\JHKR*&*3,;T;C MX+>]R]GESPXI3IW=FL0 = =1DQENWCB,WQ_((%@$!2@;B<+#6FQ"$K+O800> MW$]:L?Z9)N]BGQGO"$E]U] O0>?43C,W5?^J[E:]%MMNYN,'@&K *8P2%C9&K8TC%WCFMN6YUKS*YH;.YD;OJJ1]6G2$ F/H,9^370.49&X;EWNI))J5*?SD?9 M>-\XK0M7 SIOGE].&_\Q5!)4F]Q5^TXHN3C(RB-\2EC;,< +VR$LY23?W\+W M[#4=*3/_DT_RY1N,\S@KQGTI18/Y07>'%<6(A??:%^Y_BZZ@TQ)^^G39[MQ; M?&?3_A071F%T?5=*45WHIZK16]5.]TJ-^U$"S=&AZ2W-_3>="VYB2^ZC[R4P M3CM8C145%Z9>LB=%K"B6+<+>]B9-W@B"O"S[HA+KK&JPK/?E$S&KJS:C7,=+ MB)H0GDO4_3*$DG_BM> 7F4 XX_+-.OSK&88F/5W:>FNS/?1 M$IH2Q7F?QI;VY*8T.;[JZG'2I;5*-^1'KI<2GW8!!-J%2%T_;]"W/5=;!,#&GY?9]8FS6RP0' M/IB@$O,N9^\_GOD6)M 3+P[6\7PJ7TAOWJ!%CV(KG>+.1NDGA/3E7ZQJCA2D MO_QUQN>+UBD!8M6(^II]1>P#QR%D()#T/WR%B=4#RQ/JC8Z:8D?CIDK.D7OJ M&4M(&<8)3<=D'WJVHS)V$W[,S50\]1)MR"IP?;5_<5QA3G,L[ W-F6&F=?9% M@73+/)$9RZ'=5K=IIC6%CS^DAH=N!$>[R2<%.,Q&OI'W>B"]9C?[GI=/UXDT+1ECW.7\19(G,-]Z; Q^"X196NS#"SO^I MU$S#H5#4.#ZRQ&&R3-F/78A)]C4E:7(T#,EH+).E+(,Q-")C*UMB1!G'UJ1L M6;.-(B,9V\@>P^#(R&YDK%.D6_>>+_>YSW.>YWYXO[R?_^_[_G__Y_6,V/O* MJ;(7K=H#('3R 38Q2*LPV;:FZ/8O?,M1TL,77]B,% B9+YKMT<_:\-CJ=6N^ MVS?<_J[0@W6NKG-Z'Y"GG>#+\/7,.>^4E^#KX3C=SZ%(1HVH.7; *%,Z@@.8CXRJD1W>7/*R"%R;I:73(,N!F>H#N3]I;'6$1]<*G\FLH)KPYJL[1F MDADP+(2"I-L:MI+>?-3C_EC25$LF\*7T'GEWAGI)C IKOAMLZX:J&-RVE@7Z MC!G;9/N3 =YDGZE$.J1D1 M(&KVYZM1 ^3 Q#M>N&NE4@_+EW;" Q%T3O)W9AG.V] MZSEDJL,P@5X"(V%O&O!.FH$:55Q>KFZ4$>VIR[,A&7LB;^SBI\R9R;N(4^0: M^SXD)IBR^);_TV3TD25P\>0 >")C?>4;Z@&+?-T[?R'4\ ? [X)9#-S"\L3] M0)NU5\^3U?[;JEI9_YT$V,..#/V[J0P _QT-R(*7W8#L+"P#C&((H#'^/17( M ?=BO?F1OI! \J=XW$]4DIQ^>T,W M)WI7H2] EDX> LP$]O=75H2@LQ>TN0$BT2 M5NW*VC8@B1YJU+VJ2;1Y6R-ZID\D%P=57LNX:&:E+&]]42 Z.W[9UR M+96%/H\Q'UA;GJ#X_7_2^$]YA^'A]]OIA>G-$ 4$E4H-,N<-,J_F9>ML0*"L MQ+:?[+Q*KTXVQ9J]+/,)-:#95Z=@E00U'BDV3JM_S,MZ&[WU*G1#=*\8;/\S.%(1SGCP(XZ+'$XAFN[9STQ0]G)]MABN4FS4%_03N&RR"YN'<.$A)O4T;3=$ M8LZ%Z^.\,Q(JCY/W.:G0@M#30T.8=Y4O^\QU1WLR6J^VU1/I-JN.T[RDH0!E M1Q&I\O(%ZU +H4=R\E9;?-38&8G.L+*ZPT%Z?R7&CS2X_.VXA0->0OFCRJ0T MAI M .>J[N[R:!3_['EV@)RJ/^2@VA"G*A^SV:EM+/.DLH3^^I%>O8:2"5$K M[<]O1,3,T\Q#0M*7;UU(YZG04R#%HZZFM63X2O"YXPVH/E#; MGD&H3D/#^R8.A3E%E9R-.99)A_@YEM'K@ZP#]66@'W4&-O*75*G"F[A'5T+D ML*;?)!=MXVYK?OOUIL'FEV7#!^=KBTO)82>_T.8_XVRPOVU22FS*DVN'D,U; M1H(2['VGH0-HB;/S"LK/D9\/O+UPN6<4@8J5;E^02B,0#=:[%8V,I!U+4G ! MD47L>T;,AE5^)+#OV302W!/S1TUW[A_]+@;],?H78G160MR22:\,,CK%>R]J M2="U\T*W2R)S0.(6(L?YZT\/I=SU''ZKHCH=43+181(8#D\\E/<;/##XN--= MQ3RX-$.W<_8="#&5_V"O*YQ6+X4=KY"TDO)QB1\7--++%NL"1DE45F*!!I8U M&2M6=IK*+>D![L(N5IS93L\Z%]+4#W<%;2*?2AF"Y[0Z!#!=>N9ZY;I M4>.N'7^WK*1?^!:JT/T:>PLV]8+C_I3DJBG(,R#@4\L1W@!&LOB:O$.J$+?= M?#7@V#W2F*ZC1FE!FOU1/3UEH'W2<,14)"Y^/PCGQDIL1X+"'&?:C9F=Z=RC M>9M7'G'+3[B>5Y';/4ENJ0(Q#.[A3!CES6K8%D[K,>5X"8^(?<-%53ZN^-,E M@+F&T'G[. PF)$V;!ED*SWZ>]ZH6EJ4^'#1;@U?8\3DJG/^*7.1:&]+_KC& M/TF<:0:GHH+-MQQ4Q1=H<5&28186+NXL%&3;DO3X][ZJ? '[D^;2VJ6* MR=OMWIR7-\45M>LJO6_KJ=C^V!6@9O[T1!3MM*IC_[NO#Y"VU( M!KPQPR WE%DPI%H0%A@,N@3Z,MI;+:XH]]*Z:8)6*JL1$/ X1!J4?J_@)'N> M 05[$WX +HQ(ZF%X]\%3A>4-%7".7*T4A0=!757'B7Z[KYGN#PK5!'R\C(++ M>+:^K+I4=Q"WHQ.B5'(TIZ$R1)W"!^WJ7(9R^+@;\)02/ENGP A"Z-2G"K(V M"K%#+40=TX]C)EZVJ8"8.69&K'( I, M(!$(WR'D^48\(5C"HI/E(I3BRL&-$ HV7N\*##SL_0%8)O)L/^SY 8B\@]&C MU+E8;5FI?^TWT)%Q^L3Q>-FMXE5G!6^J.2<@7MK.'O;PB8.Y:^&Z6:MJJT\U MO8XQ$$H?N[KZBFY:JX-Z=;1%;-]4?:AI<\@R19=<-:;5UM4P?NW*ZE09 M _;K0R.9TRQ@?_-/!-Y%U\=_'_NB$ZH?2^/X/@+PY[55=^3QYP_.>R]V0=0RB'2U^N0"O>S3H M&HPG$N,FL>_N.E!X<(9$H/IJS*.6&)J!'>(%<.Y@$R%;F9U4 [Z!S*[@Z>&6 MGEOL"8:$Q@A\I'Y5JMRD&5D/ ?:U*\CA+\L_4G-0>JR[>=I6/$[(J*IQEHC' MHL7"F MD[14EAP#.',,4-XKJ2A25F;K(N"=]P-P]>M8R!,-QG/=IWNREL?A6N[_%)C_ M\G _)OX%4$L#!!0 ( *:"6U!CBS\^16T +EZ 4 ;WES="TR,#$Y M,3(S,5]G-RYJ<&?4O 507.V6-KH)[N[204.">PA.@@4G!)<$=]< 8*[!0B0 MX.ZNC;L[A$:[27!(=[!.(/!SYLPOJJ[J?O>[GB7/6FOO M77W[^78+('HNKR0/H*"@ *_N7L#M*O 40+UW[R_ONP/M[HV.A8Z.AH:.@XF) M@86'@X>'BX.+BT] 0H1/0$R BTM$041,2D9.3HY'2$E%049%0D9.]I>3H*#> MK4%#QT9'QR;#Q\4G^R\?MST ,1;*O7M4J"A,P#UB%%1BE-L! 0 *.@H_W8 M_WZ@W+O3$0,3"QL']^X'343 /114U'MHJ'_1^N[;@+OO 31B=!)&/AD,4LW7 MF$RN9/S!27E8S+)UO>1:LW 6 3.W=]@X%)14U#2L; _8'SX2%!(6>2SZY.DS M.7D%1:7G+[1?ZNCJZ1N86UA:6=O8VKE[>'IY^_B^"0D-"X^(C(I.3GF?FI;^ M(2,SOZ"PJ+BDM*R\OJ&QJ;FEM:V]KW]@<&AX9'1L;GYA<6GY\PH$"MO^\G5G M=V__ /']].S\XA+YX^=?<*$ J"C_?_E!\1H MZ(Q\&"0RFIBO74F9^(.QR&23\NIZL9D%M.#D9FZS.!0L@E!6Q%^@_1NR?PW8 MN_\6LK\!^SLN"("'BG+G/%1B0 KX19NR9=KO6^C+@@R 6B>-6EG-.D:Q?%<2 M>S(?"'UZ+7@+Y/M"U:])# ,1Y"&(>5AS#;RW4?\HM]&8PEE;;@%BA6OVP/"<,W7QA[? .V7G M&Z9657TO!5:KFK$?R[6C;__PL[QM6#9&F^!6 =SD MV<=I+WHHJL=ZZ_N1;J+=A3?S$((RAC@.FY]-A32=!_HKH_SRXC/'.(71'9=D M/*XT*;$<3IA)[U 6_[ 1^RT01@B?OXG:#9."*SG> @.ZQ'Y7Z@8;_HS+XJ\+ M;-(?>II=: Q:E_,/=>^_54\2C ][-X1V,#DE+;_?6W'#A,R#F49(\M;5(R#X*>IL*C01 MI-FX_$*:CN?W=7_$XJVM@8E[IQ8(6O*+=!HG<"OY3LG(@C^H8+Q(AM)W"_P+ M?O"4 URZ?[.0U.\YL:[YOTZ[NJ;-B$!T?QYQHD,&2$J>,4J/!N$;8MB^AX84Y(0(=34 M[\9YBWL8B.LOY0?5XZFL\2A>*%FH\KR*'2VM&#^UW/9@G^,@R5?=]&!?'7Y\ MN=G0U?G()_6%?B/8;]S834SI1$3^5+D,2V W3.71T,Q'QRGY*4KG^PP1E#W3 MX0(#R0KPJSXW^2W^^KWF 2)?-/KWW_[@+L\W^(5I- R?[/GBBL,ACS\.*,F. MY=*18,@K%)GHX.6&)+XAEJ83^1]W^Z/B*K@W5#BL9#*PS ?4VTRA$3OJZEYH MH$"#MV49_H=/TIO;^\0.VI:*SRGQ\]8F%[6$1-ZK?-"$:$@]ED?W5HE@\R_4QNUU=.( M#E9M="V*Y+"V+3$V\C'LJ5VUDU%]/V?;;)?.&/3(G/7M*QEZ"84JMTS*GFYB MFT!J(<)HBF4:N9N"BE_EM)\H;+\8*NL5QL]2*+(2)UO> D]->=^C7/<]AHC8 M7LLB*:M\QFP@$FXKCE_FJL_<;>!8^77A6SW*,G5N@WA4*-/R5_UD*/-W!L"\ M(;6;]&HVP8([KAJH.5:CT:@6?+ $2&FADCHH[[=.1RH"?PO\.OAEG^X-Y0+8 MTM67M3+QD&;>3KC;VLM*;X)H,&(L5MCL06S\FV6S2BH+N@0[ -K]Y_S?GA_T MV/1/"?.D-)> \L]9KJ,\'D;LZLS)FH$6K>M&QSLR)'.>2\@>TAMX[R3SEQG\ M,HCNL_RIL5G?.%&^\+*7F,_+5S(2*%3B"YG.05U8AS26-P66T!R4=3T]/L.. M#XV' O1M6'11M$Z47RV=_'@E#B?]9:[8#[O8X0HAUT*2=<4&@UNKJ+:OW8F2 MI@H/)<"1W"FH%@[-XSN/&DZL'R"E)?.V:R(D&9%14,-#I6\._E+>;K/CK$61 MI+T>"'%UT"<.^7KB#\V?QC]_X=CV%'#_L"MFG\ 4\,R%VBCSF!D M1S3MG;]OW6\^X&Z33I/9RX*"]R8TK9?4OV3"*DZ\;PM-JTC-_?MY,ZA)(:P) MG_L6T(B?N@6.(,:5+>W9_K5+B6S?-EYU?R,[ECJX]*1WEZ;W_G,.\5W?/7Y! M&'$M5]K<"3U65X=_H1!NH.Z:D)RU%XQ[@S.6]7T$-ON,F MQ."GZUI#=6N)L%7]NX8 Y7TBDQ2Z$A[.2,3]RXMO<%[CC M//=\K.9.,$F>NF(D."7+]WSAKU5Y1^@JY^6A@9ET;84H"0=SP+[A0NQOJ.;/ M,W@XSW&S#*]F0E>%ZA4>RKPW/TW^&!_&[QYLE!Y\P^8OFM*[]+,[*B_8NBM[ M50@79!7"'?#O() M8ONFP5"]>"/RF086C%+Y:\:+B:34E%P6QH5$7_6(]%4!KS>@*$D:^PU41&#DL3]J M/KZA3&U'\BV@F*(>10]]!]NU^Q%^GYK!4%^/" N/T,4^L/\6()$DM;FD)-Z? MV7]B?#;$(;98/]\7-)=A),><_RJ!5T7T\89AA_LH\H4V4NPU5$+W>-G-!K0* M>0[9U#LPJ)QTN4B9Y(SD Z=Z^^TZ<--1+[A^7PI/H.SIB..^D@LQ:.B8:[)O MX/B\?N#>V?T)-\HHUQL2X2^7Y23"W^7FC0-D;@_FX#IQ-TX2]O^D2/>6&*IQ MMN;Y?$P",9;4?]WZK%7V113I6++4^W!9Q>V\+QX!/+W=..*JKM 0^A.)L0J M"<^@;*G),,9W XOEX^H@BRN6M*YUQ?Y6 \\ M*^$TFS+X4E6\HI; P48^SXIW[3]5QWAYK&<@L%O!A* M5H9V.IWT+8WM3'W3\ M:#361:@VS9V817.T5C8^1 ?O.:J4T8;&V,/6E2#NH50]^\:Z86!1^/0PA"A+ M"7X24;J_-*=D1Z'*S?=59&2BPQB%&I?4XPN:9.J@_OXM@.YO6ZY MA/W:S9S%MSJ<2-L^JH=8L_[\D&9Q.,X<2((X-"& 2R9MB8EU&#-0YX4?;!]K M_5@F43%0YV*>,HY"=;#A?;Q]*$U^'_EBJT(/C1?Y5#:7]]YV M";GW2[A\6+6Q\63I?MKRN*\-I]/QB;D^8UNH\%UCKDH9VSJL@[*@" MRO"OX0D!I2:0_OJ='XG3C*(L3,?/&*(+'J,&IQS8JT6S _G_[X(Z"+:&7P[\ M3!_B"'@SQRP4ZVZ;8KC!.5*\1(6_#,F%Z-%-L,:Z\+J?$C?J!,: 055VRYO$ MSB5P\J$.^ZH56R7[8E57JW&6D0;.HME=;6>."=FG1%2Y$#44AE,3 836U5!: MEV [ ^A*T?QU<77&%]GDTO6WXV62RXS*56W!X6_P/V,F25/?\,R\9=GO(H?+ M?]HJ6N+,GS]+8#H0Y7:P:.4?NHC!ROAB1AVK[-Z:Q]'1MBVN;<*-+)%*,(-7 MK;7GK_5;LK )A:\DZZ0?*Y-.[?T [K>\'PD!RIZ&.^A:YAUTTPMQB:BFGAT+ M0VPY9U0RDXXJ#L#<0YMYH#4[MN&POOS-T"*CE: MK0M-%$LEK1PV"2+)L=M6*N$NUP_6$TKO RAT K[7C(* M9^Z/9LFC/*_DM' Q>QM$'B03;&7L1I\GO'M#4 U#94DF&WRTZE?%/SU:&-I M9[U0"<^-"?UU&_:+D0/LLAOB\:I)^'B_.DQ*X,JVLN!*Z8.9K&NOZZ_OK5S? M,@_W_N8FW&$#DZ(J)// $Z\$SPLNDU.UUI:&=D[=T0R89=QW42HS H4B'XM- M/+#U72G9-83?Y)1LVJ1E=I59NEZ(T5:\YJIZKZG/NO9H<"SBX[";/'^)ZYIV M9P"CD<)@E!!58P#MD95EE!'-BVTH'J,\@2/QP$&(Z1'7# MX*.V*/L@"Z)-*_^8UZ):"7(7%Y0SX.>,K M"U?MK ZZO8J5L;D%; @E#B"-1S7S8U>T#;D_5)X)XX4W7PM57_N YW>4CBB/ M7SWER0BP=B:B!?<@2DF"9(]C=U-.<_I!PUV$R-%J>\C9,9U7A7?)9SE[WY+- MS@&=8_KO;>M66KQ?AMN*9!C7"&9V8P&[#1_G;G MUU^5T&1[Y DN2/S[KYZ*,K:J?=0M]R>"GQ1 I<+?Z*26?V[^Y.?,.G5HE00R M:QJH_%C OVW^< OQ45<"+@LBTC^@U'GSWIMWI3=OG\,5?W+_=J>W3/2N=A3[606)\_3?D"(8HHK]=;OANZ&> MA-B'F84L^ZY*[A;[KN*N(W4J'5:>_&)$4]^/IS3H5Y6JF8<8&)_04%_97 M<2^/N:N[1M$'BGN_2#N3CD,T>V0=)PH;$.\U>^_3!V :(]N<'T3,JS:WMPEJ&V;9?,"76;HZ#EO_P/O]J[(X>Q]TZG%%-NM\E\BABX]O2>U\*"PFN#!<%)*4/XT<_2SJYF*1LO MP\=L*:/*'BW\PP_[?.,N1G%*9)A"1L@A_M3P;[$>MP"=3_I+A$F..)=G"61% M+D"\^6A94FXGUYR3T?TT(-O>3 U#26+0K8MX[H;%IHN?L.99W8%W%Y?^ L3. MS7AULJ0YBV3=42=>(K&P-$N&FC!XTSV 6AJ=3/-OPA"XK?B6_EH4#D8UFA7L M4*5059X*7Y)@?Q[WYFIS@I@)M$%"]VW(35U\6<"YW)]L7OU:^,8<=3 M^N+8:&/6.!G%U7$<_\'/K9@[6^[&4D.X":B!5OO"&Z(++]2;[:IM3WTDZ:U4)<=F3:B9#'/2]-$[Z]LR M:I7)I 0\B--87!.QQ+%A-1@'D);^#C'3B$SY!,S(QH=.@I=ZN9OV-,/MRH[E M65XP71"'I_4/KV1[2*,QIBI\/7K%5H<"XIB9W(>KF":(=OY8 \-^L(MFTU]B MKG$3WV3_"==40K'>1G%,B7[GP3A&]G>,>%$T#@[.M^X-\B#:#UWJ^)F7T0![ M_E]EIVDZXJ=UI+@M=)ITO7%78T9K1^SQ8D3J%3QX_"'F@TO[D*3X /O$F M7 M^ I2]V&W>SHA7(%M9Y1M56T;=&'\!]/"E/&M&-?B6*ZP#J$D3'09U[R",G8 MRA)TM3P*F;.KA4VD/@/)+9!7(G?7_H9*7;\$7+VD&IS#!7\H&VX<$I=E#GT9 MOBCJS5P>_?[E*F,\()NK_[&8#Y"L;/$KXYK1-3736,O&LJ&CMBVJ.GSU@Q-; MFI4NHYLP>,[QD7;09Y;HXVZHA8_R3?@GREL @^@60&@']HW TW_A/^&YP6.\ MZ]1+40F&MZ:2;+=X2)!JJ@HZG?4(PIR+JXJL5/MT 7GFQ @VUV7E[)48 MTM%YMUUY79_&/H9C.,Y)^V'VYSXM];:/+2NP-8'&XZU[2A+>UYP)V($S\_FW MP%8?Z.91PA_0N1DX'R&@53R&38M,X,5,/_M&\+/D_>>4^B=L0%RGR+KR> Z\79[T;F=5^T^K3/VGU[9HS$!OT(_,_EFK]P>@%^7]% M^(^V ?U^;F!OK]K]-U45?@,<].0)Q\?_4-7CW_?3_!UP+D%\].X?5/WO:G4X M=2."C!GLHH5OY/"$5-$<:F9?CF8YY;#NIE,F<9Q\#B4^+;1/&9[\9DSXI_'@ M^RU2B) W@;/6P!S+B<]8:Y@1=A<[T5"6PI5>@C*C;.H9>(?/%L M!^8BU4WLLU2U5K5CM!M2E$4N7XQ=RD& 1$*^2/99%Q-2ICD-(1GY_&/L 1$\X.TYX/'^_V-L>/Q78V.1 MW@T&6Y9;>-"H=:FY.H)@CQU1#F.5GQUWC\WC!: MW#@.[03M.6A;JS(V9P9GL;((V$-WE$$S+(I$4[H\V4 JN-E/>\3V]L/KA06MBTLJ"CRW J_D3];2/% M;F+P_;956 "1Q9=MC8B4P\M2U$PX0U/UQK7L$E<-\;+ZS4A=6R:37E'3H6#Y M;*Z3KH<2[GL)[-&O\0%L;4UWD8O.J1!U)JWW;ZOGI?P@Z?^C,?FO&-C:7P6I M7N"OT]#;(>F"]X# L'_BD)930@":''3%B59[VLV9F>-IZ^ MQPW=_DDJ3DQR3N7Y;J"/*7%MJ,'[0O\7#:!'<0L0B?/XNM)1W+#,/I_J2^AEC+]0[F$W!;='Q3?2::ZNY(1MM@WB@V%$G_1F6HA^RQC;$]#K]K,@]5GV8;V+J M-/(#;"^\IR_=#2$Y,9),ZT9[D/%'R]]A(1]C1ATY%^LQFX#MS;/-9[Q$V%8) 5]@:;O M2$2>5X&.-HFP:000[T!\VG7J1X><092NC\]PG@80V*".7&QNK/NF=G#8@V/%S&>'WB+/3T/_S:^UR+HX:)XNN.H FD]S'; MV>V9L]5Y$@F_;A_PRJ9-]JERW$E&5+_JP0N>P7W-7#(AL@7G6+LVACDJ]T8H M*6_&4.KJTC2^4#=W+MD37N9?&\:I>(XH?[A!KJ\TI#0-+"VX'+K)LH*HCOM< ML!TE!UZEQ(*>9O,=#@+^5W"*\<&WC+\^7IOG(4][+R\,AK*@K33]VD_0![M* M!$\-%8UEV V4\A-YV 62^27PO->E\60S];Q;T!O@..O4\D5QH(MC0A>H%MXZKC$/'9J@&#@"39 MF3I]:8F+1#<_G=3X))BQCGS\,&S->^Y1.M^J;9J6\(R+&J8#XCR7D SIMYT0 M^69X %]!95$2QW:9QNFP[IYPO <4*WJ'?2:K3'N8>^^+%XIKQQBKC]#@_A.% M@2H&$-X!G\^C77W$U^82&/6U>I&Q;:_'5EB_$4+1#> CW%V[3"_O7),D<0[P/BUU$@H0'P8U<'<9E 8DIHJ "'S6O. M-W78B[*T-\%?KI&L8ENEB16ZR/ IX?A:<\5F2]]?!D$WHT%DXCQ;Q@)*"5#R MH9JR%1\#;/R=LJVK,M9T#3TNO<)0;@LK'C?:DZW<$X*WJ8B2Z!-Q=*COM4R% MO[5,4;^@BW@S1+7PN$O^Y4N4'M']20\1&N](+@N^:<0[*B/%UQQL MGRP*'_=RA%P;Q3_YSHXZ)F7C*#6X00,G>+=!#B]J[H3%W>^O.:C*1WI;/(D# M"]SW8Y&E"T\U[I*SH+:W:Y#3#8]]A/8C^:3?<+\FUR.S+>?.(MG5VPFG&5MB) M/.(E"P'6604('H+S#,ND \IT[E,PZS#CT_5E!L09KG'MRL0&2)19GC.8IH[0FI/@5W7<+\#YR7-#%'C'9+//6^_8G:L&>==E M8$G%!^X5&05NI2U?LZ/NFB:8D"W> E W'_)C<3Y?RHB<_A2EFN*(P@VE>\J[ M/8JAO:!K_Q]O ]/H L&/;H'(INDH$_H$O6A0N 'Y J_/.WKN<8T4&5_BRJ+0 M2?J%I+X:1NP/>8GEB71M/;@FE[]M=\>IH&&I,ZUJ*;BR_0T9RO>TBNV:Z#MZ M.4Z_YK 1K+#QC'&]6 5AJ$VEV58J.//2SD0]A=2E/T*!% :'#,^8 ML=B*6P M*B/D=,\3JX@ QS(E9Z>=N@3Y,:,U/2H^<:Y2[BA-5<$,DA1\XTU%X5UGQ3*]5W4W_%ZJ N 7H M?<34(V!-A4N9*OW2,Q4A7EU/=[QD(=3DG>I4ES*QBW0 X! M>11+)NR<)_S-34CIVBWP>N_G1TC 1+J"8O0Y2P>'*_EZ(5],1*( I]:S=/ZX M+VPKAGFX)C\>!%T[\A^GP,2GVC#M;=)"7=S$WLQW0S$1O5O7SW/^'2;UW6P) M%BDZ9*#OG#S&M"Q<-W5(FM*R\T-^?7.PQ5MTTJL;'HRT MOPE;?W + &9WO8;]AY@>$Z%W0O%2D:<*-''E%?D& &8N54E@'^%VSL^'NB D M:],M@ /L!_ZS]V;OC $*[]XSG@N$8_#O[-W>=;'ZJZRWPSM 4 MGDN0_IO[0+^KDOE;!/R9#LNI-[/9Y N<_BC\/LR]&AN;(^ZLL%UMS8^:"6H[- M@.N'[_J;Q W6;<.H3KXZ\+0"AF[',F5+UPH?2=4'Q\N7-'*%"6Y,]GI!S?%4 M4-%/U2*M/EEO*G@9>8L[-W_;^H4YG#+NM732M4*F(-VQ,Z& M/M+>0#[5[S5#@\T&@XA(@UVF9K0-M]RH8C"I?/V]V32C]G

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htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock (Tables)
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Common stock reserved for future issuance
The Company reserved common stock shares for future issuance as of December 31, 2019 and 2018 as follows:

December 31,

20192018
Conversion of Series A redeemable convertible preferred stock—  7,611,691  
Outstanding options under the 2016 Plan2,748,434  1,376,084  
Equity awards available for grants under the 2016 Plan—  216,333  
Outstanding options under the 2019 Plan29,466  —  
Unvested RSUs under the 2019 Plan23,125  —  
Equity awards available for grants under the 2019 Plan2,747,047  —  
Total5,548,072  9,204,108  
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Nov. 04, 2019
USD ($)
$ / shares
shares
Dec. 31, 2019
USD ($)
Sep. 30, 2019
USD ($)
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jun. 30, 2018
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2019
USD ($)
segment
Dec. 31, 2018
USD ($)
Subsidiary, Sale of Stock [Line Items]                      
Price per share (in usd per share) | $ / shares $ 16.00                    
Net loss | $   $ (19,724) $ (11,497) $ (10,730) $ (3,760) $ (4,011) $ (6,632) $ (2,926) $ (2,934) $ (45,711) $ (16,503)
Number of reportable segments | segment                   1  
IPO                      
Subsidiary, Sale of Stock [Line Items]                      
Number of common stock sold and issued (in shares) | shares 5,750,000                    
Aggregate gross proceeds from offering | $ $ 82,100                    
Redeemable Convertible Preferred Stock                      
Subsidiary, Sale of Stock [Line Items]                      
Conversion of preferred stock, shares converted (in shares) | shares 14,193,281                    
Office equipment                      
Property, Plant and Equipment [Line Items]                      
Property, Plant and Equipment, Useful Life                   5 years  
Furniture and fixtures                      
Property, Plant and Equipment [Line Items]                      
Property, Plant and Equipment, Useful Life                   7 years  
XML 39 R13.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company did not record a federal or state income tax provision or benefit for the for the years ended December 31, 2019 and December 31, 2018 as it has incurred net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.

The Company’s loss before provision for income taxes for the years ended December 31, 2019 and 2018 was as follows (in thousands):
Year Ended December 31,
20192018
Domestic$(45,711) $(16,503) 
International—  —  
Loss before provision for income taxes$(45,711) $(16,503) 

The Company had an effective tax rate of 0% for the years ended December 31, 2019 and 2018. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:

Year Ended December 31,
20192018
Federal statutory income tax rate21.0 %21.0 %
State taxes (tax effected)8.5 %9.2 %
Research tax credit3.3 %2.6 %
Other permanent differences(2.0)%(0.2)%
Change in valuation allowance(30.8)%(32.6)%
Provision for income taxes0.0%0 %

The components of the Company’s net deferred tax assets and liabilities as of December 31, 2019 and 2018, were as follows (in thousands):
December 31,
20192018
Deferred tax assets:
Net operating loss carryforwards$12,454  $4,826  
Credits2,408  662  
Tangible and intangible assets1,977  269  
Lease liability227  —  
Stock compensation253  —  
Other36  57  
Gross deferred tax assets17,355  5,814  
Less: Valuation allowance(16,423) (5,750) 
Deferred tax assets, net of valuation allowance 932  64  
Deferred tax liabilities:
Prepaids(708) (64) 
Right of use asset(224) —  
Net deferred tax assets$—  $—  

Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s historical operating performance and the U.S. cumulative net losses in all prior periods, the Company has provided a valuation allowance against its U.S. deferred tax assets. The Company’s valuation allowance increased by $10.7 million for the year ended December 31, 2019 and by $4.0 million for the year ended December 31, 2018.

As of December 31, 2019, the Company has U.S. federal and state net operating losses of $59.1 million and $60.7 million, respectively, which expire beginning in the year 2035. As of December 31, 2018, the Company had U.S. federal and state net operating losses of $22.8 million and $22.9 million, respectively, which expire beginning in the year 2035.

Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.

A Section 382 ownership change generally occurs if one or more stockholders or groups of stockholders who own at least 5% of the Company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. The Company has experienced an ownership change; however, the change will have no material limit on the Company’s net operating loss carryforwards. The Company is not in a taxable position and no net operating loss carryforwards have been used to date.

As of December 31, 2019 and 2018, the Company also had federal research and experimentation credit carryforwards of $2.1 million and $0.6 million, respectively, and state research and experimentation credit carryforwards of $0.4 and $0.1 million. The federal research and experimentation credit carryforwards expire beginning 2037. The California tax credit can be carried forward indefinitely.

As of December 31, 2019 and 2018, the Company had the following unrecognized tax benefits (in thousands):

Year Ended December 31,
20192018
Balance at the beginning of the year$1,989  $508  
Additions based on tax positions related to current year3,399  1,481  
Balance at the end of the year$5,388  $1,989  
The reversal of the unrecognized tax benefits would not affect the Company’s effective tax rate to the extent that it continues to maintain a full valuation allowance against its deferred tax assets. The Company does not expect any changes to uncertain tax benefits within the next twelve months.

The Company recognizes interest and penalties related to income tax matters as a component of income tax expense. No accrued interest and penalties have been recorded as of December 31, 2019 and 2018.

The Company files income tax returns in the U.S. federal, California and New Jersey jurisdictions. Due to the Company’s net losses, its federal and state income tax returns are subject to examination for federal and state purposes since inception. As of December 31, 2019, there were no ongoing examinations.
XML 40 R7.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Statement of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities    
Net loss $ (45,711) $ (16,503)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 3,266 154
Depreciation and amortization 19 0
Changes in assets and liabilities:    
Prepaid expenses and other current assets (2,643) 473
Other non-current assets 20 (20)
Accounts payable 38 44
Operating lease right-of-use asset (731) (66)
Operating lease liability 746 62
Accrued liabilities 4,181 (1,227)
Net cash used in operating activities (40,815) (17,083)
Cash flows from investing activities    
Purchases of property and equipment (200) 0
Net cash used in investing activities (200) 0
Cash flows from financing activities    
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 92,852 0
Proceeds from initial public offering, net of issuance costs 82,102 0
Proceeds from the issuance of common stock upon exercise of stock options 31 0
Net cash provided by financing activities 174,985 0
Net increase (decrease) in cash and cash equivalents 133,970 (17,083)
Cash and cash equivalents at the beginning of the period 5,228 22,311
Cash, cash equivalents and restricted cash at the end of the period 139,198 5,228
Reconciliation of cash, cash equivalents and restricted cash    
Cash, cash equivalents and restricted cash 5,228 5,228
Supplemental cash flow information    
Right-of-use for office space acquired through operating leases 897 113
Supplemental non-cash investing and financing activities    
Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering $ 135,853 $ 0
XML 41 R17.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Net Loss Per Share Attributable to Common Stockholders
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Net Loss Per Share Attributable to Common Stockholders Net Loss Per Share Attributable to Common Stockholders
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):

Year Ended December 31,
20192018
Numerator:
Net loss attributable to common stockholders$(45,711) $(16,503) 
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted4,585,146  1,411,966  
Net loss per share attributable to common stockholders, basic and diluted
$(9.97) $(11.69) 
The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

Year Ended December 31,
20192018
Series A redeemable convertible preferred stock—  7,611,691  
Options to purchase common stock2,777,900  1,376,084  
Unvested restricted stock units23,125  —  
Total2,801,025  8,987,775  
XML 42 R3.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Shares of redeemable convertible preferred stock issued (in shares) 0  
Redeemable convertible preferred stock, outstanding (in shares) 0 7,611,691
Common stock par value (in dollars per share) $ 0.001 $ 0.001
Common stock shares outstanding (in shares) 21,366,950 1,411,966
Common stock shares issued (in shares) 21,366,950 1,411,966
Common stock authorized (in shares) 1,000,000,000 10,943,000
Preferred stock authorized (in shares) 5,000,000 0
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Par value of preferred stock (in dollars per share) $ 0.001 $ 0.001
Series A redeemable convertible preferred stock    
Par value of redeemable convertible preferred stock (in dollars per share) $ 0.001 $ 0.001
Shares of redeemable convertible preferred stock authorized (in shares) 0 7,611,691
Shares of redeemable convertible preferred stock issued (in shares) 0 7,611,691
Redeemable convertible preferred stock, outstanding (in shares) 0 7,611,691
Redeemable convertible preferred stock, liquidation preference   $ 43,126,000
XML 43 R38.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Deferred Tax Assets and liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Deferred tax assets:    
Net operating loss carryforwards $ 12,454 $ 4,826
Credits 2,408 662
Tangible and intangible assets 1,977 269
Lease liability 227 0
Stock compensation 253 0
Other 36 57
Gross deferred tax assets 17,355 5,814
Less: Valuation allowance 16,423 5,750
Deferred tax assets, net of valuation allowance 932 64
Deferred tax liabilities:    
Prepaids 708 64
Right of use asset   0
Net deferred tax assets 0 $ 0
Deferred Tax Liabilities, Leasing Arrangements $ 224  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitment and Contingencies - Lease Maturity Schedules (Details) - USD ($)
$ in Thousands
Jan. 20, 2020
Dec. 31, 2019
Dec. 31, 2018
Lessee, Operating Lease, Liability, Payment, Due [Abstract]      
2019   $ 319 $ 59
2020     7
2021   316  
2022   186  
Total undiscounted cash flows   821 66
Less: imputed interest   (13) (4)
Total operating lease liability   808 62
Less: current portion   (296) (56)
Operating lease liability   $ 512 $ 6
Lease Amendment | Subsequent Event      
Lessee, Lease, Description [Line Items]      
Future minimum operating lease payments due under amended lease agreement $ 400    
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measures and Disclosures (Details) - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of financial liabilities $ 0 $ 0
Fair Value, Recurring    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total fair value of assets 138,147,000 5,228,000
Fair Value, Recurring | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds 138,147,000 5,228,000
Fair Value, Recurring | Quoted Price in Active Markets for Identical Assets (Level 1)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total fair value of assets 138,147,000 5,228,000
Fair Value, Recurring | Quoted Price in Active Markets for Identical Assets (Level 1) | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds 138,147,000 5,228,000
Fair Value, Recurring | Significant Other Observable Inputs (Level 2)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total fair value of assets 0 0
Fair Value, Recurring | Significant Other Observable Inputs (Level 2) | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds 0 0
Fair Value, Recurring | Significant Unobservable Inputs (Level 3)    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Total fair value of assets 0 0
Fair Value, Recurring | Significant Unobservable Inputs (Level 3) | Money Market Funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Money market funds $ 0 $ 0
XML 46 R12.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitment and Contingencies
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Asset Purchase of OC-02
In October 2016, the Company entered into an asset purchase agreement pursuant to which the Company acquired the compound OC-02. The agreement provides for milestone payments of up to $37.0 million upon achievement of certain milestone events. The agreement also provides for royalty payments in the mid-single digit percentage on covered product net worldwide sales. The Company’s obligation to pay royalties will terminate at the latter of patent expiration in each country or ten years. In addition, the Company is required to pay 15% of any (i) licensing revenue received that is related to OC-02 and (ii) revenue received from the sale of OC-02, up to a maximum aggregate amount of $10.0 million.

License Agreement
In October 2019, the Company entered into a non-exclusive patent license agreement (the License Agreement) with Pfizer, which granted the Company non-exclusive rights under Pfizer’s patent rights covering varenicline tartrate to develop, manufacture, and commercialize the OC-01 varenicline product candidate. Under the terms of the License Agreement, the Company made an upfront payment to Pfizer of $5.0 million, which is included in research and development expense for the year ended December 31, 2019. If the Company successfully commercializes OC-01, it may be required to pay a single milestone payment in the very low double-digit millions and tiered royalties on net sales of OC-01 at percentages ranging from the mid-single digits to the mid-teens. The royalty obligation to Pfizer will commence upon the first commercial sale of OC-01 and will expire upon the later of (a) the expiration of all regulatory or data exclusivity granted to Pfizer in connection with varenicline in the United States; and (b) the expiration or abandonment of the last valid claims of the licensed patents.
Operating Lease Obligations

In January 2018, the Company entered a lease for office space under a non-cancelable operating lease with an expiration date of March 15, 2020, in Princeton, New Jersey. Rent expense is recorded on a straight-line basis over the term of the lease. The total lease payment over the life of the lease is $0.1 million. The remaining lease term was 0.2 years as of December 31, 2019.
In April 2019, the Company entered a lease for office space under a non-cancelable operating lease in Princeton, New Jersey, commencing on July 1, 2019, for a period of three years from the commencement date. Rent expense is recorded on a straight-line basis over the term of the lease. The total lease payment over the life of the lease is $0.9 million. The remaining lease term was 2.5 years as of December 31, 2019.
At the commencement date, the Company determined the amounts of the lease liability using a discount rate of 9%, which management determined represents the Company’s incremental borrowing rate. Lease expense was $0.2 million and less than $0.1 million for the twelve months ended December 31, 2019 and December 31, 2018, respectively. Cash paid for amounts included in the measurement of the lease liability was $0.2 million and less than $0.1 million for the twelve months ended December 31, 2019 and December 31, 2018, respectively, and was included in cash flows from operating activities in the statements of cash flows.

The maturities of the lease liabilities under non-cancelable operating leases are as follows (in thousands):


As of December 31, 2018Amount
2019$59  
20207  
Total undiscounted cash flows66  
Less: imputed interest(4) 
Total operating lease liability62  
Less: current portion(56) 
Operating lease liability$6  

As of December 31, 2019Amount
2020$319  
2021316  
2022186  
Total undiscounted cash flows821  
Less: imputed interest(13) 
Total operating lease liability808  
Less: current portion(296) 
Operating lease liability$512  

In January 2020 the Company amended the lease of one its office facilities in Princeton, New Jersey to include additional office space, with an expiration date of July 31, 2022. Total future minimum lease payments under this amendment are $0.4 million.
Contingencies and Indemnifications
From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.
In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications, including for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend
any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.The Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid.
XML 47 R6.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)
$ in Thousands
 3 Months Ended
Jun. 30, 2019
USD ($)
Series B Preferred Stock  
Class of Stock [Line Items]  
Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $148 $ 148
XML 48 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity Incentive Plans
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Equity Incentive Plans Equity Incentive Plans
In 2016, the Company established its 2016 Equity Incentive Plan (the “Plan”) which provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants.

In October 2019, the Company’s Board of Directors and stockholders approved the 2019 Equity Incentive Plan (the 2019 Plan), with an initial shares reserved of 2,700,000 shares of the Company's common stock plus 99,638 shares reserved but unissued under the 2016 Plan. The 2019 Plan provides for the granting of stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company's employees, directors, and others.
The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. To date, outstanding options have a term of 10 years and generally vest monthly over a four-year period.
As of December 31, 2019, there were 2,747,047 common stock shares reserved for future grants under the 2019 Plan.

In October 2019, the Company’s Board of Directors and stockholders also approved the 2019 Employee Stock Purchase Plan (the ESPP), which qualifies as an "employee stock purchase plan" under Section 423 of the Internal Revenue Code, and pursuant to which 270,000 shares of common stock were reserved for future issuance. The ESPP is designed to enable eligible employees to purchase shares of the Company's common stock at a discount on a periodic basis through payroll deductions. There were no ESPP purchases during the year ended December 31, 2019.

Option activity under the Company’s stock option plans is set forth below (in thousands, except share and per share data):


Outstanding Awards
Number of Shares Underlying Outstanding Options
Weighted- Average Exercise Price
Weighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at January 1, 2018
1,057,373
$1.00  9.85$25  
Options granted
318,711
1.02  
Outstanding at December 31, 20181,376,084  $1.00  8.90$5,950  
Options granted1,446,823  8.01  
Options exercised(11,703) 2.64  255  
Options canceled(33,304) 5.86  
Outstanding at December 31, 2019$2,777,900  $4.59  8.73$55,146  
Shares vested and exercisable as of December 31, 2019$1,108,041  $2.10  8.29$24,757  
Vested and expected to vest as of December 31, 2019$2,777,900  $4.59  8.73$55,146  
During the years ended December 31, 2019 and 2018, the Company granted options with a weighted-average grant date fair value of $8.62 and $0.53 per share, respectively.
The fair value of options that vested during the years ended December 31, 2019 and 2018 was $2.5 million and $0.2 million, respectively.

As of December 31, 2019, the total unrecognized stock-based compensation expense for stock options was $9.4 million, which is expected to be recognized over a weighted-average period of 3.21 years.

In October 2019, the Company granted restricted stock units (RSUs) for 23,125 common stock shares that will vest one-third annually over three years, subject to continuing services to be provided to the Company. Grant date fair value was $16.00 per share, which is the common stock market price at the grant date. As of December 31, 2019, the total unrecognized stock-based compensation expense for RSUs was $0.3 million, which is expected to be recognized over a weighted-average period of 2.83 years.
Stock-Based Compensation Expense

The following table is a summary of stock compensation expense by function recognized (in thousands):
Year Ended December 31,
20192018
Research and development$579  $21  
General and administrative2,687  133  
Total stock-based compensation$3,266  $154  

Fair Value of Options Granted

Prior to the IPO, the fair value of the Company’s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company’s common stock and the general and industry-specific economic outlook. Subsequent to the IPO, the fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Global Select Market on the date of grant.

In determining fair value of the stock options granted, the Company uses the Black-Scholes model, which requires the input of several assumptions. These assumptions include: estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), risk-free interest rate and expected dividend rate. Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized.

Expected term. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.

Expected volatility. The Company used an average historical stock price volatility of a peer group of comparable publicly traded companies in biotechnology and pharmaceutical related industries to be representative of its expected future stock price volatility, as the Company did not have any trading history for its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term.

Risk-free interest rate. The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock award.

Expected dividend rate. The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero.

The fair value of options granted were calculated using the weighted average assumptions set forth below:
Year Ended December 31,
20192018
Expected volatility
69.0 - 84.0%
52.5%
Risk-free interest rate
1.48% - 2.38%
2.49% - 2.80%
Dividend yield
0.00%
0.00%
Expected term
5.04 - 6.08 years
6.02 years
XML 49 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 139,147 $ 5,228
Prepaid expenses and other current assets 3,033 390
Total current assets 142,180 5,618
Restricted cash 51 0
Operating lease right-of-use asset 797 66
Property and equipment, net 181 0
Other non-current assets 0 20
Total assets 143,209 5,704
Current liabilities:    
Accounts payable 500 462
Accrued liabilities 4,603 422
Operating lease liability 296 56
Total current liabilities 5,399 940
Operating lease liability, non-current 512 6
Total liabilities 5,911 946
Commitments and contingencies (Note 5)
Redeemable convertible preferred stock 0 43,001
Stockholders’ equity (deficit)    
Preferred stock: $0.001 par value per share - 5,000,000 shares authorized and no shares issued and outstanding as of December 31, 2019 and no shares authorized, issued and outstanding as of December 31, 2018 0 0
Common stock, $0.001 par value per share - 1,000,000,000 authorized shares at December 31, 2019, and 10,943,000 shares authorized at December 31, 2018; 21,366,950 shares issued and outstanding at December 31, 2019, and 1,411,966 shares issued and outstanding at December 31, 2018 21 1
Additional paid-in-capital 221,508 276
Accumulated deficit (84,231) (38,520)
Total stockholders’ equity (deficit) 137,298 (38,243)
Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit) 143,209 5,704
Series A redeemable convertible preferred stock    
Current liabilities:    
Redeemable convertible preferred stock $ 0 $ 43,001
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Tax Credit Carryforward [Line Items]    
Income tax provision or benefit $ 0 $ 0
Increase in valuation allowance 10,700,000 4,000,000.0
Accrued interest and penalties 0 0
State and Local Jurisdiction    
Tax Credit Carryforward [Line Items]    
Net operating loss carryforwards 60,700,000 22,900,000
Research and experimentation credit carryforward 400,000 100,000
Domestic Tax Authority    
Tax Credit Carryforward [Line Items]    
Net operating loss carryforwards 59,100,000 22,800,000
Research and experimentation credit carryforward $ 2,100,000 $ 600,000
XML 51 R31.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property, Plant, and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 200  
Accumulated depreciation 19  
Property and equipment, net 181 $ 0
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 105  
Office equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 45  
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 50  
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]    
Balance at the beginning of the year $ 1,989 $ 508
Additions based on tax positions related to current year 3,399 1,481
Balance at the end of the year $ 5,388 $ 1,989
XML 53 R45.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity Incentive Plans - Stock Based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation $ 3,266 $ 154
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation 579 21
General and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation $ 2,687 $ 133
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock (Details)
 12 Months Ended
Dec. 31, 2019
vote
$ / shares
shares
Dec. 31, 2018
$ / shares
shares
Class of Stock [Line Items]    
Common stock authorized (in shares) | shares 1,000,000,000 10,943,000
Common stock par value (in dollars per share) $ 0.001 $ 0.001
Number of votes per share | vote 1  
Common Stock    
Class of Stock [Line Items]    
Common stock par value (in dollars per share) $ 0.001  
XML 55 R49.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Results of Operations Data (unaudited) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Condensed Financial Information Disclosure [Abstract]                    
Research and development $ 15,034 $ 8,088 $ 8,101 $ 2,405 $ 3,345 $ 5,775 $ 2,261 $ 2,374 $ 33,628 $ 13,755
General and administrative 5,127 3,809 3,132 1,605 704 916 735 626 13,673 2,981
Total operating expenses 20,161 11,897 11,233 4,010 4,049 6,691 2,996 3,000 47,301 16,736
Operating Income (Loss) (20,161) (11,897) (11,233) (4,010) (4,049) (6,691) (2,996) (3,000) (47,301) (16,736)
Interest income 437 400 503 250 38 59 70 66 1,590 233
Net loss and comprehensive loss $ (19,724) $ (11,497) $ (10,730) $ (3,760) $ (4,011) $ (6,632) $ (2,926) $ (2,934) $ (45,711) $ (16,503)
Basic and diluted net loss per share $ (1.41) $ (8.10) $ (7.60) $ (2.66) $ (2.84) $ (4.70) $ (2.07) $ (2.08)    
Weighted average shares outstanding 13,993,730 1,419,064 1,412,354 1,411,966 1,411,966 1,411,966 1,411,966 1,411,966 4,585,146 1,411,966
XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 104 322 1 false 39 0 false 6 false false R1.htm 0001001 - Document - Cover Sheet http://oysterpointrx.com/role/Cover Cover Cover 1 false false R2.htm 1001002 - Statement - Balance Sheets Sheet http://oysterpointrx.com/role/BalanceSheets Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Balance Sheets (Parenthetical) Sheet http://oysterpointrx.com/role/BalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Statements of Operations and Comprehensive Loss Sheet http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit Sheet http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit Statements 5 false false R6.htm 1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) Sheet http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical) Statements 6 false false R7.htm 1006007 - Statement - Statement of Cash Flows Sheet http://oysterpointrx.com/role/StatementofCashFlows Statement of Cash Flows Statements 7 false false R8.htm 2101101 - Disclosure - Organization and Summary of Significant Accounting Policies Sheet http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPolicies Organization and Summary of Significant Accounting Policies Notes 8 false false R9.htm 2104102 - Disclosure - Fair Value Measurements Sheet http://oysterpointrx.com/role/FairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 2107103 - Disclosure - Property and Equipment, net Sheet http://oysterpointrx.com/role/PropertyandEquipmentnet Property and Equipment, net Notes 10 false false R11.htm 2110104 - Disclosure - Accrued Liabilities Sheet http://oysterpointrx.com/role/AccruedLiabilities Accrued Liabilities Notes 11 false false R12.htm 2113105 - Disclosure - Commitment and Contingencies Sheet http://oysterpointrx.com/role/CommitmentandContingencies Commitment and Contingencies Notes 12 false false R13.htm 2117106 - Disclosure - Income Taxes Sheet http://oysterpointrx.com/role/IncomeTaxes Income Taxes Notes 13 false false R14.htm 2124107 - Disclosure - Redeemable Convertible Preferred Stock Sheet http://oysterpointrx.com/role/RedeemableConvertiblePreferredStock Redeemable Convertible Preferred Stock Notes 14 false false R15.htm 2126108 - Disclosure - Common Stock Sheet http://oysterpointrx.com/role/CommonStock Common Stock Notes 15 false false R16.htm 2130109 - Disclosure - Equity Incentive Plans Sheet http://oysterpointrx.com/role/EquityIncentivePlans Equity Incentive Plans Notes 16 false false R17.htm 2136110 - Disclosure - Net Loss Per Share Attributable to Common Stockholders Sheet http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholders Net Loss Per Share Attributable to Common Stockholders Notes 17 false false R18.htm 2140111 - Disclosure - Quarterly Results of Operations Data (unaudited) Sheet http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunaudited Quarterly Results of Operations Data (unaudited) Notes 18 false false R19.htm 2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies) Sheet http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies Organization and Summary of Significant Accounting Policies (Policies) Policies http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPolicies 19 false false R20.htm 2305301 - Disclosure - Fair Value Measures and Disclosures (Tables) Sheet http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresTables Fair Value Measures and Disclosures (Tables) Tables 20 false false R21.htm 2308302 - Disclosure - Property, Plant, and Equipment (Tables) Sheet http://oysterpointrx.com/role/PropertyPlantandEquipmentTables Property, Plant, and Equipment (Tables) Tables 21 false false R22.htm 2311303 - Disclosure - Accrued Liabilities (Tables) Sheet http://oysterpointrx.com/role/AccruedLiabilitiesTables Accrued Liabilities (Tables) Tables http://oysterpointrx.com/role/AccruedLiabilities 22 false false R23.htm 2314304 - Disclosure - Commitment and Contingencies (Tables) Sheet http://oysterpointrx.com/role/CommitmentandContingenciesTables Commitment and Contingencies (Tables) Tables http://oysterpointrx.com/role/CommitmentandContingencies 23 false false R24.htm 2318305 - Disclosure - Income Taxes (Tables) Sheet http://oysterpointrx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://oysterpointrx.com/role/IncomeTaxes 24 false false R25.htm 2327306 - Disclosure - Common Stock (Tables) Sheet http://oysterpointrx.com/role/CommonStockTables Common Stock (Tables) Tables http://oysterpointrx.com/role/CommonStock 25 false false R26.htm 2331307 - Disclosure - Equity Incentive Plans (Tables) Sheet http://oysterpointrx.com/role/EquityIncentivePlansTables Equity Incentive Plans (Tables) Tables http://oysterpointrx.com/role/EquityIncentivePlans 26 false false R27.htm 2337308 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) Sheet http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables Net Loss Per Share Attributable to Common Stockholders (Tables) Tables http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholders 27 false false R28.htm 2341309 - Disclosure - Quarterly Results of Operations Data (unaudited) (Tables) Sheet http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedTables Quarterly Results of Operations Data (unaudited) (Tables) Tables http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunaudited 28 false false R29.htm 2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details) Sheet http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails Organization and Summary of Significant Accounting Policies (Details) Details http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies 29 false false R30.htm 2406402 - Disclosure - Fair Value Measures and Disclosures (Details) Sheet http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails Fair Value Measures and Disclosures (Details) Details http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresTables 30 false false R31.htm 2409403 - Disclosure - Property, Plant, and Equipment (Details) Sheet http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails Property, Plant, and Equipment (Details) Details http://oysterpointrx.com/role/PropertyPlantandEquipmentTables 31 false false R32.htm 2412404 - Disclosure - Accrued Liabilities (Details) Sheet http://oysterpointrx.com/role/AccruedLiabilitiesDetails Accrued Liabilities (Details) Details http://oysterpointrx.com/role/AccruedLiabilitiesTables 32 false false R33.htm 2415405 - Disclosure - Commitment and Contingencies (Details) Sheet http://oysterpointrx.com/role/CommitmentandContingenciesDetails Commitment and Contingencies (Details) Details http://oysterpointrx.com/role/CommitmentandContingenciesTables 33 false false R34.htm 2416406 - Disclosure - Commitment and Contingencies - Lease Maturity Schedules (Details) Sheet http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails Commitment and Contingencies - Lease Maturity Schedules (Details) Details 34 false false R35.htm 2419407 - Disclosure - Income Taxes (Details) Sheet http://oysterpointrx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://oysterpointrx.com/role/IncomeTaxesTables 35 false false R36.htm 2420408 - Disclosure - Income Taxes - Loss Before Provision for Income Taxes (Details) Sheet http://oysterpointrx.com/role/IncomeTaxesLossBeforeProvisionforIncomeTaxesDetails Income Taxes - Loss Before Provision for Income Taxes (Details) Details 36 false false R37.htm 2421409 - Disclosure - Income Taxes - Income Tax Reconciliation (Details) Sheet http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails Income Taxes - Income Tax Reconciliation (Details) Details 37 false false R38.htm 2422410 - Disclosure - Income Taxes - Deferred Tax Assets and liabilities (Details) Sheet http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails Income Taxes - Deferred Tax Assets and liabilities (Details) Details 38 false false R39.htm 2423411 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details) Sheet http://oysterpointrx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails Income Taxes - Unrecognized Tax Benefits (Details) Details 39 false false R40.htm 2425412 - Disclosure - Redeemable Convertible Preferred Stock (Details) Sheet http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails Redeemable Convertible Preferred Stock (Details) Details http://oysterpointrx.com/role/RedeemableConvertiblePreferredStock 40 false false R41.htm 2428413 - Disclosure - Common Stock (Details) Sheet http://oysterpointrx.com/role/CommonStockDetails Common Stock (Details) Details http://oysterpointrx.com/role/CommonStockTables 41 false false R42.htm 2429414 - Disclosure - Common Stock - Reserved Common Stock (Details) Sheet http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails Common Stock - Reserved Common Stock (Details) Details 42 false false R43.htm 2432415 - Disclosure - Equity Incentive Plans (Details) Sheet http://oysterpointrx.com/role/EquityIncentivePlansDetails Equity Incentive Plans (Details) Details http://oysterpointrx.com/role/EquityIncentivePlansTables 43 false false R44.htm 2433416 - Disclosure - Equity Incentive Plans - Option Activity During The Period (Details) Sheet http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails Equity Incentive Plans - Option Activity During The Period (Details) Details 44 false false R45.htm 2434417 - Disclosure - Equity Incentive Plans - Stock Based Compensation Expense (Details) Sheet http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails Equity Incentive Plans - Stock Based Compensation Expense (Details) Details 45 false false R46.htm 2435418 - Disclosure - Equity Incentive Plans - Fair Value Assumptions (Details) Sheet http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails Equity Incentive Plans - Fair Value Assumptions (Details) Details 46 false false R47.htm 2438419 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details) Sheet http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails Net Loss Per Share Attributable to Common Stockholders (Details) Details http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables 47 false false R48.htm 2439420 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details) Sheet http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details) Details 48 false false R49.htm 2442421 - Disclosure - Quarterly Results of Operations Data (unaudited) (Details) Sheet http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails Quarterly Results of Operations Data (unaudited) (Details) Details http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedTables 49 false false All Reports Book All Reports oyst-20191231.htm oyst-20191231.xsd oyst-20191231_cal.xml oyst-20191231_def.xml oyst-20191231_lab.xml oyst-20191231_pre.xml q4-19ex231.htm q4-19ex311.htm q4-19ex312.htm q4-19ex321.htm q4-19ex322.htm q4-19ex41.htm oyst-20191231_g1.jpg oyst-20191231_g10.jpg oyst-20191231_g11.jpg oyst-20191231_g12.jpg oyst-20191231_g13.jpg oyst-20191231_g14.jpg oyst-20191231_g15.jpg oyst-20191231_g16.jpg oyst-20191231_g17.jpg oyst-20191231_g18.jpg oyst-20191231_g19.jpg oyst-20191231_g2.jpg oyst-20191231_g3.jpg oyst-20191231_g4.jpg oyst-20191231_g5.jpg oyst-20191231_g6.jpg oyst-20191231_g7.jpg oyst-20191231_g8.jpg oyst-20191231_g9.jpg http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 57 R28.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Results of Operations Data (unaudited) (Tables)
 12 Months Ended
Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]  
Condensed Income Statement
Three months ended
March 31, 2019June 30, 2019September 30, 2019December 31, 2019
Operating expenses:
Research and development$2,405  $8,101  $8,088  $15,034  
General and administrative1,605  3,132  3,809  5,127  
Total operating expenses4,010  11,233  11,897  20,161  
Loss from operations(4,010) (11,233) (11,897) (20,161) 
Interest income250  503  400  437  
Net loss and comprehensive loss$(3,760) $(10,730) $(11,497) $(19,724) 
Basic and diluted net loss per share$(2.66) $(7.60) $(8.10) $(1.41) 
Weighted average shares outstanding1,411,966  1,412,354  1,419,064  13,993,730  

Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2018 (in thousands, except share and per share data):

Three months ended
March 31, 2018June 30, 2018September 30, 2018December 31, 2018
Operating expenses:
Research and development$2,374  $2,261  $5,775  $3,345  
General and administrative626  735  916  704  
Total operating expenses3,000  2,996  6,691  4,049  
Loss from operations(3,000) (2,996) (6,691) (4,049) 
Interest income66  70  59  38  
Net loss and comprehensive loss$(2,934) $(2,926) $(6,632) $(4,011) 
Basic and diluted net loss per share$(2.08) $(2.07) $(4.70) $(2.84) 
Weighted average shares outstanding1,411,966  1,411,966  1,411,966  1,411,966  
XML 58 R20.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measures and Disclosures (Tables)
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Financial assets measured and recognized at fair value
As of December 31, 2019, financial assets measured and recognized at fair value were as follows (in thousands):

Fair Value Measurements at December 31, 2019
Quoted Price in Active Markets for Identical Assets (Level 1)
Significant Other Observable Inputs (Level 2)
Significant Unobservable Inputs (Level 3)
Total
Assets
Money market funds$138,147  $—  $—  $138,147  
Total fair value of assets$138,147  $—  $—  $138,147  

As of December 31, 2018, financial assets measured and recognized at fair value were as follows (in thousands):

Fair Value Measurements at December 31, 2018
Quoted Price
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets
Money market funds$5,228  $—  $—  $5,228  
Total fair value of assets$5,228  $—  $—  $5,228  
XML 59 R24.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2019
Income Tax Disclosure [Abstract]  
Schedule of loss before provision for income taxes
Year Ended December 31,
20192018
Domestic$(45,711) $(16,503) 
International—  —  
Loss before provision for income taxes$(45,711) $(16,503) 
Schedule of effective income tax rate reconciliation
The Company had an effective tax rate of 0% for the years ended December 31, 2019 and 2018. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:

Year Ended December 31,
20192018
Federal statutory income tax rate21.0 %21.0 %
State taxes (tax effected)8.5 %9.2 %
Research tax credit3.3 %2.6 %
Other permanent differences(2.0)%(0.2)%
Change in valuation allowance(30.8)%(32.6)%
Provision for income taxes0.0%0 %
Schedule of deferred tax assets and liabilities
December 31,
20192018
Deferred tax assets:
Net operating loss carryforwards$12,454  $4,826  
Credits2,408  662  
Tangible and intangible assets1,977  269  
Lease liability227  —  
Stock compensation253  —  
Other36  57  
Gross deferred tax assets17,355  5,814  
Less: Valuation allowance(16,423) (5,750) 
Deferred tax assets, net of valuation allowance 932  64  
Deferred tax liabilities:
Prepaids(708) (64) 
Right of use asset(224) —  
Net deferred tax assets$—  $—  
Schedule of unrecognized tax benefits roll forward
As of December 31, 2019 and 2018, the Company had the following unrecognized tax benefits (in thousands):

Year Ended December 31,
20192018
Balance at the beginning of the year$1,989  $508  
Additions based on tax positions related to current year3,399  1,481  
Balance at the end of the year$5,388  $1,989  
XML 60 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Income Tax Reconciliation (Details)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]    
Federal statutory income tax rate 21.00% 21.00%
State taxes (tax effected) 8.50% 9.20%
Research tax credit (3.30%) (2.60%)
Other permanent differences (2.00%) (0.20%)
Change in valuation allowance (30.80%) (32.60%)
Provision for income taxes 0.00% 0.00%
XML 61 R33.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitment and Contingencies (Details) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 18, 2019
Oct. 31, 2016
Dec. 31, 2019
Dec. 31, 2018
Jul. 01, 2019
Apr. 30, 2019
Jan. 31, 2018
Lessee, Lease, Description [Line Items]              
Lease payments due over the life of the lease     $ 821,000 $ 66,000      
Lease discount rate         9.00%    
Lease expense (less than in 2018)     200,000 100,000      
Payments made for leases (less than in 2018)     $ 200,000 $ 100,000      
Princeton New Jersey Office Space, Lease Ending In 2020              
Lessee, Lease, Description [Line Items]              
Lease payments due over the life of the lease             $ 100,000
Remaining term on operating lease     2 months 12 days        
Princeton New Jersey Office Space, Lease Ending in 2022              
Lessee, Lease, Description [Line Items]              
Lease payments due over the life of the lease           $ 900,000  
Remaining term on operating lease     2 years 6 months        
Term of lease contract           3 years  
Acquisition Of OC-02 Compound              
Lessee, Lease, Description [Line Items]              
Maximum milestone payments for acquisition   $ 37,000,000.0          
Term of obligation to pay royalties   10 years          
Required percentage of licensing revenue   15.00%          
Maximum aggregate amount of licensing revenue   $ 10,000,000.0          
Licensing Agreements              
Lessee, Lease, Description [Line Items]              
Upfront payment for non-exclusive license agreement $ 5,000,000.0            
XML 62 R4.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:                    
Research and development $ 15,034 $ 8,088 $ 8,101 $ 2,405 $ 3,345 $ 5,775 $ 2,261 $ 2,374 $ 33,628 $ 13,755
General and administrative 5,127 3,809 3,132 1,605 704 916 735 626 13,673 2,981
Total operating expenses 20,161 11,897 11,233 4,010 4,049 6,691 2,996 3,000 47,301 16,736
Loss from operations (20,161) (11,897) (11,233) (4,010) (4,049) (6,691) (2,996) (3,000) (47,301) (16,736)
Interest income 437 400 503 250 38 59 70 66 1,590 233
Net loss and comprehensive loss $ (19,724) $ (11,497) $ (10,730) $ (3,760) $ (4,011) $ (6,632) $ (2,926) $ (2,934) $ (45,711) $ (16,503)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)                 $ (9.97) $ (11.69)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares) 13,993,730 1,419,064 1,412,354 1,411,966 1,411,966 1,411,966 1,411,966 1,411,966 4,585,146 1,411,966
XML 63 R10.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Property and Equipment, net
 12 Months Ended
Dec. 31, 2019
Property, Plant and Equipment [Abstract]  
Property and Equipment, net Property and Equipment, net
Property and equipment consisted of the following (in thousands):

December 31, 2019
Leasehold improvements$105  
Office equipment45  
Furniture and fixtures50  
200  
Accumulated depreciation(19) 
Property and equipment, net$181  

The Company did not have any property and equipment as of December 31, 2018.
XML 64 R14.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Redeemable Convertible Preferred Stock
 12 Months Ended
Dec. 31, 2019
Temporary Equity Disclosure [Abstract]  
Redeemable Convertible Preferred Stock Redeemable Convertible Preferred StockOn February 15, 2019, the Company executed the Series B Preferred Stock Purchase Agreement to sell up to 6,581,590 shares of Series B redeemable convertible preferred stock. In February and April 2019, the Company received gross cash proceeds of $85.0 million and $8.0 million, respectively, from the sale of Series B redeemable convertible preferred stock.On November 4, 2019, upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock were converted into an aggregate of 14,193,281 shares of the Company’s common stock and $135.9 million of mezzanine equity was reclassified to common stock and additional paid-in capital. As of December 31, 2019, there were no shares of redeemable convertible preferred stock issued and outstanding.
XML 65 R8.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
Organization and Summary of Significant Accounting Policies Organization and Summary of Significant Accounting Policies
Description of the Business
Oyster Point Pharma, Inc. (the “Company”) was incorporated on June 30, 2015. From inception through December 31, 2019, the Company has been primarily engaged in business planning, research, clinical development of its lead therapeutic product candidates, recruiting and raising capital. The Company is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The Company’s principal office is located in Princeton, New Jersey.
Initial Public Offering

On November 4, 2019, the Company completed its initial public offering (IPO) selling 5,750,000 shares of common stock at a price to the public of $16.00 per share. The aggregate net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were $82.1 million. In addition, upon the closing the IPO, all outstanding shares of redeemable convertible preferred stock outstanding were converted into an aggregate of 14,193,281 shares of the Company’s common stock.

Liquidity

Since inception, the Company has incurred recurring losses and negative cash flows from operations. The Company incurred net losses of $45.7 million and $16.5 million for the years ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $84.2 million as of December 31, 2019. The Company has historically financed its operations primarily through the sale and issuance of its securities. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. The Company expects to incur increased sales and marketing expenses with the commercialization of new and existing products, if approved for sale, as well as increased research and development expenses as it develops additional product candidates. The Company expects its operating losses to continue to increase for the foreseeable future.

While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms that are favorable, or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives.

The Company had cash and cash equivalents of $139.1 million as of December 31, 2019. Management believes that the Company’s current cash and cash equivalents will be sufficient to fund its planned operations for at least 12 months from the date of issuance of these financial statements.

Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Reverse Stock Split
In October 2019, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 2.832861-for-1 reverse stock split of the Company’s common stock and redeemable convertible preferred stock, which was effected on October 18, 2019. The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, redeemable convertible preferred stock, stock options, and related per share amounts as of and for the year ended December 31, 2018 and for the period through October 18, 2019 have been retroactively adjusted to give effect to the reverse stock split.
Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to the valuation of stock awards, income taxes and certain research and development accruals and for periods prior to the IPO, the valuation of convertible notes, derivative instruments, and redeemable convertible preferred stock. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.

Segments

The Company operates and manages its business as one reportable operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company's long-lived assets are located in the United States.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s cash equivalents are invested in highly rated money market funds.

Risks and Uncertainties

The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Company’s ability to attract and retain employees necessary to support its growth.

Product candidates developed by the Company will require approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance that the product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company.

The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.

The Company relies on single source manufacturers and suppliers for the supply of its product candidates. Disruption from these manufacturers or suppliers would have a negative impact on the Company’s business, financial position and results of operations. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.

Cash and Cash Equivalents

The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December 31, 2019 and 2018, cash and cash equivalents consisted of cash on deposit with a bank denominated in U.S. dollars and investment in money market funds.
Restricted Cash

As of December 31, 2019, the Company had $51,000 of long-term restricted cash deposited with a financial institution. The entire amount is held in a separate bank account to support a letter of credit agreement related to one of the Company’s office facilities lease, which expires in 2022.

Property and Equipment

Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets as follows:

Office equipment   5 years
Furniture and fixtures  7 years
Leasehold improvements  Shorter of lease term or estimated useful life

Leases

The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of a contract. The Company’s operating lease asset is included in “operating lease right-of-use asset” (“ROU asset”), and the current and non-current portions of the operating lease liability are included in “operating lease liability”, and “operating lease liability, non-current”, respectively, on the balance sheets. As of December 31, 2019 and 2018, the Company had no finance leases.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease components as a single lease component for operating leases. The Company does not record leases with terms of 12 months or less on the balance sheets.

As the implicit rate for the operating lease was not determinable, the Company used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The Company’s incremental borrowing rate was estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determined the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated.

Fair Value of Financial Instruments

The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities.

Redeemable Convertible Preferred Stock

The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition, or sale of all or substantially all of the Company’s assets (each, a “deemed liquidation event”), the redeemable convertible preferred stock have become redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of redeemable convertible preferred stock was not probable of occurring. All outstanding shares of redeemable convertible preferred stock were converted to common stock shares upon the closing of the IPO in November 2019.

Research and Development

Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (“CMOs”), costs for clinical research organizations (“CROs”), costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses within the statements of operations and comprehensive loss as incurred.
Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred.

The Company’s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.

Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, and the expected life of the award.

Comprehensive Loss

Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.

Income Taxes

The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line. Accrued interest and penalties are included within the related income tax liability line in the balance sheets. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.

Net Loss per Share Attributable to Common Stockholders

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was a participating security. The Company’s participating securities did not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.

Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.
Recently adopted accounting pronouncements
In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. This ASU simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants, preferred shares and convertible debt instruments issued by private companies and early-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in Part I should be applied (1) retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the first fiscal year and interim periods; (2) retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The ASU permits companies to reclassify disproportionate tax effects in accumulated other comprehensive income (“AOCI”) caused by the Tax Act to retained earnings. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.
Recently issued accounting pronouncements not yet adopted
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This ASU removes the requirement to disclose: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.
XML 66 R18.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Quarterly Results of Operations Data (unaudited)
 12 Months Ended
Dec. 31, 2019
Condensed Financial Information Disclosure [Abstract]  
Quarterly Results of Operations Data (unaudited) Quarterly Results of Operations Data (unaudited)
The following table sets forth our unaudited statement of operations and comprehensive loss data for each of the eight quarters in the two-year period ended December 31, 2019. The unaudited quarterly statement of operations and comprehensive loss data set forth below have been prepared on a basis consistent with the audited annual financial statements and include, in our opinion, all normal recurring adjustments necessary for a fair statement of the financial information contained in those statements. Our historical results are not necessarily indicative of the results that may be expected in the future. The following quarterly financial data should be read in conjunction with our audited financial statements and the related notes.
Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2019 (in thousands, except share and per share data):
Three months ended
March 31, 2019June 30, 2019September 30, 2019December 31, 2019
Operating expenses:
Research and development$2,405  $8,101  $8,088  $15,034  
General and administrative1,605  3,132  3,809  5,127  
Total operating expenses4,010  11,233  11,897  20,161  
Loss from operations(4,010) (11,233) (11,897) (20,161) 
Interest income250  503  400  437  
Net loss and comprehensive loss$(3,760) $(10,730) $(11,497) $(19,724) 
Basic and diluted net loss per share$(2.66) $(7.60) $(8.10) $(1.41) 
Weighted average shares outstanding1,411,966  1,412,354  1,419,064  13,993,730  

Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2018 (in thousands, except share and per share data):

Three months ended
March 31, 2018June 30, 2018September 30, 2018December 31, 2018
Operating expenses:
Research and development$2,374  $2,261  $5,775  $3,345  
General and administrative626  735  916  704  
Total operating expenses3,000  2,996  6,691  4,049  
Loss from operations(3,000) (2,996) (6,691) (4,049) 
Interest income66  70  59  38  
Net loss and comprehensive loss$(2,934) $(2,926) $(6,632) $(4,011) 
Basic and diluted net loss per share$(2.08) $(2.07) $(4.70) $(2.84) 
Weighted average shares outstanding1,411,966  1,411,966  1,411,966  1,411,966  


Per share amounts for each quarter have been calculated separately. Accordingly, quarterly amounts may not add to annual amounts.
XML 69 R47.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Net Income (Loss) Attributable to Parent [Abstract]                    
Net Income (Loss) Attributable to Parent $ (19,724) $ (11,497) $ (10,730) $ (3,760) $ (4,011) $ (6,632) $ (2,926) $ (2,934) $ (45,711) $ (16,503)
Denominator:                    
Weighted average shares outstanding 13,993,730 1,419,064 1,412,354 1,411,966 1,411,966 1,411,966 1,411,966 1,411,966 4,585,146 1,411,966
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)                 $ (9.97) $ (11.69)
XML 70 R43.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity Incentive Plans (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Oct. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Unrecognized stock-based compensation expense $ 9,400    
Weighted-average recognition period of unrecognized stock-based compensation expense (in years) 3 years 2 months 15 days    
Total (in shares) 5,548,072 9,204,108  
Fair value of options vested $ 2,500 $ 200  
Grant date fair value (in dollars per share) $ 16.00    
2016 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Weighted-average grant-date fair value of options (in dollars per share) $ 8.62 $ 0.53  
Shares authorized for 2019 Equity Incentive Plan (in shares)     99,638
Options granted (in shares) 1,446,823 318,711  
2019 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Shares authorized for 2019 Equity Incentive Plan (in shares)     2,700,000
Stock options | 2016 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percent of estimated fair value of shares 100.00%    
Term of outstanding options (in years) 10 years    
Vesting period of stock options (in years) 4 years    
Incentive Stock Options | 2016 Plan      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Percent of estimated fair value of shares 110.00%    
Percent of shares owned by individual stockholder 10.00%    
Employee Stock | 2019 ESPP      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Total (in shares)     270,000
Restricted Stock Units (RSUs)      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period of stock options (in years) 3 years    
Granted restricted stock units (in shares) 23,125    
Unrecognized stock-based compensation expense for RSUs $ 300    
Expected term of recognition of RSU compensation cost 2 years 9 months 29 days    
XML 71 oyst-20191231_htm.xml IDEA: XBRL DOCUMENT 0001720725 2019-01-01 2019-12-31 0001720725 2019-12-31 0001720725 2020-02-21 0001720725 2018-12-31 0001720725 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001720725 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001720725 2018-01-01 2018-12-31 0001720725 2017-12-31 0001720725 us-gaap:CommonStockMember 2017-12-31 0001720725 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001720725 us-gaap:RetainedEarningsMember 2017-12-31 0001720725 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001720725 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001720725 us-gaap:CommonStockMember 2018-12-31 0001720725 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001720725 us-gaap:RetainedEarningsMember 2018-12-31 0001720725 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001720725 us-gaap:SeriesBPreferredStockMember 2019-04-01 2019-06-30 0001720725 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-12-31 0001720725 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001720725 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001720725 us-gaap:CommonStockMember 2019-12-31 0001720725 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001720725 us-gaap:RetainedEarningsMember 2019-12-31 0001720725 us-gaap:IPOMember 2019-11-04 2019-11-04 0001720725 2019-11-04 0001720725 us-gaap:RedeemableConvertiblePreferredStockMember 2019-11-04 2019-11-04 0001720725 us-gaap:OfficeEquipmentMember 2019-01-01 2019-12-31 0001720725 us-gaap:FurnitureAndFixturesMember 2019-01-01 2019-12-31 0001720725 2019-10-18 2019-10-18 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001720725 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2019-12-31 0001720725 us-gaap:OfficeEquipmentMember 2019-12-31 0001720725 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001720725 oyst:AcquisitionOfOC02CompoundMember 2016-10-31 0001720725 oyst:AcquisitionOfOC02CompoundMember 2016-10-01 2016-10-31 0001720725 us-gaap:LicensingAgreementsMember 2019-10-18 2019-10-18 0001720725 oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2020Member 2018-01-31 0001720725 oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2020Member 2019-01-01 2019-12-31 0001720725 oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2022Member 2019-04-30 0001720725 oyst:PrincetonNewJerseyOfficeSpaceLeaseEndingIn2022Member 2019-01-01 2019-12-31 0001720725 2019-07-01 0001720725 oyst:LeaseAmendmentMember us-gaap:SubsequentEventMember 2020-01-20 0001720725 us-gaap:DomesticCountryMember 2019-12-31 0001720725 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001720725 us-gaap:DomesticCountryMember 2018-12-31 0001720725 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001720725 us-gaap:SeriesBPreferredStockMember 2019-02-15 0001720725 us-gaap:SeriesBPreferredStockMember 2019-02-01 2019-02-28 0001720725 us-gaap:SeriesBPreferredStockMember 2019-04-01 2019-04-30 0001720725 us-gaap:RedeemableConvertiblePreferredStockMember 2019-12-31 0001720725 us-gaap:CommonStockMember 2019-12-31 0001720725 oyst:The2016EquityIncentivePlanMember 2019-12-31 0001720725 oyst:The2016EquityIncentivePlanMember 2018-12-31 0001720725 oyst:The2019EquityIncentivePlanMember 2019-12-31 0001720725 oyst:The2019EquityIncentivePlanMember 2018-12-31 0001720725 oyst:The2019EquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001720725 oyst:The2019EquityIncentivePlanMember us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001720725 oyst:The2019EquityIncentivePlanMember 2019-10-31 0001720725 oyst:The2016EquityIncentivePlanMember 2019-10-31 0001720725 us-gaap:EmployeeStockOptionMember oyst:The2016EquityIncentivePlanMember 2019-01-01 2019-12-31 0001720725 oyst:IncentiveStockOptionsMember oyst:The2016EquityIncentivePlanMember 2019-01-01 2019-12-31 0001720725 us-gaap:EmployeeStockMember oyst:The2019EmployeeStockPurchasePlanMember 2019-10-31 0001720725 oyst:The2016EquityIncentivePlanMember 2017-12-31 0001720725 oyst:The2016EquityIncentivePlanMember 2017-01-01 2017-12-31 0001720725 oyst:The2016EquityIncentivePlanMember 2018-01-01 2018-12-31 0001720725 oyst:The2016EquityIncentivePlanMember 2019-01-01 2019-12-31 0001720725 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001720725 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001720725 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001720725 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001720725 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001720725 us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-12-31 0001720725 srt:MinimumMember 2019-01-01 2019-12-31 0001720725 srt:MaximumMember 2019-01-01 2019-12-31 0001720725 us-gaap:SeriesAPreferredStockMember 2019-01-01 2019-12-31 0001720725 us-gaap:SeriesAPreferredStockMember 2018-01-01 2018-12-31 0001720725 us-gaap:StockOptionMember 2019-01-01 2019-12-31 0001720725 us-gaap:StockOptionMember 2018-01-01 2018-12-31 0001720725 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001720725 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001720725 2019-01-01 2019-03-31 0001720725 2019-04-01 2019-06-30 0001720725 2019-07-01 2019-09-30 0001720725 2019-10-01 2019-12-31 0001720725 2018-01-01 2018-03-31 0001720725 2018-04-01 2018-06-30 0001720725 2018-07-01 2018-09-30 0001720725 2018-10-01 2018-12-31 iso4217:USD shares iso4217:USD shares oyst:segment pure oyst:vote false 0001720725 --12-31 FY 2019 .353 P4Y 10-K true 2019-12-31 false 001-39112 OYSTER POINT PHARMA, INC. DE 81-1030955 202 Carnegie Center, Suite 109 Princeton NJ 08540 609 382-9032 Common stock, par value $0.001 OYST NASDAQ No No Yes Yes Non-accelerated Filer true true true false 168000000.0 21366950 Portions of the registrant’s definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2019. 2019-12-31 139147000 5228000 3033000 390000 142180000 5618000 51000 0 797000 66000 181000 0 0 20000 143209000 5704000 500000 462000 4603000 422000 296000 56000 5399000 940000 512000 6000 5911000 946000 0.001 0.001 0 0 0 7611691 7611691 7611691 43126000 0 43001000 0.001 0.001 0.001 0.001 5000000 0 0 0 0 0 0 0 0.001 0.001 0.001 0.001 1000000000 10943000 21366950 21366950 1411966 1411966 21000 1000 221508000 276000 -84231000 -38520000 137298000 -38243000 143209000 5704000 33628000 13755000 13673000 2981000 47301000 16736000 -47301000 -16736000 1590000 233000 -45711000 -16503000 -9.97 -11.69 4585146 1411966 7611691 43001000 1411966 1000 122000 -22017000 -21894000 -16503000 -16503000 154000 154000 7611691 43001000 1411966 1000 276000 -38520000 -38243000 -45711000 -45711000 148000 6581590 92852000 9898000 5750000 6000 82096000 82102000 14193281 -135853000 14193281 14000 135839000 135853000 11703 31000 31000 3266000 3266000 0 0 21366950 21000 221508000 -84231000 137298000 -45711000 -16503000 3266000 154000 19000 0 2643000 -473000 -20000 20000 38000 44000 731000 66000 746000 62000 4181000 -1227000 -40815000 -17083000 200000 0 -200000 0 92852000 0 82102000 0 31000 0 174985000 0 133970000 -17083000 5228000 22311000 139198000 5228000 139147000 5228000 51000 0 139198000 5228000 897000 113000 135853000 0 Organization and Summary of Significant Accounting Policies<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Description of the Business</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Oyster Point Pharma, Inc. (the “Company”) was incorporated on June 30, 2015. From inception through December 31, 2019, the Company has been primarily engaged in business planning, research, clinical development of its lead therapeutic product candidates, recruiting and raising capital. The Company is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical therapies to treat ocular surface diseases. The Company’s principal office is located in Princeton, New Jersey.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Initial Public Offering</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On November 4, 2019, the Company completed its initial public offering (IPO) selling 5,750,000 shares of common stock at a price to the public of $16.00 per share. The aggregate net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were $82.1 million. In addition, upon the closing the IPO, all outstanding shares of redeemable convertible preferred stock outstanding were converted into an aggregate of 14,193,281 shares of the Company’s common stock. </span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Liquidity</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Since inception, the Company has incurred recurring losses and negative cash flows from operations. The Company incurred net losses of $45.7 million and $16.5 million for the years ended December 31, 2019 and 2018, respectively, and had an accumulated deficit of $84.2 million as of December 31, 2019. The Company has historically financed its operations primarily through the sale and issuance of its securities. To date, none of the Company’s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. The Company expects to incur increased sales and marketing expenses with the commercialization of new and existing products, if approved for sale, as well as increased research and development expenses as it develops additional product candidates. The Company expects its operating losses to continue to increase for the foreseeable future.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">While the Company has been able to raise multiple rounds of financing, there can be no assurance that in the event the Company requires additional financing, such financing will be available on terms that are favorable, or at all. Failure to generate sufficient cash flows from operations, raise additional capital or reduce certain discretionary spending would have a material adverse effect on the Company’s ability to achieve its intended business objectives.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had cash and cash equivalents of $139.1 million as of December 31, 2019. Management believes that the Company’s current cash and cash equivalents will be sufficient to fund its planned operations for at least 12 months from the date of issuance of these financial statements.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Basis of Presentation</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2019, the Company’s Board of Directors and stockholders approved an amendment to the Company’s amended and restated certificate of incorporation to effect a 2.832861-for-1 reverse stock split of the Company’s common stock and redeemable convertible preferred stock, which was effected on October 18, 2019. The par values of the common stock and redeemable convertible preferred stock were not adjusted as a result of the reverse stock split. Accordingly, all common stock, redeemable convertible preferred stock, stock options, and related per share amounts as of and for the year ended December 31, 2018 and for the period through October 18, 2019 have been retroactively adjusted to give effect to the reverse stock split.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to the valuation of stock awards, income taxes and certain research and development accruals and for periods prior to the IPO, the valuation of convertible notes, derivative instruments, and redeemable convertible preferred stock. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Segments</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company operates and manages its business as one reportable operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company's long-lived assets are located in the United States.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Concentration of Credit Risk
</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s cash equivalents are invested in highly rated money market funds.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Risks and Uncertainties</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company operates in a dynamic and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company related to intellectual property, product, regulatory, or other matters; and the Company’s ability to attract and retain employees necessary to support its growth.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Product candidates developed by the Company will require approvals from the U.S. Food and Drug Administration or other international regulatory agencies prior to commercial sales. There can be no assurance that the product candidates will receive the necessary approvals. If the Company is denied approval, approval is delayed or the Company is unable to maintain approval, it could have a materially adverse impact on the Company.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company has expended and will continue to expend substantial funds to complete the research, development and clinical testing of its product candidates. The Company also will be required to expend additional funds to establish commercial-scale manufacturing arrangements and to provide for the marketing and distribution of products that receive regulatory approval. The Company will require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources. If adequate funds are unavailable on a timely basis from operations or additional sources of financing, the Company may have to delay, reduce the scope of or eliminate one or more of its research or development programs which would materially and adversely affect its business, financial condition and operations.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company relies on single source manufacturers and suppliers for the supply of its product candidates. Disruption from these manufacturers or suppliers would have a negative impact on the Company’s business, financial position and results of operations. In addition, the Company is dependent upon the services of its employees, consultants and other third parties.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Cash and Cash Equivalents</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. As of December 31, 2019 and 2018, cash and cash equivalents consisted of cash on deposit with a bank denominated in U.S. dollars and investment in money market funds.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Restricted Cash</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the Company had $51,000 of long-term restricted cash deposited with a financial institution. The entire amount is held in a separate bank account to support a letter of credit agreement related to one of the Company’s office facilities lease, which expires in 2022.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Property and Equipment</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets as follows:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Office equipment   5 years</span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Furniture and fixtures  7 years</span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Leasehold improvements  Shorter of lease term or estimated useful life</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Leases</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of a contract. The Company’s operating lease asset is included in “operating lease right-of-use asset” (“ROU asset”), and the current and non-current portions of the operating lease liability are included in “operating lease liability”, and “operating lease liability, non-current”, respectively, on the balance sheets. As of December 31, 2019 and 2018, the Company had no finance leases.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease components as a single lease component for operating leases. The Company does not record leases with terms of 12 months or less on the balance sheets.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As the implicit rate for the operating lease was not determinable, the Company used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The Company’s incremental borrowing rate was estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determined the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Fair Value of Financial Instruments</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Redeemable Convertible Preferred Stock</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition, or sale of all or substantially all of the Company’s assets (each, a “deemed liquidation event”), the redeemable convertible preferred stock have become redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of redeemable convertible preferred stock was not probable of occurring. All outstanding shares of redeemable convertible preferred stock were converted to common stock shares upon the closing of the IPO in November 2019. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Research and Development</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (“CMOs”), costs for clinical research organizations (“CROs”), costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses within the statements of operations and comprehensive loss as incurred. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company’s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Stock-Based Compensation</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, and the expected life of the award.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Comprehensive Loss</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Income Taxes</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line. Accrued interest and penalties are included within the related income tax liability line in the balance sheets. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Net Loss per Share Attributable to Common Stockholders</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was a participating security. The Company’s participating securities did not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Recent Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently adopted accounting pronouncements</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This ASU simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants, preferred shares and convertible debt instruments issued by private companies and early-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in Part I should be applied (1) retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the first fiscal year and interim periods; (2) retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU No. 2018-02,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The ASU permits companies to reclassify disproportionate tax effects in accumulated other comprehensive income (“AOCI”) caused by the Tax Act to retained earnings. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently issued accounting pronouncements not yet adopted</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">which</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">simplify various aspects related to the accounting for income taxes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This ASU removes exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is effective for interim and annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> which modifies the disclosure requirements on fair value measurements. This ASU removes the requirement to disclose: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.</span></div> 5750000 16.00 82100000 14193281 -45700000 -16500000 -84200000 139100000 <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Basis of Presentation</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).</span></div> <div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to the valuation of stock awards, income taxes and certain research and development accruals and for periods prior to the IPO, the valuation of convertible notes, derivative instruments, and redeemable convertible preferred stock. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Segments</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company operates and manages its business as one reportable operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company's long-lived assets are located in the United States.</span></div> 1 <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Concentration of Credit Risk
</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s cash equivalents are invested in highly rated money market funds.</span></div> Cash and Cash EquivalentsThe Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents. <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Restricted Cash</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the Company had $51,000 of long-term restricted cash deposited with a financial institution. The entire amount is held in a separate bank account to support a letter of credit agreement related to one of the Company’s office facilities lease, which expires in 2022.</span></div> 51000 <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Property and Equipment</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets as follows:</span></div><div style="text-align:justify;"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Office equipment   5 years</span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Furniture and fixtures  7 years</span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Leasehold improvements  Shorter of lease term or estimated useful life</span></div> P5Y P7Y <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Leases</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of a contract. The Company’s operating lease asset is included in “operating lease right-of-use asset” (“ROU asset”), and the current and non-current portions of the operating lease liability are included in “operating lease liability”, and “operating lease liability, non-current”, respectively, on the balance sheets. As of December 31, 2019 and 2018, the Company had no finance leases.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease components as a single lease component for operating leases. The Company does not record leases with terms of 12 months or less on the balance sheets.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As the implicit rate for the operating lease was not determinable, the Company used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The Company’s incremental borrowing rate was estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determined the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated.</span></div> Fair Value of Financial InstrumentsThe carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities. Redeemable Convertible Preferred StockThe Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition, or sale of all or substantially all of the Company’s assets (each, a “deemed liquidation event”), the redeemable convertible preferred stock have become redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of redeemable convertible preferred stock was not probable of occurring. All outstanding shares of redeemable convertible preferred stock were converted to common stock shares upon the closing of the IPO in November 2019. <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Research and Development</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (“CMOs”), costs for clinical research organizations (“CROs”), costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses within the statements of operations and comprehensive loss as incurred. </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company’s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Stock-Based Compensation</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, and the expected life of the award.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Comprehensive Loss</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Income Taxes</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line. Accrued interest and penalties are included within the related income tax liability line in the balance sheets. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Net Loss per Share Attributable to Common Stockholders</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was a participating security. The Company’s participating securities did not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></div> <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Recent Accounting Pronouncements</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently adopted accounting pronouncements</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. This ASU simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants, preferred shares and convertible debt instruments issued by private companies and early-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in Part I should be applied (1) retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the first fiscal year and interim periods; (2) retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In February 2018, the FASB issued ASU No. 2018-02,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The ASU permits companies to reclassify disproportionate tax effects in accumulated other comprehensive income (“AOCI”) caused by the Tax Act to retained earnings. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Recently issued accounting pronouncements not yet adopted</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">which</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">simplify various aspects related to the accounting for income taxes.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This ASU removes exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is effective for interim and annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;">In August 2018, the FASB issued ASU No. 2018-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%;">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement,</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;"> which modifies the disclosure requirements on fair value measurements. This ASU removes the requirement to disclose: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.</span></div> Fair Value MeasurementsThe Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering <div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="text-indent:24.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-47.5pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-indent:-47.5pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, financial assets measured and recognized at fair value were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.298%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Quoted Price in Active Markets for Identical Assets (Level 1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant Other Observable Inputs (Level 2)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant Unobservable Inputs (Level 3)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2018, financial assets measured and recognized at fair value were as follows (in thousands):</span></div><div style="text-align:center;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.298%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Quoted Price</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">in Active</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Assets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Level 1)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Level 2)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Level 3)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-indent:18pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Money market funds are included in cash and cash equivalents on the balance sheets and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no financial liabilities measured and recognized at fair value as of December 31, 2019 and December 31, 2018.</span></div> The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering <div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="text-indent:24.5pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 1 Quoted prices in active markets for identical assets or liabilities.</span></div><div style="text-indent:-47.5pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></div><div style="text-indent:-47.5pt;padding-left:72pt;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.</span></div> <div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, financial assets measured and recognized at fair value were as follows (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.298%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Quoted Price in Active Markets for Identical Assets (Level 1)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant Other Observable Inputs (Level 2)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant Unobservable Inputs (Level 3)</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">138,147 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2018, financial assets measured and recognized at fair value were as follows (in thousands):</span></div><div style="text-align:center;"><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:50.298%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.494%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.498%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value Measurements at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Quoted Price</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">in Active</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Markets for</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Identical</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Assets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Level 1)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Other</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Observable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Level 2)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Significant</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Unobservable</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Inputs</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">(Level 3)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total fair value of assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:middle;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cff0fc;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,228 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cff0fc;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 138147000 0 0 138147000 138147000 0 0 138147000 5228000 0 0 5228000 5228000 0 0 5228000 0 0 Property and Equipment, net<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consisted of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.126%;"><tr><td style="width:1.0%;"/><td style="width:82.615%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.385%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Office equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div><div style="text-align:right;"><span><br/></span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any property and equipment as of December 31, 2018.</span></div> <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Property and equipment consisted of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.126%;"><tr><td style="width:1.0%;"/><td style="width:82.615%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.385%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Leasehold improvements</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">105 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Office equipment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">45 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Furniture and fixtures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">50 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">200 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated depreciation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, net</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">181 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr></table></div> 105000 45000 50000 200000 19000 181000 Accrued Liabilities<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consisted of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.264%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,214 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">367 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,163 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,219 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">422 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Accrued liabilities consisted of the following (in thousands):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:69.264%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:11.936%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.374%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.226%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,214 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">367 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued professional services</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,163 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued research and development expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,219 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued other liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,603 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">422 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1214000 367000 1163000 35000 2219000 0 7000 20000 4603000 422000 Commitments and Contingencies<div style="margin-top:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Asset Purchase of OC-02</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2016, the Company entered into an asset purchase agreement pursuant to which the Company acquired the compound OC-02. The agreement provides for milestone payments of up to $37.0 million upon achievement of certain milestone events. The agreement also provides for royalty payments in the mid-single digit percentage on covered product net worldwide sales. The Company’s obligation to pay royalties will terminate at the latter of patent expiration in each country or ten years. In addition, the Company is required to pay 15% of any (i) licensing revenue received that is related to OC-02 and (ii) revenue received from the sale of OC-02, up to a maximum aggregate amount of $10.0 million.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">License Agreement</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In October 2019, the Company entered into a non-exclusive patent license agreement (the License Agreement) with Pfizer, which granted the Company non-exclusive rights under Pfizer’s patent rights covering varenicline tartrate to develop, manufacture, and commercialize the OC-01 varenicline product candidate. Under the terms of the License Agreement, the Company made an upfront payment to Pfizer of $5.0 million, which is included in research and development expense for the year ended December 31, 2019. If the Company successfully commercializes OC-01, it may be required to pay a single milestone payment in the very low double-digit millions and tiered royalties on net sales of OC-01 at percentages ranging from the mid-single digits to the mid-teens. The royalty obligation to Pfizer will commence upon the first commercial sale of OC-01 and will expire upon the later of (a) the expiration of all regulatory or data exclusivity granted to Pfizer in connection with varenicline in the United States; and (b) the expiration or abandonment of the last valid claims of the licensed patents.</span></div><div style="text-align:justify;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;">Operating Lease Obligations</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In January 2018, the Company entered a lease for office space under a non-cancelable operating lease with an expiration date of March 15, 2020, in Princeton, New Jersey. Rent expense is recorded on a straight-line basis over the term of the lease. The total lease payment over the life of the lease is $0.1 million. The remaining lease term was 0.2 years as of December 31, 2019. </span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, the Company entered a lease for office space under a non-cancelable operating lease in Princeton, New Jersey, commencing on July 1, 2019, for a period of three years from the commencement date. Rent expense is recorded on a straight-line basis over the term of the lease. The total lease payment over the life of the lease is $0.9 million. The remaining lease term was 2.5 years as of December 31, 2019.</span><span style="background-color:rgb(255,255,255, 0.0);color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">At the commencement date, the Company determined the amounts of the lease liability using a discount rate of 9%, which management determined represents the Company’s incremental borrowing rate. Lease expense was $0.2 million and less than $0.1 million for the twelve months ended December 31, 2019 and December 31, 2018, respectively. Cash paid for amounts included in the measurement of the lease liability was $0.2 million and less than $0.1 million for the twelve months ended December 31, 2019 and December 31, 2018, respectively, and was included in cash flows from operating activities in the statements of cash flows. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The maturities of the lease liabilities under non-cancelable operating leases are as follows (in thousands):</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted cash flows</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">319 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">316 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">186 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted cash flows</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">821 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">808 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(296)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In January 2020 the Company amended the lease of one its office facilities in Princeton, New Jersey to include additional office space, with an expiration date of July 31, 2022. Total future minimum lease payments under this amendment are $0.4 million.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Contingencies and Indemnifications</span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">From time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications, including for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual any time after the execution of the agreement. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend </span></div>any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.The Company has agreed to indemnify its directors and officers for certain events or occurrences while the director or officer is, or was serving, at the Company’s request in such capacity. The indemnification period covers all pertinent events and occurrences during the director’s or officer’s service. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is not specified in the agreements; however, the Company has director and officer insurance coverage that reduces its exposure and enables the Company to recover a portion of any future amounts paid. 37000000.0 P10Y 0.15 10000000.0 5000000.0 100000 P0Y2M12D P3Y 900000 P2Y6M 0.09 200000 100000 200000 100000 <div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2018</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted cash flows</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">62 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(56)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:86.505%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:9.495%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td></tr><tr><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">319 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">316 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2022</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">186 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total undiscounted cash flows</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">821 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: imputed interest</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(13)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">808 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:24pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: current portion</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(296)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liability</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">512 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 59000 7000 66000 4000 62000 56000 6000 319000 316000 186000 821000 13000 808000 296000 512000 400000 Income Taxes <div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not record a federal or state income tax provision or benefit for the for the years ended December 31, 2019 and December 31, 2018 as it has incurred net losses since inception. In addition, the net deferred tax assets generated from net operating losses are fully offset by a valuation allowance as the Company believes it is not more likely than not that the benefit will be realized.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company’s loss before provision for income taxes for the years ended December 31, 2019 and 2018 was as follows (in thousands):</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:72.557%;"><tr><td style="width:1.0%;"/><td style="width:51.663%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.594%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:2.554%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.189%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before provision for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had an effective tax rate of 0% for the years ended December 31, 2019 and 2018. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></div><div><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.183%;"><tr><td style="width:1.0%;"/><td style="width:45.377%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:23.000%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.422%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:23.001%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal statutory income tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes (tax effected)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research tax credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent differences</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The components of the Company’s net deferred tax assets and liabilities as of December 31, 2019 and 2018, were as follows (in thousands):</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.545%;"><tr><td style="width:1.0%;"/><td style="width:45.518%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.511%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.458%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.513%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,454 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,826 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">662 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tangible and intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,977 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">227 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,355 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,814 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,423)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,750)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net of valuation allowance </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">932 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities: </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaids</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(64)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(224)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Recognition of deferred tax assets is appropriate when realization of such assets is more likely than not. Based upon the weight of available evidence, which includes the Company’s historical operating performance and the U.S. cumulative net losses in all prior periods, the Company has provided a valuation allowance against its U.S. deferred tax assets. The Company’s valuation allowance increased by $10.7 million for the year ended December 31, 2019 and by $4.0 million for the year ended December 31, 2018.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, the Company has U.S. federal and state net operating losses of $59.1 million and $60.7 million, respectively, which expire beginning in the year 2035. As of December 31, 2018, the Company had U.S. federal and state net operating losses of $22.8 million and $22.9 million, respectively, which expire beginning in the year 2035.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Utilization of the net operating loss carryforwards may be subject to a substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code of 1986, as amended, and similar state provisions. The annual limitation may result in the expiration of net operating losses and credits before utilization.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">A Section 382 ownership change generally occurs if one or more stockholders or groups of stockholders who own at least 5% of the Company’s stock increase their ownership by more than 50 percentage points over their lowest ownership percentage within a rolling three-year period. Similar rules may apply under state tax laws. The Company has experienced an ownership change; however, the change will have no material limit on the Company’s net operating loss carryforwards. The Company is not in a taxable position and no net operating loss carryforwards have been used to date.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December 31, 2019 and 2018, the Company also had federal research and experimentation credit carryforwards of $2.1 million and $0.6 million, respectively, and state research and experimentation credit carryforwards of $0.4 and $0.1 million. The federal research and experimentation credit carryforwards expire beginning 2037. The California tax credit can be carried forward indefinitely.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December 31, 2019 and 2018, the Company had the following unrecognized tax benefits (in thousands):</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.833%;"><tr><td style="width:1.0%;"/><td style="width:45.376%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.437%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.748%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.439%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at the beginning of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,989 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">508 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,399 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,481 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at the end of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,989 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The reversal of the unrecognized tax benefits would not affect the Company’s effective tax rate to the extent that it continues to maintain a full valuation allowance against its deferred tax assets. The Company does not expect any changes to uncertain tax benefits within the next twelve months.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company recognizes interest and penalties related to income tax matters as a component of income tax expense. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">No</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> accrued interest and penalties have been recorded as of December 31, 2019 and 2018.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company files income tax returns in the U.S. federal, California and New Jersey jurisdictions. Due to the Company’s net losses, its federal and state income tax returns are subject to examination for federal and state purposes since inception. As of December 31, 2019, there were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">no</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> ongoing examinations.</span></div> 0 0 <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:72.557%;"><tr><td style="width:1.0%;"/><td style="width:51.663%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.594%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:2.554%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:19.189%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Domestic</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">International</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before provision for income taxes</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> -45711000 -16503000 0 0 -45711000 -16503000 <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had an effective tax rate of 0% for the years ended December 31, 2019 and 2018. The provision for income taxes differs from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></div><div><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:82.183%;"><tr><td style="width:1.0%;"/><td style="width:45.377%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:23.000%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.422%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:23.001%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Federal statutory income tax rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">State taxes (tax effected)</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.5 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.2 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research tax credit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3.3 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.6 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other permanent differences</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.0)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change in valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30.8)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(32.6)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Provision for income taxes</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.0%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr></table></div> 0.210 0.210 0.085 0.092 -0.033 -0.026 -0.020 -0.002 -0.308 -0.326 0.0 0 <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.545%;"><tr><td style="width:1.0%;"/><td style="width:45.518%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.511%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.458%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.513%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets:</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net operating loss carryforwards</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,454 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,826 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Credits</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,408 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">662 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tangible and intangible assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,977 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">269 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Lease liability</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">227 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">253 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">57 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross deferred tax assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,355 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,814 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less: Valuation allowance</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,423)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5,750)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax assets, net of valuation allowance </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">932 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred tax liabilities: </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaids</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(708)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(64)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Right of use asset</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(224)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net deferred tax assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table> 12454000 4826000 2408000 662000 1977000 269000 227000 0 253000 0 36000 57000 17355000 5814000 16423000 5750000 932000 64000 708000 64000 224000 0 0 0 10700000 4000000.0 59100000 60700000 22800000 22900000 2100000 600000 400000 100000 <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December 31, 2019 and 2018, the Company had the following unrecognized tax benefits (in thousands):</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.833%;"><tr><td style="width:1.0%;"/><td style="width:45.376%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.437%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:1.748%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:22.439%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at the beginning of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,989 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">508 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additions based on tax positions related to current year</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,399 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,481 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at the end of the year</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,388 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,989 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1989000 508000 3399000 1481000 5388000 1989000 0 0 Redeemable Convertible Preferred Stock<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On February 15, 2019, the Company executed the Series B Preferred Stock Purchase Agreement to sell up to 6,581,590 shares of Series B redeemable convertible preferred stock. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In February and April 2019, the Company received gross cash proceeds of $85.0 million and $8.0 million, respectively, from the sale of Series B redeemable convertible preferred stock.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">On November 4, 2019, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">upon the closing of the IPO, all outstanding shares of redeemable convertible preferred stock were converted into an aggregate of 14,193,281 shares of the Company’s common stock </span>and $135.9 million of mezzanine equity was reclassified to common stock and additional paid-in capital. As of December 31, 2019, there were no shares of redeemable convertible preferred stock issued and outstanding. 6581590 85000000.0 8000000.0 14193281 0 0 Common Stock<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company amended and restated its certificate of incorporation, effective November 4, 2019, in connection with the IPO. The amended and restated certificate of incorporation authorizes the Company to issue 1,000,000,000 shares of common stock, at a par value of $0.001 per share. Each share of common stock is entitled to one vote. </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company reserved common stock shares for future issuance as of December 31, 2019 and 2018 as follows:</span></div><div><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.919%;"><tr><td style="width:1.0%;"/><td style="width:61.377%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.889%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.642%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.892%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span><br/></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of Series A redeemable convertible preferred stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,611,691 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding options under the 2016 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,748,434 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,376,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity awards available for grants under the 2016 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">216,333 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding options under the 2019 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,466 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested RSUs under the 2019 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity awards available for grants under the 2019 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,747,047 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,548,072 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,204,108 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1000000000 0.001 1 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company reserved common stock shares for future issuance as of December 31, 2019 and 2018 as follows:</span></div><div><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:85.919%;"><tr><td style="width:1.0%;"/><td style="width:61.377%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:14.889%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:2.642%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.892%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><span><br/></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Conversion of Series A redeemable convertible preferred stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,611,691 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding options under the 2016 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,748,434 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,376,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity awards available for grants under the 2016 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">216,333 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding options under the 2019 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,466 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested RSUs under the 2019 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity awards available for grants under the 2019 Plan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,747,047 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,548,072 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,204,108 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 0 7611691 2748434 1376084 0 216333 29466 0 23125 0 2747047 0 5548072 9204108 Equity Incentive Plans<div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In 2016, the Company established its 2016 Equity Incentive Plan (the “Plan”) which provides for the granting of stock options to employees and consultants of the Company. Options granted under the Plan may be either incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”). ISOs may be granted only to Company employees (including officers and directors who are also employees). NSOs may be granted to Company employees and consultants.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2019, the Company’s Board of Directors and stockholders approved the 2019 Equity Incentive Plan (the 2019 Plan), with an initial shares reserved of 2,700,000 shares of the Company's common stock plus 99,638 shares reserved but unissued under the 2016 Plan. The 2019 Plan provides for the granting of stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to the Company's employees, directors, and others.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The exercise price of an ISO and NSO shall not be less than 100% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. The exercise price of an ISO granted to a 10% stockholder shall not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. To date, outstanding options have a term of 10 years and generally vest monthly over a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQ1N2YzNTM4YTU1NzRjNTY4OTFmZmUyNmM2Yjg4MWZhL3NlYzpkNTdmMzUzOGE1NTc0YzU2ODkxZmZlMjZjNmI4ODFmYV81OC9mcmFnOjEwMDI5OWUzNjNjYzRhN2RhOWZiN2FiYzQ4NTVjOTg1L3RleHRyZWdpb246MTAwMjk5ZTM2M2NjNGE3ZGE5ZmI3YWJjNDg1NWM5ODVfOTE1_15987de4-6032-4688-86dd-838d2f22f86c">four</span>-year period.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of December 31, 2019, there were 2,747,047 common stock shares reserved for future grants under the 2019 Plan.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2019, the Company’s Board of Directors and stockholders also approved the 2019 Employee Stock Purchase Plan (the ESPP), which qualifies as an "employee stock purchase plan" under Section 423 of the Internal Revenue Code, and pursuant to which 270,000 shares of common stock were reserved for future issuance. The ESPP is designed to enable eligible employees to purchase shares of the Company's common stock at a discount on a periodic basis through payroll deductions. There were no ESPP purchases during the year ended December 31, 2019.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Option activity under the Company’s stock option plans is set forth below (in thousands, except share and per share data):</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.942%;"><tr><td style="width:1.0%;"/><td style="width:36.178%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.779%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.252%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.786%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Awards</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of Shares Underlying Outstanding Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Weighted- Average Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1,057,373</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.85</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">318,711</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.02 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,376,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.90</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,950 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446,823 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,703)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options canceled</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,304)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.86 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,777,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.73</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares vested and exercisable as of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,108,041 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.29</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,757 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest as of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,777,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.73</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the years ended December 31, 2019 and 2018, the Company granted options with a weighted-average grant date fair value of $8.62 and $0.53 per share, respectively. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of options that vested during the years ended December 31, 2019 and 2018 was $2.5 million and $0.2 million, respectively.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of December 31, 2019, the total unrecognized stock-based compensation expense for stock options was $9.4 million, which is expected to be recognized over a weighted-average period of 3.21 years.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">In October 2019, the Company granted restricted stock units (RSUs) for 23,125 common stock shares that will vest one-third annually over three years, subject to continuing services to be provided to the Company. Grant date fair value was $16.00 per share, which is the common stock market price at the grant date. As of December 31, 2019, the total unrecognized stock-based compensation expense for RSUs was $0.3 million, which is expected to be recognized over a weighted-average period of 2.83 years.</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Stock-Based Compensation Expense</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The following table is a summary of stock compensation expense by function recognized (in thousands):</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:61.063%;"><tr><td style="width:1.0%;"/><td style="width:54.470%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.470%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.741%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.470%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.449%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">579 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,687 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,266 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Fair Value of Options Granted</span></div><div style="text-align:justify;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Prior to the IPO, the fair value of the Company’s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company’s common stock and the general and industry-specific economic outlook. Subsequent to the IPO, the fair value of the Company’s common stock is based on the closing quoted market price of its common stock as reported by the NASDAQ Global Select Market on the date of grant.</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In determining fair value of the stock options granted, the Company uses the Black-Scholes model, which requires the input of several assumptions. These assumptions include: estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of the Company’s common stock price over the expected term (expected volatility), risk-free interest rate and expected dividend rate. Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected term.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected volatility.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company used an average historical stock price volatility of a peer group of comparable publicly traded companies in biotechnology and pharmaceutical related industries to be representative of its expected future stock price volatility, as the Company did not have any trading history for its common stock. For purposes of identifying these peer companies, the Company considered the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, the Company measured historical volatility over a period equivalent to the expected term.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Risk-free interest rate.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The risk-free interest rate is based on the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock award.</span></div><div style="padding-left:36pt;text-align:justify;"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Expected dividend rate.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The Company has not paid and does not anticipate paying any dividends in the near future. Accordingly, the Company has estimated the dividend yield to be zero.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of options granted were calculated using the weighted average assumptions set forth below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.511%;"><tr><td style="width:1.0%;"/><td style="width:36.307%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:28.066%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.359%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.068%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">69.0 - 84.0%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">52.5%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.48% - 2.38%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.49% - 2.80%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.00%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.00%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.04 - 6.08 years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">6.02 years</span></div></td></tr></table></div> 2700000 99638 1 0.10 1.10 10 years 2747047 270000 <div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Option activity under the Company’s stock option plans is set forth below (in thousands, except share and per share data):</span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:89.942%;"><tr><td style="width:1.0%;"/><td style="width:36.178%;"/><td style="width:1.0%;"/><td colspan="3" style="display:none;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.453%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.779%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.252%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.438%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.786%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="24" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding Awards</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Number of Shares Underlying Outstanding Options</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%;">Weighted- Average Exercise Price</span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at January 1, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1,057,373</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.85</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">318,711</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.02 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2018</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,376,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.00 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.90</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,950 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options granted</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,446,823 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.01 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options exercised</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,703)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.64 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options canceled</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33,304)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.86 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:top;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding at December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,777,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.73</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares vested and exercisable as of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,108,041 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.10 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.29</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,757 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and expected to vest as of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,777,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4.59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.73</span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">55,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 1057373 1.00 P9Y10M6D 25000 318711 1.02 1376084 1.00 P8Y10M24D 5950000 1446823 8.01 11703 2.64 255000 33304 5.86 2777900 4.59 P8Y8M23D 55146000 1108041000 1108041000 2.10 P8Y3M14D 24757000 2777900000 4.59 P8Y8M23D 55146000 8.62 0.53 2500000 200000 9400000 P3Y2M15D 23125 P3Y 16.00 300000 P2Y9M29D <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:61.063%;"><tr><td style="width:1.0%;"/><td style="width:54.470%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.470%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.741%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.470%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.449%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">579 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,687 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">133 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stock-based compensation</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,266 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">154 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table> 579000 21000 2687000 133000 3266000 154000 <div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of options granted were calculated using the weighted average assumptions set forth below:</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:64.511%;"><tr><td style="width:1.0%;"/><td style="width:36.307%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:28.066%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.359%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:28.068%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Year Ended December 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected volatility</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">69.0 - 84.0%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">52.5%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk-free interest rate</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">1.48% - 2.38%</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">2.49% - 2.80%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Dividend yield</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.00%</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">0.00%</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected term</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">5.04 - 6.08 years</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">6.02 years</span></div></td></tr></table></div> 0.690 0.840 0.525 0.0148 0.0238 0.0249 0.0280 0.0000 0.0000 P5Y14D P6Y29D P6Y7D Net Loss Per Share Attributable to Common Stockholders<div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:83.189%;"><tr><td style="width:1.0%;"/><td style="width:62.421%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.490%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.753%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.490%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.753%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.493%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Year Ended December 31,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,585,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.69)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:77.011%;"><tr><td style="width:1.0%;"/><td style="width:56.955%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.149%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.546%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.150%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Year Ended December 31,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A redeemable convertible preferred stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,611,691 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,777,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,376,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,801,025 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,987,775 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> <div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:83.189%;"><tr><td style="width:1.0%;"/><td style="width:62.421%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.490%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.753%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.490%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:14.753%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.493%;"/><td style="width:0.1%;"/></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Year Ended December 31,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(45,711)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(16,503)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,585,146 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9.97)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11.69)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr></table></div> -45711000 -16503000 4585146 1411966 -9.97 -11.69 <div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:77.011%;"><tr><td style="width:1.0%;"/><td style="width:56.955%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:18.149%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.546%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.150%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Year Ended December 31,</span></div></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2018</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Series A redeemable convertible preferred stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,611,691 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,777,900 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,376,084 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,125 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">— </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,801,025 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,987,775 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 0 7611691 2777900 1376084 23125 0 2801025 8987775 Quarterly Results of Operations Data (unaudited)<div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth our unaudited statement of operations and comprehensive loss data for each of the eight quarters in the two-year period ended December 31, 2019. The unaudited quarterly statement of operations and comprehensive loss data set forth below have been prepared on a basis consistent with the audited annual financial statements and include, in our opinion, all normal recurring adjustments necessary for a fair statement of the financial information contained in those statements. Our historical results are not necessarily indicative of the results that may be expected in the future. The following quarterly financial data should be read in conjunction with our audited financial statements and the related notes. </span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2019 (in thousands, except share and per share data):</span></div><div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:29.034%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.241%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.245%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,405 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,101 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,088 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,034 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,605 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,132 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,809 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,127 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,010 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,233 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,897 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,161 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,010)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,897)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">503 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">437 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,760)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,730)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,497)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,724)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.66)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.60)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,412,354 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,419,064 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,993,730 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2018 (in thousands, except share and per share data):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:29.034%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.241%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.245%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,374 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,775 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,345 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">916 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">704 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,996 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,691 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,049 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,996)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,691)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,049)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,926)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,632)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.08)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.07)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.70)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.84)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Per share amounts for each quarter have been calculated separately. Accordingly, quarterly amounts may not add to annual amounts.</span></div> <div style="margin-top:12pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:29.034%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.241%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.245%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,405 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,101 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,088 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,034 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,605 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,132 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,809 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,127 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,010 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,233 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,897 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,161 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,010)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,233)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,897)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(20,161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:12pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">250 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">503 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">400 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">437 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,760)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10,730)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(11,497)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(19,724)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Arial',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.66)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7.60)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8.10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.41)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,412,354 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,419,064 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,993,730 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div><div style="margin-top:12pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Presented below is a summary of the unaudited quarterly financial information for the year ended December 31, 2018 (in thousands, except share and per share data):</span></div><div><span><br/></span></div><div><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:29.034%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.373%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.367%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.241%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:1.380%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:15.245%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">June 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">September 30, 2018</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2018</span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,374 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,261 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,775 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,345 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">626 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">735 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">916 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">704 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,000 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,996 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,691 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,049 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,000)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,996)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,691)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,049)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">66 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">70 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">59 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">38 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss and comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,934)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,926)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,632)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,011)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:top;border-top:1pt solid #000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic and diluted net loss per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.08)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.07)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4.70)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2.84)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average shares outstanding</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,411,966 </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"> </span></td></tr></table></div> 2405000 8101000 8088000 15034000 1605000 3132000 3809000 5127000 4010000 11233000 11897000 20161000 -4010000 -11233000 -11897000 -20161000 250000 503000 400000 437000 -3760000 -10730000 -11497000 -19724000 -2.66 -7.60 -8.10 -1.41 1411966 1412354 1419064 13993730 2374000 2261000 5775000 3345000 626000 735000 916000 704000 3000000 2996000 6691000 4049000 -3000000 -2996000 -6691000 -4049000 66000 70000 59000 38000 -2934000 -2926000 -6632000 -4011000 -2.08 -2.07 -4.70 -2.84 1411966 1411966 1411966 1411966 XML 72 R22.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Liabilities (Tables)
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Schedule of accrued liabilities
Accrued liabilities consisted of the following (in thousands):

December 31,
20192018
Accrued compensation$1,214  $367  
Accrued professional services1,163  35  
Accrued research and development expense2,219  —  
Accrued other liabilities7  20  
Total$4,603  $422  
XML 73 R26.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity Incentive Plans (Tables)
 12 Months Ended
Dec. 31, 2019
Share-based Payment Arrangement [Abstract]  
Activity in stock option plan
Option activity under the Company’s stock option plans is set forth below (in thousands, except share and per share data):


Outstanding Awards
Number of Shares Underlying Outstanding Options
Weighted- Average Exercise Price
Weighted-Average Remaining Contractual Term (Years)Aggregate Intrinsic Value
Outstanding at January 1, 2018
1,057,373
$1.00  9.85$25  
Options granted
318,711
1.02  
Outstanding at December 31, 20181,376,084  $1.00  8.90$5,950  
Options granted1,446,823  8.01  
Options exercised(11,703) 2.64  255  
Options canceled(33,304) 5.86  
Outstanding at December 31, 2019$2,777,900  $4.59  8.73$55,146  
Shares vested and exercisable as of December 31, 2019$1,108,041  $2.10  8.29$24,757  
Vested and expected to vest as of December 31, 2019$2,777,900  $4.59  8.73$55,146  
Stock-based compensation expense
Year Ended December 31,
20192018
Research and development$579  $21  
General and administrative2,687  133  
Total stock-based compensation$3,266  $154  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
The fair value of options granted were calculated using the weighted average assumptions set forth below:
Year Ended December 31,
20192018
Expected volatility
69.0 - 84.0%
52.5%
Risk-free interest rate
1.48% - 2.38%
2.49% - 2.80%
Dividend yield
0.00%
0.00%
Expected term
5.04 - 6.08 years
6.02 years
EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 76 R46.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Equity Incentive Plans - Fair Value Assumptions (Details)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected volatility, minimum 69.00%  
Expected volatility, maximum 84.00%  
Expected volatility   52.50%
Risk-free interest rate, minimum 1.48% 2.49%
Risk-free interest rate, maximum 2.38% 2.80%
Dividend yield 0.00% 0.00%
Expected term   6 years 7 days
Minimum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 5 years 14 days  
Maximum    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term 6 years 29 days  
XML 77 R42.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock - Reserved Common Stock (Details) - shares
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Class of Stock [Line Items]      
Conversion of redeemable convertible preferred stock (in shares) 0 7,611,691 7,611,691
Outstanding options under the 2016 Plan (in shares) 2,777,900    
Total (in shares) 5,548,072 9,204,108  
2016 Plan      
Class of Stock [Line Items]      
Outstanding options under the 2016 Plan (in shares) 2,748,434 1,376,084 1,057,373
Issuance of options under the 2016 Plan (in shares) 0 216,333  
2019 Plan      
Class of Stock [Line Items]      
Outstanding options under the 2016 Plan (in shares) 29,466 0  
Issuance of options under the 2016 Plan (in shares) 2,747,047 0  
Series A redeemable convertible preferred stock      
Class of Stock [Line Items]      
Conversion of redeemable convertible preferred stock (in shares) 0 7,611,691  
Restricted Stock Units (RSUs) | 2019 Plan      
Class of Stock [Line Items]      
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number 23,125 0  
XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Commitment and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]  
Maturities of lease liabilities
As of December 31, 2018Amount
2019$59  
20207  
Total undiscounted cash flows66  
Less: imputed interest(4) 
Total operating lease liability62  
Less: current portion(56) 
Operating lease liability$6  

As of December 31, 2019Amount
2020$319  
2021316  
2022186  
Total undiscounted cash flows821  
Less: imputed interest(13) 
Total operating lease liability808  
Less: current portion(296) 
Operating lease liability$512  
XML 80 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Net Loss Per Share Attributable to Common Stockholders (Tables)
 12 Months Ended
Dec. 31, 2019
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):

Year Ended December 31,
20192018
Numerator:
Net loss attributable to common stockholders$(45,711) $(16,503) 
Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted4,585,146  1,411,966  
Net loss per share attributable to common stockholders, basic and diluted
$(9.97) $(11.69) 
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive:

Year Ended December 31,
20192018
Series A redeemable convertible preferred stock—  7,611,691  
Options to purchase common stock2,777,900  1,376,084  
Unvested restricted stock units23,125  —  
Total2,801,025  8,987,775  
XML 81 R36.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Income Taxes - Loss Before Provision for Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Income Tax Disclosure [Abstract]    
Domestic $ (45,711) $ (16,503)
International 0 0
Loss before provision for income taxes $ (45,711) $ (16,503)
XML 82 R32.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Payables and Accruals [Abstract]    
Accrued compensation $ 1,214 $ 367
Accrued professional services 1,163 35
Accrued other liabilities 7 20
Total 4,603 422
Accrued Research And Development, Current $ 2,219 $ 0
JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "oyst-20191231.htm": { "axisCustom": 2, "axisStandard": 16, "contextCount": 104, "dts": { "calculationLink": { "local": [ "oyst-20191231_cal.xml" ] }, "definitionLink": { "local": [ "oyst-20191231_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "oyst-20191231.htm" ] }, "labelLink": { "local": [ "oyst-20191231_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "oyst-20191231_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml" ] }, "schema": { "local": [ "oyst-20191231.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd" ] } }, "elementCount": 392, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 2, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 7 }, "keyCustom": 19, "keyStandard": 303, "memberCustom": 8, "memberStandard": 27, "nsprefix": "oyst", "nsuri": "http://oysterpointrx.com/20191231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://oysterpointrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Property and Equipment, net", "role": "http://oysterpointrx.com/role/PropertyandEquipmentnet", "shortName": "Property and Equipment, net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110104 - Disclosure - Accrued Liabilities", "role": "http://oysterpointrx.com/role/AccruedLiabilities", "shortName": "Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - Commitment and Contingencies", "role": "http://oysterpointrx.com/role/CommitmentandContingencies", "shortName": "Commitment and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsContingenciesAndGuaranteesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117106 - Disclosure - Income Taxes", "role": "http://oysterpointrx.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "oyst:TemporaryEquityRedeemableConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Redeemable Convertible Preferred Stock", "role": "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStock", "shortName": "Redeemable Convertible Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "oyst:TemporaryEquityRedeemableConvertiblePreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126108 - Disclosure - Common Stock", "role": "http://oysterpointrx.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130109 - Disclosure - Equity Incentive Plans", "role": "http://oysterpointrx.com/role/EquityIncentivePlans", "shortName": "Equity Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2136110 - Disclosure - Net Loss Per Share Attributable to Common Stockholders", "role": "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholders", "shortName": "Net Loss Per Share Attributable to Common Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2140111 - Disclosure - Quarterly Results of Operations Data (unaudited)", "role": "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunaudited", "shortName": "Quarterly Results of Operations Data (unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)", "role": "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Balance Sheets", "role": "http://oysterpointrx.com/role/BalanceSheets", "shortName": "Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Fair Value Measures and Disclosures (Tables)", "role": "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresTables", "shortName": "Fair Value Measures and Disclosures (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Property, Plant, and Equipment (Tables)", "role": "http://oysterpointrx.com/role/PropertyPlantandEquipmentTables", "shortName": "Property, Plant, and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311303 - Disclosure - Accrued Liabilities (Tables)", "role": "http://oysterpointrx.com/role/AccruedLiabilitiesTables", "shortName": "Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314304 - Disclosure - Commitment and Contingencies (Tables)", "role": "http://oysterpointrx.com/role/CommitmentandContingenciesTables", "shortName": "Commitment and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2318305 - Disclosure - Income Taxes (Tables)", "role": "http://oysterpointrx.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - Common Stock (Tables)", "role": "http://oysterpointrx.com/role/CommonStockTables", "shortName": "Common Stock (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfConversionsOfStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2331307 - Disclosure - Equity Incentive Plans (Tables)", "role": "http://oysterpointrx.com/role/EquityIncentivePlansTables", "shortName": "Equity Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2337308 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)", "role": "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2341309 - Disclosure - Quarterly Results of Operations Data (unaudited) (Tables)", "role": "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedTables", "shortName": "Quarterly Results of Operations Data (unaudited) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0a2fd5aee44c4c028b6030043fc11179_I20191104", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)", "role": "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "shortName": "Organization and Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0a2fd5aee44c4c028b6030043fc11179_I20191104", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:TemporaryEquitySharesOutstanding", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Balance Sheets (Parenthetical)", "role": "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "shortName": "Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:FinancialLiabilitiesFairValueDisclosure", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Fair Value Measures and Disclosures (Details)", "role": "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails", "shortName": "Fair Value Measures and Disclosures (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FinancialLiabilitiesFairValueDisclosure", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FinancialLiabilitiesFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Property, Plant, and Equipment (Details)", "role": "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails", "shortName": "Property, Plant, and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412404 - Disclosure - Accrued Liabilities (Details)", "role": "http://oysterpointrx.com/role/AccruedLiabilitiesDetails", "shortName": "Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedSalariesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415405 - Disclosure - Commitment and Contingencies (Details)", "role": "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "shortName": "Commitment and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i2306e57753ed4b398bfcf08001f284a5_I20190701", "decimals": "2", "lang": null, "name": "us-gaap:LesseeOperatingLeaseDiscountRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416406 - Disclosure - Commitment and Contingencies - Lease Maturity Schedules (Details)", "role": "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails", "shortName": "Commitment and Contingencies - Lease Maturity Schedules (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419407 - Disclosure - Income Taxes (Details)", "role": "http://oysterpointrx.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxExpenseBenefit", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420408 - Disclosure - Income Taxes - Loss Before Provision for Income Taxes (Details)", "role": "http://oysterpointrx.com/role/IncomeTaxesLossBeforeProvisionforIncomeTaxesDetails", "shortName": "Income Taxes - Loss Before Provision for Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421409 - Disclosure - Income Taxes - Income Tax Reconciliation (Details)", "role": "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails", "shortName": "Income Taxes - Income Tax Reconciliation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422410 - Disclosure - Income Taxes - Deferred Tax Assets and liabilities (Details)", "role": "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails", "shortName": "Income Taxes - Deferred Tax Assets and liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i148adfa5a83d4fad93acaaf4c25650a1_I20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423411 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)", "role": "http://oysterpointrx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ib57a1b66f4b24826942661feedade285_I20171231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i42cdfb6f25a546a5833840ab245aceb2_D20191001-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Statements of Operations and Comprehensive Loss", "role": "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss", "shortName": "Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "us-gaap:TemporaryEquitySharesOutstanding", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425412 - Disclosure - Redeemable Convertible Preferred Stock (Details)", "role": "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "shortName": "Redeemable Convertible Preferred Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "id7adb898b7844671988bc7187f36b238_I20191231", "decimals": "INF", "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428413 - Disclosure - Common Stock (Details)", "role": "http://oysterpointrx.com/role/CommonStockDetails", "shortName": "Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "INF", "lang": null, "name": "oyst:CommonStockNumberOfVotesPerShare", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Common Stock - Reserved Common Stock (Details)", "role": "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "shortName": "Common Stock - Reserved Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfConversionsOfStockTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "id6aa340b8668456a89d42eb15f4324d1_I20191231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - Equity Incentive Plans (Details)", "role": "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "shortName": "Equity Incentive Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie65be81ed55e4a409d15b9bc09dd4c42_I20191231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433416 - Disclosure - Equity Incentive Plans - Option Activity During The Period (Details)", "role": "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails", "shortName": "Equity Incentive Plans - Option Activity During The Period (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "INF", "lang": null, "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434417 - Disclosure - Equity Incentive Plans - Stock Based Compensation Expense (Details)", "role": "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails", "shortName": "Equity Incentive Plans - Stock Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435418 - Disclosure - Equity Incentive Plans - Fair Value Assumptions (Details)", "role": "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails", "shortName": "Equity Incentive Plans - Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i42cdfb6f25a546a5833840ab245aceb2_D20191001-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438419 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Details)", "role": "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2439420 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details)", "role": "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails", "shortName": "Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i42cdfb6f25a546a5833840ab245aceb2_D20191001-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442421 - Disclosure - Quarterly Results of Operations Data (unaudited) (Details)", "role": "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "shortName": "Quarterly Results of Operations Data (unaudited) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i42cdfb6f25a546a5833840ab245aceb2_D20191001-20191231", "decimals": "2", "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ib57a1b66f4b24826942661feedade285_I20171231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:TemporaryEquitySharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit", "role": "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ib57a1b66f4b24826942661feedade285_I20171231", "decimals": "-3", "lang": null, "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie9dbac80112848fd84951baa86d1a319_D20190401-20190630", "decimals": "-3", "first": true, "lang": null, "name": "oyst:TemporaryEquityIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)", "role": "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical", "shortName": "Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "ie9dbac80112848fd84951baa86d1a319_D20190401-20190630", "decimals": "-3", "first": true, "lang": null, "name": "oyst:TemporaryEquityIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - Statement of Cash Flows", "role": "http://oysterpointrx.com/role/StatementofCashFlows", "shortName": "Statement of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies", "role": "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPolicies", "shortName": "Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104102 - Disclosure - Fair Value Measurements", "role": "http://oysterpointrx.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "oyst-20191231.htm", "contextRef": "i0ab7a36ffec2479bbfaec12101eb0147_D20190101-20191231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 39, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r236" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "oyst_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/AccruedLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Research And Development, Current", "label": "Accrued Research And Development, Current", "terseLabel": "Accrued Research And Development, Current" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "oyst_AcquisitionOfOC02CompoundMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquisition Of OC-02 Compound", "label": "Acquisition Of OC-02 Compound [Member]", "terseLabel": "Acquisition Of OC-02 Compound" } } }, "localname": "AcquisitionOfOC02CompoundMember", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "oyst_AssetAcquisitionAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "stringItemType" }, "oyst_AssetAcquisitionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "oyst_AssetAcquisitionLicensingRevenueReceivedPercentRequiredToPay": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Licensing Revenue Received, Percent Required To Pay", "label": "Asset Acquisition, Licensing Revenue Received, Percent Required To Pay", "terseLabel": "Required percentage of licensing revenue" } } }, "localname": "AssetAcquisitionLicensingRevenueReceivedPercentRequiredToPay", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "percentItemType" }, "oyst_AssetAcquisitionMaximumAggregateAmountOfLicensingRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Maximum Aggregate Amount Of Licensing Revenue", "label": "Asset Acquisition, Maximum Aggregate Amount Of Licensing Revenue", "terseLabel": "Maximum aggregate amount of licensing revenue" } } }, "localname": "AssetAcquisitionMaximumAggregateAmountOfLicensingRevenue", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "oyst_AssetAcquisitionMaximumMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Maximum Milestone Payments", "label": "Asset Acquisition, Maximum Milestone Payments", "terseLabel": "Maximum milestone payments for acquisition" } } }, "localname": "AssetAcquisitionMaximumMilestonePayments", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "oyst_AssetAcquisitionRoyaltyPaymentsTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset Acquisition, Royalty Payments, Term", "label": "Asset Acquisition, Royalty Payments, Term", "terseLabel": "Term of obligation to pay royalties" } } }, "localname": "AssetAcquisitionRoyaltyPaymentsTerm", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "durationItemType" }, "oyst_CommonStockNumberOfVotesPerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Common Stock, Number Of Votes", "label": "Common Stock, Number Of Votes Per Share", "terseLabel": "Number of votes per share" } } }, "localname": "CommonStockNumberOfVotesPerShare", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommonStockDetails" ], "xbrltype": "integerItemType" }, "oyst_DeferredTaxAssetLeaseLiability": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Asset, Lease Liability", "label": "Deferred Tax Asset, Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "DeferredTaxAssetLeaseLiability", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "oyst_DeferredTaxAssetsTangibleAndIntangibleAssets": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Assets, Tangible And Intangible Assets", "label": "Deferred Tax Assets, Tangible And Intangible Assets", "terseLabel": "Tangible and intangible assets" } } }, "localname": "DeferredTaxAssetsTangibleAndIntangibleAssets", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "oyst_DeferredTaxLiabilitiesRightOfUseAsset": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Deferred Tax Liabilities, Right-Of-Use Asset", "label": "Deferred Tax Liabilities, Right-Of-Use Asset", "terseLabel": "Right of use asset" } } }, "localname": "DeferredTaxLiabilitiesRightOfUseAsset", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "oyst_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Incentive Stock Options", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "oyst_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liability", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "oyst_IncreaseDecreaseInOperatingRightOfUseAssets": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Increase (Decrease) In Operating Right-of-Use Assets", "label": "Increase (Decrease) In Operating Right-of-Use Assets", "negatedLabel": "Operating lease right-of-use asset" } } }, "localname": "IncreaseDecreaseInOperatingRightOfUseAssets", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "oyst_LeaseAmendmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Amendment", "label": "Lease Amendment [Member]", "terseLabel": "Lease Amendment" } } }, "localname": "LeaseAmendmentMember", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "domainItemType" }, "oyst_LeaseArrangementsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Axis]", "terseLabel": "Lease Arrangements [Axis]" } } }, "localname": "LeaseArrangementsAxis", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "stringItemType" }, "oyst_LeaseArrangementsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Arrangements", "label": "Lease Arrangements [Domain]", "terseLabel": "Lease Arrangements [Domain]" } } }, "localname": "LeaseArrangementsDomain", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "oyst_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating Lease, Remaining Lease Term", "label": "Lessee, Operating Lease, Remaining Lease Term", "terseLabel": "Remaining term on operating lease" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "durationItemType" }, "oyst_PrincetonNewJerseyOfficeSpaceLeaseEndingIn2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Princeton New Jersey Office Space, Lease Ending In 2020", "label": "Princeton New Jersey Office Space, Lease Ending In 2020 [Member]", "terseLabel": "Princeton New Jersey Office Space, Lease Ending In 2020" } } }, "localname": "PrincetonNewJerseyOfficeSpaceLeaseEndingIn2020Member", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "oyst_PrincetonNewJerseyOfficeSpaceLeaseEndingIn2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Princeton New Jersey Office Space, Lease Ending in 2022", "label": "Princeton New Jersey Office Space, Lease Ending in 2022 [Member]", "terseLabel": "Princeton New Jersey Office Space, Lease Ending in 2022" } } }, "localname": "PrincetonNewJerseyOfficeSpaceLeaseEndingIn2022Member", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "oyst_ShareBasedCompensationArrangementByShareBasedPaymentAwardCompanyStockOwnershipByStockholderPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Company Stock Ownership By Stockholder, Percentage", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Company Stock Ownership By Stockholder, Percentage", "terseLabel": "Percent of shares owned by individual stockholder" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCompanyStockOwnershipByStockholderPercentage", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "percentItemType" }, "oyst_ShareBasedCompensationArrangementByShareBasedPaymentAwardCostNotYetRecognizedWeightedAverageTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based compensation arrangement by share based payment award, cost not yet recognized, weighted average term", "label": "Share-based compensation arrangement by share based payment award, cost not yet recognized, weighted average term", "terseLabel": "Expected term of recognition of RSU compensation cost" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCostNotYetRecognizedWeightedAverageTerm", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "durationItemType" }, "oyst_TemporaryEquityIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Issuance Costs", "label": "Temporary Equity, Issuance Costs", "terseLabel": "Issuance of Series B redeemable convertible preferred stock, net of issuance costs of $148" } } }, "localname": "TemporaryEquityIssuanceCosts", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "oyst_TemporaryEquityRedeemableConvertiblePreferredStockTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Redeemable Convertible Preferred Stock", "label": "Temporary Equity, Redeemable Convertible Preferred Stock [Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "TemporaryEquityRedeemableConvertiblePreferredStockTextBlock", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStock" ], "xbrltype": "textBlockItemType" }, "oyst_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments", "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments", "terseLabel": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "oyst_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of Series B redeemable convertible preferred stock, net of issuance costs, shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "oyst_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments", "label": "Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments", "terseLabel": "Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "oyst_The2016EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The 2016 Equity Incentive Plan", "label": "The 2016 Equity Incentive Plan [Member]", "terseLabel": "2016 Plan" } } }, "localname": "The2016EquityIncentivePlanMember", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "domainItemType" }, "oyst_The2019EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The 2019 Employee Stock Purchase Plan", "label": "The 2019 Employee Stock Purchase Plan [Member]", "terseLabel": "2019 ESPP" } } }, "localname": "The2019EmployeeStockPurchasePlanMember", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "oyst_The2019EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The 2019 Equity Incentive Plan", "label": "The 2019 Equity Incentive Plan [Member]", "terseLabel": "2019 Plan" } } }, "localname": "The2019EquityIncentivePlanMember", "nsuri": "http://oysterpointrx.com/20191231", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Condensed Financial Information Disclosure [Abstract]" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract", "nsuri": "http://fasb.org/srt/2019-01-31", "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lower limit of the provided range.", "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "auth_ref": [ "r241" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.", "label": "Condensed Income Statement [Table Text Block]", "terseLabel": "Condensed Income Statement" } } }, "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r30" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r29" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r32" ], "calculation": { "http://oysterpointrx.com/role/AccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://oysterpointrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilitiesDetails", "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r4", "r5", "r32" ], "calculation": { "http://oysterpointrx.com/role/AccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional services" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r4", "r5", "r32" ], "calculation": { "http://oysterpointrx.com/role/AccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued compensation" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r27", "r91" ], "calculation": { "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Additional Cash Flow Elements [Abstract]", "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash" } } }, "localname": "AdditionalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r117", "r119", "r153", "r154" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r119", "r147", "r152" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive securities excluded from the computation of diluted net loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r220", "r225" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r1", "r2", "r40" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r188" ], "calculation": { "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total fair value of assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r120", "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r0", "r24", "r56" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r8", "r57", "r62", "r219" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r57", "r62" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.", "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r51", "r56", "r61" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "totalLabel": "Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r51", "r199" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockDetails", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockDetails", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r34", "r96", "r222", "r229" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsContingenciesAndGuaranteesTextBlock": { "auth_ref": [ "r95", "r97", "r98" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments, contingencies, and guarantees.", "label": "Commitments Contingencies and Guarantees [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsContingenciesAndGuaranteesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r37" ], "calculation": { "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total (in shares)", "totalLabel": "Total (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r16", "r104" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance, common stock (in shares)", "periodStartLabel": "Beginning balance, common stock (in shares)", "terseLabel": "Common stock shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.001 par value per share - 1,000,000,000 authorized shares at December\u00a031, 2019, and 10,943,000 shares authorized at December\u00a031, 2018; 21,366,950 shares issued and outstanding at December\u00a031, 2019, and 1,411,966 shares issued and outstanding at December\u00a031, 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r77", "r224" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": { "auth_ref": [ "r67", "r186" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.", "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]", "terseLabel": "Quarterly Results of Operations Data (unaudited)" } } }, "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunaudited" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r58", "r59", "r60" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Converted", "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon closing of the initial public offering" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r58", "r59", "r60" ], "lang": { "en-US": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Shares Converted", "terseLabel": "Conversion of preferred stock, shares converted (in shares)" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r171" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r174" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r172" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Deferred tax assets, net of valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r157", "r178", "r179" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r158", "r178", "r179" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets, Other", "terseLabel": "Other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r176", "r178", "r179" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "terseLabel": "Credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r157", "r178", "r179" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r173" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Less: Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Deferred Tax Liabilities, Deferred Expense [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesDeferredExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": { "auth_ref": [ "r158", "r178", "r179" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.", "label": "Deferred Tax Liabilities, Leasing Arrangements", "terseLabel": "Deferred Tax Liabilities, Leasing Arrangements" } } }, "localname": "DeferredTaxLiabilitiesLeasingArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities, Prepaid Expenses", "terseLabel": "Prepaids" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDeferredTaxAssetsandliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r54", "r84" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Equity Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r70" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)", "verboseLabel": "Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r62", "r71", "r72", "r73" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r74" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share Attributable to Common Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r66", "r163", "r164" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Provision for income taxes" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r163", "r164", "r181" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 3.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r163", "r164", "r181" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 5.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r163", "r164", "r181" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 1.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "terseLabel": "Other permanent differences" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r163", "r164", "r181" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 2.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State taxes (tax effected)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r163", "r164", "r181" ], "calculation": { "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails": { "order": 4.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-US": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent", "terseLabel": "Research tax credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesIncomeTaxReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense for RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r148" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average recognition period of unrecognized stock-based compensation expense (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r148" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Employee Stock" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r104" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r188", "r189", "r190", "r194" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r188", "r198" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Financial assets measured and recognized at fair value" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r114", "r115", "r116", "r189", "r215" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r188", "r189", "r191", "r192", "r195" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r114", "r115", "r116", "r189", "r216" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Price in Active Markets for Identical\u00a0Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r114", "r115", "r116", "r189", "r217" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r114", "r115", "r116", "r189", "r218" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r193", "r195" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r62", "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "terseLabel": "Fair value of financial liabilities" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r46" ], "calculation": { "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic", "terseLabel": "Domestic" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesLossBeforeProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign", "terseLabel": "International" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesLossBeforeProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r65" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesLossBeforeProvisionforIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.", "label": "Income (Loss) from Continuing Operations, Per Basic and Diluted Share", "terseLabel": "Basic and diluted net loss per share" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r93" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r166" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r63", "r85", "r182" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax provision or benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r43", "r62", "r161", "r162", "r169", "r170", "r175", "r183", "r232" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r53" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r53" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r53" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r53" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Temporary Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r88", "r89" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r88", "r89" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentIncomeInterestAndDividend": { "auth_ref": [ "r47" ], "calculation": { "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Interest and Dividend", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterestAndDividend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseArrangementTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Axis]", "terseLabel": "Lease Arrangement, Type [Axis]" } } }, "localname": "LeaseArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseArrangementTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.", "label": "Lease Arrangement, Type [Domain]", "terseLabel": "Lease Arrangement, Type [Domain]" } } }, "localname": "LeaseArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": { "auth_ref": [ "r90" ], "lang": { "en-US": { "role": { "documentation": "Assets held by a lessee under a capital lease and any addition or improvement to assets held under a lease arrangement (including addition or improvement to assets held by lessee under an operating lease arrangement).", "label": "Leaseholds and Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdsAndLeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r209" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r206" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee, Operating Lease, Discount Rate", "terseLabel": "Lease discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Maturities of lease liabilities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r212" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Lease payments due over the life of the lease", "totalLabel": "Total undiscounted cash flows" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r212" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2019" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r212" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r212" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r212" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r212" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of lease contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r31" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r221", "r227" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r185" ], "lang": { "en-US": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r114" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r51" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r51", "r52", "r55" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r41", "r42", "r44", "r55", "r72", "r223", "r230" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss and comprehensive loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails", "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementofCashFlows", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Income (Loss) Attributable to Parent [Abstract]", "terseLabel": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r204" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Lease expense (less than in 2018)" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r203" ], "calculation": { "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "totalLabel": "Total operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r203" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedTerseLabel": "Less: current portion", "terseLabel": "Operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r203" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability", "verboseLabel": "Operating lease liability, non-current" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r205", "r210" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Payments made for leases (less than in 2018)" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r202" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": { "auth_ref": [ "r200", "r201" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.", "label": "Operating Leases, Future Minimum Payments Due", "terseLabel": "Future minimum operating lease payments due under amended lease agreement" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r68", "r69", "r83", "r187" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Organization and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r4", "r5", "r6", "r32" ], "calculation": { "http://oysterpointrx.com/role/AccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r28" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Payments of Stock Issuance Costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "terseLabel": "Upfront payment for non-exclusive license agreement" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r48" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r120", "r149" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Par value of preferred stock (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock: $0.001 par value per share - 5,000,000 shares authorized and no shares issued and outstanding as of December 31, 2019 and no shares authorized, issued and outstanding as of December 31, 2018" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r1", "r22", "r23" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r49" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from initial public offering, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r49" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r49", "r150" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from the issuance of common stock upon exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r27", "r92" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r94" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/PropertyandEquipmentnet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r26", "r90" ], "calculation": { "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r9", "r10", "r92", "r228" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r25", "r62", "r92" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r9", "r92" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/PropertyPlantandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r9", "r90" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property, Plant and Equipment, Useful Life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RedeemableConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.", "label": "Redeemable Convertible Preferred Stock [Member]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "RedeemableConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r156", "r233" ], "calculation": { "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r62", "r156" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/FairValueMeasuresandDisclosuresDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r3", "r11", "r61", "r231" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r111", "r226" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficitAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retained Earnings (Accumulated Deficit) [Abstract]", "terseLabel": "Stockholders\u2019 equity (deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficitAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r211", "r213" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use for office space acquired through operating leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Aggregate gross proceeds from offering" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of common stock sold and issued (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share (in usd per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/AccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfConversionsOfStockTextBlock": { "auth_ref": [ "r58", "r59", "r60" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction.", "label": "Schedule of Conversions of Stock [Table Text Block]", "terseLabel": "Common stock reserved for future issuance" } } }, "localname": "ScheduleOfConversionsOfStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r174" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of deferred tax assets and liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r72" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r163" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of effective income tax rate reconciliation" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r119", "r146", "r152" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r119", "r146", "r152" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]", "terseLabel": "Schedule of loss before provision for income taxes" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r27", "r92" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/PropertyPlantandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r120", "r149" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r127", "r136", "r139" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Activity in stock option plan" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r141" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r36", "r64", "r99", "r102", "r103", "r105", "r106", "r107", "r108", "r109", "r110", "r111" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockDetails", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r168", "r180" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]", "terseLabel": "Schedule of unrecognized tax benefits roll forward" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r62" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A redeemable convertible preferred stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r53" ], "calculation": { "http://oysterpointrx.com/role/StatementofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r122" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period of stock options (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r135" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted restricted stock units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r144" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum", "terseLabel": "Risk-free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum", "terseLabel": "Risk-free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r128", "r130" ], "lang": { "en-US": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r123" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Shares authorized for 2019 Equity Incentive Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r149" ], "calculation": { "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails": { "order": 3.0, "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Issuance of options under the 2016 Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r131" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Shares vested and exercisable as of December 31, 2019 (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r133" ], "lang": { "en-US": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Options canceled (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "negatedLabel": "Options granted (in shares)", "terseLabel": "Options granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value of options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r129", "r149" ], "calculation": { "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails": { "order": 2.0, "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Outstanding options under the 2016 Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r139" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Vested and expected to vest as of December 31, 2019, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested and expected to vest as of December 31, 2019" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested and expected to vest as of December 31, 2019 (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": { "auth_ref": [ "r121" ], "lang": { "en-US": { "role": { "documentation": "Description of terms of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award", "terseLabel": "Term of outstanding options (in years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r118", "r124" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Options canceled (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r62", "r120", "r125" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r142", "r151" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r149" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Shares vested and exercisable as of December 31, 2019, aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Shares vested and exercisable as of December 31, 2019, Weighted-Average Remaining Contractual Term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted-average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest as of December 31, 2019, weighted average exercise price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r126" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value", "terseLabel": "Fair value of options vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Shares vested and exercisable as of December 31, 2019" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Percent of estimated fair value of shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansDetails" ], "xbrltype": "percentItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State and Local Jurisdiction [Member]", "terseLabel": "State and Local Jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r14", "r15", "r16", "r104" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockDetails", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r39", "r104" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Shares Granted or Issued, Share-based Payment Arrangement [Abstract]", "terseLabel": "Number of Shares Underlying Outstanding Options" } } }, "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r38", "r104", "r105", "r111" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r15", "r16", "r104", "r111" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost of $9,898 (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r15", "r16", "r104", "r111", "r132" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "verboseLabel": "Stock issued through exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/EquityIncentivePlansOptionActivityDuringThePeriodDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r39", "r104", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Conversion of redeemable convertible preferred stock into common stock upon initial public offering" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r15", "r16", "r104", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock upon initial public offering, net of issuance cost of $9,898" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r39", "r104", "r111" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Stock issued through exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]", "verboseLabel": "Options to purchase common stock" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersAntidilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r16", "r19", "r20", "r87" ], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r113" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": { "auth_ref": [ "r12", "r13", "r62", "r101" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.", "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]", "terseLabel": "Redeemable Convertible Preferred Stock" } } }, "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r112" ], "lang": { "en-US": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse stock split" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails", "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails", "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r214" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/CommitmentandContingenciesDetails", "http://oysterpointrx.com/role/CommitmentandContingenciesLeaseMaturitySchedulesDetails", "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward, Amount", "terseLabel": "Research and experimentation credit carryforward" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TaxCreditCarryforwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Tax Credit Carryforward [Line Items]", "terseLabel": "Tax Credit Carryforward [Line Items]" } } }, "localname": "TaxCreditCarryforwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardTable": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.", "label": "Tax Credit Carryforward [Table]", "terseLabel": "Tax Credit Carryforward [Table]" } } }, "localname": "TaxCreditCarryforwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [], "calculation": { "http://oysterpointrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "periodEndLabel": "Redeemable convertible preferred stock, amount, ending balance", "periodStartLabel": "Redeemable convertible preferred stock, amount, beginning balance", "verboseLabel": "Redeemable convertible preferred stock" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheets", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Temporary Equity Disclosure [Abstract]" } } }, "localname": "TemporaryEquityDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityLiquidationPreference": { "auth_ref": [ "r35" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Liquidation Preference", "verboseLabel": "Redeemable convertible preferred stock, liquidation preference" } } }, "localname": "TemporaryEquityLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityParOrStatedValuePerShare": { "auth_ref": [ "r7", "r100" ], "lang": { "en-US": { "role": { "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.", "label": "Temporary Equity, Par or Stated Value Per Share", "terseLabel": "Par value of redeemable convertible preferred stock (in dollars per share)" } } }, "localname": "TemporaryEquityParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_TemporaryEquitySharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Authorized", "terseLabel": "Shares of redeemable convertible preferred stock authorized (in shares)" } } }, "localname": "TemporaryEquitySharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Issued", "terseLabel": "Shares of redeemable convertible preferred stock issued (in shares)" } } }, "localname": "TemporaryEquitySharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r12" ], "calculation": { "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails": { "order": 1.0, "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Shares Outstanding", "periodEndLabel": "Redeemable convertible preferred stock, shares, ending balance", "periodStartLabel": "Redeemable convertible preferred stock, shares, beginning balance", "terseLabel": "Redeemable convertible preferred stock, outstanding (in shares)", "verboseLabel": "Conversion of redeemable convertible preferred stock (in shares)" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/BalanceSheetsParenthetical", "http://oysterpointrx.com/role/CommonStockReservedCommonStockDetails", "http://oysterpointrx.com/role/RedeemableConvertiblePreferredStockDetails", "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity, Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of Series B redeemable convertible preferred stock, net of issuance cost, amount" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/StatementsofRedeemableConvertiblePreferredStockandStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r159", "r167" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance at the end of the year", "periodStartLabel": "Balance at the beginning of the year" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "auth_ref": [ "r165" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties" } } }, "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "auth_ref": [ "r167" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "terseLabel": "Additions based on tax positions related to current year" } } }, "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r75", "r76", "r78", "r79", "r80", "r81", "r82" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r160" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Increase in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted average shares outstanding", "verboseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails", "http://oysterpointrx.com/role/QuarterlyResultsofOperationsDataunauditedDetails", "http://oysterpointrx.com/role/StatementsofOperationsandComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://oysterpointrx.com/role/NetLossPerShareAttributabletoCommonStockholdersDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=116854557&loc=d3e20905-112640" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770" }, "r113": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32123-109318" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "05", "SubTopic": "30", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5283-111683" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 3)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r234": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r235": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r236": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r237": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r238": { "Name": "Forms 10-K, 20-F, 40-F", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d-1" }, "r239": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r241": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "i", "Publisher": "SEC", "Section": "3", "Subsection": "10" }, "r242": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(d),(e))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(27)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r83": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r95": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r98": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" } }, "version": "2.1" } XML 84 R9.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Fair Value Measurements
 12 Months Ended
Dec. 31, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value MeasurementsThe Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering
such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
Level 1 Quoted prices in active markets for identical assets or liabilities.
Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.
As of December 31, 2019, financial assets measured and recognized at fair value were as follows (in thousands):

Fair Value Measurements at December 31, 2019
Quoted Price in Active Markets for Identical Assets (Level 1)
Significant Other Observable Inputs (Level 2)
Significant Unobservable Inputs (Level 3)
Total
Assets
Money market funds$138,147  $—  $—  $138,147  
Total fair value of assets$138,147  $—  $—  $138,147  

As of December 31, 2018, financial assets measured and recognized at fair value were as follows (in thousands):

Fair Value Measurements at December 31, 2018
Quoted Price
in Active
Markets for
Identical
Assets
(Level 1)
Significant
Other
Observable
Inputs
(Level 2)
Significant
Unobservable
Inputs
(Level 3)
Total
Assets
Money market funds$5,228  $—  $—  $5,228  
Total fair value of assets$5,228  $—  $—  $5,228  

Money market funds are included in cash and cash equivalents on the balance sheets and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.

There were no financial liabilities measured and recognized at fair value as of December 31, 2019 and December 31, 2018.
XML 85 R19.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Organization and Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Oct. 18, 2019
Dec. 31, 2019
Accounting Policies [Abstract]    
Basis of Presentation  
Basis of Presentation

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Use of Estimates  
Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses in the financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to the valuation of stock awards, income taxes and certain research and development accruals and for periods prior to the IPO, the valuation of convertible notes, derivative instruments, and redeemable convertible preferred stock. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates, and such differences could be material to the Company’s financial position and results of operations.
Segments  
Segments

The Company operates and manages its business as one reportable operating segment. The Company’s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance. All of the Company's long-lived assets are located in the United States.
Concentration of Credit Risk  
Concentration of Credit Risk

Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash is held by one financial institution that management believes is of high credit quality. Such deposits may, at times, exceed federally insured limits. The Company’s cash equivalents are invested in highly rated money market funds.
Cash and Cash Equivalents   Cash and Cash EquivalentsThe Company considers all highly liquid investments purchased with an original maturity of three months or less at the time of purchase to be cash equivalents.
Restricted Cash  
Restricted Cash

As of December 31, 2019, the Company had $51,000 of long-term restricted cash deposited with a financial institution. The entire amount is held in a separate bank account to support a letter of credit agreement related to one of the Company’s office facilities lease, which expires in 2022.
Property and Equipment  
Property and Equipment

Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful lives of the related assets as follows:

Office equipment   5 years
Furniture and fixtures  7 years
Leasehold improvements  Shorter of lease term or estimated useful life
Leases  
Leases

The Company determines if an arrangement is or contains a lease and the classification of that lease at inception of a contract. The Company’s operating lease asset is included in “operating lease right-of-use asset” (“ROU asset”), and the current and non-current portions of the operating lease liability are included in “operating lease liability”, and “operating lease liability, non-current”, respectively, on the balance sheets. As of December 31, 2019 and 2018, the Company had no finance leases.

Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at the lease commencement date. Operating lease right-of-use assets are based on the corresponding lease liability adjusted for (i) payments made at or before the commencement date, (ii) initial direct costs incurred, and (iii) tenant incentives under the lease. The Company does not account for renewals or early terminations unless it is reasonably certain to exercise these options at commencement. Operating lease expense is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease components as a single lease component for operating leases. The Company does not record leases with terms of 12 months or less on the balance sheets.

As the implicit rate for the operating lease was not determinable, the Company used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future payments. The Company’s incremental borrowing rate was estimated to approximate the interest rate on a collateralized basis with similar terms and payments, in an economic environment where the leased asset is located. The Company determined the incremental borrowing rate by considering various factors, such as its credit rating, interest rates of similar debt instruments of entities with comparable credit ratings, the lease term and the currency in which the lease was denominated.
Fair Value of Financial Instruments   Fair Value of Financial InstrumentsThe carrying amounts for financial instruments consisting of cash and cash equivalents, accounts payable and accrued liabilities approximate fair value due to their short maturities.
Redeemable Convertible Preferred Stock   Redeemable Convertible Preferred StockThe Company recorded all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. Redeemable convertible preferred stock was recorded outside of permanent equity because while it was not mandatorily redeemable, in certain events considered not solely within the Company’s control, such as a merger, acquisition, or sale of all or substantially all of the Company’s assets (each, a “deemed liquidation event”), the redeemable convertible preferred stock have become redeemable at the option of the holders of at least a majority of the then outstanding preferred shares. The Company did not adjust the carrying value of the redeemable convertible preferred stock to its liquidation preference because a deemed liquidation event obligating the Company to pay the liquidation preference to holders of shares of redeemable convertible preferred stock was not probable of occurring. All outstanding shares of redeemable convertible preferred stock were converted to common stock shares upon the closing of the IPO in November 2019.
Research and Development  
Research and Development

Research and development expenses consist of compensation costs, employee benefit costs, costs for contract manufacturing organizations (“CMOs”), costs for clinical research organizations (“CROs”), costs for sponsored research, consulting costs, costs for laboratory supplies, costs for product licenses, facility-related expenses and depreciation. All research and development costs are charged to research and development expenses within the statements of operations and comprehensive loss as incurred.
Payments associated with licensing agreements to acquire exclusive licenses to develop, use, manufacture and commercialize products that have not reached technological feasibility and do not have alternate commercial use are also expensed as incurred.

The Company’s accruals for research and development activities performed by third parties are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued liabilities on the balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accruals accordingly. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties are recorded as prepaid expenses until the services are rendered.
Stock-Based Compensation  
Stock-Based Compensation

The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option pricing model. The Company uses the Black-Scholes pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility, and the expected life of the award.
Comprehensive Loss  
Comprehensive Loss

Comprehensive loss represents all changes in stockholders’ equity (deficit) except those resulting from distributions to stockholders. There have been no items qualifying as other comprehensive income (loss) and, therefore, for all periods presented, the Company’s comprehensive loss was the same as its reported net loss.
Income Taxes  
Income Taxes

The Company accounts for income taxes using the asset and liability method whereby deferred tax asset and liability accounts are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established where necessary to reduce deferred tax assets to the amounts expected to be realized.

The Company accounts for uncertain tax positions by assessing all material positions taken in any assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. The Company’s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit. The Company recognizes interest and penalties related to unrecognized tax benefits within the income tax expense line. Accrued interest and penalties are included within the related income tax liability line in the balance sheets. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.
Net Loss per Share Attributable to Common Stockholders  
Net Loss per Share Attributable to Common Stockholders

Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, the redeemable convertible preferred stock and common stock options are considered to be potentially dilutive securities. Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class method required for participating securities as the redeemable convertible preferred stock was a participating security. The Company’s participating securities did not have a contractual obligation to share in the Company’s losses. As such, the net loss was attributed entirely to common stockholders. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.
Recent Accounting Pronouncements  
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (the “FASB”) under its accounting standard codifications (“ASC”) or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.
Recently adopted accounting pronouncements
In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. This ASU simplifies the accounting for certain financial instruments with down round features, a provision in an equity-linked financial instrument (or embedded feature) that provides a downward adjustment of the current exercise price based on the price of future equity offerings. Down round features are common in warrants, preferred shares and convertible debt instruments issued by private companies and early-stage public companies. This update requires companies to disregard the down round feature when assessing whether the instrument is indexed to its own stock, for purposes of determining liability or equity classification. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted, including adoption in any interim period. The amendments in Part I should be applied (1) retrospectively to outstanding financial instruments with a down round feature by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the first fiscal year and interim periods; (2) retrospectively to outstanding financial instruments with a down round feature for each prior reporting period presented. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.
In February 2018, the FASB issued ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. The ASU permits companies to reclassify disproportionate tax effects in accumulated other comprehensive income (“AOCI”) caused by the Tax Act to retained earnings. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this ASU effective January 1, 2019. The adoption of this ASU did not have a material effect on the Company’s financial statements and related disclosures.
Recently issued accounting pronouncements not yet adopted
In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes, which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value measurements. This ASU removes the requirement to disclose: the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy; the policy for timing of transfers between levels; and the valuation processes for Level 3 fair value measurements. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For SEC filers that are eligible to be smaller reporting companies, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its financial statements and related disclosures.
Fair Value Measurements   The Company assesses the fair value of financial instruments as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering
such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows:
Level 1 Quoted prices in active markets for identical assets or liabilities.
Level 2 Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk.
Reverse stock split .353  
XML 86 R5.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Statements of Redeemable Convertible Preferred Stock and Stockholders' Deficit - USD ($)
$ in Thousands
Total
Series B Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Redeemable convertible preferred stock, shares, beginning balance at Dec. 31, 2017 7,611,691        
Redeemable convertible preferred stock, amount, beginning balance at Dec. 31, 2017 $ 43,001        
Redeemable convertible preferred stock, shares, ending balance at Dec. 31, 2018 7,611,691        
Redeemable convertible preferred stock, amount, ending balance at Dec. 31, 2018 $ 43,001        
Beginning balance, common stock (in shares) at Dec. 31, 2017     1,411,966    
Beginning balance at Dec. 31, 2017 (21,894)   $ 1 $ 122 $ (22,017)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (16,503)       (16,503)
Stock-based compensation expense 154     154  
Ending balance at Dec. 31, 2018 $ (38,243)   $ 1 276 (38,520)
Ending balance, common stock (in shares) at Dec. 31, 2018 1,411,966   1,411,966    
Increase (Decrease) in Temporary Equity [Roll Forward]          
Issuance of Series B redeemable convertible preferred stock, net of issuance costs, shares   6,581,590      
Issuance of Series B redeemable convertible preferred stock, net of issuance cost, amount   $ 92,852      
Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities, Net Of Adjustments 14,193,281        
Temporary Equity, Stock Issued During Period, Value, Conversion Of Convertible Securities, Net Of Adjustments $ (135,853)        
Redeemable convertible preferred stock, shares, ending balance at Dec. 31, 2019 0        
Redeemable convertible preferred stock, amount, ending balance at Dec. 31, 2019 $ 0        
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net loss (45,711)       (45,711)
Issuance of common stock upon initial public offering, net of issuance cost of $9,898 (in shares)     5,750,000    
Issuance of common stock upon initial public offering, net of issuance cost of $9,898 82,102   $ 6 82,096  
Conversion of redeemable convertible preferred stock into common stock upon initial public offering (in shares)     14,193,281    
Conversion of redeemable convertible preferred stock into common stock upon initial public offering 135,853   $ 14 135,839  
Stock issued through exercise of stock options (in shares)     11,703    
Stock issued through exercise of stock options 31     31  
Stock-based compensation expense 3,266     3,266  
Ending balance at Dec. 31, 2019 $ 137,298   $ 21 $ 221,508 $ (84,231)
Ending balance, common stock (in shares) at Dec. 31, 2019 21,366,950   21,366,950    
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Payments of Stock Issuance Costs $ 9,898        
XML 87 R11.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Accrued Liabilities
 12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Accrued Liabilities Accrued Liabilities
Accrued liabilities consisted of the following (in thousands):

December 31,
20192018
Accrued compensation$1,214  $367  
Accrued professional services1,163  35  
Accrued research and development expense2,219  —  
Accrued other liabilities7  20  
Total$4,603  $422  
XML 88 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2019
Feb. 21, 2020
Cover page.    
Document Type 10-K  
Document Annual Report true  
Document Period End Date Dec. 31, 2019  
Document Transition Report false  
Entity File Number 001-39112  
Entity Registrant Name OYSTER POINT PHARMA, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-1030955  
Entity Address, Address Line One 202 Carnegie Center, Suite 109  
Entity Address, Postal Zip Code 08540  
Entity Address, City or Town Princeton  
Entity Address, State or Province NJ  
Title of 12(b) Security Common stock, par value $0.001  
Trading Symbol OYST  
Security Exchange Name NASDAQ  
Entity Well-known Seasoned Issuer No  
Entity Voluntary Filers No  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Central Index Key 0001720725  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus FY  
Current Fiscal Year End Date --12-31  
Amendment Flag false  
Local Phone Number 382-9032  
City Area Code 609  
Entity Common Stock, Shares Outstanding   21,366,950
Documents Incorporated by Reference Portions of the registrant’s definitive Proxy Statement relating to the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. The proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant’s fiscal year ended December 31, 2019.  
Entity Public Float $ 168.0  
XML 89 R15.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Common Stock
 12 Months Ended
Dec. 31, 2019
Equity [Abstract]  
Common Stock Common Stock
The Company amended and restated its certificate of incorporation, effective November 4, 2019, in connection with the IPO. The amended and restated certificate of incorporation authorizes the Company to issue 1,000,000,000 shares of common stock, at a par value of $0.001 per share. Each share of common stock is entitled to one vote.

The Company reserved common stock shares for future issuance as of December 31, 2019 and 2018 as follows:

December 31,

20192018
Conversion of Series A redeemable convertible preferred stock—  7,611,691  
Outstanding options under the 2016 Plan2,748,434  1,376,084  
Equity awards available for grants under the 2016 Plan—  216,333  
Outstanding options under the 2019 Plan29,466  —  
Unvested RSUs under the 2019 Plan23,125  —  
Equity awards available for grants under the 2019 Plan2,747,047  —  
Total5,548,072  9,204,108  

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oyst-20191231_g3.jpg begin 644 oyst-20191231_g3.jpg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�_L.#\^EM[2=7Z][]U[KWOW7NO>_= M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_UM_CW[KW7O?NO=>]^Z]U[W[KW7O? MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:XWR]P/RAI/YP&^N[/AWDZC,]R_'W^7! MT/O6N^.^0R%'BMA?+KK7+?)KOZAW_P!,;ES%6&&U>PH,+C&KM@YX*T..W':& MM!QU75 3URO+RZWM99;5S3&%VJ^W^YC%R 3)92BTMC'.JCXX]1TW$?%HJE.] M1T#[WZT[L=EL(,)V1L/)]5_*L5_9W5>^]KU\D=?M;L;8.6Q%3C\GB MJEU6*NA)222%HYG37W*V[[;R O*=T%%])S9$B$-JBD$UGIBEC88:.0$,K 5I M@@,"H\M];MS ]^/[--K9FX5&F6I!^8^VAP02"#T3W#?S3?FUN'J/$?+K;W>4 MNXM^9_;U!VU@_P"6A@OY9WRFR^R\YL/+"',XGI#!_+O';)J-P97O+);'GC:F MW7"DFSJC<7PS4X_7T5R,ZZ::9IU>+TI\GNP> MT?G)VOU!54K87J/$?"_XI?('9^U\]M=L'O\ P6[>ZMX]YX[<]'NN>:H:JBJ* M7$['QE.^/DB4T-7#,"Q+$"'MWY6SNKZHV2W2W*%/(@M M(Q# ]P(Z$MK?O<;E-;:2(A;12 $4(+EQ0BE01IS4_D*&M>_;GSQ^;4M/O':/ M3.XNI<9V#D/YX-!_+WV1F=[=>56;VSMGH7,?'C$=AUF3SV(QFY<-D,_NG:^4 MK:O)Q5,=53-6FGBHW5(G=P.MKY*Y1#6EUNUOG0WOO7Y]= ML=[9CX+=/?*796SLO\4>G^K-Y_+'YH;I^/FT]Q;_ .SNS.[JC>F0ZTZ]ZJZ) MCS^+ZNV7@Z79^T9\EN#+U,F196FHZ.CIUD:IJ02BSY+VS9H>RA4'(-01GRJ G?_;_RP[1^#?\ -R^(_=W877>"^0_P]Z+W)EMW]T=< M]8"IZ_\ DC\:^U.A=^;XVY/'UQNGGG@B0\V+:N6MMYR]KN:-HL)WV+=;U%C@EFI+:W4-S%&_ZJ(/&CC9XY8B54 MR(VB32P)Z0W]U>3[5S%MTTZB]MH"78)VNCQN10$X+ $'/:>%>N'6>]/YA55V M%\&_@UU7\H.MMKXG<_\ +U?Y)]G=[97XX[=RF\-N8+;O8G6NV-A;2Z^V$^\! MLMLFVW]TT^WZNJR/W4!I(I\BL*U9AB7VXVG(ZV7./.6Y&<[]S MG16[,SUSOKL;N3/Y#>NUJW8.QMS]F;9R%#BL3MV&#+4^)I_NYZEII$@!'=67 M(W)R;7M?,&PW.Y;QZN]FV^TLKJV:%Q%)+' M>-&T*/J5@I=95CE;3^G1W16HJE*^[WMU^ZH[1TBN9I)HV#+J&J*H8BA-* ,X M%2"0$)R3T9[KWLSYF?%CY:]!_&_Y4]T;*^6/57RXQO9>(ZH[FPO4>&Z.[.ZT M[JZGV3D.SLQL/?6T-JYW+;+W5USO7KC Y.KQ&7HHJ3(X[)XYZ2M2:.HIZCV' MK[;N5.9.6=[W_EK:)=LW#:S$T\#3M<12P32"%9(W=1(DJ2L@=&)5E8,A!#*% MD-Q?;?>65CN%V+CZ@L$<($(95+D, :4H#0CB<&E*M5!\.=S_ ,POI/\ E-47 MS#ZP[JZ;VETM\8<#\@.PMG?$^MZ=BS_^G7J3JSN;M+/[]K>TNZ:_.C=&P.P> MP*"BRAP46VZ%,;A1%0/5K7--510R9S7;\C[Q[FORIN.SW4F\[C);1/>BVI]RL]@7DO0O;?\Q[N_%]1;%W=!U=\2_Y?^\^LAP=- :E98-OTU16SQ(^ME(,V[DD;UM? M(.T/N2ZLZQVYLO+UL WJG0_<& W1NGM2;A5%172X)8D"H&K!)K@"AM2]QMT>=>]^Z]U[W[KW7O?NO=>]^Z]U M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7S-_\ A2A_V^%[J_\ $/?'@?7C_CR: MGWT1^[Q_TZS:?^>JY_ZNGJ"N>_\ E8?]M_UBAZI5QI'^]'_;#D_X>YH?-.G] MI_#TN*"]Q_K#G^I_XD^V&P.I-VO@O2QHOQ_L+_U_V/MH^74B;9P%.E;1?13_ M (@?\1S_ (>VFXGH=[?^&AZ4E-_C?\?['_&U_P GW7SZ&]A6@]>G^G_'^V_V M''T]ZX]#&S\AT^0'C_8_\4_'O1Z%5G^'/3M#?C_8_P"^X]ZZ$MM@*>G.+Z#_ M 'W^\?GW[TZ/;?RZFK;3^/\ ;?6__$6]^ -3T<0\1]O2HV5O/>/7&\=K=B]= M;HS.R-_['S%/G]G[OP,_V^7P&7I[JL\#D-#4TM5"S05=),LE-64TCPS(\;L/ M;%[966YV-UMFY6J3[=.A22-Q574^1\P0:%6%&5@&4@CI3=6-EN=E=;;N5HD^ MWSH4DC<55U/D?,$'*L*,K ,I!'6]9_*V_FD;,^=FRQL??#8?97RCV3B(I][[ M(@D^VQ>]\53^.F?LCKB.ID::KP%7,R_?T&J2JPU4_CEU0O3SS8#>Z_M1?<@7 MWU]@'GY4G>D4IRT3'/@S4P' ^!\+*HJ*,&5<#O=?VHON0;WZ^P#S\ISO2*4Y M:)CGP9J8#@? ^%E45%&#*MN?N'.H=Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO> M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[ MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_ M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K MWOW7NJ%/YKN'R&9^SX*K;<:J8XG@^YF\Y\3#2]YK]LY8XN3?<=IN9IMHB\3;:W,:RNR MGQ+BB:8662C^9!H*9\N@?S$&;=M@";>MTQ6X_38J <1Y)<%<<:'SX=)+LG>. M[-C[B^'/5F6^$70_PU3L3I?^:G7Y;J7!8?I_L//]?+LWJ7:F2Q&X>K^S>L,5 MA,#L<]GC,O5[B@QU.)LE&T4%8S/#I^R9?CE)N'^63T!\A^U_D31?&/L;Y;[BVQLQ-F M[+V%U[UWUKU#USA\YCX-U[\W!1Y.>KS>Y(?X-B\9BV2**IK*B)(CRYY+L-SY MA]R>;-RV\7ZQ\Q7-K#:F[BLE=]DD&\-;[=L M>VQW#0S-812&01--0$!0 J@Y)!^(4\ZU&DV4_P M+Y?=X=V[T[TZ/[FJ=P]O M8SJJ@V1NWJ;Y='XO]O?%G =U;2WD,M29W9VZ^NNS\#BL=ANX.JMP8D19%L#- M+B,EC,C1544-+)YXO<>^X/*^T;1:[/N^U(EK)F\)6H:@LI:6BE>^N,G2;GCGV>ZR+?VJ5)>*.Y M,8OX5RS*:#ZM5JR2'Q6 5RQWM]Y+;[5:1WCCP;BV5HV- SQZC'G R:("?0+ M4=J,?076'6_:.U?^$SNQNT>N]D=B[.G^'_>L]3L[?^T<#N[;4E50?$;JZ2CG MFV]N/'Y#%M54,E_&[0ZXB3I(N?:K>MPO]LN/O"7>V7TUO=+NML \3M&X!O9@ M0&0@T(XYZ1P(ET>28[E1(CV\NH-W!OTD;N!J#D YKD \>C=?(OXW]*? 7Y18E"NP[[NW.W+/.FQ\TWTE[%8;8][ M;33L9)K>6&6%2BRL2_ASH_AM&S,M0A0*U3T;WEO!M-WM5QM]MH\6=875 NA M@QJ5 H IJ>W35F!8F@!%3^?#M_=&XOY9/>%+MO=U'M2FI]S])3[J@K]H8S>5 M/NO;4_=>P<9)MB2CRM924^.CES61H:Z2H F,D5"U,T92H=D0>RT]M;^XFS-< M6IE8QW 2CE"CBWE.NH!)[0RTQ0MJK50#KG!)'V"[\.32 R5Q6HUJ*?+)!K\J M>?3/D=V?-K?'>%+_ "_OCUWOUGU?D?C5T3UMV?\ *OY>UGQ]VUELSN+=79?+Y_*5E3DX*6(4M-2P&:6:5;QVO*-GM!YW MWW9;BYBW"\EAL[(7+J%2!8C-+/R:W;_4_P @.K?E9V]A-C]=[EW7UDVYLG5[!WA'4X?<>"W+0T>3FI*> MHIHJ_'OXIHXD.]EY(Y1W_F#DF_MEN8>4]W6]66 R:IK::S@:215ET 2)W1/$ MQ3402KBH/2.]W>^LK+_POY$]TX?O;LNNS^9SE;NW;G6>)ZHVYAL;EI(I\?LC;VV,9E M"EKZ^KJ,G61$/4N9+^XEWV[V:\OO$V':'LMO"*H1Y6F=B.,C.54!GP2JJ$4X M44Z$5I'=1PA;RY$LY-20ND#A@"IP#6A))]>AS]DW2KKWOW7NO>_=>Z][]U[K MWOW7NO>_=>Z][]U[K__7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W M[KW7O?NO=>]^Z]T5W&?&+%XWYG[Q^9*;QRTN:WA\:=@_&V?8+8W'K@Z'&["[ M-[ [*IMVPY<,$RRKIN>-\N.5]KY6GG+6UC>">WDU-XD-%8>&IK30 M&;6N-2L* Z: -C:[87TM\!F2)D9:#2VH@DG%H\?,DF-Z&P7S%IJZ/LC$]9XJB MB3$TE3#C1NRFV_&E!'FU5%E CF]Q-EN;N7?[GD&RDYP>K-<-)(;9ICQN&L:> M$96/>1K\$R$N8JGI$FT7L12"/>'&VK@1Z%U 4POBUKI'$#3_ $?@[>A[^0_P M?["WQW=M7Y,_%WY/[A^*?>F)ZFCZ&WEE:KK;;?>_7G:G4>/S];NW:N&WMU]O M3,8.I;=>P]T96NJ\-GJ++TE=$F1JZ>I%73SF-2?8><;&SV>YY>YDY=3<]F:Z M^IC42M;2PSE0CM'+&K=DB*JO&R%3I5ETL*]/7NUS2W"7MA>FWO @0MI\0,@) M(!5B!4$DAN/EPJ"B=C_ROMI;,Z^^/^V:CNOL7=^^^J_FZWS\[7[\4%!1X>GBCP^,P]%1PZU1Y'5W?N- M=75]O=PNTP165SL_[MA@1GT6ML'C= C$EI&4QDL7/>SNQI@"@V.$):#Q3XL= MT+AFH!KDTE34# J#3S-!FISTO_D'\(MZ[U[VI/E/\7_DKN;XG?(&OV'C>J>S M,K3; VUW#U1W9UQM_)9;-[-QW9_4FY\A@(*[=_7>7SU>^W]Q8W*XS*4-+D:R MCF>IHYQ#&AV+F^SL]F;ESF/E^/<]C68S1*97@FMY6"JYAG0,0DJJOB1.CHQ5 M7 5A4O7FW3RSB[L+XV]T5TL=(=6 X:D)&1Y,"#3%:8Z9-E?RY<#M[XX?+[J7 M=W=78/:/=?SHVGV%A?D5\I-X8O;2[YW#F=Z]95_5."J=N[.P]'CMF;1V1U9M M.K2FVSMFCB7'X^")E9I99ZB>5VZY\FFW_E?=+7:8;;:-FEC:ULT9_#18YA,P M9V)=Y)G%993W,?(3J;O^G["S^6R'5/PKIOAE2[6JL/B*?&9O#4V]]C[U'85;7T_^74N M?>;9"4YHXO\ )/'4NWZE7V7W_-LM]L6Y[&UBBQW.[F_+AF)5C')'X0!P5_4) MU'NJ!Z]6@VM(+VVO!,2T=KX%*"A&I6U?;V\.'1?-U?R[NZMJ;_[ESWPX^=&_ MOB7US\B=WYKLGM;J>'I[KGN?$X3M+=^C_2!V3T-F]]3TM;T_N3L"HC_B&3IY MHL_AFS4LV0AH89IGN=VW/.T7-EM!"[EG70&U$Y)#$@J3ZY.<<%TEF^2?\N:IP>Z M_P"4Q\<_C#E^_>IM@_'[?OR7W;+\DNOJJGW5OOK/?U7T;O/.XGLSMS<^ZL/F M\!NZ3NGM3.5D>YZ++TGV.ZYLU5TCK$DZA!#R_P ]1S6ON7OW,<=E=7UY#:(+ M66J1S1B=$:*%$967P( #$RL6A\-'R5KT7;AM9(H%:4F1 "4.G6&) M(TC7(*,* ,&9* &G1V.D?@UV'AN_L!\HOEK\HY8Y=7;-JGD22X_6>XFG:,DQJ\K*@$49.I8U0#7W$EL]&EIMLZ3) M=;C>BXN$KH/AA @(H: %LD5!-<0AFT$VXC 74>ZC>&"3Y5-.JP;/'#LK;,92\1C="Q&2 M'+$U (_BI@@_,'ILK_Y:'3F[\E\G*?M7.9SL?8?RG^,WQZ^,N^-B5E+2X*+% M8'X^T/8=+A]W[?W#AY8\Q0[LRE;OX5\,Z%&Q5=CJ>:F8.+AQ/<'=;:/EX[;" MEO>;;N%U=QR EJM=&(LC*<% (])'XU8@CUV-EMBUV9>]9HHXR"/*.NDYJN"= M0[<'C44 2&SO@O\ ,.DS?6F#[-_FE]]=@=)=5;CV_GL=M+;_ %5UAU?W-V72 M[.K8*O:^VN]_D/MK[K,[^P$JTD,.>7&87;E1N:(2"OED\\I93=\X\JM!?S;= M[U>BQ-DF/5)((C30 !U2+;=R$J^/O3O:*:A0@5 ML$$!I 26 H:BK DDEJ$6G>XXZ.^O>_=>Z][]U[KWOW7NJ#?E+\_>_OB)_,O M[ J,OCZOL+X ]??$WH#??R@PN+@_B6^?CJ.PNVNXMET7R=V9@*"BFSF[.N]L MIMR*/L*@IC-48[!QQYB")A0U,V/AR"#G6?<[F.T9L1W7A00 M2&TD8D*DC:R;9C0-)6(D:P0%[K=+JSWR:(1M)8+#$S@9*:WD76!Q-"%J!Y5) M!Q0T]#\@X16?&9?Y6FT?D#14%)N3%UG5#Y&O^1&\Z67N&BR5, M9:"H%=L"C@09*.I>EDQL:,MU]9#K['&OMO#,=JIS#_61[8DH1-06L9\ @Y%) M2>RE0Y_+I\7C?UA>/ZG_ !']WB2E>ROBMW_[SYUX= EF/YOG95'TWN+YBX7^ M7/\ )'1[-*VV4J)-: D>3>&2"$/FQ.%[B-(KT*6Z M_P"9UNR;?'1'7'1'P][&^0N]NR_BKUK\S>R=K;;[3ZCV5G>LND>SLS%MS#OM M.EWYG<-1]S[VH&>19KB%=3:S&K&",J5TLP8DDC11&(EYW#\]^Q:/O/?7QS^(7Q'WM\P>RNF,-MK+]^Y*C[-V!TCU M=U/D-Z8R+/;1ZZJ.Q>P6J:3=?;F;VS/%E6PF.I9(:#&U5--6UE-]Q&OM!M7) M=@^T6>^0O&"\0"P7(AD4NJG6#$) =(:-CI( M#*>BB]WB6YM(Y(898'2_MXR":$ZG34#I/#N*D5()!!\QU83_ #/JWY*X[X4] MMU_Q27L%NT*.HV-49@=-T^'J^\_]$$6_MM/WD>AJ7<$%5A*CNL=1C,?W:2>- MV.3\7@5JKP @7V\78'YMVQ.9/ _=Q$@7QRPM_&\-_I_J"I#>!XVCQ:&FFNKM MU='F[FY%A.;77XF*Z*:]-ZG10?CGWUUC\7/@3\E?G#UK\P>]O MGY\4-J[0KNV]@[3[CW)3[J[MZFGV'@JL]L=89WM+><-!V'6YNHS(CE;!;MI8 M,CM>:%Z4:DE FWS9[_F3G/8>4K_ )9LMEYCEF\&1X$T6\H=@(I5ACK&% !K M)$S"6M3333I#:2"QL+FZAO);JW4 JKFK@Y)!F4VM34'R9W;O;K3([KV'MS?%718[:79?>?QVP>4J] M_P#4_6F0KLC!]W7/4Y&MPM-413Y*CI%\HB3'VWL+B:XV;:.=+.\YPB#5M(XI M@DCI4O%;W+*(YI0 :*%57((1V KUY=[F5?JKK;7AVL@$2LZUH>!9!E1YU)^5 M*D B^G\P+=6X?FKW%\0.N?B]O/=>)^-F9ZEF^1?R&S?8_7^QNI^M=@]N=6Q= MEX?[@304H=)R.@"JOYN'8M9UEN7Y8;'_ )>OR'W]\"-O8K=&YJ3Y'XG=_6F- M[#WAU[M>GK6E[FV5\8;&#G1V13:F.9HTD>GZ#W:*T0G%:% I02?I>)JZ8??+I5-TFSR-M@ M!_4UH" #348VH0HXEJX7)�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end GRAPHIC 26 oyst-20191231_g4.jpg begin 644 oyst-20191231_g4.jpg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end GRAPHIC 27 oyst-20191231_g5.jpg begin 644 oyst-20191231_g5.jpg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end GRAPHIC 28 oyst-20191231_g6.jpg begin 644 oyst-20191231_g6.jpg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oyst-20191231_g7.jpg begin 644 oyst-20191231_g7.jpg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oyst-20191231_g8.jpg begin 644 oyst-20191231_g8.jpg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end GRAPHIC 31 oyst-20191231_g9.jpg begin 644 oyst-20191231_g9.jpg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end XML 32 R48.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Net Loss Per Share Attributable to Common Stockholders - Antidilutive Securities (Details) - shares
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted net loss per share 2,801,025 8,987,775
Series A redeemable convertible preferred stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted net loss per share 0 7,611,691
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted net loss per share 2,777,900 1,376,084
Restricted Stock Units (RSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities excluded from the computation of diluted net loss per share 23,125 0